# CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CROI FOUNDATION</td>
<td>2</td>
</tr>
<tr>
<td>IAS–USA</td>
<td>2</td>
</tr>
<tr>
<td>CROI 2017 PROGRAM COMMITTEE</td>
<td>3</td>
</tr>
<tr>
<td>Scientific Program Committee</td>
<td>3</td>
</tr>
<tr>
<td>Community Liaison Subcommittee</td>
<td>5</td>
</tr>
<tr>
<td>EXTERNAL REVIEWERS</td>
<td>6</td>
</tr>
<tr>
<td>SCHOLARSHIP AWARDEES</td>
<td>8</td>
</tr>
<tr>
<td>Young Investigator Awardees</td>
<td>8</td>
</tr>
<tr>
<td>International Investigator Awardees</td>
<td>13</td>
</tr>
<tr>
<td>Community Educator Awardees</td>
<td>13</td>
</tr>
<tr>
<td>CONTINUING MEDICAL EDUCATION</td>
<td>15</td>
</tr>
<tr>
<td>GENERAL INFORMATION</td>
<td>17</td>
</tr>
<tr>
<td>Overview</td>
<td>17</td>
</tr>
<tr>
<td>Americans With Disabilities Act</td>
<td>17</td>
</tr>
<tr>
<td>Commercial Support</td>
<td>17</td>
</tr>
<tr>
<td>Emergency Services</td>
<td>17</td>
</tr>
<tr>
<td>Embargo Policies and Social Media</td>
<td>18</td>
</tr>
<tr>
<td>Welcome Reception</td>
<td>18</td>
</tr>
<tr>
<td>Meals</td>
<td>18</td>
</tr>
<tr>
<td>Overflow Accommodations for Oral Sessions</td>
<td>19</td>
</tr>
<tr>
<td>USB Flash Drive</td>
<td>19</td>
</tr>
<tr>
<td>Mobile App</td>
<td>19</td>
</tr>
<tr>
<td>Website</td>
<td>19</td>
</tr>
<tr>
<td>Webcasts</td>
<td>20</td>
</tr>
<tr>
<td>Affiliated Activities Policy</td>
<td>20</td>
</tr>
<tr>
<td>Wi-Fi Access at the Conference</td>
<td>20</td>
</tr>
<tr>
<td>Conference Badges</td>
<td>20</td>
</tr>
<tr>
<td>Child Care</td>
<td>21</td>
</tr>
<tr>
<td>Conference Etiquette</td>
<td>21</td>
</tr>
<tr>
<td>CROI HOTELS</td>
<td>21</td>
</tr>
<tr>
<td>CONFERENCE SERVICES</td>
<td>22</td>
</tr>
<tr>
<td>ABSTRACT PROCESS</td>
<td>26</td>
</tr>
<tr>
<td>ORAL SESSIONS (including Preconference Sessions)</td>
<td>28</td>
</tr>
<tr>
<td>POSTER SESSIONS, BY DAY</td>
<td>73</td>
</tr>
<tr>
<td>POSTER SESSIONS, BY CATEGORY</td>
<td>212</td>
</tr>
<tr>
<td>DISCLOSURE OF FINANCIAL RELATIONSHIPS WITH COMMERCIAL CONCERNS</td>
<td>216</td>
</tr>
<tr>
<td>INDEX OF STUDIES RELATED TO RESEARCH IN WOMEN</td>
<td>227</td>
</tr>
<tr>
<td>AUTHOR INDEX</td>
<td>232</td>
</tr>
<tr>
<td>CONFERENCE SCHEDULE OVERVIEW</td>
<td>INSIDE BACK COVER</td>
</tr>
<tr>
<td>CONVENTION CENTER FLOOR PLANS</td>
<td>BACK COVER</td>
</tr>
<tr>
<td>AREA MAP</td>
<td>BACK COVER</td>
</tr>
</tbody>
</table>

Printed in USA on acid-free paper
© Copyright 2017 CROI Foundation/IAS–USA. All rights reserved.
ISBN #978-0-692-83838-9

CROI 2017 1
CROI FOUNDATION

The CROI Foundation is a 501(c)(3) not-for-profit professional education organization that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the Conference on Retroviruses and Opportunistic Infections (CROI).

Roles and Responsibilities of the CROI Foundation Volunteer Board of Directors

- Works closely with the CROI Scientific Program Committee (CROI PC) and the CROI Secretariat to accomplish the mission of CROI
- Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with the CROI Secretariat
- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed to be taken by the CROI PC or the CROI Secretariat that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification

CROI Foundation Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Organization</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constance A. Benson, MD</td>
<td>President</td>
<td>University of California San Diego</td>
<td>San Diego, CA, United States</td>
</tr>
<tr>
<td>John M. Coffin, PhD</td>
<td>Secretary-Treasurer</td>
<td>Tufts University</td>
<td>Boston, MA, United States</td>
</tr>
<tr>
<td>Elaine J. Abrams, MD</td>
<td></td>
<td>ICAP at Columbia University</td>
<td>New York, NY, United States</td>
</tr>
<tr>
<td>Susan P. Buchbinder, MD</td>
<td></td>
<td>San Francisco Department of Public Health</td>
<td>San Francisco, CA, United States</td>
</tr>
<tr>
<td>Judith S. Currier, MD, MSc</td>
<td></td>
<td>University of California Los Angeles</td>
<td>Los Angeles, CA, United States</td>
</tr>
<tr>
<td>Kevin M. De Cock, MD</td>
<td></td>
<td>Centers for Disease Control and Prevention</td>
<td>Nairobi, Kenya</td>
</tr>
<tr>
<td>Scott M. Hammer, MD</td>
<td></td>
<td>Columbia University Medical Center/</td>
<td>New York, NY, United States</td>
</tr>
<tr>
<td>Richard A. Koup, MD</td>
<td></td>
<td>Vaccine Research Center, National Institute of Allergy and Infectious Diseases</td>
<td>Bethesda, MD, United States</td>
</tr>
<tr>
<td>John W. Mellors, MD</td>
<td></td>
<td>University of Pittsburgh</td>
<td>Pittsburgh, PA, United States</td>
</tr>
<tr>
<td>Julie M. Overbaugh, PhD</td>
<td></td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>Seattle, WA, United States</td>
</tr>
<tr>
<td>Robert T. Schooley, MD</td>
<td></td>
<td>University of California San Diego</td>
<td>La Jolla, CA, United States</td>
</tr>
</tbody>
</table>

The International Antiviral Society–USA is a 501(c)(3) not-for-profit professional education organization. The IAS–USA partners with the CROI Foundation to organize CROI. The mission of the IAS–USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

Executive Director: Donna M. Jacobsen
Address: 425 California Street, Suite 1450
San Francisco, CA 94104-2120
Phone: 415-544-9400
Website: www.iasusa.org
CROI 2017 PROGRAM COMMITTEE

The Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are up to 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The PC members are responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; or organizing, conducting, or convening workshops, symposia, and special sessions.

Scientific Program Committee

- Elaine J. Abrams, MD
  - ICAP at Columbia University
  - New York, NY, United States

- Adaora Adimora, MD*
  - University of North Carolina at Chapel Hill
  - Chapel Hill, NC, United States

- Galit Alter, PhD
  - Ragon Institute of MGH, MIT and Harvard
  - Cambridge, MA
  - United States

- Constance A. Benson, MD
  - University of California
  - San Diego
  - San Diego, CA, United States

- Paul Bieniasz, PhD*
  - The Rockefeller University
  - New York, NY, United States

- Richard A. Koup, MD
  - Vaccine Research Center
  - National Institute of Allergy and Infectious Diseases
  - National Institutes of Health
  - Bethesda, MD, United States

- Connie L. Celum, MD, MPH*
  - University of Washington
  - Seattle, WA, United States

- Richard E. Chaisson, MD
  - The Johns Hopkins University
  - Baltimore, MD, United States

- Nicolas Chomont, PhD*
  - Université de Montréal
  - Montreal, Canada

- John M. Coffin, PhD
  - Tufts University
  - Boston, MA, United States

- Kevin M. De Cock, MD
  - Centers for Disease Control and Prevention
  - Nairobi, Kenya

- Judith S. Currier, MD, MSc
  - University of California
  - Los Angeles
  - Los Angeles, CA, United States

- Susan P. Buchbinder, MD
  - CROI 2017 Chair
  - San Francisco Department of Public Health
  - San Francisco, CA
  - United States

- Judith S. Currier, MD, MSc
  - CROI 2017 Vice Chair
  - University of California
  - Los Angeles
  - Los Angeles, CA, United States

- Connie L. Celum, MD, MPH*
  - University of Washington
  - Seattle, WA, United States

- Richard E. Chaisson, MD
  - The Johns Hopkins University
  - Baltimore, MD, United States

- Nicolas Chomont, PhD*
  - Université de Montréal
  - Montreal, Canada

- John M. Coffin, PhD
  - Tufts University
  - Boston, MA, United States

- Kevin M. De Cock, MD
  - Centers for Disease Control and Prevention
  - Nairobi, Kenya

- Richard A. Koup, MD
  - CROI 2017 Vice Chair
  - Vaccine Research Center
  - National Institute of Allergy and Infectious Diseases
  - National Institutes of Health
  - Bethesda, MD, United States
Community Liaison Subcommittee

The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.

Mark Hubbard
Tennessee Association of People With AIDS
Nashville, TN, United States

Morenike Ukpong, FWACS, MBA, BChD
Obafemi Awolowo University
Ile-Ife, Nigeria

Jeff Taylor
Committee Lead
AIDS Treatment Activists Coalition
Palm Springs, CA
United States

Lisa Diane White, MPH*
SisterLove, Inc.
Atlanta, GA, United States

*Joined the Scientific Program Committee or Community Liaison Subcommittee in 2016

The CROI Foundation wishes to thank for their service the following individuals who rotated off the Scientific Program Committee in 2016: Bruce J. Brew, Ellen G. Chadwick, Mario Stevenson, and Amalio Telenti; and from the Community Liaison Subcommittee: Steven F. Wakefield.
EXTERNAL REVIEWERS

We gratefully acknowledge the contributions of the following, who served as volunteer external reviewers of abstracts for CROI 2017.

Edward P. Acosta, PharmD
University of Alabama at Birmingham
Birmingham, AL, United States

Peter L. Anderson, PharmD
University of Colorado
Aurora, CO, United States

Till Baernighausen, MD, PhD, ScD, MSc
Institute of Public Health, Heidelberg University
Heidelberg, Germany

John M. Blandford, PhD
Centers for Disease Control and Prevention
Atlanta, GA, United States

Marta Boffito, MD, PhD
Chelsea and Westminster NHS Foundation Trust
London, United Kingdom

Jacob Bor, PhD
Boston University
Boston, MA, United States

William Borkowsky, MD
New York University
New York, NY, United States

Bruce J. Brew, MD, MBBS
University of New South Wales
Sydney, Australia

Todd T. Brown, MD, PhD
The Johns Hopkins University
Baltimore, MD, United States

Corey Casper, MD
Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Ellen G. Chadwick, MD
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, IL, United States

David B. Clifford, MD
Washington University
St. Louis, MO, United States

David Evans, PhD
University of Wisconsin Madison
Madison, WI, United States

Charles W. Flexner, MD
The Johns Hopkins University
Baltimore, MD, United States

Patricia M. Flynn, MD
St. Jude Children’s Research Hospital
Memphis, TN, United States

Jennifer Furin, MD, PhD
Case Western Reserve University
Cleveland, OH, United States

Dana H. Gabuzda, MD
Dana Farber Cancer Institute, Harvard Medical School
Boston, MA, United States

Monica Gandhi, MD, MPH
University of California San Francisco
San Francisco, CA, United States

Gerardo García-Lerma, PhD
Centers for Disease Control and Prevention
Atlanta, GA, United States

Carlo Giaquinto, MD
University of Padova
Padova, Italy

Beatrice H. Hahn, MD
University of Pennsylvania
Philadelphia, PA, United States

James G. Hakim, MD
University of Zimbabwe
Harare, Zimbabwe

P. Richard Harrigan, MD
British Columbia Centre for Excellence in HIV/AIDS
Vancouver, Canada

Priscilla Hsue, MD
University of California San Francisco
San Francisco, CA, United States

Angela Kashuba, PharmD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

Susan E. Krown, MD
AIDS Malignancy Consortium
New York, NY, United States

Raphael J. Landovitz, MD
University of California Los Angeles
Los Angeles, CA, United States

Bruno Ledergerber, PhD
University of Zurich
Zurich, Switzerland

Scott L. Letendre, MD
University of California San Diego
San Diego, CA, United States

Sharon R. Lewin, MD
University of Melbourne
Melbourne, Australia

Annie F. Luetkemeyer, MD
University of California San Francisco
San Francisco, CA, United States

Patrick W. G. Mallon, PhD, MBBS
University College Dublin
Dublin, Ireland
Natasha Martin, DPhil  
University of California San Diego  
San Diego, CA, United States

Grace A. McComsey, MD  
Case Western Reserve University  
Cleveland, OH, United States

Jonathan Mermin, MD, MPH  
Centers for Disease Control and Prevention  
Atlanta, GA, United States

Victor Musiime, PhD, MBChB  
Makerere University College of Health Sciences  
Kampala, Uganda

Susanna Naggie, MD, MHS  
Duke University  
Durham, NC, United States

Jean-Michel Pawlotsky, MD, PhD  
Henri Mondor University Hospital  
Creteil, France

Martina Penazzato, MD, PhD  
World Health Organization  
Geneva, Switzerland

Paul Revill, MSc  
University of York  
York, United Kingdom

Lesley Scott, MD  
National Health Laboratory Service  
Johannesburg, South Africa

Kenneth E. Sherman, MD  
University of Cincinnati  
Cincinnati, OH, United States

James H. Stein, MD  
University of Wisconsin  
Madison, WI, United States

Mario Stevenson, PhD  
University of Miami  
Miami, FL, United States

Amalio Telenti, MD, PhD  
J. Craig Venter Institute  
La Jolla, CA, United States

Timothy Wilkin, MD  
Weill Cornell Medicine  
New York, NY, United States

David L. Wyles, MD  
Denver Health, University of Colorado  
Denver, CO, United States

Robert Yarchoan, MD  
National Cancer Institute  
Bethesda, MD, United States

Clement Zeh, PhD, MPH  
Centers for Disease Control and Prevention  
Atlanta, GA, United States
CROI is committed to supporting young and early career investigators working in HIV research to help them further their education and to network with other researchers in the field. Young Investigator Scholarship awardees are presenting authors on accepted abstracts and have been highly recommended by their mentors.

In addition, CROI offers scholarships to international researchers and community educators working in resource-limited countries who would otherwise be unable to attend CROI. Through their applications and letters of recommendation, these awardees have shown that they will greatly benefit from the opportunity to participate in CROI.

**Young Investigator Awardees**

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hadega Aamer</td>
<td>Seattle Children’s Research Institute</td>
</tr>
<tr>
<td>Hosiana Abewe</td>
<td>University of California San Diego</td>
</tr>
<tr>
<td>Rana Abutaima</td>
<td>University of Liverpool</td>
</tr>
<tr>
<td>Emily Adland</td>
<td>The University of Oxford</td>
</tr>
<tr>
<td>Erika Ahlgren</td>
<td>Sahlgrenska Academy</td>
</tr>
<tr>
<td>Giuseppe Ancona</td>
<td>University of Gothenburg</td>
</tr>
<tr>
<td>Nisha Andany</td>
<td>Women’s College Research Institute</td>
</tr>
<tr>
<td>Elizabeth M. Anderson</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Suvaporn Anugulruengkit</td>
<td>Chulalongkorn University</td>
</tr>
<tr>
<td>Marilia L. Araújo</td>
<td>Universidade de São Paulo</td>
</tr>
<tr>
<td>Nadine Bachmann</td>
<td>University Hospital Zurich</td>
</tr>
<tr>
<td>Anani D. Badje</td>
<td>l’Institut National de la Santé et de la Recherche Médicale</td>
</tr>
<tr>
<td>Francesca Bai</td>
<td>University of Milan</td>
</tr>
<tr>
<td>Samuel Bailin</td>
<td>Vanderbilt University Medical Center</td>
</tr>
<tr>
<td>Kayode Balogun</td>
<td>University Health Network</td>
</tr>
<tr>
<td>Riddhima Banga</td>
<td>Centre Hospitalier Universitaire Vaudois</td>
</tr>
<tr>
<td>Ariola Bardhi</td>
<td>Albert Einstein College of Medicine</td>
</tr>
<tr>
<td>Joshua A. Barocas</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>Lisa Bebell</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>Angela Bengtson</td>
<td>University of North Carolina at Chapel Hill</td>
</tr>
<tr>
<td>Priya Bhagwat</td>
<td>University of California Los Angeles</td>
</tr>
<tr>
<td>Elisa Biliotti</td>
<td>Sapienza University of Rome</td>
</tr>
<tr>
<td>Anne Boerekamps</td>
<td>Erasmus University Medical Center</td>
</tr>
<tr>
<td>Pauline Bollen</td>
<td>Radboud University Medical Center</td>
</tr>
<tr>
<td>Michal Bonar</td>
<td>Case Western Reserve University</td>
</tr>
<tr>
<td>Kobus Bosman</td>
<td>University Medical Center Utrecht</td>
</tr>
<tr>
<td>Giorgio Bozzi</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>Kirsty Brittain</td>
<td>University of Cape Town</td>
</tr>
<tr>
<td>Jordan Broekhuis</td>
<td>University of Nebraska Medical Center</td>
</tr>
<tr>
<td>Kristina M. Brooks</td>
<td>Clinical Center</td>
</tr>
<tr>
<td>Maria C. Brühl</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>Marcus Buggert</td>
<td>Sahlgrenska University Hospital</td>
</tr>
<tr>
<td>Supranee Buranapraditkun</td>
<td>Chulalongkorn University</td>
</tr>
<tr>
<td>Zahid A. Butt</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Valentina Cambiano</td>
<td>University College London</td>
</tr>
<tr>
<td>Elvira S. Cannizzo</td>
<td>University of Milan</td>
</tr>
</tbody>
</table>
Adam Capoferri  
The Johns Hopkins University

Itziar Carrasco Garcia  
Puerta de Hierro Research Institute and University Hospital

Heather Carryl  
Howard University

Valeria Cento  
University of Rome Tor Vergata

Antoine Chaillon  
University of California San Diego

Austin W. H. Chan  
Duke University

Phillip Chan  
SEARCH  
The Thai Red Cross AIDS Research Center

Johanna Chapin-Bardales  
Emory University

Glen Chew  
University of Hawaii

Meredith Clement  
Duke University Medical Center

Lauren F. Collins  
Duke University

Sarah Dabydeen  
University of California San Diego

Raghubendra S. Dagur  
University of Nebraska Medical Center

Jennifer M. Dan  
University of California San Diego

Michelle L. D’Antoni  
University of Hawaii

Mirela D’arc  
Universidade Federal do Rio de Janeiro

Thibaut Davy  
University of North Carolina at Chapel Hill

Lesley R. de Armas  
University of Miami

Davide De Francesco  
University College London

Carolina De La Flor  
University of Texas Southwestern Medical Center

Heloise M. Delagreverie  
Hôpital Saint Louis

Anne Deraché  
Africa Health Research Institute

Belete A. Desimmie  
National Cancer Institute

Amy K. Dickey  
Massachusetts General Hospital

Maartje Dijkstra  
Public Health Service Amsterdam

Adam Dingens  
Fred Hutchinson Cancer Research Center

Horacio A. Duarte  
University of Washington

Vanessa El Kamari  
Case Western Reserve University

Ceri Evans  
Queen Mary University of London

Michelli Faria de Oliveira  
University of California San Diego

Carolina Fernández McPhee  
Instituto de Investigación Sanitaria Gregorio Marañón  
University Hospital Gregorio Marañon

Nina C. Flerin  
Albert Einstein College of Medicine

J. Morgan Freiman  
Boston Medical Center

Pierre Gantner  
Hôpitaux Universitaires de Strasbourg

Erin I. Garcia  
University of Washington

Claudia García-Morales  
National Institute of Respiratory Diseases

Esther Gathogo  
King’s College London

Alexander J. Gill  
University of Pennsylvania

Leila B. Giron  
Federal University of Sao Paulo

Aleksandr Gorin  
University of California Los Angeles

Louise Greathead  
Imperial College London

Sharon A. Greene  
University of Washington

Diane Gu  
University of California Los Angeles

Akshay Gupte  
The Johns Hopkins University

Ahmad Haeri Mazanderani  
National Institute for Communicable Diseases

Gustaf O. Hammarlund  
Sahlgrenska Academy  
University of Gothenburg

Nathan Hanan  
University of California San Diego

Said Hassounah  
Lady Davis Institute, McGill AIDS Centre

Jason M. Hataye  
National Institutes of Health
Tiffany Hensley-McBain
University of Washington
Lucas E. Hermans
University Medical Center Utrecht
Sabine Hermans
Amsterdam Institute for Global Health and Development
Linn Herrmannsson
Sahlgrenska Academy
University of Gothenburg
Raul Ulises Hernandez-Ramirez
Yale University
Bonnie Hiener
The Westmead Institute for Medical Research
Simone H. Hijlkema
Erasmus University Medical Center
Akarin Hiransuthikul
HIV-NAT, The Thai Red Cross AIDS Research Centre
Admire Hlupeni
University of Zimbabwe
Martin Hoenigl
University of California San Diego
Malon Van den Hof
Academic Medical Center
Elks Hoornenborg
Public Health Service Amsterdam
Szuhan Huang
George Washington University
Brandon M. Imp
Robert Wood Johnson Medical School
Sergio Ita
University of California San Diego
Watsamon Jantarabenjakul
Chulalongkorn University
Mathew L. Jones
University of Oxford
Claus Kadelka
University of Zurich
Mariah M. Kalmin
The George Washington University
Justin A. Kaplan
National Cancer Institute
Samantha Kaplan
Yale University
Harpreet Kaur
Cleveland Clinic Foundation
Christine Kelly
University College Dublin
Jérôme Kervevan
l’Institut National de la Santé et de la Recherche Médicale
Moliehi Khaketa
University of British Columbia
Zahra Kiani
McGill University
Ditte M. Kirkegaard-Klitbo
Hvidovre Hospital
Astrid R. Krarup
Aarhus University Hospital
Stefanie Kroeze
Amsterdam Institute for Global Health and Development
Steven Lada
University of California San Diego
Camille Lange
National Institutes of Health
Leah T. Le
Yale University
Lorna Leal
Hospital Clinic de Barcelona
Guinevere Q. Lee
Ragon Institute of MGH, MIT and Harvard
Louise Leyre
University of Montreal Hospital Research Centre
Andrea Lisco
National Institutes of Health
Yang Liu
National Cancer Institute
Sarah Lofgren
University of Minnesota
Claire Loiseau
l’Institut National de la Santé et de la Recherche Médicale
Francesca Lombardi
Catholic University of Sacred Heart
Briana Lynch
National Institutes of Health
Christine E. MacBrayne
University of Colorado
João I. Mamede
Northwestern University
Maura Manion
National Institute of Allergy and Infectious Diseases
Madeleine C. P. Mankowski
The Johns Hopkins University
Jennifer Manne-Goehler
Beth Israel Deaconess Medical Center
Alyssa R. Martin
The Johns Hopkins University
Enrique Martin-Gayo
Ragon Institute of MGH, MIT and Harvard
Tafireyi Marukutira
Macfarlane Burnet Institute
Michela Masetti
University of Milan
Aviva Mattingly  
National Institutes of Health

Rodrigo Matus Nicodemos  
Vaccine Research Center  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health

Allison M. McFall  
The Johns Hopkins University

Vanessa McMahan  
University of Washington

Luz M. Medrano  
Institute of Health Carlos III

Natasha Mehta  
University of California San Francisco

Caroline Melhado  
University of North Carolina at Chapel Hill

Esther Merlino  
University of Milan

Kate Michel  
Georgetown University

Brooks I. Mitchell  
University of Hawaii

Julie Mitchell  
US Military HIV Research Program

Aaloke Mody  
University of California San Francisco

Michalina A. Montano  
University of Washington

Rocio Montejano  
Hospital Universitario La Paz

Caitlin A. Moran  
Emory University

Sara Moron-Lopez  
IrsiCaixa

Sikhulile Moyo  
Botswana Harvard AIDS Institute Partnership

Andrew Musick  
National Cancer Institute

Shalena Naidoo  
Stellenbosch University

Megan Neary  
University of Liverpool

Anne M. Neilan  
Massachusetts General Hospital

Kristin N. Nelson  
Emory University

Mariia Novikova  
National Cancer Institute

Piotr Nowak  
Karolinska Institute

Jane A. O’Halloran  
University College Dublin

Oluwasolape M. Olawore  
The Johns Hopkins University

Lorenzo Onorato  
Second University of Naples

Edmund Osei-Kuffour  
Heinrich-Heine-University Hospital

Laurence Palk  
University of California Los Angeles

Nandagopal Paneerselvam  
YR Gaitonde Center for AIDS Research and Education

Nivedha Panneer  
Centers for Disease Control and Prevention

Alexander Pasternak  
Academic Medical Center

Chansavath Phetsouphanh  
University of Oxford

Tamsin Phillips  
University of Cape Town

Jillian Pintye  
University of Washington

Mariia R. Pinzone  
University of Pennsylvania

Timothy Pilitnik  
University of Miami

Joan T. Price  
University of North Carolina at Chapel Hill

Christina Psomas  
University Hospital of Montpellier

Maria Pujantell  
IrsiCaixa

Sarah Rasmussen  
The Johns Hopkins University

Ludy Registre  
Boston University School of Medicine

Michael J. A. Reid  
University of California San Francisco

Lindsey Reif  
Columbia University

Chiara Resnati  
University of Milan

Lara Rheinemann  
University of Utah

Owain Roberts  
University of Liverpool

Cristina Rodriguez-Hart  
The Johns Hopkins University

Anna Joy Rogers  
University of Alabama at Birmingham

Julia K. Rohr  
Harvard University

Casper Rokx  
Erasmus University Medical Center
International Investigator Awardees

Andrew M. Abaasa  
MRC/UVRI Uganda  
Research Unit on AIDS

Gbolahan Ajibola  
Botswana Harvard AIDS Research Institute Partnership

Stable Besa  
Zambart

Sergio M. de Almeida  
Universidade Federal do Paraná

Paolo Denti  
University of Cape Town

Kostyantyn Dumchev  
Ukrainian Institute on Public Health Policy

Trupti I. Gilada  
Union Medicare and Research Center

Ashraf Grimwood  
Kheth’Impilo

Cheryl J. Hendrickson  
University of the Witwatersrand

Arvind Kaimal  
Infectious Diseases Institute

Atupele P. Kapito-Tembo  
University of Malawi College of Medicine

Margaret P. Kasaro  
University of North Carolina

Agnes Kiragga  
Makerere University

Zachary A. Kwena  
Kenya Medical Research Institute

Kwana Lechiile  
Botswana-UPenn Partnership  
University of Pennsylvania

Tshepo B. Leeme  
Botswana-UPenn Partnership  
University of Pennsylvania

Maia Lesosky  
University of Cape Town

Sekai C. Mathabire  
Epicentre

Lydia Nakiyingi  
Infectious Diseases Institute

Mastula Nanfuka  
The Support Organisation

McNeil Ngongondo  
University of North Carolina  
Project-Malawi

Thanh T. Nguyen  
Oxford University

Thu T. M. Nguyen  
Oxford University

Harriet Nuwagaba-Biribonwoha  
ICAP at Columbia University

Moussa Seydi  
Centre Hospitalier Universitaire de Fann

Tavitiya Sudjaritruk  
Chiang Mai University

Gaëlle F. Tchouwa  
Virology Laboratory IMPM-IRD, Centre de Recherche Sur les Maladies Emergentes et Reemergentes

Community Educator Awardees

Giorgio Barbareschi  
European AIDS Treatment Group

Tamás Bereczky  
European AIDS Treatment Group

Aisuluu Bolotbaeva  
Central Asian HIV Foundation

Giulio M. Corbelli  
AVAC

Michael Dorosh  
Treatment Educat10n Network

Florita C. Durueke  
New HIV Vaccine and Microbicides Advocacy Society

Angel L. Hernández  
University of Puerto Rico

Andrew H. Kaytes  
Christie's Place

Tapiwanashe Kujinga  
Pan-African Treatment Access Movement

Michael Meulbroek  
Asociación para el Trasplante de Organos a Seropositivos

Kennedy Mupeli  
Centre for Youth of Hope

Lillian K. Mworeko  
Makerere University Kampala
Robert Newells  
AIDS Project of the East Bay

Adeolu O. Ogunrombi  
University of Liverpool

Godfrey O. Okumu  
Impact Research and 
Development Organization

Simon O. Ondiek  
Nyanza Reproductive Health Society

David A. Palm  
University of North Carolina  
at Chapel Hill

Julia M. Patterson  
University Hospital AIDS Clinical 
Research Site  
Case Western Reserve University

Elias Phiri  
Addington Afro Ethnic Health 
Promotion Group

Ferran Pujol Roca  
Projecte dels NOMS-Hispanosida

Jorge Saz Berges  
Joves Positius

Cissy Ssuuna  
Children's Foundation  
Baylor College of Medicine

Moses N. Supercharger  
Joint Clinical Research Centre

Manuel A. Venegas  
University of Washington

Ntando Yola  
Desmond Tutu HIV Foundation
CONTINUING MEDICAL EDUCATION

Accreditation Statement
The International Antiviral Society—USA (IAS—USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS—USA designates this live activity for a maximum of 17.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives
After participating in CROI, learners will be able to:
• Describe results of basic science research on HIV transmission and infection and advances toward a cure
• List the most recent findings from trials related to the clinical aspects of HIV infection and its complications, including relevant coinfections and comorbidities, and implications of these data for treatment strategies
• Describe current epidemiologic data on the prevalence of HIV infection and the biobehavioral approaches to prevention

Statement of Need
Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993 by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections.

CME Credit Information
Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in CROI. CME credits can be claimed for plenary lectures, symposia, opening session lectures, and special sessions. CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, or poster sessions. For physician attendees whose certificate is through the American Board of Internal Medicine (ABIM), Maintenance of Certification (MOC) points are available for participation in CROI. Other researchers, practitioners, and clinicians can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).
ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.25 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation

During the conference, daily evaluations will be e-mailed to all CROI participants in the e-mail account used to register for the conference. On the final day of the conference, all CROI participants will receive a final e-mail that will contain their registration confirmation number and a link to the overall CROI evaluation. In addition, a secure web page has been created on the CROI website. The links to the daily and final evaluation can be found at www.croiconference.org/electronic-materials. You will need your email address and registration ID to access this page. To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, this final evaluation must be completed by March 31, 2017. Once the evaluation is submitted, participants will receive the link to claim and print their certificate.

To determine the number of CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate time spent attending the conference, including opening and plenary lectures, workshops, and symposia. For example, if you attended 2 plenary talks (8:30 AM to 9:30 AM), and a symposium (4:00 PM to 6:00 PM), you would have a total of 3 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day. At the end of CROI, please add the total hours you attended for your certificate. You may claim a maximum of 17.25 AMA PRA Category 1 Credits™ and 17.25 ABIM MOC points for this activity.

ABIM MOC points will only be awarded after the successful completion of the evaluation component demonstrating knowledge gained at all meetings through a series of multiple choice questions. ABIM MOC points are intended for internal medicine physicians, in the United States, who are maintaining their ABIM Board Certification.

A CME/ABIM MOC hour worksheet can be found at www.croiconference.org/sites/default/files/uploads/croi2017-cmeworksheet.pdf

Disclosure of Financial Relationships

It is the policy of the IAS—USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (speakers, presenters, etc) participating in IAS—USA-sponsored activities are required to disclose to the program audience any financial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. (The ACCME defines a financial interest as an interest in any amount.) The information is intended to make the IAS—USA audience aware of author and contributor interests and commitments with commercial companies or other entities, enabling the audience members to form their own judgments about such associations.

Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS—USA policy, the IAS—USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Disclosure information will be included with the Program and Abstracts eBook on the web.

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
GENERAL INFORMATION

Overview
CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and includes up to 4000 HIV research and care leaders internationally. The goal of the conference is to help researchers translate their laboratory and clinical findings into tangible progress against the HIV pandemic. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

Americans With Disabilities Act
CROI endeavors to comply fully with the legal requirements of the Americans With Disabilities Act (ADA). If you require assistance on-site, please visit the Seattle Visitor Center and Concierge Services in the Upper Pike Street Lobby during the conference.

Commercial Support
CROI is largely supported by participant registration fees. Please note, CROI registration fees cover all attendee meals (including the welcome reception) and travel expenses for selected invited participants (eg, speakers, leaders, moderators, and CROI PC), as well as selected meeting materials and other conference expenses.

In addition, CROI seeks grants from commercial companies, particularly from companies with competing products. These companies have no input in or control over the selection of faculty or content of the presentations. Commercial support is used to cover some of the costs of the convention center, audiovisual services, and other conference services.

CROI 2017 received grant support commitments from the following commercial companies:

**PLATINUM SUPPORTERS**
- Merck
- ViiV Healthcare

**GOLD SUPPORTERS**
- Bristol-Myers Squibb
- Gilead Sciences, Inc
- Janssen Therapeutics

**SILVER SUPPORTER**
- AbbVie

Emergency Services
In the event of a medical emergency, please contact Security Control immediately. You may contact Security Control by dialing 5127 from any house phone located in the Washington State Convention Center (WSCC). In addition, there are red “hot line” phones located around the WSCC. These phones ring directly into the Security Control office.

IAS–USA staff or any uniformed WSCC personnel with a 2-way radio can also assist you in an emergency. Contacting Security Control will greatly minimize response time in the event an emergency medical unit needs to report to the WSCC. Security personnel can quickly assess the situation and bring emergency personnel directly to the individual in need. For this reason, WSCC requests that our clients and guests NOT contact 911 directly.
Embargo Policies and Social Media

The research presented at CROI 2017 is embargoed until the conclusion of the session in which it is presented. For example, if a study is presented from 1:45 PM to 2:00 PM as part of a session that ends at 2:45 PM, the embargo on that study lifts at 2:45 PM. Embargoes on poster presentations lift at the conclusion of the session in which the poster is presented. If a study to be presented at CROI 2017 is included in an official CROI press conference and that press conference takes place before the official presentation of the study at the conference, the embargo lifts at the conclusion of the press conference in which the study is featured.

CROI embargo policies apply to any public dissemination of research information presented at the conference, including electronic publications (eg, blogs) or social media (eg, Facebook, Twitter). No public dissemination of research information from the conference is permitted prior to the lifting of the conference embargo. Individuals or organizations that violate the conference embargo policy may have their conference credentials revoked and may forfeit the opportunity to participate in future conferences.

Welcome Reception

All registered CROI attendees are invited to join us for a Welcome Reception immediately following the Opening Session on Monday evening. The reception will be held at the Convention Center.

This unique Welcome Reception will offer attendees the opportunity to network with colleagues. Light hor d’oeuvres will be served. Each attendee will be given 2 drink tickets with their registration materials to be used for alcoholic or nonalcoholic beverages.

Meals

Morning coffee and light continental breakfast will be available to conference registrants from 7:30 AM to 8:30 AM, Tuesday, Wednesday, and Thursday, in the 4AB Auditorium. An afternoon snack break will be available at 2:30 PM in the Poster Hall. Attendees are on their own for all other meals, including lunch and dinner, each day. Below is a list of food service options located in the WSCC or within a short walking distance.

Food Service at the Convention Center

| 820 Pike Street – Pan Asian Cuisine | Subway Sandwiches |
| Crêpes Voilá | Taco Del Mar |
| Cyber Dogs – Internet Café | The Juicy Café |
| Espresso Caffé Dior | Tully’s Coffee |
| Goldberg’s Deli | Wild Rye Café Bakery |

Restaurants Within 4 Blocks of the Convention Center

| Blueacre Seafood | 1700 7th Ave | 206-659-0737 | blueacresafood.com |
| Blue C Sushi | 1510 7th Ave | 206-467-4022 | bluesushi.com |
| Café Yumm! | 717 Pine St | 206-624-9866 | cafeyumm.com |
| Daily Grill | 629 Pike St | 206-624-8400 | dailygrill.com |
| Dragonfish Asian Café | 722 Pine St | 206-467-7777 | dragonfishcafe.com |
| FareStart | 700 Virginia St | 206-267-7606 | farestart.org |
| Gameworks | 1511 7th Ave | 206-521-0951 | gameworks.com |
| Gordon Biersch Brewery Restaurant | 600 Pine St, Ste 401 | 206-405-2707 | gordonbiersch.com |
| Il Fornaio | 600 Pine St, Ste 132 | 206-264-0994 | ilfornaio.com |
| MOD Superfast Pizza | 1302 6th Ave | 206-332-0200 | modsuperfast.com |
| Morton’s Steakhouse | 1511 6th Ave | 206-223-2751 | mortons.com |
| NYC Hyatt Deli Market | 1520 7th Ave | 206-682-7011 | |
| Palomino | 6th and Union | 206-623-1300 | r-u-i.co |
Restaurants within 4 Blocks of the Convention Center (continued)

<table>
<thead>
<tr>
<th>Restaurant Name</th>
<th>Address</th>
<th>Phone Number</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pike Place Chowder</td>
<td>600 Pine St, Ste 404</td>
<td>206-838-5680</td>
<td></td>
</tr>
<tr>
<td>Potbelly Sandwich Shop</td>
<td>1429 4th Ave</td>
<td>206-623-0099</td>
<td>potbelly.com</td>
</tr>
<tr>
<td>RN74</td>
<td>1425 4th Ave</td>
<td>206-456-7474</td>
<td>michaelmina.net</td>
</tr>
<tr>
<td>Rock Bottom Restaurant</td>
<td>1333 5th Ave</td>
<td>206-623-3070</td>
<td>rockbottom.com</td>
</tr>
<tr>
<td>Ruth's Chris Steak House</td>
<td>727 Pine St</td>
<td>206-624-8524</td>
<td>rutschris.com</td>
</tr>
<tr>
<td>Soup's On!</td>
<td>1420 5th Ave</td>
<td>206-625-9976</td>
<td>soupsonusa.com</td>
</tr>
<tr>
<td>Sullivan's Steakhouse</td>
<td>612 Union St</td>
<td>206-494-4442</td>
<td>sullivanstekhouse.com</td>
</tr>
<tr>
<td>Tango Restaurant &amp; Lounge</td>
<td>1100 Pike St</td>
<td>206-583-0382</td>
<td>tangorestaurant.com</td>
</tr>
<tr>
<td>Tap House Grill</td>
<td>1506 6th Ave</td>
<td>206-816-3314</td>
<td>taphousegrill.com</td>
</tr>
<tr>
<td>Thai Ginger</td>
<td>600 Pine St</td>
<td>206-749-9100</td>
<td><a href="http://www.thaiginger.com">www.thaiginger.com</a></td>
</tr>
<tr>
<td>The Capital Grille</td>
<td>1301 4th Ave</td>
<td>206-382-0900</td>
<td>thecapitalgrille.com</td>
</tr>
<tr>
<td>The Cheesecake Factory</td>
<td>700 Pine St</td>
<td>206-652-5400</td>
<td>thecheesecakefactory.com</td>
</tr>
<tr>
<td>Toss'd Custom Salads</td>
<td>1420 5th Ave</td>
<td>206-682-6700</td>
<td></td>
</tr>
<tr>
<td>Veggie Grill</td>
<td>1427 4th Ave</td>
<td>206-624-1332</td>
<td>veggiegrill.com</td>
</tr>
</tbody>
</table>

Overflow Accommodations for Oral Sessions

There is a simultaneous overflow area located in the Atrium Lobby. There are 6 screens, and each will be live streaming one of the 6 concurrent oral sessions (Oral Abstracts, Themed Discussions, or Symposia). Headsets with an audio switch will be available for easy transitioning between the concurrent sessions. Overflow monitors for individual session rooms will become available as needed. CROI staff will direct you to these locations.

USB Flash Drive

Any registrant who purchased a USB flash drive with the Abstract eBook preloaded onto it will receive it in their welcome packet at registration. Abstracts can also be found in the Abstract eBook and searchable database on the CROI website after the session in which the abstract is presented.

Mobile App:

The CROI 2017 mobile App has many features to enhance your conference experience:

• View abstracts
• Find information about speakers and other CROI attendees
• Create a personal calendar of the sessions you plan to attend
• E-mail session notes
• Receive the latest changes to the CROI program
• View electronic posters

The mobile App is compatible with iOS and Android devices. Search “CROI 2017” in your mobile device App store. Access is restricted to registered attendees only. Your log-in information and password will be provided with your registration materials.

Website

For additional information about the conference and to access electronic materials please visit the website at www.CROIconference.org.

The final Abstract eBook (flip book and PDF versions) will be available for public download following the conference. Abstracts from CROI 2017 can be viewed and downloaded in the searchable database during the conference. Abstracts and electronic posters from CROI 2014, 2015, 2016 are available at www.croiconference.org/abstracts/search-abstracts/
Webcasts
Plenaries, symposia, scientific overviews, oral abstract sessions, and themed discussions are available as webcasts. Webcasts are also available as streaming video for the Apple iPad and iPhone.
Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI webcasts. Webcasts will be available within 24 hours of the end of the relevant session.

Affiliated Activities Policy
The goal of CROI is to promote meaningful, high-level scientific interchange of ideas and debate in order to find better ways to prevent, treat, and cure HIV/AIDS. In keeping with this goal, organizations (commercial companies and their agents, not-for-profit groups, government agencies, etc) have been approved to host Affiliated Activities occurring outside CROI session times. Affiliated Activities are not sponsored by, endorsed by, or supported by the IAS—USA, the CROI Foundation, or CROI 2017.
If an affiliated activity is found to have violated the Guidelines for Affiliated Activities, the sponsoring organization, the supporting organization, and the organizer of the meeting may be prohibited from holding an Affiliated Activity at future CROI conferences and may have their current registration revoked by the IAS—USA, the CROI Foundation, or CROI 2017.
If you have organized a meeting or activity that includes CROI attendees, as described in the Affiliated Activity guidelines, and have not completed the Affiliated Activity application, please see an IAS—USA staff member in the IAS—USA office (room 603) for assistance.

Wi-Fi Access at the Conference
Complimentary Wi-Fi access is provided at the WSCC. Network information is as follows:
Network name: CROI2017
The Wi-Fi password will change daily to prevent devices from automatically connecting to the network. Limiting the number of concurrent devices will assist in maximizing the internet speeds for those devices actively in use. The password for each day of the conference are listed below, and are NOT case sensitive.

Monday password: monday2017
Tuesday password: tuesday2017
Wednesday password: wednesday2017
Thursday password: thursday2017

If you are having issues with Wi-Fi access, please contact an IAS—USA staff member. Additional Internet hotspots not located in the session rooms are listed in the Convention Center map on the back of the Program.

Conference Badges
Badge pickup is available at the registration lobby; please bring government-issued photo identification that clearly shows your name. You must wear your name badge to gain entry to all official meeting activities, including the poster sessions. DO NOT LOSE YOUR BADGE. Payment of US $850 will be required to replace a lost badge.
Child Care

Children are not permitted entry into any meeting room, including the poster area. If you should require child care, please contact the concierge of your hotel or the Visitor Information Center on Level 1 at the WSCC.

Conference Etiquette

In consideration of the work of presenters at CROI, and the CROI copyright policy, attendees should not photograph posters, record parts of talks, or post other people's data. Please ensure all cell phones and pagers are off or are set on SILENT mode. No photography is permitted in session rooms.

CROI HOTELS

Conference attendees are required to stay in one of the official conference hotels. The few exceptions to this include registrants who live in the Seattle area (ie, within a 50-mile radius of the WSCC) and registrants who are sharing a room with an approved CROI attendee with accommodations booked via the CROI housing system. Please inform the Conference Secretariat if you have inadvertently booked a hotel stay outside of the CROI housing system.

CROI 2017 hotels are listed below.

**Crowne Plaza Seattle Downtown**
1113 6th Avenue
Seattle, WA 98101
PH: 206-464-1980

**Motif Seattle**
1415 5th Avenue
Seattle, WA 98101
PH: 206-971-8000

**The Fairmont Olympic Hotel**
411 University Street
Seattle, WA 98101
PH: 206-621-1700

**Hyatt at Olive 8**
1635 8th Avenue
Seattle, WA 98101
PH: 206-685-1234

**Grand Hyatt Seattle**
721 Pine Street
Seattle, WA 98101
PH: 206-774-1234

**Renaissance Seattle Hotel**
515 Madison Street
Seattle, WA 98104
PH: 206-583-0300

**Hilton Garden Inn**
1821 Boren Avenue
Seattle, WA 98101
PH: 206-467-7770

**Sheraton Seattle Hotel**
1400 6th Avenue
Seattle, WA 98101
PH: 206-621-9000

**Hilton Seattle**
1301 6th Avenue
Seattle, WA 98101
PH: 206-624-0500

**W Seattle**
1112 4th Avenue
Seattle, WA 98101
PH: 206-264-6000

**Mayflower Park Hotel**
405 Olive Way
Seattle, WA 98101
PH: 206-623-8700

**The Westin Seattle**
1900 5th Avenue
Seattle, WA 98101
PH: 206-728-1000
# General Information

## Services

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seattle Visitor Center and</td>
<td>Upper Pike St. Lobby</td>
<td>Monday to Friday: 9:00 AM – 5:00 PM</td>
</tr>
<tr>
<td>Concierge Services</td>
<td>Level 1</td>
<td></td>
</tr>
<tr>
<td>Bag and Coat Check</td>
<td>Hall 4C-3, 4 Level 4</td>
<td>Monday: 8:00 AM – 10:30 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday: 7:30 AM – 8:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wednesday and Thursday: 7:30 AM – 6:30 PM</td>
</tr>
<tr>
<td>Cyber Cafe</td>
<td>4D Skybridge Level 4</td>
<td>Sunday: 3:00 AM – 5:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday to Wednesday: 7:30 AM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thursday: 7:30 AM – 6:00 PM</td>
</tr>
<tr>
<td>Bag and Coat Check</td>
<td>Hall 4C-3, 4 Level 4</td>
<td>Monday: 8:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Media Center</td>
<td>Room 400 Level 4</td>
<td>Sunday: 3:00 AM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday: 7:00 AM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td>Media Center</td>
<td>Room 400 Level 4</td>
<td>Sunday: 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday: 6:00 AM – 6:00 PM</td>
</tr>
<tr>
<td>Badge Pickup</td>
<td>Room 620 Level 6</td>
<td>Sunday: 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td>Attendee Services</td>
<td>Hall 4C-3, 4 Level 4</td>
<td>Sunday: 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td>Housing Information</td>
<td></td>
<td>Monday: 7:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Scholarship Badge Pickup</td>
<td></td>
<td>Tuesday: 7:00 AM – 6:00 PM</td>
</tr>
<tr>
<td>Media Badge Pickup</td>
<td></td>
<td>Wednesday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td>Speaker Ready Room</td>
<td>Room 620 Level 6</td>
<td>Sunday: 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td>Personal Considerations Room</td>
<td>Room 507 Level 5</td>
<td>Sunday: 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday: 9:00 AM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wednesday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thursday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td>New Mother’s Room</td>
<td>Room 416 Level 4</td>
<td>Sunday: 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday: 9:00 AM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wednesday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thursday: 8:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>
CONFERENCE SERVICES

Notes

Full-service concierge assistance, including maps, guides, tickets, restaurant reservations, tours, ground transportation, and personal services is available.

Bag and coat check are free of charge.

Computers with Internet access are available for webcasts and abstract searches.

There is no on-site press registration. Registered press can pick up press kits and obtain location for press conferences at this location.

Badges and conference materials can be picked up at this location.

Oral abstract, invited, and themed discussion session speakers must drop off presentations at least 24 hours before their presentation.

Poster presenters must submit an electronic version of their poster for placement on the CROI website by February 7, 2017.

The Personal Considerations Room is a room set aside for those who require a short-term private space for personal health needs. Use of this room is available on a first-come, first-served basis.

The New Mother’s Room is a room set aside for nursing mothers who require a short-term private room. Use of this room is available on a first-come, first-served basis.
CROI HOTELS
1. Sheraton Seattle Hotel
2. Crowne Plaza Seattle
3. The Fairmont Olympic Hotel
4. Grand Hyatt Seattle
5. Hilton Garden Inn
6. Hilton Seattle
7. Hyatt at Olive 8
8. Mayflower Park Hotel
9. Motif Seattle
10. Renaissance Seattle Hotel
11. W Seattle
12. The Westin Seattle
ABSTRACT PROCESS

Scientific Categories
A. Virology
B. Molecular Epidemiology and HIV/SIV Evolution
C. Pathogenesis: Human Studies and Animal Models
D. Host Immune Responses to Infection, Vaccines, and Immunotherapy
E. HIV Reservoirs, Latency, and All Curative Strategies Including Therapeutic Vaccines and Gene Therapy
F. Neuropathogenesis and CNS HIV Complications
G. Clinical Pharmacology
H. Antiretroviral Therapy: Pre-Clinical and Randomized Trials
I. Antiretroviral Therapy: Efficacy and Effectiveness Studies
J. HIV Drug Resistance
K. HIV Diagnostics
L. Hepatitis Viruses and Liver Complications
M. Malignancies
N. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy
O. Other Complications of HIV Infection and Antiretroviral Therapy
P. Tuberculosis and Other Opportunistic Infections
Q. Maternal/Fetal HIV
R. Pediatrics and Adolescents
S. Epidemiology
T. Prevention Interventions
U. Prevention Scale-Up
V. Contraceptive and Reproductive Health in Women
W. Implementation and Scale-Up of Treatment and Care
X. Population and Cost Modeling
Y. Emerging Viruses: Zika Virus

Abstract Content
Author names, institutions, abstract titles, and abstracts in the Program and Abstracts eBook are generally presented as submitted by the corresponding author.

Abstract Review Process
The PC and a panel of volunteer external reviewers reviewed approximately 2000 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise. PC members and external experts in the field reviewed the abstracts for the quality and originality of the work and scored them numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate. Scores ranged from 1 (definite oral presentation) to 5 (rejected).

Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores are identified and censored. Abstracts with high variability in scores were discussed individually during a series of conference calls. Abstracts were accepted for oral presentations, for poster presentations, or rejected. Late-breaking abstract reviews included an assessment of the late-breaking nature of the work (versus just being a late submission).
Common Reasons for Abstract Rejection
• Information is not new enough
• Methodology is inadequate or insufficient to support conclusions
• Background does not summarize the hypothesis
• Submission is poorly written
• Abstract is duplicative of other submissions
• Abstract is not appropriate for CROI
• Controls are absent or inadequate
• Statistical evaluation is inadequate or absent
• Summary of essential results is inadequate or absent
• Data are inadequate or insufficient to support conclusions
• Submission reports clinical trial and data from unplanned analysis or incomplete or ongoing studies
• Format does not follow guidelines (eg, section[s] missing, more than 1 graphic, table, or figure submitted)

Statistics for Abstracts
General abstract submitted ................................................. 1751
General abstracts accepted ................................................ 948
  General oral abstracts .................................................. 80
  General poster abstracts ................................................. 868
Late-breaking abstracts submitted .................................... 159
Late-breaking abstracts accepted ................................. 53
  Late-breaking oral abstracts ........................................... 16
  Late-breaking poster abstracts ....................................... 37
Total abstracts submitted .............................................. 1910
Total abstract accepted .................................................. 1001

All Authors on Accepted Abstracts

<table>
<thead>
<tr>
<th>Region</th>
<th>N</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td>265</td>
<td>14</td>
</tr>
<tr>
<td>Asia</td>
<td>99</td>
<td>5.2</td>
</tr>
<tr>
<td>Australia</td>
<td>35</td>
<td>1.8</td>
</tr>
<tr>
<td>Europe</td>
<td>432</td>
<td>22.5</td>
</tr>
<tr>
<td>Latin and South America</td>
<td>29</td>
<td>1.5</td>
</tr>
<tr>
<td>North America</td>
<td>1050</td>
<td>55</td>
</tr>
</tbody>
</table>

![Pie chart showing the distribution of accepted abstracts by region]
PRECONFERENCE SESSIONS

MONDAY, FEBRUARY 13, 2017

Workshop W1: PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

Ballroom 6AB  9:00 AM-12:15 PM

Target Audience: This workshop is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic). It is open to all CROI attendees, however.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for less than 3 years.

Conveners
John W. Mellors, Univ of Pittsburgh, Pittsburgh, PA, USA
Serena S. Spudich, Yale Univ, New Haven, CT, USA

1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

MOLECULAR VIROLOGY: ADVANCES IN THE UNDERSTANDING OF HIV-1
Paul Bieniasz, Howard Hughes Medical Center, New York, NY, USA

ADVANCES IN ANTIBODIES
Richard A. Koup, VRC, NIAID, NIH, Bethesda, MD, USA

ADVANCES IN HIV PREVENTION: NEW BIOMEDICAL AND BEHAVIORAL APPROACHES
James A. McIntyre, Anova Health Institute, Johannesburg, South Africa

HIV COMPLICATIONS: PERSISTENT THREAT OR A PROBLEM OF THE PAST?
Judith S. Currier, Univ of California Los Angeles, Los Angeles, CA, USA

HIV RESERVOIRS: OBSTACLES TO AN HIV CURE
Nicolas Chomont, Univ de Montréal, Montreal, QC, Canada
LUNCH AND MARTIN DELANEY PRESENTATION, FROM LAB TO LICENSURE: THE IMPORTANCE OF GOOD PARTICIPATORY PRACTICE IN RESEARCH
Room 6 AB 12:15 PM - 1:45 PM

Description: The Martin Delaney Presentation is held annually during the workshops for Young Investigators, International Investigators, and Community Educators in honor of pioneering HIV/AIDS activist Martin Delaney (1945–2009). It recognizes the important contributions of community advocacy and engagement in research.

Target Audience: This session is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators. Attendance is mandatory for all scholarship recipients. It is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for less than 1 year.

Objectives: After attending this presentation, participants will be able to:
• List the 6 fundamental principles of Good Participatory Practice (GPP)
• Explain the importance of GPP and describe several practical ways it can be implemented in current and future biomedical HIV treatment and prevention trials
• Explain why GPP principles are important and how they can be applied in future HIV cure research

Moderator
Mark Hubbard, Tennessee Association of People with AIDS, Nashville, TN, USA

HISTORY AND PRINCIPLES OF GOOD PARTICIPATORY PRACTICE GUIDELINES
Stacey Hannah, AIDS Vaccine Advocacy Coalition, New York, NY, USA

GPP AS A GUIDE TO BIOMEDICAL HIV PREVENTION TRIAL DESIGN AND IMPLEMENTATION
Deborah Baron, Wits RHI, Johannesburg, South Africa

APPLYING GPP PRINCIPLES TO CURE RESEARCH
David Evans, Project Inform, San Francisco, CA, USA
Workshop W2: CLINICAL TRIAL DESIGN AND ANALYSIS
Room 6 C  2:15 PM - 4:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies.

Level of Knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and basic HIV epidemiology.

Objectives: At completion of the session, participants will be able to:

- Provide examples of different study designs to assess efficacy of new prevention methods in the era of preexposure prophylaxis (PrEP)
- Describe approaches to designing and evaluating implementation science trials
- Evaluate strengths and limitations of respondent-driven sampling as a method for recruiting and understanding under-studied populations

Conveners
Susan P. Buchbinder, San Francisco Dept of PH, San Francisco, CA, USA
Richard Chaisson, The Johns Hopkins Univ, Baltimore, MD, USA

3  PREVENTION TRIAL DESIGN IN THE ERA OF PREP
Deborah J. Donnell, Fred Hutchinson Cancer Rsr Center, Seattle, WA, USA

4  IMPLEMENTATION SCIENCE TRIALS: DO THE RULES OF RCTS APPLY?
James R. Hargreaves, London Sch of Hygiene and Trop Med, London, United Kingdom

5  RESPONDENT DRIVEN SAMPLING & OTHER METHODS FOR RECRUITING HARD TO REACH POPULATIONS
Carl A. Latkin, The Johns Hopkins Univ, Baltimore, MD, USA

Workshop W3: FRONTIERS IN LABORATORY SCIENCE
Room 611-614  2:15 PM - 4:00 PM

Target Audience: This session is directed to students, researchers and clinicians who are interested in learning about the application of hot new technologies aimed at profiling the immune response to infection and the intracellular molecular mechanisms exploited by HIV during cellular infection.

Level of Knowledge: It is assumed that the participants are familiar with basic immunology and virology.

Objectives:

- Describe how the CRISPR/Cas9 system may be exploited to explore the molecular mechanisms underlying HIV infection
- Describe the role of RNA structure in HIV infection and latency
- Describe how high-dimensional time-of-flight mass spectrometry may be used to explore single cell immune profile dynamics during infection

Conveners
Galit Alter, Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Frank Kirchhoff, Ulm Univ Medical Center, Ulm, Germany

6  HIGH-THROUGHPUT GENOME ENGINEERING IN PRIMARY CD4+ T CELLS
Judd F. Hultquist, Univ of California San Francisco, San Francisco, CA, USA
IDENTIFYING AND PROFILING VIRUS-SPECIFIC T CELLS USING MASS CYTOMETRY
Evan William Newell, Singapore Immunol Network, Singapore, Singapore

QUANTIFYING HIV-1 MRNA STRUCTURE AND TRANSLATION EFFICIENCY IN CELLS
Silvi Rouskin, Whitehead Institute, Cambridge, MA, USA

Workshop W4: INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C
Room 6 E
2:15 PM - 4:00 PM

Target Audience: This session is directed to persons interested in the management of hepatitis C virus (HCV) infection.

Level of Knowledge: It is assumed that participants are familiar with the general principles of HCV treatment and the medications used.

Objectives: At completion of the session, participants will be able to:
• Recognize the limitations of current approaches to fibrosis staging
• Develop a framework for selection of HCV therapy
• Recognize common situations where resistance testing is indicated
• Recognize and manage common drug interactions with coinfection
• Recognize how treatment approaches differ for persons with cirrhosis

Conveners
Susanna Naggie, Duke Univ, Durham, NC, USA
David Wyles, Denver Health, Denver, CO, USA

SESSION DESCRIPTION: INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C

APPROACHES TO STAGING AND TREATMENT OF EARLY STAGE HCV
John D. Scott, Univ of Washington, Seattle, WA, USA

EFFECT OF RAVs ON DAA TREATMENT AND RE-TREATMENT OF PTS WITH CHRONIC HCV INFECTION
Alessandra Mangia, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

COMMON DRUG INTERACTIONS WITH HIV/HCV COINFECTION
Debika Bhattacharya, Univ of California Los Angeles, Los Angeles, CA, USA

CIRRHOSIS ISSUES
Sanjay Bhagani, Royal Free Hosp, London, United Kingdom
OPENING SESSION
Auditorium - 4 AB
5:00 PM - 7:00 PM

Session Hosts
Susan P. Buchbinder, CROI 2017 Chair
San Francisco Dept of PH, San Francisco, CA, USA

Judith S. Currier, CROI 2017 Vice Chair
Univ of California Los Angeles, Los Angeles, CA, USA

Richard A. Koup, CROI 2017 Vice Chair
VRC, NIAID, NIH, Bethesda, MD, USA

Bernard Fields Lecture
The Bernard Fields Lecture, named in tribute to the exemplary work of the esteemed microbiologist and virologist Bernard Fields, is given during the Opening Session, usually by a basic scientist recognized for his or her important and relevant contributions to the fields of virology and viral pathogenesis.

10 INSIGHTS INTO HIV PREVENTION, PATHOGENESIS AND TREATMENT FROM NONHUMAN PRIMATE MODELS
Jeffrey D. Lifson, Frederick National Laboratory for Cancer Research, Frederick, MD, USA

N’Galy-Mann Lecture
The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for his or her important and relevant work in the fields of epidemiology or clinical research. The Lecture is named in honor of Drs Bosenge N’Galy and Jonathan Mann for their crucial, pioneering work in HIV science in Africa.

11 HIV/AIDS RESEARCH IN ZIMBABWE: PROVIDING THE EVIDENCE FOR QUALITY CARE
James G. Hakim, University of Zimbabwe, Harare, Zimbabwe

CROI Foundation Special Event
Musical performance by Zimbabwean human rights activist Oliver Mtukudzi and his band, the Black Spirits.
TUESDAY, FEBRUARY 14, 2017

Plenary PL-1: TUESDAY PLENARY SESSION
Auditorium - 4 AB  8:30 AM - 9:30 AM

12  THE EMERGING POTENTIAL FOR HIV CURE FOR INFANTS, CHILDREN, AND ADULTS
  8:30
  Jintanat Ananworanich, US Military HIV Rsr Prog, USA and The Thai Red Cross AIDS Rsr Cntr, Thailand

13  ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV
  9:00
  Carl H. June, Univ of Pennsylvania, Philadelphia, PA, USA

Oral Abstract 0-1: GETTING HIV THROUGH THE CELL
Room 611-614  10:00 AM - 12:00 PM

Oral Abstract Moderators
Jaisri Lingappa, Univ of Washington, Seattle, WA, USA
John M. Coffin, Tufts Univ, Boston, MA, USA

14LB  QUATERNARY CONFIGURATION OF THE FUNCTIONAL CD4-BINDING SITE IN THE HIV-1 ENV TRIMER
  10:00
  Qingbo Liu1, Priyamvada Acharya1, Michael Dolan1, Peng Zhang1, Aliaksandr Druz2, William Rice3, Bridget Carragher3, Clinton Potter2, Peter D. Kwong3, Paolo Lusso1
  1NIH, Bethesda, MD, USA, 2New York Structural Bio Cntr, New York, NY, USA, 3NIAID, Bethesda, MD, USA

15  EARLY CYTOPLASMIC UNCOATING IS NECESSARY FOR INFECTIVITY OF HIV-1
  10:15
  João I. Mamede, Gianguido C. Cianci, Meegan R. Anderson, Thomas Hope Northwestern Univ, Chicago, IL, USA

16  ECCENTRIC VIRAL GENOMIC RNA AND INTEGRASE ARE PREMATURELY DEGRADED IN TARGET CELLS
  10:45
  Michaela Madison1, Dana Q. Lawson1, Jennifer Elliott1, Ayse N. Ozanturk2, Pratibha Chowdry Koneru1, James R. Fuchs3, Mamuka Kvaratskhelia3, Sebla B. Kutluay1
  1Washington Univ in St. Louis, St. Louis, MO, USA, 2Bilkent Univ, Ankara, Turkey, 3Ohio State Univ, Columbus, OH, USA

17  DYNAMICS OF NUCLEAR ENVELOPE ASSOCIATION AND NUCLEAR IMPORT OF HIV-1 COMPLEXES
  11:00
  Ryan C. Burdick, Jianbo Chen, Jaya Sastri, Wei-Shau Hu, Vinay K. Pathak NCI, Frederick, MD, USA

18  CYPA REGULATES HIV-1 ACCESS TO AN FG-GUIDED NUCLEAR ENTRY PATHWAY
  11:15
  Guangai Xue1, Vineet KewalRamani1, Shih Lin Goh1, Hyun Jae Yu1, Anna Gres2, KyeongEun Lee1, Stefan G. Sarafianos1, Jeremy Luban2
  1NCI, Frederick, MD, USA, 2Univ of Massachusetts, Worcester, MA, USA, 3Univ of Missouri, Columbia, MO, USA

19  A COMPREHENSIVE CRISPR SCREEN IDENTIFIES NOVEL HIV RESTRICTION FACTORS
  11:30
  Molly Ohainle, Louisa Pendergast, Jolien Vermeire, Michael Emerman Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA
20  A RETROTRANSPOSED ESCRT-III FACTOR BLOCKS HIV-1
BUDDING WITHOUT INDUCING CYTOTOXICITY
Lara Rheinemann, Diane Downhour, Gaelle Mercenne, Alesia McKeown,
John McCullough, Wes Sundquist, Nels Elde
Univ of Utah, Salt Lake City, UT, USA

21  DESIGNED PROTEINS INDUCE THE FORMATION OF
NANOCAGE-CONTAINING EXTRACELLULAR VESICLES
Joerg Votteler1, Cassie Ogohara2, Sue Yi2, Yang Hsia2, Una Nattermann2,
David M Belnap1, Neil P King2, Wes Sundquist1
1Univ of Utah, Salt Lake City, UT, USA, 2Univ of Washington, Seattle, WA, USA

Oral Abstract O-2: CRITICAL ISSUES IN WOMEN’S HEALTH, MTCT, AND
HIV TREATMENT IN CHILDREN
Room 606-609  10:00 AM - 12:00 PM

Oral Abstract Moderators
Mary Glenn Fowler, The Johns Hopkins Univ, Baltimore, MD, USA
Paolo Rossi, Children Hosp Bambino Gesù, Rome, Italy

22  RANDOMIZED TRIAL OFLEEP VS CRYOTHERAPY TO TREAT CIN2/3
IN HIV-INFECTED WOMEN
Sharon A. Greene1, Evans Nyongesa-Malava1, Barbra A. Richardson1,
Grace John-Stewart1, Hugo De Vuyst2, Nelly Yatich1, Catherine Kiptinness1,
Sameh Sakr1, Nelly Mugo1, Michael H. Chung1
1Univ of Washington, Seattle, WA, USA, 2Intl Agency for Rsr on Cancer, Lyon,
France, 3Coptic Hosp, Nairobi, Kenya, 4KEMRI, Nairobi, Kenya

23  NATURAL HISTORY OF CERVICAL INTRAEPITHELIAL
NEOPLASIA-2 AMONG HIV-INFECTED WOMEN
Christine Colie1, L. Stewart Massad2, Cuuiwei Wang1, Kate Michel1,
Gysamber D’Souza3, Joel Palefsky4, Howard Minkoff5, Howard D. Strickler6,
Seble Kassaye1
1Georgetown Univ, Washington, DC, USA, 2Washington Univ, St. Louis, MO,
USA, 3The Johns Hopkins Univ, Baltimore, MD, USA, 4Univ of California San
Francisco, San Francisco, CA, USA, 5Maimonides Med Cntr, Brooklyn, NY, USA,
6Albert Einstein Coll of Med, Bronx, NY, USA

24  INTEGRATION OF POSTNATAL SERVICES IMPROVES MCH AND
ART OUTCOMES: A RANDOMISED TRIAL
Landon Myer1, Tamsin Phillips3, Allison Zerbe2, Kirsty Brittain1, Stanzi M.
Le Roux1, Robert Remien2, Claude A. Mellins4, James A. McIntyre4, Elaine J.
Abrams2, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART)
study
1Univ of Cape Town, Cape Town, South Africa, 2Columbia Univ, New York, NY,
USA, 3New York State Psychiatric Inst, New York, NY, USA, 4Anova Hlth Inst,
Johannesburg, South Africa

25  ADVERSE BIRTH OUTCOMES DIFFER BY ART REGIMEN FROM
CONCEPTION IN BOTSWANA
Rebecca Zash1, Denise Jacobson1, Modiegi Diseko2, Gloria Mayondi1,
Mompati Mmalane1, Chipo Petlo1, Max Essex1, Shahin Lockman2, Joseph
Makhema1, Roger L. Shapiro2
1Beth Israel Deaconess Med Cntr, Boston, MA, USA, 2Harvard Univ, Boston, USA,
3Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, 4Ministry of
Hlth, Botswana, Gaborone, Botswana, 5Brigham and Women’s Hosp, Boston,
MA, USA
Oral Sessions • Tuesday
Program and Agenda
CROI 2017

26  11:00  EFFECT OF POINT-OF-CARE TESTING ON ANTIRETROVIRAL-
THERAPY INITIATION RATES IN INFANTS

Ilesh Jani1, Bindiya Meggi1, Osvaldo Loquiha2, Ocean Tobaiwa2, Chishamiso Mudenya2, Dadirayi Mutsaka2, Nedio Mabunda2, Adolfo Vubi1, Lara Vojnov, Trevor Peter4
1Instituto Nacional de Saude, Maputo, Mozambique, 2Clinton Hlth Access Initiative, Maputo, Mozambique

27  11:15  TREATMENT OF ACUTE HIV INFECTION IN NEONATES

Louise Kuhn1, Karl Technau2, Renate Strehlau2, Stephanie Shiau1, Faeezah Patel2, Gayle G. Sherman1, Caroline Tiemessen1, Grace M. Aldrovandi4, Ashraf Coovadia1, Elaine J. Abrams3
1Columbia Univ, New York, NY, USA, 2Empilweni Service and Rsr Unit, Johannesburg, South Africa, 3Nat Inst of Communicable Diseases, Johannesburg, South Africa, 4Univ of California Los Angeles, Los Angeles, CA, USA, 3ICAP at Columbia Univ, New York, NY, USA

28  11:30  RAPID DECLINE OF TOTAL HIV DNA IN CHILDREN STARTING ART
       WITHIN 8 DAYS OF BIRTH

Kirsten A. Veldsman1, Jean Maritz2, Shahieda Isaacs1, Mary Grace K. Katusiime1, Heleen la Grange1, Barbara Laughton1, John Mellors3, Mark Cotton2, Gert U. van Zyl1
1Stellenbosch Univ, Parow, South Africa, 2Stellenbosch Univ, Cape Town, South Africa, 3 Univ of Pittsburgh, Pittsburgh, PA, USA

29B  11:45  LOPINAVIR/RITONAVIR 1:1 SUPER-BOOSTING OVERCOMES
       RIFAMPICIN INTERACTIONS IN CHILDREN

Helena Rabie1, Paolo Denti2, Janice Lee3, Mhleli Masango4, Ashraf Coovadia1, Sandy Pillay1, Afaaf Liberty4, Helen Mcilleron2, Mark Cotton1, Marc Lallemant3
1Stellenbosch Univ, Cape Town, South Africa, 2Univ of Cape Town, Cape Town, South Africa, 3Drug for Neglected Diseases Initiative, Geneva, Switzerland, 4Univ of the Witwatersrand, Johannesburg, South Africa, 4Enhancing Care Foundation, Wentworth Hosp, Durban, South Africa

Oral Abstract O-3: HIDING IN PLAIN SIGHT: DISCOVERING THE UNDIAGNOSED AND UNDERTREATED HIV EPIDEMIC

Room 6 E
10:00 AM - 12:00 PM

Oral Abstract Moderators
Carlos del Rio, Emory Univ, Atlanta, GA, USA
Aleny Couto, Ministry of Health, Maputo, Mozambique

30  10:00  HIV INCIDENCE, PREVALENCE, AND UNDIAGNOSED INFECTIONS
        IN MEN WHO HAVE SEX WITH MEN

Sonia Singh, Ruiguang Song, Anna S. Johnson, Eugene McCray, Irene Hall
CDC, Atlanta, GA, USA

31  10:15  VIRAL-LOAD DYNAMICS AMONG PERSONS WITH DIAGNOSED HIV: UNITED STATES, 2014

Nicole Crepaz1, Tian Tang2, Gary Marks1, Irene Hall1
1CDC, Atlanta, GA, USA, 2ICF Intl, Atlanta, GA, USA
32 TIME SPENT WITH HIV VIRAL LOAD >1500 COPIES/ML AMONG PATIENTS IN HIV CARE, 2000-2014

Kate Buchacz1, Maria Mendoza1, Carl Armon1, Frank J. Palella1, Charles Rose1, Ellen Tedaldi1, Richard Novak1, Lytt Gardner1, for the the HIV Outpatient Study

1CDC, Atlanta, GA, USA, 2Cerner Corp, Kansas City, MO, USA, 3Northwestern Univ, Chicago, IL, USA, 4Temple Univ, Philadelphia, PA, USA, 5Univ of Illinois, Chicago, IL, USA

33 A RANDOMIZED TRIAL OF NOVEL STRATEGIES TO INCENTIVIZE HIV TESTING AMONG MEN IN UGANDA

Gabriel Chamie1, Elisabeth Schaffer1, Alex Nyabakira1, Alex Emperador1, Dalsone Kwarisima1, Diane V. Havlir1, James Kahn1, Moses R. Kamya1, Harsha Thirumurthy1

1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Makerere Univ and Univ of California San Francisco Rsr Collab, Mbarara, Uganda, 4Makerere Univ Joint AIDS Prog, Kampala, Uganda, 5Makerere Univ Coll of Hlth Scis, Kampala, Uganda

34LB COMBINATION HIV PREVENTION AND HIV INCIDENCE IN RAKAI, UGANDA

Mary K. Grabowski1, Gertrude Nakigozi2, Fred Nalugoda3, Thomas Quinn1, Godfrey Kigozi1, Ronald H. Gray1, David Serwadda1, Maria Wawer1, Steven J. Reynolds2, Larry W. Chang1

1The Johns Hopkins Univ, Baltimore, MD, USA, 2Rakai Health Sciences Prog, Kalisizo, Uganda, 3Makerere Univ, Kampala, Uganda, 4NIAID, Washington, DC, USA

35 NAMIBIA PILOTS SENTINEL POPULATION SURVEILLANCE OF HIV INCIDENCE AND VIRAL SUPPRESSION

Tuli Nakanyala1, Andrew D. Maher1, Nicholas Mutenda1, Karen M. Banda2, Anna Jonas1, Charity Ntema1, Ndapewa Hamunime1, David W. Lowrance2, Sadhna V. Patel5, Willi McFarland1

1Ministry of Hlth and Social Services, Windhoek, Namibia, 2Univ of California San Francisco, San Francisco, CA, USA, 3US CDC, Windhoek, Namibia, 4Development Aid from People to People, Windhoek, Namibia, 5CDC, Atlanta, GA, USA

36 SOCIAL NETWORKS AND HIV PREVALENCE IN KENYA IN THE SEARCH STUDY

Wenjing Zheng1, Norton Sang2, Gabriel Chamie1, Laura B. Balzer1, Craig Cohen1, Tamara D. Clark1, Edwin D. Charlebois1, Moses R. Kamya2, Diane V. Havlir1, Maya L. Petersen1

1Univ of California Berkeley, Berkeley, CA, USA, 2Kenya Med Rsr Inst, Nairobi, Kenya, 3Univ of California San Francisco, San Francisco, CA, USA, 4Harvard Univ, Boston, MA, USA, 5Makerere Univ Coll of Hlth Scis, Kampala, Uganda

37 HIGH RATE OF DISEASE PROGRESSION IN UNTREATED HIV-2 INFECTION

Joakim Esbjörnsson1, Fredrik Månsson1, Anders Kvist1, Zacarias J. da Silva1, Jacob Lindman1, Angelica Palm1, Marianne Jansson1, Patrik Medstrand1, Hans Norrgren1, for the SWEGUB CORE Group

1Univ of Oxford, Oxford, UK, 2Lund Univ, Malmö, Sweden, 3Lund Univ, Lund, Sweden, 4LNSP, Bissau, Guinea-Bissau
Oral Abstract O-4: NEW HIV DRUGS, FORMULATIONS, COMBINATIONS, AND RESISTANCE
Room 6 AB 10:00 AM - 12:00 PM

Oral Abstract Moderators
Sally Hodder, West Virginia Clinical and Translational Science Inst, Morgantown, WV, USA
Yazdan Yazdanpanah, Inserm, IAME, Paris, France

38  DISCOVERY OF NOVEL POTENT HIV CAPSID INHIBITORS WITH LONG-ACTING POTENTIAL
10:00
Gilead Scis, Inc, Foster City, CA, USA

39  HUMAN CONFIRMATION OF ORAL DOSE REDUCTION POTENTIAL OF NANOPARTICLE ARV FORMULATIONS
10:15
Andrew Owen1, Steve Rannard1, Akil Jackson2, Laura Dickinson1, Marco Giardiello1, Marco Siccredi1, Paul Domanico1, Melynda Watkins1, Yao Cheng2, Marta Boffito2
1Univ of Liverpool, Liverpool, UK, 2Chelsea and Westminster Hosp, London, UK

40  CLINICAL PHARMACOLOGY OF THE HIV INTEGRASE STRAND TRANSFER INHIBITOR BICTEGRAVIR
10:30
Heather Zhang, Joseph M. Custodio, Xuelian Wei, Hui Wang, Amanda Vu, John Ling, Hal Martin, Erin Quirk, Brian P. Kearney
Gilead Sci, Foster City, CA, USA

41  RANDOMIZED TRIAL OF BICTEGRAVIR OR DOLUTEGRAVIR WITH FTC/TAF FOR INITIAL HIV THERAPY
10:45
Paul E. Sax1, Edwin DeJesus2, Gordon Crofoot3, Douglas Ward4, Paul Benson5, Xuelian Wei6, Kirsten L. White6, Hal Martin6, Andrew Cheng6, Erin Quirk6
1Brigham and Women's Hosp, Boston, MA, USA, 2Orlando Immunol Cntr, Orlando, FL, USA, 3The Crofoot Rsr Cntr, Houston, TX, USA, 4Dupont Circle Physicians Group, Washington, DC, USA, 5Be Well Med Cntr, Berkley, MI, USA, 6Gilead Scis, Inc, Foster City, CA, USA

42  PATHWAYS OF RESISTANCE IN SUBJECTS FAILING DOLUTEGRAVIR MONOTHERAPY
11:00
José L. Blanco, Celia Oldenbuettel, Réjean Thomas, Josep Mallolas, Eva Wolff, Bluma Brenner, Christoph D. Spinner, Mark A. Winberg, Esteban Martinez, for the Redo Group
1Hosp Clinic Barcelona, Barcelona, Spain, 2MVZ Karlsplatz, HIV Rsr and Clinical Care Cntr, München, Germany, 3Clinique Médicale l’Actuel, Montreal, QC, Canada, 4MUC Rsr, Munich, Germany, 5McGill Univ, Montreal, Quebec, Canada, 6Univ Hosp Klinikum Rechts der Isar, Munich, Germany

43  PREVALENCE AND IMPACT OF PRETREATMENT DRUG RESISTANCE IN THE ANRS 12249 TASP TRIAL
11:15
Anne Derache, Collins C. Iwuji, Siva Danaviah, Anne- Geneviève Marcelin, Vincent Calvez, Tulio de Oliveira, François Dabis, Deenan Pillay, for the ANRS 12249 Treatment as Prevention
1Africa Hlth Rsr Inst, Mbubutu, South Africa, 2Univ Coll London, London, UK, 3Pitie-Salpetriere Hosp, Paris, France, 4Univ of KwaZulu-Natal, Durban, South Africa, 5Univ de Bordeaux, Bordeaux, France
38  CROI 2017

44LB  PHASE III SWORD 1&2: SWITCH TO DTG+RPV MAINTAINS VIROLOGIC SUPPRESSION THROUGH 48 WKS
10:30

Josep M. Llibre1, Chien-Ching Hung2, Cynthia Brinson3, Francesco Castelli4, Pierre-Marie Girard5, Lesley Kahl6, Elizabeth Blair7, Brian Wynn8, Kati Vandermeulen9, Michael Aboud10
1Univ Hosp Germans Trias, Badalona, Barcelona, Spain, 2Natl Taiwan Univ Hosp, Taipei, Taiwan, 3Central Texas Clinical Rsr, Austin, TX, USA, 4ASST Spedali Civili di Brescia, Brescia, Italy, 5Saint-Antoine Hosp, Paris, France, 6ViiV Hlthcare, Brentford, Middlesex, UK, 7ViiV Hlthcare, Rsr Triangle Park, NC, USA, 8ViiV Hlthcare, Collegeville, PA, USA, 9Janssen, Beerse, Belgium

45LB  DORAVIRINE IS NON-INFERIOR TO DARUNAVIR/R IN PHASE 3 TREATMENT-NAÏVE TRIAL AT WEEK 48
11:45

Jean-Michel Molina1, Kathleen Squires2, Paul E. Sax3, Pedro Cahn1, Johan Lombaard1, Edwin DeJesus4, Xia Xu1, Bach-Yen T. Nguyen5, George Hanna6, Carey Hwang7
1Hosp St Louis, Paris, France, 2Thomas Jefferson University, Philadelphia, PA, USA, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, 4Fundación Huesped, Buenos Aires, Argentina, 5Joshua Research, Bloemfontein, South Africa, 6Orlando Immunology Center, Orlando, FL, USA, 7Merck & Co, Inc, Kenilworth, NJ, USA

Themed Discussion TD-1: CD8 T CELLS: WHERE AND HOW THEY KILL Room 615-617 1:30 PM - 2:30 PM

Themed Discussion Leader
Nicole Frahm, FHCRC, Seattle, WA, USA

266  LYMPH NODE HIV-SPECIFIC CXCR5+ CTLS ARE ASSOCIATED WITH ENHANCED VIRAL CONTROL

Zaza Ndhlovu1, Funsho Gunshola2, Omolara Baiyegunhi2, Nikoshia Mewatali1, Amber Moodley1, Krista Dong1, Thumbi Ndungu1, Bruce D. Walker1
1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, 2Univ of KwaZulu Natal, Durban, South Africa

267  RESIDENT MEMORY CD8+ T CELLS FORM THE FRONT-LINE DEFENSE IN HIV-INFECTED LYMPH NODES

Marcus Buggert1, Lalit Beura2, Son Nguyen1, David Canaday1, Ali Najib1, Constantinos Petrovas1, Gustavo Reyes-Terán1, Steven G. Deeks1, David Masopust1, Michael R. Betts2
1Univ of Pennsylvania, Philadelphia, PA, USA, 2Univ of Minnesota, Minneapolis, MN, USA, 3Case Western Reserve Univ, Cleveland, OH, USA, 4Hosp of the Univ of Pennsylvania, Philadelphia, PA, USA, 5NIH, Bethesda, MD, USA, 6Rsr Cntr in Infectious Diseases, Mexico City, Mexico, 7Univ of California San Francisco, San Francisco, CA, USA

268  HIV-1 ESCAPE FROM CD8+ CYTOTOXIC T-LYMPHOCYTES DEFINED AT CLONAL RESOLUTION

Aleksandr Gorin1, Yushen Du, Ren Sun, Otto Yang
Univ of California Los Angeles, Los Angeles, CA, USA

269  INVESTIGATING THE ROLE OF TCR STRUCTURE IN FUNCTIONAL ACTIVITY OF HIV-SPECIFIC CTLs

Nina C. Flerin1, Tynisha Glover1, Huabiao Chen1, Jianhua Zheng1, Harris Goldstein1
1Albert Einstein Coll of Med, Bronx, NY, USA, 2Ragon Inst of Massachusetts General Hosp, Cambridge, MA, USA
HIV-SPECIFIC CD8 T CELLS IN PERSONS TREATED IN FIEBIG I ACUTE INFECTION WHO STOP ART

Hiroshi Takata¹, Donn Colby², Eugene Kroon³, Suteeaporn Pinyakorn⁴, Nelson L. Michael⁵, Merlin L. Robb⁶, Jintana Intasan⁷, Jintanat Anaworanch⁷, Lydie Trautmann⁷, for the RV411 and RV254/SEARCH010 Study Groups

¹Walter Reed Army Inst of Rsr, Silver Spring, MD, USA, ²SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ³Walter Reed Army Inst of Rsr, Silver Spring, MD, USA, ⁴US Military HIV Rsr Prog, Silver Springs, MD, USA

Themed Discussion TD-2: VIRUS AND CELL RNA IN HIV REPLICATION
Room 611-614 1:30 PM - 2:30 PM

Themed Discussion Leader
Kate Bishop, The Francis Crick Inst, London, UK

161 UBP43 (USP18) ABROGATES SAMHD1-MEDIATED RESTRICTION OF HIV-1

Edmund Osei-Kuffour¹, Kerstin Schott¹, Dieter Häussinger¹, Philipp A. Lang¹, Karl S. Lang¹, Renate König¹, Carsten Münk¹

¹Heinrich Heine Univ Hosp, Düsseldorf, Germany, ²Paul Ehrlich Institut, Fed Inst for Vaccines and BioMeds, Düsseldorf, Germany, ³Univ Hosp, Essen, Düsseldorf, Germany, ⁴Paul Ehrlich Institut, Langen, Germany

162 LNCRNA DISCOVERY IN THE HIV REPLICATION CYCLE ADDS A NEW LAYER IN HIV-Host INTERPLAY

Wim Trypsteen¹, Pejman Mohammadi¹, Clarissa Van Hecke¹, Pieter Mestdagh¹, Steve Lefever¹, Pieter De Blaser¹, Jo Vandesompele¹, Angela Ciuffi¹, Ward De Spieglaelare¹, Linos Vandekerckhove¹

¹Ghent Univ, Ghent, Belgium, ²Univ of Lausanne, Lausanne, Switzerland, ³Inflammation Rsr Cntr, Flanders Inst of BioTech, Ghent, Belgium

163 SPLICING IN A PANEL OF HIV-1 TRANSMITTED/FOUNDER VIRUSES

Ann Emery, Ronald Swanstrom
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

164 THE ROLES OF 5 CONSERVED LENTIVIRAL RNA STRUCTURES IN HIV-1 REPLICATION

Yang Liu¹, Olga A. Nikolaitchik¹, Belete A. Desimmie¹, Vinay K. Pathak¹, Kevin M. Weeks¹, Wei-Shau Hu¹

¹NCI, Frederick, MD, USA ²Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

165 EXPONENTIAL GROWTH OF HIV DEPENDENT ON BURST SIZE BREAKTHROUGH OF THE ALLEE THRESHOLD

Jason M. Hataye¹, Joseph P. Casazza², David R. Ambrozak¹, Takuya Yamamoto², Daniel Douek³, Alan S. Perelson⁴, Richard A. Koup⁵

¹NIH, Bethesda, MD, USA, ²Osaka Univ, Sutka, Osaka, Japan, ³NIAID, Bethesda, MD, USA, ⁴Los Alamos Natl Lab, Los Alamos, NM, USA
Oral Sessions • Tuesday
Program and Agenda
CROI 2017

Themed Discussion TD-3: HIV, MIGRATION, AND ACCESS TO CARE
Room 606-609
1:30 PM - 2:30 PM

Themed Discussion Leader
Andrea Howard, Columbia Univ, New York, NY, USA

1015 MIGRATION, GENDER, AND HIV INCIDENCE IN RAKAI, UGANDA
Oluwasolape M. Olawore1, Aaron Tobian2, Fred Nalugoda2, Ronald H. Gray1, Maria Wawer1, Robert Seекубугу2, John Santelli2, Larry W. Chang2, David Serwadda3, Kate Grabowski1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Rakai Hlth Scis Prog, Kalisizo, Uganda, 3Columbia Univ, New York, NY, USA, 4Makerere Univ, Kampala, Uganda

1016 OUTCOMES ALONG THE HIV CARE CONTINUUM AMONG UNDOCUMENTED IMMIGRANTS IN CLINICAL CARE
Jonathan Ross, Uriel Felsen, Chinazo Cunningham, Viraj V. Patel, David B. Hanna
Albert Einstein Coll of Med, Bronx, NY, USA

1017 IMMIGRANTS AND BOTSWANA’S ART PROGRAM: POTENTIAL BARRIERS TO EPIDEMIC CONTROL
Tafireyi Marukutira1, Mary Grace Alwano1, Stephanie Behel1, Joseph N. Jarvis1, Unoda Chakalisa2, Kathleen Powis1, William Bapati1, Gene Ussery6, Refeletswe Lebelonyane3, Pamela J. Bachanas3
1US CDC, Gaborone, Botswana, 2CDC, Atlanta, GA, USA, 3Botswana Harvard Partnership, Gaborone, Botswana, 4Harvard Univ, Boston, MA, USA, 5Tebelopele Voluntary Counseling and Testing Cntr, Gaborone, Botswana, 6Northrop Grumman Corporation, Atlanta, GA, USA, 7Botswana Ministry of Hlth, Gaborone, Botswana

1018 CASCADE OF CARE OF HIV SEROCONVERTERS IN THE CONTEXT OF UNIVERSAL “TEST AND TREAT”
Joseph Larmarange1, Mamadou H. Diallo1, Collins C. Iwuji2, Joanna Orne-Gliemann1, Nuala McGrath1, Mélanie Plazy1, Frank Tanser2, Rodolphe Thiébaut1, Deenan Pillay3, François Dabis5
1IRD, Paris, France, 2Univ Coll London, UK, London, UK, 3INSERM, Bordeaux, France, 4Univ of Southampton, Southampton, UK, 5Africa Hlth Rsr Inst, Mtubatuba, South Africa, 6Univ de Bordeaux, Bordeaux, France

Themed Discussion TD-4: OBESITY AND FATTY LIVER DISEASE
Room 6 C
1:30 PM - 2:30 PM

Themed Discussion Leader
John Koethe, MD, Vanderbilt University Medical Center, Nashville, TN, USA

693 BODY MASS INDEX AND THE RISK OF SERIOUS NON-AIDS EVENTS: THE D:A:D STUDY
Amit C. Achhra1, Caroline Sabin1, Lene Ryom1, Antonella d’Arminio Monforte1, Stephane de Wit2, Andrew Phillips1, Christian Pradier2, Jens D. Lundgren3, Matthew Law1, for the the DAD Study Group
1Kirby Inst, Sydney, Australia, 2Univ Coll London, London, UK, 3CHIP, Copenhagen, Denmark, 4Univ of Milan, Milan, Italy, 5Univ Libre de Bruxelles, Brussels, Belgium, 6Nice Univ Hosp, Nice, France, 7Univ of Copenhagen, Copenhagen, Denmark
694 RANDOMIZED TRIAL OF BEHAVIORAL WEIGHT LOSS FOR HIV-INFECTED PATIENTS

Katie Becofsky1, Edward J. Wing2, Jeanne McCaffery3, Matthew Boudreau1, Rena R. Wing1

1Univ of Massachusetts Amherst, Amherst, MA, USA, 2Brown Univ, Providence, RI, USA, 3The Miriam Hosp, Providence, RI, USA

695 PREDICTORS OF SEVERE WEIGHT/BODY MASS INDEX GAIN FOLLOWING ANTIRETROVIRAL INITIATION

Priya Bhagwat1, Igho Ofotokun2, Grace A. McComsey3, Todd Brown4, Carlee Moser5, Catherine A. Sugar1, Judith S. Currier1

1Univ of California Los Angeles, Los Angeles, CA, USA, 2Emory Univ, Atlanta, GA, USA, 3Case Western Reserve Univ, Cleveland, OH, USA, 4The Johns Hopkins Univ, Baltimore, MD, USA, 5Harvard Univ, Boston, MA, USA

696 RALTEGRAVIR SWITCH AND BIOMARKERS OF LIVER STEATOSIS AND METABOLIC SYNDROME IN WOMEN

David Reynoso1, Anoma Somasunderam1, Maitreyee Nigalye1, Judith S. Currier2, Netanya S. Utay1, Jordan E. Lake1

1Univ of Texas Med Branch at Galveston, Galveston, TX, USA, 2Univ of California Los Angeles, Los Angeles, CA, USA, 3Univ Texas Houston, Houston, TX, USA

697 CHANGES IN LIVER STEATOSIS AFTER SWITCHING EFAVIRENZ TO RALTEGRAVIR: THE STERAL STUDY

Juan Macías1, Dolores Merino2, Francisco Téllez3, Federico Pulido4, Juan González-García5, Manuel Marquez6, Antonio Rivero7, Maria Mancebo1, Juan A. Pineda1, for the RIS-HEP09

1Hosp Univ de Valme, Sevilla, Spain, 2Complejo Hospario Univ de Huelva, Huelva, Spain, 3Hosp Univ de Puerto Real, Cádiz, Spain, 4Hosp 12 de Octubre, Madrid, Spain, 5Hosp Univ La Paz, Madrid, Spain, 6Hosp Virgen de la Victoria, Málaga, Spain, 7Hosp Univ Reina Sofia, Cordoba, Spain

Themed Discussion TD-5: PREP WITHOUT BORDERS: NEW DELIVERY OPTIONS

Room 6 E
1:30 PM - 2:30 PM

Themed Discussion Leader
Aaron Siegler, Emory Univ, Atlanta, GA, USA

961 FEASIBILITY OF A PHARMACIST-RUN HIV PREP CLINIC IN A COMMUNITY PHARMACY SETTING

Elyse Tung1, Annalisa Thomas1, Allyson Eichner1, Peter Shalit2

1Kelley-Ross Pharm, Seattle, WA, USA, 2Univ of Washington, Seattle, WA, USA

962 ASSESSING THE EFFICACY AND FEASIBILITY OF A RETAIL PHARMACY-BASED HIV TESTING PROGRAM

Bryan C. Collins, Heather W. Bronson, Elaine G. Martin

Virginia Dept of Hlth, Richmond, VA, USA

963 MIDWEST PHARMACISTS’ KNOWLEDGE OF & WILLINGNESS TO PROVIDE PREEXPOSURE PROPHYLAXIS

Jordan Broekhuis, Kimberly K. Scarsi, Harlan Sayles, Donald Klepser, Joshua Havens, Susan Swindells, Sara H. Bares

Univ of Nebraska, Omaha, NE, USA

964 TEXT MESSAGING IS ASSOCIATED WITH IMPROVED RETENTION IN A CLINIC-BASED PREP PROGRAM

Christine M. Khosropour1, Richard T. Lester1, Matthew R. Golden1, Julia C. Dombrowski1

1Univ of Washington, Seattle, WA, USA, 2Univ of British Columbia, Vancouver, British Columbia, Canada
965  BRIEF BEHAVIORAL INTERVENTION INCREASES PREP DRUG LEVELS IN A REAL-WORLD SETTING
Sarit A. Golub1, Stephanie Pena2, Amy Hilley3, John Pachankis4, Asa Radix2
1City Univ of New York, New York, NY, USA, 2Callen-Lorde Community Hlth Cntr, New York, NY, USA, 3Hunter HIV/AIDS Rsr Team, New York, NY, USA, 4Yale Univ, New Haven, CT, USA

Symposium S-1 VISIONS OF HIV CURE
Room 6 E  4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the mechanisms of HIV persistence during antiretroviral therapy and the novel strategies developed to cure HIV infection or at least reduce the size of the viral reservoir.

Level of Knowledge: It is assumed that the participants are familiar with the concept of viral reservoirs, HIV latency and cure strategies.

Objectives: At the completion of the session, participants will be able to:

• Describe the methods used to identify and quantify persistently infected cells during antiretroviral therapy
• Evaluate the potential of novel curative strategies
• Describe the mechanism by which an immune intervention (vaccine, immune checkpoint blockers) may reduce the size of the viral reservoir

Conveners
R. Brad Jones, George Washington Univ, Washington, DC, USA
Sharon Lewin, Univ of Melbourne, Melbourne, Australia

46  VISUALIZING PERSISTENT HIV IN CLINICAL SAMPLES
4:00  Daniel E. Kaufmann, Univ of Montreal, Montreal, QC, Canada

47  CHARACTERIZING HIV EXPRESSION IN VIVO
4:30  Mary F. Kearney, NCI, NIH, Frederick, MD, USA

48  IMMUNE-BASED INTERVENTIONS TARGETING INFLAMMATION AND VIRAL PERSISTENCE
5:00  Mirko Paiardini, Emory Univ Sch of Med, Atlanta, GA, USA

49  THERAPEUTIC VACCINATION FOR HIV/SIV: WHAT WILL IT TAKE FOR CURE?
5:30  Louis J. Picker, Oregon Hlth & Sci Univ, Beaverton, OR, USA
Room 606-609  4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and researchers interested in the pathogenesis, clinical manifestations, diagnosis, treatment and prevention of tuberculosis (TB) and its complications, including HIV and TB co-infection.

Level of knowledge: It is assumed that participants are familiar with basic TB biology, epidemiology, clinical features and treatment.

Objectives: At the completion of the session, participants will be able to:
- Describe the epidemiology of and factors associated with transmission of multidrug resistant TB (MDR-TB)
- Identify appropriate regimens utilizing new and investigational drugs for treatment of MDR-TB, including the challenges associated with their use in children
- Assess the role of new and existing technologies for diagnosis of MDR-TB

Conveners
Constance Benson, Univ of California San Diego, San Diego, CA, USA
Roxana Rustomjee, NIAID, NIH, DHHS, Rockville, MD, USA

50  MDR-TB EPIDEMIOLOGY AND TRANSMISSION DYNAMICS
4:00  N. Sarita Shah, CDC, Atlanta, GA, USA

51  EMERGING TREATMENT ISSUES IN MDR-TB
4:30  Francesca Conradie, Univ of the Witswatersrand, Johannesburg, South Africa

52  NEW DIAGNOSTIC TECHNOLOGIES FOR MDR-TB
5:00  Catharina C. Boehme, Fndn for Innovative New Diagnostics (FIND), Geneva, Switzerland

53  THE CHALLENGES OF TREATING MDR-TB IN CHILDREN
5:30  H. Simon Schaaf, Stellenbosch Univ, Cape Town, South Africa
Symposium S-3 STRANGERS IN THE NIGHT: CHALLENGES AND OPPORTUNITIES IN STI CONTROL
Room 6 C  4:00 PM - 6:00 PM

Target audience: This session is directed to clinicians and scientists who are interested in understanding the prevention and management of sexually transmitted infections, and their relationship to HIV.

Level of knowledge: It is assumed that the participants are familiar with basic HIV and STI epidemiology.

Objectives:
At the completion of the session, participants will be able to:
• Describe the role of the vaginal microbiome in susceptibility of HIV acquisition
• Discuss strategies for prevention of sexually transmitted infections
• Identify the promise of point of care tests for sexually transmitted infections

Conveners
Deborah Money, Univ of British Columbia, Vancouver, BC, Canada
Arlene Sena, Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

54  VAGINAL MICROBIOME AND SUSCEPTIBILITY TO HIV
4:00  R. Scott McClelland, Univ of Washington, Seattle, WA, USA

55  ANTIBIOTIC PROPHYLAXIS FOR STIs: PROMISES OR PERILS
4:30  Jean-Michel Molina, Univ of Paris Diderot, Paris, France

56  SYPHILIS IN THE ERA OF TREATMENT AS PREVENTION AND PRE-EXPOSURE PROPHYLAXIS
5:00  Matthew R. Golden, Univ of Washington, Seattle, WA, USA

57  SCALE-UP OF POINT-OF-CARE TESTS FOR SEXUALLY TRANSMISSIBLE INFECTIONS
5:30  Rebecca J. Guy, Kirby Inst, Univ of New South Wales, Sydney, Australia
WEDNESDAY, FEBRUARY 15, 2017

Plenary PL-2 WEDNESDAY PLENARY SESSION
Auditorium - 4 AB 8:30 AM - 9:30 AM

58 8:30 (PREVENTING) THE COMING EPIDEMIC: HIV IN YOUTH
Shannon L. Hader, CDC, Atlanta, GA, USA

59 9:00 ANTIVIRAL VACCINE DEVELOPMENT FROM A (AIDS) TO Z (ZIKA)
Barney S. Graham, NIAID, VRC, NIH, Bethesda, MD, USA

Oral Abstract O-5 ROLE OF HOST AND IMMUNE FACTORS IN HIV INFECTION
Room 611-614 10:00 AM - 12:00 PM

Oral Abstract Moderators
Michael Betts, Univ of Pennsylvania, Philadelphia, PA, USA
Irini Sereti, NIAID, Bethesda, MD, USA

60 10:00 IMMUNE CORRELATES OF HIV ACQUISITION
Krystelle Ngalou Makamdop1, Slim Fourati2, Jianfei Hu3, Amy Ransier3, Farida Laboune1, Rafick-Pierre Sekaly4, Daniel Douek1
1NIAID, Bethesda, MD, USA, 2Case Western Reserve Univ, Cleveland, OH, USA

61 10:15 MARKED CHANGES IN CELLULAR BUT NOT VIRUS TRANSCRIPTOME IN CD4-LOW HIV-INFECTED CELLS
Joseph P. Casazza1, Eli Boritz2, David R. Ambrozak2, Amy R. Henry2, Farida Laboune2, Sam Darko1, Jianfei Hu3, Christine Grech2, Daniel Douek2, Richard A. Koup2
1NIH, Bethesda, MD, USA, 2VRC, NIAID, Bethesda, MD, USA

62LB 10:30 SINGLE CELL TRANSCRIPTIONAL PROFILING REVEALS A NOVEL POPULATION OF MUCOSAL TFH CELLS
Andrew R. Rahmberg1, Preema A. Rajakumar1, James M. Billingsley2, Surinder P. Gill1, R. Paul Johnson1
1Emory Univ, Atlanta, GA, USA, 2Yerkes Natl Primate Rsr Cntr, Decatur, GA, USA

63 10:45 HIGH HIV PERMISSIVITY OF T FOLLICULAR REGULATORY CELLS IS RELATED TO Ki67 EXPRESSION
Shannon Miller1, Brodie Miles1, Joy Folkvord2, Amie Meditz1, Martin McCarter1, Mario Santiago1, David N. Levy4, Samantha MaWhinney4, Elizabeth Connick2
1Univ of Colorado Denver, Aurora, CO, USA, 2Univ of Arizona, Tucson, AZ, USA, 3Boulder Community Hosp, Boulder, CO, USA, 4New York Univ Coll of Dentistry, New York, NY, USA

64LB 11:00 VIRION INCORPORATION OF INTEGRIN α4β7: IMPLICATIONS FOR HIV-1 PATHOGENESIS
Christina Guzzo, David Ichikawa, Chung Park, Cathy Rehm, Claudia Cicala, James Arthos, Anthony S. Fauci, John Kehrl, Paolo Lusso
NIAID, Bethesda, MD, USA
DEFINING THE NATURE OF CD8+ T-CELL RESPONSES IN LYMPH NODES OF HIV ELITE CONTROLLER
Son Nguyen1, Marcus Buggert1, Ali Naji2, Perla Del Rio-Estrada3, Gustavo Reyes-Terán1, Steven G. Deeks4, Michael R. Betts1
1Univ of Pennsylvania, Philadelphia, PA, USA, 2Hosp of the Univ of Pennsylvania, Philadelphia, PA, USA, 3Rsr Cntr in Infectious Diseases, Mexico City, Mexico, 4Univ of California San Francisco, San Francisco, CA, USA

HIV-SPECIFIC BINDING ANTIBODY PROFILES ASSOCIATED WITH BROADLY NEUTRALIZING ACTIVITY
Claus Kadelka, Thomas Liechti, Hanna Ebner, Peter Rusert, Roger Kouyos, Huldrych F. Günthard, Alexandra Trkola
Univ of Zurich, Zurich, Switzerland

THE IMPACT OF HIV-GENETICS ON IMPRINTING ANTIBODY RESPONSES: THE SWISS 4.5K SCREEN
Roger Kouyos, Peter Rusert, Claus Kadelka, Alex Marzel, Thomas Liechti, Merle Schanz, Hanna Ebner, Huldrych F. Günthard, Alexandra Trkola, for the Swiss HIV Cohort Study
Univ of Zurich, Zurich, Switzerland

Oral Abstract 0-6 CNS RESERVOIRS, NEUROPATHOGENESIS, AND HOST FACTORS
Room 606-609 10:00 AM - 12:00 PM

INTENSITY OF SUPPRESSION LINKED WITH SHIFTING COMPARTMENTALIZATION OF CNS HIV DNA
Benjamin B. Gelman1, Joshua G. Lisinicchia1, Lalita D. Singh1, Vipulkumar N. Patel1, Alexander J. Gill2, Colleen E. Kovacsics2, Dennis L. Kolson2
1Univ of Texas Med Branch, Galveston, TX, USA, 2Univ of Pennsylvania, Philadelphia, PA, USA

CNS PARENCHYMA AND CHOROID PLEXUS, NOT CSF, ARE VIRAL RESERVOIRS IN MONKEYS WITH AIDS
Jaclyn Mallard1, Brittany Rife1, Emily Papazian1, Arianna Noggle1, David J. Nolan2, Marco Salemi2, Kenneth C. Williams1
1Boston Coll, Chestnut Hill, MA, USA, 2Univ of Florida, Gainesville, FL, USA

EARLY MACROPHAGE-INDEPENDENT INFLAMMATION AND SHIV-RNA IN CNS IN A RHESUS SHIV MODEL
Denise C. Hsu1, Piyanate Sunyakumthorn2, Matthew Wegner2, Jacob D. Estes3, Claire Deleage3, Robert J. O’Connell2, Victor Valcour4, Serena Spudich3, Nelson L. Michael3, Sandhya Vasan1
1US Military HIV Rsr Prog, Bangkok, Thailand, 2Armed Forces Rsr Inst of Med Scis, Bangkok, Thailand, 3Frederick Natl Lab for Cancer Rsr, Leidos Biomed Rsr Inc, Frederick, MD, USA, 4Univ of California San Francisco, San Francisco, CA, USA, 5Yale Univ, New Haven, CT, USA, 6US Military HIV Rsr Prog, Silver Spring, MD, USA
71 10:45 DEEP SEQUENCING REVEALS RARE CNS COMPARTMENTALIZATION IN ACUTE HIV-1 INFECTION
Rujipas Sirijatuphat1, James L. Fletcher2, Eric Sanders-Buell3, Jintanat Ananworanich1, Nelson L. Michael1, Victor Valcour4, Sodsai Tovanabutra3, Gustavo Kijak5, Serena Spudich6, for the RV254/SEARCH 010 Team and MHRP Viral Sequencing Core
1Mahidol Univ, Bangkok, Thailand, 2South East Asia Rsr Collab with Hawaii (SEARCH), Bangkok, Thailand, 3US Military HIV Rsr Prog, Silver Spring, MD, USA, 4Univ of California San Francisco, San Francisco, USA, 5Yale Univ, New Haven, CT, USA

72 11:00 CD4/CD8 RATIO ASSOCIATES WITH NEUROPSYCHOLOGIC PERFORMANCE DURING EARLY HIV INFECTION
Leah T. Le7, Kevin Robertson1, Brinda Emu1, Richard W. Price7, Magnus Gisslen8, Henrik Zetterberg9, Roxane Fabre9, Christian Pradier10, Serena Spudich1, Matteo Vassallo11
1Yale Univ, New Haven, CT, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Univ of California San Francisco, San Francisco, CA, USA, 4Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, 5Univ de Nice-Sophia Antipolis, Nice, France, 6Cntr Hosp de Cannes, Cannes, France

73 11:15 ASYMPTOMATIC HIV-1 CSF ESCAPE IS UNCOMMON AND IS NOT ASSOCIATED WITH NEURONAL DAMAGE
Sarah Beth Joseph1, Laura P. Kincer1, Natalie M. Bowman1, Henrik Zetterberg2, Magnus Gisslen2, Kevin Robertson1, Serena Spudich1, Joseph J. Eron1, Richard W. Price1, Ronald Swanstrom2
1Univ of North Carolina Chapel Hill, Chapel Hill, NC, USA, 2Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, 3Yale Univ, New Haven, CT, USA, 4Univ of California San Francisco, San Francisco, CA, USA

74 11:30 GENETIC VARIATION IN EIF2AK3 IS ASSOCIATED WITH NEUROCOGNITIVE IMPAIRMENT IN HIV
Scott Letendre1, Cagla Akay-Espinoza2, Ajay Bharti1, Peilin Jia3, Asha R. Kallianpur4, Donald Franklin5, Gerard D. Schellenberg1, Robert K. Heaton1, Igor Grant6, Kelly L. Jordan-Sciutto2
1Univ of California San Diego, San Diego, CA, USA, 2Univ of Pennsylvania, Philadelphia, PA, USA, 3Univ of Texas Houston, Houston, TX, USA, 4Cleveland Clinic Lerner Coll of Med, Cleveland, OH, USA, 5Univ of California San Diego, La Jolla, CA, USA

75 11:45 CEREBRAL SMALL-VESSEL DISEASE IN HIV-INFECTED PATIENTS WELL CONTROLLED ON CART
Antoine Moulinier1, Julien Savatovsky1, Ophélie Godin1, Nadia Valin2, François-Xavier Lescure1, Roland Tubiana2, Ana Canestri1, Cédric Lamirel1, Dominique Costagioli1, for the MICROBREAK ANRS study group
Oral Abstract 0-7 TB AND OTHER OPPORTUNISTIC INFECTIONS
Room 6 C  10:00 AM - 12:00 PM

Oral Abstract Moderators
Haileyesus Getahun, World Health Organization, Geneva, Switzerland
Richard Hafner, NIAID, NIH, Bethesda, MD, USA

76LB  A MULTICENTER DIAGNOSTIC ACCURACY STUDY OF THE XPERT ULTRA FOR TUBERCULOSIS DIAGNOSIS
Samuel G. Schumacher1, Pamela Nabeta1, Catharina C. Boehme1, Jerrold Ellner2, David Alland3, Susan E. Dormann4, Claudia M. Denkinger5, for the TB Clinical Diagnostics Research Consortium and FIND Trial Consortium
1FIND, Geneva, Switzerland, 2Boston Med Ctr, Boston, MA, USA, 3Univ of Med and Dentistry of New Jersey, Newark, NJ, USA, 4The Johns Hopkins Univ, Baltimore, MD, USA

77  WHOLE-GENOME SEQUENCING AND SPATIAL ANALYSIS OF XDR TB TRANSMISSION IN SOUTH AFRICA
Kristin N. Nelson1, Neel R. Gandhi1, Sara C. Auld1, James C. Brust2, Barun Mathema3, Nazir Ismail4, Pravi Moodley4, Angela Campbell5, Salim Allana6, N. Sarita Shah7
1Emory Univ, Atlanta, GA, USA, 2Albert Einstein Coll of Med, Bronx, NY, USA, 3Columbia Univ, New York, NY, USA, 4NICD, Johannesburg, South Africa, 5Univ of KwaZulu-Natal, Durban, South Africa, 6CDC, Atlanta, GA, USA

78  SIX-MONTH IPT REDUCES MORTALITY INDEPENDENTLY OF ART IN AFRICAN ADULTS WITH HIGH CD4
Anani D. Badje1, Raoul Moh2, Delphine Gabillard1, Calixte Guehi2, Mathieu Kabran1, Hervé Menan1, André Inwoley1, Christine Danel1, Serge Eholié1, Xavier Anglaret1
1INSERM, Bordeaux, France, 2Prog PAC-CI, ANRS Rsr site, Abidjan, Cote d’Ivoire

79  THE ESSENTIALITY OF INH DURING THE FIRST 14 DAYS OF TB THERAPY: THE A5307 EBA TRIAL
Andreas H. Diacon1, Sachiko Miyahara2, Xin Sun2, Richard Hafner3, Florian von Groote-Bidlingmaier4, Courtney Fletcher5, Evelyn Hogg6, Rodney Dawson7, Susan Swindells8, William Bishai3
1Stellenbosch Univ, Cape Town, South Africa, 2Harvard Univ, Boston, MA, USA, 3NIH, Bethesda, MD, USA, 4TASK Applied Sci, Cape Town, South Africa, 5Univ of Nebraska Med Ctr, Omaha, NE, USA, 6Social &Scientific Systems, Silver Spring, MD, USA, 7Univ of Cape Town, Mowbray, South Africa, 8The Johns Hopkins Univ, Baltimore, MD, USA

80LB  THE NIX-TB TRIAL OF PRETOMANID, BEDAQUILINE AND LINEZOLID TO TREAT XDR-TB
Francesca Conradie1, Andreas H. Diacon2, Daniel Everitt3, Carl Mendel4, Christo van Niekerk5, Pauline Howell6, Kyla Comins6, Mel Spigelman7

81LB  RANDOMIZED CONTROLLED TRIAL OF PREDNISONE FOR PREVENTION OF PARADOXICAL TB-IRIS
Graeme Meintjes1, Cari Stek2, Liz Blumenthal3, Friederic Thienemann4, Charlotte Schutz1, Jozefien Buyze5, Gary Maartens6, Robert Wilkinson7, Lutgarde Lynen8, for the PredART Trial Team
1Univ of Cape Town, Cape Town, South Africa, 2Inst of Tropical Med, Antwerp, Belgium, 3Imperial Coll, London, UK
82 11:30 AMBITION-CM: HIGH-DOSE LIPOSOMAL AMPHOTERICIN FOR HIV-RELATED CRYPTOCOCCAL MENINGITIS
Joseph N. Jarvis1, Tshepo B. Leeme2, Awilly A. Chofele3, Gabriella Bidwell1, Mooketsi Molefi1, Katlego Tsholotsho2, Nametso Lekwape2, Charles Muthoga3, Sile Molloy4, Thomas S. Harrison1

83 11:45 A RANDOMISED CONTROLLED TRIAL OF INDUCTION THERAPY OF TALAROMYCES MARNEFFEI INFECTION
Thuy Le1, Nguyen V. Kinh2, Nguyen Le Nhu Tung3, Thanh Thuy Pham Thi4, Pham T. Phuc5, Doan T. Hanh6, Jeremy Day1, Guy Thwaites1, Marcel Wolbers1, for the IVAP Investigators

Oral Abstract 0-8 COMMON BEDFELLOWS: PREP, STIs, AND THE MICROBIOME
Room 6 AB 10:00 AM - 12:00 PM
Oral Abstract Moderators
Gita Ramjee, South African Medical Research Council, Tygerberg, South Africa
Hyman Scott, Bridge HIV, San Francisco, CA, USA

84 10:00 RESISTANCE EMERGENCE IN MACAQUES ADMINISTERED CABOTEGRAVIR LA DURING ACUTE INFECTION
Jessica Radzio1, Olivia Council1, Mian-er Cong1, James Mitchell1, Shanon Ellis1, Wei Huang1, William Spreen2, Walid Heneine3, Gerardo Garcia-Lerma1
1CDC, Atlanta, GA, USA, 2Monogram BioScis, San Francisco, CA, USA, 3ViiV Hlthcare, Rsr Triangle Park, NC, USA

85 10:15 DAILY ORAL PREP IS EFFECTIVE AMONG WOMEN WITH ABNORMAL VAGINAL MICROBIOTA
Renee Heffron1, R. Scott McClelland1, Jennifer Balkus1, Connie L. Celum1, Craig Cohen1, Nelly Mugo1, Elizabeth A. Bukusi1, Deborah J. Donnell1, Jared Bae ten1, for the Partners PrEP Study Team
1Univ of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 3Univ of California San Francisco, San Francisco, CA, USA, 4Univ of Washington, Seattle, WA, USA, 5Kenya Med Rsrs Inst, Nairobi, Kenya

86LB 10:30 IMPACT OF VAGINAL MICROBIOTA ON GENITAL TISSUE AND PLASMA CONCENTRATIONS OF TENOFOVIR
Sharon L. Hillier1, Leslie A. Meyn2, Katherine Bunge2, Michele Austin2, Bernard J. Moncla1, Charlene S. Dezzutti1, Jill Schwartz1, Mark A. Marzinke2, Craig Hendrix2, Lisa C. Rohan1
1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA, 3Magee-Womens Rsrs Inst, Pittsburgh, PA, USA, 4CONRAD, Arlington, VA, USA, 5Johns Hopkins Univ, Baltimore, MD, USA
87 ABUNDANCE OF PENILE ANAEROBES, IL-8, AND THE RISK OF HIV ACQUISITION, RAKAI, UGANDA

Cindy M. Liu1, Jessica Prodgler2, Aaron Tobian3, Rupert Kaul1, Alison Abraham2, Godfrey Kigozi3, Fred Nalugoda1, David Serwadda2, Lance Price1, Ronald H. Gray2

1George Washington Univ, Washington, DC, USA, 2Johns Hopkins Univ, Baltimore, MD, USA, 3Univ of Toronto, Toronto, Ontario, Canada, 4Rakai Hlth Scis Prg, Kalisizo, Uganda, 5Makerere Univ, Kampala, Uganda

88 DAPIVIRINE RING USE DOES NOT DIMINISH THE EFFECTIVENESS OF HORMONAL CONTRACEPTION

Jennifer Balkus1, Thesla Palance-Phillips2, Samantha Siva1, Clemensia Nakibito3, Gonanasangrie Nair4, Samuel Kabwigu1, Ishana Harkoo1, Catherine Chappell1, Lydia Soto-Torres1, Jared Baeten1

1Fred Hutchinson Cancer Res Cntr, Seattle, WA, USA, 2Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, 3South African Med Rsr Council, Durban, South Africa, 4Makerere Univ-Johns Hopkins Univ Rsr Collab, Kampala, Uganda, 5Emavundleni Rsr Cntr, Cape Town, South Africa, 6CAPRISA, Durban, South Africa, 7Magee-Womens Hosp of UPMC, Pittsburgh, PA, USA, 8NIH, Bethesda, MD, USA, 9Univ of Washington, Seattle, WA, USA

89 STD PARTNER SERVICES TO MONITOR AND PROMOTE PREP USE AMONG MEN WHO HAVE SEX WITH MEN

David A. Katz1, Julia C. Dombrowski1, Teal Bell2, Matthew R. Golden1

1Univ of Washington, Seattle, WA, USA, 2Washington State Dept of Hlth, Olympia, WA, USA

90 CHALLENGES OF TRANSLATING PREP INTEREST INTO UPTAKE AMONG YOUNG BLACK MSM IN ATLANTA

Charlotte-Paige M. Rolle1, Aaron S. Siegler1, Travis Sanchez1, Nicole Luisi1, Scott R. Cotro2, Carlos del Rio3, Patrick Sullivan2, Eli Rosenberg1, Colleen F. Kelley1

1Emory Univ, Atlanta, GA, USA, 2Kaiser Permanente, Atlanta, GA, USA

91B ON DEMAND POST EXPOSURE PROPHYLAXIS WITH DOXYCYCLINE FOR MSM ENROLLED IN A PREP TRIAL

Jean-Michel Molina1, Isabelle Charreau2, Christian Chidiac3, Gilles Pialoux4, Eric Cua1, Constance Delaugerre4, Catherine Capitant1, Daniela Rojas-Castro1, Laurence Meyer1, for the ANRS IPERGAY Study Group

1St. Louis, Hosp, Paris, France, 2INSERM, Villejuif, France, 3Univ of Lyon, Lyon, France, 4Tenon Hosp, Paris, France, 5CHU de Nice, Nice, France, 6AIDES, Pantin, France, 7AP-HP, Le Kremlin-Bicetre, France

Themed Discussion TD-6 INTRACELLULAR AND TISSUE PHARMACOLOGY

Room 615-617 1:30 PM - 2:30 PM

Themed Discussion Leader

Catia Marzolini, Univ Hosp Basel, Basel, Switzerland

404 LEDIPASVIR/SOFOSBUVIR RAISES TENOFOVIR DIPHOSPHATE CONCENTRATIONS IN RED CELLS

Christine MacBrayne1, Daniel S. Fierer2, Kristen M. Marks3, Peter L. Anderson1, Lane R. Bushman3, Kimberly M. Hollabaugh1, Michael D. Hughes1, Raymond T. Chung4, Susanna Naggie2, Jennifer J. Kiser1

1Univ of Colorado, Aurora, CO, USA, 2Cahn Sch of Med at Mt Sinai, New York, NY, USA, 3Weill Cornell Med, New York, NY, USA, 4Harvard Univ, Boston, MA, USA, 5MGH, Boston, USA, 6Duke Univ, Durham, NC, USA
405 TENOFOVIR DIPHOSPHATE ARISING FROM TAF IS QUANTIFIABLE IN DRIED BLOOD SPOTS
Jose Castillo-Mancilla, Ryan P. Coyle, Jia-Hua Zheng, Lucas Ellison, Laura Roon, Jordan Fey, Lane Bushman, Jennifer J. Kiser, Peter Anderson
Univ of Colorado, Aurora, CO, USA

406 EXTRA/INTRA-CELLULAR NUCLEOSIDE/TIDE SEMEN PHARMACOLOGY: IMPLICATIONS FOR ERADICATION
Julie B. Dumond, Stephen A. Greene, Heather M. Asher Prince, Jingxian Chen, Brian Maas, Craig Sykes, Amanda Schauer, Cynthia L. Gay, Angela Kashuba, Myron S. Cohen
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

407 INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPHOID VS GI TISSUES
Sulggi Lee1, Hiroyu Hatano1, Angela Kashuba2, Mackenzie L. Cottrell2, Teri Liegler3, Sophie Stephenson1, Ma Somsouk1, Peter W. Hunt1, Steven G. Deeks1, Radojka M. Savic1
1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

408 PLASMA AND INTRACELLULAR PK OF TENOFOVIR IN PATIENTS SWITCHED FROM TDF TO TAF
Anthony Podany, Sara H. Bares, Joshua Havens, Ravi Dyavar Shetty, Jennifer O’Neill, Sarah Lee, Courtney Fletcher, Susan Swindells, Kimberly K. Scarsi
Univ of Nebraska, Omaha, NE, USA

Themed Discussion TD-7 CNS TREATMENT STRATEGIES: RISK AND BENEFITS
Room 611-614 1:30 PM - 2:30 PM

Themed Discussion Leader
Ned Sacktor, MD, The Johns Hopkins Univ, Baltimore, MD, USA

380 CAN WE AFFORD TO WAIT? ART AND THE CNS
Kevin Robertson1, Javier R. Lama2, Christopher D. Pilcher2, Jessica Rios2, Peter Brandes2, Eduardo Ruiz2, Eline Appelmans4, Serena Spudich5, Ann Duer4, for the SABES Team
1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Asociacion Civil Impacta Salud y Educacion, Lima, Peru, 3Univ of California San Francisco, San Francisco, CA, USA, 4Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 5Yale Univ, New Haven, CT, USA

350 COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION
Leah H. Rubin1, Gayle Springer1, Pauline M. Maki1, Kathryn Anastos3, Deborah Gustafson4, Maria Villacres5, Drenna Waldrop-Valverde6, David Vance7, Hector Bolivar8, Victor Valcour9
1Univ of Illinois at Chicago, Chicago, IL, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Albert Einstein Coll of Med, Bronx, NY, USA, 4SUNY Downstate Med Cntr, Brooklyn, NY, USA, 5Univ of Southern California, Los Angeles, CA, USA, 6Emory Univ, Atlanta, GA, USA, 7Univ of Alabama at Birmingham, Birmingham, AL, USA, 8Univ of Miami, Miami, FL, USA, 9Univ of California San Francisco, San Francisco, CA, USA
381 CENICRIVIROC IMPROVES NEUROCognition AND REDUCes MONocyte ACTIVATION IN TREATED HIV
Lishomwa C. Ndhlovu1, Michelle L. D’Antoni1, Robert Paul2, Kalpana J. Kallianpur3, Laurent Fischer4, Eric Lefebvre1, Star Seyedkazemi5, Beau K. Nakamoto6, Debra Ogata-Arakaki1, Cecilia Shikuma1
1Univ of Hawaii, Honolulu, HI, USA, 2Univ of Missouri–St. Louis, St. Louis, MO, USA, 3Tobira Therapeutics, Inc, South San Francisco, CA, USA

382 CSF INFLAMMATORY MARKERS AFTER ADDING MARAVIROC TO MONOTHERAPY DARUNAVIR/RITONAVIR
Tristan Barber1, Arkaitz Imaz2, Marta Boffito1, Daniel Podzamczer3, Anton Pozniak1, Rosa Fortuny2, Nicholas Davies1, Jordi Niubo1, Sundhiya Mandalia1, Brian Gazzard4
1Chelsea and Westminster NHS Fndn Trust, London, UK, 2Hosp Univ de Bellvitge, Barcelona, Spain, 3Imperial Coll London, London, UK

384 EXTENSIVE EFAVIRENZ METABOLISM IS ASSOCIATED WITH GREATER CNS TOXICITY
Marijana Vujkovic1, Scarlett Bellamy2, Athena Zuppa3, Marc Gastonguay3, Xiaoyan Han4, Mosepele Mosepele5, Gregory Bisson4, Richard Aplenc4, Robert Gross6
1Children’s Hosp of Philadelphia, Philadelphia, PA, USA, 2Drexel Univ, Philadelphia, PA, USA, 3Metrum Rsr Group, Tariffville, CT, USA, 4Univ of Pennsylvania, Philadelphia, PA, USA, 5Univ of Botswana, Gaborone, Botswana

Themed Discussion TD-8 SCREENING FOR HSIL: ALTERNATIVES TO CYTOLOGY
Room 606-609 1:30 PM - 2:30 PM

Themed Discussion Leader
Timothy Wilkin, MD, Weill Cornell Medicine, New York, NY, USA

592 MULTITEST SCREENING STRATEGIES ADD VALUE FOR PREDICTING BIOPSY-PROVEN HSIL FOR MSM
Dorothy J. Wiley1, Hilary K. Hsu1, Matthew G. Moran1, Jenny Brook1, David Elashoff3, Martha Ganse1, Stephen Young2, David Morris3, Otoniel Martinez-Maza1, Ronald T. Mitsuyasu4
1Univ of California Los Angeles, Los Angeles, CA, USA, 2Tricore Reference Labs, Albuquerque, NM, USA, 3Desert AIDS Proj, Palm Springs, CA, USA

596 IMPACT OF ART COVERAGE AND SCREENING ON ANAL CANCER IN HIV+ MEN WHO HAVE SEX WITH MEN
Nello Blaser1, Barbara Bertisch2, Manuel Koller1, Marcel Stoeckle2, Matthias Cavassini3, Roger Kourys4, Janne Estill1, Matthias Egger1, Olivia Keiser1, for the Swiss HIV Cohort Study
1Univ of Bern, Bern, Switzerland, 2Univ Hosp Basel, Basel, Switzerland, 3Univ of Lausanne, Lausanne, Switzerland, 4Univ of Zurich, Zurich, Switzerland

594 MULTIPLE HPV INFECTIONS AND ANAL PRECANCEROUS LESIONS IN HIV-INFECTED MEN
Shu-Hsing Cheng1, Chien-Yu Cheng1, Chi-Chao Wang1, Fang-Yeh Chu2, Yu-Mei Hsueh1
1Taoyuan General Hosp, Taoyuan, Taiwan, 2Far Eastern Memorial Hosp, New Taipei, Taiwan, 3Taipei Med Univ, Taipei, Taiwan
595 SCREENING FOR PRECANCEROUS ANAL LESIONS WITH P16/KI67 DUAL STAIN CYTOLOGY IN HIV

Sergio Serrano-Villar1, Beatriz Hernández-Novoa2, Amparo de Benito1, Jorge Romero1, Antonio Ocampo2, Laura Pérez-Martínez3, Mar Masía4, Elena Sendagorta5, Gonzalo Sanz6, José Antonio Pérez-Molina3

1Hosp Univ Ramón y Cajal, Madrid, Spain, 2Brystol-Myers-Squibb, Madrid, Spain, 3Centro Sandoval, Madrid, Spain, 4Hosp Xeral de Vigo, Vigo, Pontevedra, 5Hosp San Pedro, Logroño, Spain, 6Hosp General Univ de Elche, Elche, Spain, 7Hosp Univ La Paz, Madrid, Spain, 8Hosp Clinico San Carlos, Madrid, Spain

Themed Discussion TD-9 HIV SELF-TESTING: KNOW YOURSELF
Room 6 C
1:30 PM - 2:30 PM

Themed Discussion Leader
Joanne Stekler, MD, Univ of Washington, Seattle, WA, USA

891 HIV SELF-TEST (HIVST) AWARENESS, EXPOSURE, AND USE, NEW YORK CITY, 2015–2016

Paul M. Salcuni, Zoe R. Edelstein, Demetra C. Daskalakis, Julie Myers
New York City DHMH, Queens, NY, USA

893 PEER-LED ORAL HIV-SELF TESTING FINDS UNDIAGNOSED HIV AMONG MSM IN MALINDI, KENYA

Elisabeth M. van der Elst1, Mahmoud Shally1, Clifford Oduor1, Oscar Chirro1, Fauz Ibrahim1, Bernadette Kombo1, Susan M. Graham2, Eduard Sanders1

1KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya, 2Kilifi County Dept of Hlth, Kilifi, Kenya, 3Univ of Washington, Seattle, WA, USA, 4Kenya Med Rsr Inst, Kilifi, Kenya

894 ROLE OF PARTNER VIOLENCE IN WOMEN’S ABILITY TO DISTRIBUTE SELF-TESTS TO MALE PARTNERS

Elisabeth Schaffer1, Kawango Agot2, Harsha Thirumurthy1

1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Impact Rsr and Development Org, Kisumu City, Kenya

895 INFORMING HIV SELF-TESTING SERVICES IN MALAWI USING DISCRETE CHOICE EXPERIMENTS

Pitchaya Indravudh1, Marc D’Elbee1, Moses Kumwenda1, Augustine Choko1, Doreen Sakala1, Thokozani Kalua1, Cheryl Johnson2, Karin Hatzd3, Liz Corbett1, Fern Terrius-Prestholdt1


896 PROVIDING USER SUPPORT FOR HIV SELF-TESTING BEYOND INSTRUCTIONS-FOR-USE IN MALAWI

Pitchaya Indravudh1, Moses Kumwenda1, Melissa Neuman2, Blessings Chisunkha1, Karin Hatzd3, Chiwawa Nkhoma1, Thokozani Kalua1, Cheryl Johnson2, Miriam Taegtmeyer1, Liz Corbett1

Themed Discussion TD-10 HIV PERSISTENCE: CLONES, CLONES, AND MORE CLONES

Room 6 AB 1:30 PM - 2:30 PM

Themed Discussion Leader
Thor Wagner, University of Washington/Seattle Children’s, Seattle, WA, USA

292 CLONAL EXPANSION OF GENOME-INTACT HIV-1 IN FUNCTIONALLY POLARIZED T-CELL SUBSETS
Guinevere Q. Lee, Nina Orlova, Erik Serrao, Xiaoming Sun, Navin F. Chowdhury, Eric Rosenberg, Alan N. Engelman, Xu G. Yu, Mathias Lichterfeld

1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, 2Dana-Farber Cancer Inst, Boston, MA, USA, 3Massachusetts General Hosp, Boston, MA, USA, 4Brigham and Women’s Hosp, Boston, MA, USA

293 INTACT PROVIRUSES ARE UNEQUALLY DISTRIBUTED IN T CELL SUBSETS DURING ART
Bonnie Hiener, Bethany A. Horsburgh, John-Sebastian Eden, Kirston Barton, Eunok Lee, Steven G. Deeks, Jeffery Milush, Nicolas Chomont, Rémi Fromentin, Sarah Palmer

1The Westmead Inst for Med Rsr, Westmead, Australia, 2The Univ of Sydney, Sydney, Australia, 3Univ of California San Francisco, San Francisco, CA, USA, 4Univ de Montréal, Montreal, QC, Canada

294 A SMALL FRACTION OF PROVIRUSES IN EXPANDED CLONES EXPRESS UNSPLICED HIV RNA IN VIVO
Andrew Musick, Jonathan Spindler, Brandon Keele, Michael J. Bale, Wei Shao, Ann Wiegand, John Mellors, John Coffin, Frank Maldarelli, Mary F. Kearney

1NCI, Frederick, MD, USA, 2Leidos Biomed, Inc, Frederick, MD, USA, 3Univ of Pittsburgh, Pittsburgh, PA, USA, 4Tufts Univ, Boston, MA, USA

295 PROLIFERATION OF CD4+ T CELLS CONTAINING REPLICATION-COMPETENT HIV-1
Zheng Wang, Ya-Chi Ho, Janet Siliciano, Robert Siliciano
Johns Hopkins Univ, Baltimore, MD, USA

296 CYTOTOXIC T LYMPHOCYTES MAY SHAPE THE HIV-1 PROVIRAL LANDSCAPE
R. Brad Jones, Mihaela Pertea, Katherine Bruner, Ross Pollack, Adam Capoferri, Robert Siliciano, Ya-Chi Ho

1The George Washington Univ, Washington, DC, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA
**Oral Sessions • Wednesday**

**Program and Agenda**

**CROI 2017**

**Room 6 E**

1:30 PM - 2:30 PM

**Themed Discussion TD-11**

**INTEGRATION OF SCREENING AND TREATMENT OF NCD INTO HIV CARE IN RESOURCE LIMITED SETTINGS**

**Themed Discussion Leader**

Matthias Egger, MD, Inst of Social and Preventive Medicine, Univ of Bern, Bern, Switzerland

**637**

**INTEGRATING CARDIOVASCULAR DISEASE RISK-FACTOR SCREENING IN HIV SERVICES IN SWAZILAND**

Miriam Rabkin1, Anton M. Palma1, Margaret L. McNairy1, Samkelo Simelane1, Averie B. Gachuhi1, Raymond A. Bitchong1, Harriet Nuwagaba-Biribonwoha1, Pido Bongomin1, Velephi Okello1, Wafaa M. El-Sadr1

1ICAP at Columbia Univ, New York, NY, USA, 2ICAP Swaziland, Mbabane, Swaziland, 3Raleigh Fitkin Memorial Hosp, Manzini, Swaziland, 4Swaziland Ministry of Hlth, Mbabane, Swaziland

**638**

**COMPOSITE “HIV/ HYPERTENSION/ DIABETES CONTROL” OUTCOME IN SEARCH CHRONIC CARE MODEL**

Dalsone Kwariisima1, Jeanna Wallenta2, James Ayieko1, Florence Mwangwa3, Asiphas Owaragani3, Tamara D. Clark1, Edwin D. Charlebois1, Maya L. Petersen1, Diane V. Havelri1, Moses R. Kamya1

1Makerere Univ Joint AIDS Prog, Kampala, Uganda, 2Univ of California San Francisco, San Francisco, CA, USA, 3Kenya Med Rsr Inst, Nairobi, Kenya, 4Infectious Diseases Rsr Collab, Kampala, Uganda, 5Univ of California Berkeley, Berkeley, CA, USA, 6Makerere Univ Coll of Hlth Scis, Kampala, Uganda

**639**

**THE ART ADVANTAGE: HEALTHCARE UTILIZATION FOR DIABETES & HYPERTENSION IN SOUTH AFRICA**


1Beth Israel Deaconess Med Cntr, Boston, MA, USA, 2Harvard Univ, Cambridge, MA, USA, 3Massachusetts General Hosp, Acornhoek, South Africa, 4Harvard Univ, Boston, MA, USA, 5Univ of the Witwatersrand, Acornhoek, South Africa, 6MRC/Wits Rural Pub Hlth and Hlth Transitions Rsr Unit, Johannesburg, South Africa, 7Univ of Witwatersrand, Johannesburg, South Africa, 8Heidelberg Univ, Heidelberg, Germany, 9Brigham and Women’s Hosp, Boston, MA, USA

**640**

**CARDIOVASCULAR RISK ASSESSMENT IN A SUB-SAHARAN AFRICA HIV CLINICAL COHORT**

Mosepele Mosepele1, Linda C. Hemphill1, Tommy Palai1, Isaac Nkele1, Kara Bennett4, Shahin Lockman1, Virginia Triant1

1Univ of Botswana, Gaborone, Botswana, 2Massachusetts General Hosp, Boston, MA, USA, 3Botsana--Harvard AIDS Partnership, Gaborone, Botswana, 4Bennett Statistical Consulting Inc, New York, NY, USA, 5Harvard Univ, Boston, MA, USA

**641**

**HIV AND IMMUNE ACTIVATION ARE RISK FACTORS FOR ENDOTHELIAL DAMAGE IN ADULT MALAWIANS**

Christine Kelly1, Henry Mwandumba2, Rob Heyderman1, Raphael Kamng’ona2, Mishek Chammudzi2, Irene Sheha2, Jane E. Malewawa2, Sarah Walker1, Nigil Klein2, Saye Khoo1

1Univ Coll Dublin, Dublin, Ireland, 2Malawi Liverpool Wellcome Clinical Rsr Prag, Blantyre, Malawi, 3Univ Coll London, London, UK, 4Univ of Malawi, Blantyre, Malawi, 5Univ of Liverpool Inst of Translational Med, Liverpool, UK
Target audience: This session is directed to clinicians and scientists who are interested in the assembly of HIV-1 particles and mature capsids, viral genome packaging and recognition of the mature HIV-1 capsid by the TRIM5alpha antiviral protein.

Level of knowledge: It is assumed that participants are familiar with basic concepts in HIV-1 particle assembly and structure.

Objectives: At the completion of the session, participants will be able to:

- Describe how HIV-1 Gag assembles into immature particles and then transitions to a mature infectious form
- Describe how variation in HIV-1 genomic RNA structure facilitates packaging of viral RNA into virions
- Describe how RNA interactions with integrase are required for the correct maturation of virions
- Describe how the TRIM5alpha protein recognizes the mature HIV-1 capsid

Conveners

Sebla Kutluay, Washington Univ in St. Louis, St Louis, MO, USA

Victoria D’Souza, Harvard Univ, Cambridge, MA, USA

92  THE FATES AND FOLDS OF HIV-1 RNA
4:00  Alice Telesnitsky, Univ of Michigan, Ann Arbor, MI, USA

93  STRUCTURE AND FUNCTION OF IMMATURE AND MATURE HIV CAPSIDS
4:30  Hans-Georg Kräusslich, Heidelberg Univ, Heidelberg, Germany

94  A ROLE OF HIV-1 INTEGRASE IN ENCAPSIDATION OF THE VIRAL RNA GENOME
5:00  Mamuka Kvaratskhelia, The Ohio State Univ, Columbus, OH, USA

95  TRIM5ALPHA RECOGNITION OF THE HIV CAPSID
5:30  Barbie K. Ganser-Pornillos, Univ of Virginia, Charlottesville, VA, USA
Symposium S-5 HEPATITIS/LIVER
Room 6 E 4:00 PM - 6:00 PM

Target audience: This session is directed to investigators and clinicians who are interested in the epidemiology, basic science, public health impact, and future trends in hepatitis B and hepatitis C therapy.

Level of knowledge: It is assumed that participants are familiar with the general principles of hepatitis B and hepatitis C virology and treatment.

Objectives:
- To identify the limitations and the potential for virologic and immunologic approaches to the cure of HBV infection
- To compare the approach to preventing vertical transmission of HIV to HBV
- To appreciate the opportunities and challenges to achieving the UN HCV elimination goals
- To understand the prevalence of fatty liver disease and recognize the difference between steatosis and steatohepatitis

Conveners
Marion G. Peters, Univ of California San Francisco, San Francisco, CA, USA
Massimo Puoti, ASST GOM Niguarda, Milan, Italy

96 HEPATITIS B: PROGRESS AND PROSPECTS IN HEPATITIS B VIRUS CURE
4:00 Patrick Kennedy, Queen Mary Univ London, London, United Kingdom

97 MANAGEMENT OF CHRONIC HEPATITIS B DURING PREGNANCY
4:30 Mindie H. Nguyen, Stanford Univ Med Cntr, Palo Alto, CA, USA

98 HEPATITIS C VIRUS: GONE BY 2030?
5:00 John W. Ward, CDC, Atlanta, GA, USA

99 FATTY LIVER DISEASE: A GROWING CONCERN
5:30 Rohit Loomba, Univ of California San Diego, La Jolla, CA
### Symposium S-6 THE FIRST AGE: INFANTS ON THE WORLD STAGE

**Room 606-609**  
4:00 PM - 6:00 PM

**Target Audience:** This session is directed to clinicians and scientists who are interested in understanding the impact of HIV and ART on newborns and infants.

**Level of Knowledge:** It is assumed that the participants are familiar with the basic concepts of HIV acquisition, prevention, and treatment in infants and newborns.

**Objectives:** At the completion of the session, participants will be able to:

- Describe the impact of HIV and ART on pregnancy outcomes among women with HIV infection.
- Discuss the short- and long-term outcomes of ART-exposure in uninfected infants and children born to women with HIV.
- Review approaches to early diagnosis of HIV in newborns and infants.
- Describe experiences with, and outcomes of, early ART in HIV infected infants.

**Conveners**

Mutsa Bwakura-Dangarembizi, Univ of Zimbabwe, Harare, Zimbabwe  
Thanyawee Puthanakit, Chulalongkorn Univ, Bangkok, Thailand

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Institution and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00</td>
<td>MTCT: EVOLVING EPIDEMIOLOGY AND PREGNANCY OUTCOMES</td>
<td>Roger L. Shapiro</td>
<td>Harvard Schl of Pub Hlth, Boston, MA, USA</td>
</tr>
<tr>
<td>4:30</td>
<td>THE ART AND SCIENCE OF INFANT DIAGNOSIS</td>
<td>Martina Penazzato</td>
<td>WHO, Geneva, Switzerland</td>
</tr>
<tr>
<td>5:00</td>
<td>THE HIV-EXPOSED AND UNINFECTED CHILD: WHAT’S TO WORRY?</td>
<td>Claire Thorne</td>
<td>Univ College London, London, United Kingdom</td>
</tr>
<tr>
<td>5:30</td>
<td>THE TREATMENT OF NEWBORNS AND INFANTS LIVING WITH HIV</td>
<td>Elizabeth Maleche Obimbo</td>
<td>Univ of Nairobi, Nairobi, Kenya</td>
</tr>
</tbody>
</table>
Symposium S-7 GETTING TO THE THIRD 90
Room 6 C  4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding progress and challenges in maximizing the percentage of people on antiretroviral therapy who have viral load suppression, particularly in low and middle income settings, and how global targets for viral suppression can be achieved in the future.

Level of Knowledge: It is assumed that the participants are familiar with effects of antiretroviral treatment on HIV viral load, the basic concepts of viral load measurement, and the influences of adherence and drug resistance.

Objectives: At the completion of the session, participants will be able to:
- Describe the issues related to implementation of monitoring of ART in low and middle income settings
- Describe challenges in achieving the target of 90% virally suppressed

Conveners
Laura Broyles, Centers for Disease Control and Prevention, Atlanta, GA, USA
Velephi Okello, Swaziland Ministry of Health, Mbabane, Swaziland

104 ACTING OR NOT ACTING ON VIRAL LOAD
4:00 Steven J. Reynolds, NIAID, NIH, Washington, DC, USA

105 MEASURING VIRAL LOAD: INNOVATIONS AND TAKING TO SCALE
4:30 Rosanna W. Peeling, London Sch of Hygiene and Trop Medicine, London, United Kingdom

106 USING TECHNOLOGY TO IMPROVE ADHERENCE
5:00 Richard T. Lester, Univ of British Columbia, Vancouver, Canada

107 REACHING KEY AND VULNERABLE POPULATIONS TO ACHIEVE THE THIRD 90
5:30 Ruanne V. Barnabas, Univ of Washington, Seattle, USA
THURSDAY, FEBRUARY 16, 2017

Plenary PL-3 THURSDAY PLENARY SESSION
Auditorium - 4 AB
8:30 AM - 9:30 AM

108 IF YOU CAN MAKE IT THERE: ENDING THE HIV EPIDEMIC IN NEW YORK
8:30
Demetre C. Daskalakis, NYC DHMH, New York, NY, USA

109 HTLV-1: THE OTHER HUMAN RETROVIRUS
9:00
Charles R. Bangham, Imperial Coll London, London, UK

Oral Abstract O-10 IMPROVING THE HIV CARE CASCADE
Room 6 C
10:00 AM - 12:00 PM

Oral Abstract Moderators
Loice Achieng, Univ of Nairobi, Nairobi, Kenya
Valdilea Veloso, Oswaldo Cruz Foundation - Fiocruz, Rio de Janeiro, Brazil

110 A COMBINATION INTERVENTION STRATEGY FOR HIV LINKAGE AND RETENTION IN MOZAMBIQUE
10:00
Baty Elul1, Matthew R. Lamb1, Maria Lahuerta1, Fatima Abacassamo2, Laurence Ahoua1, Stephanie Kujawski3, Maria To2, Ilesh Jani4
1Columbia Univ, New York, NY, USA, 2Cntr for Collab in Hlth, Maputo City, Mozambique, 3ICAP at Columbia Univ, Maputo City, Mozambique, 4Inst Nacional de Saude, Maputo, Mozambique

111 PEER NAVIGATION ENHANCES HIV CARE RETENTION: AN RCT IN SOUTH AFRICAN PRIMARY CLINICS
10:15
Wayne T. Steward1, Emily Agnew1, Julia DeKadt1, Hailey Gilmore2, Mary-Jane Ratlhagana2, Jessica Grignon3, Starley B. Shade4, John Tumbo5, Scott Barnhart6, Sheri A Lippman1
1Univ of California San Francisco, San Francisco, CA, USA, 2Intl Training and Educ Cntr for Hlth–South Africa, Pretoria, South Africa, 3Univ of Washington, Seattle, WA, USA, 4Rustenburg Sub-District Office, Rustenburg, South Africa

112 COST-EFFECTIVENESS OF POLICY OPTIONS WHEN PRETREATMENT NNRTI DRUG RESISTANCE IS HIGH
10:30
Andrew Phillips1, Valentina Cambiano1, Michael Jordan2, Fumiyo Nakagawa1, Marco Vitoria1, Meg Doherty1, Paul Revill1, Elliot Raizes2, Silvia Bertagnolio3, for the Working Group on Modelling Drug Resistance in Sub-Saharan Africa
1Univ Coll London, London, UK, 2Tufts Univ, Boston, MA, USA, 3WHO, Geneva, Switzerland, 4Univ of York, York, UK, 5CDC, Atlanta, GA, USA

113 INCREASED RISK OF CART FAILURE AFTER LOW-LEVEL VIREMIA UNDER WHO GUIDELINES
10:45
Lucas E. Hermans1, Michelle A. Moorhouse2, Sergio Carmona2, Diederick Grobbee1, Laura Marije Hofstra1, Douglas D. Richman1, Hugo Tempelman1, Willem D. Venter2, Annemarie Wensing1, for the Ndlovu Research Consortium
1Univ Med Cntr Utrecht, Utrecht, Netherlands, 2Univ of Witwatersrand, Johannesburg, South Africa, 3Univ Med Cntr Utrecht, Utrecht, Netherlands, 4Univ of California San Diego, San Diego, California, USA, 5Ndlovu Care Group, Groblersdal, South Africa
Oral Sessions • Thursday
Program and Agenda
CROI 2017

114LB REAL PROGRESS IN THE HIV EPIDEMIC: PHIA FINDINGS FROM ZIMBABWE, MALAWI, AND ZAMBIA
Jessica E. Justman1, David Hoos1, Graham Kalton2, Rose Nyirenda3, Crispin Moyo4, Owen Mugurungi5, Andrew Voetsch5, Hetal Patel5, Laura Porter6, for the PHIA Project Teams for Malawi, Zambia and Zimbabwe

115 STRATEGIES TO ACHIEVE 90-90-90: MODELING INSIGHTS FROM ZIMBABWE
Jack Olney, Jeffrey Eaton, Ellen McRobie, Timothy B. Hallett
Imperial Coll London, London, UK

116 HIV CASCADE OF CARE INTERVENTIONS IN KENYA: CLINICAL IMPACT AND COST-EFFECTIVENESS
Liem Binh Luong Nguyen1, Yazdan Yazdanpanah2, David Maman1, Stephen Wanjala2, Alexandra Vandenbulcke3, Elisabeth Szumilin4, William Hennequin5, Robert Parker6, Pierre Mendiharat7, Kenneth Freedberg5
1INSERM, Paris, France, 2Epicentre, Cape Town, South Africa, 3MSF, Nairobi, Kenya, 4MSF, Paris, France, 5Massachusetts General Hosp, Boston, MA, USA

117 A RANDOMIZED TRIAL OF READY-TO-USE SUPPLEMENTARY FOOD AT ART INITIATION IN AFRICA
Jane E. Mallewa1, Alexander J. Szubert2, Jay Berkley3, Sanele Nkomani4, Abraham Silika5, Peter Mugyenyi1, Andrew Prendergast, Sarah Walker1, Diana Gibb1, for the REALITY Trial Team
1Malawi–Liverpool–Wellcome Trust Clinical Rsr Prog, Blantyre, Malawi, 2Univ Coll London, London, UK, 3KEMRI Wellcome Trust Rsr Prog, Kilifi, Malawi, 4Univ of Michigan, USA, 5Curtin University, Australia, 6Messina College, USA, 7Queen Mary Univ of London, London, UK

Oral Abstract 0-11 HIV PERSISTENCE AND REACTIVATION
Room 6 E
10:00 AM - 12:00 PM

118 TLR7 AGONIST GS-9620 INCREASES IMMUNE-MEDIATED CLEARANCE OF HIV-INFECTED CELLS
Alivelu Irrinki1, Angela Tsai1, Jasmine Kaur1, Jay Lalezari2, Tomas Cihlar1, George Kukolj1, Derek D. Sloan3, Jeffrey Murry1
1Gilead Scis, Inc, Foster City, CA, USA, 2Quest Clinical Rsr, San Francisco, CA, USA, 3Agenovir, South San Francisco, CA, USA

119LB VIRAL CONTROL INDUCED BY HIVCONSV VACCINES & ROMIDEPSIN IN EARLY TREATED INDIVIDUALS
Beatriz Mothe1, José Moltó2, Christian Manzardo1, Josep Coll1, Maria C. Puertas1, Javier Martinez-Picado3, Tomas Hanke4, Bonaventura Clotet1, Christian Brander1, for the BCN02-Romi Study Group
1IrsiCaixa AIDS Rsr Inst, Badalona, Spain, 2Fundació Lluita Contra la Sida, Badalona, Spain, 3Univ of Barcelona, Barcelona, Spain, 4The Jenner Inst, Oxford, UK
120  
10:30  NO EVIDENCE OF ONGOING HIV REPLICATION AFTER 7 YEARS ON ART
Mary Grace K. Katusiime, Gert U. van Zyl, Ann Wiegand, Elias K. Halvas, Valerie F. Boltz, Barbara Laughton, Susan Engelbrecht, Mark Cotton, John W. Mellors, Mary F. Kearney
1Stellenbosch Univ, Parow, South Africa, 2NCI, Frederick, MD, USA, 3Univ of Pittsburgh, Pittsburgh, PA, USA

121  
10:45  A PROPORTION OF LATENT HIV IS MISSED BY ASSAYING ONLY RESTING CD4 T CELLS
Anthony R. Cillo, Michele Sobolewski, Taylor Buckley, John Bui, Joshua C. Cyktor, John W. Mellors
Univ of Pittsburgh, Pittsburgh, PA, USA

122  
11:00  CTLs PARE DEFECTIVE HIV PROVIRUSES WITHOUT IMPACTING INFECTIOUS LATENT RESERVOIRS
Szuhan Huang, Allison S. Thomas, Sara Karandish, Dora Chari, Adam Ward, Ya-Chi Ho, Erika Benko, Colin Kovacs, R. Brad Jones
1The George Washington Univ, Washington, DC, USA, 2Boston Univ, Boston, MA, USA, 3The Johns Hopkins Univ, Baltimore, MD, USA, 4Maple Leaf Med Clinic, Toronto, Ontario, Canada, 5Univ of Toronto, Toronto, Ontario, Canada

123  
11:15  DEVELOPMENT OF A PKC AGONIST DERIVED FROM INGENOL FOR HIV LATENCY DISRUPTION IN VIVO
Jessica Brehm, Vincent Tai, David Irlbeck, Robert Ferris, Nancie Archin, Matt Kanke, Jean-Pierre Routy, David M. Margolis, Jun Tang, David Favre
1GlaxoSmithKline, Durham, NC, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3McGill Univ Hlth Cntre, Glen Site, Montréal, QC, Canada

124  
11:30  HIV RNA REBOUND POSTINTERRUPTION IN PERSONS SUPPRESSED IN FIEBIG I ACUTE HIV
Donn Colby, Nicolas Chomont, Eugene Kroon, Louise Leyre, Suteeraporn Pinyakorn, Nelson L. Michael, Merlin L. Robb, Nittaya Phanuphak, Jintanat Ananworanich, for the RV411 and RV254/SEARCH010 Study Groups
1SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 2Ctr de Rsr du Cntr Hosp de l’Univ de Montréal, Montréal, QC, Canada, 3US Military HIV Rsr Prog, Bethesda, MD, USA

125  
11:45  EARLY DETECTION OF HIV REBOUND BY INNATE SENSORS POST ART INTERRUPTION
Julie Mitchell, Eugene Kroon, Khunthalee Benjaponpong, Suteeraporn Pinyakorn, Praphan Phanunphak, Sharon R. Lewin, Jintanat Ananworanich, Mark de Souza, Lydie Trautmann, for the Search 019 Study Group
1Henry M. Jackson Fndn, Silver Spring, MD, USA, 2SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 3Henry M. Jackson Fndn, Bethesda, MD, USA, 4Doherty Inst for Infection and Immunity, Melbourne, Australia
Oral Abstract O-12

**INFLAMMATION AND AGE-RELATED COMPLICATIONS**

Room 6 AB  
10:00 AM - 12:00 PM

Oral Abstract Moderators

Jason Baker, HCMC / Univ of Minnesota, Minneapolis, MN, USA  
Heidi Crane, Univ of Washington, Seattle, WA, USA

**126**  
**IL-β INHIBITION SIGNIFICANTLY REDUCES ATHEROSCLEROTIC INFLAMMATION IN TREATED HIV**

Priscilla Hsue1, Steven G. Deeks1, Amorina E. Ishaï2, Sophia Hur1, Danny Li1, Felicia Sterman1, Jay Lalezari1, Adam Rupert3, Peter Ganz1, Ahmed Tawakol1  
1Univ of California San Francisco, San Francisco, CA, USA, 2Massachusetts General Hosp, Boston, MA, USA, 3California Pacific Med Ctr, San Francisco, CA, USA, 4Quest Clinical Rsr, San Francisco, CA, USA, 5Natl Inst of Hlth, Frederick, MD, USA

**127**  
**HYPERBILIRUBINEMIA PREVENTS CARDIOVASCULAR DISEASE FOR HIV+ AND HIV- INDIVIDUALS**

Vincent C. Marconi1, Kaku So-Armah2, Janet Tate3, Joseph Lim3, Vincent Lo Re3, Adeel A. Butt4, Matthew B. Goetz2, Maria Rodriguez-Barradas4, Amy Justice4, Matthew Freiberger5  
1Emory Univ, Atlanta, GA, USA, 2Boston Univ, Boston, MA, USA, 3VA Connecticut Hlthcare System, West Haven, CT, USA, 4Yale Univ, New Haven, CT, USA, 5Univ of Pennsylvania, Philadelphia, PA, USA, 6Weill Cornell Med Coll, New York, NY, USA, 7VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, 8Baylor Coll of Med, Houston, TX, USA, 9Vanderbilt Univ, Nashville, TN, USA

**128LB**  
**ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS**

Lene Ryom1, Jens D. Lundgren2, Wafaa M. El-Sadr1, Peter Reiss4, Andrew Phillips3, Ole Kirk2, Rainer Weber6, Caroline Sabin2, Amanda Mocroft3, for the D:A:D Study Group  
1CHIP, Copenhagen, Denmark, 2Univ of Copenhagen, Copenhagen, Denmark, 3ICAP at Columbia Univ, New York, NY, USA, 4Stichting HIV Monitoring and Academic Med Ctr Amsterdam, Amsterdam, Netherlands, 5Univ Coll London, London, UK, 6Rigshosp, Copenhagen, Denmark, 7Univ of Zurich, Zurich, Switzerland, 8Univ Coll London, London, UK

**129**  
**CARDIOVASCULAR PREVENTION POLICY IN HIV: RECOMMENDATIONS FROM A MODELING STUDY**

Rosan van Zoest1, Mikaela Smit2, Brooke Nichols3, Ilonca Vaartjes4, Colette Smit5, Marc van der Valk6, Ferdinand Wit7, Timothy B. Hallett2, Peter Reiss3, for the Netherlands ATHENA Observational HIV Cohort  
1Amsterdam Inst for Global Hlth and Development and Academic Med Ctr Amsterdam, Amsterdam, Netherlands, 2Imperial Coll London, London, UK, 3Erasmus Univ Med Ctr, Rotterdam, Netherlands, 4Univ Med Ctr Utrecht, Utrecht, Netherlands, 5Stichting HIV Monitoring, Amsterdam, Netherlands, 6Academic Med Ctr Amsterdam, Amsterdam, Netherlands

**130**  
**IMPACT OF SMOKING, HYPERTENSION & CHOLESTEROL ON MYOCARDIAL INFARCTION IN HIV+ ADULTS**

Keri N. Althoff1, Frank J. Palella2, Kelly Gebo1, Stephen J. Gange1, Charles Rabkin1, Jennifer E. Thorne2, Michele A. Horberg1, Daniel B. Klein1, Mari Kitahata2, Richard D. Moore4  
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Northwestern Univ, Chicago, IL, USA, 3NCI, Rockville, MD, USA, 4Kaiser Permanente Mid-Atlantic States, Rockville, MD, USA, 5Kaiser Hosp, San Leandro, CA, USA, 6Univ of Washington, Seattle, WA, USA
Oral Sessions • Thursday
Program and Agenda
CROI 2017

131 CESSATION OF CIGARETTE SMOKING AND THE IMPACT ON CANCER INCIDENCE IN THE D:A:D STUDY
Leah Shepherd1, Lene Ryom2, Kathry Petoumenos2, Camilla Ingrid Hatleberg2, Antonella d’Arminio Monforte3, Fabrice Bonnet4, Peter Reiss6, Jens D. Lundgren2, Amanda McOroft1, for the D:A:D study group
1Univ Coll London, London, London, UK, 2CHIP, Copenhagen, Denmark, 3Kirby Inst, Sydney, Australia, 4Univ of Milan, Milan, Italy, 5CHU de Bordeaux, Bordeaux, France, 6Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands

132 BONE DENSITY AND TRABECULAR BONE SCORE IMPROVE FRACTURE PREDICTION IN HIV+ WOMEN
Jingyan Yang1, Anjali Sharma1, Josh Aschheim1, Kathryn Anastos1, Mardge H. Cohen1, Elizabeth T. Golub1, Deborah Gustafson1, Daniel Merenstein1, Phyllis Tien1, Michael T. Yin1
1Columbia Univ Med Cntr, New York, NY, USA, 2Albert Einstein Coll of Med, Bronx, NY, USA, 3Arcadia Hlth, New York, USA, 4John H.Stroger Jr. Hosp of Cook County, Chicago, IL, USA, 5The Johns Hopkins Univ, Baltimore, MD, USA, 6SUNY Downstate Med Cntr, Brooklyn, NY, USA, 7Georgetown Univ, Washington, DC, USA, 8Univ of California San Francisco, San Francisco, CA, USA

133 FRAILTY PROGRESSION AND RECOVERY AMONG PERSONS AGING WITH HIV AND SUBSTANCE USE
Damani A. Piggott, Karen Bandeen-Roche, Shruti H. Mehta, Todd Brown, Huanje Yang, Jeremy D. Walston, Sean X. Leng, Gregory D. Kirk
The Johns Hopkins Univ, Baltimore, MD, USA

Oral Abstract O-9 HEPATITIS C: PROBLEMS AND PROGRESS
Room 606-609 10:00 AM - 12:00 PM

Oral Abstract Moderators
Juan Berenguer, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Annie Luetkemeyer, Univ of California San Francisco, San Francisco, CA, USA

134 INCIDENCE OF HEPATITIS C AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN, 2000–2015
Antoine Chaillon1, Christy M. Anderson1, Thomas C. Martin1, Edward R. Cachay1, David L. Wyles2, Davey M. Smith1, Susan J. Little1, Richard S. Garfein1, Natasha Martin1
1Univ of California San Diego, San Diego, CA, 2Denver Health, Denver, CO, USA

135 MODELING HIV-HCV EPIDEMIOLOGY IN THE DAA ERA: THE ROAD TO ERADICATION
Victor Virlogeux1, Laurent Cotte1, Pascal Puglièse1, Isabelle Poizot-Martin1, Marc-Antoine Valantin1, Lise Cuzin1, Jacques Reynes1, Eric Billaud1, Thomas Huleux1, for the DatAIDS Study Group
1INSERM, Lyon, France, 2Hospices Civils de Lyon, Lyon, France, 3CHU de Nice, Nice, France, 4Assistance Publique–Hôpitaux de Marseille, Marseille, France, 5Assistance Publique–Hôpitaux de Paris, Paris, France, 6CHU Toulouse, Toulouse, France, 7CHU de Montpellier, Montpellier, France, 8CHU de Nantes, Nantes, France, 9Cntr Hosp de Tourcoing, Tourcoing, France
136 10:30
UNRESTRICTED DAA ACCESS IN THE NETHERLANDS: RAPID THERAPY UPTAKE IN HIV+HCV+ PATIENTS
Anne Boerekamps¹, Astrid Newsum², Colette Smit³, Peter Reiss⁴, Clemens Richter⁵, Marc van der Valk⁶, Joop Arends⁷, Kees Brinkman⁸, Bart Rijnders¹, for the Netherlands ATHENA HIV observational cohort and the NVHB-SHM Hepatitis Working Group
¹Erasmus Univ Med Cntr, Rotterdam, Netherlands, ²Pub Hlth Service of Amsterdam and Academic Med Cntr, Amsterdam, Netherlands, ³Stichting HIV Monitoring, Amsterdam, Netherlands, ⁴Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands, ⁵Rijnstate Hosp, Arnhem, Netherlands, ⁶Academic Med Cntr, Amsterdam, Netherlands, ⁷Univ Med Cntr Utrecht, Utrecht, Netherlands, ⁸OLVG, Amsterdam, Netherlands

137LB 10:45
SUBSTANTIAL DECLINE IN ACUTE HCV INFECTIONS AMONG DUTCH HIV+MSM AFTER DAA ROLL OUT
Anne Boerekamps¹, Guido van den Berk², Fanny Lauw³, Eliane Leyten⁴, Joop Arends¹, Marjo Kasteren⁵, Mark Claassen⁶, Charles Boucher⁷, Bart Rijnders¹, for the Dutch Acute HCV in HIV (DAHHS) study group
¹Erasmus Univ Med Cntr, Rotterdam, Netherlands, ²OLVG, Amsterdam, Netherlands, ³Slotervaart MC, Amsterdam, Netherlands, ⁴MC Haaglanden, The Hague, Netherlands, ⁵Univ Med Cntr Utrecht, Utrecht, Netherlands, ⁶St. Elizabeth Ziekenhuis Tilburg, Netherlands, ⁷Rijnstate Hosp, Arnhem, Netherlands

138 11:00
CORRELATION OF RENAL BIOMARKERS AND TENOFOVIR AUC IN THE ION-4 STUDY COHORT
Austin W. Chan¹, Larry Park¹, Lauren F. Collins¹, Curtis Cooper², Michael Saag³, Douglas Dieterich⁴, Mark Sulkowski⁵, Susanna Naggie⁶, for the ION-4 Study Group
¹Duke Univ, Durham, NC, USA, ²Ottawa General Rsr Inst, Ottawa, Ontario, ³Univ of Alabama at Birmingham, Birmingham, AL, USA, ⁴Icahn Sch of Med at Mt Sinai, New York, NY, USA, ⁵The Johns Hopkins Univ, Baltimore, MD, USA

139 11:15
HEPATOCELLULAR CARCINOMA AFTER SVR WITH IFN-FREE REGIMENS IN HIV/HCV COINFECTION
Nicolás Merchante¹, Boris Revollo², Francisco Rodríguez-Arrondo³, Esperanza Merino⁴, María J. Galindo⁵, Marta Montero⁶, Antonio Rivero-Juárez⁷, Marcial Delgado-Fernández⁸, María J. Rios-Villegas⁹, Juan A. Pineda¹
¹Hosp Univ de Valme, Sevilla, Spain, ²Hosp German Trias i Pujol, Badalona, Spain, ³Hosp Univ de Donostia, San Sebastián, Spain, ⁴Hosp General Univ de Alicante, Alicante, Spain, ⁵Hosp Clinico de Valencia, Valencia, Spain, ⁶Hosp Univ y Politécnico La Fe, Valencia, Spain, ⁷Hosp Univ Reina Sofia, Córdoba, Spain, ⁸Hosp Regional Univ de Málaga, Málaga, Spain, ⁹Hosp Univ Virgen Macarena, Sevilla, Spain

140 11:30
IDENTIFICATION OF HCV INTER-SUBTYPE RECOMBINANT STRAINS WITH BREAKPOINTS IN NSSA
Suqin Cai, Alicia Newton, Wei Huang, Jeannette Whitcomb
Monogram BioScis, South San Francisco, CA, USA

141 11:45
SYNERGY BETWEEN COMBINATIONS OF ANTI-HCV BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES
Madeleine C. Mankowski¹, Andrew I. Flyak², Stuart C. Ray³, James E. Crowe¹, Justin R. Bailey³
¹Johns Hopkins Univ, Severna Park, MD, USA, ²Vanderbilt Univ, Nashville, TN, USA, ³Johns Hopkins Univ, Baltimore, MD, USA
Themed Discussion TD-12 THE IMPOSSIBLE DREAM: POPULATION PERSPECTIVES ON 90:90:90 IN ADOLESCENTS AND YOUNG ADULTS
Room 615-617 1:30 PM - 2:30 PM

Themed Discussion Leader
Mary-Ann Davies, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa

834 COMMUNITY INTERVENTION IMPROVES ADOLESCENT HIV STATUS KNOWLEDGE:HPTN 071 STUDY ZAMBIA

Kwame Shanaube1, Mwate J. Chaila1, David Macleod2, Ab Schapa1, Sian Floyd3, Conred Jani1, Graeme Hoddingott3, Richard Hayes1, Sarah Fidler4, Helen Ayles5

835 A NOVEL MODEL OF COMMUNITY COHORT CARE FOR HIV-INFECTED ADOLESCENTS IMPROVES OUTCOMES

Lindsey Reif6, Rachel Bertrand2, Vanessa Rivera3, Bernadette Jospeh2, Benedict Anglade2, Jean W. Pape1, Daniel Fitzgerald1, Margaret McNairy3
1Columbia Univ, New York, NY, USA, 2GHESKIO, Port-au-Prince, Haiti, 3Weill Cornell Med, New York, NY, USA

836 LOCAL SOCIAL NETWORKS PREDICT RETENTION & SUPPRESSION IN YOUNG WOMEN IN SEARCH TRIAL

Lillian Brown1, Wenjing Zheng1, James Ayieko3, Asiphas Owaragarani1, Florence Mwangwa1, Tamara D. Clark1, Edwin D. Charlebois3, Moses R. Kamya1, Diane V. Havlir2, Maya L. Petersen2
1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of California Berkeley, Berkeley, CA, USA, 3Kenya Med Rsr Inst, Nairobi, Kenya, 4Infectious Diseases Rsr Collab, Kampala, Uganda, 5Makerere Univ, Kampala, Uganda

837 TEENAGE PREGNANCY: A CRITICAL BARRIER TO RETENTION ON ANTIRETROVIRAL THERAPY

Harriet Nuwagaba-Biribonwoha1, Agnes Kiragga2, Constantin Yiannoutsos1, Beverly Musick1, Kara K. Wool-Kaloustian1, Elaine J. Abrams1, Batya Elul1, for the International Epidemiologic Databases to Evaluate AIDS (IeDEA) East Africa Collaboration
1ICAP at Columbia Univ, New York, NY, USA, 2Makerere Univ, Kampala, Uganda, 3Indiana Univ, Indianapolis, IN, USA, 4Columbia Univ, New York, NY, USA

838 IMPACT OF SUBSTANCE USE, MENTAL HEALTH, AND AGE ON RETENTION AND VIRAL SUPPRESSION

Brian C. Zanoni1, Sara Lammert1, Jessica Haberer1, Gregory K. Robbins1, Heidi M. Crane2, Michael J. Mugavero1, Katerina Christopoulos3, Kenneth H. Mayer2
1Massachusetts General Hosp, Boston, MA, USA, 2Univ of Washington, Seattle, WA, USA, 3Univ of Alabama at Birmingham, Birmingham, AL, USA, 4Univ of California San Francisco, San Francisco, CA, USA, 5Fenway Hlth, Boston, MA, USA
Oral Sessions • Thursday
Program and Agenda
CROI 2017

Themed Discussion TD-13 HOT FLASHES: HORMONAL CONTRACEPTION AND HIV RISK
Room 611-614  1:30 PM - 2:30 PM

Themed Discussion Leader
Laneta Dorflinger, Contraceptive Technology Innovation, FHI360, Durham, NC, USA

944 DEPOT MEDROXYPROGESTERONE ACETATE INCREASES HIV-1 REPLICATION IN MUCOSAL TISSUE
Charlene S. Dezzutti1, Sea Yong Park1, Ingrid Macio2, Kenneth Marks3, Sidney Lawlor3, Catherine Chappell3, Katherine Bunge4
1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Univ of Pittsburgh Med Cntr, Pittsburgh, PA, USA, 3Magee-Womens Rsr Inst, Pittsburgh, PA, USA, 4Magee-Womens Hosp of UPMC, Pittsburgh, PA, USA

943 CHANGES IN GENITAL-TRACT HIV TARGET CELLS WITH THREE PROGESTIN-BASED CONTRACEPTIVES
Lisa B. Haddad1, Alison S. Kohlmeier2, Richard Haaland2, Nakita Brown1, David Lupo2, Christina Mehta1, Anandi N. Sheth1, Khemia Titanji1, Clyde Hart1, Igho Ofotokun1
1Emory Univ, Atlanta, GA, USA, 2CDC, Atlanta, GA, USA

945 ZIM-CHIC: IMPACT OF CONTRACEPTIVE INITIATION ON IMMUNE CELLS IN THE CERVIX AND PBMCs
Sharon L. Achilles1, Feliz Mhlanga2, Leslie A. Meyn1, Kevin A. Stoner3, Allen T. Matubu2, Zvavahera M. Chirenje3, Sharon L. Hillier1
1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Univ of Zimbabwe, Harare, Zimbabwe, 3Magee–Womens Rsr Inst, Pittsburgh, PA, USA

946 HIV GENITAL-TRACT SHEDDING WHILE ON PROGESTIN CONTRACEPTION
Julie A. Nelson1, Jeff Wiener2, Jennifer H. Tang1, Lamechin Chinula1, Stacey Hurst1, Gerald Tegha3, Albans Msika1, Mina C. Hosseinipour1, Lisa B. Haddad4, Athena Kourtis5
1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2CDC, Atlanta, GA, USA, 3Univ of North Carolina Proj–Malawi, Lilongwe, Malawi, 4Emory Univ, Atlanta, GA, USA, 5FHI 360, Durham, NC, USA, 6Kenya Med Rsr Inst, Nairobi, Kenya, 7KEMRI, Nairobi, Kenya

947 HORMONAL CONTRACEPTION DOES NOT AFFECT ART EFFECTIVENESS OR GENITAL HIV SHEDDING
Rena Patel1, Jared Baeten1, Renee Heffron3, Ting Hong1, Nicole Davis2, Kavita Nanda1, Robert Cooms1, Elizabeth A. Bukusi6, Athena Kourtis2, Nelly Mugo5
1Univ of Washington, Seattle, WA, USA, 2CDC, Atlanta, GA, USA, 3FHI 360, Durham, NC, USA, 4Kenya Med Rsr Inst, Nairobi, Kenya, 5KEMRI, Nairobi, Kenya

Themed Discussion TD-14 HIV AND SUBSTANCE ABUSE: DOUBLE TROUBLE
Room 606-609  1:30 PM - 2:30 PM

Themed Discussion Leader
Steven Shoptaw, Univ of California Los Angeles, Los Angeles, CA, USA

869 “HOOKED ON PAINKILLERS” PRIOR TO FIRST INJECTION AMONG PWID IN 16 U.S. CITIES
Dita Broz1, Maria Zlotozynska2, Michael Spiller1, Gabriella Paz-Bailey1, for the NHBS Study Group
1CDC, Atlanta, GA, USA, 2Emory Univ, Atlanta, GA, USA
870  **OPIOID SUBSTITUTION THERAPY AND INITIATION INTO INJECTION DRUG USE IN SAN DIEGO, CA**

Maria Luisa Mittal, Devesh Vashishtha, Xiaoying Sun, Sonia Jain, Richard S. Garfein, Steffanie A. Strathdee, Dan Werb

1 Univ of California San Diego, La Jolla, CA, USA, 2 Univ of California San Diego, San Diego, CA, USA

871  **CHANGES IN PRESCRIPTION OPIOID, METH, AND COCAINE USE AMONG MSM IN 20 US CITIES**

Brooke Hoots, Dita Broz, Lina Nerlander, Gabriela Paz-Bailey

CDC, Atlanta, GA, USA

872  **CHANGING PATTERN OF CRYSTAL METH USE IN BLACK & WHITE MSM, WASHINGTON, DC, 2008–2014**

Irene Kuo, Rudy Patrick, Jenevieve Opoku, Anthony Rawls, Manya Magnus, James Peterson, Michael Kharfen, Alan Greenberg

1 The George Washington Univ, Washington, DC, USA, 2 District of Columbia Dept of Hlth, Washington, DC, USA

873  **INCREASING METHAMPHETAMINE USE AMONG NON-MSM WHO INJECT DRUGS IN KING COUNTY, WA**

Sara N. Glick, Richard Burt, Kim Kummer, Joe Tinsley, Caleb Banta-Green, Matthew R. Golden

1 Univ of Washington, Seattle, WA, USA, 2 Pub Hlth - Seattle & King County, Seattle, WA, USA

---

**Themed Discussion TD-15 I WANT A NEW DRUG**

Room 6 C  

1:30 PM - 2:30 PM

**Themed Discussion Leader**

Karl Salzwedel, National Institutes of Health, Bethesda, MD, USA

433  **NOVEL HIV PI WITH HIGH RESISTANCE BARRIER AND POTENTIAL FOR UNBOOSTED QD ORAL DOSING**

John O. Link, Darryl Kato, Michael Moore, Andrew Mulato, Bernard Murray, Judy Mwangi, Nathan D. Shapiro, George Stepan, Yujin Wang, Zheng-Yu Yang

Gilead Scis, Inc, Foster City, CA, USA

434  **NOVEL NON-CATALYTIC SITE INTEGRASE INHIBITOR WITH IMPROVED RESISTANCE PROFILE**

Michael L. Mitchell, Mini Balakrishnan, Gediminas Brizgys, Ruby Cai, Eric Lansdon, Andrew Mulato, Mark Osier, Jianhong Wang, Helen Yu, Roman Sakowicz

Gilead Scis, Inc, Foster City, CA, USA

435  **MK-8591 CONCENTRATIONS AT SITES OF HIV TRANSMISSION AND REPLICATION**

Jay Grobler, Carolyn McHale, Carol Freddo, Dan Dreyer, Li Sun, Marissa Vavrek, Sheila Breidinger, Kerry Fillgrove, Daria Hazuda, Ming-Tain Lai

Merck & Co, Inc, West Point, PA, USA

436  **GS-9131 IS A NOVEL NRTI WITH ACTIVITY AGAINST NRTI-RESISTANT HIV-1**

Kirsten L. White, Nicolas Margot, Kirsten Stray, Helen Yu, George Stepan, Constantine Boojamra, Richard Mackman, Adrian Ray, Michael D. Miller, Tomas Cihlar

Gilead Scis, Inc, Foster City, CA, USA
437 PRO140 SINGLE-AGENT MAINTENANCE THERAPY FOR HIV-1 INFECTION: A 2-YEAR UPDATE
Jay Lalezari 1, Kush Dhody 2, Ula Kowalczyk 1, Kazem Kazempour 2, Nader Pourhassan 1, Paul J. Maddon 4
1Quest Clinical Rsr, San Francisco, CA, USA, 2Amarex Clinical Rsr, LLC, Germantown, MD, USA, 3CytoDyn, Inc, Vancouver, WA, USA, 4Maddon Advisors LLC, Scarsdale, NY, USA

Themed Discussion TD-16 HOW DOES THE MICROBIOME AFFECT HIV INFECTION?
Room 6 E 1:30 PM - 2:30 PM

Themed Discussion Leader
Cara Wilson, MD, Univ of Colorado-Anschutz Medical Campus, Aurora, CO, USA

207 IMPACT OF MSM-ASSOCIATED MICROBIOTA ON IMMUNE ACTIVATION AND IN VITRO HIV INFECTION
Sam Li, Abigail Armstrong, Charles P. Neff, Catherine Lozupone, Brent E. Palmer
Univ of Colorado, Aurora, CO, USA

208 FECAL MICROBIOTA FROM HIV-INFECTED SUBJECTS INCREASES IMMUNE ACTIVATION AND INFECTION
Charles P. Neff, Sam Li, Abigail Armstrong, Catherine Lozupone, Brent E. Palmer
Univ of Colorado, Aurora, CO, USA

209 MARAVIROC INHIBITS HIV TARGET T-CELL TRAFFICKING INTO THE FEMALE GENITAL LUMEN
Alison S. Kohlmeier 1, Sean McMaster 2, Jessica Radzio 1, Mian-er Cong 1, Chuong Dinh 1, Amy Martin 1, Jacob E. Kohlmeier 2, Gerardo Garcia-Lerma 1
1CDC, Atlanta, GA, USA, 2Emory Univ, Atlanta, GA, USA

210 INVESTIGATING THE EFFECT OF PH ON CERVICOVAGINAL MUCUS BARRIER PROPERTIES TO HIV
Julie K. Shade, Thuy Hoang, Kevin Delong, Justin Hanes, Richard Cone, Laura Ensign
The Johns Hopkins Univ, Baltimore, MD, USA

Themed Discussion TD-17 EMERGING VIRUSES: THE ZIKA VIRUS
Room 6 AB 1:30 PM - 2:30 PM

Themed Discussion Leader
Robert T. Schooley, Univ of California San Diego, La Jolla, CA, USA

1054 CHARACTERIZATION OF MORE THAN 10,000 ZIKA VIRUS TEST RESULTS IN THE US
Joseph M. Volpe 1, Dajie Luo 1, Arren Fisher 1, Mindy Nye 1, Barbara Body 1, Marcia Eisenberg 1
1LabCorp, Durham, NC, USA, 2LabCorp, Burlington, NC, USA

1055LB ZIKA VIRUS PERSISTENCE IN BODY FLUIDS
Gabriela Paz-Bailey 1, Eli Rosenberg 2, Katherine Doyle 1, Jorge Munoz-Jordan 1, Gilberto Santiago 1, Liore Klein 1, Janice Perez 1, Stephen Waterman 1, Luisa Alvarado 1, Tyler Sharp 1
1CDC, Atlanta, GA, USA, 2Emory Univ, Atlanta, GA, USA, 3Caduceus Healthcare, Inc, Ponce, PR, USA, 4Ponce Univ, Ponce, PR, USA
Oral Sessions • Thursday
Program and Agenda
CROI 2017

1056LB NEUROLOGIC CONSEQUENCES OF POSTNATAL ZIKA VIRUS INFECTION IN INFANTS
Maud Mavigner1, Justin O’Neal2, Siddhartha Bhaumik1, Jakob Habib1, Cameron Robinson1, Maria Alvarado3, Xiaodong Zhang1, Jens Wrammert1, Mehul Suthar1, Ann Chahroudi1
1Emory Univ, Atlanta, GA, USA, 2Emory Vaccine Center, Atlanta, GA, USA, 3Yerkes Natl Primate Rsr Cntr, Atlanta, GA, USA

1057LB ZIKA VIRUS PROTECTION BY A SINGLE LOW-DOSE NUCLEOSIDE-MODIFIED mRNA VACCINATION
Michael J. Hogan1, Norbert Pardi1, Rebecca S. Pelc2, Hanne Anderson1, Charles McGee3, Michael J. Hope3, Mark G. Lewis1, Theodore C. Pierson1, Barton F. Haynes4, Drew Weissman1
1Univ of Pennsylvania, Philadelphia, PA, USA, 2NIAID, Bethesda, MD, USA, 3Bioqual, Inc, Rockville, MD, USA, 4Duke Univ, Durham, NC, USA, 5Acuitas Therapeutics, Vancouver, BC, Canada

Symposium S-8 PATHS INTERTWINED: BROADLY NEUTRALIZING ANTIBODIES AND THE HIV-1 ENVELOPE TRIMER
Room 606-609 4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding how broadly neutralizing antibody responses in HIV-1 infection develop, how they may be harnessed for preventive vaccines, and exploited for HIV cure.

Level of Knowledge: It is assumed that the participants are familiar with the basic principles of how antibodies function.

Objectives:
- Describe how broadly neutralizing antibodies are stimulated during infection and following vaccination
- Describe the structural properties of broadly neutralizing antibodies and their interaction with the HIV Envelope
- Describe the potential of exploiting broadly neutralizing antibodies for functional cure

Conveners
Nicole Doria-Rose, National Institutes of Health, Bethesda, MD, USA
Gabriella Scarlatti, Global HIV Vaccine Enterprise, New York, NY, USA

142 NEUTRALIZING ANTIBODY DEVELOPMENT DURING HIV-1 INFECTION
4:00
Penelope Moore, Univ of the Witwatersrand, Johannesburg, South Africa

143 IMMUNOGEN DESIGN TO INDUCE HIV NEUTRALIZING ANTIBODIES
4:30
William R. Schief, Scripps Rsr Inst, La Jolla, CA, USA

144 STRUCTURAL STUDIES OF HIV NEUTRALIZING ANTIBODIES
5:00
Andrew B. Ward, Scripps Rsr Inst, La Jolla, CA, USA

145 CLINICAL STUDIES WITH BROADLY NEUTRALIZING ANTIBODIES
5:30
Michel Nussenzweig, Rockefeller Univ, New York, NY, USA

70 CROI 2017
Symposium S-9 MODERN ART
Room 6 E
4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding contemporary antiretroviral therapy and HIV drug resistance

Level of Knowledge: It is assumed that the participants are familiar with the principles of HIV drug resistance and antiretroviral therapy

Objectives: At the completion of the session, participants will be able to:
  • Describe trends in transmitted HIV drug resistance and resistance emergence on ART
  • Compare strategies for simplification of antiretroviral therapy in patients suppressed on therapy
  • Summarize the challenges in developing an initial antiretroviral regimen for the global HIV epidemic

Conveners
Ying-Ru Lo, World Health Organization, Geneva, Switzerland
Paul E. Sax, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

0146  HIV-1 DRUG RESISTANCE IN RESOURCE-LIMITED SETTINGS
4:00
Ravindra K. Gupta, Univ College London, London, UK

0147  LONG-ACTING ANTIRETROVIRAL THERAPY: A SHOT IN THE DARK OR A PARADIGM SHIFT?
4:30
Charles W. Flexner, The Johns Hopkins Univ, Baltimore, MD, USA

148   SIMPLE ART: MORE COMPLEX THAN THOUGHT
5:00
Jose R. Arribas, Hospital La Paz, Madrid, Spain

149   TOWARD AN IDEAL ANTIRETROVIRAL REGIMEN FOR THE GLOBAL EPIDEMIC
5:30
Beatriz Grinsztejn, Oswaldo Cruz Foundation - Fiocruz, Rio de Janeiro, Brazil
Symposium S-10 LEVERAGING THE PLATFORM: RESPONDING TO NONCOMMUNICABLE DISEASES
Room 6 C  4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the potential for synergies between global efforts to reduce premature mortality from noncommunicable diseases and global efforts to improve the quality and length of life of people living with HIV.

Level of Knowledge: It is assumed that participants are familiar with basic clinical management of HIV and a range of noncommunicable diseases, including prevention, care and treatment. Some familiarity with health care systems in low resource settings will enhance the value of this session.

Objectives: At the completion of the session, participants will be able to:

- Understand the global burden of noncommunicable diseases associated with HIV
- Understand the use of HIV treatment infrastructure to address noncommunicable diseases
- Understand the benefits and challenges of integrating services for HIV and noncommunicable diseases at different levels of the health system

Conveners
Peter Godfrey-Faussett, UNAIDS, Geneva, Switzerland
Irene Mukui, National AIDS and STI Control Program, Nairobi, Kenya

150  OVERVIEW OF THE GLOBAL BURDEN OF NONCOMMUNICABLE DISEASES IN HIV INFECTION
4:00
Pragna Patel, CDC, Atlanta, GA, USA

151  CARDIOVASCULAR DISEASE AMONGST PEOPLE LIVING WITH HIV IN AFRICA
4:30
Gerald Yonga, Aga Khan Univ, Nairobi, Kenya

152  CAN WE LEVERAGE HIV PLATFORMS FOR PREVENTION OF CERVICAL CANKER IN LMICs IN SSA?
5:00
Doreen Ramogola-Masire, Univ of Botswana-Univ of Pennsylvania Collaboration, Gaborone, Botswana

153  MINIMIZING MORBIDITY: INTEGRATING CARE FOR DEPRESSION & HIV IN LOW RESOURCE SETTINGS
5:30
Pamela Collins, NIMH, Bethesda, MD, USA
73

POSTER SESSIONS BY DAY

TUESDAY, FEBRUARY 14, 2017

**Poster P-A1: VIROLOGY TRAFFICKING**
**Poster Hall - 4 EF**
2:30 PM - 4:00 PM

154  **PHENOTYPING AND SORTING OF INDIVIDUAL FREE INFECTIONOUS HIV PARTICLES BY FLOW CYTOMETRY**
Michał Bonar, John Tilton
Case Western Reserve Univ, Cleveland, OH, USA

155  **SINGLE VIRUS IMAGING OF HIV-1 WITH FLUORESCENTLY LABELED CA**
Zeger Debyser, Irena Zurnic, Lieve Dirix, Veerle Lemmens, Veerle Lemmens, Susana Rocha, Johan Hofkens, Jelle Hendrix, **Frauke Christ**
Katholieke Univ Leuven, Leuven, Belgium

156  **CHARACTERIZING CELLULAR FACTORS INVOLVED IN HIV-1 GAG TRAFFICKING TO ASSEMBLY SITES**
Rachel Van Duyne, Philip R. Tedbury, Eric O. Freed
NCI, Frederick, MD, USA

157  **HIV-1 RESISTANCE TO KF116 REVEALS INTEGRASE’S ROLE DURING POLYPROTEIN PROCESSING**
Ashley C. Hoyte1, Augusta V. Jamin2, Pratibha Chowdary Koneru1, Stephanie Rebensburg2, Jason Anderson2, Matthew Kobe1, Emma N. Ivanauskas1, James R. Fuchs2, Alan N. Engelman2, Mamuka Kvaratskhelia1
1The Ohio State Univ, Columbus, OH, USA, 2Dana-Farber Cancer Inst, Boston, MA, USA

158  **ROLE OF MA TRIMERIZATION IN HIV-1 ENVELOPE GLYCOPROTEIN INCORPORATION**
Mariia Novikova, Philip R. Tedbury, Eric O. Freed
NCI, Frederick, MD, USA

159  **PRODUCTION OF HIV-1 PROTEINS FROM “DEFECTIVE” HIV-1 PROVIRUS**
Hiromi Imamichi1, Joseph Adelsberger2, H. Clifford Lane3
1NIAID, Bethesda, MD, USA, 2Leidos Biomed Rsr, Inc, Frederick, MD, USA

160LB  **NUCLEAR PORE HETEROGENEITY AFFECTS HIV-1 INFECTION AND THE ANTIVIRAL ACTIVITY OF MX2**
Melissa Kane1, Stephanie Rebensburg2, Matthew Takata1, Trinity Zang1, Masahiro Yamashita3, Mamuka Kvaratskhelia1, Paul Bieniasz4
1The Rockefeller Univ, New York, NY, USA, 2The Ohio State Univ, Columbus, OH, USA, 3Aaron Diamond AIDS Rsr Cntr, New York, NY, USA, 4Howard Hughes Med Cntr, New York, NY, USA
182  IDENTIFICATION OF MAJOR ROUTES OF HIV TRANSMISSION THROUGHOUT MESOAMERICA
Antoine Chaillon1, Joel O. Wertheim1, Santiago Avila-Rios1, Ann M. Dennis3, Claudia García-Morales2, Carlos Mejía-Villatoro5, Elsa Y. Palou5, Gustavo Reyes-Terán4, Sanjay R. Mehta1, for the The Mesoamerican Project Group
1Univ of California, San Diego, San Diego, CA, USA, 2Nat! Inst of Respiratory Diseases, Mexico City, Mexico, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Roosevelt Hosp, Guatemala City, Guatemala, 5 Hosp Escuela Univ, Tegucigalpa, Honduras, 6Rsr Cntr in Infectious Diseases, Mexico City, Mexico

183  REVEALING THE MOLECULAR EPIDEMIOLOGY OF THE COLOGNE, GERMANY, HIV EPIDEMIC
Melanie Stecher1, Martin Hoenigl2, Joerg Janne Vehreschild1, Clara Lehmann1, Gerd Fätkenheuer3, Rolf Kaiser1, Sanjay R. Mehta2, Antoine Chaillon2
1Univ of Cologne, Cologne, Germany, 2Univ of California San Diego, San Diego, CA, USA, 3Cologne Univ Hosp, Cologne, Germany

184  STRUCTURE OF HIV-1C TRANSMISSION NETWORK IN SOUTHERN BOTSWANA, 2016
Vlad Novitsky1, Sikhulile Moyo2, Melissa Zahralban-Steele1, Baitshepi Mokaleng3, Dorcas Maruapula2, Mary F. McLane1, Kathleen Wirth1, Lisa A. Mills1, Simani Gaseitsiwe2, Max Essex1
1Harvard Univ, Boston, MA, USA, 2Botswana Harvard AIDs Rsr Inst Partnership, Gaborone, Botswana, 3CDC Botswana, Gaborone, Botswana

185  PHYLOGENETICS OF A RECENT HIV OUTBREAK AMONG PEOPLE WHO INJECT DRUGS IN SCOTLAND
Manon Ragonnet-Cronin1, Celia Jackson2, Amanda Bradley-Stewart3, Celia Aitken4, Andrew McAuley3, Norah Palmateer1, David Goldberg1, Catriona Milosevic2, Andrew Leigh Brown1
1Univ of Edinburgh, Edinburgh, UK, 2NHS Greater Glasgow and Clyde, Glasgow, UK, 3Hlth Protection Scotland, Scotland, Glasgow, UK

186  NONDISCLOSED MSM LINK TOGETHER IN HIV TRANSMISSION NETWORKS
Manon Ragonnet-Cronin1, Stéphane Hué2, Anna Tostevin2, Anton Pozniak1, Tracy Fawcett4, Alison E. Brown1, David Dunn3, Andrew Leigh Brown1, for the UK HIV Drug Resistance Database

187  MATING THE EFFECT OF COMPLETENESS OF HIV SEQUENCING DATA ON TRANSMISSION NETWORKS
Sharoda Dasgupta1, Anne Marie France1, Mary-Grace Brandt2, M Cheryl B. Ocfemia1, Tianchi Zhang1, Nivedha Panneer1, Angela Hernandez2, Alexandra Oster1
1CDC, Atlanta, GA, USA, 2Michigan Dept of Community Hlth, Detroit, MI, USA
188  TEMPORAL CHANGES IN HIV TRANSMISSION PATTERNS AMONG YOUNG MEN WHO HAVE SEX WITH MEN

Nivedha Panneer1, Y. O. Whiteside2, Anne Marie France3, Joel O. Wertheim3, Alexandra Oster4
1Oak Ridge Inst for Sci and Educ, Atlanta, GA, USA, 2CDC, Atlanta, GA, USA, 3Univ of California San Diego, San Diego, CA, USA

189  PHYLDYNAMIC ANALYSIS AIDS PARTNER SERVICES BY IDENTIFYING UNREPORTED TRANSMISSION

Ellsworth Campbell1, Anupama Shankar1, Emily Westheimer2, Cynithia L. Gay3, Stephanie E. Cohen3, Jin-Fen Li4, Jeffrey A. Johnson5, Philip J. Peters1, William M. Switzer6
1CDC, Atlanta, GA, USA, 2New York City DHMH, New York, NY, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4San Francisco Dept of Pub Hlth, San Francisco, CA, USA

190  NEUTRALIZING ANTIBODIES IN HUMANS INFECTED WITH ZOONOTIC SIMIAN FOAMY VIRUSES

Caroline Lambert, Julie Gouzil, Léa Richard, Régane Rua, Edouard Betsem, Antoine Gessain, Florence Buseyne
Inst Pasteur, Paris, France

Poster P-C4: ANIMAL MODELS OF HIV INFECTION
Poster Hall - 4 EF 2:30 PM - 4:00 PM

216  ANTIBIOTICS DISRUPT GASTROINTESTINAL BACTERIA AND HOST IMMUNITY IN RHESUS MACAQUES

Alexander S. Zevin, Jennifer A. Manuzak, Tiffany Hensley-McBain, Ryan Cheu, Charlene Miller, Jacob Modesitt, Jeremy Smedley, Nichole Klatt
Univ of Washington, Seattle, WA, USA

217  ALCOHOL CONSUMPTION INCREASES SIV FOUNDER VIRUS DIVERSITY TO ALTER DISEASE COURSE

Spencer Robichaux, Angela M. Amedee
Louisiana State Univ, New Orleans, LA, USA

218  GORILLA ENTERIC VIROME DYNAMICS IN ASSOCIATION WITH SIV INFECTION

Mirela D’arc1, Carolina Furtado, Juliana D. Siqueira2, Ahidjo Ayoub3, Martine Peeters1, Marcelo A. Soares2
1Univ Fed do Rio de Janeiro, Rio de Janeiro, Brazil, 2Inst Nacional de Câncer, Rio de Janeiro, Brazil, 3IRD, Montpellier, France

219  EARLY HIV-1 DETECTION IN HUMANIZED MICE

Hang Su, Prasanta Dash, Larisa Y. Poluektova, Santhi Gorantla, Howard E. Gendelman
Univ of Nebraska, Omaha, NE, USA

220  AN ENGINEERED RNA VIRUS CAUSES ACUTE AIDS IN HUMAN CD4,CCR5 TRANSGENIC MICE

Rachel A. Liberatore, Emily J. Mastrocola, Elena Cassella, Jessie Willen, Fabian Schmidt, Dennis Voronin, Trinity Zang, Theodora Hatzioannou, Paul Bieniasz
The Rockefeller Univ, New York, NY, USA
221 RAPID T FOLLICULAR HELPER CELL RECONSTITUTION IN LYMPH NODES AFTER ART INITIATION
Chun-Shu Wong1, Afroditi Boulougoura1, Angela Kibi2, Jeremy Davis3, Stefania Pittaluga3, Maura Manion1, Andrea Lisco1, Virginia Sheikh4, JoAnn Mican1, Irini Sereti1
1NIAID, Bethesda, MD, USA, 2Leidos Biomed Rsr, Bethesda, MD, USA, 3NCI, Bethesda, MD, USA, 4FDA, Silver Spring, MD, USA

222 INFLAMMASOME AND PYROPTOSIS ARE INVOLVED IN THE LACK OF IMMUNE RESPONSE DURING CART
Michela Masetti1, Massimiliano Fabbiani2, Maria Biasin3, Antonio Muscatello4, Nicola Squilace5, Elisa Colella6, Mario Clerici3, Andrea Gori1, Daria Trabattoni4, Alessandra Bandera5
1Univ of Milan, Milan, Italy, 2San Gerardo Hosp, Monza, Italy, 3Univ of Milan, Segrate, Milan, Italy

223 INCREASED IL-18/IL-1B RATIO BLUNTS CCL20 PRODUCTION AND TH17 GUT HOMING DURING CART
Claire Loiseau1, Mary Requena2, Anne Laure Iscache3, Michelle Cazabat4, Nicolas Carrere5, Bertrand Suc6, Bruno Marchou7, Jacques Izepe8, Pierre Delobel2
1INSERM, Toulouse, France, 2CHU Toulouse, Toulouse, France

224 GENITAL HIV SHEDDING WHEN ANTIRETROVIRAL THERAPY (ART) SUPPRESSES PLASMA HIV RNA
Marta E. Bull1, Caroline Mitchell1, Corey Williams1, Jaime Soria1, Eduardo Ticona2, Eduardo Ticona2, Alberto M. La Rosa2, Joan Dragavon3, Robert Coombs4, Lisa Frenkel3
1Univ of Washington, Seattle, WA, USA, 2Massachusetts General Hosp, Boston, MA, USA, 3Seattle Children’s Rsr Inst, Seattle, WA, USA, 4Hosp Nacional Dos de Mayo, Lima, Peru, 5Hosp Dos de Mayo, Lima, Peru, 6Asociación Civil Impacta Salud y Educación, Lima, Peru

225 PREDICTORS OF IMMUNE RECOVERY AFTER ART IN VERY ADVANCED DISEASE
Pablo F. Belaunzaran-Zamudio1, Alejandro Olmedo1, Irini Sereti1, Yanink Caro-Vega1, Adam Rupert1, Alondra López2, Ian Sanne3, Juan Sierra-Madero4, Michael M. Lederman5
1Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zuirán, Mexico, Mexico, 2NIAID, Bethesda, MD, USA, 3Leidos Biomed Rsr, Inc, Frederick, VA, USA, 4Univ of the Witwatersrand, Johannesburg, South Africa, 5Case Western Reserve Univ, Cleveland, OH, USA

226 PARADOXICAL CD4 DECLINE ON ART: A NOVEL, RARE, AND PERPLEXING IMMUNOLOGIC OUTCOME
Andrea Lisco1, Itzhak Levy2, Jason Brophy2, Claire Deleage4, Chun-Shu Wong3, Adam Rupert4, Caryn G. Morse5, Shanna Chan6, Jacob D. Estes3, Irini Sereti1
1NIAID, Bethesda, MD, USA, 2Academic Med Cntr Hosp, Tel Aviv, Israel, 3Children’s Hosp of Eastern Ontario, Ottawa, Canada, 4Frederick Natl Lab for Cancer Rsr, Frederick, USA, 5Leidos Biomed Rsr, Inc, Frederick, MD, USA, 6NIH, Bethesda, MD, USA, 7Winnipeg Regional Hlth Authority, Manitoba, Canada
**227 EFFECT OF EXOGENOUS INTERFERON ALPHA ON HIV VIRAL POPULATIONS IN VIVO**

Giorgio Bozzi, Wei Shao, Robin L. Dewar, Vinay K. Pathak, Belete A. Desimmi, Ryan C. Burdick, Sara Jones, Claudia Balotta, Mary E. Wright, Frank Maldarelli

1NCI, Frederick, MD, USA, 2Leidos Biomed Rsr, Inc, Frederick, MD, USA, 3Leidos BiomedRs, Inc, Bethesda, MD, USA, 4Univ of Milan, Milan, Italy, 5NIAID, Bethesda, MD, USA

**242 A BROAD POLYCLONAL RESPONSE IS MEDIATED BY SUPERINFECTION WITH 2 DISTINCT VIRUSES**

Bingjie Wang, Katherine L. Williams, Valerie Cortez, James A. Williams, Kelly K. Lee, R. Scott McClelland, Julie Overbaugh

1Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 2Univ of Washington, Seattle, WA, USA

**243 HIGH-RESOLUTION MAPPING OF AN ENV EPITOPE BY COMPREHENSIVE ESCAPE MUTANT SELECTION**

Adam Dingens, Hugh Haddox, Julie Overbaugh, Jesse Bloom

Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

**244 INITIAL HIV DIVERSITY & NEUTRALIZING ANTIBODY DEVELOPMENT IN PEOPLE WHO INJECT DRUGS**

Andrew D. Redd, Nicole Doria-Rose, Matthew Seivers, Stephen Schmidt, Oliver Laeyendecker, Stephen Porcella, Gregory D. Kirk, John R. Mascola, Shruti H. Mehta, Thomas C. Quinn

1NIAID, Bethesda, MD, USA, 2NIH, Bethesda, MD, USA, 3The Johns Hopkins Univ, Baltimore, MD, USA, 4NIAID, Hamilton, MT, USA, 5Vaccine Rsr Cntr, Bethesda, MD, USA

**245 ELITE NEUTRALIZATION AND UNIQUE EPITOPE SPECIFICITY OF A VIREMIC NONPROGRESSOR**

Nandagopal Paneerselvam, Chinnambedu Ravichandran Swathirajan, Sunil S. Solomon, Jayantha Bhattacharya, Bimal K. Chakrabarti, Rajat Goyal, Aylur K. Srikrishnan, Kailapuri G. Murugavel

1YRG CARE, Chennai, India, 2HIV Vaccine Translational Rsr Lab, Faridabad, India, 3Intl AIDS Vaccine Initiative, New York, NY, USA

**246 USING EMPIRIC SATURATION MUTAGENESIS TO IDENTIFY NOVEL ENV TRIMERS FOR VACCINES**

Maria Jose Duenas Decamp, Li Jiang, Dan Bolon, Paul Clapham

1Univ of Massachusetts, Worcester, MA, USA, 2Harvard Univ, Boston, MA, USA

**247 OLEYLIC ACID DERIVATIVE OKS3-019 AS A NOVEL BIFUNCTIONAL HIV-1 ENTRY INHIBITOR**

Shigeyoshi Harada, Kasumi Oghihara, Yuta Hikichi, Tetsumo Matano, Tetsuo Narumi, Kazuhisa Yoshimura

1Natl Inst of Infectious Diseases, Shinjuku-ku, Tokyo, Japan, 2Shizuoka Univ, Hamamatsu, Shizuoka, Japan

**248 GP41 ANTIGENIC RECOGNITION AND RESPONSE IN HIV-NEGATIVE MEN WHO HAVE SEX WITH MEN**

Katie McFaul, Jia Guo, Elizabeth Atkins, Xiao-Ning Xu, Peter Kelleher, for the Centre for Immunology and Vaccinology

Imperial Coll London, London, UK
249 B-CELL RESPONSES POST-ART INTERRUPTION IN PERSONS TREATED IN FIEBIG I
Supranee Buranapraditkun1, Donn Colby2, Suwanna Pattamasavin2, Suteeraporn Pinyakorn2, Rapee Trichaviroj2, Nelson L. Michael2, Merlin L. Robb2, Jintanat Ananworanich2, Lydie Trautmann2, for the RV411 and RV254/SEARCH010 study groups

1Henry M. Jackson Fndn for the Advancement of Military Med, Bethesda, MD, USA, 2SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 3US Military HIV Rsr Prog, Bethesda, MD, USA, 4Armed Forces Rsr Inst of Med Sci, Bangkok, Thailand, 5Walter Reed Army Inst of Rsr, Silver Spring, MD, USA

250 DC FUNCTIONALITY DISTINGUISHES HIV-1 CONTROLLERS WITH NEUTRALIZING ANTIBODY BREADTH
Enrique Martin-Gayo1, Zhengyu Ouyang1, Dhohyung Kim1, Kellie E. Kolb2, Bruce D. Walker1, Alex K Shalek2, Xu G. Yu1

1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, 2MIT Inst for Med Engineering & Sci (IMES), Cambridge, MA, USA

277 RESIDUAL LOW-LEVEL VIREMIA ON ART NOT ASSOCIATED WITH LOWER SYSTEMIC EXPOSURE TO ARVs
Monica Gandhi1, Andrei Stefanescu1, Ronald Bosch2, Rajesh T. Gandhi3, Joshua C. Cyktor2, Howard Hornig1, Joseph J. Eron3, John W. Mellors4, Deborah McMahon1

1Univ of California San Francisco, San Francisco, CA, USA, 2Harvard Univ, Boston, MA, USA, 3Massachusetts General Hosp, Boston, MA, USA, 4Univ of Pittsburgh, Pittsburgh, PA, USA, 5Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

278 ANTIGP41 TITERS REFLECT RESIDUAL REPLICATION IN VIROLOGICALLY SUPPRESSED ART PATIENTS
Heloise M. Delagreverie1, Maxime Grudé2, Sidonie Lambert3, François Raffi1, Catherine Leport4, Cécile Goujard3, Lorraine Plessis4, Christine Katlama5, Francis Barin5, Constance Delaugerre6

1Hôpital Saint Louis, PARIS, France, 2INSERM, Paris, France, 3Institut Pierre Louis d’Épidémiologie et de Santé, Paris, France, 4CHU Hotel-Dieu Nantes, Nantes, France, 5Hôpital Bichat, Paris, France, 6AP-HP, Le Kremlin-Bicêtre, France, 7INSERM, Villejuif, France, 8Pierre and Marie Curie Univ, Paris, France, 9INSERM, Tours, France, 10Hôpital Saint Louis, Paris, France

279 ANTIBODY LEVELS CORRELATE WITH THE INFECTED CELL POPULATION IN HIV PATIENTS ON ART
Sheila Keating1, Christina Lalama1, Ronald Bosch1, Deborah McMahon1, Joshua Cyktor1, John Mellors3, Joseph J. Eron3, Rajesh T. Gandhi3, Michael P. Busch1, for the ACTG 5321 team

1Blood Systems Rsr Inst, San Francisco, CA, USA, 2Harvard Univ, Boston, MA, USA, 3Univ of Pittsburgh, Pittsburgh, PA, USA, 4Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 5Massachusetts General Hosp and Ragon Inst, Boston, MA, USA

280 PERSISTENT IMMUNE ACTIVATION DESPITE ART: THE “DIE IS CAST” BEFORE ART INITIATION
Rajesh T. Gandhi1, Deborah McMahon1, Ronald Bosch1, Christina Lalama1, Bernard Macatangay2, Joshua Cyktor3, Ann Collier4, Charles Rinaldo2, Joseph J. Eron3, John Mellors2

1Massachusetts General Hosp and Ragon Inst, Boston, MA, USA, 2Univ of Pittsburgh, Pittsburgh, PA, USA, 3Harvard Univ, Boston, MA, USA, 4Univ of Washington, Seattle, WA, USA, 5Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA
281 SEX-BASED DIFFERENCES IN HIV RESERVOIR ACTIVITY AND RESIDUAL IMMUNE ACTIVATION

Eileen Scully1, Monica Gandhi2, Rowena Johnston3, Rob Gorelick4, Jeffrey D. Lifson5, Sharon R. Lewin6, Jonathan Karn7, Nicolas Chomont8, Peter Bacchetti9, Steven G. Deeks9

1The Johns Hopkins Univ, Baltimore, MD, USA, 2Univ of California San Francisco, San Francisco, CA, USA, 3amfAR, New York, NY, USA, 4Leidos Biomed Rsr, Inc, Frederick, MD, USA, 5Frederick Natl Lab, Frederick, MD, USA, 6Univ of Melbourne, Melbourne, Australia, 7Case Western Reserve Univ, Cleveland, OH, USA, 8Univ de Montréal, Montréal, QC, Canada

Poster Sessions • Tuesday
Program and Agenda
CROI 2017

Poster P-E5: PARSING PERSISTENT PROVIRUSES
Poster Hall - 4 EF
2:30 PM - 4:00 PM

300 NOVEL ASSAY TO MEASURE INTEGRATED HIV DNA IN PBMC FROM ART-SUPPRESSED PERSONS

Steven Lada1, Jake VanBelzan2, Caroline Ignacio1, Matthew Strain1, Una O’Doherty2, Douglas D. Richman1

1Univ of California San Diego, La Jolla, CA, USA, 2Univ of Pennsylvania, Philadelphia, PA, USA

301 PARALLEL NEXTGEN FULL-LENGTH HIV PROVIRAL DNA SEQUENCE AND INTEGRATION SITE ANALYSIS

Mathew L. Jones, Emanuele Marchi, Jacob Hurst, Nicola Robinson, John Frater

Univ of Oxford, Oxford, UK

302 HIV-1 INTEGRATION SITES ANALYSIS REVEALS DIFFERENT COMPARTMENTS OF THE HIV RESERVOIR

Eva Malatinkova1, Wei Wang1, Stephanie Laufs2, Ward De Spieghelaere1, Ning Wu3, Saira Afzal1, Raffaele Fronza2, Sabine Kinloch-de Loes3, Manfred Schmidt4, Linos Vandekerckhove1

1HIV Cure Rsr Cntr, Ghent Univ, Ghent, Belgium, 2German Cancer Rsr Cntr and Natl Cntr for Tumor Diseases, Heidelberg, Germany, 3Royal Free Hosp, London, UK

303 ENRICHMENT OF DEFECTIVE PROVIRUSES LACKING TAT-REV DURING LONG-TERM ART

Francesco R. Simonetti1, Paolo Cattaneo1, Alessia Lai1, Elizabeth M. Anderson1, Stefano Rusconi1, Melissa Tosiano1, John Mellors2, Frank Maldarelli2, Massimo Galli1, Claudia Balotta1

1Univ of Milan, Milan Italy, 2NCI, Frederick, MD, USA, 3Univ of Pittsburgh, Pittsburgh, PA, USA, 4Luigi Sacco Univ Hosp, Milan, Italy

304 HIV INTEGRATION SITE/ORIENTATION CONFER SELECTIVE ADVANTAGE FOR PERSISTENCE ON ART

Hadega Aamer1, Malika Aid2, Sherry McLaughlin1, Thomas R. Sibley3, Evan J. Silberman1, Wenjie Deng1, Paul Edlefsen1, Rafick-Pierre Sekaly1, Lisa Frenkel1, James Mullins1

1Seattle Children’s Rsr Inst, Seattle, WA, USA, 2Harvard Univ, Boston, USA, 3Univ of Washington, Seattle, WA, USA, 4Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 5Case Western Reserve Univ, Cleveland, OH, USA
305 ROMIDEPSIN-INDUCED HIV-1 VIREMIA IS OLIGOCOLONAL WITH LIMITED DELETERIOUS MUTATIONS
Anni Winckelmann1, Kirston Barton2, Bonnie Hiener2, Timothy E. Schlub3, Wei Shao4, Thomas A. Rasmussen1, Lars Østergaard1, Ole S. Søgaard1, Martin Tøstrup1, Sarah Palmer4
1Aarhus Univ Hosp, Aarhus, Denmark, 2Univ of Sydney, Westmead, Australia, 3Univ of Sydney, Camperdown, New South Wales, Australia, 4Leidos Biomed Rsr, Inc, Frederick, MD, USA

317 INDUCIBLE HIV-1 LATENT RESERVOIR INCREASES AFTER HIV+ OR HIV- SOLID ORGAN TRANSPLANT
Alyssa R. Martin1, Andrew D. Redd2, Gregory Laird1, Robert Siliciano1, Diane Brown1, Darin Ostrander1, Thomas Quinn3, Dorry Segev1, Aaron Tobian1, Christine Durand1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2NIAID, Bethesda, MD, USA

318 PERSISTENCE OF A MINORITY HIV VARIANT DESPITE ALLOBMT WITH COMPLETE DONOR CHIMERISM
Adam Capoferri1, Andrew D. Redd3, Daniel I. Rosenbloom2, Roberto Ramirez2, Subul Beg1, Andrew Timmons5, Christopher Gocke6, Robert Siliciano1, Richard Ambinder1, Christine Durand1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2NIAID, Bethesda, MD, USA, 3Columbia Univ, New York, NY, USA, 4Uni of California San Diego, La Jolla, CA, USA, 5Univ of Minnesota, Minneapolis, MN, USA

319 TWO HUNDRED EIGHTY-EIGHT–DAY DRUG-FREE REMISSION FROM HIV REBOUND BY ALLOGENEIC PBSCT
Nathan Cummins1, Stacey Rizza2, Jason Baker2, Nicolas Chomont3, Tae-Wook Chun4, Mathias Lichterfeld5, Douglas D. Richman6, Timothy Schacker7, Joseph D. Yao1, Andrew Badley1
1Mayo Clinic, Rochester, MN, USA, 2Univ of Minnesota, Minneapolis, MN, USA, 3Univ de Montréal, Montreal, QC, Canada, 4NIH, Bethesda, MD, USA, 5Massachusetts General Hosp, Boston, MA, USA, 6Univ of California San Diego, La Jolla, CA, USA, 7Univ of Minnesota, Minneapolis, MN, USA

320 PERSISTENCE OF HIV DNA IN TISSUES EARLY AFTER TRANSPLANTATION WITH CCR5Δ32 STEM CELLS
Kobus Bosman1, Monique Nijhuis1, Anke Bruns1, Maria Salgado2, Gero Hütter1, Lodewijk Brosens1, Javier Martinez-Picado2, Jürgen Kuball1, Annemarie Wensing1, for the IciStem consortium
1Univ Med Cntr Utrecht, Utrecht, Netherlands, 2AIDS Rsr Inst IrsiCaixa, Badalona, Spain, 3Cellex, Dresden, Germany, 4ICREA, Barcelona, Spain

321 IMMUNE DYSREGULATION DICTATES SHIV REBOUND AFTER STEM-CELL TRANSPLANTATION IN MACAQUES
Christopher Peterson1, Clarisse Benne1, Patricia Polacino1, Keith Jerome1, Shiu-Lok Hu2, Nichole Klaat4, Stephen DeRosa1, Rafick-Pierre Sekaly1, Hans-Peter Kiem1
1Fred Hutchinson Cancer Cntr, Seattle, WA, USA, 2Case Western Reserve Univ, Cleveland, OH, USA, 3Washington Natl Primate Rsr Cntr, Seattle, WA, USA, 4Univ of Washington, Seattle, WA, USA
322 CONTROL OF PATHOGENIC SHIV INFECTION IN TRANSPLANTED MACAQUES
Christopher Peterson, Kevin G. Haworth, Bryan P. Burke, Patricia Polacino, Shiu-Lok Hu, Brandon Keele, Jeffrey S. Bartlett, Geoff P. Symonds, Hans-Peter Kiem
1Fred Hutchinson Cancer Res Ctr, Seattle, WA, USA, 2Calimmune, Inc, Pasadena, CA, USA, 3Washington Ntl Primate Res Ctr, Seattle, WA, USA, 4Univ of Washington, Seattle, WA, USA, 5NCI, Frederick, MD, USA

Poster Sessions • Tuesday
Program and Agenda
CROI 2017

373 PROGRESSIVE HIPPOCAMPAL NEURONAL LOSS IN PEDIATRIC SIV INFECTION
Heather Carryl, Koen Van Rompay, Kristina De Paris, Mark W. Burke
1Howard Univ, Washington, DC, USA, 2Univ of California Davis, Davis, CA, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

374 HIV GENE VARIANTS ALTERING CORECEPTOR BINDING & DRUG RESISTANCE PREDICT CNS PHENOTYPES
Debashis Sahoo, Sarah Dabydeen, Kumud K. Singh
Univ of California San Diego, La Jolla, CA, USA

375 IFNγ-INDUCED PROTEASOMAL DEGRADATION OF ASTROCYTIC HO-1 IN HIV NEUROPATHOGENESIS
Alexander J. Gill, Colleen E. Kovacsics, Suren A. Ambegaokar, Benjamin B. Gelman, Dennis L. Kolson
1Univ of Pennsylvania, Philadelphia, PA, USA, 2Ohio Wesleyan Univ, Delaware, OH, USA, 3Univ of Texas Med Branch, Galveston, TX, USA

377 CNS IRON STATUS IS ASSOCIATED WITH NEUROCOGNITIVE FUNCTION OVER TIME IN HIV+ ADULTS
1Cleveland Clinic, Cleveland, OH, USA, 2Case Western Reserve Univ, Cleveland, OH, USA, 3Univ of California San Diego, San Diego, CA, USA, 4Penn State, Hershey, PA, USA, 5Vanderbilt Univ, Nashville, TN, USA

378 DIFFERENTIAL IN VITRO NEUROTOXICITY OF ANTIRETROVIRAL DRUGS
Cagla Akay-Espinoza, Anna L. Stern, Rebecca I. Nara, Nina Panvelker, Jiean Li, Kelly L. Jordan-Sciutto
1Univ of Pennsylvania, Philadelphia, PA, USA

379 DISCORDANT HIV RNA IN OLFATORY MUCOSA OF HIV-POSITIVE PATIENTS
Andrea Calcagno, Tiziano Allice, Luca Bertero, Mattia Trunfio, Maria Enrica Amasio, Daniele Imperiale, Valeria Ghisetti, Giovanni Di Perri, Paola Cassoni, Stefano Bonora
1Univ of Torino, Torino, Italy, 2Ospedale Amedeo di Savoia, Torino, Italy, 3Ospedale Maria Vittoria, Torino, Italy
380 CAN WE AFFORD TO WAIT? ART AND THE CNS
Kevin Robertson1, Javier R. Lama2, Christopher D. Pilcher3, Jessica Rios2, Peter Brandes4, Eduardo Ruiz2, Eline Appelmans4, Serena Spudich5, Ann Duer2, for the SABES Team

1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Asociacion Civil Impacta Salud y Educacion, Lima, Peru, 3Univ of California San Francisco, San Francisco, CA, USA, 4Fred Hutchinson Cancer Rsr Ctr, Seattle, WA, USA, 5Yale Univ, New Haven, CT, USA

381 CENICRIVIROC IMPROVES NEUROCOGNITION AND REDUCES MONOCYTE ACTIVATION IN TREATED HIV
Lishomwa C. Ndhlovu1, Michelle L. D’Antoni1, Robert Paul2, Kalpana J. Kallianpur3, Laurent Fischer1, Eric Lefebvre1, Star Seyedkazemi1, Beau K. Nakamoto1, Debra Ogata-Arakaki1, Cecilia Shikuma1

1Univ of Hawaii, Honolulu, HI, USA, 2Univ of Missouri–St. Louis, St. Louis, MO, USA, 3Tobira Therapeutics, Inc, South San Francisco, CA, USA

382 CSF INFLAMMATORY MARKERS AFTER ADDING MARAVIROC TO MONOTHERAPY DARUNAVIR/RITONAVIR
Tristan Barber1, Arkaitz Imaz2, Marta Boffito3, Daniel Podzamczer1, Anton Pozniak1, Rosa Fortuny2, Nicholas Davies3, Jordi Niubo2, Sundhiya Mandalia1, Brian Gazzard1

1Chelsea and Westminster NHS Fndn Trust, London, UK, 2Hosp Univ de Bellvitge, Barcelona, Spain, 3Imperial Coll London, London, UK

383 CSF LEVELS OF THE GLIAL MARKER YKL-40 STRONGLY ASSOCIATED WITH NEURONAL INJURY IN HIV
Linn Hermansson1, Markus Axelsson1, Kai Bleenow1, Dietmar Fuchs3, Lars Hagberg1, Jan Lycke1, Henrik Zetterberg1, Magnus Gisslén1

1Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, 2Sahlgrenska Univ Hosp, Gothenburg, Sweden, 3Innsbruck Med Univ, Innsbruck, Austria

384 EXTENSIVE EFAVIRENZ METABOLISM IS ASSOCIATED WITH GREATER CNS TOXICITY
Marijana Vujkovic1, Scarlett Bellamy1, Athena Zuppa1, Marc Gastonguay3, Xiaoyan Han1, Mosepele Mosepele1, Gregory Bisson4, Richard Aplenc1, Robert Gross1

1Children’s Hosp of Philadelphia, Philadelphia, PA, USA, 2Drexel Univ, Philadelphia, PA, USA, 3Metrum Rsr Group, Tariffville, CT, USA, 4Univ of Pennsylvania, Philadelphia, PA, USA, 5Univ of Botswana, Gaborone, Botswana

385 EXHAUSTED T CELLS AND INFLAMMATORY MONOCYTES ARE LINKED TO BRAIN ATROPHY IN HIV
Brooks I. Mitchell1, Glen Chew1, Kalpana J. Kallianpur1, Mary Margaret Byron1, Robert Paul2, Beau K. Nakamoto1, Dominic Chow1, Scott A. Souza2, Cecilia Shikuma1, Lishomwa C. Ndhlovu1

1Univ of Hawaii, Honolulu, HI, USA, 2Univ of Missouri–St. Louis, St. Louis, MO, USA

Poster P-F6 INTERVENTION-FOCUSED
Poster Hall - 4 EF 2:30 PM - 4:00 PM

Poster P-F7 HOST AND VIRAL BIOMARKERS
Poster Hall - 4 EF 2:30 PM - 4:00 PM
<table>
<thead>
<tr>
<th>Poster Session ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>386</td>
<td>CSF AND SERUM BIOMARKERS OF NEURONAL INJURY AND AGING IN HIV-INFECTED PARTICIPANTS</td>
<td>Sergio M. de Almeida, Clea E. Ribeiro, Indianara Rotta, Mauro Plovesan, Sonia M. Raboni, Scott Letendre, Bin Tang, Florin Vaida, Ronald J. Ellis</td>
<td>1Univ Fed do Paraná, Curitiba, Brazil, 2Univ of California San Diego, San Diego, CA, USA</td>
</tr>
<tr>
<td>387</td>
<td>CSF S100B AND CX3CR1 MONOCYTES IN ACUTE HIV INFECTION PREDICT PUTAMEN ATROPHY</td>
<td>Lishomwa C. Ndhlouvé, Kalpana J. Kallianpur, Eugene Kroom, Thep Chalermchai, Khunthalee Benjapornpong, Shelly J. Krebs, Serena Spudich, Jintanat Ananworanich, Victor Valcour</td>
<td>1Univ of Hawaii, Honolulu, HI, USA, 2SEARCH, The Thai Red Cross AIDS Rsr Ctr, Bangkok, Thailand, 3SEARCH, Bangkok, Thailand, 4Thai Red Cross AIDS Rsr Ctr, Bangkok, Thailand, 5US Military HIV Rsr Prag, Silver Spring, MD, USA, 6Yale Univ, New Haven, CT, USA, 7Univ of California San Francisco, San Francisco, CA, USA</td>
</tr>
<tr>
<td>388</td>
<td>TELOMERE LENGTH: NEUROCOGNITIVE BIOMARKER IN HIV-1-INFECTED SUBJECTS</td>
<td>Marília L. Araújo, Maria Rita, P Gascón, Raquel Paiva, Bárbara Santana, Rodrigo Calado, Wellington Duarte, Luiz A. Fonseca, Augusto César P. Oliveira, Jorge Cassebi</td>
<td>1Univ de São Paulo, São Paulo, Brazil, 2Inst de Infectologia Emílio Ribas, São Paulo, Brazil, 3Univ de São Paulo Ribeirão Preto, Ribeirão Preto, Brazil</td>
</tr>
<tr>
<td>389</td>
<td>CEREBROSPINAL FLUID CONCENTRATION OF THE SYNAPTIC MARKER NEUROGRANIN IN HIV</td>
<td>Maria C. Brühl, Aylin Yilmaz, Lars Hagberg, Dietmar Fuchs, Kai Bliennow, Henrik Zetterberg, Richard W. Price, Magnus Gisslén</td>
<td>1Sahlgrenska Univ Hosp, Gothenburg, Sweden, 2Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, 3Innsbruck Med Univ, Innsbruck, Austria, 4San Francisco General Hosp, San Francisco, CA, USA</td>
</tr>
<tr>
<td>390</td>
<td>THE HUMAN GUT MICROBIOME AND HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS</td>
<td>Josue Perez-Santiago, Sara Gianella, Ajay Bharti, Debralee Cookson, Robert K. Heaton, Igor Grant, Scott Letendre, Scott N. Peterson</td>
<td>1Univ of California San Diego, San Diego, CA, USA, 2Univ of California San Diego, La Jolla, CA, USA, 3Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA, USA</td>
</tr>
<tr>
<td>391</td>
<td>HIV ANTIBODIES IN CSF AND SERUM IN UNTREATED AND TREATED INFECTION</td>
<td>Magnus Gisslén, Richard W. Price, Serena Spudich, Lars Hagberg, Steven G. Deeks, Peter Burbelo</td>
<td>1Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, 2Univ of California San Francisco, San Francisco, CA, USA, 3Yale Univ, New Haven, CT, USA, 4NIDCR, Bethesda, MD, USA</td>
</tr>
<tr>
<td>392</td>
<td>NUCLEAR-MITOCHONDRIAL INTERACTIONS AND NEUROCOGNITIVE IMPAIRMENT IN HIV+ ADULTS</td>
<td>Sandra P. Smieszek, Asha R. Kallianpur, David C. Samuel, Donald Franklin, Robert K. Heaton, Scott Letendre, Ronald J. Ellis, Todd Hulgan, William S. Bush</td>
<td>1Case Western Reserve Univ, Cleveland, OH, USA, 2Cleveland Clinic Lerner Coll of Med, Cleveland, OH, USA, 3Vanderbilt Univ, Nashville, TN, USA, 4Univ of California San Diego, San Diego, CA, USA, 5Univ of California San Diego, La Jolla, CA, USA</td>
</tr>
</tbody>
</table>
404 LEDIPASVIR/SOFOSBUVIR RAISES TENOFOVIR DIPHOSPHATE CONCENTRATIONS IN RED CELLS

Christine MacBrayne1, Daniel S. Fierer2, Kristen M. Marks3, Peter L. Anderson1, Lane R. Bushman4, Kimberly M. Hollabaugh4, Michael D. Hughes4, Raymond T. Chung5, Susanna Naggie6, Jennifer J. Kiser1

1Univ of Colorado, Aurora, CO, USA, 2Icahn Sch of Med at Mt Sinai, New York, NY, USA, 3Weill Cornell Med, New York, NY, USA, 4Harvard Univ, Boston, MA, USA, 5MGH, Boston, USA, 6Duke Univ, Durham, NC, USA

405 TENOFOVIR DIPHOSPHATE ARISING FROM TAF IS QUANTIFIABLE IN DRIED BLOOD SPOTS

Jose Castillo-Mancilla, Ryan P. Coyle, Jia-Hua Zheng, Lucas Ellison, Laura Roon, Jordan Fey, Lane Bushman, Jennifer J. Kiser, Peter Anderson

Univ of Colorado, Aurora, CO, USA

406 EXTRA/INTRA-CELLULAR NUCLEOSIDE/TIDE SEMEN PHARMACOLOGY: IMPLICATIONS FOR ERADICATION

Julie B. Dumond, Stephen A. Greene, Heather M. Asher Prince, Jingxian Chen, Brian Maas, Craig Sykes, Amanda Schauer, Cynthia L. Gay, Angela Kashuba, Myron S. Cohen

Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

407 INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPHOID VS GI TISSUES

Sulggi Lee1, Hiroyu Hatano1, Angela Kashuba2, Mackenzie L. Cottrell2, Teri Liegler1, Sophie Stephenson1, Ma Somsouk1, Peter W. Hunt1, Steven G. Deeks1, Radojka M. Savic1

1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

408 PLASMA AND INTRACELLULAR PK OF TENOFOVIR IN PATIENTS SWITCHED FROM TDF TO TAF

Anthony Podany, Sara H. Bares, Joshua Havens, Ravi Dyavar Shetty, Jennifer O’Neill, Sarah Lee, Courtney Fletcher, Susan Swindells, Kimberly K. Scarsi

Univ of Nebraska, Omaha, NE, USA
415  PHARMACOKINETICS ANALYSIS OF VRC01, A BROADLY NEUTRALIZING HIV-1 MONOCLONAL ANTIBODY

Yunda Huang1, Lily Zhang1, Nicole Grunenberg1, Robert Bailor2, Abby Isaacs1, Julie Ledgerwood3, Kelly Seaton3, Kenneth Mayer2, Larry Corey1, Peter Gilbert1

1Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 2NIAID, Gaithersburg, MD, USA, 3NIAID, Bethesda, MD, USA, 4Duke Human Vaccine Inst, Durham, NC, USA, 5The Fenway Inst, Boston, MA, USA

416  EFFECT OF CYP3A4*22 ON ORAL RILPIVIRINE PLASMA CONCENTRATIONS

Rana Abutaima1, Marta Boffito1, Andrea Calcagno1, Jessica Cusato1, Antonio D'Avolio1, Laura Else1, Chris Higgs1, Saye Khoob1, Marco Siccardi1, Andrew Owen1

1Univ of Liverpool, Liverpool, UK, 2St. Stephen's AIDS Trust, Chelsea and Westminster Hosp, London, UK, 3Univ of Turin, Turin, Italy

417  EFFECT OF CYP3A5 GENOTYPE ON THE PK OF MARAVIROC AND METABOLITES IN HEALTHY SUBJECTS

Manoli Vourvahis1, Sunil Nepa1, Annie Fang1, Gwendolyn Faye1, Linda S. Wood2, Jean-Claude Marshall3, Andrew Clark3, Jayvant Heera4

1Pfizer, New York, NY, USA, 2Pfizer, Biostatistics, Collville, PA, USA, 3Pfizer, Groton, CT, USA, 4ViiV Hlthcare, London, UK

418  ABCG2 RS2231142 INFLUENCES TFV CONCENTRATIONS IN PLASMA AND URINE

Margherita Bracchi1, Megan Neary1, Nicole Pagani1, Laura Else2, Saye Khoob1, Zaheer Abbas1, David Hawkins1, Graeme Moyle1, Andrew Owen2, Marta Boffito1

1Chelsea and Westminster Hosp, London, UK, 2Univ of Liverpool, Liverpool, UK, 3Chelsea and Westminster NHS Fndn Trust, London, UK

419  TFV-DP IN DRIED BLOOD SPOTS (DBS) FOLLOWING DIRECTLY OBSERVED THERAPY: DOT-DBS STUDY

Peter Anderson1, Albert Y. Liu1, Jose Castillo-Mancilla1, Sharon Seifert1, Cricket McHugh1, Theresa Wagner1, Susan Buchbinder1, Lane Bushman1, Jennifer J. Kiser1, Samantha Whining1

1Univ of Colorado Denver, Aurora, CO, USA, 2San Francisco Dept of Pub Hlth, San Francisco, CA, USA

420  IN VITRO AND IN VIVO EVALUATION OF BIODEGRADABLE IMPLANT CONTAINING TAF FOR HIV PREP

Phillip G. Durham1, Greg Gatto1, Leah Johnson1, Mark A. Marzinke2, Stephanie Swarner2, Ginger Rothrock2, Tejal Desai3, Ian McGowan3, Ida Washington3, Ariane van der Straaten4

1RTI Intl, Durham, NC, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Univ of California San Francisco, San Francisco, CA, USA, 4Univ of Pittsburgh, Pittsburgh, PA, 5Magee-Womens Rsr Inst, Pittsburgh, PA, USA, 6RTI Intl, San Francisco, CA, USA
421LB  HPTN 076: TMC278 LA SAFE, TOLERABLE, AND ACCEPTABLE FOR HIV PRE-EXPOSURE PROPHYLAXIS

Linda-Gail Bekker, Shuying S. Li, Betsy Tolley, Mark A. Marzinke, Nyaradzo Mgodi, Jessica E. Justman, Shobha Swaminathan, Adeola Adeyeye, Jennifer H. Farrior, Nirupama Sista

1Univ of Cape Town, Cape Town, South Africa, 2FRCHC, Seattle, WA, USA, 3FHI 360, Durham, NC, USA, 4Johns Hopkins Univ, Baltimore, MD, USA, 5Univ of Zimbabwe, Harare, Zimbabwe, 6ICAP at Columbia Univ, New York, NY, USA, 7Rutgers Univ, Newark, NJ, USA, 8NIH, Rockville, MD, USA

422LB  TRANSCUTANEOUS REFILLABLE NANOFLUIDIC IMPLANT FOR CONSTANT DELIVERY OF HIV PREP

Corrine Xuan Chua, Priya Jain, Ming Hu, Peter L. Anderson, Jason T. Kimata, Jagannadha Sastry, Roberto Arduino, Alessandro Grattoni

1Houston Methodist Rsr Inst, Houston, TX, USA, 2Univ of Houston, Houston, TX, USA, 3Univ of Colorado Denver, Aurora, CO, USA, 4Baylor Coll of Med, Houston, TX, USA, 5Univ of Texas, Houston, TX, USA

441 WITHDRAWN

442  LONG-TERM SAFETY AND EFFICACY OF CAB AND RPV AS 2-DRUG ORAL MAINTENANCE THERAPY

David A. Margolis, Cynthia Brinson, Graham H. Smith, Joseph J. Eron, Gary J. Richmond, Roger P. LeBlanc, Peter E. Williams, William Spreen, Kenneth Sutton, Britt S. Stancil

1ViiV Hlthcare, Rsr Triangle Park, NC, USA, 2Central Texas Clinical Rsr, Austin, TX, USA, 3Maple Leaf Med Clinic, Toronto, Ontario, Canada, 4Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 5Gary J Richmond MD PA, Ft Lauderdale, FL, USA, 6Clinique OPU5, Montréal, Québec, Canada, 7Janssen Rsr and Development, Beerse, Belgium, 8ViiV Hlthcare, Raleigh, NC, USA, 9PAREXEL Intl, Durham, NC, USA

443  EFFICACY & SAFETY OF SWITCHING TO EVG/COBI/FTC/TAF IN VIROLOGICALLY SUPPRESSED WOMEN

Sally Hodder, Kathleen Squires, Cissy Kityo, Debbie Hagins, Anchalee Avihingsanon, Yulia Plotnikova, Shuping Jiang, Rima Kulkarni, Andrew Cheng, Huyen Cao

1West Virginia Clinical and Translational Sci Inst, Morgantown, WV, USA, 2Thomas Jefferson Univ, Philadelphia, PA, USA, 3Joint Clinical Rsr Ctr, Kampala, Uganda, 4Chatham CARE Ctrn, Savannah, GA, USA, 5HIV-NAT, Thai Red Cross AIDS Rsr Ctrn, Bangkok, Thailand, 6Irktusk Regional Ctrn for Prevention and Control of AIDS and Infectious Diseases, Irktusk, Russian Federation, 7Gilead Scis, Inc, Foster City, CA, USA

444  THE FDA SNAPSHOT ALGORITHM MAY OVERESTIMATE THE EFFICACY OF INITIAL ART

Stephen J. Kerr, Andrew Carr

1The Thai Red Cross AIDS Rsr Ctrn, Bangkok, Thailand, 2St. Vincent’s Hosp, Sydney, Australia
445  **CELLULAR HIV-1 DNA LEVELS AFTER 96 WEEKS OF SWITCH TO ATV/R +3TC IN THE ATLAS-M TRIAL**

Francesca Lombardi1, Simone Belmonti1, Eugenia Quirios-Roldan1, Alessandra Latini1, Chiara Picarelli2, Arianna Emiliozzi1, Massimiliano Fabbiani1, Roberto Cauda1, Andrea De Luca1, for the ATLAS-M study group

1Catholic Univ of Sacred Heart, Rome, Italy, 2Spedali Civili di Brescia, Brescia, Italy, 3IFG S. Gallicano Inst (IRCCS), Rome, Italy, 4Univ of Milan, Milan, Italy, 5Siena Univ Hosp, Siena, Italy

**446 DYNAMICS OF VIRAL LOAD AND CYTOKINES WHEN ART IS INITIATED SOON AFTER HIV ACQUISITION**

Trupti I. Gilada1, Javier R. Lama2, Rachel A. Bender Ignacio3, Ricardo Alfaro2, Carmela Ganoza2, Angela K. Ulrich2, Socorro M. Harb2, Rogelio M. Valdez2, Robert Coombs1, Ann Duer3

1Unison Medicare and Rsr Cntr, Mumbai, India, 2Asociacion Civil Impacta Salud y Educacion, Lima, Peru, 3Univ of Washington, Seattle, WA, USA, 4Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

**447 VALACYCLOVIR DOES NOT ATTENUATE CD4 COUNT DECLINE IN CART-UNTREATED HIV INFECTION**

Darrell H. Tan1, Janet M. Raboud2, Leah Szadkowski3, Beatriz Grinsztejn4, Jose Valdez Madruga5, Pedro Cahn6, Amanda Clarke6, Wendy Zubyk6, Sharon Walmsley10

1St. Michael's Hosp, Toronto, Ontario, Canada, 2Univ of Toronto, Toronto, Ontario, Canada, 3Toronto General Rsr Inst, Toronto, Ontario, Canada, 4Inst Nacional de Infectologia (INI-Fiocruz), Rio de Janeiro, Brazil, 5Centro de Referência e Treinamento em DST/AIDS-SP, Sao Paulo, Brazil, 6Fundación Huesped, Buenos Aires, Argentina, 7St. Stephen's AIDS Trust, London, UK, 8Brighton & Sussex Univ Hosps NHS Trust, Brighton, UK, 9Canadian HIV Trials Network, Vancouver, British Columbia, Canada, 10Univ of Toronto, Toronto, Ontario, Canada

**448 RALTEGRAVIR/EMTRICITABINE/TENOFOVIR IN HIV-2 INFECTION (ANRS 159 VIH-2 PILOT TRIAL)**

Sophie Matheron1, Diane Descamps1, Sébastien Gallien2, Amel Besseghir3, Roland Tubiana4, Florence Diamond5, Fideline Collin5, Francoise Brun-Vezinet5, Genevieve Chene6, for the ANRS 159 VIH2 trial Study Group

1Hopital Bichat-Claude Bernard, AP-HP, Paris, France, 2Hopital Saint Louis, AP-HP, Paris, France, 3INSERM, Bordeaux, France, 4Hopital Pitié-Salpêtrière, AP-HP, Paris, France

**449LB LONG-ACTING IBALIZUMAB IN PATIENTS WITH MULTI-DRUG RESISTANT HIV-1: A 24-WEEK STUDY**

Stanley Lewis1, Jeffry Fessel1, Brinda Emu2, Shannon Schrader4, Princy Kumar5, Gary J. Richmond2, Steven Weinheimer5, Christian Marsolais7

1TaiMed Biologics USA, Irvine, CA, USA, 2Kaiser Permanent Med Cntr, San Francisco, CA, USA, 3Yale Univ, New Haven, CT, USA, 4Schrader Clinic, Houston, TX, USA, 5Georgetown Univ, Washington, DC, 6Gary J Richmond MD PA, Ft Lauderdale, FL, USA, 7Theratechnologies, Inc, Montreal, Canada

**450LB A PHASE 2 OPEN-LABEL TRIAL OF ANTIBODY UB-421 MONOTHERAPY AS A SUBSTITUTE FOR HAART**

Chang-Yi Wang1, Wingwai Wong2, Hung-Chin Tsai1, Mei-June Liao2, Shugene Lynn3, for the United BioPharma UB-421 Clinical and Research Team

1United Biomed, Inc, Hauppauge, NY, USA, 2Taipei Veterans General Hosp, Taipei, Taiwan, 3Kaohsiung Veterans General Hosp, Kaohsiung, Taiwan, 4Kaohsiung Med Univ and Hosp, Kaohsiung, Taiwan, 5United Biopharma, Inc, Hsinchu, Taiwan, 6UBI Asia, Hsinchu, Taiwan
451LB Dolutegravir as Maintenance Monotherapy for HIV-1: A Randomized Clinical Trial

Ingeborg Wijting1, Casper Rokx1, Charles Boucher1, Dorine de Vries-Stuijs2, Karin Schuurink3, Elroyo Andrinopoulou4, Eric van Gorp5, Wouter Bierman1, Bart Rijnders1, for the DOMONO study-group

1Erasmus Univ Med Cntr Rotterdam, Rotterdam, Netherlands, 2Univ Med Cntr Groningen, Groningen, Netherlands

452LB Elsulfavirine as Compared to Efavirenz in Combination with TDF/FTC: 48-Week Study

Robert Murphy1, Alexey V. Kravchenko2, Elena Orlova-Morozova3, Firaya Nagimova1, Oleg Kozirev4, Tatyana Shimonava4, Marina Deulina2, Natalia Vostokova2, Olga Zozulya5, Vadim Bichko6

1Northwestern Univ, Chicago, IL, USA, 2Russia AIDS Federal Cntr, Moscow, Russian Federation, 3Moscow Region AIDS Cntr, Moscow, Russian Federation, 4Republic Tartarstan AIDS Cntr, Kazan, Russian Federation, 5Volgograd Region AIDS Cntr, Volgograd, Russian Federation, 6Moscow City AIDS Cntr, Moscow, Russian Federation, 7IPHARMA Moscow, Moscow, Russian Federation, 8Virion, Inc, San Diego, CA, USA

Poster P-I1 ART: Safety and Prescribing Over the Long Term
Poster Hall - 4 EF 2:30 PM - 4:00 PM

453 Significant Efficacy & Long-Term Safety Difference with TAF-Based STR in Naïve Adults

Jose R. Arribas1, Melanie Thompson2, Paul E. Sax3, Bernhard Haas4, Cheryl McDonald5, David Wohl6, Edwin DeJesus1, Amanda Clarke5, Moupali Das3, Scott McCallister9

1Hosp Univ La Paz, Madrid, Spain, 2AIDS Rsr Consortium of Atlanta, Atlanta, GA, USA, 3Brigham and Women’s Hosp, Boston, MA, USA, 4Hosp Graz West, Graz, Austria, 5Tarrant County Infectious Disease Associates, Fort Worth, TX, USA, 6Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 7IPHARMA Moscow, Moscow, Russian Federation, 8Brighton & Sussex Univ Hospns NHS Trust, Brighton, UK, 9Gilead Scis, Inc, Foster City, CA, USA

454 Patterns of Efavirenz Use as First-Line Therapy in the United States: 1999–2015

Angela Bengtson1, Brian W. Pence1, Ellen F. Eaton1, Jessie K. Edwards1, Joseph J. Eron1, W. C. Mathews1, Katie Mollan1, Richard D. Moore3, Connall O’Cleirigh5, Michael J. Mugavero2

1Univ of Alabama at Birmingham, Birmingham, AL, USA, 2Univ of California San Diego, San Diego, CA, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Univ of California San Diego, San Diego, CA, USA, 5Johns Hopkins, Baltimore, MD, USA, 6Massachusetts General Hosp, Boston, MA, USA

455 ART Initiation, Regardless of Composition, Improves Patient-Reported Depression

Ellen Eaton, Ashutosh Tamhane, Michael J. Mugavero

Univ of Alabama at Birmingham, Birmingham, AL, USA

456 The Clinical and Economic Impact of Dolutegravir-Based First-Line Art in India

Amy Zheng1, Nagalingeswaran Kumarasamy2, Mingshu Huang1, A. David Paltiel3, Kenneth H. Mayer4, Bharat Bhushan Rewari5, Rochelle P. Walensky3, Kenneth Freedberg6

1Massachusetts General Hosp, Boston, MA, USA, 2YR Gaitonde Cntr for AIDS Rsr and Educ, Chennai, India, 3Yale Univ, New Haven, CT, USA, 4Fenway Hlth, Boston, MA, USA, 5WHO, New Delhi, India
**Poster Sessions • Tuesday**

**Program and Agenda**

**CROI 2017**

---

**Poster P-I2 MAINTENANCE: SECOND- AND THIRD-LINE THERAPY**

**Poster Hall - 4 EF: 2:30 PM - 4:00 PM**

**Poster Sessions • Tuesday**

**Program and Agenda**

**CROI 2017**

---

**457 QUALITY OF LIFE IMPROVEMENT DURING SECOND-LINE THERAPY IN RESOURCE-LIMITED SETTINGS**

**Thiago S. Torres**, 1, Linda J. Harrison1, Alberto M. La Rosa2, Lu Zheng1, Sandra W. Cardoso1, Selvamuthu Poongulali4, McNeil Ngongondo5, Ann Collier1, Michael D. Hughes1, for the AIDS Clinical Trials Group (ACTG) A5273 Study Group

1Harvard Univ, Boston, MA, USA, 2Asociación Civil Impacta Salud y Educación, Lima, Peru, 3Inst Nacional de Infectologia (INI/Fiocruz), Rio de Janeiro, Brazil, 4YRCARE Med Cntr, Chennai, India, 5UNC-Proj Malawi, Lilongwe, Malawi, 6Univ of Washington, Seattle, WA, USA

**458 PROMISING RESULTS OF DOLUTEGRAVIR + LAMIVUDINE MAINTENANCE IN ANRS 167 LAMIDOL TRIAL**

**Veronique Joly**1, Charles Burdet1, Roland Landman2, François Raffi4, Christine Katlama3, André Cabié4, Aida Benalycherif5, Gilles Peytavin1, Diane Descamps1, Yzadzai Yazdanpanah1

1Hôpital Bichat, Paris, France, 1INSERM, Paris, France, 3IMEA, Paris, France, 4CHU Hotel-Dieu Nantes, Nantes, France, 5Pierre et Marie Curie Univ, Paris, France, 6CHU Fort de France, Fort de France, Martinique, France

**459 ADVERSE DRUG REACTIONS AMONG PATIENTS RECEIVING SECOND-LINE ART IN SOUTH AFRICA**

**Dorina Onoya**1, Kamban Hirasen1, Lawrence Long1, Matthew Fox2

1Univ of the Witwatersrand, Johannesburg, South Africa, 2Boston Univ, Boston, MA, USA

**460 LONG-TERM EFFICACY OF DOLUTEGRAVIR 50 MG BID IN INI-RESISTANT FAILING HIV-1 SUBJECTS**

**Antonella Castagna**1, Micol Ferrara2, Laura Galli3, Laura Comi4, Gaetana Starrantino1, Giovanni Cenderello5, Mauro Zaccarelli1, Emanuele Focà6, Andrea Roncadori1, Adriano Lazzarini18

1Univ Vita-Salute San Raffaele, Milan, Italy, 2Univ di Torino, Torino, Italy, 3Ospedale San Raffaele, Milano, Italy, 4Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, 5Azienda Ospedaliera Univ Careggi, Firenze, Italy, 6Galliera Hosp, Genoa, Italy, 7Nat Inst for Infectious Diseases, Rome, Italy, 8ASST Spedali Civili di Brescia, Brescia, Italy, 9CINECA, Casalecchio di Reno, Italy, 10San Raffaele Vita-Salute Univ, Milan, Italy

**Poster P-J3 INTEGRASE STRAND TRANSFER INHIBITOR RESISTANCE**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

**Poster Sessions • Tuesday**

**Program and Agenda**

**CROI 2017**

---

**495 EVOLUTION OF ARCHIVED HIV-1 QUASISPECIES IN INDIVIDUALS TREATED WITH DOLUTEGRAVIR**

**Pierre Gantner**1, Guinevere Q. Lee2, David Rey1, Thibault Mesplede1, Marialuisa Partisani1, Geneviève Beck-Wirth1, Jean-Pierre Faller1, Martin Martinot1, Mark Wainberg1, Samira Fafi-Kremer1

1Hôpitaux Univ de Strasbourg, Strasbourg, France, 2BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 3McGill Univ, Montreal, Quebec, Canada, 4Groupe Hosp Regional—Mulhouse Sud Alsace, Mulhouse, France, 5Hôpital Nord Franche Comté, Belfort, France, 6Hôpital Civil de Colmar, Colmar, France
**IMPACT OF CLINICALLY OBSERVED INTEGRASE MUTATIONS ON Dolutegravir Resistance**

Atsuko Hachiya, Masaaki Nakashima, Yoko Ido, Urara Shigemi, Masakazu Matsuda, Reiko Okazaki, Junji Imamura, Yoshiyuki Yokomaku, Yasumasa Iwatani

Natl Hosp Org Nagoya Med Cntr, Nagoya, Japan

---

**BICTEGRAVIR DISSOCIATION HALF-LIFE FROM HIV-1 G140S+Q148H INTEGRASE/DNA COMPLEXES**

Kirsten L. White, Anita Niedziela-Majka, Nikolai Novikov, Michael D. Miller, Haolun Jin, Scott E. Lazerwith, Manuel Tsiang

Gilead Scis, Inc, Foster City, CA, USA

---

**PHENOTYPIC SUSCEPTIBILITY OF SIV AND HIV-1 VARIANTS TO BICTEGRAVIR, A NOVEL INSTI**

Said Hassounah, Thibault Mesplede, Bonnie Spira, Nathan Osman, Mark A. Wainberg

McGill Univ, Montréal, Quebec, Canada

---

**A HIGH-LEVEL RESISTANCE TO INTEGRASE INHIBITORS SELECTED OUTSIDE INTEGRASE HIV-1 GENE**

Isabelle Malet, Frédéric Subra, Charlotte Charpentier, Gilles Collin, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, Olivier Delelis

1Pitié-Salpêtrière Hosp, Paris, France, 2École Normale Supérieure de Cachan, Cachan, France, 3INSEERM, Paris, France, 4Bichat Hosp, Paris, France

---

**EMERGENCE OF INTEGRASE RESISTANCE MUTATIONS DURING INITIAL THERAPY WITH TDF/FTC/DTG**

Jennifer A. Fulcher, Yushen Du, Ren Sun, Raphael J. Landovitz

1Univ of California Los Angeles, Los Angeles, CA, USA, 2UCLA Cntr for Clinical AIDS Rsr & Educ, Los Angeles, CA, USA

---

**CROSS-RESISTANCE PROFILES OF THE NNRTIS IN DEVELOPMENT TO PREVENT HIV-1 INFECTION**

Nicholas S. Giacobbi, Nicolas Sluis-Cremer

Univ of Pittsburgh, Pittsburgh, PA, USA

---

**DRUG RESISTANCE AFTER CESSATION OF Efavirenz-BASED ANTIRETROVIRAL TREATMENT**

Gbolahan Ajibola, Christopher Rowley, Kathleen M. Powis, Sihkullile Moyo, Jean Leidner, Kara Bennett, Florence Chilisa, Joseph Makhema, Roger L. Shapiro, Shahin Lockman

1Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, 2Harvard Univ, Boston, MA, USA, 3Massachusetts General Hosp, Boston, MA, USA, 4Goodtables Consulting, Oklahoma, OK, USA, 5Bennett Statistical Consulting Inc, New York, NY, USA

---

**4′-MODIFIED NRTIS’ POTENT ANTI-HIV ACTIVITY STEMS FROM STRONG RT ACTIVE-SITE BINDING**

Kenji Maeda, Yuki Takamatsu, Debanna Das, Satoru Kohgo, Shinichiro Hattori, Hironori Hayashi, Kouki Matsuda, Stefan G. Sarafianos, Hiroaki Mitsuya

1Natl Cntr for Global Hlth and Med Rsr Inst, Shinjuku, Tokyo, Japan, 2NIH, Bethesda, MD, USA, 3Sojo Univ, Kumamoto, Japan, 4Univ of Missouri, Columbia, MO, USA
**Poster Sessions • Tuesday**

**Program and Agenda**

**CROI 2017**

---

**Poster Session**

**91**

**504LB** RISING TRANSMITTED RESISTANCE FORCES ABANDONMENT OF WHO RECOMMENDED THERAPY IN ARUBA

Laura Marije Hofstra¹, Elena Sánchez Rivas², Monique Nijhuis¹, Eduan Wilkinson³, Karina Kelly³, Tania Mudriko³a, Rob Schuurman¹, Tulio de Oliveira¹, Jaclyn De Kort¹, Annemarie Wensing²

¹Univ Med Cntr Utrecht, Utrecht, Netherlands, ²Dr. Horacio E. Oduber Hosp, Oranjestad, Aruba, ³Univ of KwaZulu-Natal, Durban, South Africa

---

**Poster Session**

**505** LOW HIV-1 RESISTANCE IN SUBJECTS USING DARUNAVIR ONCE-DAILY REGIMENS ACROSS STUDIES

Erkki Lathouwers¹, Eric Y. Wong⁴, Donghan Luo⁵, Sareh Seyedkazemi⁶, Sandra De Meyer⁷, Kimberly Brown⁸

¹Janssen Infectious Diseases BVBA, Beerse, Belgium, ⁷Janssen Scientific Affairs, LLC, Titusville, NJ, USA

---

**Poster Session**

**506** EVOLUTION OF GAG AND GP41 IN PATIENTS RECEIVING FIRST-LINE PI AND NNRTI REGIMENS

Justen Manasa¹, Vici Varghese¹, Soo-Yon Rhee¹, Jeffry Fessel¹, Karen S. Jang⁸, Elizabeth White¹, David Katzenstein¹, Robert Shafer¹

¹Stanford Univ, Stanford, CA, USA, ⁸Kaiser Permanent Med Cntr, San Francisco, CA, USA

---

**Poster Session**

**507** RESISTANCE TO POTENT AND BROADLY ACTIVE HIV-1 MATURATION INHIBITORS

Justin A. Kaplan¹, Emiko Urano¹, Sherimay Ablan¹, Nishani Kuruppu¹, David Martin², T.J. Nitz², Ritu Gaur³, Eric Freed¹

¹NCI, Frederick, MD, USA, ²DFH Pharma, Inc, Gaithersburg, MD, USA, ³South Asian Univ, Akbar Bhawan, Chanakyapuri, New Delhi, India

---

**Poster Session**

**508** CLINICAL VALIDATION OF A NOVEL DIAGNOSTIC HIV-2 TOTAL NUCLEIC ACID QUALITATIVE ASSAY

Ming Chang¹, Audrey J. Wong², Dana Raugi², Robert Smith¹, Jose Ortega¹, Selly Ba¹, Moussa Seydi¹, Geoffrey Gottlieb², Robert Coombs¹, for the University of Washington–Dakar HIV-2 Study Group

¹Univ of Washington, Seattle, WA, USA, ²CHU de Fann, Dakar, Senegal

---

**Poster Session**

**509** EVALUATION OF FDA-APPROVED RAPID HIV TESTS FOR LABORATORY DIAGNOSIS OF HIV INFECTION

Kevin P. Delaney, Steven Ethridge, Hongwei Jia, Silvina Masciotra, Laura Wesolowski

CDC, Atlanta, GA, USA

---

**Poster Session**

**510** PERFORMANCE OF DRIED BLOOD SPOTS AS A SAMPLE TYPE FOR HIV AG/AB COMBO ASSAY

Vera Holzmayer, Kelly Coller, Jill Fuhrman, Mary Rodgers, Gavin Cloherty

Abbott Labs, Abbott Park, IL, USA
**Poster Sessions • Tuesday**

**Program and Agenda**

**CROI 2017**

---

### Poster P-L1 HCV TRANSMISSION: THE CASCADE IS NOT RUNNING DRY

**Poster Hall - 4 EF**

2:30 PM - 4:00 PM

---

### 511 REGENCY STAGING OF HIV INFECTIONS THROUGH ROUTINE DIAGNOSTIC TESTING

Eduard Grebe¹, Alex Welte¹, Jake Hall², Michael P. Busch³, Shelley Facente⁴, Sheila Keating⁵, Kara Marson⁶, Christopher D. Pilcher⁷, **Gary Murphy⁸**, for the CEPHIA


### 512 DEVELOPMENT OF A HIGH-THROUGHPUT MULTIPLEX ASSAY FOR MEASURING HIV INCIDENCE

Martin Stengelin¹, Daisy Roy¹, Sudeep Kumar¹, Kara Marson¹, Steven G. Deeks², Gary Murphy³, Michael P. Busch⁴, **Christopher D. Pilcher⁵**, ¹Meso Scale Diagnostics, LLC, Rockville, MD, USA, ²Univ of California San Francisco, San Francisco, CA, USA, ³Pub Hlth England, London, UK, ⁴Blood Systems Rsr Inst, San Francisco, CA, USA

### 513 IDENTIFYING RECENT HIV INFECTIONS: AN INDIVIDUALIZED ASSESSMENT OF RISK

Jaythoon Hassan¹, Joanne Moran¹, Kate O'Donnell¹, Gary Murphy³, Derval Igoe³, Cillian De Gascun¹, for the Monitoring Recently Acquired HIV Infection Group

¹Univ Coll Dublin, Dublin, Ireland, ²Hlth Protection Surveillance Cntr, Dublin, Ireland, ³Pub Hlth England, London, UK

### 514 THE HIV GENOMIC INCIDENCE ASSAY MEETS FRR AND MDRI PERFORMANCE STANDARDS

Sung Yong Park¹, Tanzy Love¹, Kathryn Anastos¹, Jack DeHovitz⁴, Chenglong Liu⁴, Kord Kobert⁴, Mardge Cohen⁴, Wendy Mack⁴, Elizabeth T. Golub⁴, **Ha Youn Lee⁵**

¹Univ Southern California, Los Angeles, CA, USA, ²Univ of Rochester, Rochester, NY, USA, ³Albert Einstein Coll of Med, Bronx, NY, USA, ⁴SUNY Downstate Med Cntr, Brooklyn, NY, USA, ⁵Georgetown Univ, Washington, DC, USA, ⁶Univ of California San Francisco, San Francisco, CA, USA, ⁷Stroger Hosp, Chicago, IL, USA, ⁸Johns Hopkins Univ, Baltimore, MD, USA

### 515 DURATION OF ACUTE HEPATITIS C INFECTION AND IMPLICATIONS FOR INCIDENCE ESTIMATION

Eshan Patel¹, Anna Eisenberg¹, Jeffrey Quinn¹, Thomas C. Quinn¹, Aaron Tobian¹, Oliver Laeyendecker¹

¹Johns Hopkins Univ, Baltimore, MD, USA, ²NIAID, Baltimore, MD, USA, ³NIAID, Bethesda, MD, USA

### 516 HEPATITIS C VIRUS GENOTYPE AND IG-G AVIDITY RESPONSE DURING RECENT INFECTION

Veronica Bruce¹, Eshan Patel¹, Andrea Cox¹, Shruti H. Mehta¹, Denali Boon², Jacob Konikoff², David Thomas², Thomas C. Quinn¹, Kimberly Page¹, Oliver Laeyendecker¹

¹Univ of New Mexico, Albuquerque, NM, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³NIAID, Bethesda, MD, USA

### 517 IDENTIFICATION OF RISK FACTORS FOR HEPATITIS-C TESTING IN NON-BIRTH COHORT PATIENTS

Amanda E. Smart¹, Alexander Geboy², Peter Basch², Whitney Nichols², Alexander Zeymo², Idene Perez², Maria Hafeez², Ilan Fleisher², Stephen Fernandez², Dawn Fishbein²

¹Georgetown Univ, Washington, DC, USA, ²MedStar Hlth Rsr Inst, Hyattsville, MD, USA
518 ESTABLISHING EPIDEMIOLOGICAL LINKAGE WITHIN HCV NETWORKS USING GENETIC DISTANCE

Rebecca Rose1, Susanna Lamers2, Guido Massaccesi3, William Osburn1, Stuart C. Ray1, Andrea Cox1, Oliver Laeyendecker4

1BioInfoExperts, Norfolk, VA, USA, 2BioInfoExperts, Thibodaux, LA, USA, 3Johns Hopkins Univ, Baltimore, MD, USA, 4NIADD, Baltimore, MD, USA

519 HIGH PREVALENCE OF HEPATITIS-C VIRUS AMONG HIV NEGATIVE MSM IN AMSTERDAM PREP PROJECT

Elske Hoornenborg1, Maria Prins1, Roel C.A. Achterbergh1, Maarten F. Schim van der Loeff1, Udi Davidovich4, Arjan Hogewoning4, Henry J.C. de Vries4, Janke Schinkel1, Thijs J.W. van der Laar1, for the Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam Consortium (H-team)

1Pub Hlth Service Amsterdam, Amsterdam, Netherlands, 2Academic Med Cntr, Amsterdam Zuidoost, Netherlands, 3Stichting Sanquin Bloedvoorziening, Amsterdam, Netherlands

520 HIGH CLUSTERING OF ACUTE HCV INFECTIONS AMONG HIV-POSITIVE MEN WHO HAVE SEX WITH MEN

Eve Todesco1, Nesrine Day2, Corinne Amiel4, Veronique Schneider4, Georges Kreplak2, Laurent Roudrière1, Stéphane Hué1, Christine Katlama1, Anne-Geneviève Marcelin1, Marc-Antoine Valantin1


521 SYSTEMATIC HCV-RNA SCREEN IN HIV+ MSM REVEALS HIGH NUMBERS OF POTENTIAL TRANSMITTERS

Dominique L. Braun1, Roger Koyouso1, Benjamin H. Hampel1, Christina Grube1, Huldrych F. Günthard1, Jürg Böni2, Jan S. Fehr1, for the Swiss HIV Cohort Study

1Univ Hosp Zurich, Zurich, Switzerland, 2Univ of Zurich, Zurich, Switzerland


Gavin Cloherty1, Vera Holzmayer1, Jacques Pepin2, Eric H. Frost4, Michael Fried1, Anto Tshefu1, Franck Rwambwa2, Jérémie Muwanga1, Steven R. Meshnick1, Jonathan Parr1

1Abbott Labs, Abbott Park, IL, USA, 2Univ of Sherbrooke, Sherbrooke, Quebec, Canada, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Univ of Kinshasa, Kinshasa, Democratic Republic of the Congo, 5Natl AIDS Control Prog (PNLS), Kinshasa, Democratic Republic of the Congo

523 LOW HCV PREVALENCE AMONG HIV+ INDIVIDUALS IN SUB-SAHARAN AFRICA

Anne Loarec1, Lucas Molfino2, Kizito Walter2, Winnie Muyindike4, Valentina Carmimeo1, Isabelle Andrieux-Meyer1, Suya Balkan4, Yvonne Nzomukunda1, David Maman2, Juliet Mwanga-Amupaire5

1MSF, Epicentre, Paris, France, 2MSF, Maputo, Mozambique, 3MSF, Nairobi, Kenya, 4Mbarara Univ of Sci and Tech, Mbarara, Uganda, 5MSF, Geneva, Switzerland, 6MSF, Paris, France, 7Epicentre, Cape Town, South Africa, 8MSF, Epicentre, Mbarara, Uganda

524 EFFECT OF OST AND PSYCHOTHERAPY ON HIV RISK AMONG HCV INFECTED INDIVIDUALS

Zahid A. Butt1, Nabin Shrestha1, Naveed Z. Janjua2, for the The BC-HTC Team

1Univ of British Columbia, Vancouver, British Columbia, Canada, 2BC Cntr for Disease Control, Vancouver, British Columbia, Canada
525 PROGRESSION OF LIVER FIBROSIS IN HIV-MONONINFECTED ADULTS WITH ELEVATED TRANSMINASES
Rebecca Krakora1, Mary McLaughlin2, David E. Kleinер1, Nina Kvaratskhelia1, Raissa Canales Santos1, Colleen Hadigan1, Joseph A. Kovacs1, Theo Heller4, Caryn G. Morse1
1NIH, Bethesda, MD, USA, 2NIAID, Bethesda, MD, USA, 3NCI, Bethesda, MD, USA, 4NIDDK, Bethesda, MD, USA

526 GUT EPITHELIAL DAMAGE, IMMUNE ACTIVATION & LIVER FIBROSIS IN HIV AND HCV INFECTION
Michael J. Reid1, Yifei Ma1, Rebecca Scherzer1, Jennifer Price1, Audrey French1, Michael Plankey2, Carl Grunfeld1, Phyllis Tien1
1Univ of California San Francisco, San Francisco, CA, USA 2Rush Univ, Chicago, IL, USA, 3Georgetown Univ, Washington, DC, USA

527 VERTICALLY HIV/HCV- VS HCV-INFECTED CHILDREN: HCV TREATMENT & PROGRESSION TO FIBROSIS
Carolina Fernández McPhee1, Talía Sainz1, Loreto Hierro2, Antoni Noguera-Julián3, María José Mellado3, Marta Montero3, María Isabel González-Tome4, Paloma Jara2, Carmen Diaz1, Maria Luisa Navarro1
1Univ Hosp Gregorio MarañON, Madrid, Spain, 2Hosp La Paz and IdiPaz, Madrid, Spain, 3Univ Hosp La Paz, Madrid, Spain, 4Univ de Barcelona, Barcelona, Spain, 3Hosp Univ y Politécnico La Fe, Valencia, Spain, 4Univ Hosp 12 de Octubre, Madrid, Spain

528 THE ASSOCIATION BETWEEN HCV AND COMORBID CONDITIONS IN 2 LARGE PATIENT COHORTS
Sarah E. Rowan1, Joshua Durfee1, David C. Tabano2, Suzanne Dircksen1, Edward Havranek1, Aimee Truesdale1, Arthur Davidson1
1Denver Hlth and Hosp Authority, Denver, CO, USA, 2Kaiser Permanente Colorado, Denver, CO, USA

529 CAUSE & PREDICTORS OF MORTALITY IN AN HIV/HEPATITIS-C–COINFECTED COHORT IN SCOTLAND
Rebecca Metcalfe1, Gordon Proctor2, Joe Schofield3, Emma Thomson2
1Brownlee Cntr for Infectious Diseases, NHS Greater Glasgow and Clyde, Glasgow, UK, 2Univ of Glasgow, Glasgow, UK, 3Pub Hlth Protection Unit, NHS Greater Glasgow and Clyde, Glasgow, UK

530 ADAR1 SNPS INVOLVED IN SEVERITY OF LIVER DISEASE IN HIV/HCV-COINFECTED PATIENTS
Luz M. Medrano1, Amanda Fernández-Rodriguez1, Juan Berenguer1, Maria A. Jimenez-Sousa1, Teresa Aldamín-Echevarría2, Francisco Tejerina3, Cristina Diez1, Lorena Vigón1, Salvador Resino1, for the Institute of Health Carlos Ill (ISCIII)
1Inst of Hlth Carlos Ill, Madrid, Spain, 2Hosp Gregorio MarañON, Madrid, Spain

531 CB2-RR VARIANT, LINKED TO LIVER DAMAGE IN HIV/HCV CASES, MAY FAVOR HIV ACQUISITION
Caterina Sagnelli1, Marco Merli1, Caterina Uberti-Foppa2, Giulia Bellini1, Hamid Hasson2, Nicola Coppola1, Adriano Lazzarin1, Evangelista Sagnelli1, Francesca Rossi1
1Second Univ of Naples, Naples, Italy, 2San Raffaele Scientific Inst, Milan, Italy
**PNPLA3_RS738409 VARIANT INFLUENCES PROGRESSION TO CIRRHOSIS IN HIV/HCV COINFECTION**

Luis M. Real¹, Juan Macías¹, María Mancebo¹, Mario Frías², Giovanni Dolci³, Francisco Téllez³, Dolores Merino², Giovanni Guaraldi¹, Antonio Rivero-Juárez², Juan A. Pineda¹

¹Hosp Univ de Valme, Sevilla, Spain, ²Hosp Univ Reina Sofia, Córdoba, Spain, ³Univ of Modena and Reggio Emilia, Modena, Italy, ¹Hosp de la Línea, La Línea de la Concepción, Spain, Complexo Hospario Univ de Huelva, Huelva, Spain

**FIB-4 CUTOFFS FOR PREDICTION OF LIVER-RELATED EVENTS IN HIV/HCV COINFECTION**

Leire Pérez Latorre¹, Marisa Montes², Miguel A. Von Wichmann³, Manuel Crespo³, Marta Montero³, Carmen Quereda³, María J. Téllez³, José M. Bellón³, Juan González-García³, Juan Berenguer¹

¹Hosp General Univ Gregorio Marañón, Madrid, Spain, ²Hosp Univ La Paz, Madrid, Spain, ³Hosp Univ Donostia, San Sebastián, Spain, Complexo Hospario Univ de Vigo, Vigo, Pontevedra, Spain, Hosp Univ y Politécnico La Fe, Valencia, Spain, Hosp Ramon y Cajal, Madrid, Spain, Hosp Clínico de San Ildefonso, Madrid, Spain

**EFFECTIVENESS OF DAA s IN HIV/HCV-COINFECTED PATIENTS WITH DECOMPENSATED CIRRHOSIS**

Juan Berenguer¹, Lourdes Domínguez-Dominguez¹, Ángela Gil-Martín¹, Carmen Quereda¹, Teresa Aldámic-Echevarría¹, Ignacio Santos¹, Pablo Ryan¹, Gabriel Gaspar¹, Inma Jarrín¹, Juan González-García¹

¹Gregorio Maranon Hosp, Madrid, Spain, ²Hosp Univ 12 de Octubre, Madrid, Spain, ³Servicio Madrileño de Salud, Madrid, Spain, ⁴Hosp Ramon y Cajal, Madrid, Spain, ⁵Hosp Univ de la Princesa, Madrid, Spain, ⁶Infanta Leonor Hosp, Madrid, Spain, ⁷Hosp Univ de Getafe, Getafe, ²⁸⁹⁰, ⁸Inst of Hlth Carlos III, Madrid, Spain, ⁹Hosp Univ La Paz, Madrid, Spain

**EFFICACY AND SAFETY OF DAA s IN CIRRHOTIC HCV/HIV COINFECTED PATIENTS**

Jordi Navarro¹, Montse Laguno², Helem Haydee Vilchez³, Josep M. Guardiola³, Jose A. Carrion³, Luis Force³, Mireia Cairó³, Carmen Cifuentes³, Manuel Crespo³, for the Catalano-Balear Study Group

¹Hosp Univ Vall d’Hebron, Barcelona, Spain, ²Hosp Clinic i Provincial de Barcelona, Barcelona, Spain, ³Hosp Univ de San Espases, Palma de Mallorca, Spain, ⁴Hosp de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Hosp del Mar, Barcelona, Spain, ⁶Hosp de Mataró, Mataró, Spain, ⁷Hosp Univ Mútua de Terrassa, Terrassa, Spain, ⁸Hosp de Son Llàtzer, Palma de Mallorca, Spain, ⁹Hosp Univ de la Vall d’Hebron, Barcelona, Spain

**INFLUENCE OF HIV ON CHANGES IN LIVER FUNCTION IN CIRRHOSIS AFTER ANTI-HCV TREATMENT**

Juan Macías¹, Luís E. Morano-Amado², Francisca Cuenca-Lopez², Dolores Merino¹, Manuel Márquez², Karin Neukami, María J. Rios-Villegas³, Francisco Téllez³, Juan A. Pineda¹

¹Hosp Univ de Valme, Sevilla, Spain, ²Hosp Univ Alvaro Cunqueiro, Vigo, Spain, ³Hosp Univ Reina Sofia, Córdoba, Spain, Complexo Hospario Univ de Huelva, Huelva, Spain, Hosp Virgen de la Victoria, Málaga, Spain, Hosp Univ Virgen Macarena, Sevilla, Spain, Hosp de La Línea, La Línea de la Concepción, Spain
537  LIVER MICRORNA HSA-MIR-125A-5P MAY EXERT AN ONCOSUPPRESSOR EFFECT ON HCC
Lorenzo Onorato1, Giorgio de Stefano1, Valentina Lodice2, Nunzia Farella3, Nicoletta Potenza3, Evangelista Sagnelli1, Aniello Russo1, Carmine Minichini1, Mario Starace1, Nicola Coppola1
1Second Univ of Naples, Naples, Italy, 2AORN dei Colli, PO Catugno, Naples, Italy, 3Second Univ of Naples, Caserta, Italy

538  REAL-LIFE TREATMENT RATES FOR HEPATOCELLULAR CARCINOMA IN HIV-INFECTED PATIENTS
Nicolás Merchante1, Francisco Rodríguez-Arrondo1, Esperanza Merino1, Boris Revollo2, Sofia Ibarra2, Miguel García-Deltoro6, Francisco Téllez7, Joseba Portu1, Albert Romero-Palacios1, Juan A. Pineda1
1Hosp Univ de Valme, Sevilla, Spain, 2Hospital Univ de Donostia, San Sebastián, Spain, 3Hospital General Univ de Alicante, Alicante, Spain, 4Hospital German Trias i Pujol, Badalona, Spain, 5Hospital de Basurto, Basurto, Spain, 6Hospital General de Valencia, Valencia, Spain, 7Hospital de La Línea, La Línea de la Concepción, Spain, 8Hospital de Txagorritxu, Vitoria, Spain, 9Hospital de Puerto Real, Puerto Real, Spain

539  PREDICTORS OF HEPATOCELLULAR CARCINOMA IN HIV/HCV COINFECTED PATIENTS WITH CIRRHOSIS
Aaron P. Thrift, Kathryn E. Royse, Christine Hartman, Jennifer R. Kramer, Elizabeth Chiao
Baylor Coll of Med, Houston, TX

540  IFN-FREE THERAPY IS EFFECTIVE AND SAFE FOR HCV RECURRENCE IN LT HCV/HIV COINFECTION
Christian Manzardo1, Maria Carlota Londono1, Ana Moreno1, Luis Castells1, Victoria Aquilera1, Jose R. Fernandez1, Jorge Calvo-Pulido1, Judith Peñafiel1, Antoni Rimola1, Jose M. Miro1
1Univ of Barcelona, Barcelona, Spain, 2Hospital Ramon y Cajal, Madrid, Spain, 3Hospital Univ Vall d’Hebron, Barcelona, Spain, 4Hospital Univ La Fe, Valencia, Spain, 5Hospital Univ de Cruces, Barakaldo, Spain, 6Hospital 12 de Octubre, Madrid, Spain

541  RISK FACTORS OF ACUTE REJECTION AFTER LIVER TRANSPLANTATION IN HIV+/HCV+ PATIENTS
Christian Manzardo1, Sandra Silva Arrieta2, Antonio Rafecas3, Sandra Franco1, Santos del Campo1, Elisa Cordero1, Judith Peñafiel1, Antoni Rimola1, Christian Brander2, Jose M. Miro1
1Univ of Barcelona, Barcelona, Spain, 2IrsiCaixa Inst for AIDS Rsr, Badalona, Spain, 3L’Hosp de Llubregat, Spain, 4Hospital Ramon y Cajal, Madrid, Spain, 5Univ of Sevilla, Sevilla, Spain

542LB  HCC DEVELOPMENT IN HCV PATIENTS AFTER DAA: THE EXPERIENCE OF THE SCOLTA PROJECT
Barbara Menzaghi1, Carlo Magni1, Laura A. Nicolini1, Giovanni Cenderello4, Vito Fiore4, Maria Gussio4, Roberto Gulminetti5, Francesca Vichi6, Paolo Bonfanti7
1Busto Arsizio Hosp, Busto Arsizio, Italy, 2ASST Fatebenefratelli, Milan, Italy, 3Univ of Genova, Genova, Italy, 4Galliera Hosp, Genoa, Italy, 5Unit of Infectious Diseases, Sassari, Italy, 6Garibaldi Hosp, Catania, Italy, 7IRCCS Policlinico San Matteo Fdnh Univ of Pavia, Pavia, Italy, 8S. Maria Annunziata Hosp, Milan, Italy, 9A. Manzoni Hospital, Lecco, Italy
**591** MULTIPLE-TEST SCREENING STRATEGIES IMPROVE BIOSPY-PROVEN HSIL-DETECTION IN HIV+ WOMEN

Dorothy J. Wiley1, Elizabeth Chiao1, Jeanette Lee2, Ashish A. Deshmukh3, Scott B. Cantor4, Joel Palefsky5, Elizabeth A. Stier6

1Univ of California Los Angeles, Los Angeles, CA, USA, 2Baylor Coll of Med, Houston, TX, USA, 3Univ of Arkansas for Med Scis, Little Rock, AR, USA, 4Univ of Florida, Gainesville, FL, USA, 5Univ Of Texas MD Anderson Cancer Cntr, Houston, TX, USA, 6Univ of California San Francisco, San Francisco, CA, USA

**592** SCREENING STRATEGIES ADD VALUE FOR PREDICTING BIOSPY-PROVEN HSIL FOR MSM

Dorothy J. Wiley1, Hilary K. Hsu1, Matthew G. Moran1, Jenny Brook1, David Elashoff2, Martha Ganser1, Stephen Young1, David Morris3, Otoniel Martinez-Maza1, Ronald T. Mitsuyasu1

1Univ of California Los Angeles, Los Angeles, CA, USA, 2Tricore Reference Labs, Albuquerque, NM, USA, 3Desert AIDS Proj, Palm Springs, CA, USA

**593** ANAL HIGH-RISK HPV ASSOCIATIONS WITH SERUM CYTOKINES/CHEMOKINES AND FREE TESTOSTERONE

Dorothy J. Wiley1, Hilary K. Hsu1, Sitram Vangala1, David Elashoff2, Xiang Lu1, Todd Brown1, Gysamber D’Souza1, Elizabeth Breen1, Stephen Young1, Nancy Joste1

1Univ of California Los Angeles, Los Angeles, CA, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Tricore Reference Labs, Albuquerque, NM, USA, 4Univ of New Mexico Hlth Scs Cntr, Albuquerque, NM, USA

**594** MULTIPLE HPV INFECTIONS AND ANAL PRECANCEROUS LESIONS IN HIV-INFECTED MEN

Shu-Hsing Cheng1, Chien-Yu Cheng1, Chi-Chao Wang1, Fang-Yeh Chu1, Yu-Mei Hsieh1

1Taoyuan General Hosp, Taoyuan, Taiwan, 2Far Eastern Memorial Hosp, New Taipei, Taiwan, 3Taipie Med Univ, Taipei, Taiwan

**595** SCREENING FOR PRECANCEROUS ANAL LESIONS WITH P16/KI67 DUAL STAIN CYTOLOGY IN HIV

Sergio Serrano-Villar1, Beatriz Hernández-Novoa2, Amparo de Benito1, Jorge Romero1, Antonio Ocampo1, Laura Pérez-Martínez2, Mar Masia2, Elena Sendagorta2, Gonzalo Sanz2, José Antonio Pérez-Molina2

1Hosp Univ Ramón y Cajal, Madrid, Spain, 2Brystol-Myers-Squibb, Madrid, Spain, 3Centro Sandoval, Madrid, Spain, 4Hosp Xeral de Vigo, Vigo, Pontevedra, 5Hosp San Pedro, Logroño, Spain, 6Hosp General Univ de Elche, Elche, Spain, 7Hosp Univ La Paz, Madrid, Spain, 8Hosp Clínico San Carlos, Madrid, Spain

**596** IMPACT OF ART COVERAGE AND SCREENING ON ANAL CANCER IN HIV+ MEN WHO HAVE SEX WITH MEN

Nello Blaser1, Barbara Bertisch1, Manuel Koller1, Marcel Stoeckle2, Matthias Cavassini3, Roger Koyou3, Janne Estill1, Matthias Egger1, Olivia Keiser1, for the Swiss HIV Cohort Study

1Univ of Bern, Bern, Switzerland, 2Univ Hosp Basel, Basel, Switzerland, 3Univ of Lausanne, Lausanne, Switzerland, 4Univ of Zurich, Zurich, Switzerland

**597** PREVALENCE OF HPV TYPES COVERED BY CURRENT VACCINES IN HIV-INFECTED MEN, SUN STUDY

Pragna Patel1, Tim Bush1, Lois Conley1, Elizabeth Unger1, Teresa Darragh1, Keith Henry1, Gerome Escota1, Joel Palefsky2, John T. Brooks2, Erna M. Kojic1

1CDC, Atlanta, GA, USA, 2Univ of California San Francisco, San Francisco, CA, USA, 3Hennepin County Med Cntr, Minneapolis, MN, USA, 4Washington Univ, St Louis, MO, USA, 5Brown Univ, Providence, RI, USA
623 ASSOCIATION OF INFLAMMATION AND COAGULATION WITH CLINICAL RISK IN THE START TRIAL
Jason Baker, Shweta Sharma, Birgit Grund, for the INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group
Univ of Minnesota, Minneapolis, MN, USA

624 HIV VIRAL BURDEN ASSOCIATED WITH SUBCLINICAL CORONARY ARTERY DISEASE IN HIV+ MEN
Sabina Haberlen1, Ruibin Wang1, Frank J. Palella2, Lisa Jacobson1, Todd Brown1, Mallory Witt1, Kathryn Berlacher4, Matthew Budoff1, Alison Abraham1, Wendy Post1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Northwestern Univ, Chicago, IL, USA, 3Los Angeles Biomed Rsr Inst at Harbor—UCLA Med Cntr, Torrance, CA, USA, 4Univ of Pittsburgh, Pittsburgh, PA, USA, 5Harbor—UCLA Med Cntr, Torrance, CA, USA

625 HIGHER CARNITINE LEVELS ARE ASSOCIATED WITH SUBSEQUENT MYOCARDIAL INFARCTIONS IN HIV
Arjun Sinha1, Peter W. Hunt1, Jeffrey N. Martin1, Yifei Ma1, Heidi M. Crane2, Daniel Drozd3, Peter Ganz1, Stanley Hazen1, Priscilla Hsue1
1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of Washington, Seattle, WA, USA, 3Cleveland Clinic, Cleveland, OH, USA

626 VACS INDEX IS SUPERIOR TO NADIR CD4 COUNT FOR PREDICTING AMI AND MORTALITY
Christopher Rentsch1, Janet Tate1, Vincent C. Marconi2, Matthew Budoff1, Adeel A. Butt1, Matthew Freiherg1, Matthew Goetz1, Maria Rodriguez-Barradas1, David Rimland1, Amy Justice1
1VA Connecticut Hlthcare System, West Haven, CT, USA, 2Emory Univ, Atlanta, GA, USA, 3Harbor—UCLA Med Cntr, Torrance, CA, USA 4Weill Cornell Med Coll, New York, NY, USA, 5Vanderbilt Univ, Nashville, TN, USA, 6VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, 7Baylor Coll of Med, Houston, TX, USA, 8Atlanta VA Med Cntr, Decatur, GA, USA, 9VA Connecticut Hlthcare System, West Haven, CT, USA

627 EPICARDIAL FAT, IMMUNE ACTIVATION, AND CORONARY PLAQUE AMONG HIV+ AND HIV- WOMEN
Suman Srinivasa1, Michael Lu1, Kathleen V. Fitch1, Travis R. Hallett1, Tricia H. Burdo1, Janet Lo1, Sara E. Looby1, Udo Hoffmann1, Steven K. Grinspoon1, Markella V. Zanni1
1Massachusetts General Hosp, Boston, MA, USA, 2Temple Univ, Philadelphia, PA, USA

628 DIVERGENT EFFECTS OF HIV AND SMOKING ON AORTIC INFLAMMATION
Chris T. Longenecker1, Claire E. Sullivan2, Justin T. Morrison3, Corrilyn Q. Hileman1, David A. Zidar1, Robert Gilkeson1, James O’Donnell1, Grace A. McComsey1
1Case Western Reserve Univ, Cleveland, OH, USA, 2Univ Hosps of Cleveland Med Cntr, Cleveland, OH, USA
**629** CRP PREDICTS SUBCLINICAL CVD PROGRESSION IN HIV- BUT NOT HIV+ WOMEN

Caitlin A. Moran¹, Aswani Vunnava¹, Anandi N. Sheth¹, Christina Mehta¹, Phyllis Tien¹, Michael Plankey¹, Elizabeth T. Golub¹, Arshed Quyyumi¹, Robert C. Kaplan¹, Igho Ofotokun¹

¹Emory Univ, Atlanta, GA, USA, ²Univ of California San Francisco, San Francisco, CA, USA, ³Georgetown Univ, Washington, DC, USA, ⁴The Johns Hopkins Univ, Baltimore, MD, USA, ⁵Albert Einstein Coll of Med, Bronx, NY, USA

**630** SERUM ST2 IS AN INDEPENDENT PREDICTOR OF ALL-CAUSE MORTALITY IN HIV-INFECTED PATIENTS

Rodolphe Thiebaut¹, Sophie Hue², Fabien LeMarec¹, Jean Daniel Lelievre², Michel Dupon³, Emile Foucat³, Isabelle Pellegrin³, Christine Lacabara², Fabrice Bonnet¹, Yves Levy³

¹INSERM, Bordeaux, France, ²INSERM, Créteil, France, ³CHU de Bordeaux, Bordeaux, France

**631** A LOWER CD COUNT PREDICTS MOST CAUSES OF DEATH EXCEPT CARDIOVASCULAR DEATHS

Gisela Leierer¹, Armin Rieger¹, Brigitte Schmied¹, Mario Sarcletti¹, Maria Geit³, Bernhard Haas³, Ninon Taylor⁴, Michaela Rappold¹, Bruno Ledergerber¹, Robert Zangerle¹

¹Med Univ of Innsbruck, Innsbruck, Austria, ²Med Univ of Vienna, Vienna, Austria, ³Otto-Wagner Hosp, Vienna, Austria, ⁴Kepler Univ Hosp Linz, Linz, Austria, ⁵General Hosp Graz South-West, Graz, Austria, ⁶Paracelsus Med Univ, Salzburg, Austria, ⁷Univ of Zurich, Zurich, Switzerland

**632** ASSOCIATIONS BETWEEN HIV CONTROLLER STATUS AND SUBCLINICAL CAROTID ATHEROSCLEROSIS

Rebeccah McKibben¹, David B Hanna², Sabina Haberlen¹, Robert C Kaplan², Frank J Palella³, Elizabeth T Golub¹, Peter Bacchetti², Ruth Greenblatt¹, Todd Brown⁴, Wendy Post¹

¹Johns Hopkins Univ, Baltimore, MD, USA, ²Albert Einstein Coll of Med, Bronx, NY, USA, ³Johns Hopkins Bloomberg SPH, Baltimore, MD, USA, ⁴Northwestern Univ, Chicago, IL, USA, ⁵Univ of California, San Francisco, San Francisco, CA, USA, ⁶Johns Hopkins Univ, Baltimore, MD, USA

**633** ASSOCIATION BETWEEN CARDIOVASCULAR EVENTS AND HIV-SPECIFIC RISK FACTORS

Stefan Esser¹, Norbert H. Brockmeyer¹, Martin Hower¹, Volker Holzendorf¹, Christina Schulze¹, Marina Arendt¹, Till Neumann¹, Nico Reinsch¹, for the HIV HEART Study Group

¹Univ Hosp Duisburg-Essen, Essen, Germany, ²Ruhr-Univ Bochum, Bochum, Germany, ³City Hosp Dortmund, Dortmund, Germany, ⁴Univ Leipzig, Leipzig, Germany, ⁵Univ Hosp Essen, Essen, Germany, ⁶Cardiologic Outpatient Clinic Staubach, Bochum, Germany, ⁷Alfried Krupp Hosp, Essen, Germany

**634** IMPAIRED ANTIVASCULAR CONTRACTION OF PERIVASCULAR ADIPOSE TISSUE IN HIV INDIVIDUALS

Dan Wang, Cheng Wang, Cuiwei Wang, Chenglong Liu, Jennifer Verbesey, Philena Sun, Seble Kassay, Mary Young, Christopher Wilcox, for the Hypertension, Kidney and Vascular Research Center and DC Women's Interagency HIV Study

Georgetown Univ, Washington, DC, USA
635LB NOVEL IMAGING STRATEGY SHOWS HIGH-LEVEL AORTIC CD206+ MACROPHAGE INFILTRATION IN HIV

Markella V. Zanni1, Mabel Toribio1, Moses Q. Wilks1, Michael T. Lu1, Tricia H. Burdo2, Fred Cope3, Udo Hoffmann4, Kenneth C. Williams5, Georges El-Fakhri6, Steven K. Grinspoon7

1Massachusetts General Hosp, Boston, MA, USA, 2Temple Univ, Philadelphia, PA, USA, 3Navidea Biopharmaceuticals, Dublin, OH, USA, 4Boston Coll, Chestnut Hill, MA, USA

636LB GUT MICROBIOTA, TRYPTOPHAN CATABOLISM AND ATHEROSCLEROSIS IN HIV INFECTION

Qibin Qi1, Simin Hua2, David B. Hanna3, Clary Clish4, Jason Lazar2, Wendy Post4, Kathryn Anastas5, Robert Burk6, Robert C. Kaplan7

1Albert Einstein Coll of Med, Bronx, NY, USA, 2Broad Inst of MIT and Harvard, Cambridge, MA, USA, 3SUNY Downstate Med Ctr, Brooklyn, NY, USA, 4Johns Hopkins Univ, Baltimore, MD, USA

Poster P-N6 INTEGRATION OF SCREENING AND TREATMENT OF NCD INTO HIV CARE IN RESOURCE-LIMITED SETTINGS

Poster Hall - 4 EF 2:30 PM - 4:00 PM

637 INTEGRATING CARDIOVASCULAR DISEASE RISK-FACTOR SCREENING IN HIV SERVICES IN SWAZILAND

Miriam Rabkin1, Anton M. Palma1, Margaret L. McNairy1, Samkelo Simelane2, Averie B. Gachuh1, Raymond A. Bitchong1, Harriet Nuwagara-Bibronw6, Pido Bongomin1, Velephi Okello2, Wafa M. El-Sadr1

1ICAP at Columbia Univ, New York, NY, USA, 2ICAP Swaziland, Mbabane, Swaziland, 3Raleigh Fitkin Memorial Hosp, Manzini, Swaziland, 4Swaziland Ministry of Hlth, Mbabane, Swaziland

638 COMPOSITE “HIV/ HYPERTENSION/ DIABETES CONTROL” OUTCOME IN SEARCH CHRONIC CARE MODEL

Dalsone Kwarrisima1, Jeanna Wallenta2, James Ayieko3, Florence Mwangwa4, Asiphas Owaramoj5, Tamara D. Clark2, Edwin D. Charlebois2, Maya L. Petersen3, Diane V. Havelir4, Moses R. Kamya6

1ICAP at Columbia Univ, New York, NY, USA, 2Univ of California San Francisco, San Francisco, CA, USA, 3Kenya Med Rsr Inst, Nairobi, Kenya, 4Infectious Diseases Rsr Collab, Kampala, Uganda, 5Univ of California Berkeley, Berkeley, CA, USA, 6Makerere Univ Coll of Hlth Scis, Kampala, Uganda

639 THE ART ADVANTAGE: HEALTHCARE UTILIZATION FOR DIABETES & HYPERTENSION IN SOUTH AFRICA


1Beth Israel Deaconess Med Ctr, Boston, MA, USA, 2Harvard Univ, Cambridge, MA, USA, 3Tintswalo Hosp, Acornhoeck, South Africa, 4Harvard Univ, Boston, MA, USA, 5Univ of the Witwatersrand, Acornhoeck, South Africa, 6MRC/Wits Rural Pub Hlth and Hlth Transitions Rsr Unit, Johannesburg, South Africa, 7Univ of Witwatersrand, Johannesburg, South Africa, 8Heidelberg Univ, Heidelberg, Germany, 9Brigham and Women’s Hosp, Boston, MA, USA

640 CARDIOVASCULAR RISK ASSESSMENT IN A SUB-SAHARAN AFRICA HIV CLINICAL COHORT

Mosepele Mosepele1, Linda C. Hempfill2, Tommy Palai1, Isaac Nkele3, Kara Bennett5, Shahin Lockman5, Virginia Triant2

1Univ of Botswana, Gaborone, Botswana, 2Massachusetts General Hosp, Boston, MA, USA, 3Botswana—Harvard AIDS Partnership, Gaborone, Botswana, 4Bennett Statistical Consulting Inc, New York, NY, USA, 5Harvard Univ, Boston, MA, USA
641 HIV AND IMMUNE ACTIVATION ARE RISK FACTORS FOR ENDOTHELIAL DAMAGE IN ADULT MALAWIANS
Christine Kelly¹, Henry Mwandumba², Rob Heyderman³, Raphael Kamng‘ona⁴, Mishek Chammudzi⁵, Irene Sheha³, Jane E. Mallewa⁶, Sarah Walker⁷, Nigel Klein⁷, Saye Khoo⁷
¹Univ Coll Dublin, Dublin, Ireland, ²Malawi Liverpool Wellcome Clinical Rsr Prog, Blantyre, Malawi, ³Univ Coll London, London, UK, ⁴Univ of Malawi, Blantyre, Malawi, ⁵Univ of Liverpool Inst of Translational Med, Liverpool, UK

642 INCREASING PREVALENCE OF HYPERTENSION AMONG HIV-POSITIVE ADULTS IN SENEGAL, 1994–2015
Noelle A. Benzekri¹, Papa Salif Sow², Moussa Seydi², Stephen E. Hawes¹, Geoffreyt Gottlieb¹
¹Univ of Washington, Seattle, WA, ²CHU de Fann, Dakar, Senegal

Poster P-01 IMMUNOLOGIC PREDICTORS OF MORBIDITY AND MORTALITY
Poster Hall - 4 EF 2:30 PM - 4:00 PM

643 MITOCHONDRIAL D-LOOP SNPs ASSOCIATED WITH AGE-RELATED COMORBIDITIES IN HIV PATIENTS
Rumi Minami, Soichiro Takahama, Yasunori Koga, Masahiro Yamamoto
Natl Hosp Org, Kyushu Med Cntr, Fukuoka, Japan

644 IMMUNOLOGIC AND VIROLOGIC MEASURES AND MORTALITY AFTER NCD IN HIV+ ADULTS
Vanderbilt Univ, Nashville, TN, USA

645 VITAMIN D METABOLITES AND MORTALITY RISK AMONG HAART-TREATED HIV-INFECTED MEN
Long Zhang¹, Todd Brown¹, Joseph B. Margolick¹, Sabina Haberlen¹, Mallory Witt¹, Frank J. Palella¹, Lawrence Kingsley¹, Andrew Hoofnagle¹, Lisa Jacobson¹, Alison Abraham¹
¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Los Angeles Biomed Rsr Inst at Harbor–UCLA Med Cntr, Torrance, CA, USA, ³Northwestern Univ, Chicago, IL, USA, ⁴Univ of Pittsburgh, Pittsburgh, PA, USA, ⁵Univ of Washington, Seattle, WA, USA

646 LONGITUDINAL HIV VIRAL TRAJECTORIES AND COMORBIDITIES IN THE WIHS
Seble Kassaye¹, Cuiwei Wang¹, Jeff Collmann¹, Tracey Wilson¹, Kathryn Anastos¹, Mardge H. Cohen¹, Ruth Greenblatt¹, Joel Milam², Stephen J. Gange², Michael Plankey¹
¹Georgetown Univ, Washington, DC, USA, ²SUNY Downstate Med Cntr, Brooklyn, NY, USA, ³Albert Einstein Coll of Med, Bronx, NY, USA, ⁴John H. Stroger Jr. Hosp of Cook County, Chicago, IL, USA, ⁵Univ of California San Francisco, San Francisco, CA, USA, ⁶Univ of Southern California, Los Angeles, CA, USA, ⁷The Johns Hopkins Univ, Baltimore, MD, USA
647 **OXIDATIVE STRESS PREDICTS SERIOUS NON-AIDS EVENTS IN HIV-INFECTED PATIENTS**

Mar Masia1, Sergio Padilla2, Marta Fernández2, Xavier Barber1, Santiago Moreno1, José A. Iribarren1, Joaquín Portilla1, Alejandro Peña2, Francesc Vidal1, Félix Gutiérrez2

1Hosp General Univ de Elche, Elche, Spain, 2Univ Miguel Hernández, Elche, Spain, 3Hosp Ramon y Cajal, Madrid, Spain, 4Hosp Donostia, San Sebastián, Spain, 5Hosp General Univ de Alicante, Alicante, Spain, 6Hosp Univ San Cecilio, Granada, Spain, 7Hosp Univ de Tarragona Joan XXIII, Tarragona, Spain

648 **INFLAMMATION BIOMARKERS PREDICT CLINICAL TREATMENT FAILURE IN HIV-INFECTED ADULTS**

Rupak Shivakoti1, Nikhil Gupta1, Sandy Pillay2, Cynthia Riviere3, Sandra W. Cardoso1, Ashwin Balagopal1, Richard Sembal3, Thomas Campbell4, Amita Gupta1, for the NWCS 319 and ACTG 5175 PEARLS Study Team

1The Johns Hopkins Univ, Baltimore, MD, USA, 2BJGMC Clinical Trials Unit, Pune, India, 3Dublin Univ of Tech, Dublin, South Africa, 4Les Cntrs GHESKIO, Port-Au-Prince, Haiti, 5Inst Nacional de Infectologia (INI/Fiocruz), Rio de Janeiro, Brazil, 6Univ of Colorado Denver, Aurora, CO, USA

---

**Poster P-O2 ART TOXICITY**

**Poster Hall - 4 EF**

2:30 PM - 4:00 PM

649 **ART EFFECTS ON RENAL AND BONE HEALTH IN LIFELONG HIV SURVIVORS**

Aviva Mattingly1, Sara Jones1, Aylin Unsal1, Julia Purdy1, James Reynolds1, Jeffrey Kopp3, Rohan Hazra3, Colleen Hadigan1

1NIAID, Bethesda, MD, USA, 2Liedos Biomed Rsr Inc, Frederick, MD, USA, 3NIH, Bethesda, MD, USA, 4NIDDK, Bethesda, MD, USA, 5NICHD, Bethesda, MD, USA

650 **FACTORS ASSOCIATED WITH RAPID EGFR DECLINE IN PATIENTS RECEIVING TDF AND/OR ATV**

Lisa Hamzah1, Sophie Jose1, Rachael Jones3, Deborah Williams4, David Chadwick1, Andrew Phillips2, Caroline Sabin3, Frank Post4


651 **DISCONTINUATION OF DTG, EVG/C, AND RAL DUE TO TOXICITY IN A PROSPECTIVE COHORT**

Josep M. Llibre1, Anna Esteve1, Jose M. Miro1, Gracia Mateo1, Adrià Curran1, Daniel Podzamczer1, Melchor Riera1, Francesc Homar1, Luis Force1, for the the PISCIS Cohort Study Group

1Univ Hosp Germans Trias, Barcelona, Spain, 2Cntr d’Estudis Epidemiològics Sobre les ITS i Sida de Catalunya, Barcelona, Spain, 3Univ of Barcelona, Barcelona, Spain, 4Hosp Sant Pau, Barcelona, Spain, 5Hosp Vall d’Hebró, Barcelona, Spain, 6Hosp Univ de Bellvitge, Barcelona, Spain, 7Hosp Univ Son Espases, Palma de Mallorca, Spain, 8Hosp Son Llàtzer, Palma de Mallorca, Spain, 9Hosp de Mataró, Mataró, Spain

652 **IMPACT OF TENOFOVIR DIFUMARATE ON TELOMERE LENGTH OF AVIREMIC HIV-INFECTED PATIENTS**

Rocio Montejeano1, Natalia Stella-Ascariz2, Susana Monge2, Jose I. Bernardino1, Ignacio Pérez-Valero1, Laura Pintado1, Marisa Montes1, Jesus Mingorance1, Rosario Perona1, Jose R. Arribas1

1Inst de Investigación Hosp Univ La Paz, Madrid, Spain, 2Univ de Alcalá de Henares, Madrid, Spain, 3Inst of Biomed Rsr “Alberto Sols,” Madrid, Spain

---

**Poster Sessions • Tuesday**

**Program and Agenda**

**CROI 2017**
653 **DARUNAVIR/R USE AND INCIDENT CHRONIC KIDNEY DISEASE IN HIV-POSITIVE PERSONS**

Lene Ryom¹, Jens D. Lundgren¹, Peter Reiss², Ole Kirk¹, Matthew Law³, Michael Ross⁴, Philippe Morlat⁵, Christoph A. Fux⁶, Amanda Mocroft⁷, for the D:A:D Study Group

¹CHIP, Rigshosp, Copenhagen, Denmark, ²Stichting HIV Monitoring and Academic Med Cntr Amsterdam, Amsterdam, Netherlands, ³Kirby Inst, Sydney, Australia, ⁴Mt Sinai Sch of Med, New York, NY, USA, ⁵CHU Bordeaux, Bordeaux, France, ⁶Clinic for Infectious Diseases and Hosp Hygiene, Kantonsspital Aarau, Aarau, Switzerland, ⁷Univ Coll London, London, UK

**Poster P-P1 TB PREVENTION**

**Poster Hall - 4 EF**

### 705 CO-TRIMOXAZOLE PROPHYLAXIS DECREASES TUBERCULOSIS RISK AMONG ASIAN PATIENTS WITH HIV

Wen-Wei Ku¹, Awachana Jiamsakul¹, Kedar Joshi¹, Mark Kristoffer Ungos Pasayan¹, Alvina Widhani³, Romanee Chaiwarmith², Sasisopin Khertiburanakul¹, Kiat Ruxrungtham³, Ly Penh Sun³, Wingwai Wong¹

¹Taipei Veterans General Hosp, Taipei, Taiwan, ²Kirby Inst, Sydney, Australia, ³Inst of Infectious Diseases, Pune, India, ⁴Rsr Inst for Trop Med, Manila, Philippines, ⁵Cipto Mangunkusumo Hospital, Univ of Indonesia, Jakarta, Indonesia, ⁶Rsr Inst for Hlth Scis, Chiang Mai Univ, Chiang Mai, Thailand, ⁷Mahidol Univ, Bangkok, Thailand, ⁸HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁹Univ of Hlth Scis, Phnom Penh, Cambodia

### 706 ISONIAZID PREVENTIVE THERAPY INITIATION, COMPLETION, & RETENTION IN CARE IN ETHIOPIA

Andrea Howard¹, Katharine Yuengling¹, Yael Hirsch-Moverman¹, Suzue Saito¹, Tsigereda Gadisa², Wafaa M. El-Sadr³, Zenebe Melaku³

¹ICAP at Columbia Univ, New York, NY, USA, ²ICAP at Columbia Univ, Maseru, Lesotho, ³ICAP at Columbia Univ, Addis Ababa, Ethiopia

### 707 IPT COVERAGE IN NURSE-LED SCREENING OF CHILD TUBERCULOSIS CONTACTS

Nicole Salazar-Austin¹, Silvia Cohn¹, Grace Barnes¹, Molefi Tladi², Katlego Matthaoleng³, Neil Martinson³, Richard Chaissong³

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Perinatal HIV Rsr Unit, Soweto, South Africa

### 708 WITHDRAWN

### 709 DOES THE BENEFIT OF IPT FOR PERSONS WITH HIV WHO CONSUME ALCOHOL OUTWEIGH THE RISK?

J. Morgan Freiman¹, Winnie Muyindike¹, Karen Jacobson¹, C. Robert Horsburgh¹, Jerrold Ellner¹, Judith Hahn¹, Benjamin Linas³

¹Boston Med Cntr, Boston, MA, USA, ²Mbarara Univ of Sc and Tech, Mbarara, Uganda, ³Boston Univ, Boston, MA, USA, ⁴Univ of California San Francisco, San Francisco, CA, USA
710 HEPATOTOXICITY DURING IPT AND ART IN SEVERELY IMMUNOSUPPRESSED PEOPLE

McNeil Ngongondo1, Sachiko Miyahara2, Michael D. Hughes3, Xin Sun2, Amita Gupta2, Johnstone Kumwenda3, Thiago S. Torres3, Gregory Bisson4, Mina C. Hosseinipour1, for the Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team

1UNC Proj-Malawi, Lilongwe, Malawi, 2Harvard Univ, Boston, MA, USA, 3The Johns Hopkins Univ, Baltimore, MD, USA, 4Coll of Med-Johns Hopkins Rsr Proj, Blantyre, Malawi, 5Inst Nacional de Infectologia (INI-Fiocruz), Rio de Janeiro, Brazil, 6Univ of Pennsylvania, Philadelphia, PA, USA

711 THE SENSITIVITY OF QUANTIFERON-TB GOLD PLUS IS NOT AFFECTED BY HIV STATUS


712 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION ASSAY TO DIAGNOSE TUBERCULOSIS IN RURAL UGANDA

Lydia Nakiyingi1, Prossy Nakwagali2, Tifu Agaba1, Mark Mugenyi3, Frank Mubiru1, Moses L. Joloba1, Yukari C. Manabe5

1Infectious Diseases Inst, Kampala, Uganda, 2Baylor Coll of Med Children’s Fndn, Kampala, Uganda, 3Kiboga Hosp, Kiboga, Uganda, 4Makerere Univ, Kampala, Uganda, 5The Johns Hopkins Univ, Baltimore, MD, USA

713 WITHDRAWN

714 EXTRAPULMONARY TB AT ART PROGRAMS IN LOWER-INCOME COUNTRIES: DIAGNOSTICS AND OUTCOMES

Kathrin Zürcher1, Marie Ballif1, Sasisopin Kiertiburanakul2, Marcel Yotebieng3, Beatriz Grimsztejn4, Denna Michael5, Henri Chenal6, Matthias Egger1, April C. Pettit7, Lukas Fenner4

1Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland, 2Mahidol Univ, Bangkok, Thailand, 3The Ohio State Univ, Columbus, OH, USA, 4Inst Nacional de Infectologia (INI-Fiocruz), Rio de Janeiro, Brazil, 5Natl Inst for Med Rsr, Kisesa HDSS, Mwanza, Tanzania, United Republic of, 6CIRBA, Abidjan, Côte d’Ivoire, 7Vanderbilt Univ, Nashville, TN, USA

715LB LOW-LEVEL M. TB GENOTYPIC HETERORESISTENCE PREDICTS PHENOTYPIC DRUG RESISTANCE

John Z. Metcalfe1, Elizabeth Streicher2, Christopher Allender3, Darrin Lemmer3, Rebecca Colman4, Grant Theron2, Rob Warren2, David M. Engelthaler1

1Univ of California San Francisco, San Francisco, CA, USA, 2Stellenbosch Univ, Tygerberg, South Africa, 3Translational Genomics Rsr Inst, Flagstaff, AZ, USA, 4Univ of California San Diego, San Diego, CA, USA
716LB  HUMAN AND MOUSE HEMATOPOIETIC STEM CELLS ARE A DEPOT FOR DORMANT M. TUBERCULOSIS
Julia Tornack1, Stephen Reece1, Wolfgang Bauer1, Alexis Vogelzang1, Silke Bandermann1, Ulrike Zedler1, Georg Stingl2, Stefan Kaufmann1, Fritz Melchers1
1Max Planck Inst for Infection Bio, Berlin, Germany, 2Med Univ of Vienna, Vienna, Austria

Poster P-P3 TB TREATMENT, OUTCOMES, AND MORTALITY
Poster Hall - 4 EF
2:30 PM - 4:00 PM

717  RISK FACTORS FOR DEATH IN ADVANCED HIV-INFECTED ADULTS IN AN EMPIRIC TB THERAPY TRIAL
Gregory Bisson1, Ritesh Ramchandani2, Sachiko Miyahara2, Xin Sun2, Jing Bao2, Amita Gupta3, Mina C. Hosseinipour4, Johnstone Kumwenda4, for the Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team
1Univ of Pennsylvania, Philadelphia, PA, USA, 2Harvard Univ, Boston, MA, USA, 3NIH, Bethesda, MD, USA, 4Univ of North Carolina Proj—Malawi, Lilongwe, Malawi, 5Malawi Coll of Med—Johns Hopkins Univ Rsr Proj, Blantyre, Malawi

718  DOES TIME TO ART INITIATION IMPACT EARLY RESPONSES TO DR-TB TREATMENT?
Erika K. Mohr1, Johnny Daniels1, Odelia Muller1, Bongani Chabalala1, Jennifer Hughes1, Virginia de Azevedo1, Amir Shroufi2, Sarah Jane Steele1, Gabriella Ferlazzo3, Laura Trivino Duran1
1MSF, Khayelitsha, Cape Town, South Africa, 2City of Cape Town Dept of Hlth, Cape Town, South Africa, 3MSF, Cape Town, South Africa

719  HIV-RELATED TB TREATMENT INTERMITTENCY IN THE CONTINUATION PHASE AND MORTALITY
Brenda Crabtree-Ramirez1, Cathy Jenkins2, Bryan E. Shepherd3, Karu Jayathilake4, Valdilea Veloso5, Eduardo Gotuzzo6, Claudia P. Cortes7, Denis Padgett7, Catherine McGowan8, Timothy R. Sterling9
1Inst Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico, Mexico, 2Vanderbilt Univ, Nashville, TN, USA, 3Oswaldo Cruz Fndn—Fiocruz, Rio de Janeiro, Brazil, 4Univ Peruana Cayetano Heredia, Lima, Peru, 5Univ of Chile, Santiago, Chile, 6Hosp Seguro Social, Tegucigalpa, Honduras

720  IMPACT OF INH ADHERENCE ON TB INCIDENCE AND MORTALITY BY WEEK 96 IN ACTG 5274 TRIAL
Amita Gupta1, Xin Sun1, Sachiko Miyahara1, Mitch Matoga1, Deborah Langat1, Cynthia Riviere1, Gregory Bisson2, Johnstone Kumwenda3, Mina C. Hosseinipour1, for the ACTG A5274/REMEMBER Study Team
1Johns Hopkins Univ, Baltimore, MD, USA, 2Harvard Univ, Boston, MA, USA, 3Univ of North Carolina Proj—Malawi, Lilongwe, Malawi, 4KEMRI/Walter Reed Proj, Kericho, Kenya, 5Les Cttrs GHESKIO, Port-Au-Prince, Haiti, 6Univ of Pennsylvania, Philadelphia, PA, USA, 7Malawi Coll of Med—Johns Hopkins Univ Rsr Proj, Blantyre, Malawi

721  WITHDRAWN
722 OUTCOMES ACROSS THE TUBERCULOSIS TREATMENT CASCADE AMONG ADOLESCENTS IN HAITI

Lindsey Reif, Rachel Bertrand, Eric Kutscher, Vanessa Rivera, Pierrot Julma, Serena Koenig, Jean W. Pape, Daniel Fitzgerald, Margaret McNairy

1Columbia Univ, New York, NY, USA, 2GHESKIO, Port-au-Prince, Haiti, 3Weill Cornell Med, New York, NY, USA, 4Harvard Univ, Boston, MA, USA

723LB WITHDRAWN

724LB EFFICACY OF BEDAQUILINE, PRETOMANID, MOXIFLOXACIN & PZA (BPAMZ) AGAINST DS- & MDR-TB

Rodney Dawson, Kendra Harris, Almari Conradie, Divan Burger, Stephen Murray, Carl Mendel, Mel Spigelman

1Univ of Cape Town, Mowbray, South Africa, 2Global Alliance for TB Drug Development, New York, NY, USA, 3QuintilesIMS, Bloemfontein, South Africa, 4Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA

761 MOTHER-TO-CHILD TRANSMISSION OF HIV IN KENYA: A MULTIYEAR NATIONAL EVALUATION

Lucy Ng’ang’a, Christine J. McGrath, Agnes Langat, Jillian Pintye, Mary Schmitz, Abraham Katana, Rose Wafula, John Kinuthia, Grace John-Stewart, Kevin De Cock

1US CDC, Nairobi, Kenya, 2Univ of Texas Med Branch, Galveston, TX, USA, 3Univ of Washington, Seattle, WA, USA, 4Natl AIDS and STD Control Prog, Ministry of Hlth, Nairobi, Kenya, 5Kenyatta Natl Hosp, Nairobi, Kenya

762 MISSED OPPORTUNITIES FOR REPEAT HIV TESTING AND EARLY ART INITIATION IN PREGNANCY

Anna Joy Rogers, Eliud Akama, Elly Weke, Justin Blackburn, George Owino, Elizabeth A. Bukusi, Patrick Oyaro, Zachary A. Kwenia, Craig Cohen, Janet M. Turan


763 LOW HIV INCIDENCE IN SOUTH AFRICAN PREGNANT WOMEN RECEIVING A PREVENTION INTERVENTION

Geoffrey Fatti, Ashraf Grimwood, Bon Egbujie, Eula Mothibi, Najma Shaikh, Debra Jackson, Brian Eley

1Kheth’Impilo, Cape Town, South Africa, 2UNICEF, New York, NY, USA, 3Univ of Cape Town, Cape Town, South Africa

764 HIV INCIDENCE, CASCADE, AND TESTING AMONG MOTHERS IN WESTERN KENYA

Alliance Nikuze, Stephen Wanjala, Jihane Ben-Farhat, Willis Omwoyo, Laura Oyiengo, Elisabeth Szumilin, Leon Salumu, Alexandra Vandenbulcke, Valarie S. Opollo, David Maman

765 DETECTION OF HIV IN BREAST MILK AMONG PREGNANT/POSTPARTUM WOMEN WITH RECENT HIV
Alison L Drake1, John Kinuthia2, Daniel Matemo2, Barbra A. Richardson1, Sandy Emery3, Vrasha Chohan1, Julie Overbaugh1, Grace John-Stewart1
1Univ of Washington, Seattle, WA, USA, 2Kenyatta Natl Hosp, Nairobi, Kenya, 3Fred Hutchinson Cancer Rsr Ctr, Seattle, WA, USA

766 UPTAKE AND RETENTION IN CARE OF PREGNANT WOMEN STARTING OPTION B+ IN MAPUTO
Esmeralda Karajeanes1, Dulce Bila1, Orvalho Augusto2, Maria Lain1, Basilio Muianga1, Chadreque Muluana1, Nello Macuacua1, Victorino Chavane1, Paula Vaz1
1Fundaçao Ariel Glaser Contra o Sida Pediatrico, Maputo, Mozambique, 2Univ Eduardo Mondlane, Maputo, Mozambique, 3Direcção Provincial de Saúde de Maputo, Maputo Provincia, Mozambique

767 STRATEGIES FOR VIRAL-LOAD MONITORING DURING PREGNANCY IN RESOURCE-LIMITED SETTINGS
Maia Lesosky1, Elaine J. Abrams2, Nei-Yuan M. Hsiao3, Landon Myer1, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) study
1Univ of Cape Town, Cape Town, South Africa, 2Columbia Univ, New York, NY, USA, 3NHLS, Cape Town, South Africa

768 VIRAL SUPPRESSION AMONG HIV+ PREGNANT WOMEN ENTERING ANTENATAL CARE ON ART IN UGANDA
Catherine A. Koss1, Paul Natureeba2, Deborah Cohan1, Teddy Ochieng2, Theodore Ruel1, Miriam Nakalembe3, Tamara D. Clark1, Edwin D. Charlebois1, Moses R. Kamya1, Diane V. Havlir1
1Univ of California San Francisco, San Francisco, CA, USA, 2Makerere Univ–Univ of California San Francisco Rsr Collab, Kampala, Uganda, 3Makerere Univ Coll of Hlth Scis, Kampala, Uganda

769 MEASURES OF ENGAGEMENT IN ROUTINE HIV CARE TO PREDICT ELEVATED VIRAL LOAD ON ART
Tamsin Phillips1, Allison Zerbe2, Agnes Ronan2, Nei-Yuan M. Hsiao3, Greg Petro2, James A. McIntyre4, Andrew Bouillé1, Elaine J. Abrams2, Landon Myer1, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) study
1Univ of Cape Town, Cape Town, South Africa, 2ICAP at Columbia Univ, New York, NY, USA, 3Natl Hlth Lab Service, Cape Town, South Africa, 4Anova Hlth Inst, Johannesburg, South Africa

770 SELF-REPORT AND DRY BLOOD SPOTS AS Markers OF ANTIRETROVIAL ADHERENCE IN PREGNANCY
Maria L. Alcaide1, Shandir Ramlagan2, Violeta Rodriguez2, Ryan Cook2, Karl Peltzer2, Stephen Weiss1, Deborah Jones1
1Univ of Miami, Miami, USA, 2HIV/AIDS, STIs, and TB Rsr Prog, Pretoria, South Africa, 3Univ of California Los Angeles, Los Angeles, CA, USA

771 UNINTENDED PREGNANCY PREDICTS SUBSEQUENT RAISED VIRAL LOAD IN THE POSTNATAL PERIOD
Kirsty Brittain1, Tamsin Phillips1, Allison Zerbe2, Agnes Ronan1, Greg Petro2, Nei-Yuan M. Hsiao3, James A. McIntyre4, Elaine J. Abrams2, Landon Myer1, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) Study
1Univ of Cape Town, Cape Town, South Africa, 2ICAP at Columbia Univ, New York, NY, USA, 3NHLS, Cape Town, South Africa, 4Anova Hlth Inst, Johannesburg, South Africa, 5ICAP at Columbia Univ, New York, NY, USA
780 MITOCHONDRIAL DNA CONTENT IN HIV-EXPOSED UNINFECTED INFANTS IN CAMEROON
Jennifer Jao¹, Kathleen M. Powis², Brian Kirmse³, Chunli Yu⁴, Fanny Epie⁵, Elaine J. Abrams⁶, Derek LeRoith⁷, Mitchell Geffner⁸, Irwin J. Kurland⁹, Helene C. Cote⁰
¹Icahn Sch of Med at Mt Sinai, New York, NY, USA, ²Massachusetts General Hosp, Boston, MA, USA, ³Univ of Mississippi, Jackson, MS, USA, ⁴Cameroon Baptist Convention Hlths Services, Bamenda, Cameroon, ⁵Columbia Univ, New York, NY, USA, ⁶Univ of Southern California, Los Angeles, CA, USA, ⁷Alpert Einstein Coll of Med, Bronx, NY, USA, ⁸Univ of British Columbia, Vancouver, Canada

781 LOPINAVIR/RITONAVIR INITIATED AT 7 DAYS OF LIFE IMPAIRS INFANT GROWTH
Nicolas Nagot¹, Thorkild Tylleskär², Chipepo Kankasa³, Nicolas MEDA⁴, James Tumwine⁵, Mandisa Singata⁶, Marianne Periès⁷, Philippe Van de Perre⁸, Stephane Blanche⁹, for the ANRS 12174 Trial Group
¹INSERM, Montpellier, France, ²Univ of Bergen, Bergen, Norway, ³Univ Teaching Hosp, Lusaka, Zambia, ⁴Ctr MURAZ, Bobo-Doulasso, Burkina Faso, ⁵Univ of Makerere, Kampala, Uganda, ⁶Univ of Fort Hare, East London, South Africa, ⁷Necker Hosp, Paris, France

782 GROWTH OUTCOMES OF HIV-EXPOSED UNINFECTED CHILDREN BY BIRTH PERIOD IN MALAWI
Malango T. Msukwa¹, Andreas Haas², Lyson Tenthani³, Cristina B. Hofer³, Frank M. Chimbwandira³, Adrian Spoerri⁴, Joep J. van Oosterhout⁵, Olivia Keiser⁶, for the Umoyo Study Group
¹Univ of Bern, Lilongwe, Malawi, ²Univ of Bern, Bern, Switzerland, ³Ministry of Hlth, Lilongwe 3, Malawi, ⁴Dignitas Intl, Zomba, Malawi

783 GROWTH IN INFANTS EXPOSED TO EFV AND TDF THROUGH BREASTMILK: MALAWI PMTCT OPTION B+
Atupele P. Kapito-Tembo¹, Austin Wesevich², Andy Bauleni³, Mina C. Hosseinipour⁴, Dennis Ongubo⁵, Queen Dube⁶, Amanda Corbett⁷, Don Mathanga⁸, Victor Mwapasa⁹, Sam Phiri⁰
¹Univ of Malawi, Blantyre, Malawi, ²Univ of North Carolina Proj—Malawi, Lilongwe, Malawi, ³Ministry of Hlth Queen Elizabeth Central Hosp, Blantyre, Malawi, ⁴Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁵Lighthouse Trust, Lilongwe, Malawi

784 PREDICTORS OF NEURODEVELOPMENT IN CHILDREN OF HIV-INFECTED AND -UNINFECTED WOMEN
Jean Leidner¹, Paige L. Williams², Gloria Mayondi³, Penny Holding⁴, Adam Cassidy⁵, Joseph Makhema⁶, Chipo Petlo⁷, Charlotte Mdluli⁸, Shahin Lockman⁹, Betsy Kammerer⁰
¹Goodtables Consulting, Oklahoma, OK, USA, ²Harvard Univ, Boston, MA, USA, ³Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, ⁴Independent Consultant, Nairobi, Kenya, ⁵Boston Children’s Hosp, Boston, MA, USA, ⁶Ministry of Hlth, Botswana, Gaborone, Botswana

785 B-CELL SUBSETS PROFILE AND VACCINE RESPONSE IN HIV-EXPOSED UNINFECTED (HEU) CHILDREN
Laurence Raymond Marchand¹, Catherine Gravel¹, Armelle Le Campion¹, Marc Boucher¹, Normand Lapointe², Valerie Lamarré³, Fatima Kakkar¹, Helene C. Cote¹, Hugo Soudéyns¹, for the CIHR Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)
¹CHU Sainte Justine, Montreal, Canada, ²Univ of Montreal, Montreal, Canada, ³Univ of British Columbia, Vancouver, Canada
786 INFLAMMATORY RESPONSES ASSOCIATED WITH CMV AND MATERNAL HIV IN ZIMBABWEAN INFANTS
Ceri Evans1, Bernard Chasekwa2, Sandra Rukobo2, Margaret Ghova2, Kuda Mutas2, Robert Ntozini3, Jean Humphrey4, Andrew Prendergast5
1Queen Mary Univ of London, London, UK, 2Zvitambo Inst for Maternal and Child Hlth Rsr, Harare, Zimbabwe

787 MATERNAL ART ASSOCIATED WITH IMPROVED PROTECTIVE TRANSPLACENTAL ANTIBODY TRANSFER
Scott Dryden-Peterson1, Elize de Bruyn1, Gloria Mayondo1, Betsy Kammers1, Jean Leidner1, Roger L. Shapiro4, Haruna Jibril6, Shabir Madhi6, Shahin Lockman6
1Brigham and Women’s Hosp, Boston, MA, USA, 2Respiratory and Meningeal Pathogens Rsr Unit, Soweto, South Africa, 3Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, 4Boston Children’s Hosp, Boston, MA, USA, 5Goodtables Consulting, Norman, OK, USA, 6Harvard Univ, Boston, MA, USA, 7Botswana Ministry of Hlth, Gaborone, Botswana

Poster P-R5 COMORBIDITIES AND COMPLICATIONS IN CHILDREN AND YOUTH
Poster Hall - 4 EF 2:30 PM - 4:00 PM

818 TREATMENT OUTCOMES OF KAPOSI SARCOMA IN HIV-1-INFECTED CHILDREN IN MOZAMBIQUE
Faizana Amodo1, Yolanda Cachomba2, Dalila Rego1, Orvalho Augusto1, Dulce Bila1, Paula Vaz1
1Hosp Central de Maputo, Maputo, Mozambique, 2Univ Eduardo Mondlane, Maputo, Mozambique, 3Fundação Ariel Glaser Contra o Sida Pediatrico, Maputo, Mozambique

819 DURABLE GAINS IN BONE MASS AMONG SOUTH AFRICAN CHILDREN SWITCHING TO EFAVIRENZ
Stephen M. Arpadi1, Stephanie Shiah1, Renate Strehlau1, Faeezah Patel2, Ndileka Mbete2, Louise Kuhn3, Ashraf Coovadia4, Michael T. Yin1
1Columbia Univ, New York, NY, USA, 2Empilweni Service and Rsr Unit, Johannesburg, South Africa

820 EFFECTS OF CALCIUM AND VITAMIN D SUPPLEMENTATION ON BONE HEALTH IN HIV-INFECTED YOUTH
Tavitiya Sudjaritruk1, Linda Aurpibul1, Torsak Bunupuradah2, Suparat Kanjanavanit3, Tawalchaya Chotecharoenpani4, Sineenart Taejaroenkul5, Pradthana Ounchanum6, Piyarat Suntarattiwong7, Thanayweewee Puthanakit8, for the CAL-D Study Group
1Chiang Mai Univ, Chiang Mai, Thailand, 2HIV Netherlands Australia Thailand Rsr Collab (HIV-NAT), 3Nakornping Hosp, Chiang Mai, Thailand, 4Chiang Rai Prachanukroh Hosp, Chiang Rai, Thailand, 5Queen Sirikit Natl Inst of Child Hlth, Bangkok, Thailand, 6Chulalongkorn Univ, Bangkok, Thailand

821 METABOLIC PROFILES OF ADULTS VERTICALLY INFECTED WITH HIV AND THE GENERAL POPULATION
Elise Arrive1, Jean-Paul Viard2, Elisa Arezes3, Feriel Ayat3, Benoit Salanave4, Sophie Matheron5, Véronique Reliquet6, Corinne Vigouroux7, Josiane Warszawski8, for the ANRS CO19 COVERTE Study Group
1Univ of Bordeaux, Bordeaux, France, 2Hôtel-Dieu de Paris, Paris, France, 3INSERM, Le Kremlin-Bicêtre, France, 4Equipe de Surveillance et d’Epidémiologie Nutritionnelle/Agence Natl de Santé Publique, Bobigny, France, 5Bichat-Claude Bernard Hosp, Paris, France, 6CHU Hôtel Dieu, Nantes, France, 7INSERM, Paris, France
822  EFFECTS OF VITAMIN D SUPPLEMENTATION ON CAROTID INTIMA-MEDIA THICKNESS IN HIV+ YOUTH
Allison R. Eckard1, Paolo Raggi2, Mary Ann O’Riordan3, Julia C. Rosebush4, Danielle Labbato1, Ann Chahroudi4, Joshua H. Ruff5, Chris T. Longenecker4, Vin Tangpricha4, Grace A. McComsey4
1Med Univ of South Carolina, Charleston, SC, USA, 2Mazankowski Alberta Heart Inst, Edmonton, Canada, 3Case Western Reserve Univ, Cleveland, OH, USA, 4Emory Univ, Atlanta, GA, USA

823  DOES PREMATURE VASCULAR STIFFNESS SLOWLY IMPROVE FOLLOWING EARLY ART? DATA FROM CHER
Steve Innes1, Mark Cotton1, Kennedy N. Otwombe1, Barbara Laughton1, Sara H Browne1
1Stellenbosch Univ, Cape Town, South Africa, 2Univ of the Witwatersrand, Johannesburg, South Africa, 3Univ of California San Diego, San Diego, CA, USA

824  SVCAM AND MCP-1 INVOLVED IN PREMATURER ARTERIAL WALL STIFFNESS IN PREPUBERTAL CHILDREN
Steve Innes1, Richard Glashoff1, Shalena Naidoo1, Kennedy N. Otwombe1, Barbara Laughton1, Maile Karris1, Mark Cotton1, Sara H Browne1
1Stellenbosch Univ, Cape Town, South Africa, 2Univ of the Witwatersrand, Johannesburg, South Africa, 3Univ of California San Diego, San Diego, CA, USA

825  VASCULAR HEALTH AND CEREBRAL BLOOD FLOW IN PERINATALLY HIV-INFECTED CHILDREN
Charlotte Blokhuis1, Sophie Cohen1, Henriëtte J. Scherbier2, Henk-Jan M. Mutsaerts3, Joost C. Meijers1, Henriëtte J. Scherpbier1, Henk-Jan Mutsaerts2, Joost C. Meijers3, Neeltje A. Kootstra2, Peter Reiss3, Ferdinand Wit4, Charlotte E. Teunissen3, Dasja Pajkrt1
1Emma Children’s Hosp/Academic Med Cntr, Amsterdam, Netherlands, 2Academic Med Cntr, Amsterdam, Netherlands, 3Sanquin Rsr, Amsterdam, Netherlands, 4Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands, 5VU Univ Med Cntr, Amsterdam, Netherlands

826  NEUROPSYCHOLOGICAL OUTCOMES IN A TWO-YEAR AFRICAN-BASED PEDIATRIC OBSERVATIONAL STUDY
Michael J. Boivin1, Miriam Chernoff1, Barbara Laughton1, Mutsha Bwakura-Dangarembizi1, Portia Kamthunzi1, Linda Barlow-Mosha1, Avy Violar1, Mark Cotton1, Paul Palumbo1, for the IMPAACT P1104s Study Team
1Michigan State Univ, East Lansing, MI, USA, 2Harvard Univ, Boston, MA, USA, 3Stellenbosch Univ, Cape Town, South Africa, 4Univ of Zimbabwe, Harare, Zimbabwe, 5Univ of North Carolina Proj—Malawi, Lilongwe, Malawi, 6Makerere Univ—Johns Hopkins Univ Rsr Collab, Kampala, Uganda, 7Univ of the Witwatersrand, Johannesburg, South Africa, 8Dartmouth-Hitchcock Med Cntr, Lebanon, NH, USA

827  PLASMA HEME OXYGENASE-1 IS ASSOCIATED WITH COGNITIVE DECLINE IN CHILDREN WITH HIV
David Bearden1, Alexander J. Gill1, Paige L. Williams1, Dennis L. Kolson2, Laura Schankel1, Allison Agwu1, Russell B. Van Dyke3, Steven D. Douglas1, for the Pediatric HIV/AIDS Cohort Study (PHACS) network and the IMPAACT 219C Study Team
1Univ of Rochester, Rochester, NY, USA, 2Univ of Pennsylvania, Philadelphia, PA, USA, 3Harvard Univ, Boston, MA, USA, 4Children’s Hosp of Philadelphia, Philadelphia, PA, USA, 5The Johns Hopkins Univ, Baltimore, MD, USA, 6Tulane Univ, Metairie, LA, USA
828 BIOMARKERS OF COGNITIVE DECLINE IN PERINATALLY INFECTED CHILDREN WITH HIV

David Bearden1, Alexander J. Gill2, Paige L. Williams3, Dennis L. Kolson2, Laura Schankel4, Allison Agwu5, Russell B. Van Dyke6, Steven D. Douglas7, for the The Pediatric HIV/AIDS Cohort Study (PHACS) network and the IMPAACT 219C study team

1Univ of Rochester, Rochester, NY, USA, 2Univ of Pennsylvania, Philadelphia, PA, USA, 3Harvard Univ, Boston, MA, USA, 4Children’s Hosp of Philadelphia, Philadelphia, PA, USA, 5The Johns Hopkins Univ, Baltimore, MD, USA, 6Tulane Univ, Metairie, LA, USA

829 MONOCYTES MAY BE ANTIVIRAL TARGETS TO LIMIT PEDIATRIC HIV-RELATED CNS MANIFESTATIONS

Erica L. Johnson, Dominika Swieboda, Christina Gavegnano, Rana Chakroborty, Raymond F. Schinazi

Emory Univ, Atlanta, GA, USA

830 CENTRAL NERVOUS SYSTEM PENETRATION OF ANTIRETROVIRAL THERAPY IN HIV-INFECTED CHILDREN

Malon V. Hof1, Charlotte Blokhuis2, Sophie Cohen2, Henriëtte J. Scherpieber1, Ferdinand Wit3, Marcel Pistorius1, Neeltje A. Kootstra1, Charlotte E. Teunissen3, Ron Mathot1, Dasja Pajkrt1

1Academic Med Cntr, Amsterdam, Netherlands, 2Emma Children’s Hosp/ Academic Med Cntr, Amsterdam, Netherlands, 3Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands, 4VU Univ Med Cntr, Amsterdam, Netherlands

876 ASSESSING UTILITY OF HIV INCIDENCE ASSAYS IN ESTIMATING INDIVIDUAL INFECTION TIMES

Christopher D. Pilcher1, Shelley Facente1, Eduard Grebe2, Sheila Keating1, Reshma Kassanjee3, Matt A. Price1, Michael P. Busch4, Gary Murphy5, Alex Welte1, Travis C. Porco1


877 A MULTIPLEX ASSAY FOR MONITORING RECENT HIV-1 TRANSMISSION IN LOCALIZED OUTBREAKS

Kelly Curtis, Ellsworth Campbell, Krystin A. Price, William M. Switzer

CDC, Atlanta, GA, USA

878 INFERENC OF HIV-1 INFECTION DATES IN AN OUTBREAK USING ANTIBODY-BASED RECENCY ASSAYS

Ellsworth Campbell1, Kelly Curtis1, Krystin A. Price1, Debra Hanson1, Sara J. Blosser1, Joan Duwve1, Pam Pontones1, Philip J. Peters1, William M. Switzer1

1CDC, Atlanta, GA, USA, 2Indiana State Hlth Dept, Indianapolis, IN, USA, 3Indiana Univ, Indianapolis, IN, USA
IDENTIFICATION AND VALIDATION OF AN INCIDENCE-TESTING ALGORITHM FOR HIV-1 SUBTYPE C
Oliver Laeyendecker1, Jacob Konikoff2, Douglas Morrison3, Ronald Brookmeyer1, Jing Wang4, Connie L. Celum5, Charles S. Morrison6, Quarraisha Abdool Karim7, Audrey Pettifor8, Susan H. Eshleman9
1NIAID, NIH, Baltimore, MD, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Univ of California Los Angeles, Los Angeles, CA, USA, 4Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 5Univ of Washington, Seattle, WA, USA, 6FHI 360, Durham, NC, USA, 7CAPRISA, Durban, South Africa, 8Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 9The Johns Hopkins Univ, Baltimore, MD, USA

VALIDATION OF LIMITING ANTIGEN AVIDITY ASSAY TO ESTIMATE HIV INCIDENCE IN EAST AFRICA
Oliver Laeyendecker1, Ronald H. Gray2, Kate Grabowski2, Steven Reynolds1, Anthony Ndyanabo1, Joseph Ssekasanzu2, Gilad Bismut2, Maria Wawer2, David Serwadda2, Thomas C. Quinn1
1NIAID, Baltimore, MD, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Rakai Hlth Scis Prog, Kalisizo, Uganda, 4Makerere Univ, Kampala, Uganda

MISCLASSIFICATION RATE OF HIV ANTIBODY AVIDITY ASSAYS IN INDIVIDUALS FROM CAMEROON
Briana Lynch1, Eshan Patel1, Colleen R. Courtney1, Aubin J. Nanfack1, Thomas Quinn1, Oliver Laeyendecker1, Phillipe N. Nyambi2, Ralf Dürr1, Andrew D. Reed1, for the Medical Diagnostic Center, Yaoundé, Cameroon
1NIH, Bethesda, MD, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3New York Univ, New York, NY, USA, 4’NIAID, Baltimore, MD, USA, 5’NIAID, Bethesda, MD, USA

WITHDRAWN

HIGH HIV INCIDENCE AMONG PWID AND MSM ATTENDING INTEGRATED CARE CENTERS IN INDIA
Allison M. McFall1, Sunil S. Solomon1, Gregory M. Lucas1, Aylur K. Srikrishnan1, Muniratnam S. Kumar1, Santhanam Anand1, Canjeevaram K. Vasudevan1, David D. Celentano1, Shruti H. Mehta1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2‘YR Gaitonde Cntr for AIDS Rsr and Educ, Chennai, India

TRENDS IN HIV INCIDENCE AMONG PWID, MSM AND CSW USING PREVENTION SERVICES IN UKRAINE
Kostyantyn Dumchev1, Olga Varetska2, Yana Sazonova2, Pavlo Smyrnov2
1Ukrainian Inst on Pub Hlth Policy, Kyiv, Ukraine, 2’Alliance for Pub Hlth, Kyiv, Ukraine

IMPROVED EVALUATION OF HIV PREVALENCE ADJUSTING FOR INFORMATIVE NONPARTICIPATION
Linbo Wang1, Erik VanWidenfelt2, Chloe Auletta-Young1, Nealia Khan1, Etienne Kadima1, Unoda Chakalisa1, Tendani Gaolathe1, Eric Tchetgen Tchetgen1, Kathleen Wirth1
1Harvard Univ, Boston, MA, 2Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana
Poster Sessions • Tuesday
Program and Agenda
CROI 2017

113

Poster P-S7 HIV SELF TESTING: KNOW YOURSELF
Poster Hall - 4 EF
2:30 PM - 4:00 PM

891 HIV SELF-TEST (HIVST) AWARENESS, EXPOSURE, AND USE, NEW YORK CITY, 2015–2016
Paul M. Salcuni1, Zoe R. Edelstein, Demetre C. Daskalakis, Julie Myers
New York City DHMH, Queens, NY, USA

892 ETEST: A “SMART” HOME HIV TESTING SYSTEM ENABLING REAL-TIME FOLLOW-UP AFTER TESTING
Tyler B. Wray1, Philip A. Chan1, Don Operario1, Erik Simpanen1
1Brown Univ, Providence, RI, USA, 2The Miriam Hosp, Providence, RI, USA

893 PEER-LED ORAL HIV SELF-TESTING FINDS UNDIAGNOSED HIV AMONG MSM IN MALINDI, KENYA
Elisabeth M. van der Elst1, Mahmoud Shally1, Clifford Oduor1, Oscar Chirro1, Fauz Ibrahim1, Bernadette Kombo1, Susan M. Graham1, 2Eduard Sanders2
1KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya, 2Kilifi County Dept of Hlth, Kilifi, Kenya, 3Univ of Washington, Seattle, WA, USA, 4Keny Med Rsr Inst, Kilifi, Kenya

894 ROLE OF PARTNER VIOLENCE IN WOMEN’S ABILITY TO DISTRIBUTE SELF-TESTS TO MALE PARTNERS
Elisabeth Schaffer1, Kawango Agot2, Harsha Thirumurthy1
1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Impact Rsr and Development Org, Kisumu City, Kenya

895 INFORMING HIV SELF-TESTING SERVICES IN MALAWI USING DISCRETE CHOICE EXPERIMENTS
Pitchaya Indravudh1, Marc D’Elbee2, Moses Kumwenda1, Augustine Choko1, Doreen Sakala2, Thokozani Kalua2, Cheryl Johnson2, Karin Hatzold2, Liz Corbett2, Fern Terris-Presthol2

896 PROVIDING USER SUPPORT FOR HIV SELF-TESTING BEYOND INSTRUCTIONS-FOR-USE IN MALAWI
Pitchaya Indravudh1, Moses Kumwenda1, Melissa Neuman1, Blessings Chisunkha1, Karin Hatzold2, Chiwawa Nkhoma2, Thokozani Kalua2, Cheryl Johnson2, Miriam Taegtmeyer2, Liz Corbett2

897 ACCEPTABILITY OF SELF-COLLECTED RECTAL SWABS FOR HIV EXPOSURE TESTING AMONG MSM/TGW
Hong Van Tieu1, Maria Lemos1, Michele Andrasik2, Ira Fleming2, Vijay Nandi3, Geneva Ortiz3, Debbie Lucy3, Martin Musurun3, Julie McElrath3, Beryl A. Kobrin3
1New York Blood Cntr, New York, NY, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 3Univ of Illinois, Peoria, IL, USA

898 FEASIBILITY AND REACH OF A HOME-TEST GIVEAWAY IN NEW YORK CITY, 2015–2016
Zoe R. Edelstein1, Paul M. Salcuni1, Benjamin Tsoi1, Paul Kobrak1, Adriana Andaluz1, David A Katz2, Demetre C. Daskalakis3, Julie Myers1
1New York City DHMH, Queens, NY, USA, 2Univ of Washington, Seattle, WA, USA

CROI 2017 113
899  STATE-LEVEL ESTIMATES OF HIV INCIDENCE, PREVALENCE, AND UNDIAGNOSED INFECTIONS
Anna S. Johnson, Ruiguang Song, Irene Hall
CDC, Atlanta, GA, USA

900  ESTIMATING THE UNDIAGNOSED FRACTION: A COMPARISON OF NEW METHODS
Jeanette Birnbaum¹, Jason Carr², Martina Morris¹
¹Univ of Washington, Seattle, WA, USA, ²Washington State Dept of Hlth, Olympia, USA

901  HIV TESTING MOTIVATIONS OF US MEN WHO HAVE SEX WITH MEN IN A NATIONAL ONLINE SURVEY
David A. Katz¹, Patrick Sullivan², Robert C. Sineath, Jennie McKenney², Maria Zlotorzynska³, Susan Cassels¹, Joanne Stekler¹
¹Univ of Washington, Seattle, WA, USA, ²Emory Univ, Atlanta, GA, USA, ³Univ of California Santa Barbara, Santa Barbara, CA, USA

902  INCREASES IN HIV TESTING FREQUENCY AMONG MEN WHO HAVE SEX WITH MEN, UNITED STATES
Qian An, Ruiguang Song, Teresa Finlayson, Cyprian Wejnert, Gabriela Paz-Bailey
CDC, Atlanta, GA, USA

903  UNDIAGNOSED HIV AND HCV IN A NEW YORK CITY EMERGENCY ROOM, 2015
Lucia V. Torian¹, Uriel Felsen², Qiang Xia³, Eric Rude³, Herbert Rose⁴, Angelica Bocour⁵, Gary J. Williams⁶, Bob F. Bridgforth⁷, Lisa A. Forgione⁸, Barry S. Zingman⁹
¹New York City DHMH, New York, NY, USA, ²Albert Einstein Coll of Med, Bronx, NY, USA, ³New York City DHMH, Long Island City, NY, USA, ⁴Montefiore Med Ctr, Bronx, NY, USA, ⁵Quest Diagnostics, San Clemente, CA, USA

904  EXAMINATION OF UNRECOGNIZED AND MISREPORTED HIV STATUS IN BALTIMORE MSM AND PWID
Danielle German¹, Kate Shearer¹, Colin Flynn¹, Carl A. Latkin¹, Oliver Laeyendecker¹, Thomas Quinn¹, William Clarke¹
¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Maryland DHMH, Baltimore, MD, USA, ³NIAID, Baltimore, MD, USA

905  SPATIAL VARIATION ALONG THE HIV CARE CONTINUUM IN WASHINGTON, DC, 2014–2015
Arpi Terzian¹, Naji Younes¹, Jenevieve Opoku¹, Johnathan Hubbard¹, Rena R. Jones¹, Princy Kumar¹, Amanda D. Castel¹, for the The DC Cohort Executive Committee
¹The George Washington Univ, Washington, DC, USA, ²District of Columbia Dept of Hlth, Washington, DC, USA, ³NCI, Bethesda, MD, USA

906  TRENDS AND DISPARITIES IN ART USE AMONG PERSONS WITH HIV IN SAN FRANCISCO, 2006–2015
Ling Hsu¹, Sandy Schwarcz¹, Susan Scheer¹
¹San Francisco Dept of Pub Hlth, San Francisco, CA, USA

907  CARE CONSTANCY AND VIRAL SUPPRESSION AMONG ADULTS IN HIV CLINICAL CARE, UNITED STATES
Heather Bradley, Kate Buchacz, Yunfeng Tie, Oluwatosin Olayi, R. L. Shouse
CDC, Atlanta, GA, USA
908  **BEYOND THE STATIC HIV CONTINUUM: CAPTURING THE DYNAMIC PROCESS OF RETENTION**  
Hana Lee¹, Xiaotian Wu¹, Michael J. Mugavero², Stephen R. Cole³, Bryan Lau¹, **Becky L. Genberg**¹, Joseph Hogan¹  
¹Brown Univ, Providence, RI, USA, ²Univ of Alabama at Birmingham, Birmingham, AL, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴The Johns Hopkins Univ, Baltimore, MD, USA  

909  **ASSOCIATION BETWEEN 4 MEASURES OF RETENTION IN CARE AND VIROLOGIC FAILURE**  
Mariah M. Kalmin, Amanda D. Castel, Alan Greenberg, Heather Young, Heather Hoffman, for the DC Cohort Executive Committee  
George Washington Univ, Washington, DC, USA  

910  **USING SURVEILLANCE DATA TO MEASURE PROGRESS ALONG THE HIV CARE CONTINUUM**  
Nancy A. Hessol¹, Ling Hsu², Sharon Pipkin², Susan Scheer²  
¹Univ of California San Francisco, San Francisco, CA, USA, ²San Francisco Dept of Pub Hlth, San Francisco, CA, USA  

**Poster P-S9 FACTORS INFLUENCING HIV OUTCOMES**  
**Poster Hall - 4 EF**  
2:30 PM - 4:00 PM  

911  **IMPROVED HIV CARE OUTCOMES FOR INMATES REFERRED TO COMMUNITY PROGRAMS IN PHILADELPHIA**  
Makeda Carroll¹, Tanner Nassau¹, Melissa Miller¹, Cody Poerio², Hannah Zellman¹, Bruce Herdman¹, Coleman Terrell¹, Kathleen Brady¹  

912  **HEALTH LITERACY AND DEMOGRAPHIC DISPARITIES IN HIV-1 VIRAL SUPPRESSION**  
Peter F Rebeiro¹, Tristan McPherson², Kathryn Goggins², Megan M. Turner¹, Sally S. Bebawy¹, Lauren Brinkley-Rubinstein¹, Anna K. Person¹, Timothy R. Sterling¹, Sunil Kripalani¹, April C. Pettit¹  
¹Vanderbilt Univ, Nashville, TN, USA, ²Columbia Univ, New York, NY, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA  

913  **FOOD INSECURITY AND HIV TREATMENT OUTCOMES IN THE WOMEN’S INTERAGENCY HIV STUDY**  
Sheri Weiser¹, Lila A. Sheira¹, Kartika Palar¹, Tracey Wilson¹, Lisa Metsch¹, Adaora Adimora¹, Igho Ofotokun¹, Eryka Wentz², Phyllis Tien¹, Edward A. Frongillo¹  
¹Univ of California San Francisco, San Francisco, CA, USA, ²SUNY Downstate Med Cntr, Brooklyn, NY, USA, ³Columbia Univ, New York, NY, USA, ⁴Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁵Emory Univ, Atlanta, GA, USA, ⁶The Johns Hopkins Univ, Baltimore, MD, USA, ⁷Univ of South Carolina, Columbia, SC, USA  

914  **HIV STATUS AWARENESS AND ART COVERAGE AMONG FEMALE SEX WORKERS IN JUBA, SOUTH SUDAN**  
Avi Hakim¹, Victoria Achut¹, Alfred Okiria¹, Alex Bolo¹, Jennifer Wesson², Joel Katoro¹, Gilda Caesars¹, Acaga Taban¹, Lee Hundley¹  
¹South Sudan Ministry of Hlth, Juba, South Sudan, ²IntraHlth Intl, Juba, South Sudan, ³CDC–South Sudan, Juba, South Sudan, ⁴IntraHlth Intl, Chapel Hill, NC, USA, ⁵Emory Univ, Atlanta, USA
915 “TEST AND TREAT" ANTIRETROVIRAL THERAPY AMONG FEMALE SEX WORKERS IN KAMPALA, UGANDA
Yunia Mayanja, Onesmus Kamacooko, Daniel Bagiire, Gertrude Namale, Janet Seeley
MRC/UVRI Uganda Rsr Unit on AIDS, Entebbe, Uganda

916 VALIDATING SELF-REPORTED USE OF ANTIRETROVIRAL THERAPY IN AGINCOURT, SOUTH AFRICA
1Beth Israel Deaconess Med Cntr, Boston, MA, USA, 2Harvard Univ, Cambridge, MA, USA, 3Tintswalo Hosp, Acorndoek, South Africa, 4Univ of the Witwatersrand, Acorndoek, South Africa, 5Univ of the Witwatersrand, Johannesburg, South Africa, 6Heidelberg Univ, Heidelberg, Germany

917 REDUCING THE DEMAND FOR VIRAL-LOAD MONITORING IN THE CONTEXT OF TREATMENT FOR ALL
Denise Evans1, Mouhamed Abdou Salam Mbengue1, Dorina Ononya1, Charles Chasela1, Matthew Fox1
1Univ of the Witwatersrand, Johannesburg, South Africa, 2Boston Univ, Boston, MA, USA

Poster Sessions • Tuesday

Poster P-U1 STRATEGIES TO INCREASE HIV TESTING
Poster Hall - 4 EF 2:30 PM - 4:00 PM

956 A PRAGMATIC RANDOMIZED CLINICAL TRIAL OF RAPID HIV SCREENING IN EMERGENCY DEPARTMENTS
Jason Haukoos1, Michael S. Lyons2, Douglas A. White3, Emily Hopkins4, Meggan Bucozzi1, Sarah Pfeil3, Andrew Ruffner4, Danielle Signer4, Richard Rothman1, for the HIV TESTED Trial Investigators
1Denver Hlth Med Cntr, Denver, CO, USA, 2Univ of Cincinnati Coll of Med, Cincinnati, OH, USA, 3Highland Hosp, Oakland, CA, USA, 4Johns Hopkins Univ, Baltimore, MD, USA

957 OPT-OUT HIV/HCV TESTING AMONG JAIL INMATES
Carolina De La Flor1, Esmaeil Porsa2, Ank E. Nijhawan1
1Univ of Texas Southwestern Med Cntr, Dallas, TX, USA, 2Parkland Hlth and Hosp Systems, Dallas, TX, USA

958 STRENGTHENING MALE-PARTNER TESTING IN ANTENATAL CARE: FINDINGS FROM SOUTH AFRICA
Amy M. Medley1, Nienke van Schaik2, Carlos Toledo1, Makungureyi Mlambo3, Sello Moremi2, Kabelo Baloyi3, Nompumelelo Khanyile3, Sphindile Magwaza3, Cila Kabongo4, John Tumbo4
1CDC, Atlanta, GA, USA, 2Hlth Systems Trust, Durban, South Africa, 3US CDC, Pretoria, South Africa, 4Rustenburg Sub-District Office, Rustenburg, South Africa

959 HPTN 071 HOME-BASED TESTING IMPROVES UPTAKE OF HCT AMONG PREGNANT WOMEN IN ZAMBIA
Stable Besa1, Ab Schaap1, Mwate J. Chaila1, S. Floyd2, Richard Hayes2, Sarah Fidler3, Kwame Shanaube1, H. Ayles4, for the Zambart Study Group
Poster P-W2 INTERVENTIONS TO IMPROVE THE CARE CASCADE
Poster Hall - 4 EF
2:30 PM - 4:00 PM

997 HIV TESTING, LINKAGE TO CARE, AND VIRAL SUPPRESSION AMONG GAY MEN IN NIGERIA
Habib R. Omari1, Uchenna Ononaku2, Rebecca G. Nowak3, Ifeanyi Orazulike1, Trevor Crowell4, Nicaise Ndembu5, Hongjie Liu6, Stefan Baral7, Man Charurat1
1Univ of Maryland, Baltimore, MD, USA, 2Inst of Human Virology Nigeria, Abuja, Nigeria, 3Intl Ctr on Advocacy and Rights to Hlth, Abuja, Nigeria, 4US Military HIV Rsr Prog, Bethesda, MD, USA, 5Univ of Maryland Coll Park, Coll Park, MD, USA, 6The Johns Hopkins Univ, Baltimore, MD, USA

998 ART INITIATION AND RETENTION IN AFTER-HOUR VERSUS DAILY MALE HEALTH CLINICS
Tali Cassidy1, Amir Shroufi1, Sarah Jane Steele1, Morna Cornell2, Virginia de Azevedo1, David Binza2, Rodd Gerstenhaber1
1Médecins Sans Frontières, Cape Town, South Africa, 2Univ of Cape Town, Cape Town, South Africa, 3City of Cape Town Dept of Hlth, Cape Town, South Africa, 4Western Cape Provincial Dept of Hlth, Cape Town, South Africa

999 THE IMPACT OF CARE NAVIGATORS ON ENGAGEMENT IN HIV CARE IN WESTERN KENYA
Becky L. Genberg1, Violet Naanyu2, Alfred Keter3, Anthony Ngeresa3, Juddy Wachira2, Alfred Keter3, Anthony Ngeresa3, Juddy Wachira2, Joseph Hogan1, Paula Braitstein4, 1Brown Univ, Providence, RI, USA, 2Moi Univ, Eldoret, Kenya, 3Academic Model Providing Access to Hlthcare, Eldoret, Kenya, 4Univ of Toronto, Toronto, Canada

1000 IMPROVED RETENTION WITH LONGER FOLLOW-UP INTERVALS FOR STABLE PATIENTS IN ZAMBIA
Aaloke Mody1, Nancy Padian2, Nancy Czaicki3, Carolyn Bolton Moore4, Charles Holmes5, Elvin Geng6, Izuankji Sikazwe5
1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of California Berkeley, Berkeley, CA, USA, 3Univ of Alabama at Birmingham—CIDRZ, Lusaka, Zambia, 4The Johns Hopkins Univ—CIDRZ, Bethesda, MD, USA, 5Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia

1001 EXPERIENCES WITH RETENTION IN CARE AND VIRAL SUPPRESSION IN A PHARMACY REFILL PROGRAM
Arvind Kaimal1, Barbara Castelnuovo1, Martha Atwiine2, Rachel Musomba1, Maria S. Nabaggala1, Rosalind P. Ratanshi1, Mohammed Lamorde1
1Makerere Univ, Kampala, Uganda, 2Univ of Cambridge, Cambridge, UK

1002 VIROLOGIC OUTCOMES WHEN ANTIRETROVIRAL THERAPY IS USED FOR PREVENTION: HPTN 052
Jessica M. Fogel1, Xinyi C. Zhang2, Estelle Piwowar-Manning1, Nagalingeswaran Kumarasamy1, James G. Hakim1, Beatriz Grinsztejn1, Ying Q. Chen1, Myron S. Cohen2, Susan H. Eshleman1, for the HPTN 052 Study Team
1The Johns Hopkins Univ Sch of Med, Baltimore, MD, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 3YRG CARE, Chennai, India, 4Inst of Zimbabwe, Harare, Zimbabwe, 5Inst de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil, 6Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1003 USERS MAY LACK CONFIDENCE IN ART FOR HIV PREVENTION: A QUALITATIVE ANALYSIS

Monique A. Wyatt1, Emily E Pisarski2, Jared Baeten3, Renee Heffron2, Edith Nakku-Joloba2, Timothy R. Mwonge6, Elly T Katabira1, Connie L. Celum1, Norma C. Ware1
1Harvard Univ, Boston, MA, USA, 2Univ of Washington, Seattle, WA, USA, 3Makerere Univ, Kampala, Uganda, 4Infectious Diseases Inst, Kampala, Uganda

1004 UPTAKE AND ADAPTATION OF COMMUNITY ADHERENCE GROUPS IN ZAMBIA

Monika Roy1, Mpande Mukumbwa-Mwenechanya3, Emilie Efronson2, Mwansa Lumpa2, Anjali Sharma2, Izukanji Sikazwe2, Nancy Padian1, Carolyn Bolton Moore4, Elvin Geng1, Charles Holmes2
1Univ of California San Francisco, San Francisco, CA, USA, 2Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia, 3Univ of California Berkeley, Berkeley, CA, USA, 4Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia, 5Johns Hopkins Univ, Baltimore, MD, USA

1005 ASSESSING RETENTION IN A CLUSTER RANDOMIZED TRAIL TO ACCELERATE ART INITIATION

Richard Katuramu1, Fred Semitala2, Gideon Amanyire1, Jennifer Namusobya1, Leatitia Kampiire1, Jeanna Wallenta1, David Glidden3, Moses R. Kamya2, Diane V. Havlir3, Elvin Geng3
1Makerere Univ Joint AIDS Prog, Kampala, Uganda, 2Makerere Univ Coll of Hlth Scis, Kampala, Uganda, 3Univ of California San Francisco, San Francisco, CA, USA

1006 LOWER RETENTION IN CARE WHEN ART IS INITIATED WITH CD4 ≥ 500 CELLS/ML

Isabelle A. Meyer-Andrieux1, Jim Todd2, Robert Keango2, Elisabeth Poulet3, Prince Nkhoma1, Elisabeth Szumilin4, David Maman2, Leon Salumu4
1MSF, Geneva, Switzerland, 2London Sch of Hygiene & Trop Med, London, UK, 3MSF, Lilongwe, Malawi, 4MSF, Paris, France, 5Epicentre, Cape Town, South Africa

1007 ART INITIATION FOR NEWLY DIAGNOSED PLHIV: IMPLICATIONS FOR TEST & TREAT, SOUTH AFRICA

Anna Larsen1, Mireille Cheyip1, Abraham Tesfay2, Peter Vranken1, Henry Fomundam2, Anthony Wutoh2, Getahun Aynalem1
1US CDC, Pretoria, South Africa, 2Howard Univ, Pretoria, South Africa

1008 TREATMENT NEED AND FAST-TRACK ART IN THE BOTSWANA COMBINATION PREVENTION PROJECT

Refeletswe Lebelonyane1, Lisa A. Mills3, Joe Theu1, Lisa Block1, Michael Kasonde1, Tony Chebani1, Shenaaz el-Halabi1, Elliot Raizes1, Shahin Lockman1, Joseph N. Jarvis2
1Botswana Ministry of Hlth, Gaborone, Botswana, 2CDC Botswana, Gaborone, Botswana, 3CDC Atlanta, Atlanta, USA, 4Harvard Univ, Boston, MA, USA
1009 LINKAGE TO CARE OUTCOMES IN THE BOTSWANA COMBINATION PREVENTION PROJECT
Mary Grace Alwano, Pamela J. Bachanas, Catherine Motswere, Tafireyi Marukutira, Bareaed W Sento, Nokuthula Majingo, Shahin Lockman, Molly Pretorius Holme, Huisheng Wang, Janet Moore
1US CDC, Gaborone, Botswana, 2CDC, Atlanta, GA, USA, 3Tebelapele HIV Testing and Counseling Ctr, Gaborone, Botswana, 4Ministry of Hlth, Gaborone, Botswana, 5Harvard Univ, Boston, MA, USA, 6Northrup Grumman, Atlanta, GA, USA

1010 ART COVERAGE AFTER 2 YEARS OF A UTT INTERVENTION IN ZAMBIA: FINDINGS FROM HPTN071
Sian Floyd, Mwelwa Phiri, Ab Schaap, David Macleod, Kwame Shanaube, Sam Griffith, Nulda Beyers, Richard Hayes, Sarah Fidler, Helen Ayles

1011 REACHING 90-90-90? FINDINGS AFTER 2 YEARS OF HPTN 071 (PopART) INTERVENTION IN ZAMBIA
Richard Hayes, S. Floyd, Ab Schaap, Kwame Shanaube, Peter Bock, Sam Griffith, Nulda Beyers, H. Ayles, Sarah Fidler, for the HPTN 071 (PopART) Study Team

1012 HEALTH CARE COVERAGE AND VIRAL SUPPRESSION PRE- AND POST-ACA IMPLEMENTATION
Heather Bradley, Joseph Prejean, Lindsey Dawson, Antigone Dempsey, Jennifer Kates, Pamela W. Klein, R. L. Shouse
1CDC, Atlanta, GA, USA, 2Kaiser Family Fndn, Washington, DC, USA, 3HRSA, HIV/AIDS Bureau, Rockville, MD, USA

1013 HOUSING STABILITY IS ASSOCIATED WITH HIV VIRAL SUPPRESSION IN A HOUSING PLACEMENT RCT
Yaoyu Zhong, Ellen Wiewel, Vivian L. Towe, Rachel Johnson, Laura McAllister-Hollod, Joanne Hsu, Sarah Brauningstein, John Rojas
1New York City DHMH, Long Island City, NY, USA, 2RAND Corporation, Arlington, VA, USA

1014 ADVANCING “TASP” USING A MEDICAL-CARE COORDINATION MODEL IN LOS ANGELES COUNTY
Wendy H. Garland, Sonali P. Kulkarni
Los Angeles County, Los Angeles, CA, USA

1019 FACTORS ASSOCIATED WITH LATE PRESENTATION FOR HIV CARE IN SOUTH AFRICA
Henry Fomundam, Abraham Tesfay, Shelter Mushipe, Myriam Mosina, Carol Boshielo, Hanson Tebe, Anna Larsen, Mireille Cheyip, Getahun Aynalem, Yogam Pillay
1Howard Univ, Pretoria, South Africa, 2US CDC, Pretoria, South Africa, 3South African Natl Dept of Hlth, Pretoria, South Africa
1020 SOUTH AFRICA’S NATIONAL THIRD-LINE ART COHORT: DESCRIPTIVE ANALYSIS

Francesca Conradie1, Matthew Fox2, Michelle A. Moorhouse3, Gary Maartens4, Willem D. Venter1, Mahomed-Yunus Moosa4, Khadija Jamaloodien5

1Univ of the Witswatersrand, Johannesburg, South Africa, 2Boston Univ, Boston, MA, 3Univ of Cape Town, Cape Town, South Africa, 4Univ of KwaZulu-Natal, Durban, South Africa, 5South African Natl Dept of Hlth, Pretoria, South Africa

1021 “I WON’T DIE WITH THE CAUSE OF AIDS”: 10 YEARS ON ART IN SOUTH AFRICA’S HIV PROGRAM

Cheryl J. Hendrickson1, Sophie Pascoe1, Aneesa Moolla1, Mhairi Maskew1, Matthew Fox2

1Univ of the Witwatersrand, Johannesburg, South Africa, 2Boston Univ, Boston, MA

1022 OUTCOMES OF AHI SCREENING AND IMMEDIATE ART INITIATION IN COASTAL KENYA

Edward Sanders1, Oscar Chirro2, Juma Mangi2, Elizabeth Wahome3, Matt A. Price1, Huub C. Gelderblom1, Elisabeth M. van der Elst1, Susan M. Graham5


1023 TEN YEARS OF SUPPORTING SCALE-UP OF HIV CARE AND EXPANSION OF ART IN 4 COUNTRIES

Chloe A. Teasdale1, Chunhui Wang, Jessica E. Justman, David Hoos, Mark Hawken, Zenebe Melaku, Antonio Musa, Wafaa M. El-Sadr, Elaine J. Abrams

ICAP at Columbia Univ, New York, NY, USA

Poster P-X2 COST-EFFECTIVENESS OF HIV TESTING AND SCREENING STRATEGIES

Poster Hall - 4 EF

2:30 PM - 4:00 PM

1028 EFFECTIVENESS AND COST-EFFECTIVENESS OF HIV SCREENING STRATEGIES ACROSS EUROPE

Guillaume Mabileau1, Julia Del Amo2, Cristian Rüütel1, A. David Paltiel1, Liis Lemalu2, Asunción Díaz2, Jesús Martín Fernández2, Rochelle P. Walensky4, Kenneth Freedberg2, Yazdan Yazdanpanah1

1INSERM, Paris, France, 2Inst of Hlth Carlos III, Madrid, Spain, 3Natl Inst for Hlth Development, Tallinn, Estonia, 4Yale SPH, New Haven, CT, USA, 5Univ Rey Juan Carlos, Madrid, Spain, 6Massachusetts General Hosp, Boston, MA, USA

1029 COST-EFFECTIVENESS OF HIV SCREENING OF HETEROSEXUALS IN THE UNITED STATES

Angela B. Hutchinson1, Katherine A. Hicks2, Emine Yaylali1, Emily Tucker1, Evin Jacobson1, Stephanie L. Sansom1

1CDC, Atlanta, GA, USA, 2RTI Hlth Solutions, Rsr Triangle Park, NC, USA, 3Univ of Michigan, Ann Arbor, MI, USA
1030 COST-EFFECTIVENESS OF DIFFERENT DELIVERY APPROACHES FOR HIV SELF-TESTING

Valentina Cambiano\(^1\), Cheryl Johnson\(^1\), Carmen Figueroa\(^2\), Paul Revill\(^3\), Rachel Baggage\(^2\), Elizabeth L. Corbett\(^2\), Tsitsi Apollo\(^2\), Karin Hatzold\(^6\), Frances Cowan\(^1\), Andrew Phillips\(^1\)


1031 THE COST OF NOT RETESTING: HIV MISDIAGNOSIS IN THE ART “TEST-AND-OFFER” ERA

Jeffrey Eaton\(^1\), Cheryl Johnson\(^2\), Simon Gregson\(^1\)

\(^1\)Imperial Coll London, London, UK, \(^2\)WHO, Geneva, Switzerland

1032 MODELING THE COST-EFFECTIVENESS OF ASSISTED PARTNER NOTIFICATION FOR HIV IN KENYA

Monisha Sharma\(^1\), Jennifer Smith\(^2\), Carey Farquhar\(^3\), Roger Ying\(^1\), Peter Cherutich\(^4\), Beatrice Wamuti\(^5\), Matthew R. Golden\(^1\), Felix Abuna\(^6\), Ruanne V. Barnabas\(^7\)

\(^1\)Univ of Washington, Seattle, WA, USA, \(^2\)Imperial Coll London, London, UK, \(^3\)Weill Cornell Med Coll, New York, NY, USA, \(^4\)Ministry of Hlth, Nairobi, Kenya, \(^5\)Kenyatta Natl Hosp, Nairobi, Kenya, \(^6\)Univ of Washington, Seattle, USA

1054 CHARACTERIZATION OF MORE THAN 10,000 ZIKA VIRUS TEST RESULTS IN THE US

Joseph M. Volpe\(^1\), Dajie Luo\(^1\), Arren Fisher\(^1\), Mindy Nye\(^2\), Barbara Body\(^2\), Marcia Eisenberg\(^1\)

\(^1\)LabCorp, Durham, NC, USA, \(^2\)LabCorp, Burlington, NC, USA

1055LB ZIKA VIRUS PERSISTENCE IN BODY FLUIDS

Gabriela Paz-Bailey\(^1\), Eli Rosenberg\(^2\), Katherine Doyle\(^3\), Jorge Munoz-Jordan\(^4\), Gilberto Santiago\(^5\), Liore Klein\(^6\), Janice Perez\(^7\), Stephen Waterman\(^8\), Luisa Alvarado\(^9\), Tyler Sharp\(^10\)

\(^1\)CDC, Atlanta, GA, USA, \(^2\)Emory Univ, Atlanta, GA, USA, \(^3\)Caduceus Healthcare Inc, Ponce, PR, USA, \(^4\)Ponce Univ, Ponce, PR, USA

1056LB NEUROLOGIC CONSEQUENCES OF POSTNATAL ZIKA VIRUS INFECTION IN INFANTS

Maud Mavigner\(^1\), Justin O’Neal\(^2\), Siddhartha Bhamik\(^1\), Jakob Habib\(^1\), Cameron Robinson\(^1\), Maria Alvarado\(^1\), Xiaodong Zhang\(^1\), Jens Wrammert\(^1\), Mehul Suthar\(^2\), Ann Chahroudi\(^1\)

\(^1\)Emory Univ, Atlanta, GA, USA, \(^2\)Emory Vaccine Center, Atlanta, GA, USA, \(^3\)Yerkes Natl Primate Rsr Cntr, Atlanta, GA, USA

1057LB ZIKA VIRUS PROTECTION BY A SINGLE LOW-DOSE NUCLEOSIDE-MODIFIED mRNA VACCINATION

Michael J. Hogan\(^1\), Norbert Pardi\(^1\), Rebecca S. Pelc\(^2\), Hanne Anderson\(^1\), Charles McGee\(^3\), Michael J. Hope\(^1\), Mark G. Lewis\(^1\), Theodore C. Pierson\(^4\), Barton F. Haynes\(^5\), Drew Weissman\(^1\)

\(^1\)Univ of Pennsylvania, Philadelphia, PA, USA, \(^2\)NIAID, Bethesda, MD, USA, \(^3\)Bioqual, Inc, Rockville, MD, USA, \(^4\)Duke Univ, Durham, NC, USA, \(^5\)Acuitas Therapeutics, Vancouver, BC, Canada
**161**  
**UBP43 (USP18) ABROGATES SAMHD1-MEDIATED RESTRICTION OF HIV-1**  
Edmund Osei-Kuffour, Kerstin Schott, Dieter Häussinger, Philipp A Lang, Karl S. Lang, Renate König, Carsten Münk  
1Heinrich Heine Univ Hosp, Düsseldorf, Germany, 2Paul Ehrlich Institut, Fed Inst for Vaccines and BioMeds, Düsseldorf, Germany, 3Univ Hosp, Essen, Düsseldorf, Germany, 4Paul Ehrlich Institut, Langen, Germany

**162**  
**LNCRNA DISCOVERY IN THE HIV REPLICATION CYCLE ADDS A NEW LAYER IN HIV-HOST INTERPLAY**  
Wim Trypsteen, Pejman Mohammadi, Clarissa Van Hecke, Pieter Mestdagh, Steve Lefever, Pieter De Bleser, Jo Vandesompele, Angela Ciuffi, Ward De Spieghelaere, Linos Vandekerckhove  
1Ghent Univ, Ghent, Belgium, 2Univ of Lausanne, Lausanne, Switzerland, Inflammation Rsr Cntr, Flanders Inst of BioTech, Ghent, Belgium

**163**  
**SPLICING IN A PANEL OF HIV-1 TRANSMITTED/FOUNDER VIRUSES**  
Ann Emery, Ronald Swanstrom  
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

**164**  
**THE ROLES OF 5 CONSERVED LENTIVIRAL RNA STRUCTURES IN HIV-1 REPLICATION**  
Yang Liu, Olga A. Nikolaitchik, Belete A. Desimmie, Vinay K. Pathak, Kevin M. Weeks, Wei-Shau Hu  
1NCI, Frederick, MD, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

**165**  
**EXPONENTIAL GROWTH OF HIV DEPENDENT ON BURST SIZE BREAKTHROUGH OF THE ALLEE THRESHOLD**  
Jason M. Hataye, Joseph P. Casazza, David R. Ambrozak, Takuya Yamamoto, Daniel Douek, Alan S. Perelson, Richard A. Koup  
1NIH, Bethesda, MD, USA, 2Osaka Univ, Sukta, Osaka, Japan, 3NIAID, Bethesda, MD, USA, 4Los Alamos Natl Lab, Los Alamos, NM, USA

**172**  
**CHARACTERIZING APOBEC3H FUNCTION AND EVOLUTION IN AFRICAN GREEN MONKEYS**  
 Erin I. Garcia, Michael Emerman  
1Univ of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

**173**  
**MAPPING THE HIV-1 VIF-CBFβ INTERACTION INTERFACE AND IDENTIFICATION OF DETERMINANTS**  
Belete A. Desimmie, Jessica Smith, Hiroshi Matsuo, Wei-Shau Hu, Vinay K. Pathak  
1NCI, Frederick, MD, USA, 2Univ of Minnesota, Minneapolis, MN, USA

**174**  
**THE ABILITY OF HIV-1 TO EVADE SAMHD1-MEDIATED RESTRICTION IN MACROPHAGE**  
Timothy Plitnik, Mark Sharkey, Mario Stevenson  
Univ of Miami, Miami, FL, USA
175 MHC DOWN-MODULATION IN HIV-INFECTED CELLS OCCURS LATE IN THE VIRUS REPLICATIVE CYCLE
Rodrigo Matus Nicodemos, Daniel Douek, Richard A. Koup
Vaccine Rsr Cntr, NIAID, Bethesda, MD, USA

191 ESTIMATING THE HERITABILITY OF AN HIV-1 TRAIT IN A CLINICAL SETTING
Nadine Bachmann1, Teja Turk1, Alex Marzel1, Claus Kadelka2, Thomas Klimkait3, Vincent Aubert2, Jürg Bön1, Huldrych F. Günthard1, Roger Koyos2
1Univ Hosp Zurich, Zurich, Switzerland, 2Univ of Zurich, Zurich, Switzerland, 3Dept of Biomed, Basel, Switzerland, 4Univ Hosp Lausanne, Lausanne, Switzerland

192 NGS ANALYSIS OF HIV-1 GROUP O RT RESIDUE 181C PREVALENCE AND EVOLUTION OVER TIME
Marie Lez1, Myriam Vezain2, Elodie Alessandri1, Sophie Cautant2, Guillaume Unal1, Isabelle Tournier2, Francois Simon2, Jean-Christophe Plantier1
1Rouen Univ Hosp, Rouen, France, 2Normandie Univ, Rouen, France, 3COREVIH Haute-Normandie, Rouen, France, 4Saint Louis Hosp, Paris, France

193 ANALYSIS OF NEARLY FULL-GENOME HIV-1 SEQUENCES FROM UGANDA: RESULTS FROM PANGEA_HIV
Gonzalo Yebra1, Deogratius Ssemwanga2, Dan Frampton3, Brian Magambo4, Nicholas Bbosa2, Frederick Lyagoba2, Rebecca N. Nsubuga2, Pontiano Kaleebu4, Andrew Leigh Brown3, for the PANGEA_HIV Consortium
1Univ of Edinburgh, Edinburgh, UK, 2MRC Uganda Virus Rsr Inst, Entebbe, Uganda, 3Farr Inst of Hlth Informatics Rsr, London, UK

194 LTR GENETIC DIVERSITY AMONG HIV-2 ARV-NAÏVE PATIENTS IN THE ANRS CO5 HIV-2 COHORT
Quentin Le Hingrat1, Benoit Visseaux1, Melanie Bertine2, Fideline Collin2, Florence Damond1, Olivier Schwartz2, Sophie Matheron1, Diane Descamps1, Charlotte Charpentier1, for the ANRS HIV-2 CO5 Cohort
1Bichat Hosp, Paris, France, 2INSERM, Bordeaux, France, 3Inst Pasteur, Paris, France

195 PHYLOGEOGRAPHIC STUDY OF HIV-2 GROUPS A AND B EARLY EPIDEMICS IN WESTERN AFRICA
Benoit Visseaux1, Stephane Hu1, Florence Damond2, Fideline Collin2, Alexandre Storto1, Genevieve Chene1, Sophie Matheron1, Charlotte Charpentier1, Diane Descamps1, for the French ANRS COS HIV-2 Cohort
**Poster P-C1 PRIMARY HIV INFECTION AND SPREAD**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

**202 FEW ACUTE HIV-1 SYMPTOMS AND HIGH SET-POINT VIRAL LOAD IN SUBTYPE-C INFECTIONS**

Amin S. Hassan1, Jonathan Hare2, Matt A. Price3, Per Bjorkman4, Susan Allen5, Jill Gilmour6, Thumbi Ndung’u7, Sarah Rowland-Jones8, Eduard Sanders8, Joakim Esbjörnsson9


**203 GRANULOCYTIC MYELOID-DERIVED SUPPRESSOR CELLS IN PRIMARY HIV INFECTION**

Nicola Tumino, Maria Teresa Bilotta, Adriana Ammassari, Annalisa Mondi, Casetti Rita, Veronica Bordoni, Eleonora Cimini, Federico Martini, Chiara Agrati, Sacchi Alessandra

Natl Inst for Infectious Diseases Lazzaro Spallanzani, Rome, Italy

**204 HIV-1 EXPLOITS THE INTERPLAY BETWEEN EPITHELIAL AND TH17 CELLS FOR DISSEMINATION**

Tomas Raul Wiche Salinas1, Annie Gosselin1, Dragos Vlad2, Yuwei Zhang3, Huicheng Chen1, Cécile Tremblay1, Jean-Pierre Routy1, Petronela Ancuta1

1Cntr de Rsr du Cntr Hosp de l’Univ de Montréal, 2McGill Univ Hlth Cntr, Glen site, Montréal, Canada

**205 PLASMA-SOLUBLE CD163 IS SUPPRESSED UPON EARLY ART INITIATION IN ACUTE HIV INFECTION**

Michelle L. D’Antoni1, Somporn Tipsuk2, Shelly J. Krebs3, Thep Chalermchai4, Duangthai Suttichom5, Nittaya Phanuphak6, Victor Valcour6, Jintanat Ananworanich7, Lishomwa C. Ndhlouv7, for the RV254/SEARCH 010, SEARCH013, and SEARCH011 Study Groups

1Univ of Hawaii, Honolulu, HI, USA, 2SEARCH, South East Asia Rsr Collab with Hawaii, Bangkok, Thailand, 3US Military HIV Rsr Prog, Silver Spring, MD, USA, 4Univ of California San Francisco, San Francisco, CA, USA

**206 CMV REPLICATION DURING PRIMARY HIV INFECTION IS ASSOCIATED WITH T-CELL DYSFUNCTION**

Jennifer M. Dan1, Antoine Chaillon1, Masato Nakazawa1, Davey M. Smith1, Milenka Vargas2, Rachel Schrier2, Susan J. Little3, Sara Gianella1

1Univ of California San Diego, La Jolla, CA, USA, 2Univ of California San Diego, San Diego, CA, USA

**Poster P-C2 HOW DOES THE MICROBIOME AFFECT HIV INFECTION?**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

**207 IMPACT OF MSM-ASSOCIATED MICROBIOTA ON IMMUNE ACTIVATION AND IN VITRO HIV INFECTION**

Sam Li, Abigail Armstrong, Charles P. Neff, Catherine Lozupone, Brent E. Palmer

Univ of Colorado, Aurora, CO, USA

**208 FECAL MICROBIOTA FROM HIV-INFECTED SUBJECTS INCREASES IMMUNE ACTIVATION AND INFECTION**

Charles P. Neff, Sam Li, Abigail Armstrong, Catherine Lozupone, Brent E. Palmer

Univ of Colorado, Aurora, CO, USA
209 MARAVIROC INHIBITS HIV TARGET T-CELL TRAFFICKING INTO THE FEMALE GENITAL LUMEN
Alison S. Kohlmeier1, Sean McMaster1, Jessica Radzio1, Mian-er Cong1, Chuong Dinh1, Amy Martin1, Jacob E. Kohlmeier1, Gerardo Garcia-Lerma1
1CDC, Atlanta, GA, USA, 2Emory Univ, Atlanta, GA, USA

210 INVESTIGATING THE EFFECT OF pH ON CERVICOVAGINAL MUCUS BARRIER PROPERTIES TO HIV
Julie K. Shade1, Thuy Hoang1, Kevin Delong2, Justin Hanes3, Richard Cone3, Laura Ensign3
1The Johns Hopkins Univ, Baltimore, MD, USA

Poster P-C3 HIV INFECTION AND THE MICROBIOME
Poster Hall - 4 EF 2:30 PM - 4:00 PM

211 INFLAMMATORY GUT ILCs ASSOCIATE WITH DYSBIOSIS DURING UNTREATED HIV-1 INFECTION
Stephanie Dillon1, Daniel N. Frank1, Gregory Austin1, Sara Gianella2, Moriah Castleman1, Andrew Cogswell1, Alan Landay1, Edward Barker1, Cara Wilson1
1Univ of Colorado Anschutz Med Campus, Aurora, CO, USA, 2Univ of California San Diego, La Jolla, CA, USA, 3Rush Univ, Chicago, IL, USA

212 GUT-MICROBIOTA–RELATED METABOLIC PATHWAYS IN ELITE CONTROLLERS AND HIV PROGRESSORS
Piotr Nowak1, Javier Rivera2, Jan Vesterbacka1, Marc Noguera-Julian2, Kajsa Noyan1, Maria L. Calle1, Roger Paredes2, Anders Sönnerborg4
1Karolinska Inst, Stockholm, Sweden, 2IrsiCaixa Inst for AIDS Rsr, Badalona, Spain, 3Univ of Vic–Central Univ of Catalonia, Barcelona, Spain, 4Karolinska Univ Hosp, Stockholm, Sweden

213 CHANGES IN THE ORAL MICROBIOME WITH ART INITIATION
Rachel Presti1, Scott Handley1, Lindsay Droit1, Mahmoud Ghannoum1, Mark Jacobson1, Caroline H. Shiboski1, Jennifer Webster-Cyriaque1, Todd Brown3, Michael T. Yin3, Edgar T. Overton4
1Washington Univ in St. Louis, St. Louis, MO, USA, 2Washington Univ, St. Louis, MO, USA, 3Case Western Reserve Univ, Cleveland, OH, USA, 4Univ of California San Francisco, San Francisco, CA, USA, 5Univ of North Carolina at Chapel Hill, NC, USA, 6The Johns Hopkins Univ, Baltimore, MD, USA, 7Columbia Univ, New York, NY, USA, 8Univ of Alabama at Birmingham, Birmingham, AL, USA

214 ACUTE HIV INFECTION AND HUMAN GUT MICROBIOME BEFORE AND AFTER ANTIRETROVIRAL THERAPY
Ornella Sortino1, Nittaya Phanuphak1, Nitya Chomchev1, Yasmine Belkaid2, Jacquine Davis3, Mariam Quinones3, Suteeraporn Pinyakorn3, Jintanat Ananworanich4, Jason Brenchley5, Irini Sereti6
1Leidos Biomed Rsr, Inc, Frederick, MD, USA, 2SEARCH, Thai Red Cross AIDS Rsr Ctr, Bangkok, Thailand, 3SEARCH, Bangkok, Thailand, 4NIAD, Bethesda, MD, USA, 5Henry M. Jackson Fndn for the Advancement of Military Med, Bethesda, MD, USA

215 TWO-YEAR CART DOES NOT RESTORE PERIPHERAL BLOOD AND INTESTINAL HIV-RELATED DYSBIOSIS
Camilla Tincati1, Giuseppe Ancona1, Esther Merlini1, Antonella d’Arminio Monforte1, Giulia Marchetti1
1Univ of Milan, Milan, Italy
Poster Sessions • Wednesday

Program and Agenda

CROI 2017

Poster Sessions • Wednesday

Program and Agenda

CROI 2017

126

LYMPH NODE HIV-SPECIFIC CXCR5+ CTLs ARE ASSOCIATED WITH ENHANCED VIRAL CONTROL

Zaza Ndhlovu1, Funsho Ogunshola2, Omolara Baiyegunhi2, Nikoshia Mewalal2, Amber Moodley2, Krista Dong1, Thumbi Ndung’u2, Bruce D. Walker1

1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, 2Univ of KwaZulu Natal, Durban, South Africa

RESIDENT MEMORY CD8+ T CELLS FORM THE FRONT-LINE DEFENSE IN HIV-INFECTED LYMPH NODES

Marcus Buggert1, Lalit Beura2, Son Nguyen1, David Canaday1, Ali Naji3, Constantinos Petrosas3, Gustavo Reyes-Terán4, Steven G. Deeks2, David Masopust5, Michael R. Betts1

1Univ of Pennsylvania, Philadelphia, PA, USA, 2Univ of Minnesota, Minneapolis, MN, USA, 3Case Western Reserve Univ, Cleveland, OH, USA, 4Hosp of the Univ of Pennsylvania, Philadelphia, PA, USA, 5NIH, Bethesda, MD, USA, 6Rsr Cntr in Infectious Diseases, Mexico City, Mexico, 7Univ of California San Francisco, San Francisco, CA, USA

HIV-1 ESCAPE FROM CD8+ CYTOTOXIC T-LYMPHOCYTES DEFINED AT CLONAL RESOLUTION

Aleksandr Gorin, Yushen Du, Ren Sun, Otto Yang

Univ of California Los Angeles, Los Angeles, CA, USA

INVESTIGATING THE ROLE OF TCR STRUCTURE IN FUNCTIONAL ACTIVITY OF HIV-SPECIFIC CTLs

Nina C. Flerin1, Tynisha Glover1, Huabiao Chen2, Jianhua Zheng1, Harris Goldstein1

1Albert Einstein Coll of Med, Bronx, NY, USA, 2Ragon Inst of Massachusetts General Hosp, Cambridge, MA, USA

HIV-SPECIFIC CD8 T CELLS IN PERSONS TREATED IN FIEBIG I ACUTE INFECTION WHO STOP ART

Hiroshi Takata1, Donn Colby2, Eugene Kroon2, Suteeraporn Pinyakorn2, Nelson L. Michael2, Merlin L. Robb2, Jintana Intasan2, Jintanat Ananworanich2, Lydie Trautmann2, for the RV411 and RV254/SEARCH010 Study Groups

1Walter Reed Army Inst of Rsr, Silver Spring, MD, USA, 2SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 3Walter Reed Army Inst of Rsr, Silver Spring, MD, USA, 4US Military HIV Rsr Prog, Silver Springs, MD, USA

EARLY CART OF HIV-1 INFECTED SUBJECTS PRESERVES ANTVIRAL FUNCTION OF CD8+ T CELLS

Miriam Rosas Umbert1, Beatriz Mothe2, Gemma Hancock3, Hongbing Yang2, Christian Manzano4, Josep Coll5, Christian Brandner3, Lucy Dorrell5

1IrsiCaixa AIDS Rsr Inst, Badalona, Spain, 2Hosp Germans Trias i Pujol, Badalona, Spain, 3Univ of Oxford, Oxford, UK, 4Univ of Barcelona, Barcelona, Spain

ROLE OF CTL IN PEDIATRIC HIV CURE STRATEGIES FOLLOWING EARLY WIDESPREAD VIRAL ESCAPE

Ellen M. Leitman1, Christina F. Thobakgale2, M. Azim Ansari2, Jayna Raghwani2, Emily Adland1, Oliver Pybus1, Paul Kellam2, Philippa C. Matthews1, Astrid Gall2, Philip J. Goulder1

Poster P-D5 NK AND MAIT CELLS  
Poster Hall - 4 EF  
2:30 PM - 4:00 PM

273 TRAIL-SHORT REDUCES THE CYTOTOXIC CAPACITY OF NK CELLS  
Fatma Aboulnasr, Nathan Cummins, Zilin Nie, Stephen Burke, Andrew Badley  
*Mayo Clinic, Rochester, MN, USA*

274 OF THE TB01 MOTIF KIR GENES, KIR3DS1 PLAYS ROLE IN HIV RESISTANCE & NK CELL FUNCTION  
Zahra Kiani1, Elise Jackson1, Xin Yu Zhang1, Irene Lisovsky1, Benjamin Tallon1, Julie Bruneau2, Jean-Pierre Routy2, Nicole Bernard3  
1McGill Univ, Montreal, Quebec, 2Univ of Montreal, Montreal, Canada, 3McGill Univ Hlth Cntr, Glen site, Montréal, Canada

275 NO RECOVERY OF VA7.2 MAIT CELLS AFTER THERAPEUTIC IMMUNISATION PLUS IL-2/GM-CSF/RHGH  
Louise Greathed, Alexander Cocker, Anna Hersasimtschuk, Sundhiya Mandalia, Peter Kelleher, Nesrina Imami  
*Imperial Coll London, London, UK*

276 REDUCED CD161 EXPRESSION ON MAIT CELLS IN HIV-INFECTED SUBJECTS WITH IMMUNE FAILURE  
Michael L. Freeman, Michael M. Lederman  
*Case Western Reserve Univ, Cleveland, OH, USA*

Poster P-E3 WHERE IS HIV HIDING?  
Poster Hall - 4 EF  
2:30 PM - 4:00 PM

288 CCR6+ RECTAL CD4+ T-CELLS ARE A SIGNIFICANT RESERVOIR ON ART  
Jenny L. Anderson1, Gabriela Khoury1, Rémi Fromentin2, Nicolas Chomont2, Ma Somsouk4, Wendy Hartogensis1, Peter Bacchetti1, Paul Cameron1, Steven G. Deeks1, Sharon R. Lewin1  
1Univ of Melbourne, Melbourne, Australia, 2Univ de Montréal, Montréal, Canada, 3Univ of California San Francisco, San Francisco, CA, USA

289 BLOOD CXCR3+ CD4 T CELLS ARE ENRICHED IN INDUCIBLE REPLICATION-COMPETENT HIV  
Riddhima Banga, Francesco Procopio, Matthias Cavassini, Giuseppe Panteleo, Matthieu Perreau  
*Lausanne Univ Hosp, Lausanne, Switzerland*

290 SKEWED DISTRIBUTION OF HIV-2 RESERVOIR WITH LIMITED INPUT OF CENTRAL MEMORY T CELLS  
Assia Samri1, Charlotte Charpentier1, Mélanie Bertine2, Mariama Diallo1, Sophie Even1, Sophie Matheron1, Rodolphe Thiébaut4, Brigitte Autran1, Francoise Brun-Vezinet1, for the ANRS COS IMMUNOVIR-2 Study Group  
ALTERED STABILITY OF HIV-INFECTED MEMORY CELLS FOLLOWING VERY EARLY ART

Louise Leyre¹, Jintanat Ananworanich², Claire Vandergeeten¹, Eugene Kroon¹, Nitiya Chomchey³, Sritiaw Akapirat⁴, Merlin L. Robb⁵, Nittaya Phanuphak⁷, Nicolas Chomont⁶, for the RV254/SEARCH010 and RV304 Study Groups

¹Cntr de Res du Cntr Hosp de l’Univ de Montréal, Montréal, Québec, Canada ²US Military HIV Rsr Prog, Silver Spring, MD, USA, ³Vaccine and Gene Therapy Inst, Port St Lucie, FL, USA, ⁴SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁵Armed Forces Rsr Inst of Med Scis, Bangkok, Thailand, ⁶Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁷Univ de Montréal, Montreal, QC, Canada

POSTER P-E6 LATENCY REVERSAL
Poster Hall - 4 EF
2:30 PM - 4:00 PM

MURINE MODEL TO PREDICT VIRAL REBOUND IN HIV+ ALLOTRANSPLANTED SUBJECTS

Maria Salgado¹, Mi Kwon², Cristina Galvez Celada¹, Monique Nijhuis³, Cristina Vilaplana¹, Alessandra Bandera⁴, Annemarie Wensing⁵, Jose Luis Diez², Javier Martinez-Picado¹, for the IciStem Consortium

¹IrsiCaixa AIDS Rsr Inst, Badalona, Spain, ²Gregorio Maranon Hosp, Madrid, Spain, ³Univ Med Cntr Utrecht, Utrecht, Netherlands, ⁴Inst for Hlth Sci Rsr Germans Trias i Pujol, Badalona, Spain, ⁵Univ of Milano—Biocca, Milan, Italy

ROLE OF HIGH-MOBILITY GROUP A1 (HMGA1) GENE EXPRESSION IN REACTIVATION OF LATENT HIV

Hosiana Abewe¹, Amey Mukim², Savitha Deshmukh², Celsa A. Spina¹, Douglas D. Richman¹, Nadejda Beliakova-Bethell²

¹Univ of California San Diego, La Jolla, CA, USA, ²VA San Diego Hlthcare System, San Diego, CA, USA

INVESTIGATING THE MECHANISMS OF HIV-1 LATENCY BY HIGH-RESOLUTION MICROSCOPY

Luca Sardo¹, Angel Lin¹, Svetlana Khakhina¹, Lucas Beckman¹, Weam Elbezanti¹, Tara Jaison¹, Harshad D. Vishwasrao², Hari Shroff², Christopher J. Janetopoulos¹, Zachary A. Klase¹

¹Univ of the Scis, Philadelphia, PA, USA, ²NIH, Bethesda, MD, USA

CURRENT LATENCY REVERSING AGENTS REACTIVATE A SMALL FRACTION OF LATENT PROVIRUSES

Anthony R. Cillo¹, Joshua C. Cyktor¹, Michele Sobolewski¹, Taylor Buckley¹, Joseph Hesselgesser¹, Tomas Cihlar¹, Romas Geleziunas¹, Jeffrey Murry¹, John W. Mellors¹

¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Gilead Scis, Foster City, CA, USA

LATENCY REVERSAL USING SPECIFIC ANTIGENS INCLUDING THOSE OF HIV-1

Thomas Vollbrecht¹, Aaron Angerstein², John Guatelli²

¹Veterans Med Rsr Fndn, San Diego, CA, USA, ²Univ of California San Diego, La Jolla, CA, USA

IDENTIFICATION OF LRAS ACTIVE IN DIVERSE PRIMARY T-CELL MODELS OF HIV LATENCY

Richard Barnard¹, Jenny L. Anderson², Daria Hazuda², Sharon R. Lewin², Laura J. Martins³, Mauricio Montano⁴, Vicente Planelles⁵, Celsa A. Spina³, for the CARE Collaboratory

¹Merck & Co, Inc, West Point, PA, USA, ²The Univ of Melbourne, Melbourne, Australia, ³Univ of Utah, Salt Lake City, UT, USA, ⁴Univ of California San Francisco, San Francisco, CA, USA, ⁵VA San Diego Hlthcare System, San Diego, CA, USA

Program and Agenda

Poster Sessions - Wednesday

128 CROI 2017
312 STIMULATING THE RIG-I PATHWAY TO KILL LATENT HIV-INFECTED CELLS USING ACITRETIN
Peilin Li¹, Philipp Kaiser¹, Harry Lampiris¹, Peggy Kim², Steven A. Yukl¹, Diane V Havlir³, Warner C. Greene⁴, Joseph K. Wong⁵
¹San Francisco VA Med Cntr/Univ of California San Francisco, San Francisco, CA, USA, ²San Francisco VA Med Cntr, San Francisco, CA, USA, ³San Francisco General Hosp, Univ of California San Francisco, San Francisco, CA, USA, ⁴Gladdone Inst of Virology and Immunol, San Francisco, CA, USA

313 TLR7 AGONIST GS-986 MARKEDLY ACTIVATES T & B CELLS FROM ART-SUPPRESSED DONORS
Joshua C. Cyktor¹, Anthony R. Cillo¹, John Bui¹, Joseph Hesselgesser³, Tomas Cihlar¹, Jeffrey Murry¹, John Mellors¹
¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Gilead Scis, Foster City, PA, USA

314 TLR9 AGONIST TRIGGERS POTENT INTESTINAL ANTIVIRAL RESPONSE IN HIV+ INDIVIDUALS ON ART
Astrid R. Krarup¹, Mariane H. Schleimann¹, Line K. Vibholm¹, Mohamed Abdel Mohsen², Anders K. Dige¹, Lars Østergaard¹, Thomas Benfield¹, Satish K. Pillai², Ole S. Søgaard¹, Paul W. Denton¹
¹Aarhus Univ Hosp, Aarhus, Denmark, ²Blood Systems Rsr Inst, San Francisco, CA, USA, ³Copenhagen Univ Hosp, Hvidovre, Denmark

315 SMALL-MOLECULE INHIBITION OF INTRINSIC STRESS PATHWAYS REDUCES HIV TRANSCRIPTION
Andrew Timmons, Robert Siliciano, Cynthia K. Bullen
The Johns Hopkins Hosp, Baltimore, MD, USA

316 NNRTIS DECREASE HIV-1 PRODUCTION FROM RCD4+ T CELLS FOLLOWING LATENCY REVERSAL
Jennifer M. Zerbato¹, Gilda Tachedjian², Nicolas Sluis-Cremer¹
¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Burnet Inst, Melbourne, Australia

---

Poster P-E9 NEW TREATMENTS TO MODIFY THE HIV RESERVOIR
Poster Hall - 4 EF 2:30 PM - 4:00 PM

331 ENHANCEMENT OF THE CD4 CHIMERIC ANTIGEN RECEPTOR AGAINST HIV INFECTION
Anjie Zhen, Mayra A. Carrillo, Valerie Rezek, Scott G. Kitchen
Univ of California Los Angeles, Los Angeles, CA, USA

332 HEMATOPOIETIC STEM-CELL–BASED CHIMERIC ANTIGEN RECEPTOR THERAPY FOR HIV INFECTION
Anjie Zhen¹, Christopher Peterson², Mayra A. Carrillo¹, Valerie Rezek¹, Masakazu Kamata¹, Jerome Zack¹, Hans-Peter Kiern¹, Scott G. Kitchen¹
¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

333 LENTIVIRAL DENDRITIC CELL VACCINE RAISES PROTECTIVE CTLS AND TARGETS LATENT HIV
Thomas D. Norton¹, Anjie Zhen², Takuya Tada¹, Scott G. Kitchen², Nathaniel R. Landau¹
¹New York Univ, New York, NY, USA, ²Univ of California Los Angeles, Los Angeles, CA, USA
134  SELF-ACTIVATING VECTORS THAT EXPRESS VIF-RESISTANT APOBEC3G FOR HIV-1 GENE THERAPY
Krista Delviks-Frankenberry1, Daniel Ackerman1, Nina Timberlake2, Maria Hamscher2, Olga A Nikolaitchik1, Wei-Shau Hu1, Bruce E. Torbett4, Vinay K. Pathak1
1NCI, Frederick, MD, USA, 2The Scripps Rsr Inst, La Jolla, CA, USA

135  ENGINEERING HIV-RESISTANT ANTI-HIV CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
Malika Hale1, Taylor Mesojednik1, Guillermo Romano Ibarra1, Jaya Sahni1, Bryan Sands1, Karen Sommer1, Andrew M. Scharenberg2, David J. Rawlings1, Thor Wagner2
1Seattle Children's Rsr Inst, Seattle, WA, USA, 2Univ of Washington, Seattle, WA, USA

136  VIRAL OUTCOMES AFTER ANALYTICAL TREATMENT INTERRUPTIONS TO EVALUATE A FUNCTIONAL CURE
Lorna Leal1, Constanza Lucero1, Montserrat Plana1, Nuria Climent1, Esteban Martinez1, Pedro Castro1, Beatriz Mothe2, Juan Carlos López-Bernaldo1, Jose M. Gatell1, Felipe Garcia1
1IDIBAPS, Barcelona, Spain, 2IrsiCaixa Inst for AIDS Rsr, Badalona, Spain, 3Hosp Gregorio Marañón, Madrid, Spain

137  A BISPECIFIC APPROACH FOR TARGETING IMRS IN HIV-1 LATENCY
Debbie S. Ruelas1, Yanyan Zheng1, Fahimeh Raoufi1, Laurence Fayadat-Dilman,2, Yuan Li1, Julie Strizki2, Richard Barnard2, Mohammad Tabrizifard1, Daniel Gorman1
1Merck & Co, Palo Alto, CA, USA, 2Merck & Co, Inc, West Point, PA, USA

338LB  TLR7 AGONIST TREATMENT OF SIV+ MONKEYS ON ART CAN LEAD TO COMPLETE VIRAL REMISSION
So-Yon Lim1, Christa Osuna1, Joseph Hesselgesser1, Alison Hill1, Michael D. Miller1, Tomas Cihlar2, Romas Geleziunas2, William Lee1, James Whitney1
1Beth Israel Deaconess Med Cntr, Boston, MA, USA, 2Gilead Scis, Inc, Foster City, PA, USA, 3Boston College, Chestnut Hill, MA, USA

346  THE ROLE OF PRESTROKE IMMUNE STATUS IN STROKE MECHANISMS IN HIV+ INDIVIDUALS
Jose Gutierrez1, Camilla Ingrid Hatleberg1, Henry W. Evans1, Michael T. Yin1
1Columbia Univ, New York, NY, USA, 2CHIP, Copenhagen, Denmark

347  TYPES OF ISCHEMIC STROKES AMONG HIV-INFECTED INDIVIDUALS ACROSS THE UNITED STATES
Heidi M. Crane1, Robin M. Nance1, Felicia C. Chow1, Christina Marra1, Joseph Zunt1, Emily Ho1, Richard D. Moore1, Daniel Drozd1, Mari Kitahata1, David Tirschwell1
1Univ of Washington, Seattle, WA, USA, 2Univ of California San Francisco, San Francisco, CA, USA, 3Harborview Med Cntr, Seattle, WA, USA, 4The Johns Hopkins Univ, Baltimore, MD, USA

348  WITHDRAWN
CNS MONITORING OF CART INTERRUPTION IN INDIVIDUALS TREATED DURING FIEBIG I ACUTE HIV
Phillip Chan1, Donn Colby2, Victor Valcour2, Napapon Sailasuta3, Shelly J. Krebs4, Linda Jaqzdinski5, Robert Paul6, Jintanat Ananworanich7, Serena Spudich8, for the RV411 and RV254/SEARCH 010 Study Groups
1SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 2Univ of California San Francisco, San Francisco, USA, 3Univ of Hawaii, Honolulu, HI, USA, 4US Military HIV Rsr Prog, Silver Spring, MD, USA, 5Univ of Missouri–St. Louis, St. Louis, MO, USA, 6Yale Univ, New Haven, CT, USA

CSF HIV-1 COMPARTMENTALIZATION BY ENV DEEP SEQUENCING: RELATION TO NEURONAL INJURY
Richard W. Price1, Magnus Gisslén1, Laura P. Kincer2, Ean Spielvogel3, Amy Lin1, Jaser Eusuff4, Serena Spudich5, Ronald Swanstrom3, Sarah Beth Joseph9, for the THINC Study Group
1Univ of California San Francisco, San Francisco, CA, USA, 2Sahlgenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Univ of California Berkeley, Berkeley, CA, USA, 5Yale Univ, New Haven, CT, USA

EARLY EMERGENCE OF MAC-TROPIC HIV VARIANTS IN BRAIN OF PATIENTS WITH NORMAL NEUROLOGY
Maria Paz Gonzalez-Perez, Paul P. Peters, Paul Clapham
Univ of Massachusetts, Worcester, MA, USA

BLOOD BRAIN BARRIER FUNCTION, ART NEUROACTIVITY, AND RISK OF CSF HIV ESCAPE
Carmela Pinnetti, Massimo Tempestilli, Patrizia Lorenzini, Valentina Fedele, Stefania Carta, Valentina Mazzotta, Chiara Agrati, Adriana Ammassari, Carlo F. Perno, Andrea Antinori
Natl Inst for Infectious Diseases, Rome, Italy

SEX-BASED DIFFERENCES IN HIV RESERVOIRS IN BRAIN AND NEUROCOGNITION
Michelli Faria de Oliveira1, Masato Nakazawa1, Andrej Vitomirov1, Mitchell Zhao1, Ben Gouaux2, David Moore3, Ronald J. Ellis4, Davey M. Smith1, Sara Gianella1
1Univ of California San Diego, La Jolla, CA, USA, 2Univ of California San Diego, San Diego, CA, USA

THE EFFECT OF CRYPTOCOCCAL MENINGITIS ON THE HIV RESERVOIR IN THE CNS
Maura Manion1, Camille Lange2, Kathy Huppler Hullsiek2, Brandon Keele4, Helene Highbarger1, David Meya2, Frank Maldarelli2, David Boulware3, Irini Sereti1
1NIAID, Bethesda, MD, USA, 2NIH, Frederick, MD, USA, 3Univ of Minnesota, Minneapolis, MN, USA, 4NCI, Frederick, MD, USA, 5Leidos Biomed, Inc, Frederick, MD, USA, 6Makerere Univ, Kampala, Uganda

HIV CNS COMPARTMENTALIZATION AMONG SUBJECTS WITH HIV-1 SUBTYPES G AND CRF02_AG
Olubusuyi M. Adewumi1, Elena Dukhovlinova1, Nathan Shehu2, Shuntai Zhou2, Maxwell Akanbi3, Babafemi Taiwo4, Adesola Oggunniyi1, Kevin Robertson2, Ronald Swanstrom2
1Univ of Ibadan, Ibadan, Nigeria, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Jos Univ Teaching Hosp, Jos, Nigeria, 4Northwestern Univ Feinberg Sch of Med, Chicago, IL, USA
**370** EXPRESSION OF UNIQUE AND DIVERSE HIV VARIANTS IN CEREBROSPINAL FLUID DURING ART

Jeffrey A. Johnson¹, Sarah Malik¹, Sam Nightingale¹, Jin-fen Li¹, Apostolis Beloukas², Tom Solomon³, Saye Khoo³, Anna Maria Geretti³

¹CDC, Atlanta, GA, USA, ²Univ of Liverpool, Liverpool, UK, ³Univ of Liverpool Inst of Translational Med, Liverpool, UK

**371** CSF ESCAPE IN TREATED HIV INFECTION SHOWS X4 TROPISM AND DEFECTIVE VIRAL SEQUENCES

Bryan Smith¹, Guhan Li¹, Hiromi Imamichi², Brad Sherman², Manori De Alwis¹, Govind Nair¹, Joseph Snow¹, Daniel S. Reich¹, H. Clifford Lane¹, Avindra Nath¹

¹NIH, Bethesda, MD, USA, ²NIH, Frederick, MD, USA, ³NIAID, Bethesda, MD, USA

**372** NEUROPSYCHIATRIC ADVERSE EVENTS ASSOCIATED WITH INTEGRASE STRAND TRANSFER INHIBITORS

Prabha Viswanathan, Elande Baro, Guoxing Soon, Adam Sherwat, Kimberly Struble

FDA, Silver Spring, MD, USA

---

**394** MRS MEASURES ASSOCIATE WITH IMPAIRED NEUROPSYCHOLOGICAL PERFORMANCE IN ACUTE HIV

Joanna Hellmuth¹, James L. Fletcher², Victor Valcure¹, Napapon Saisutas¹, Sompong Tipsuk¹, Jintanat Ananworanich⁴, Bonnie Sliker⁴, Robert Paul⁵, Seraphina Suduch⁶, for the SEARCH 010/RV254 Study Group

¹Univ of California San Francisco, San Francisco, CA, USA, ²SEARCH, Bangkok, Thailand, ³Univ of Hawaii, Honolulu, HI, USA ⁴US Military HIV Rsr Prtr, Silver Spring, MD, USA, ⁵Univ of Missouri-St. Louis, St. Louis, MO, USA, ⁶Yale Univ, New Haven, USA

**395** CIRCULATING HIV DNA IS ASSOCIATED WITH WEAKER INTRINSIC BRAIN CONNECTIVITY

Kalpana J. Kallianpur¹, Bruce Shiramizu¹, Melissa Agsalda-Garcia¹, Robert Paul¹, Cecilia Shikuma¹, Gregory Kirk¹, Rasmus Birn¹

¹Univ of Hawaii–Manoa, Honolulu, HI, USA, ²Univ of Missouri St. Louis, St. Louis, MO, USA

**396** RETINAL LAYERS THICKNESS AS MARKER OF ACCELERATED NEUROCOGNITIVE DECAY IN HIV DISEASE

Chiara Resnati¹, Alessandro Invernizzi¹, Alessandra Acquistapace¹, Marta Ferrari¹, Sara Bochicchio¹, Valentina Leta¹, Cristina Gervasoni¹, Stefano Rusconi¹, Simone Pomati², Agostino Riva²

¹Univ of Milan, Milano, Italy, ²Luigi Sacco Univ Hosp, Milano, Italy

**397** LONGITUDINAL ASSESSMENT OF REGIONALLY SPECIFIC BRAIN VOLUMES IN TREATED HIV+ PATIENTS

Ryan Sanford¹, Lesley K. Fellows¹, Louis Collins¹, Beau M. Ances²

¹Montreal Neuro Inst, Montreal, Canada, ²Washington Univ, St. Louis, MO, USA

**398** BRAIN HIV LATENCY LEADS TO A COMPLEX PATTERN OF NEUROCHEMICAL DYSREGULATION

Lucette Cysique¹, Michael V. Tobia¹, Thomas Gates¹, Lauriane Juge¹, Simon Jones¹, Caroline Rae¹, Bruce Brew¹

¹NeuroSci Rsr Australia, Randwick, Australia, ²Univ of New South Wales, Randwick, Australia, ³St. Vincent’s Hosp, Sydney, Australia, ⁴Univ of New South Wales, Darlinghurst, Australia
CEREBRAL ENDOTHELIAL FUNCTION CORRELATES WITH PERFORMANCE ON COGNITIVE SCREENING TEST
Natasha Mehta1, Yanling Li2, Yinghuan Hu2, Huanling Wang3, Weihai Xu2, Taisheng Li3, Felicia C Chow4
1Univ of California San Francisco, San Francisco, CA, USA, 2Peking Union Med Coll Hosp, Beijing, China

RANDOMIZED TRIAL OF BRAIN FUNCTION CHANGE AFTER STARTING TDF/FTC+ATV/R OR ABC/3TC+EFV
Ignacio Pérez-Valero1, Alicia Gonzalez-Baeza1, Lucía Bailón1, Belén Alejos1, Rocío Montejoiano1, Victor Hontanon1, Helena Melero1, Marisa Montes1, Carmen Bayón1, Jose R. Arribas1
1Hosp Univ La Paz, Madrid, Spain, Spain, 2Instituto de Salud Carlos III, Madrid, Spain, 3Univ Rey Juan Carlos, Alcorcón, Spain

RESTING CEREBRAL BLOOD FLOW AND RISKY DECISION-MAKING IN HIV+ AND HIV– YOUNG ADULTS
Robert S. Smith1, Anika Guha2, Aaron Tanenbaum1, Florin Vaida3, Robert Paul4, Beau M. Ances1
1Washington Univ in Saint Louis, Saint Louis, MO, USA, 2Univ of California Los Angeles, Los Angeles, CA, USA, 3Univ of California San Diego, San Diego, USA, 4Univ of Missouri–St. Louis, St. Louis, MO, USA

MRI REVEALS ENLARGED INTRACRANIAL ARTERIES IN HIV-ASSOCIATED NEUROCOGNITIVE DISORDER
Govind Nair, Angela Summers, Joseph Snow, Daniel S. Reich, Sally Steinbach, Paba M. DeAlwis, Bryan Smith, Avindra Nath
NIH, Bethesda, MD, USA

WORKING MEMORY IN HIV+ YOUNG ADULTS: FUNCTIONAL IMAGING USING MAGNETOENCEPHALOGRAPHY
Sharon Nichols1, Ashley R. Swan2, Annemarie A. Quinto2, Chris Fennema-Notestine2, Mingxiong Huang3
1Univ of California San Diego, La Jolla, CA, USA, 2Univ of California San Diego, San Diego, USA

COBICISTAT, BUT NOT RITONAVIR, INCREASES DABIGATRAN EXPOSURE
Kristina M. Brooks1, Lori A. Gordon2, Scott Penzak3, Anela Kellogg4, Maryellen McManus1, Khanh Nghiem1, Jay Lozier1, Jomy M. George1, Colleen Hadigan2, Parag Kumar1
1NIH, Bethesda, MD, USA, 2Xavier Univ of Louisiana, New Orleans, LA, USA, 3Univ of North Texas, Fort Worth, TX, USA, 4Leidos Biomed Rsr, Inc, Bethesda, MD, USA, 5NIAID, Bethesda, MD, USA

EARLY TERMINATION OF A PK STUDY BETWEEN DOLUTEGRAVIR AND WEEKLY ISONIAZID/RIFAPENTINE
Kristina M. Brooks1, Alice K. Pau2, Jomy M. George1, Raul Alfaro1, Anela Kellogg1, Mary McLaughlin4, Maryellen McManus1, Colleen Hadigan1, Joseph A. Kovacs1, Parag Kumar1
1NIH Clinical Center, Bethesda, MD, USA, 2NIAID, NIH, Bethesda, MD, USA, 3Leidos Biomedical Research, Inc, Bethesda, MD, USA
410 INCREASED DOLUTEGRAVIR EXPOSURE IN HIV PATIENTS SWITCHED FROM RITONAVIR TO COBICISTAT
Cristina Gervasoni, Agostino Riva, Amedeo Capetti, Valeria Cozzi, Giuliano Rizzardini, Massimo Galli, Emilio Clementi, Dario Cattaneo
Luigi Sacco Univ Hosp, Milan, Italy

411 EFFECT OF COBICISTAT ON TENOFOVIR PLASMA CONCENTRATION: A CROSS-SECTIONAL STUDY
Cristina Gervasoni1, Davide Minisici1, Sara Baldelli1, Cristina Mazzali2, Andrea Giacomelli1, Laura Milazzo1, Paola Meraviglia1, Emilio Clementi1, Massimo Galli1, Dario Cattaneo1
1Luigi Sacco Univ Hosp, Milano, Italy, 2Politecnico di Milano, Italy, Milano, Italy

412 MULTIPLE-DOSE TREATMENT WITH RITONAVIR INCREASES THE EXPOSURE OF DORAVIRINE
Sauzanne Khalilieh1, Matt Anderson1, Tine Laethem2, Kelly Yee3, Rosa Sanchez1, Li Fan4, Monali Sura1, Luc Van Bortel3, Greit Van Lancker3, Marian Iwamoto1
1Merck & Co, Inc, Kenilworth, NJ, USA, 2MSD Belgium, Brussels, Belgium, 3Ghent Univ Hosp, Ghent, Belgium

413 GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS
Matthew P. Kosloski, Sandeep Dutta, Rolando M. Viani, Xin Qi, Roger Trinh, Andrew Campbell, Wei Liu
AbbVie, North Chicago, IL, USA

414 EFFECT OF LOW-DOSE METHOTREXATE ON THE PHARMACOKINETICS OF TENOFOVIR
David Gingich1, Heather Ribaudo2, Amy Kantor3, James H. Stein3, Judith S. Currier4, Priscilla Hsue5, Francesca Aweeka1
1Univ of California San Francisco, San Francisco, CA, USA, 2Harvard Univ, Boston, MA, USA, 3Univ of Wisconsin, Madison, WI, USA, 4Univ of California Los Angeles, Los Angeles, CA, USA

Poster P-G4 EXPOSURE-RESPONSE RELATIONSHIPS OF ANTIRETROVIRAL DRUGS
Poster Hall - 4 EF
2:30 PM - 4:00 PM

423 AN IN VITRO–IN SILICO STUDY OF REDUCED-DOSE EFAVIRENZ INTERACTION WITH LEVONORGESTREL
Owain Roberts1, Paul Curley1, Rajith Kumar Reddy Rajoli1, Darren M. Moss1, Mohammed Lamorde2, Andrew Owen1, Kimberly K. Scarsi2, Marco Siccardi1
1Univ of Liverpool, Liverpool, UK, 2Infectious Diseases Inst Ltd, Kampala, Uganda, 3Univ of Nebraska, Omaha, NE, USA

424 PHARMACOKINETICS, SAFETY & EFFICACY OF E/C/F/TAF IN HIV-INFECTED CHILDREN (6-12 YRS)
Aditya Gaur1, Eva Natukunda2, Pope Kosalarksa3, Jag Batara4, Natella Rakhmanina5, Amy Coluci6, Yongwu Shao6, Heathran Zhang6, Cheryl Pikora6, Martin Rhee4
1St. Jude Children’s Rsr Hosp, Memphis, TN, USA, 2Joint Clinical Rsr Cntr, Kampala, Uganda, 3Khon Kaen Univ, Khon Kaen, Thailand, 4Miller Children’s Hosp, Long Beach, CA, USA, 5Children’s Rsr Inst–Children’s Natl Med Cntr, Washington, DC, USA, 6Gilead Scis, Inc, Foster City, CA, USA
PHARMACOKINETICS, SAFETY, AND EFFICACY OF ATV OR DRV WITH COBI IN ADOLESCENTS

Elizabeth J. McFarland¹, Gloria P. Heresi², Jag Batra³, Torsak Bunupuradath⁴, Kulkanya Cheokephaibulkit⁵, Pope Kosalarksa⁶, Pamela Wong⁷, Heather Zhang⁸, Cheryl Pikora⁹, Martin Rhee¹

¹Univ of Colorado, Aurora, CO, USA, ²Univ of Texas, Houston, TX, USA, ³Miller Children’s Hosp, Long Beach, CA, USA, ⁴HIV-NAT, Thai Red Cross AIDS Rsr, Bangkok, Thailand, ⁵Mahidol Univ, Bangkok, Thailand, ⁶Khon Kaen Univ, Khon Kaen, Thailand, ⁷Gilead Scis, Inc, Foster City, CA, USA

EFFECT OF DOLUTEGRAVIR PLASMA CONCENTRATION ON CENTRAL NERVOUS SYSTEM SIDE EFFECTS

Hiroki Yagura¹, Dai Watanabe², Takao Nakauchi³, Kosuke Tomishima³, Daizuke Kasai⁴, Yasuharu Nishida⁴, Munehiro Yoshino⁴, Tomoko Uehira⁴, Kunio Yamazaki⁵, Takuma Shirasaka⁵

¹Natl Hosp, Osaka, Japan, ²Natl Hosp Org Osaka Minami Med Cntr, Osaka, Japan

EVALUATION OF RPV/FTC/TAF EXPOSURE-EFFICACY AND EXPOSURE-SAFETY RELATIONSHIPS

Sophia R. Majeed¹, Kavitha Bhasi¹, Yongwu Shao¹, William Garner¹, Jenna Scott¹, Carlos P. Ruixo², Devi SenGupta², Huyen Cao¹, Brian P. Kearney¹, Joseph M. Custodio¹

¹Gilead Scis, Foster City, CA, USA, ²Janssen Rsr and Development, Beerse, Belgium

NOVEL HIV PI WITH HIGH RESISTANCE BARRIER AND POTENTIAL FOR UNBOOSTED QD ORAL DOSING

John O. Link¹, Darryl Kato, Michael Moore, Andrew Mulato, Bernard Murray, Judy Mwangi, Nathan D. Shapiro, George Stepan, Yujin Wang, Zheng-Yu Yang

¹Gilead Scis, Inc, Foster City, CA, USA

NOVEL NON-CATALYTIC SITE INTEGRASE INHIBITOR WITH IMPROVED RESISTANCE PROFILE

Michael L. Mitchell¹, Mini Balakrishnan, Gediminas Brizgys, Ruby Cai, Eric Lansdon, Andrew Mulato, Mark Osier, Jianhong Wang, Helen Yu, Roman Sakowicz

¹Gilead Scis, Inc, Foster City, CA, USA

MK-8591 CONCENTRATIONS AT SITES OF HIV TRANSMISSION AND REPLICATION

Jay Grobler¹, Carolyn McHale, Carol Freddo, Dan Dreyer, Li Sun, Marissa Vavrek, Sheila Breidinger, Kerry Fillgrove, Daria Hazuda, Ming-Tain Lai

¹Merrick & Co, Inc, West Point, PA, USA

GS-9131 IS A NOVEL NRTI WITH ACTIVITY AGAINST NRTI-RESISTANT HIV-1

Kirsten L. White¹, Nicolas Margot, Kirsten Stray, Helen Yu, George Stepan, Constantino Boojamra, Richard Mackman, Adrian Ray, Michael D. Miller, Tomas Cihlar

¹Gilead Scis, Inc, Foster City, CA, USA
PRO140 SINGLE-AGENT MAINTENANCE THERAPY FOR HIV-1 INFECTION: A 2-YEAR UPDATE
Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan, Paul J. Maddon
1Quest Clinical Rsr, San Francisco, CA, USA, 2Amarex Clinical Rsr, LLC, Germantown, MD, USA, 3CytoDyn Inc, Vancouver, WA, USA, 4Maddon Advisors LLC, Scarsdale, NY, USA

INTRAMUSCULAR IBALIZUMAB: PHARMACOKINETICS, SAFETY, AND EFFICACY VS IV ADMINISTRATION
Hsi-Hsun Lin, Susan Shin-Jung Lee, Ning-Chi Wang, Ying-An Lai, Kwei-Ling Kuo, Steven Weinheimer, Stanley Lewis
1E-Da Hosp, Kaohsiung City, Taiwan, 2Kaohsiung Veterans General Hosp, Kaohsiung, Taiwan, 3Tri-Service General Hosp, Taipei City, Taiwan, 4TaiMed Biologics, Taipei City, Taiwan, 5TaiMed Biologics USA, Irvine, CA, USA

A LONG-ACTING NANOFORMULATED CABOTEGRAVIR PRODRUG FOR IMPROVED ANTIRETROVIRAL THERAPY
Tian Zhou, Benson Edagwa, JoEllyn McMillan, Howard E. Gendelman
Univ of Nebraska, Omaha, NE, USA

ANTIVIRAL ACTIVITY OF EFDA AGAINST NRTI-SENSITIVE AND -RESISTANT STRAINS OF HIV-2
Vincent Wu, Robert Smith, Sara Masoum, Dana Raugi, Sally Ba, Moussa Seydi, Jay Grobler, Geoffrey Gottlieb, for the University of Washington—Dakar HIV-2 Study Group
1Univ of Washington, Seattle, WA, USA, 2CHU de Fann, Dakar, Senegal, 3Merck & Co, West Point, PA, USA

VIROLOGICAL RESPONSE TO ANTIRETROVIRAL TREATMENT IN AN EASTERN EUROPEAN COHORT STUDY
Radko Avi, Merit Pauskar, Heli Rajasaar, Ene-Ly Jõgeda, Pillerin Soodla, Irja Lutsar, Kristi Huik, for the Estonian HIV Positive Patients Database
Univ of Tartu, Tartu, Estonia

DURABILITY OF NNRTI BASED REGIMENS AFTER 7 YEARS OF TREATMENT IN RURAL UGANDA
Mastula Nanfuka, Zishan Cui, Stephen Okoboi, Josephine Birungi, Pontiano Kaleebu, Julia Zhu, Samuel Tibengana, David Moore
1The AIDS Support Organization, Kampala, Uganda, 2BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 3Med Rsr Council, Entebbe, Uganda, 4Univ of British Columbia, Vancouver, British Columbia, Canada

LONG-TERM VIRAL SUPPRESSION DURING INITIAL ANTIRETROVIRAL THERAPY IN HANOI, VIETNAM
Junko Tanuma, Shoko Matsumoto, Sebastien Haneueze, Cuong Do Duy, Thanh Thuy Pham Thi, Dung T. Nguyen, Kinh V. Nguyen, Shinichi Oka
1Natl Cntr for Global Hlth and Med, Tokyo, Japan, 2Harvard Univ, Boston, MA, USA, 3Bach Mai Hosp, Hanoi, Vietnam, 4Natl Hosp for Trop Diseases, Hanoi, Vietnam
464 OUTCOMES AND SIDE EFFECTS OF PATIENTS ON ART FOR MORE THAN 10 YEARS IN MALAWI
Sekai C. Mathabire1, Alia Tayea1, Joseph Bitilinyu-Bangoh2, Elkin H. Bermudez1, Leon Salumu1, Isabel A. Quiles1, Elisabeth Szumilin1, Zengani Chirwa2, Fernanda Rick1, David Maman1
1MSF France, Chiradzulu, Malawi, 2Queen Elizabeth Central Hosp, Blantyre, Malawi, 3MSF France, Paris, France, 4MSF France, Lilongwe, Malawi, 5Ministry of Hlth, Malawi, Lilongwe, Malawi, 6Epicentre, Cape Town, South Africa

465 INCREASED PERSISTENCE OF INITIAL ART WITH INSTI-CONTAINING REGIMENS
Thibaut Davy, Sonia Napravnik, Oksana Zakharova, Joseph J. Eron
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

466 DYNAMICS OF ULTRA-DEEP SUPPRESSED HIV VIREMIA (<5 CP/ML) IN CART-TREATED PATIENTS
Alessandra Amendola, Adriana Ammassari, Assunta Navarra, Giulia Bibbolino, Carmela Pinnetti, Isabella Abbate, Gabriella Rozera, Annalisa Mondi, Enrico Girardi, Maria R. Capobianchi
Natl Inst for Infectious Diseases Lazzaro Spallanzani, Rome, Italy

Poster P-I4 ART: PREDICTORS OF OUTCOMES
Poster Hall - 4 EF 2:30 PM - 4:00 PM

467 SUBOPTIMAL IMMUNE RECOVERY DESPITE SUPPRESSIVE ANTIRETROVIRAL THERAPY IN AFRICA
Stefanie Kroeze1, Pascale Ondoa1, Cissy Kityo2, Margaret Siwale1, Sonia Boender1, Peter Reiss1, Ferdinand Wit1, Tobias F. Rinke de Wit1, Raph L. Hamers1, for the PASER Study Group
1Amsterdam Inst for Global Hlth and Development, Amsterdam, Netherlands, 2Joint Clinical Rsr Cntr, Kampala, Uganda, 3Lusaka Trust Hosp, Lusake, Zambia, 4Stichting HIV Monitoring and Academic Med Cntr Amsterdam, Amsterdam, Netherlands

468 CURRENT STATIN USE REDUCES RISK OF VIRAL REBOUND ON SUPPRESSIVE CART
Henning J. Drechsler1, Colby Ayers2, James Cutrell1, Naim Maalouf1, Pablo Tebas1, Roger Bedimo1
1VA North Texas Hlth Care Cntr, Dallas, TX, USA, 2Univ of Texas Southwestern, Dallas, TX, USA, 3Univ of Texas Southwestern Med Cntr, Dallas, TX, USA, 4Univ of Pennsylvania, Philadelphia, PA, USA

469 HIV-RELATED PILL AVERSION: CHARACTERIZING A NOVEL BARRIER TO ADHERENCE
Robin Dorman, Sarah H. Sutton, Lynn M. Yee
Northwestern Univ, Chicago, IL, USA

Poster P-L4 HCV: THE RAINBOW AT THE END OF THE CASCADE
Poster Hall - 4 EF 2:30 PM - 4:00 PM

543 HEPATITIS C CASCADE OF CARE IN NON-BIRTH COHORT PATIENTS WITHIN A LARGE HEALTH SYSTEM
Chinyere Ukaegbu1, Alexander Geboy1, Whitney Nichols1, Amanda E. Smart2, Stephen Fernandez2, Peter Basch1, Dawn Fishbein1
1MedStar Hlth Rsr Inst, Washington, DC, USA, 2Georgetown Univ, Washington, DC, USA, 3MedStar Hlth Rsr Inst, Hyattsville, MD, USA
544 STRATEGIES FOR UTILIZING EHR TO IMPROVE BIRTH COHORT TESTING IN THE HOSPITAL SETTING
Lorlette Moir, Shuchin Shukla, Uriel Felsen, Jeffrey Weiss, Kimberly Cartmill, Jonathan M. Schwartz, Paul Meissner, Kimberly Yu, Yuming Ning, Alain H. Litwin
Montefiore Med Cntr, Bronx, NY, USA

545 IMPLEMENTATION OF AN EHR PROMPT REVEALS LOW ADHERENCE TO HCV TESTING RECOMMENDATIONS
Alexander Geboy1, Whitney Nichols1, Chinyere Ukaegbu1, Stephen Fernandez2, Peter Basch1, Dawn Fishbein1
1MedStar Hlth Rsr Inst, Washington, DC, USA, 2MedStar Hlth Rsr Inst, Hyattsville, MD, USA

546 DEVELOPMENT OF AN EMR-BASED ALGORITHM TO PLACE PATIENTS IN THE HCV CARE CASCADE
Jason Zucker, Justin Aaron, Henry W. Evans, Peter Gordon, Michael T. Yin
Columbia Univ, New York, NY, USA

547 COST-EFFECTIVENESS OF HCV SCREENING AND LINKAGE IN MMT: RELEVANCE OF HIV COINFECTION
Bruce R. Schackman1, Jared A. Leff1, Jake R. Morgan2, Sarah Gutkind1, Czarina N. Behrends1, Kevin L. Delucchi1, Courtney McKnight4, David C. Perlman1, Carmen L. Masson2, Benjamin Linas1
1Weill Cornell Med Coll, New York, NY, USA, 2Boston Med Cntr, Boston, MA, USA, 3Univ of California San Francisco, San Francisco, CA, USA, 4Icahn Sch of Med at Mt Sinai, New York, NY, USA, 5Boston Univ, Boston, MA, USA

548 PROVIDING HCV CURES IN THE MEDICAL HOME: TRAINING A NEW GENERATION OF PROVIDERS
Sarah Rojas, Christian B. Ramers, Stephanie Constantino
Family Hlth Cntrs of San Diego, San Diego, CA, USA

549 HCV RNA DETECTION IN SMALL VOLUME CAPILLARY BLOOD FOR POINT-OF-CARE APPLICATIONS
Mark Hopkins1, Rachael Dagnall2, Athanassios Papadimitropoulos2, Paula Davies1, Jillian Williams1, Eimear Railton1, Sarah Sarah Hau1, Apostolos Beloukas2, Anna Maria Geretti2
1Royal Liverpool Univ Hosp, Liverpool, UK, 2Univ of Liverpool, Liverpool, UK

550 HIV/HCV COINFECTION IN THE DAA ERA: “EN ROUTE FOR ERADICATION”? 
Laurent Cotte1, Pascal Pugièse2, Isabelle Poizot-Martin3, Marc-Antoine Valantin4, Lise Cuzin5, Jacques Reynes6, Eric Billaud7, Thomas Huleux6, Pierre Pradat1, for the DataAIDS Study Group
1Hospices Civils de Lyon, Lyon, France, 2CHU de Nice, Nice, France, 3Assistance Publique – Hôpitaux de Marseille, Marseille, France, 4Assistance Publique - Hôpitaux de Paris, Paris, France, 5CHU Toulouse, Toulouse, France, 6CHU de Montpellier, Montpellier, France, 7CHU de Nantes, Nantes, France, 8Cntr Hosp de Tourcoing, Tourcoing, France
551 SAME SAME BUT DIFFERENT? RISK OF DAA THERAPY FAILURE IN REAL-LIFE HCV/HIV COINFECTION
Christoph Boesecke1, Patrick Ingliz2, Florian Berger3, Thomas Lutz4, Knud Schewe5, Julian Schulze zur Wiesch6, Axel Baumgarten7, Stefan Christensen7, Jürgen K. Rockstroh8, Stefan Mauss3
1Univ Hosp Bonn, Bonn, Germany, 2Cntr for Infectiology, Berlin, Germany, 3Cntr for HIV and Hepatogastroenterology, Dusseldorf, Germany, 4Infektiologikum, Frankfurt, Germany, 5dagnae e.V., Berlin, Germany, 6Univ Med Cntr, Hamburg—Eppendorf, Hamburg, Germany, 7CIM Infectious Diseases, Münster, Germany

552 DIRECT-ACTING ANTIVIRALS IMPROVE ACCESS TO CARE AND CURE FOR PATIENTS WITH HIV-HCV
Lauren F. Collins, Austin Chan, Jiayin Zheng, Shein-Chung Chow, Julius M. Wilder, Andrew J. Mui, Susanna Naggie
Duke Univ, Durham, NC, USA

553 DIRECT ACTING ANTIVIRAL UPTAKE DISPARITIES IN HIV/HCV–COINFECTED POPULATIONS
Sahar Saeed1, Erin C. Strumpf1, Sharon Walmsley2, Curtis Cooper1, Brian Conway1, Valerie-Martel Laferriere1, Neora Pick1, Alexander Wong1, Marina Klein1, for the Canadian Co-Infection Cohort Study
1McGill Univ, Montreal, Canada, 2Univ of Toronto, Toronto, Ontario, Canada, 3Ottawa General Rsr Inst, Ottawa, Ontario, Canada, 4Vancouver Infectious Diseases Cntr, Vancouver, Canada, 5Cntr Hosp de l’Univ de Montréal, Montreal, Canada, 6Oak Tree Clinic, Vancouver, Canada, 7Regina Qu’Appelle Hlth Region, Regina, Canada, 8McGill Univ Hlth Cntr Rsr Inst, Montreal, Ontario, Canada

554 HCV TREATMENT IN PEOPLE WHO INJECT DRUGS COLOCATED WITHIN NEEDLE AND SYRINGE PROGRAM
Benjamin Eckhardt1, Kristen M. Marks2, Brian Edlin3
1New York Univ, New York, NY, USA, 2Weill Cornell Med, New York, NY, USA, 3Natl Development and Rsr Insts, New York, NY, USA

555 HIGH EFFICACY OF IFN-FREE ANTI-HCV REGIMENS FOR INDIVIDUALS ON OPIATE AGONIST THERAPY
Juan Macías1, Luis E. Morano-Amado2, Francisca Cuenca-Lopez3, Miriam Serrano4, Karin Neukam1, Francisco Téllez2, Manuel Márquez2, Dolores Merino4, Juan A. Pineda1
1Hosp Univ de Valme, Sevilla, Spain, 2Hosp Univ Alvaro Cunqueiro, Vigo, Spain, 3Hosp Univ Reina Sofia, Cordoba, Spain, 4Hosp Univ de Gran Canaria Dr Negrín, Las Palmas, Gran Canaria, 5Hosp de La Línea, La Línea de la Concepción, Spain, 6Hosp Virgen de la Victoria, Málaga, Spain, 7Complejo Hospario Univ de Huelva, Huelva, Spain

556 SVR12 FOR PATIENTS WITH BEHAVIORAL HEALTH CONDITIONS TREATED FOR HEPATITIS C IN FQHCS
Sophy S. Wong, Megan Crowley, Jan Diamond
Alameda Hlth Consortium, San Leandro, CA, USA

557 REAL-WORLD OUTCOMES OF HCV TREATMENT IN HOMELESS AND MARGINALLY HOUSED ADULTS
Joshua A. Barocas1, Marguerite Beiser2, Casey Leon2, Molly Ingemi2, Paul McCabe1, Lena Cardoso2, Benjamin Linaas3, James O’Connell1
1Massachusetts General Hosp, Boston, MA, USA, 2Boston Hlth Care for the Homeless, Boston, MA, USA, 3Quinnipiac Univ, North Haven, CT, USA, 4Boston Univ, Boston, MA, USA
558 TREATMENT READINESS FOR HEPATITIS C INFECTION AMONG PWID IN CHENNAI, INDIA
Eshan U. Patel1, Sunil S. Solomon2, Allison M. McFall1, Aylur K. Srikrishnan1, Amrose Pradeep2, Jungen Yi1, Oliver Laeyendecker3, David Thomas2, Mark Sulkowski1, Shruti H. Mehta2
1Johns Hopkins Univ, Baltimore, MD, USA, 2YRG CARE, Chennai, India, 3NIAID, Baltimore, MD, USA

559 FIELD-BASED DELIVERY OF HCV THERAPY WITH MINIMAL MONITORING TO PWID IN CHENNAI, INDIA
Sunil S. Solomon1, Amrose Pradeep2, Mark Sulkowski1, Aylur K. Srikrishnan1, Nandagopal Paneerselvam3, Shanmugam Saravanan2, Santhanam Anand2, Muniratnam S. Kumar4, David Thomas2, Shruti H. Mehta2
1Johns Hopkins Univ Sch of Med, Baltimore, MD, USA, 2YRG CARE, Chennai, India, 3Johns Hopkins Univ, Baltimore, USA

560 HIGH RATES OF HCV CURE AMONG URBAN BLACK AND NON-BLACK HIV-INFECTED PATIENTS
Oluwaseun Falade-Nwulia1, Juhi Moon1, Geetanjali Chander2, Tanyaporn Wansom2, Catherine Sutcliffe1, Shruti H. Mehta2, David Thomas1, Richard D. Moore1, Mark Sulkowski2
1Johns Hopkins Univ, Baltimore, MD, USA, 4US Military HIV Rsr Prog, Bethesda, MD, USA

561 GLOBAL ORIGINS OF RESISTANCE-ASSOCIATED VARIANTS IN THE NSSA REGION OF HCV
Bradley R. Jones1, Jeffrey Joy2
1BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 2Univ of British Columbia, Vancouver, British Columbia, Canada

562 IMPACT OF HCV NSSA RESISTANCE ON TREATMENT RESPONSE IN HIV AND HIV/HCV PATIENTS
Itziar Carrasco Garcia1, Ana Arias2, Laura Benitez2, Silvia Requena1, Miriam Cuesta1, Luis Otero2, Valentin Cuervas-Mons1, Carmen de Mendoza Fernandez2, for the Internal Medicine Department
1Puerta de Hierro Rsr Inst and Univ Hosp, Madrid, Spain, 2Hosp Puerta de Hierro, Madrid, Spain, 3Hosp de Cabueñes, Asturias, Spain

563 CATALOGING THE IMPACT OF Y93 SUBSTITUTIONS ON HCV NSSA INHIBITOR SUSCEPTIBILITY
Alicia Newton, Charity Ting, Arne Frantzell, Jennifer Cook, Christos Petropoulos, Wei Huang
Monogram BioScis, South San Francisco, CA, USA

564 NATURAL HCV RESISTANCE IS COMMON IN ITALY AND DIFFERENTLY ASSOCIATED TO GENOTYPES
Valeria Cento1, Ada Bertoli1, Giustino Parruti1, Giuliano Rizzardini2, Gloria Taliani1, Caterina Pasquazzi1, Massimo Andreoni1, Carlo F. Perno1, Francesca Ceccherini Silberstein1, for the Vironet Cohort
1Univ of Rome Tor Vergata, Rome, Italy, 2Pescara Hosp, Pescara, Italy, 1Luigi Sacco Univ Hosp, Milan, Italy, 3Sapienza Univ of Rome, Rome, Italy
Program and Agenda

565 OPTIMAL EFFICACY OF HCV-RESISTANCE–BASED RETREATMENTS AFTER PI FAILURE
Valeria Cento1, Silvia Barbaliscia1, Stefano Bonora2, Sergio Babudieri1, Alessia Ciancio1, Giuliano Rizzardi1, Mario Angelico3, Carlo F. Perno4, Francesca Ceccherini Silberstein5, for the Vironet Cohort

1Univ of Rome Tor Vergata, Rome, Italy, 2Univ degli Studi di Torino, Torino, Italy, 3Univ of Sassari, Sassari, Italy, 4City of Hlth and Sci of Turin, Turin, Italy, 5Luigi Sacco Univ Hosp, Milano, Italy, 4Hosp of Rome Tor Vergata, Rome, Italy

566 RETREATMENT OPTIONS AFTER FAILING A FIRST LINE OF DAAS AGAINST HEPATITIS C VIRUS
Ana B. Perez1, Natalia Chueca1, Miguel García-Deltoro2, Ana María Martínez-Sapiña1, Daniel Navarro3, Dolores Merino3, Miguel Jiménez4, Juan Manuel Pascasio5, Antonio Rivero5, Federico García1

1Complejo Hospario Univ de Granada, Granada, Spain, 2Hospital General de Valencia, Valencia, Spain, 3Hospital Miguel Servet, Zaragoza, Spain, 4Complejo Hospario Univ de Santiago, Santiago de Compostela, Spain, 5Complejo Hospario Univ de Huelva, Huelva, Spain, 6Hospital Regional Carlos Haya, Málaga, Spain, 7Hospital Virgen del Rocio, Sevilla, Spain, 8Hospital Reina Sofia, Cordoba, Spain

567 HCV REINFECTION AFTER SUCCESSFUL DAA TREATMENT: A GECCO ANALYSIS
Patrick Ingiliz1, Stefan Christensen1, Florian Berger1, Torben Kimhofer4, Knud Schewe2, Christoph Boesecke5, Dietrich Hueppe6, Julian Schulze zur Wiesch7, Thomas Lutz3, Stefan Mauss1

1Cnr for Infectiology, Berlin, Germany, 2CIM Infectious Diseases, Münster, Germany, 3Cnr for HIV and Hepatogastroenterology, Duesseldorf, Germany, 4Imperial Coll London, London, UK, 5Danae e.V., Berlin, Germany, 6University Hosp Bonn, Bonn, Germany, 7Gastroenterology Practice, Herne, Germany, 8University Med Ctr, Hamburg-Eppendorf, Germany, Hamburg, Germany, 9Infektiologikum, Frankfurt, Germany

568LB LEDIPASVIR/SOFOSBUVIR±RIBAVIRIN IN HCV AND HCV/HIV PRIOR SOF-BASED Virologic FAILURES
Edward Tam1, Robert S. Brown, Jr2, Sanjaya Satapathy3, Gregory Camus4, Amanda Copans5, Lorenzo Rossaro6, William D. Guyer7, Richard Haubrich4, Minhee Kang8, Annie Luetkemeyer9

1LAIR Ctr, Vancouver, Canada, 2Weill Cornell Med, New York, NY, USA, 3University of Tennessee, Memphis, TN, USA, 4Gilead Scis, Inc, Foster City, CA, USA, 5Harvard Univ, Boston, MA, USA, 6University of California San Francisco, San Francisco, CA

Poster Sessions: Wednesday

569 NINETY-SIX % SVR RATES USING IMPORTED GENERIC DAAS FOR PATIENTS WITH HEPATITIS C
Andrew Hill1, Giten Khwairakpam2, James Wang2, Sergey Golovin3, Julia Dragunova3, Rachel Smith4, Vicky Houghton-Price5, Roxanna S Korologou-Linden6, Anton Pozniak6, Greg Jefferys6

570 VIRAL KINETICS PREDICT RESPONSE TO ALL-ORAL THERAPY AGAINST HCV GENOTYPE 3 INFECTION
Juan A. Pineda1, Luis E. Morano-Amado2, Rafael Granados3, Juan Macías4, Francisco Téllez1, Miguel García-Deltoro6, María J. Ríos-Villegas5, Antonio Collado6, Karin Neukam4, for the GEHEP-MONO/HEPAVIR-DAA, RIS-HEP07 and RIS-HEP13 Study Groups
1Hosp Univ de Valme, Seville, Spain, 2Hosp Univ Alvaro Cunqueiro, Vigo, Spain, 3Hosp Univ de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, 4Hosp Univ de Valme, Seville, Spain, 5Hosp de La Línea, La Línea de la Concepción, Spain, 6Hosp General de Valencia, Valencia, Spain, 7Hosp Univ Virgen Macarena, Sevilla, Spain, 8Hosp Univ Torrecárdenas, Almería, Spain

571 ALL ORAL DAA THERAPY IN HCV GENOTYPE 4 INFECTION WITH AND WITHOUT HIV COINFECTION
Juan A. Pineda1, Luis E. Morano-Amado2, Francisco Téllez1, Blanca Figueruelo López2, Marcial Delgado-Fernández3, Antonio Rivero-Juárez5, Dolores Merino3, Montserrat Pérez-Pérez3, Karin Neukam4, for the GEHEP-MONO/HEPAVIR-DAA, RIS-HEP07 and RIS-HEP13 Study Groups
1Hosp Univ de Valme, Seville, Spain, 2Hosp Univ Alvaro Cunqueiro, Vigo, Spain, 3Hosp de La Línea, La Línea de la Concepción, Spain, 4Hosp Univ de Valme, Seville, Spain, 5Hosp Regional Univ de Málaga, Málaga, Spain, 6Hosp Univ Reina Sofia, Córdoba, Spain, 7Complejo Hospario Univ de Huelva, Huelva, Spain, 8Hosp La Línea, AGS Campo de Gibraltar, La Línea de la Concepción, Spain

572 EFFECTIVENESS OF ALL-ORAL DAA s FOR HCV GENOTYPE 3 IN HIV/HCV-COINFECTED PATIENTS
Juan González-García1, Ana Moreno2, Encarnnnacion Cruz2, Lourdes Domínguez-Dominguez2, Victoria Moreno2, Jorge Vergas2, Jose Sanz2, Laura Benitez3, Beatriz Álvarez4, Juan Berenguer4
1Hosp Univ La Paz, Madrid, Spain, 2Hosp Ramon y Cajal, Madrid, Spain, 3Subdireccion General de Farmacia, Madrid, Spain, 4Hosp Univ 12 de Octubre, Madrid, Spain, 5Hosp Clinico San Carlos, Madrid, Spain, 6Hosp Príncipe de Asturias, Alcalá de Henares (Madrid), Spain, 7Clinica Puerta de Hierro, Majadahonda (Madrid), Spain, 8Hosp Univ Fundación Jimenez Diaz, Madrid, Spain, 9Hosp General Univ Gregorio Marañón, Madrid, Spain

573 SOFOSBUVIR/LEDIPASVIR AS CHOLESTEROL-INCREASE RISK FACTOR IN HIV SUBJECTS
Hosp Univ Reina Sofia, Cordoba, Spain

574 LIPID LEVELS AND THE RISK OF ACUTE MYOCARDIAL INFARCTION AMONG HCV+ AND HCV- PERSONS
Adeel A. Butt1, Peng Yan2, Kara Chew2, Judith S. Currier4, Kathleen Corey4, Raymond Chung4, Abdul-Badi Abou-Samra4, Javed Butler4, Matthew Freiberg5, for the ERCHIVES
1Hamad Hlthcare Quality Inst and Hamad Med Corporation, Doha, Qatar, 2VA Pittsburgh Hlthcare System, Pittsburgh, PA, USA, 3Univ of California Los Angeles, Los Angeles, CA, USA, 4Massachusetts General Hosp, Boston, USA, 5Hamad Medica Corporation, Doha, Qatar, 6SUNY Stonybrook, Stony Brook, NY, USA, 7Vanderbilt Univ Sch of Med, Nashville, TN, USA

575 EFFECT OF INTERFERON-FREE TREATMENT ON LIPID AND GLUCOSE METABOLISM IN HEPATITIS C
Elisa Biliotti, Donatella Palazzo, Marco Serani, Rozenn Esvan, Paola Maidai, Paola Perinelli, Martina Spazianti, Alessandro Maria Silvestri, Lorenzo Volpicelli, Gloria Taliani
Sapienza Univ of Rome, Rome, Italy
Influence of DAA Therapy on ALT Levels in HCV- and HIV/HCV-Infected Patients (Gecco)

Stefan Mauss1, Christoph Boesecke2, Florian Berger3, Patrick Ingliz1, Thomas Lutz2, Knud Schewe2, Malte Wehmeyer4, Axel Baumgarten1, Jürgen K Rockstroh1, Stefan Christensen5

1Cntr for HIV and Hepatogastroenterology, Duesseldor, Germany, 2Univ Hosp Bonn, Bonn, Germany, 3Cntr for Infectiology, Berlin, Germany, 4Infektiologikum, Frankfurt, Germany, 5dagnae e. V., Berlin, Germany, 6I. Univ Hosp Hamburg—Eppendorf, Hamburg, Germany, 7Bonn Univ Hosp, Bonn, Germany, 8CIM Infectious Diseases, Münster, Germany

Poster Sessions • Wednesday
Program and Agenda
CROI 2017

598 Earlier Versus Delayed Antiretroviral Therapy Initiation and Risk of Cancer

Michael J. Silverberg1, Wendy Leyden1, Haiquin Lin2, Li Qin2, Chad J. Achenbach3, Gysamber D’Souza4, Eric A. Engels1, Charles Rabkin3, Keri N. Althoff1, Romain Neugebauer1

1Kaiser Permanente, Oakland, CA, USA, 2Yale Univ, New Haven, CT, USA, 3Northwestern Univ, Chicago, IL, USA, 4Johns Hopkins Univ, Baltimore, MD, USA, 5NCI, Rockville, MD, USA

Timing of CART Initiation Influences Cancer Risk Among Women Living with HIV

Kate Salters1, Monica Ye2, Neora Pick2, Angela Kaida1, Sam Wiseman1, Shahab Jabbari1, Mark Hull1, Jean A. Shoveller2, Julio S. Montaner3, Robert S. Hogg1

1Simon Fraser Univ, Burnaby, British Columbia, Canada, 2BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 3Oak Tree Clinic, Vancouver, British Columbia, Canada, 4St. Paul’s Hosp, Vancouver, British Columbia, Canada

Cancer Risk Among HIV-Infected People in the US During the Modern Treatment Era

Raul Ulisses Hernandez-Ramirez1, Meredith S. Shiels2, Robert Dubrow1, Eric A. Engels2

1Yale Univ, New Haven, CT, USA, 2NCI, Rockville, MD, USA

Cancer Incidence Among Persons on Modern Suppressive ART, 2000–2012

Ann N. Burchell1, Kate Salters1, Oghenowede Eyawo1, Joanne Lindsay1, Jason Chia3, Michelle Cotterchio6, Mark Hull1, Monica Ye1, Janet M. Raboud1, Robert S. Hogg1

1St. Michael’s Hosp, Toronto, Ontario, Canada, 2Simon Fraser Univ, Vancouver, British Columbia, Canada, 3BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 4St. Michael’s Hosp, Toronto, Canada, 5Cancer Care Ontario, Toronto, Canada, 6Univ of Toronto, Toronto, Ontario, Canada

Cancer Burden Among HIV+ Individuals on Art in Malawi: A Record Linkage Study

Marie-Josephe Horner1, Steady Chasimpha2, Adrian Spoerri3, Julia Bohlius1, Hannock Tweya1, Eddie Moffo Phiri1, Sam Phiri1, Kennedy Malisita1, Charles Dzamalala1, Satish Gopal7

1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Malawi Cancer Registry, Blantyre, Malawi, 3Univ of Bern, Bern, Switzerland, 4Lighthouse Trust Clinic, Lilongwe, Malawi, 5Queen Elizabeth Hosp ART Clinic, Blantyre, Malawi, 6Lighthouse Trust, Lilongwe, Malawi, 7Univ of North Carolina Proj–Malawi, Lilongwe, Malawi
Poster P-N1 CARDIOVASCULAR RISK AND ART EFFECTS
Poster Hall - 4 EF  2:30 PM - 4:00 PM

608 THE EFFECT OF ART ON INFLAMMATION, COAGULATION, AND VASCULAR INJURY IN START
Jason Baker, Shweta Sharma, Birgit Grund, for the INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group
Univ of Minnesota, Minneapolis, MN, USA

609 PROTHROMBOTIC EFFECTS OF ABACAVIR IN AN IN VIVO MODEL
Isabel Andujar1, Victor Collado-Diaz1, Samuel Orden1, Ainhoa Sanchez-Lopez2, Maria Angeles Martinez-Cuesta2, Angeles Alvarez2, Juan V. Esplugues2
1FISABIO, Valencia, Spain, 2Univ of Valencia, Valencia, Spain

610 A SWITCH TO RALTEGRAVIR DOES NOT LOWER PLATELET REACTIVITY IN HIV-INFECTED ADULTS
Wouter A. van der Heijden, Marjolein Bosch, Reinout van Crevel, Monique Keuter, André van der Ven, Quirijn de Mast
Radboud Univ Med Cntr, Nijmegen, Netherlands

Poster P-N2 DYSLIPIDEMIA AND HDL FUNCTION
Poster Hall - 4 EF  2:30 PM - 4:00 PM

611 DYSFUNCTIONAL HDL FROM HIV+ INDIVIDUALS PROMOTES FOAM-CELL FORMATION IN VITRO
Thomas A. Angelovich1, Anna Hearps1, Margaret D. Shi1, Theodoros Kelesidis2, Anthony Jaworowski1
1Burnet Inst, Melbourne, Australia, 2Univ of California Los Angeles, Los Angeles, CA, USA

612 HDL CHOLESTEROL EFFLUX CAPACITY IS INVERSELY RELATED TO CLASSICAL MONOCYTE NUMBER
Santhosh R. Mannem1, Dominic Chow1, Martin Playford Playford2, Beau K. Nakamoto2, Kalpana J. Kallianpur1, Mary Margaret Byron2, Brooks I. Mitchell2, Cecilia Shikuma2, Nehal N. Mehta2
1Univ of Hawaii, Honolulu, HI, USA, 2Natl Heart, Lung and Blood Inst, Bethesda, MD, USA

613 EFFECT OF ART INITIATION ON MONOCYTE AND HDL FUNCTION
Jane A. O’Halloran1, Theodoros Kelesidis2, Luke O’Brien1, Therese Herlihy1, Louise Rainford3, John Lambert4, Gerard Sheehan4, Niall Mahon4, Leo Lawler1, Patrick W. Mallon3
1Univ Coll Dublin, Dublin, Ireland, 2Univ of California Los Angeles, Los Angeles, CA, USA, 3Mater Misericordiae Univ Hosp, Dublin, Ireland

614 CHOLESTEROL EFFLUX RESPONDS TO THE IMMUNE STATUS IN PROGRESSION OF HIV INFECTION
Olivia Tort1, Roque Pastor1, Felipe Garcia2, Esteban Martinez2, Montserrat Plana2, Tuixent Escrivá1, Montserrat Cofán1, Emma Fernández2, Jose M. Gatell1, Mireia Arnedo1
1IDIBAPS, Barcelona, Spain, 2Hosp Clinic of Barcelona, Barcelona, Spain
**Poster P-N3 INTERVENTIONS TO PREVENT AND TREAT CARDIOVASCULAR DISEASE**
**Poster Hall - 4 EF**
**2:30 PM - 4:00 PM**

615 **LOWER RATES OF CVD PROCEDURES IN HIV-INFECTED PATIENTS WITH ACUTE CORONARY SYNDROME**
- Meredith Clement1, Li Lin2, Ann M. Navar1, Nwora L. Okeke3, Susanna Naggie4, Pamela Douglas5
  1Duke Univ, Durham, NC, USA, 2Duke Clinical Rsr Inst, Durham, NC, USA

616 **EXERCISE, OXIDATIVE STRESS, AND FIBRINOLYTIC FUNCTION IN HIV-1 INFECTED ADULTS**
- Elizabeth Connick1, Jared Greiner2, Caitlin Dow3, Kyle Diehl4, Brian Stauffer5, Christopher DeSouza6
  1Univ of Arizona, Tucson, AZ, USA, 2Univ of Colorado Boulder, Boulder, CO, USA, 3Univ of Colorado Denver, Aurora, CO, USA

617 **VITAMIN D DEFICIENCY IMPAIRS THE BENEFICIAL EFFECTS OF STATIN IN TREATED HIV**
- Corrilynn O. Hileman1, Vin Tangpricha2, Abdus Sattar3, Grace A. McComsey4
  1Case Western Reserve Univ, Cleveland, OH, USA, 2Emory Univ, Atlanta, GA, USA

618 **EFFECT OF STATIN ON ARGinine METABOLITES IN TREATED HIV INFECTION**
- Sahera Dirajlal-Fargo1, Vanessa El Kamari2, Abdus Sattar3, Nicholas Funderburg1, W. H. Wilson Tang4, Grace A. McComsey2
  1Rainbow Babies and Children’s Hosp—Case Western Sch of Med, Cleveland, OH, USA, 2Case Western Reserve Univ, Cleveland, OH, USA, 3Ohio State Univ, Columbus, OH, USA, 4Cleveland Clinic, Cleveland, OH, USA

619 **THE LARGE GAP BETWEEN STATIN ELIGIBILITY AND PRESCRIPTION AMONG HIV+ IN NORTH AMERICA**
- Keri N. Althoff1, Micheal A. Horberg2, Joseph J. Eron3, Stephen J. Gange1, Heidi M. Crane4, Amy Justice5, Mari Kitahata6, Joseph B. Margolick1, Oghenowede Eyawo7, Richard D. Moore8
  1The Johns Hopkins Univ, Baltimore, MD, USA, 2Kaiser Permanente Mid-Atlantic States, Rockville, MD, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Univ of Washington, Seattle, WA, USA, 5VA Connecticut Hlthcare System, West Haven, CT, USA, 6BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

---

**Poster P-N4 VASCULAR, CARDIAC, AND PULMONARY EVENTS**
**Poster Hall - 4 EF**
**2:30 PM - 4:00 PM**

620 **FIRST AND RECURRENT VENOUS THROMBOSIS IN HIV PATIENTS OF THE DUTCH ATHENA COHORT**
- Casper Rokx1, Jaime Borjas Howard1, Colette Smit1, Ferdinand Wit1, Elise D Pieterman1, Karina Meijer2, Wouter Bierman3, Vladimir Tichelaar1, Bart Rijnders1
  1Erasmus Univ Med Cntr, Rotterdam, Netherlands, 2Univ Med Cntr Groningen, Groningen, Netherlands, 3Stichting HIV Monitoring, Amsterdam, Netherlands

621 **PREVALENCE AND PROGNOSTIC IMPACT OF PULMONARY HYPERTENSION IN HIV-INFECTED ADULTS**
- Courtney Zola2, John R. Koethe1, Meng Xu1, Quinn S. Wells2, Eric Farber-Eger, Evan L. Brittain1
  1Vanderbilt Univ, Nashville, TN, USA
622 BODY-MASS INDEX AND ADJUDICATED HEART FAILURE IN A LARGE ELECTRONIC HIV COHORT
Matthew J. Feinstein, Alexandra B. Steverson, Anna Pawlowski, Daniel Schneider, Prasanth Nannapaneni, Sadiya S. Khan, Mercedes Carnethon, Chad J. Achenbach, Sanjiv J. Shah, Donald M Lloyd-Jones
Northwestern Univ, Chicago, IL, USA

Poster P-O3 PULMONARY COMPLICATIONS
Poster Hall - 4 EF 2:30 PM - 4:00 PM

654 HIV AS A RISK FACTOR OF AIRWAY OBSTRUCTIVE DISEASE
Alain Makinson¹, Sabrina Eymard-Duvernoy², Céline Ribet³, Lucie Marchand⁴, Maurice Hayot⁵, Gilles Pialoux⁶, Jacques Reyes⁷, Marie Zins⁸, Vincent Le Moing⁹, for the ANRS EP48 HVCHEST Study Team
¹Univ Hosp Montpellier, Montpellier, France, ²INSERM, Montpellier, France, ³INSERM, Villejuif, France, ⁴France Recherche Nord et Sud Sida-HIV et Hépatites, Paris, France, ⁵Tenon Hosp, Paris, France, ⁶CHU de Montpellier, Montpellier, France

655 CHRONIC HIV PULMONARY DISEASE (CHPD) IN NEVER-SMOKING HIV PATIENTS
Antonella Santoro¹, Riccardo Scaglioni¹, Giulia Besutti¹, Andrea Malagoli¹, Jonathon Leipsic², Janice Leung², Gabriella Orlando³, Stefano Zona³, Guido Ligabue³, Giovanni Gueraldi³
¹Univ of Modena and Reggio Emilia, Modena, Italy, ²Univ of British Columbia, Vancouver, British Columbia, Canada

656 THE INFLUENCE OF HIV INFECTION ON PULMONARY FUNCTION IN A RURAL AFRICAN POPULATION
Alinda Vos¹, Meri Varkila¹, Hugo Tempelman¹, Walter Devillë¹, Roos Barth¹, Diederick Grobbee¹, Roel Coutinho¹, Kerstin Klipstein-Grobusch¹, for the Ndlovu Research Group
¹Univ Med Cntr Utrecht, Utrecht, Netherlands, ²Ndlovu Care Group, Groblersdal, South Africa

657 FACTORS ASSOCIATED WITH PULMONARY IMPAIRMENT IN HIV-INFECTED SOUTH AFRICAN ADULTS
Akshay Gupte¹, Michelle Wong¹, Reginah Msandiwa¹, Grace Barnes¹, Jonathan Golub¹, Richard Chatison¹, Chris Hoffmann¹, Neil Martinson¹
¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Univ of the Witwatersrand, Soweto, South Africa, ³Perinatal HIV Rsr Unit, Soweto, South Africa

658 CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND MORTALITY IN HIV
Matthew Triplette¹, Sheldon T. Brown², Matthew B. Goetz², Joon W. Kim², Maria Rodriguez-Barradas², Guy W. Soo Hoo², Cherry Wongtrakool³, Kathleen Akgün³, Amy Justice³, Kristina Grothers³
¹Univ of Washington, Seattle, WA, USA, ²James J. Peters VA Med Cntr, Bronx, NY, USA, ³VA Greater Los Angeles Hilth Care System, Los Angeles, CA, USA, ⁴James J. Peters VA Med Cntr, Bronx, NY, USA, ⁵Baylor Coll of Med, Houston, TX, USA, ⁶Emory Univ, Atlanta, GA, USA, ⁷Yale Univ, New Haven, CT, USA, ⁸VA Connecticut Hilthcare System, West Haven, CT, USA

659 SPIROMETRIC AND RADIOLOGICAL PREDICTORS OF INCIDENT COPD IN A SPANISH COHORT
Francisco Fanjul, Gloria Sampériz, Javier Verdú, Helem Haydee Vilchez, Antoni Campins, Luisa Martín, María Peñaranda, María Angeles Ribas, María Leyes, Melchor Riera
Hosp Univ Son Espases, Palma de Mallorca, Spain
660  EFFECT OF HIV INFECTION ON ALPHA-1 ANTITRYPSIN FUNCTION: ROLE IN EMPHYSEMA?
Sarah E. Stephenson1, Engi F. Attia2, Carole L. Wilson1, Cherry Wongtrakool3, Kristina Crothers1, Irina Petraceh4, Lynn M. Schnapp1
1Med Univ of South Carolina, Charleston, SC, USA, 2Univ of Washington, Seattle, WA, USA, 3Emory Univ, Atlanta, GA, USA, 4Natl Jewish Hlth, Univ of Colorado, Denver, CO, USA

661  HIV AND CIRCULATING LEVELS OF PRO-SURFACTANT PROTEIN B AND SURFACTANT PROTEIN D
Meredith S. Shie1, Gregory D. Kirk2, M. Brad Drummond3, Dilsher Dhillon4, Samir Hanash4, Ayumu Taguchi5, Eric A. Engels1
1NCI, Rockville, MD, USA, 2Johns Hopkins Univ, Baltimore, MD, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4MD Anderson Cancer Cntr, Houston, TX, USA

Poster P-O4 FRAILTY AND MULTIMORBIDITY
Poster Hall - 4 EF
2:30 PM - 4:00 PM

662  TREND IN MULTIMORBIDITY AMONG HIV+ ADULTS IN CLINICAL CARE IN THE US
Cherise Wong1, Stephen J. Gange2, Richard D. Moore2, Amy Justice3, Alison Abraham4, Kelly Gebo4, Jeffrey N. Martin4, Angel Mayor5, Keri N. Althoff1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2VA Connecticut Hlthcare System, West Haven, CT, USA, 3Univ of Calgary, Calgary, Canada, 4Univ of California San Francisco, San Francisco, CA, USA, 5Univ Central del Caribe, Bayamon, Puerto Rico

663  NON-AIDS ILLNESS BURDEN DIFFERS BY SEX, RACE, AND INSURANCE TYPE IN AGING HIV+ ADULTS
Frank J. Palella1, Rachel Hart2, Carl Armon3, Ellen Tedaldi4, Bienvenido Yangco5, Richard Novak6, Linda Battalora7, Douglas Ward8, Bonnie Dean9, Kate Buchacz8
1Northwestern Univ, Chicago, IL, USA, 2Cerner Corporation, Kansas City, MO, USA, 3Temple Univ, Philadelphia, PA, USA, 4Infectious Disease Rsr Inst, Tampa, FL, USA, 5Univ of Illinois, Chicago, IL, USA, 6Colorado Sch of Mines, Golden, CO, USA, 7Dupont Circle Physicians Group, Washington, DC, USA, 8CDC, Atlanta, GA, USA

664  PSYCHIATRIC DISORDERS OBSERVED IN HIV+ PATIENTS USING 6 COMMON THIRD AGENTS IN OPERA
Ricky Hsu1, Jennifer Fusco2, Cassidy Henegar2, Felix Carpio3, Karam Mounzer4, Michael Wohlfeiler5, Vani Vannappagari6, Michael Aboud7, Lloyd Curtis8, Gregory Fusco2
1New York Univ, New York, NY, USA, 2Epividian, Durham, NC, USA, 3Altamed Hlth Services, Los Angeles, CA, USA, 4Philadelphia FIGHT, Philadelphia, PA, USA, 5AIDS Hlthcare Fndn, Los Angeles, CA, USA, 6ViiV Hlthcare, Rsr Triangle Park, NC, USA, 7ViiV Hlthcare, Brentford, UK, 8GlaxoSmithKline, Uxbridge, UK

665  FRAILTY HAS A STRONGER ASSOCIATION THAN NEUROCOGNITIVE IMPAIRMENT WITH POOR OUTCOMES
Kristine Erlandson1, Mona Abd2, Kevin Robertson3, Susan L. Koletar4, Robert Kalajian5, Babafemi Taiwo6, Frank J. Palella6, Katherine Tassiopoulos7, for the A5322 Study Team
1Univ of Colorado, Aurora, CO, USA, 2Harvard Univ, Boston, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Ohio State Univ, Columbus, OH, USA, 5MetroHlth Med Cntr, Cleveland, OH, USA, 6Northwestern Univ, Chicago, IL, USA
**Poster Sessions • Wednesday**

**Program and Agenda**

**CROI 2017**

---

**666**

**FRAILTY STATUS AND RISK OF FALLS IN HIV-INFECTED OLDER ADULTS IN THE ACTG A5322 STUDY**

Katherine Tassiopoulos, Mona Abdo, Susan L. Koletar, Frank J. Paella, Babafemi Taiwo, Kristine Erlandson, for the A5322 Study Team

1Harvard Univ, Boston, MA, USA, 2Ohio State Univ, Columbus, OH, USA, 3Northwestern Univ, Chicago, IL, USA, 4Univ of Colorado, Aurora, CO, USA

---

**667**

**PHYSICAL FUNCTION AND INFLAMMATION IN OLDER HIV-INFECTED MEN**

Hillary McClintic, Matthew Freiberg, Stephen Crystal, David Leaf, Julie A. Womack, Karen Nieves-Lugo, Janet Tate, Kristina Crothers, Amy Justice, Krisann Oursler

1Virginia Tech, Roanoke, VA, USA, 2Vanderbilt Univ, Nashville, TN, USA, 3Rutgers, The State Univ of New Jersey, New Brunswick, NJ, USA, 4VA Greater Los Angeles Hlthcare System, Los Angeles, CA, USA, 5VA Connecticut Hlthcare System, Branford, CT, USA, 6The George Washington Univ, Washington, DC, USA, 7VA Connecticut Hlthcare System, West Haven, CT, USA, 8Univ of Washington, Seattle, WA, USA, 9Salem VA Med Cntr, Salem, VA, USA

---

**668**

**VACS INDEX AS A PREDICTOR FOR NON-AIDS DEFINING CONDITIONS IN A LONGITUDINAL COHORT**

Brian K. Agan, Seung Hyun Won, Christina Schofield, Anuradha Ganesan, Margaret Glancey, Jason Okulicz, Edmund C. Tramont, Julie Pavlin, for the IDCRP HIV Working Group

1Uniformed Services Univ of the Hlth Scis, Bethesda, MD, USA, 2Madigan Army Med Cntr, Tacoma, WA, USA, 3San Antonio Military Med Cntr, Fort Sam Houston, TX, USA, 4NIAID, Bethesda, MD, USA

---

**669**

**AMERICAN GINSENG FOR THE TREATMENT OF HIV FATIGUE: A RANDOMIZED CLINICAL TRIAL**

Adriana Andrade, Jeff Sloan, Chun-Su Yuan, Brent Bauer, Paul Novotny, Judith Rabkin, Jeffrey Hsu, Adrian Dobs, Todd Brown

1The Johns Hopkins Univ, Baltimore, MD, USA, 2Mayo Clinic, Rochester, MN, USA, 3Univ of Chicago Med, Chicago, IL, USA, 4Columbia Univ, New York, NY, USA

---

**670**

**APPLES—THE AUSTRALIAN POSITIVE & PEERS LONGEVITY EVALUATION STUDY**

Kathy Petoumenos, Robin Huang, Jennifer Hoy, Mark Bloch, David J. Templeton, David Baker, Michelle Giles, Matthew Law, David A. Cooper

1Kirby Inst, Sydney, Australia, 2The Alfred Hosp and Monash Univ, Melbourne, Australia, 3Holdsworth House Med Practice, Sydney, Australia, 4RPA Sexual Hlth, Camperdown, Australia, 5East Sydney Doctors, Darlinghurst, Australia, 6Monash Hlth, Melbourne, Australia

---

**671**

**PATIENTS’ BELIEFS ABOUT THEIR HAART IN COMPARISON WITH THEIR CHRONIC COTREATMENTS**

Susan Kamal, Olivier Bugnon, Matthias Cavassini, Marie-Paule Schneider, for the Swiss HIV Cohort Study

1Univ of Lausanne, Lausanne, Switzerland, 2Univ of Geneva, Univ of Lausanne, Lausanne, Switzerland
725  **TUBERCULOSIS IN SOUTH AFRICA IS MORE CONCENTRATED BY RACE THAN POVERTY**
Stanford Univ, Stanford, CA, USA

726  **HIGH TB INFECTION RATE IN CHILDREN & YOUNG ADULTS IN RURAL UGANDA IN THE SEARCH TRIAL**
Carina Marquez¹, Atukunda Mucunuzi², Gabriel Chami³, Dalsone Kwarissima³, Theodore Ruel¹, Laura B. Balzer², Tamara D. Clark¹, Edwin D. Charlebois¹, Maya L. Petersen¹, Diane V. Havlir¹
¹Univ of California San Francisco, San Francisco, CA, USA, ²Infectious Diseases Rsr Collab, Kampala, Uganda, ³Makerere Univ Joint AIDS Prog, Kampala, Uganda, ⁴Harvard Univ, Boston, MA, USA, ⁵Univ of California Berkeley, Berkeley, CA, USA

727  **THE HIV-ASSOCIATED BURDEN OF RECURRENT TB DISEASE IN CAPE TOWN, SOUTH AFRICA**
Sabine Hermans¹, Nesbert Zinyakatira², Judy Caldwell³, Frank Cobelens⁴, Andrew Boule³, Robin Wood²
¹Amsterdam Inst for Global Hlth and Development, Amsterdam, Netherlands, ²Univ of Cape Town, Cape Town, South Africa, ³City Hlth, Cape Town, South Africa, ⁴Univ of Amsterdam, Amsterdam Zuidoost, Netherlands

728  **HIV TESTING UPTAKE AMONG HOUSEHOLD CONTACTS OF MDR-TB INDEX CASES IN 8 COUNTRIES**
Valarie S. Opollo¹, Xingye Wu², Richard Lando³, Susan Swindells⁴, Amita Gupta⁵, Anneke Hesseling⁶, Rodney Dawson⁷, Michael D. Hughes⁸, N. Sarita Shah⁹, for the A5300/I2003 Study Team
¹Kenya Med Rsr Inst, Kisumu, Nyanza, Kenya, ²Harvard Univ, Boston, MA, USA, ³Kenya Med Rsr Inst, Kisumu, Kenya, ⁴Univ of Nebraska, Omaha, NE, USA, ⁵The Johns Hopkins Univ, Baltimore, MD, USA, ⁶Stellenbosch Univ, Tygerberg, South Africa, ⁷Univ of Cape Town, Mowbray, South Africa, ⁸CDC, Atlanta, GA, USA

729  **HIV CONTINUUM AND EXPEDITED TB DIAGNOSIS IN TB/HIV COINFECTED PATIENTS IN BOTSWANA**
Diane Gu¹, Sanghyuk S Shin¹, Chawangwa Modongo², Cynthia Caiphus³, Othusitse Fanè³, Matsiri Ogopotse³, Mbatsi Dima³, Nicola M Zetola⁴
¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Botswana–UPenn Partnership, Gaborone, Botswana, ³Princess Marina Hosp, Gaborone, Botswana, ⁴Univ of Pennsylvania, Gaborone, Botswana

730  **IMPROVEMENT OF HIV/TB CARE: TIME-SERIES ANALYSIS OF HEALTH FACILITY DATA**
Nehaben Ramanlal¹, Dulce Bila¹, Orvalho Augusto², Nello Macuacua³, Victorino Chavane¹, Leonel Zevo¹, Chadreque Muluna³, Esmeralda Karajeanes¹, Paula Vaz¹
¹Fundação Ariel Glaser Contra o Sida Pediatrico, Maputo, Mozambique, ²Univ Eduardo Mondlane, Maputo, Mozambique, ³Direccção Provincial de Saúde de Maputo, Maputo Província, Mozambique
**Poster P-P6 TB AND OI IRIS**

**Poster Hall - 4 EF**

2:30 PM - 4:00 PM

731 **INTEGRASE INHIBITORS ARE AN INDEPENDENT RISK FACTOR FOR IRIS: AN ATHENA COHORT STUDY**

Ingeborg Wijting1, Casper Rokx1, Ferdinand Wit1, Anneloes Postma1, Andy Hoeipelman1, Ineke van der Ende1, Peter Reiss2, Bart Rijnders1

1Erasmus Univ Med Cntr, Rotterdam, Netherlands, 2Stichting HIV Monitoring, Amsterdam, Netherlands, 3Univ Med Cntr Utrecht, Utrecht, Netherlands

732 **INITIATION OF ART BASED ON INTEGRASE INHIBITORS INCREASES THE RISK OF IRIS**

Marine Dutertre1, Lise Cuzin2, Pascal Puglisi2, Veronique Joly1, Marc-Antoine Valantin1, Laurent Cotte1, Thomas Huleux1, Pierre Delobel2, Guillaume Martin-Blondel1, for the Dat’AIDS

1Toulouse Univ Hosp, Toulouse, France, 2CHU Toulouse, Toulouse, France, 3CHU de Nice, Nice, France, 4Bichat Hosp, Paris, France, 5AP–HP, Paris, France, 6Hospices Civils de Lyon, Lyon, France, 7Cntr Hosp de Tourcoing, Tourcoing, France

733 **INFLAMMASOMES PLAY A MAJOR ROLE IN TB IRIS PATHOGENESIS**

Denise C. Hsu1, Daniel Sturdevant2, Eleanor Wilson1, Virginia Sheikh1, Ornella Sortino3, Silvia Lage1, Timothy G. Myers1, Stephen Porcella1, Irini Sereti1

1NIAID, Bethesda, MD, USA, 2NIAID, Hamilton, MT, USA, 3Leidos Biomed Rsr Inc, Frederick, MD, USA

**Poster P-P7 TB COMORBIDITIES**

**Poster Hall - 4 EF**

2:30 PM - 4:00 PM

734 **THE DIABETES-TUBERCULOSIS COMORBIDITY AMONG PERSONS WITH HIV**

Monica Sane Schepisi1, Jalal Miah1, Anna Kaluzhenina1, Katerina Manika Manika1, Emanuele Pontali1, Monica Rios Prego2, Maria Nieves Altet Altet1, Diana Sanchez Mellado Sanchez Mellado1, Enrico Girardi1, for the TB NET

1Natl Inst for Infectious Diseases L. Spallanzani, Rome, Italy, 2Newham Univ Hosp Barts NHS Trust, London, UK, 3Volgograd State Med Univ, Volgograd, Russian Federation, 4Aristotle Univ of Thessaloniki, Thessaloniki, Greece, 5Galliera Hosp, Genova, Italy, 6Complexo Hospario Univ de Pontevedra, Pontevedra, Spain, 7Unidad de Prevención y Control de la TB de Barcelona, Barcelona, Spain, 8IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain

735 **RISK PROFILES IN MONOINFECTED TB PATIENTS AND THOSE COINFECTED WITH HCV AND/OR HIV**

David Roth1, James Johnston1, Jason Wong1, Mel Krajden1, Zahid A. Butt2, Nabin Shrestha1, Mark Gilbert1, Victoria Cook1, Naveed Z. Janjua1

1BC Cntr for Disease Control, Vancouver, British Columbia, Canada, 2Univ of British Columbia, Vancouver, British Columbia, Canada

736 **PROBLEM DRUG USE PREDICTS HIGHER HIV PREVALENCE IN UK TUBERCULOSIS CASES, 2010–2014**

Joanne R. Winter1, Helen R. Stagg1, Colette J. Smith1, Maeve K. Lalor2, Alison E. Brown1, H. L. Thomas2, Valerie Delpech2, Ibrahim Abubakar1

Poster Sessions • Wednesday  
Program and Agenda
CROI 2017

788 EVALUATION OF MATERNAL AND INFANT HIV POINT-OF-CARE DIAGNOSTICS AT BIRTH IN TANZANIA
Issa Sabi¹, Hellen Mahiga¹, Jimson Mgaya², Otto Geisenberger², John France³, Michael Hoelscher³, Arne Kroidi⁴
¹NIMR–Mbeya Med Rsr Cntr (MMRC), Mbeya, Tanzania, ²Univ of Munich, Munich, Germany, ³Mbeya Referral Hosp, Mbeya, Tanzania

789 EVALUATION OF THE CEPHEID HIV-1 QUAL POINT-OF-CARE TEST FOR HIV DIAGNOSIS AT BIRTH
Maryanne R. Ibrahim¹, Sikhuilile Moyo¹, Terence Mohammed², Kenneth Maswabi², Gbolahan Ajibola³, Rebecca Gelman³, Chloe Auletta-Young³, Shahin Lockman², Joseph Makhema³, Roger L. Shapiro¹
¹Doris Duke Intl Clinical Rsr Fellowship, Los Angeles, CA, USA, ²Botswana Harvard AIDS Rsr Inst Partnership, Gaborone, Botswana, ³Dana–Farber Cancer Inst, Boston, MA, USA

790 TARGETED HIV SCREENING AT BIRTH CAN IDENTIFY THE MAJORITY OF IN UTERO TRANSMISSIONS
Maryanne R. Ibrahim¹, Kenneth Maswabi², Gbolahan Ajibola³, Sikhuilile Moyo¹, Michael D. Hughes¹, Chloë Auletta-Young¹, Daniel R. Kuritzkes¹, Mathias Lichterfeld³, Joseph Makhema³, Roger L. Shapiro¹
¹Doris Duke Intl Clinical Rsr Fellowship, Los Angeles, CA, USA, ²Botswana Harvard AIDS Rsr Inst Partnership, Gaborone, Botswana, ³Harvard Univ, Boston, MA, USA, ⁴Brigham and Women’s Hosp, Boston, MA, USA, ⁵Massachusetts General Hosp, Boston, MA, USA

791 IMPACT OF BIRTH PCR ON RETENTION IN CARE OF HIV-EXPOSED INFANTS IN PRIMARY CARE
Aurelie Nelson¹, Laura Trivino Duran¹, Tali Cassidy¹, Gilles van Cutsem², Sarah Jane Steele³, Mark Cotton³, Janet Giddy², Jean Maritz³
¹MSF, Khayelitsha, South Africa, ²MSF, Cape Town, South Africa, ³Stellenbosch Univ, Cape Town, South Africa, ⁴KESS, Cape Town, South Africa

792 IMPACT OF EXPANDED SCREENING AND POC ON INFANT DIAGNOSIS AND ART INITIATION
Alliance Nikuze¹, Stephen Wanjala¹, Jihane Ben-Farhat¹, Willis Omwoyo¹, Laura Oyiengo¹, Elisabeth Szumilin², Leon Salumu³, Alexandra Vandenbulcke³, Valarie S. Opollo⁴, David Maman⁵

793 DELAYED HIV DNA PCR DETECTION AMONG INFANTS WHO RECEIVED COMBINATION ART PROPHYLAXIS
Thanyawee Puthanakit¹, Archawin Rojanawiwat¹, Tanawan Samleerat², Hansa Thaisri², Jiratchaya Sophonphan², Sarawut Boonsuk³, Sumet Ongwandee⁴, Varunee Jinarat², for the Thailand ACC Program
¹Chulalongkorn Univ, Bangkok, Thailand, ²Ministry of Pub Hlth, Nonthaburi, Thailand, ³Chiang Mai Univ, Chiang Mai, Thailand, ⁴HIV Netherlands Australia Thailand Rsr Collab,Thai Red Cross AIDS Rsr, Bangkok, Thailand, ⁵Ministry of Pub Hlth, Nonthaburi, Thailand

794 HIV VIRAL-LOAD TRENDS WITHIN SOUTH AFRICA’S EARLY INFANT DIAGNOSIS PROGRAM, 2010–2015
Ahmad Haeri Mazanderani¹, Faith Moyo¹, Tendesayi Kufa-Chakeza¹, Gayle G. Sherman²
¹NCID, Johannesburg, South Africa, ²Univ of the Witwatersrand, Johannesburg, South Africa
**Poster Sessions • Wednesday**

**Program and Agenda**

**CROI 2017**

**Poster Sessions • Wednesday**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

**Poster P-R1 HIV DETECTION AND LATENT RESERVOIR IN CHILDREN**

**Poster Hall - 4 EF**

152

**DETECTION OF INDUCIBLE HIV IN CHILDREN ON ART DESPITE LOW HIV-1 DNA**

Shalena Naidoo1, Michele Sobolewski2, Taylor Buckley3, Joshua C. Cyktor2, Melissa Tosiano4, Mary Grace K. Katusiime1, Gert U. van Zyl1, Mark Cotton1, Richard Glashoff5, John Mellors5

1Stellenbosch Univ, Cape Town, South Africa, 2Univ of Pittsburgh, Pittsburgh, PA, USA, 3Stellenbosch Univ, Parow, South Africa

**HIV RESERVOIR SIZE IS NOT INCREASED BY SHORT ART INTERRUPTION IN KENYAN INFANTS**

Mark D. Pankau1, Dalton Walamw2, Sarah Benki-Nugent1, Agnes Langat3, Ken Tapia1, Elizabeth Maleche-Obimbo4, Julie Overbaugh1, Grace John-Stewart5, Dara Lehman1

1FRCHC, Seattle, WA, USA, 2Univ of Nairobi, Nairobi, Kenya, 3Univ of Washington, Seattle, WA, USA, 4US CDC, Nairobi, Kenya, 5Kenyatta Natl Hosp, Nairobi, Kenya

**HIV SUBTYPE D IS ASSOCIATED WITH INCREASED LATENT RESERVOIR SIZE IN CHILDREN**

Leila B. Giron1, Jane Achan2, Paul Bangirana3, Moses R. Kamya3, Diane V. Havlir4, Joseph K. Wong5, Theodore Ruel1, Satish K. Pillai6

1Fed Univ of Sao Paulo/Blood Systems Rsr Inst, Sao Paulo, Brazil, 2Disease Control and Elimination Theme, Med Rsr Unit, Fajara, Gambia, 3Makerere Univ, Kampala, Uganda, 4Univ of San Francisco, San Francisco, USA, 5Blood Systems Rsr Inst/UCSF, San Francisco, CA, USA

**Poster P-R2 IMMUNE RESPONSE AND ACTIVATION IN CHILDREN**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

**Poster P-R2 IMMUNE RESPONSE AND ACTIVATION IN CHILDREN**

**Poster Hall - 4 EF**

798

**B-CELL RESPONSES IN EARLY TREATED LONG TERM VIRAL SUPPRESSED SERONEG HIV+ CHILDREN**

Paolo Palma1, Paola Zangari1, Nicola Cotugno1, Eleni Nastouli1, Laura McCoy3, Salvatore Rocca1, Bridget Ferns3, Savita Pahwa1, Paolo Rossi1, for the EPIICAL Consortium


**RAPID RESTORATION OF EFFECTIVE ANTI-HIV CD4+ T-CELL ACTIVITY IN ART-TREATED CHILDREN**

Emily Adland1, Luisa Mori2, Leana Laker3, Alice Swordy4, Anna Csala5, Masahiko Mori1, Philippa C. Matthews1, Pieter Jooste6, Philip J. Goulder6


**PD-1+ MEMORY CD4 T CELLS, PROLIFERATIVE CAPACITY, AND INFLAMMATION IN HIV+ CHILDREN**

Julia Foldi1, Lina Kozhaya1, Max Kilberg1, Mussia Mwamzuka1, Fatma Marshed2, Aabid Ahmed2, William Borkowsky1, Derya Unutmaz1, Alka Khaitan2

1New York Univ, New York, NY, USA, 2Bomu Hosp, Mombasa, Kenya
801 MICROBIAL TRANSLOCATION DOES NOT DRIVE IMMUNE ACTIVATION IN UGANDAN CHILDREN WITH HIV
Felicity Fitzgerald1, Edouard Lhomme2, Kathryn Harris3, Julia Kenny1, Ronan Doyle1, Cissy Kityo3, Sarah Walker3, Rodolphe Thiébaut4, Nigel Klein4, for the CHAPAS-3 Trial Team

802 TARGETING IMMUNOACTIVATION IN HIV+ CHILDREN BY MODIFICATION OF THE GUT MICROBIOTA
Talía Sainz1, Nuria Jiménez-Hernández2, Laura Diaz3, Sergio Serrano-Villar4, María José Mellado1, Luis Prieto2, Jose Tomas Ramos3, M. Ángeles Muñoz-Fernández2, Maria José Gosalbes1, Maria Luisa Navarro1
1Hosp La Paz Inst for Hlth Rsr, Madrid, Spain, 2FISABIO–Salud Pública, Valencia, Spain, 3Gregorio Maranon Hosp, Madrid, Spain, 4Hosp Univ Ramón y Cajal, Madrid, Spain, 5Hosp de Getafe, Madrid, Spain, 6Hosp Clínico San Carlos, Madrid, Spain

803 B- AND T-CELL SUBSETS AND IMMUNOGENICITY OF ROTAVIRUS VACCINE IN PHIV & PHEU INFANTS
Adriana Weinberg1, Jane Lindsey2, Ronald Bosch2, Deborah Persaud1, Paul Sato1, Barbara Heckman2, Kelly Richardson1, Amanda Zadzilka1, Margaret Nelson1, Myron Levin1
1Univ of Colorado, Aurora, CO, USA, 2Harvard Univ, Boston, MA, USA, 3The Johns Hopkins Univ, Baltimore, MD, USA, 4DAIDS, NIAID, Bethesda, MD, USA, 5Data Mgmt Cntr, Amherst, NY, USA, 6Frontier Sci and Tech Rsr Fndn, Amherst, NY, USA, 7Merck & Co, Inc, Upper Gwynedd, PA, USA

804 IMMUNOLOGICAL RESPONSE AFTER A BOOSTER DOSE OF HBV VACCINE IN HIV-INFECTED YOUTH
Vania Giaconet1, Daria Trabattoni2, Pilar Nannini2, Michela Masetti2, Federica Forlanini2, Mario Clerici2, Gian Vincenzo Zuccotti2
1L. Sacco Hosp, Milan, Italy, 2Univ of Milan, Milan, Italy, 3Univ of Milan, Segrate, Milan, Italy, 4Ospedale dei Bambini V. Buzzi, Milan, Italy

805 HPV4 VACCINE IMMUNOGENICITY/EFFECTIVENESS IN PERINATALLY HIV-INFECTED (PHIV) YOUTH
Anna-Barbara Moscicki1, Brad Karalius2, Katherine Tassiopoulos2, Denise Jacobson1, Kunjal Patel2, Murli U. Purswani2, George R. Seage2, Tzy-Jyun Yao2
1Univ of California Los Angeles, Los Angeles, CA, USA, 2Harvard Univ, Boston, MA, USA, 3Bronx Lebanon Hosp, Bronx, NY, USA

Poster Sessions: Wednesday
Poster P-R6 APPROACHING 90:90:90 IN ADOLESCENTS AND YOUNG ADULTS
Poster Hall - 4 EF
2:30 PM - 4:00 PM
831 CURRENT TRENDS IN CHILDREN WITH HIV DIAGNOSED IN THE UK AND IRELAND
Helen Peters, Kate Francis, Intira J. Collins, Ali Judd, Claire Thorne
Univ Coll London, London, UK
832 BASELINE POPULATION HIV CASCADE AND 2-YR OUTCOME OF HIV+ CHILDREN IN THE SEARCH TRIAL
Laura B. Balzer1, Norton Sang1, Albert Plenty1, Teri Liegler1, Craig Cohen1, Elizabeth A. Bukusi2, Moses R. Kamya3, Maya L. Petersen4, Diane V. Havlir1, Theodore Ruel1
1Univ of California San Francisco, San Francisco, CA, USA, 2Kenya Med Rsr Inst, Nairobi, Kenya, 3Makerere Univ, Kampala, Uganda, 4Univ of California Berkeley, Berkeley, CA, USA

833 COST-EFFECTIVENESS OF HIV SCREENING: US ADOLESCENTS AND YOUNG ADULTS (AYA) AGED 13–24
Anne M. Neilan1, Richard Dunville2, Cheryl B. Ocfemia2, Joshua A. Salomon2, Li Yan Wang2, Katherine K. Hsu3, Elizabeth DiNenno4, Rochelle P. Walensky5, Robert A. Parker1, Andrea L. Ciaranello6
1Massachusetts General Hosp, Boston, MA, USA, 2CDC, Atlanta, GA, USA, 3Harvard SPH, Boston, MA, USA, 4Massachusetts Dept of Pub Hlth, Boston, MA, USA

834 COMMUNITY INTERVENTION IMPROVES ADOLESCENT HIV STATUS KNOWLEDGE: HPTN 071 STUDY ZAMBIA
Kwame Shanaube1, Mwate J. Chaila1, David Macleod2, Ab Schaap3, Sian Floyd4, Conred Jani5, Graeme Hoddinott2, Richard Hayes2, Sarah Fidler4, Helen Ayles6

835 A NOVEL MODEL OF COMMUNITY COHORT CARE FOR HIV-INFECTED ADOLESCENTS IMPROVES OUTCOMES
Lindsey Reif1, Rachel Bertrand2, Vanessa Rivera1, Bernadette Jospeh2, Benedict Anglade2, Jean W. Pape3, Daniel Fitzgerald4, Margaret McNairy5
1Columbia Univ, New York, NY, USA, 2GHESKIO, Port-au-Prince, Haiti, 3Weill Cornell Med, New York, NY, USA

836 LOCAL SOCIAL NETWORKS PREDICT RETENTION & SUPPRESSION IN YOUNG WOMEN IN SEARCH TRIAL
Lillian Brown1, Wenjing Zheng2, James Ayieko3, Asiphas Owaraganise1, Florence Mwangwa4, Tamara D. Clark1, Edwin D. Charlebois1, Moses R. Kamya3, Diane V. Havlir1, Maya L. Petersen2
1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of California Berkeley, Berkeley, CA, USA, 3Kenya Med Rsr Inst, Nairobi, Kenya, 4Infectious Diseases Rsr Collab, Kampala, Uganda, 5Makerere Univ, Kampala, Uganda

837 TEENAGE PREGNANCY: A CRITICAL BARRIER TO RETENTION ON ANTIRETROVIRAL THERAPY
Harriet Nuwagaba-Biribonwoha1, Agnes Kiragga2, Constantin Yiannoutos1, Beverly Musicik1, Kara K. Wools-Kaloustian1, Elaine J. Abrams3, Batya Elul4, for the International Epidemiologic Databases to Evaluate AIDS (IeDEA) East Africa Collaboration
1ICAP at Columbia Univ, New York, NY, USA, 2Makerere Univ, Kampala, Uganda, 3Indiana Univ, Indianapolis, IN, USA, 4Columbia Univ, New York, NY, USA
838 IMPACT OF SUBSTANCE USE, MENTAL HEALTH, AND AGE ON RETENTION AND VIRAL SUPPRESSION

Brian C. Zanoni\textsuperscript{1}, Sara Lammert\textsuperscript{1}, Jessica Haberer\textsuperscript{1}, Gregory K. Robbins\textsuperscript{1}, Heidi M. Crane\textsuperscript{2}, Michael J. Mugavero\textsuperscript{1}, Katerina Christopoulos\textsuperscript{1}, Kenneth H. Mayer\textsuperscript{1}

\textsuperscript{1}Massachusetts General Hosp, Boston, MA, USA, \textsuperscript{2}Univ of Washington, Seattle, WA, USA, \textsuperscript{3}Univ of Alabama at Birmingham, Birmingham, AL, USA, \textsuperscript{4}Univ of California San Francisco, San Francisco, CA, USA, \textsuperscript{5}Fenway Hlth, Boston, MA, USA

839 THE MACARTI STUDY: CLOSING THE GAPS IN HIV CARE AMONG YOUTH IN ATLANTA, GA

Andres Camacho-Gonzalez\textsuperscript{1}, Scott Gillespie\textsuperscript{1}, Lateshia Thomas-Seaton\textsuperscript{2}, Krystal Frieson\textsuperscript{1}, Sophia A. Hussan\textsuperscript{1}, Ashley Murray\textsuperscript{1}, Zenata Gaul\textsuperscript{1}, Madeline Sutton\textsuperscript{1}, Chanda Graves\textsuperscript{1}, Rana Chakraborty\textsuperscript{1}

\textsuperscript{1}Emory Univ, Atlanta, GA, USA, \textsuperscript{2}Children’s Hlthcare of Atlanta, Atlanta, GA, USA, \textsuperscript{3}Atlanta VA Med Cntr, Decatur, GA, USA, \textsuperscript{4}Emory Univ, Atlanta, GA, USA, \textsuperscript{5}CDC, Atlanta, GA, USA, \textsuperscript{6}ICF Intl, Atlanta, GA USA

840 RETENTION, ART USE, AND VIRAL SUPPRESSION AMONG YOUNG ADULTS NEWLY LINKED TO HIV CARE

Fidel A. Desir\textsuperscript{1}, Peter F. Rebeiro\textsuperscript{2}, Richard D. Moore\textsuperscript{1}, Heidi M. Crane\textsuperscript{3}, Karyn Gabler\textsuperscript{1}, Joseph B. Margolick\textsuperscript{1}, Michael A. Horberg\textsuperscript{1}, Michael J. Silverberg\textsuperscript{1}, Keri N. Althoff\textsuperscript{1}

\textsuperscript{1}The Johns Hopkins Univ, Baltimore, MD, USA, \textsuperscript{2}Vanderbilt Univ, Nashville, TN, USA, \textsuperscript{3}Univ of Washington, Seattle, WA, USA, \textsuperscript{4}BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, \textsuperscript{5}Harvard Univ, Boston, MA, USA, \textsuperscript{6}Kaiser Permanente Mid-Atlantic States, Rockville, MD, USA, \textsuperscript{7}Kaiser Permanente Northern California, Oakland, CA, USA

841LB WITHDRAWN

Poster P-S4 HIV AND SUBSTANCE USE: DOUBLE TROUBLE

Poster Hall - 4 EF 2:30 PM - 4:00 PM

869 “HOOKED ON PAINKILLERS” PRIOR TO FIRST INJECTION AMONG PWID IN 16 U.S. CITIES

Dita Broz\textsuperscript{1}, Maria Zlotorzynska\textsuperscript{2}, Michael Spiller\textsuperscript{1}, Gabriela Paz-Bailey\textsuperscript{1}, for the NHBS Study Group

\textsuperscript{1}CDC, Atlanta, GA, USA, \textsuperscript{2}Emory Univ, Atlanta, GA, USA

870 OPIOID SUBSTITUTION THERAPY AND INITIATION INTO INJECTION DRUG USE IN SAN DIEGO, CA

Maria Luisa Mittal\textsuperscript{1}, Devesh Vashishtha\textsuperscript{1}, Xiaoying Sun\textsuperscript{1}, Sonia Jain\textsuperscript{1}, Richard S. Garfein\textsuperscript{2}, Steffanie A. Strathdee\textsuperscript{3}, Dan Werb\textsuperscript{1}

\textsuperscript{1}Univ of California San Diego, La Jolla, CA, USA, \textsuperscript{2}Univ of California San Diego, San Diego, CA, USA

871 CHANGES IN PRESCRIPTION OPIOID, METH, AND COCAINE USE AMONG MSM IN 20 US CITIES

Brooke Hoots, Dita Broz, Lina Nerlander, Gabriela Paz-Bailey

CDC, Atlanta, GA, USA
872 CHANGING PATTERN OF CRYSTAL METH USE IN BLACK & WHITE MSM, WASHINGTON, DC, 2008–2014

Irene Kuo1, Rudy Patrick1, Jenevieve Opoku2, Anthony Rawls1, Manya Magnus1, James Peterson1, Michael Kharfen2, Alan Greenberg1

1The George Washington Univ, Washington, DC, USA, 2District of Columbia Dept of Hlth, Washington, DC, USA

873 INcreasing METHamphetamINE USE AMONG Non-MSM WHO INJECT DRUGS IN King County, WA

Sara N. Glick1, Richard Burt1, Kim Kummer1, Joe Tinsley1, Caleb Banta-Green1, Matthew R. Golden1

1Univ of Washington, Seattle, WA, USA, 2Pub Hlth - Seattle & King County, Seattle, WA, USA

874 REDUCING ALCOHOL CONSUMPTION IMPROVED HIV VIRAL SUPPRESSION IN WOMEN

Robert L. Cook1, Zhi Zhou1, Maria J. Miguez2, Babette Brumback1, John Lewis1, Luis Espinoza1, Kendall J. Bryant1

1Univ of Florida, Gainesville, FL, USA, 2Florida Intl Univ, Miami, FL, USA, 3Univ of Miami, Miami, FL, USA, 4Natl Inst on Alcohol Abuse and Alcoholism, Bethesda, MD, USA

875 THE RELATIVE IMPACTS OF ART AND HARM REDUCTION ON HIV INCIDENCE IN BRITISH COLUMBIA

Bohdan Nosyk, Xiao Zang, Jeong E. Min, Emanuel Krebs, Viviane D. Lima, M-J Milloy, Jean A. Shoveller, Rolando Barrios, Evan Wood, Julio S. Montaner

BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

Poster P-T1 FERTILITY, CONTRACEPTION, PREGNANCY, AND REPRODUCTIVE HEALTH

2:30 PM - 4:00 PM

934 PREP USED IN PREGNANCY DOES NOT INCREASE POOR BIRTH OUTCOMES

Renee Heffron1, Nelly Mugo2, Ting Hong1, Elizabeth A. Bukusi2, Elly T. Katabira3, Stephen Asiimwe3, Mark A. Marzinke2, Connie L. Celum1, Jared Baeten1, for the Partners Demonstration Project and Partners PrEP Study Teams

1Univ of Washington, Seattle, WA, USA, 2Kenya Med Rsr Inst, Nairobi, Kenya, 3Makerere Univ, Kampala, Uganda, 4Kabwohe Clinical Rsr Cntr, Kabwohe, Uganda, 5The Johns Hopkins Univ, Baltimore, MD, USA

935 PREGNANCY INCIDENCE AND OUTCOMES AMONG WOMEN USING THE DAPIVIRINE VAGINAL RING

Bonus Makanani1, Jennifer Balkus1, Thesla Palanee-Phillips1, Yamikani Mbilizi1, Jeanna Piper1, Kenneth Kintu1, Tchangani Tembo2, Lisa Noguchi3, Helen Rees3, Jared Baeten1

1Malawi Coll of Med–Johns Hopkins Univ Rsr Proj, Blantyre, Malawi, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 3Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, 4NIH, Bethesda, MD, USA, 5Makerere Univ–Johns Hopkins Univ Rsr Collab, Kampala, Uganda, 6Univ of North Carolina Proj–Malawi, Lilongwe, Malawi, 7The Johns Hopkins Univ, Baltimore, MD, USA, 8Univ of Washington, Seattle, WA, USA
936  PREFERENCE AND CHOICE OF MULTIPURPOSE PREVENTION TECHNOLOGIES IN YOUNG AFRICAN WOMEN

Ariane van der Straten1, Helen Cheng1, Kawango Agot2, Khatija Ahmed3, Rachel Weinrib1, Kghahisho Manenzhe1, Fredrick Owino2, Alexandra Minnis2, for the Trio Study Team

1RTI Intl, San Francisco, CA, USA, 2Impact Rsr and Development Org, Kisumu, Kenya, 3Setshaba Rsr Ctnt, Pretoria, South Africa

937  MODERN CONTRACEPTIVE USE AND UNPROTECTED SEX IN HIGH-RISK HIV-POSITIVE WOMEN IN KENYA

Diya Surie1, Krista Yuhas1, Kate Wilson1, Linnet N. Masese1, Juma Shafi2, John Kinuthia3, Walter Jaako2, R. Scott McClelland1

1Univ of Washington, Seattle, WA, USA, 2Univ of Nairobi, Nairobi, Kenya, 3Kenya Natl Hosp, Nairobi, Kenya

938  INTERACTION BETWEEN ETONOGESTREL-RELEASING IMPLANT AND 3 ANTIRETROVIRAL REGIMENS

Regis Kreitchmann1, Alice Stek2, Brookie Best3, Edmund Capparella3, Jiajia Wang4, David E. Shapiro4, Nahida Chakhtoura5, Sandra Burchett6, Mark Mirochnick2, for the IMPAACT P1026s Protocol Team

1Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil, 2Univ of Southern California, Los Angeles, CA, USA, 3Univ of California San Diego, La Jolla, CA, USA, 4Harvard Univ, Boston, MA, USA, 5NICHD, Bethesda, MD, USA, 6Boston Children’s Hosp, Boston, MA, USA

939  FERTILITY AND REPRODUCTIVE OUTCOMES OF HIV+ AND HIV-WOMEN IN THE CARMA COHORT STUDY

Clara E. Van Ommen1, Ariane Y. Albert2, Ariel Nesbitt2, Shanlea Gordon3, Evelyn J. Maan3, Helene C. Cote4, Neora Pick5, Deborah M. Money2, Melanie C. Murray1, for the CHF team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)

1Univ of British Columbia, Vancouver, Canada, 2Women’s Health Rsr Inst, Vancouver, Canada, 3Oak Tree Clinic, Vancouver, Canada

940  EARLY ONSET MENOPAUSE AMONG WOMEN LIVING WITH HIV IN CANADA

Nisha Andany1, Angela Kaida2, Alexandra de Pokomandy3, Lu Wang1, V. Logan Kennedy1, Mark Yudin1, Cath Webster1, Anita Benoit2, Mona Loutfy1, for the CHIROS Research Team

1Women’s Coll Rsr Inst, Toronto, Ontario, Canada, 2Simon Fraser Univ, Burnaby, British Columbia, Canada, 3McGill Univ, Montreal, Canada, 4BC Ctr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 5St. Michael’s Hosp, Toronto, Ontario, Canada, 6CHIROS Study, Vancouver, Canada, 7Univ of Toronto, Toronto, Ontario, Canada

941  COST-EFFECTIVENESS OF 2 METHODS TO TREAT CERVICAL DYSPLASIA IN HIV-POSITIVE WOMEN

Naomi Lince-Deroche1, Craig Van Rensburg1, Jane Phiri1, Pamela Michelow2, Jennifer Smith1, Cindy Firnhaber1

1Hlth Economics and Epi Rsr Office, Johannesburg, South Africa, 2NHLS, Johannesburg, South Africa, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Right to Care, Johannesburg, South Africa

942  FERTILITY DESIRES OF HIV-POSITIVE MEN AND WOMEN IN THE US

Susan E. Cohn1, Lisa B. Haddad2, Christina S. Hayford1, Anandi N. Sheth3, Justin A. Schmandt1, Joan S. Chmiel1

1Northwestern Univ, Chicago, IL, USA, 2Emory Univ, Atlanta, GA, USA
Poster P-T2 HOT FLASHES: HORMONAL CONTRACEPTION AND HIV RISK
Poster Hall - 4 EF  2:30 PM - 4:00 PM

943  CHANGES IN GENITAL-TRACT HIV TARGET CELLS WITH THREE PROGESTIN-BASED CONTRACEPTIVES
Lisa B. Haddad1, Alison S. Kohlmeier2, Richard Haaland2, Nakita Brown1, David Lupo1, Christina Mehta1, Anandi N. Sheth1, Kehmia Titanji2, Clyde Hart2, Igho Ofotokun1
1Emory Univ, Atlanta, GA, USA, 2CDC, Atlanta, GA, USA

944  DEPOT MEDROXYPROGESTERONE ACETATE INCREASES HIV-1 REPLICA TION IN MUCOSAL TISSUE
Charlene S. Dezzutti1, Seo Young Park1, Ingrid Macio1, Kenneth Marks3, Sidney Lawlor3, Catherine Chappell1, Katherine Bunge4
1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Univ of Pittsburgh Med Cntr, Pittsburgh, PA, USA, 3Magee-Womens Rsr Inst, Pittsburgh, PA, USA, 4Magee-Womens Hosp of UPMC, Pittsburgh, PA, USA

945  ZIM-CHIC: IMPACT OF CONTRACEPTIVE INITIATION ON IMMUNE CELLS IN THE CERVIX AND PBMCs
Sharon L. Achilles1, Feliz Mhlanga2, Leslie A. Meyn1, Kevin A. Stoner3, Allen T. Matubu2, Zvavahera M. Chirenje2, Sharon L. Hillier1
1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Univ of Zimbabwe, Harare, Zimbabwe, 3Magee–Womens Rsr Inst, Pittsburgh, PA, USA

946  HIV GENITAL-TRACT SHEDDING WHILE ON PROGESTIN CONTRACEPTION
Julie A. Nelson1, Jeff Wiener2, Jennifer H. Tang1, Lameck Chinula3, Stacey Hurst4, Gerald Tegha4, Albans Msika1, Mina C. Hosseinipour1, Lisa B. Haddad4, Athena Kourtis2
1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2CDC, Atlanta, GA, USA, 3Univ of North Carolina Proj–Malawi, Lilongwe, Malawi, 4Emory Univ, Atlanta, GA, USA

947  HORMONAL CONTRACEPTION DOES NOT AFFECT ART EFFECTIVENESS OR GENITAL HIV SHEDDING
Rena Patel1, Jared Baeten1, Renee Heffron1, Ting Hong1, Nicole Davis2, Kavita Nanda2, Robert Coombs2, Elizabeth A. Bukusi2, Athena Kourtis2, Nelly Mugo1
1Univ of Washington, Seattle, WA, USA, 2CDC, Atlanta, GA, USA, 3FHI 360, Durham, NC, USA, 4Kenya Med Rsr Inst, Nairobi, Kenya, 5KEMRI, Nairobi, Kenya

Poster P-T3 GENITAL INFECTIONS: MISHAPS AT THE MUCOSA
Poster Hall - 4 EF  2:30 PM - 4:00 PM

948  ASYMPTOMATIC ANAL CHLAMYDIA AND GONORRHEA ARE ASSOCIATED WITH CD8+ T-CELL ACTIVATION
Vinícius A. Vieira1, Natalia B. Cerqueira1, Dayane A. Costa1, Priscilla R. Costa1, Vivian I. Avelino-Silva1, Ricardo D. Vasconcelos2, Jose Valdez Madruga3, Valdirlea Veloso1, Beatrix Grinsztejn1, Esper G. Kallas1
1Univ of Sao Paulo, Sao Paulo, Brazil, 2Centro de Referência e Treinamento DST/AIDS–SP, Sao Paulo, Brazil, 3Osvaldo Cruz Fdn–Fiocruz, Rio de Janeiro, Brazil
MUCOSAL INFLAMMATION ABROGATES TENOFOVIR-GEL–MEDIATED PROTECTION FROM HIV INFECTION

Lyle McKinnon¹, Lenine Liebenberg², Nonhlanhla Yende², Lindi Masson³, Angela Kashuba⁴, Derseree Archary⁴, Quarraisha Abdool Karim², Salim Abdool Karim⁴, Jo-Ann Passmore⁵, for the CAPRISA Mucosal Immunology Collaboration

¹Univ of Manitoba, Winnipeg, Manitoba, Canada, ²CAPRISA, Durban, South Africa, ³Univ of Cape Town, Cape Town, South Africa, ⁴Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

IS SYNDROMIC DIAGNOSIS OF REPRODUCTIVE TRACT INFECTIONS ANTIQUATED IN THE HIV ERA?

Harriet Nuwagaba-Biribonwoha¹, Hannah Chung¹, Asungushe Kayombo¹, Deodatha Mugisha¹, Kokuhumbya Kazaura¹, Oscar Ernest¹, Gissenge J. Lija¹, Deborah Kajoka¹, Jessica E. Justman¹, Elaine J. Abrams¹

¹ICAP at Columbia Univ, New York, NY, USA, ²Natl Inst of Med Rsr, Mwanza, Tanzania, United Republic of, ³CDC Tanzania, Dar es Salaam, Tanzania, ⁴Tanzania Ministry of Hlth, Community Development, Gender, Elderly and Children, Dar es Salaam, Tanzania

FEASIBILITY OF A PHARMACIST-RUN HIV PREP CLINIC IN A COMMUNITY PHARMACY SETTING

Elyse Tung¹, Annalisa Thomas¹, Allyson Eichner¹, Peter Shalit²

¹Kelley-Ross Pharm, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA

ASSESSING THE EFFICACY AND FEASIBILITY OF A RETAIL PHARMACY-BASED HIV TESTING PROGRAM

Bryan C. Collins¹, Heather W. Bronson, Elaine G. Martin

Virginia Dept of Hlth, Richmond, VA, USA

MIDWEST PHARMACISTS’ KNOWLEDGE OF & WILLINGNESS TO PROVIDE PREEXPOSURE PROPHYLAXIS

Jordan Broekhuis¹, Kimberly K. Scarsi, Harlan Sayles, Donald Klepser, Joshua Havens, Susan Swindells, Sara H. Bares

Univ of Nebraska, Omaha, NE, USA

TEXT MESSAGING IS ASSOCIATED WITH IMPROVED RETENTION IN A CLINIC-BASED PREP PROGRAM

Christine M. Khosropour¹, Richard T. Lester², Matthew R. Golden¹, Julia C. Dombrowski¹

¹Univ of Washington, Seattle, WA, USA, ²Univ of British Columbia, Vancouver, British Columbia, Canada

BRIEF BEHAVIORAL INTERVENTION INCREASES PREP DRUG LEVELS IN A REAL-WORLD SETTING

Sarit A. Golub¹, Stephanie Pena², Amy Hilley³, John Pachankis⁴, Asa Radix²

¹City Univ of New York, New York, NY, USA, ²Callen-Lorde Community Hlth Cntr, New York, NY, USA, ³Hunter HIV/AIDS Rsr Team, New York, NY, USA, ⁴Yale Univ, New Haven, CT, USA
Poster P-U3 PREP AWARENESS, TARGETING, AND UPTAKE
Poster Hall - 4 EF
2:30 PM - 4:00 PM

966 FOUR-YEAR TRENDS IN AWARENESS AND USE OF HIV PREP AMONG GBMSM IN VANCOUVER, CANADA
Moliehi Khaketla1, Nathan J. Lachowsky2, Heather L. Armstrong1, Zishan Cui1, Mark Hull1, Paul Sereda2, Robert S. Hogg1, Julio S. Montaner2, Eric Roth2, David Moore1
1Univ of British Columbia, Vancouver, Canada, 2Univ of Victoria, Victoria, Canada, 3BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

967 KNOWLEDGE ABOUT PREP AMONG MSM AND TRANS* METHAMPHETAMINE USERS IN SEATTLE
Vanessa McMahan1, Aleks Martin2, Lindsay Garske3, Jared Baeten1, Caleb Banta-Green1, Joanne Stekler1
1Univ of Washington, Seattle, WA, USA, 2Proj NEON, Seattle, WA, USA

968 A CLINICAL HIV PREEXPOSURE PROPHYLAXIS EDUCATION INTERVENTION AMONG MSM
Julia Raifman1, Catherine E. Oldenburg2, Amy Nunn1, Madeline C. Montgomery1, Alexi Almonte1, Allison Agwu3, Renata Arrington-Sanders3, Philip A. Chan4
1The Johns Hopkins Univ, Baltimore, MD, 2Univ of California San Francisco, San Francisco, CA, USA, 3Brown Univ, Providence, RI, USA, 4Miriam Hosp, Providence, RI, USA

969 PREP GUIDELINES HAVE LIMITED ACCURACY IDENTIFYING YOUNG MSM PRIOR TO SEROCONVERSION
Nicola Lancki, Ellen Almirol, Leigh Alon, Moira McNulty, John A. Schneider
Univ of Chicago, Chicago, IL, USA

970 IDENTIFYING PREGNANT WOMEN FOR PREP USING ROUTINE ANTENATAL CARE INDICATORS IN KENYA
Jillian Pintye1, Benson Singa2, Kennedy Wanyonyi2, Janet Itindi2, John Kinuthia3, Lucy Ng’ang’a3, Agnes Langat4, Abraham Katana4, Christine J. McGrath4, Grace John-Stewart1
1Univ of Washington, Seattle, WA, USA, 2Kenya Med Rsr Inst, Nairobi, Kenya, 3Kenyatta Natl Hosp, Nairobi, Kenya, 4US CDC, Nairobi, Kenya, 5Univ of Texas Med Branch, Galveston, TX, USA

971 PREP UPTAKE DISPARITIES IN A DIVERSE ON-LINE SAMPLE OF US MEN WHO HAVE SEX WITH MEN
Kenneth H. Mayer1, Katie Biello2, David S. Novak1, Douglas Krakower1, Matthew J. Mimiaga2
1Fenway Hlth, Boston, MA, USA, 2Browm Univ, Providence, RI, USA, 3On-Line Buddies, Inc, Cambridge, MA, USA, 4Beth Israel Deaconess Med Cntr, Boston, MA, USA
**Poster Sessions • Wednesday**

**Program and Agenda**

**CROI 2017**

---

**972 IMPACT OF INSURANCE COVERAGE ON PREEXPOSURE PROPHYLAXIS FOR HIV PREVENTION**

Rupa R. Patel¹, Leandro Mena², Amy Nunn³, Timothy McBride¹, Laura C. Harrison¹, Catherine E. Oldenburg⁴, Jingxia Liu⁴, Kenneth H. Mayer⁵, Philip A. Chan⁶

¹Washington Univ in St. Louis, St. Louis, MO, USA, ²Univ of Mississippi, Jackson, MS, USA, ³Brown Univ, Providence, RI, USA, ⁴Univ of California San Francisco, San Francisco, USA, ⁵Fenway Hlth, Boston, USA, ⁶The Miriam Hosp, Providence, RI, USA

---

**973 CONCORDANT POPULATION-LEVEL INCREASES IN PREP FOUND WITH NOVEL PUBLIC HEALTH METHODS**

Susan Buskin¹, Julia Hood¹, Sara N. Glick², Warren Dinges³, Matthew R. Golden²

¹Pub Hlth–Seattle & King County, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA, ³Seattle Infectious Disease Clinic, Seattle, WA, USA

---

**974 RACIAL/ETHNIC DISPARITIES IN PERSISTENCE AMONG PREP USERS IN SAN FRANCISCO**

Hyman Scott¹, Miranda Nordell¹, Anne Hirozawa², Monica Gandhi², Catherine James¹, Hali Hammer¹, Susan Buchbinder³, Susan Scheer¹

¹San Francisco Dept of Pub Hlth, San Francisco, CA, USA, ²Univ of California San Francisco, San Francisco, CA, USA

---

**975 URINE TENOFOVIR TESTING TO MEASURE PREP ADHERENCE AMONG YOUTH IN A REAL WORLD SETTING**

Linden Lalley-Chareczko¹, Devon Clark¹, Ganesh S. Moorthy², Athena Zuppa³, Caitlin Conyngham¹, Karam Mounzer¹, Pablo Tebas³, Helen C. Koenig³

¹Philadelphia FIGHT, Philadelphia, PA, USA, ²Univ of Pennsylvania, Philadelphia, PA, USA, ³Children’s Hosp of Philadelphia, Philadelphia, PA, USA

---

**976 COMBINING MEASURES OF ADHERENCE CAN ASSESS PATTERNS OF PREP DRUG-TAKING**

Andrew M. Abaasa¹, Craig Hendrix², Monica Gandhi³, Peter Anderson⁴, Anatoli Kamali⁵, Eduard Sanders⁶, Gaudensia Mutua⁷, Frances Priddy⁸, Haberer Jessica⁹

¹MRC/UVRI Uganda Rsr Unit on AIDS, Entebbe, Uganda, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³Univ of California San Francisco, San Francisco, CA, USA, ⁴Univ of Colorado, Aurora, CO, USA, ⁵Intl AIDS Vaccine Initiative, New York, NY, USA, ⁶Univ of Nairobi, Nairobi, Kenya, ⁷Cntr for Global Hlth, Massachusetts General Hosp, Boston, MA, USA

---

**977 SUBSTANCE-USING MSM ON HIV PREEXPOSURE PROPHYLAXIS HAVE BETTER ADHERENCE**

Martin Hoenigl¹, Sonia Jain², David J Moore³, Deborah Collins¹, Xiaoying Sun¹, Peter L. Anderson⁴, Katya Calvo⁵, Michael Dube⁶, Sheldon Morris¹, for the California Collaborative Treatment Group (CCTG) 595 Team

¹Univ of California San Diego, San Diego, CA, USA, ²Univ of California San Diego, La Jolla, CA, USA, ³Univ of Colorado Denver, Aurora, CO, USA, ⁴Los Angeles Biomed Rsr Inst at Harbor–UCLA Med Cntr, Torrance, CA, USA, ⁵Univ of Southern California, Los Angeles, CA, USA
978  **OLDER AGE ASSOCIATED WITH BOTH ADHERENCE AND RENAL DECLINE IN THE PREP DEMO PROJECT**

Monica Gandhi¹, Peter Bacchetti¹, Catherine A. Koss¹, Chengshi Jin¹, Howard Horng¹, Richard Eliion¹, Michael Kolber¹, Stephanie E. Cohen¹, Susan Buchbinder¹, Albert Y. Liu⁴

¹Univ of California San Francisco, San Francisco, CA, USA, ²The George Washington Univ, Washington, DC, USA, ³Univ of Miami, Miami, FL, USA, ⁴San Francisco Dept of Pub Hlth, San Francisco, CA, USA

979  **CHANGES IN SEXUAL BEHAVIOR AND STI DIAGNOSES AMONG MSM USING PREP IN SEATTLE, WA**

Michalina A. Montano, Julia C. Dombrowski, Lindley A. Barbee, Matthew R. Golden, Christine M. Khosropour

Univ of Washington, Seattle, WA, USA

980  **LABORATORY TESTING OF A US COHORT OF PRIVATELY INSURED USERS OF HIV PREP, 2011–2014**

Ya-Lin A. Huang, Guoyu Tao, Taraz Samandari, Karen W. Hoover

CDC, Atlanta, GA, USA

981  **BONE CHANGES WITH TDF-CONTAINING AND NON–TDF-CONTAINING PREP IN US MEN AND WOMEN**

Todd Brown¹, Timothy Wilkin², Kenneth H. Mayer³, Raphael J. Landovitz⁴, Ying Q. Chen⁵, Alicia Young⁶, Mark A. Marzinke⁷, Wairimu Chege⁸, Marybeth McCauley⁹, Roy M. Gulick¹⁰

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Weill Cornell Med, New York, NY, USA, ³Fenway Hlth, Boston, MA, USA, ⁴Univ of California Los Angeles Cntr for Clinical AIDS Rsr & Educ, Los Angeles, CA, USA, ⁵Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ⁶Statistical Cntr for HIV/AIDS Rsr and Prevention, Seattle, WA, USA, ⁷NIH, Bethesda, MD, USA, ⁸FHI 360, Washington, DC, USA

Poster P-W1 MEASURING THE GLOBAL HIV CARE CASCADE

Poster Hall - 4 EF 2:30 PM - 4:00 PM

988  **WITHDRAWN**

989  **POPULATION-LEVEL VIRAL-LOAD MONITORING TO MEASURE PROGRESS TOWARDS THE “THIRD 90”**

Maia Lesosky¹, Nei-Yuan M. Hsiao¹, Wolfgang Preiser², Jean Maritz², Landon Myer²

¹Univ of Cape Town, Cape Town, South Africa, ²Stellenbosch Univ, Cape Town, South Africa, ³NHLS, Cape Town, South Africa

990  **CONTEMPORARY DISENGAGEMENT FROM ANTIRETROVIRAL THERAPY IN KHAYELITSHA, SOUTH AFRICA**

Samantha Kaplan¹, Christa Oosthuizen¹, Kathryn Stinson², Francesca Little³, Jonathan Euvrard³, Meg Osler³, Katherine Hilderbrand³, Andrew Boullie³, Graeme Meintjes³

¹Yale Univ Sch of Med, New Haven, CT, USA, ²Univ of Cape Town, Cape Town, South Africa
163

SELF-REPORTED AND BIOMARKER HIV TREATMENT CASCADES FOR OLDER SOUTH AFRICAN ADULTS

Julia K. Rohr1, Jennifer Manne-Goehler2, Xavier Gomez-Olive1, Joshua A. Salomon1, Pascal Geldsetzer1, Ryan Wagner1, Molly Rosenberg1, Chodziwadziwa Kabudula4, Kathleen Kahn1, Till Baernighausen1

1Harvard Univ, Cambridge, MA, USA, 2Beth Israel Deaconess Med Ctr, Boston, MA, USA, 3Tintswalo Hosp, Acornhoek, South Africa, 4Univ of the Witwatersrand, Acornhoek, South Africa, 5Indiana Univ, Bloomington, IN, USA, 6Univ of the Witwatersrand, Johannesburg, South Africa, 7Heidelberg Univ, Heidelberg, Germany

MISDIAGNOSED HIV INFECTION IN PREGNANT WOMEN INITIATING UNIVERSAL ART IN SOUTH AFRICA

Allison Zerbe1, Nei-yuan Hsiao2, Tamsin Phillips1, Kirsty Brittman1, Elaine J. Abrams1, Landon Myer1, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) Study

1ICAP at Columbia Univ, New York, NY, USA, 2Div of Med Virology, Cape Town, South Africa, 3Univ of Cape Town, Cape Town, South Africa

ACCURACY OF HIV AND CD4 FIELD TESTING IN THE BOTSWANA COMBINATION PREVENTION PROJECT

Ebi Bile1, Pamela J. Bachanas2, Fiona Maurice1, Sylvia Modise1, Liziwe Chebani1, Vongai Makovore1, Peter Fonjungo2, Mary Grace Alwano1, William Bapati1, Joseph N. Jarvis1

1US CDC Botswana, Gaborone, Botswana, 2CDC, Atlanta, GA, USA, 3Botswana Ministry of Hlth, Gaborone, Botswana, 4Tebelopele Voluntary Counseling and Testing Cntr, Gaborone, Botswana

PATIENTS’ OUT-OF-POCKET EXPENDITURES FOR ART IN SWAZILAND

Maria Vaikath1, Shaukat Khan2, Emma Mafara2, Ndumiso Dlamini2, Phiwayinkhosi Dlamini2, Nothando Ndzinisa2, Njabulo Simelane2, Velephi Okello1, Till Baernighausen1, Pascal Geldsetzer1

1Harvard Univ, Boston, MA, 2Clinton Hlth Access Initiative, Mbabane, Swaziland, 3Swaziland Ministry of Hlth, Mbabane, Swaziland, 4Heidelberg Univ, Heidelberg, Germany

MARKED MORTALITY AND RETENTION UNDER-REPORTING IN A LARGE HIV PROGRAM IN ZAMBIA

Charles Holmes1, Izukanjii Sikazwe1, Ingrid Eshun-Wilson2, Nancy Czaicki3, Kombatende Sikombe1, Sandra Simbeza1, Carolyn Bolton Moore4, Cardinal Hantuba1, Nancy Padian3, Elvin Geng4

1Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia, 2Stellenbosch Univ, Cape Town, South Africa, 3Univ of California Berkeley, Berkeley, USA, 4Univ of Alabama at Birmingham in Lusaka, Zambia, 5Univ of California San Francisco, San Francisco, CA, USA

DIFFERENTIAL UPTAKE OF HIV CARE AND TREATMENT BY SEXUAL RISK BEHAVIORS

Veena G. Billoux1, Larry W. Chang1, Kate Grabowski1, Steven Reynolds2, Gertrude Nakigozi1, Joseph Sekasanvu1, Robert Ssekubugu1, Ronald H. Gray1, Maria Wawer1, for the Rakai Health Sciences Program

1The Johns Hopkins Univ, Baltimore, MD, USA, 2NIAID, Washington, DC, USA, 3Rakai Hlth Scis Prog, Kalisizo, Uganda
1015 MIGRATION, GENDER, AND HIV INCIDENCE IN RAKAI, UGANDA

Oluwasolape M. Olawore1, Aaron Tobian2, Fred Nalugoda2, Ronald H. Gray1, Maria Wawer1, Robert Sekekubug1, John Santelli1, Larry W. Chang1, David Serwadda4, Kate Grabowski1

1The Johns Hopkins Univ, Baltimore, MD, USA, 2Rakai Hlth Scis Prog. Kalisizo, Uganda, 3Columbia Univ, New York, NY, USA, 4Makerere Univ, Kampala, Uganda

1016 OUTCOMES ALONG THE HIV CARE CONTINUUM AMONG UNDOCUMENTED IMMIGRANTS IN CLINICAL CARE

Jonathan Ross, Uriel Felsen, Chinazo Cunningham, Viraj V. Patel, David B. Hanna

Albert Einstein Coll of Med, Bronx, NY, USA

1017 IMMIGRANTS AND BOTSWANA’S ART PROGRAM: POTENTIAL BARRIERS TO EPIDEMIC CONTROL

Tafireyi Marukutira1, Mary Grace Alwano2, Stephanie Behel2, Joseph N. Jarvis1, Unoda Chakalisa3, Kathleen Powis4, William Bapat1, Gene Ussery6, Refeletswe Lebelonyane5, Pamela J. Bachanas2

1US CDC, Gaborone, Botswana, 2CDC, Atlanta, GA, USA, 3Botswana Harvard Partnership, Gaborone, Botswana, 4Harvard Univ, Boston, MA, USA, 5Tebelopele Voluntary Counseling and Testing Cntr, Gaborone, Botswana, 6Northrop Grumman Corporation, Atlanta, GA, USA, 7Botswana Ministry of Hlth, Gaborone, Botswana

1018 CASCADE OF CARE OF HIV SEROCONVERTERS IN THE CONTEXT OF UNIVERSAL “TEST AND TREAT”

Joseph Larmarange1, Mamadou H. Diallo2, Collins C. Iwuji3, Joanna Orne-Gliemann1, Nuala McGrath4, Mélanie Plazy4, Frank Tanser5, Rodolphe Thiébaut6, Deenan Pillay5, François Dabis6

1IRD, Paris, France, 2Univ Coll London, UK, London, UK, 3INSERM, Bordeaux, France, 4Univ of Southampton, Southampton, UK, 5Africa Hlth Rsr Inst, Mtubatuba, South Africa, 6Univ de Bordeaux, Bordeaux, France

1033 PREP TARGETING STRATEGIES FOR US ADOLESCENT SEXUAL MINORITY MALES: A MODELING STUDY

Steven M. Goodreau1, Deven T. Hamilton1, Patrick Sullivan2, Samuel Jenness3, Rachel A. Kearns2, Li Yan Wang3, Richard Dunville1, Lisa C. Barrios1, Eli Rosenberg2

1Univ of Washington, Seattle, WA, USA, 2Emory Univ, Atlanta, GA, USA, 3CDC, Atlanta, GA, USA

1034 STI INCIDENCE AMONG MSM FOLLOWING HIV PREEXPOSURE PROPHYLAXIS: A MODELING STUDY

Samuel Jenness1, Kevin Weiss1, Steven M. Goodreau2, Thomas Gift1, Harrell Chesson1, Karen W. Hoover1, Dawn K. Smith1, Patrick Sullivan1, Eli Rosenberg1

1Emory Univ, Atlanta, GA, USA, 2Univ of Washington, Seattle, WA, USA, 3CDC, Atlanta, GA, USA
1035  **ANTICIPATED ADHERENCE, EFFICACY, AND IMPACT OF WEEKLY ORAL PREEXPOSURE PROPHYLAXIS**

Christian Selinger1, Ameya Kirtane2, Omar Abouzid2, Robert Langer2, Carlo G. Traverso2, Anna Bershteyn1

1Inst for Disease Modeling, Bellevue, WA, USA, 2Massachusetts Inst of Tech, Cambridge, MA, USA, 3Brigham and Women’s Hosp, Boston, MA, USA

1036  **POPULATION-LEVEL IMPACT AND COST-EFFECTIVENESS OF AN HIV VACCINE IN SOUTH AFRICA**

Christian Selinger1, Anna Bershteyn1, Dobromir Dimitrov1, Timothy B. Hallett1, Linda-Gail Bekker4, Helen Rees5, Glenda Gray6, for the Pox-Protein Public-Private Partnership Global Access Committee

1Inst for Disease Modeling, Bellevue, WA, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 3Imperial Coll London, London, UK, 4Univ of Cape Town, Cape Town, South Africa, 5Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, 6Perinatal HIV Rsr Unit, Soweto, South Africa

1037  **COST-EFFECTIVENESS OF PREEXPOSURE PROPHYLAXIS ACROSS COUNTIES IN WESTERN KENYA**

Anna Bershteyn1, Daniel J. Klein1, Adam N. Akullian1, Zindoga Mukandavire2, Graham F. Medley3, Wanjiru Mukoma3, Michael K. Kiragu3, Kennedy Mutai1, Katharine Kripke2, for the OPTIONS Consortium

1Inst for Disease Modeling, Bellevue, WA, USA, 2London Sch of Hygiene and Trop Med, London, United Kingdom, 3LVCT Hlth, Nairobi, Kenya, 4National AIDS Control Council, Ministry of Hlth, Nairobi, Kenya, 5Avenir Hlth, Washington, DC, USA

1038  **THE POTENTIAL IMPACT AND COST-EFFECTIVENESS OF MULTIPURPOSE PREVENTION TECHNOLOGIES**

Ide Cremin1, Jennifer Smith1, Rebecca Geary2, Timothy B. Hallett1


1039  **THE IMPORTANCE OF A LOCAL PERSPECTIVE IN MONITORING THE SUCCESS OF HIV PREVENTION**

Sarah-Jane Anderson1, Joanne Enstone2, Geoff P. Garnett2, Timothy B. Hallett1

1Imperial Coll London, London, UK, 2Univ of Nottingham, Nottingham, UK, 3Bill and Melinda Gates Fndn, Seattle, WA, USA
166 Detection and Characterization of Cells Expressing HIV RNA by Flow Cytometry
Aaron Christensen-Quick, Amey Mukim, Celsa A. Spina, Sara Gianella, Davey M. Smith
1University of California San Diego, San Diego, CA, USA, 2VA San Diego Healthcare System, San Diego, CA, USA, 3University of California San Diego, La Jolla, CA, USA

167 Inflammation-Regulated Cytokine IL-37 Inhibits HIV-1 Replication in Primary Human CD4
Neel Sangal, Guido Massaccesi, Jeffrey Quinn, Andrea Cox, Matthew Winter, Michael Chattergoon
Johns Hopkins Univ, Baltimore, MD, USA

168 BCA2 Interferes with HIV-1 Transcription by Enhancing the SUMOylation of IKBA
Marta Colomer-Lluch, Ruth Serra-Moreno
Texas Tech Univ, Lubbock, TX, USA

169 Rho Family GTPases Enhance HIV-1 Infection
Mark Lucera, Zach Fleissner, Caroline Tabler, Daniela Schlatzer, Zach Troyer, John Tilton
1University of Colorado, Aurora, CO, USA, 2Case Western Reserve Univ, Cleveland, OH, USA

170 Semen Factors Associated with Semen Viral Load and Infection-Enhancing Activity
Christopher D. Pilcher, Kara Marson, Peter Bacchetti, Sheila Keating, Wendy Hartogensis, Teri Liegler, H. Ewa Witkowska, Satish K. Pillai, Frederick M. Hecht, Nadia R. Roan
1University of California San Francisco, San Francisco, CA, USA, 2Blood Systems Rsr Inst, San Francisco, CA, USA, 3Gladstone Inst of Virology, San Francisco, CA, USA

171LB Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase
Kushol Gupta, Vesa Turkki, Scott Sherrill-Mix, Young Hwang, Grant Eilers, Robert T. Nolte, Emile Velthuisen, Jerry Jeffrey, Gregory Van Duyne, Frederic Bushman
1University of Pennsylvania, Philadelphia, PA, USA, 2Glaxosmithkline, Rsr Triangle Park, NC, USA

166 CROI 2017
178 MEASURING FITNESS OF IN VIVO ESCAPE MUTATIONS IN SIV ENV BY FITSEQ  
Sergio Ita¹, Alison Hill², Evan Lam², Ismael B. Fofana², Welkin E. Johnson²  
¹Univ of California San Diego, La Jolla, CA, USA, ²Boston Coll, Chestnut Hill, MA, USA

179 SIV ESCAPE FROM A VACCINE TARGETING CLEAVAGE SITES IS ASSOCIATED WITH A FITNESS LOSS  
So-Yon Lim¹, David Tang², David La³, Shaun Tyler³, Ben Liang⁴, Francis Plummer⁴, Ma Luo⁴, James Whitney¹  
¹Beth Israel Deaconess Med Cntr, Boston, MA, USA, ²Natl MicroBio Lab, Winnipeg, Canada

180 MUTATIONS IN HIV-1 ENV RESCUE REPLICATION DEFECTS DESPITE POOR CELL-FREE INFECTIVITY  
Rachel Van Duyne, Lillian Kuo, Ken Fujii, Eric O. Freed  
NCI, Frederick, MD, USA

181LB RESISTANCE TO TYPE I INTERFERONS IS A MAJOR DETERMINANT OF HIV-1 TRANSMISSION FITNESS  
Shilpa S. Iyer¹, Frederic Bibollet-Ruche¹, Scott Sherill-Mix¹, Gerald H. Learn¹, Lindsey J. Plenderleithe², Andrew G. Smith¹, Ronnie M. Russell², Paul M. Sharp², Persephone Borrow³, Beatrice H. Hahn¹  

Poster P-B3 TIMING INFECTION AND DEFINING FOUNDER SEQUENCES AND DUAL INFECTIONS
Poster Hall - 4 EF 2:30 PM - 4:00 PM

196 BLIND DATING: PHYLOGENETIC DETERMINATION OF LATENT HIV SEQUENCE AGES WITHIN HOST  
Bradley R. Jones¹, Joshua Horacsek¹, Jeffrey Joy¹, Zabrina Brumme¹, Art Poon¹  
¹Simon Fraser Univ, Burnaby, British Columbia, Canada, ²Univ of British Columbia, Vancouver, British Columbia, Canada

197 HIV-1 SEQUENCES FROM EARLY INFECTION PREDICT THE AGE OF THE INFECTION  
Morgane Rolland¹, Christopher L. Owen¹, Sodsai Tovanabutra¹, Eric Sanders-Buell¹, Lucas Maganga¹, Hannah Kibuuka¹, Sorachai Nitayaphan¹, Fredrick Sawe¹, Merlin L. Robbi¹, Nelson L. Michael¹  
¹US Military HIV Rsr Prog, Silver Spring, MD, USA, ²MMRP, Mbeya, Tanzania, ³Univ of North Carolina, Chapel Hill, Chapel, NC, USA, ⁴AFRIMS, Bangkok, Thailand, ⁵Kenya Med Reseach Inst/Walter Reed Proj, Kericho, Kenya

198 USING PRIMER ID DEEP SEQUENCING TO IDENTIFY RECENT HIV INFECTION IN NORTH CAROLINA  
Shuntai Zhou¹, Christopher Sellers¹, Marc Potempa¹, Scott J. Zimmerman¹, Erkia Samoff¹, William C. Miller¹, Joseph J. Eron¹, Myron S. Cohen¹, Ronald Swanstrom¹, Ann M. Dennis¹  
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²North Carolina State Lab of Pub Hlth, Raleigh, NC, USA, ³North Carolina Div of Pub Hlth, Raleigh, NC, USA, ⁴Ohio State Univ, Columbus, OH, USA
199 CHARACTERIZATION OF RECTAL TRANSMISSION BOTTLENECK USING SIV-MACAQUE MODEL
Zhe Yuan1, Fangrui Ma1, Andrew J. Demers1, Dong Wang2, Jianqing Xu1, Mark G. Lewis1, Qingsheng Li1
1Univ of Nebraska—Lincoln, Lincoln, NE, USA, 2Dow AgroScis, LLC, Indianapolis, IN, USA, 3Fudan Univ, Shanghai, China, 4BIOQUAL, Inc, Rockville, MD, USA

200 HIV-1 SUPERINFECTION AFTER RECENT INFECTION IS UNCOMMON IN SUB-SAHARAN AFRICA
Gabriel A. Wagner1, Parris S. Jordan1, Sergei L. Kosakovsky Pond2, Matt A. Price1, Eric Hunter4, Susan Allen1, William Kilembe1, Douglas D. Richman1, Antoine Chaillon1, for the IAVI
1Univ of California San Diego, La Jolla, CA, USA, 2Temple Univ, Philadelphia, PA, USA, 3Intl AIDS Vaccine Initiative, New York, NY, USA, 4Emory Univ, Atlanta, GA, USA, 5Zambia—Emory HIV Rsr Proj, Atlanta, GA, USA

201 FREQUENT INTRASUBTYPE HIV DUAL INFECTION IN TREATED CHRONICALLY INFECTED INDIVIDUALS
Gabriel A. Wagner1, Antoine Chaillon1, Gemma Caballero2, Donald Franklin1, Sergei L. Kosakovsky Pond2, Robert K. Heaton1, Douglas D. Richman1, Davey M. Smith1, for the CHARTER
1Univ of California San Diego, La Jolla, CA, USA, 2VA San Diego Hlthcare System, La Jolla, CA, USA, 3Temple Univ, Philadelphia, PA, USA

Poster P-C6 CORRELATES OF HIV DISEASE
Poster Hall - 4 EF 2:30 PM - 4:00 PM

228 GENOME-WIDE METHYLATION IS ASSOCIATED WITH HIV-1 INFECTION AND DISEASE PROGRESSION
Sara Moron-Lopez1, Judith Dalmau1, Victor Ureza1, Miguel Lopez2, Maria C. Puertas1, Beatriz Mothe1, Christian Brander1, Manel Esteller2, Maria Berdasco1, Javier Martinez-Picado1
1IrsiCaixa Inst for AIDS Rsr, Badalona, Spain, 2Bellvitge Biomed Rsr Inst, L’Hosp de Llobregat, Spain

229 MITOCHONDRIAL HAPLOGROUP AND HLA-B MAY JOINTLY INFLUENCE HIV VIRAL LOAD AND CD4 COUNT
Samuel Bailin, Mark Pilkinton, David C. Samuels, Silvana Gaudieri, Spyros Kalams, Todd Hulgan
Vanderbilt Univ, Nashville, TN, USA

230 T-CELL PHENOTYPE AND RECEPTOR DIVERSITY IN BLOOD & ADIPOSE TISSUE FROM HIV+ PERSONS
Vanderbilt Univ, Nashville, TN, USA

231 REDUCED APOPTOSIS CONTRIBUTES TO GASTROINTESTINAL NEUTROPHIL INFLTRATION IN HIV
Tiffany Hensley-McBain1, Jennifer Manuzak1, Charlene Miller1, Alexander S. Zevin2, Eric Lee3, Cara Wilson2, Thomas Hope3, Adam Burgener1, Nichole Klett1
1Univ of Washington, Seattle, WA, USA, 2Univ of Colorado Anschutz Med Campus, Aurora, CO, USA, 3Northwestern Univ, Evanston, IL, USA, 4Pub Hlth Agency of Canada, Winnipeg, Canada
**232** HIV INDUCES LIPID ACCUMULATION IN ALVEOLAR MACROPHAGES IN VITRO
Amy K. Dickey1, Bjorn Corleis2, Abigail Schiff3, Antonella Lisante2, Benjamin Medoff1, Josalyn Cho4, Douglas Kwon3
1Massachusetts General Hosp, Boston, MA, USA, 2Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA, 3Harvard Univ, Boston, MA, USA

**233** TIM-3 IS A MARKER OF PDC DYSFUNCTION IN HIV INFECTION
Jordan A. Schwartz1, Kiera L. Clayton1, Shariq Mujib1, Hongliang Zhang1, Nur-ur Rahman1, Jun Liu2, Feng Yun Yue1, Erika Benko1, Colin Kovacs1, Mario Ostrowski1
1Univ of Toronto, Toronto, Canada, 2Maple Leaf Med Clinic, Toronto, Canada

**234** IMMUNE CHECKPOINT MOLECULES IN HIV AND AGING
Lesley R. de Armas, Suresh Pallikkuth, Sidney Lane, Rajendra Pahwa, Varghese George, Stefano Rinaldi, Margaret Fischl, Gordon Dickinson, Allan Rodriguez, Savita Pahwa
Univ of Miami, Miami, FL, USA

**235** SOLUBLE UPAR PREDICTS ALL-CAUSE MORTALITY FROM HIV-1 INFECTION
Ditte M Kirkegaard-Klitbo, Anne Langkilde, Niels Mejer, Ove Andersen, Jesper Eugen-Olsen, Thomas Benfield
Hvidovre Hosp, Hvidovre, Denmark

**236** R5-TROPIC HIV RESISTANCE IN A SUBSET OF ELITE AND VIREMIC CONTROLLERS
Elena Gonzalez-Gil, Patrick Rapuano, Jimmy Auer, Zach Porterfield, Uchenna Ikediobi, Ayse Coskun, Richard Sutton
Yale Univ, New Haven, CT, USA

**237** MULTI-ANCESTRY GWAS IDENTIFIES NOVEL VARIANTS ASSOCIATED WITH HIV-1 VIRAL LOAD
Eric O. Johnson1, Dana B. Hancock1, Nathan C. Gaddis1, Christina A Markunas1, Yuelong Guo1, Elizabeth T. Golub1, Mardge H. Cohen1, Kathryn Anastos1, Ruth Greenblatt2, Bradley E. Aouizerat6
1RTI Intl, Rsr Triangle Park, NC, USA, 2Johns Hopkins Univ, Baltimore, MD, USA, 3Stroger Hosp, Chicago, IL, USA, 4Albert Einstein Coll of Med, Bronx, NY, USA, 5Univ of California San Francisco, San Francisco, CA, USA, 6New York Univ, New York, NY, USA

**238** 18F-FDG-PET/CT ABNORMALITIES ARE ASSOCIATED WITH HIGHER RISK OF IRIS IN HIV
Dima A. Hammoud1, Georgios Z. Papadakis1, Afroditi Boulougoura2, Virginia Sheikhi1, Lori E. Dodd3, Jing Wang1, Angela Kibiy6, JoAnn Micana, Corina Millo1, Irini Sereti1
1NIH, Bethesda, MD, USA, 2NIAID, Bethesda, MD, USA, 3FDA, Silver Spring, MD, USA, 4NIH, Bethesda, MD, USA, 5Leidos Biomed Rsr, Rockville, MD, USA, 6Leidos Biomed Rsr, Bethesda, MD, USA

**239** MAIT CELLS, MICROBIAL TRANSLOCATION AND THE MICROBIOME IN HIV/HCV CHRONIC INFECTIONS
Esther Merlini1, Maddalena Cerrone1, Bonnie van Wilgenburg2, Leo Swadling2, Camilla Tincati1, Elvira S. Cannizzo1, Antonella d’Arminio Monforte1, Paul Klenerman2, Giulia Marchetti1
1Univ of Milan, Milan, Italy, 2Univ of Oxford, Oxford, UK
240 IMPACT OF MUCOSAL CMV AND EBV REPLICATION ON ENTERIC MICROBIOME DURING HIV INFECTION
Antoine Chaillon1, Sara Gianella2, Ece A. Mutlu3, Phillip A. Engen3, Robin M. Voigt1, Ali Keshavarzian1, John Losurdo1, Steven Lada2, Masato Nakazawa3, Alan Landay1
1Univ of California San Diego, San Diego, CA, USA, 2Univ of California San Diego, La Jolla, CA, 3Rush Univ Med Cntr, Chicago, IL, USA

241 EFFECT OF HIV STATUS, CMV, AND EBV REPLICATION ON MUCOSAL GENE EXPRESSION IN THE GUT
Sara Gianella1, Antoine Chaillon2, Ece A. Mutlu3, Phillip A. Engen3, Robin M. Voigt1, Ali Keshavarzian1, John Losurdo1, Steven Lada2, Masato Nakazawa3, Alan Landay1
1Univ of California San Diego, La Jolla, CA, USA, 2Univ of California San Diego, San Diego, CA, USA, 3Rush Univ, Chicago, IL, USA

251 TELMISARTAN DOES NOT IMPROVE LYMPH NODE OR FAT FIBROSIS IN TREATED HIV INFECTION
Netanya S. Utay1, Douglas Kitch2, Carl Fichtenbaum1, Michael M. Lederman1, Jacob D. Estes2, Clara Magyar3, Karin Klingman4, Judith S. Currier5, Jordan E. Lake6, for the A5317 Team
1Univ of Texas, Galveston, TX, USA, 2Harvard Univ, Boston, MA, USA, 3Univ of Cincinnati, Cincinnati, OH, USA, 4Case Western Reserve Univ, Cleveland, OH, USA, 5Frederick Natl Lab for Cancer Rsr, Frederick, MD, USA, 6Univ of California Los Angeles, Los Angeles, CA, USA

252 PHARMACOLOGIC INHIBITION OF IDO BLUNTS FEATURES OF SIV-RELATED CHRONIC INFLAMMATION
Richard M. Dunham1, Kevin W. Brown1, James M. Billingsley2, Zhong-Min Ma3, Gregory K. Tharp4, Christopher J. Miller4, Steven E. Bosinger5, Brian A. Johns1, David Favre1
1GlaxoSmithKline, Durham, NC, USA, 2Yerkes Natl Primate Rsr Cntr, Atlanta, GA, USA, 3Univ of California Davis, Davis, CA, USA

253 HIV-SPECIFIC ANTIBODIES ENHANCE TYPE I INTERFERON PRODUCTION FROM PLASMACYTOID DCS
Rebecca Veenhuis1, Zachary Freeman1, Jack Korleski1, Alessandra Tomasi1, Austin Boesch2, Margaret Ackerman1, Joseph B. Margolick1, Joel Blankson1, Michael Chattergoon1, Andrea Cox1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Dartmouth Coll, Hanover, NH, USA

254 TARGETING TYPE I INTERFERON-MEDIATED IMMUNE ACTIVATION TO CONTROL HIV INFECTION
Anjie Zhen1, Mayra A. Carrillo1, Valerie Rezek1, David Brooks2, Scott G. Kitchen1
1Univ of California Los Angeles, Los Angeles, CA, USA, 2Princess Margaret Cancer Cntr, Toronto, Ontario, Canada

255 METFORMIN REDUCES T-CELL EXHAUSTION IN A CLINICAL TRIAL OF HIV-INFECTED ADULTS ON ART
Glen Chew1, Dominic Chow1, Scott A. Souza1, Lindsay Kohorn1, Richard M. Watanabe1, Ivo Sah Bandara1, Eun-Young Park1, Mary Margaret Byron1, Lishomwa C. Ndhlovu2, Cecilia Shikuma1
1Univ of Hawaii, Honolulu, HI, USA, 2Univ of Southern California, Los Angeles, CA, USA
256  P2X PURINERGIC RECEPTORS AS THERAPEUTIC TARGETS OF HIV-1 INFECTION AND INFLAMMATION
Talia Swartz¹, Natasha Durham¹, Alexandra Soare¹, Meagan O’Brien¹, Nina Bhawardj¹, Benjamin K. Chen¹
¹Icahn Sch of Med at Mt Sinai, New York, NY, USA, ²Tufts Univ, Boston, MA, USA

257  AGE AND HIV DO NOT SYNERGISTICALLY IMPACT T-CELL MATURATION OR ACTIVATION
Shelli Farhadian¹, Emilie Jalbert², Yanhong Deng³, Matthew B. Goetz⁴, Lesley Park⁵, Amy Justice⁵, Robert Dubrow⁵, Brinda Emu⁶, for the VACS Project Team
¹Yale Univ, New Haven, CT, USA, ²Univ of Colorado, Aurora, CO, USA, ³VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, ⁴Stanford Med, Stanford, CA, USA, ⁵VA Connecticut Hlthcare System, West Haven, CT, USA

258  CELLULAR IMMUNE ACTIVATION IN THE ERA OF CART AND AN AGING HIV+ POPULATION
Lesley R. de Armas¹, Suresh Pallikkuth, Rajendra Pahwa, Stefano Rinaldi, Varghese George, Li Pan, Allan Rodriguez, Margaret Fischl, Gordon Dickinson, Savita Pahwa
Univ of Miami, Miami, FL, USA

259  ADAR1, A TARGET TO BOOST HIV-1 IMMUNE RESPONSE
Maria Pujantell¹, Ester Ballana, Eva Riveira-Muñoz, Bonaventura Clotet, Jose A. Este
IrsiCaixa Inst for AIDS Rsr, Badalona, Spain

260LB  LIVER INFLAMMATION CORRELATES WITH SIV LEVELS AND IS ONLY PARTLY REVERSED WITH CART
Bridget Fisher¹, Rachel Brown¹, Matthew Wood¹, Richard Green², Cole Fisher¹, Michael Gale², Guido Silvestri², Ann Chahroudii³, Nichole Klatt², Donald Sodora³
¹Cntr for Infectious Disease Rsr, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA, ³Emory Univ, Atlanta, GA, USA

Poster P-D3 CD4 T CELLS: MORE THAN JUST HELP
Poster Hall - 4 EF  2:30 PM - 4:00 PM

261  CD57+ CYTOTOXIC CD4+ EFFECTOR T CELLS INCREASE IN CHRONIC HIV INFECTION
Chansavath Phetsouphanh¹, Jodi Meyerowitz¹, Lyle Murray¹, Dominique Goedhals², Cloete Van Vuuren², Sarah Fidler², Paul Klenerman¹, John Frater¹

262  TARGETING LC WITH ANTI-LANGERIN HIV FUSION MONOCLONAL AB PROMOTES TFH DIFFERENTIATION
Jérôme Kervevan¹, Aurélie Chaigneau¹, Sandy Zurawski², Marion Bonnet³, Romain Marlin¹, Marie-Thérèse Nugeyre¹, Elisabeth Menu¹, Gerard Zurawski², Yves Levy¹, Sylvain Cardinaud¹
¹INSERM, Créteil, France, ²Baylor Inst for Immunol Rsr, Dallas, TX, USA, ³Univ of Cardiff, Cardiff, UK, ¹Inst Pasteur, Paris, France

263  HIV-1-INFECTION–ASSOCIATED CHANGES IN THE HUMAN CD4+ T-CELL PROTEOME
Johannes Nemeth¹, Valentina Vongrad¹, Karin Metzner¹, Victoria P. Strouvelle², Rainer Weber², Patrick Pedrioli², Ruedi Aebersold¹, Huldrych F. Günthard², Ben Collins¹
¹Cntr for Infectious Disease Rsr, Seattle, WA, USA, ²Univ of Zürich, Zürich, Switzerland, ³ETH Zürich, Zürich, Switzerland

Poster Sessions • Thursday
CROI 2017  171
CHARACTERIZATION OF PREEXISTING HIV-SPECIFIC CD4 T CELLS IN UNINFECTED INDIVIDUALS
Audrey Daigneault¹, Nathalie Brassard², Amy E. Baxter¹, Lucie Barblu¹, Colin Havenar-Daughton¹, Roxanne Charlebois¹, Jean-Pierre Routy¹, Shane Crotty¹, Daniel E. Kaufmann¹
¹Cntr de Rsr du Cntr Hosp de l’Univ de Montréal, ²La Jolla Inst for Allergy and Immunol, La Jolla, CA, USA, ³McGill Univ Hlth Cntr, Glen site, Montréal, Canada

TFH CELLS FUNCTIONAL PROFILE DRIVES ABNORMAL B CELL MATURATION IN HIV INFECTION
Giuseppe Pantaleo¹, Alessandra Noto¹, Andrew McDavid², Phu Van³, Agostino Riva¹, Guy Cavet², Song Ding³, Raphael Gottardo¹, Craig Fenwick¹
¹Univ Hosp of Lausanne, Lausanne, Switzerland, ²FRCHC, Seattle, WA, USA, ³Luigi Sacco Univ Hosp, Milan, Italy, Milano, Italy, ⁴Areca, Redwood City, CA, USA, ⁵Eurovacc Foundation, Amsterdam, Netherlands

CHARACTERIZING THE HIV RESERVOIR
Soluble biomarkers in acute HIV infection reveal insight into HIV reservoir
Jeffrey E. Teigler¹, Bonnie Silke¹, Nicolas Chomont¹, Eugene Kroon¹, Merlin L. Robb¹, Jintanat Ananworanich¹, Nelson L. Michael¹, Hendrik Streeck¹, Shelly J. Krebs¹, for the RV254/RV217 Study Groups
¹US Military HIV Rsr Prog, Silver Spring, MD, USA, ²Univ de Montréal, Montréal, QC, Canada, ³SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁴Inst for HIV Rsr, Essen, Germany

FAST VALIDATION TO STUDY THE BASELINE AND INDUCIBLE HIV RESERVOIR
Marilia R. Pinzone¹, Xiaohe Liu², Lidia Sambucetti², Giuseppe Nunnari³, Una O’Doherty¹
¹Univ of Pennsylvania, Philadelphia, PA, USA, ²SRI Intl, Menlo Park, USA, ³Univ of Messina, Messina, Italy

HOST TRANSCRIPTOMIC DETERMINANTS OF HIV PERSISTENCE IN VIVO
Mohamed Abdel Mohsen¹, Xutao Deng¹, Sheila Keating¹, Andrew Worlock¹, Christopher D. Pilcher¹, Michael P. Busch¹, Steven G. Deeks¹, Satish K. Pillai¹
¹Blood Systems Rsr Inst, San Francisco, CA, USA, ²Hologic Corporation, Bedford, MA, USA, ³Univ of California, San Francisco, San Francisco, CA, USA

LOW INDUCIBILITY OF THE HIV RESERVOIR IN EARLY ART-TREATED THAI CHILDREN
Marta Massanella¹, Jintanat Ananworanich¹, Louise Leyre¹, Thidarat Jupimai², Mark de Souza³, Piyarat Suntarattiwong³, Pope Kosalaraka³, Thanyawee Puthanakit³, Nicolas Chomont³, for the HIVNAT’209 and HIVNAT’194 Study Groups
¹Cntr de Rsr du Cntr Hosp de l’Univ de Montréal, Montréal, Canada, ²Henry M. Jackson Fndn for the Advancement of Military Med, Bethesda, MD, USA, ³HIV—NAT Rsr Collab, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁴SEARCH, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁵Queen Sirikit Natl Inst of Child Hlth, Bangkok, Thailand, ⁶Khon Kaen Univ, Khon Kaen, Thailand, ⁷Chulalongkorn Univ, Bangkok, Thailand

CELL-ASSOCIATED HIV RNA PREDICTS POSTTREATMENT HIV CONTROL AND CD4+ T-CELL LOSS
Alexander Pasternak, Jan Prins, Ben Berkhout
Univ of Amsterdam, Amsterdam, Netherlands
287 PRE-ART TUBERCULOSIS AND TB-IRIS AFFECT THE HIV-1 RESERVOIR
Camille Lange1, Maura Manion2, Gregg Roby1, Rob Gorelick5, Virginia Sheikh4, Joseph Adelsberger4, Frank Maldarelli2, Irini Sereti1
1NCI, Frederick, MD, USA, 2NIAID, Bethesda, MD, USA, 3NIH, Rockville, MD, USA, 4AIDS and Cancer Virus Prog, Frederick, MD, USA, 5FDA, Silver Spring, MD, USA, 6Leidos Biomed Rsr, Inc, Frederick, MD, USA

292 CLONAL EXPANSION OF GENOME-INTACT HIV-1 IN FUNCTIONALLY POLARIZED T-CELL SUBSETS
Guinevere Q. Lee1, Nina Orlova1, Erik Serra2, Xiaoming Sun1, Navin F. Chowdhury1, Eric Rosenberg1, Alan N. Engelmann2, Xu G. Yu1, Mathias Lichterfeld1
1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, 2Dana-Farber Cancer Inst, Boston, MA, USA, 3Massachusetts General Hosp, Boston, MA, USA, 4Brigham and Women’s Hosp, Boston, MA, USA

293 INTACT PROVIRUSES ARE UNEQUALLY DISTRIBUTED IN T CELL SUBSETS DURING ART
Bonnie Hiener1, Bethany A. Horsburgh1, John-Sebastian Eden2, Kirston Barton1, Eunok Lee1, Steven G. Deeks1, Jeffery Milush1, Nicolas Chomont1, Rémi Fromentin1, Sarah Palmer1
1The Westmead Inst for Med Rsr, Westmead, Australia, 2The Univ of Sydney, Sydney, Australia, 3Univ of California San Francisco, San Francisco, CA, USA, 4Univ de Montréal, Montreal, QC, Canada

294 A SMALL FRACTION OF PROVIRUSES IN EXPANDED CLONES EXPRESS UNSPLICED HIV RNA IN VIVO
Andrew Musick1, Jonathan Spindler1, Brandon Keele2, Michael J. Bale1, Wei Shao1, Ann Wiegand1, John Mellors1, John Coffin1, Frank Maldarelli1, Mary F. Kearney1
1NCI, Frederick, MD, USA, 2Leidos Biomed, Inc, Frederick, MD, USA, 3Univ of Pittsburgh, Pittsburgh, PA, USA, 4Tufts Univ, Boston, MA, USA

295 PROLIFERATION OF CD4+ T CELLS CONTAINING REPLICATION-COMPETENT HIV-1
Zheng Wang, Ya-Chi Ho, Janet Siliciano, Robert Siliciano
Johns Hopkins Univ, Baltimore, MD, USA

296 CYTOTOXIC LYMPHOCYTES MAY SHAPE THE HIV-1 PROVIRAL LANDSCAPE
R. Brad Jones1, Mihaela Pertea1, Katherine Bruner1, Ross Pollack2, Adam Capoferri1, Robert Siliciano2, Ya-Chi Ho2
1The George Washington Univ, Washington, DC, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA

297 DYNAMICS OF HIV CLONAL EXPANSION AND PERSISTENCE DURING ART
Elizabeth M Anderson1, Shawn Hill1, Jennifer Bell1, Francesco R. Simonetti1, Cathy Rehm1, Sara Jones4, Rob Gorelick5, John Coffin2, Frank Maldarelli1
1NCI, Frederick, MD, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3NIAID, Bethesda, MD, USA, 4Leidos Biomed Rsr, Inc, Frederick, MD, USA, 5Tufts Univ, Boston, MA, USA
298 CLONES OF HIV-INFECTED CELLS ARISE IN VIVO IN THE FIRST FEW WEEKS FOLLOWING INFECTION

David Wells1, Jennifer M. Zerbato2, Joann D. Kuruc3, Joseph J. Eron3, Mary F. Kearney2, John Coffin4, Frank Maldarelli1, Xiaolin Wu1, John W. Mellors3, Stephen H. Hughes3

1Liedos Biomed Rsr, Inc, Frederick, MD, USA, 2Univ of Pittsburgh, Pittsburgh, PA, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4NCI, Frederick, MD, USA, 5Tufts Univ, Boston, MA, USA

299LB RESURGENCE OF HIV-1 FOUNDER VIRUSES FOLLOWING ANTIRETROVIRAL TREATMENT INTERRUPTION

Morgane Rolland1, Eric Sanders-Buell1, Meera Bose1, Nittaya Phanuphak1, Mark de Souza2, Nelson L. Michael1, Merlin L. Robbi2, Jintanat Ananworanich1, Sodsai Tovanabutra1, for the RV254/SEARCH 010 Study Groups

1US Military HIV Rsr Prog, Silver Spring, MD, USA, 2Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 3SEARCH, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand

Poster P-E8 MODIFYING THE RESERVOIR: CLINICAL STUDIES

Poster Hall - 4 EF 2:30 PM - 4:00 PM

323 HIV-1 DNA BLOOD RESERVOIRS ARE NOT ALTERED BY HIGH-DOSE CHEMOTHERAPY FOR LYMPHOMA

Heloise M. Delagreverie1, Antoine Chaillon2, Laurence Gerard1, Marie-Laure Néré1, Romain Palich1, Sylvain Chawki1, Lionel Galicier1, Eric Oksenhaendler1, Marie-Laure Chaix Baudier1, Constance Delaugerre1

1Saint Louis Hosp, Paris, France, 2Univ of California San Diego, San Diego, CA, USA, 3Pitié-Salpêtrière Hosp, Paris, France

324 THE IMPACT OF IMMUNOGLOBULIN IN PRIMARY HIV INFECTION ON THE HIV RESERVOIR

Juan Tiraboschi1, Prabhjeet Phalora1, Nicola Robinson2, Emily Hopkins2, Steve Kaye1, Jeremy Sanderson1, Sarah Fidler1, Paul Klenerman2, John Frater1, Julie Fox1


325 RATES OF VIRAL DECAY IN HIV-1 CONTROLLERS INITIATING ANTIRETROVIRAL THERAPY

Jonathan Li1, Heloise M. Delagreverie2, Rachel Getz1, Christina Lalama2, Ronald Bosch1, Daniel R. Kuritzkes1, Alan Landay4, Florence Pereyra1, Paul E. Sax1, for the AIDS Clinical Trials Group A5308 Study Team

1Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA, 2Saint Louis Hosp, Paris, France, 3Harvard Univ, Boston, MA, USA, 4Rush Univ Med Cntr, Chicago, IL, USA

326 PEGYLATED IFN-ALPHA-2B DECREASES LATENT HIV MEASURES IN ART-SUPPRESSED SUBJECTS

Livio Azzoni1, Emmanouil Papasavvas1, Nicolas Chomont2, Qingsheng Li3, Bonnie J. Howell1, Douglas D. Richman2, Pablo Tebas2, Karam Mounzer1, Jay Kostman1, Luis Montaner1

1Wistar Inst, Philadelphia, PA, USA, 2Univ de Montréal, Montreal, QC, Canada, 3Univ of Nebraska, Lincoln, NE, USA, 4Merck & Co, Inc, West Point, PA, USA, 5Univ of California San Diego, La Jolla, CA, USA, 6Univ of Pennsylvania, Philadelphia, PA, USA, 7Philadelphia FIGHT, Philadelphia, PA, USA, 8Philadelphia FIGHT Community Hlth Cntrs, Philadelphia, PA, USA
327  **EFFECTS OF PEG-IFNa ON THE HIV-1 DNA LEVELS IN HIV-1/HCV COINFECTED INDIVIDUALS**
Victoria P. Strouvelle, Valentina Vongrad, Dominique L. Braun, Yik Lim Kok, Roger Kouyos, Karin Metzner, Huldrych F. Günthard, for the Swiss HIV Cohort Study
Univ of Zürich, Zürich, Switzerland

328  **IN VIVO CONTROL OF HIV INFECTION BY AN ENGINEERED BI-SPECIFIC ANTI-HIV FUSION PROTEIN**
Ariola Bardhi, Weizao Chen, Yanping Wang, Jennifer Jones, John C. Kappes, Christina Ochsenbauer, Dimitr S. Dimitrov, Harris Goldstein
1Albert Einstein Coll of Med, Bronx, NY, USA, 2NIH, Frederick, MD, USA, 3Univ of Alabama at Birmingham, Birmingham, AL, USA

329  **PGT121 ANTIBODY ENGINEERING: ENHANCED INFECTED CELL KILLING AND DRUG-LIKE PROPERTIES**
Mini Balakrishnan, Nathan D. Thomsen, Craig S. Pace, Yue Zhang, Magdeleine Hung, Mark R. Nagel, Brian A. Carr, Y. E. Hu, Helen Yu, John A. Corbin
Gilead Scis, Inc, Foster City, CA, USA

330LB  **VRC01 INFUSION HAS NO EFFECT ON HIV-1 PERSISTENCE IN ART-SUPPRESSED CHRONIC INFECTION**
Sharon Riddler, Christine Durand, Lu Zheng, Justin Ritz, Richard A. Koup, Julie Ledgerwood, Bernard Macatangay, Joshua C. Cytkor, John W. Mellors, for the ACTG A5342 Protocol Team
1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Johns Hopkins Univ, Baltimore, MD, USA, 3Harvard Univ, Boston, MA, USA, 4NIAID, Bethesda, MD, USA

---

**Poster P-F1 THE CNS AND SYSTEMATIC IMMUNE ACTIVATION**
Poster Hall - 4 EF  2:30 PM - 4:00 PM

339  **HEIGHTENED SYSTEMIC AND CNS IMMUNE ACTIVATION IN ACUTE HIV INFECTION WITH SYPHILIS**
Phillip Chan, Donn Colby, Eugene Kroon, Victor Valcour, Napapon Sailsata, Joanna Hellmuth, Shelly J. Krebs, Jintanat Ananworanich, Serena Spudich, for the RV254/SEARCH 010 Study Group
1SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 2Univ of California San Francisco, San Francisco, USA, 3Univ of Hawaii, Honolulu, HI, USA, 4US Military HIV Rsr Prog, Silver Spring, MD, USA, 5Yale Univ, New Haven, CT, USA

340  **CNS INFLAMMATION STILL PRESENT AFTER >10 YEARS OF EFFECTIVE ANTIRETROVIRAL THERAPY**
Gustaf O. Hammarlund, Arvid Edén, Åsa Mellgren, Dietmar Fuchs, Henrik Zetterberg, Lars Hagberg, Staffan Nilsson, Aylin Yilmaz, Magnus Gisslen
1Univ of Gothenburg, Gothenburg, Sweden, 2South Älvsborgs Hosp, Borås, Sweden, 3Innsbruck Med Univ, Innsbruck, Austria, 4Chalmers Univ of Tech, Gothenburg, Sweden

341  **MONOCYTE ACTIVATION IS ASSOCIATED WITH COGNITION IN SUPPRESSED HIV-INFECTED WOMEN**
Brandon M. Imp, Leah H. Rubin, Phyllis Tien, Michael Plankey, Elizabeth T. Golub, Audrey French, Victor Valcour, for the Women’s Intergency HIV Study (WIHS)
1Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ, USA, 2Univ of Illinois at Chicago, Chicago, IL, USA, 3Univ of California San Francisco, San Francisco, CA, USA, 4Georgetown Univ, Washington, DC, 5The Johns Hopkins Univ, Baltimore, MD, USA, 6Rush Univ, Chicago, IL, USA
342 SYSTEMIC INFLAMMATORY AND IMMUNE BIOMARKERS IN NEUROCOGNITIVE CHANGE WITH INITIAL ART

Kevin Robertson1, Sachiko Miyahara2, Alan Landay1, Todd Brown4, Carl Fichtenbaum1, Joseph J. Eron6, Athie Tsibris1, Babafemi Taiwo8, for the ACTG 5303 team

1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Harvard Univ, Boston, MA, USA, 3Rush Univ, Chicago, IL, USA, 4The Johns Hopkins Univ, Baltimore, MD, USA, 5Univ of Cincinnati, Cincinnati, OH, USA, 6Massachusetts General Hosp, Cambridge, MA, USA, 7Northwestern Univ, Chicago, IL, USA

343 IMPACT OF ADVANCING AGE ON COGNITION IN HIV+ PERSONS ON A FIRST SUPPRESSIVE REGIMEN

Hamza Coban1, Kevin Robertson2, Kunling Wu3, Ronald Bosch3, Ronald J. Ellis1

1Univ of California San Diego, La Jolla, CA, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Harvard Univ, Boston, MA, USA, 4Univ of California, San Diego, CA, USA

344 WITHDRAWN

345 IMMUNE MARKERS OF CRYPTOCOCCAL REACTIVATION IN HIV INFECTION

Admire Hlupeni1, Kathryn F. Boyd2, Azure T. Makadzange3, Chiratidzo E. Ndhlovu1

1Univ of Zimbabwe, Harare, Zimbabwe, 2Infectious Disease Rsr Lab, Harare, Zimbabwe, 3Massachusetts General Hosp, Cambridge, MA, USA

Poster P-F3 NEUROCognitive Functioning, Viral Suppression, and Associated Risks

Poster Hall - 4 EF 2:30 PM - 4:00 PM

349 HIV NEUROLOGICAL DISORDERS CAN OCCUR IN PATIENTS WITH SUPPRESSED HIV-1 VL IN PLASMA

Cathia Soulie1, Maxime Grudé2, Corinne Amiel1, Laurence Morand-Joubert4, Stephanie Raymond4, Coralie Pallier4, Pantxika Bellecave7, Diane Descamps8, Anne-Geneviève Marcelin1, for the ANRS Resistance AC11 Group

177

350 COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION
Leah H. Rubin¹, Gayle Springer², Pauline M. Maki³, Kathryn Anastos¹, Deborah Gustafson⁴, Maria Villacres⁵, Drena Waldrop-Valverde⁶, David Vance⁷, Hector Bolivar⁸, Victor Valcour⁹
¹Univ of Illinois at Chicago, Chicago, IL, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³Albert Einstein Coll of Med, Bronx, NY, USA, ⁴SUNY Downstate Med Cntr, Brooklyn, NY, USA, ⁵Univ of Southern California, Los Angeles, CA, USA, ⁶Emory Univ, Atlanta, GA, USA, ⁷Univ of Alabama at Birmingham, Birmingham, AL, USA, ⁸Univ of Miami, Miami, FL, USA, ⁹Univ of California San Francisco, San Francisco, CA, USA

351 COGNITIVE TRAJECTORIES IN SUPPRESSED HIV INFECTION INDICATE EVOLVING DISEASE ACTIVITY
Chloe Gott¹, Thomas Gates², Nadene Dermody³, Bruce Brew⁴, Lucette Cysique⁵
¹Macquarie Univ, North Ryde, NSW, Australia, ²St Vincent’s Hosp, Sydney, Darlinghurst, NSW, Australia, ³Univ of New South Wales, Darlinghurst, NSW, Australia, ⁴NeuroSci Rsr Australia, Randwick, NSW, Australia

352LB LONGITUDINAL ANALYSIS SHOWS NO EVIDENCE FOR ACCELERATED BRAIN AGING IN TREATED HIV
James H. Cole¹, Matthain W. Caan², Jonathan Underwood¹, Rosan van Zoest³, Davide De Francesco⁴, Alan Winston¹, Caroline Sabin¹, David J. Sharp¹, Peter Reiss⁵, for the CO-morBidity in Relation to AIDS (COBRA) Collaboration
¹Imperial College London, London, United Kingdom, ²Academic Medical Center Amsterdam, Amsterdam, Netherlands, ³Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands, ⁴UCL, London, UK, ⁵Stichting HIV Monitoring and Academic Medical Center Amsterdam, Amsterdam, Netherlands

353 DECREASE IN EXECUTIVE FUNCTION IS ASSOCIATED WITH DETECTABLE PLASMA HIV DURING CART
Albert Anderson¹, Josue Perez-Santiago², Andrea Knezevic¹, Xiaohie Yang¹, Eugene Huang¹, Jennifer Ludicello², David Moore³, Ronald J. Ellis⁴, Robert K. Heaton⁵, Scott Letendre⁶
¹Emory Univ, Atlanta, GA, USA, ²Univ of California San Diego, San Diego, CA, USA, ³Univ of California at San Diego, La Jolla, CA, USA

354 DAA IMPROVE VACS BUT DO NOT INFLUENCE COGNITIVE IMPAIRMENT IN HIV/HCV COINFECTED
Ilaria Mastrorosa, Patrizia Lorenzini, Martina Ricottini, Gabriele Fabbri, Pietro Balestra, Alessandra Vergori, Carmela Pinnetti, Mauro Zaccarelli, Adriana Ammassari, Andrea Antinori
Nati Inst for Infectious Diseases, Rome, Italy

355 LIMITATIONS OF THE INTERNATIONAL HIV DEMENTIA SCALE IN THE CURRENT ERA
Benedetta Milanini¹, Emmanuel Bahemana², Babajide Keshinro Keshinro¹, Francis Kiweewa², Rither Langat², Winnie Rehema², Isabel E. Allen¹, Christina Polyak², Julie Ake², Victor Valcour¹
¹Univ of California San Francisco, San Francisco, CA, USA, ²Walter Reed Prog—Tanzania, Mbeya, Tanzania, United Republic of, ³Walter Reed Prog—Nigeria, Abuja, Nigeria, ⁴Makerere Univ Walter Reed Proj, Kampala, Uganda, ⁵KEMRI/Walter Reed Proj, Kericho, Kenya, ⁶KEMRI/Walter Reed Proj, Kisumu, Kenya, ⁷US Military HIV Rsr Prog, Bethesda, MD, USA
356  EFFECTS OF AGE AND OBESITY ON NEUROCOGNITIVE PERFORMANCE IN THE MACS COHORT

Kristine Erlandson1, Long Zhang2, Lisa Jacobson2, James T. Becker1, Cynthia Munro1, Jordan E. Lake1, Eileen Martin1, Andrew Levine2, Todd Brown2, Ned Sacktor2

1Univ of Colorado, Aurora, CO, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA

357  CSF TO PLASMA HIV-RNA RATIO ≥1 IS ASSOCIATED WITH HAND IN UNTREATED HIV PATIENTS

Francesca Bai, Francesca Iannuzzi, Esther Merlino, Lidia Borghi, Teresa Bini, Giulia Marchetti, Antonella d’Arminio Monforte

Univ of Milan, Milan, Italy

358  POST-TRAUMATIC STRESS AND NEUROCOGNITIVE IMPAIRMENT IN A US MILITARY COHORT

Robert Deiss1, Raeanne Moore2, Nancy Crum-Cianflone3, Scott Letendre2, Anuradha Ganesan1, Jason Okulicz1, Mary F. Bavaro4, David J. Moore3, Brian K. Agan1

1Uniformed Services Univ of the Hlth Scis, Rockville, MD, USA, 2Univ of California San Diego, San Diego, CA, USA, 3Infectious Disease Service, San Antonio, TX, USA, 4Naval Med Cntr of San Diego, San Diego, CA, USA

359  ANTIRETROvirals IMPROVE HAND STAGE IN HIV+ PATIENTS WITH SUBTYPE D AND A IN UGANDA

Ned Sacktor1, Deanna Saylor1, Gertrude Nakigozi2, Kevin Robertson1, Noeline Nakasujja1, Ronald H. Gray1, Maria Wawer1

1The Johns Hopkins Univ, Baltimore, MD, USA, 2Rakai Hlth Scis Prog, Kalisizo, Uganda, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Makarere Univ, Kampala, Uganda

360  ADDITIONAL SCREENING TESTS FOR HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS

Mattia Trunfio1, Chiara Montrucchio1, Daniela Vai1, Daniele Imperiale2, Alessandro Livelli2, Giancarlo Orofino2, Alice Trentalange1, Stefano Bonora1, Giovanni Di Perri1, Andrea Calcagno1

1Univ of Torino, Torino, Italy, 2Maria Vittoria Hosp, Torino, Italy, 3Amedeo di Savoia Hosp, Torino, Italy

361  COGNITIVE COMPLAINTS AND DEVELOPMENT OF FALLS AMONG HIV+ AND HIV- WOMEN

Anjali Sharma1, Donald R. Hoover2, Qiuhu Shi3, Michael Plankey4, Phyllis Tien1, Kathleen M. Weber5, Michelle Floris-Moore1, Hector Bolivar6, Marica M. Holstad2, Michael T. Yin10

1Albert Einstein Coll of Med, Bronx, NY, USA, 2Rutgers, the State Univ of New Jersey, Piscataway, NJ, USA, 3New York Med Coll, Valhalla, NY, USA, 4Georgetown Univ, Washington DC, USA, 5Univ of California San Francisco, San Francisco, CA, USA, 6Cook County Hlth & Hosps System, Chicago, IL, USA, 7Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 8Univ of Miami, Miami, FL, USA, 9Emory Univ, Atlanta, GA, USA, 10Columbia Univ, New York, NY, USA
362 PREVALENCE OF NEUROCOGNITIVE DISORDERS IN A WELL-TREATED AND AGING SWISS HIV-COHORT
Melanie Metral, Isabella Locatelli, Peter Brugger, Klemens Guthbrod, Ursula Kunze, Isaure Nadin, Marc Schwind, Riccardo Pignatti, Matthias Cavassini, Renaud Du Pasquier
1Univ of Lausanne, Lausanne, Switzerland, 2Univ Hosp of Zürich, Zürich, Switzerland, 3Univ Hosp of Bern, Bern, Switzerland, 4Felix Platter Hosp, Basel, Switzerland, 5Univ Hosp of Geneva, Geneva, Switzerland, 6Klinik für Neuro, St. Gallen, Switzerland, 7Servizio di Malattie Infettive, Lugano, Switzerland

Poster Sessions • Thursday
Program and Agenda
CROI 2017

Poster P-G5 ANTIRETROVIRAL PHARMACOKINETICS: SPECIAL PROBLEMS AND POPULATIONS
Poster Hall - 4 EF
2:30 PM - 4:00 PM

428 EFFECT OF SORBITOL ON 3TC PK AFTER ADMINISTRATION OF LAMIVUDINE SOLUTION IN ADULTS
Kimberly K. Adkison, Cynthia McCoig, Allen Wolstenholme, Yu Lou, Zhiping Zhang, Amy Eld, Katy Hayward, Mark Shafer
1ViiV Hlthcare, Rsr Triangle Park, NC, USA, 2ViiV Hlthcare, Tres Cantos, Madrid, Spain, 3GlofoxSmithKline, Collville, PA, USA, 4PAREXEL Intl, Durham, NC, USA, 5ViiV Hlthcare, Brentford, UK

429 CRUSHING OF DOLUTEGRAVIR COMBINATION TABLETS INCREASES DOLUTEGRAVIR EXPOSURE
Marieke Roskam-Kwint, Pauline Bollen, Angela Colbers, Marjolijn Duijssenberg-van Essenborg, Veroniek Harbers, Reinout van Crevel, David M. Burger
1Radboud Univ Med Cntr, Nijmegen, Netherlands, 2Elisabeth–TweeSteden Ziekenhuis, Tilburg, Netherlands

430 EFFECT OF SEVERE RENAL IMPAIRMENT ON DORAVIRINE PHARMACOKINETICS
Wendy Ankrom, Kelly Yee, Rosa Sanchez, Adedayo Adedoyin, Li Fan, Thomas Marbury, Richard A. Preston, Sauzanne Khallieieh, Marian Iwamoto
1Merck & Co, Inc, Kenilworth, NJ, USA, 2Orlando Clinical Rsr Cntr, Orlando, FL, USA, 3Univ of Miami, Miami, FL, USA

431 HIGHER PLASMA LEVELS AND MORE SIDE EFFECTS IN ELDERLY DARUNAVIR-TREATED PATIENTS
1Univ of Gothenburg, Gothenburg, Sweden, 2Karolinska Inst, Stockholm, Sweden, 3Chalmers Univ of Tech, Gothenburg, Sweden, 4Karolinska Univ Hosp, Stockholm, Sweden, 5Sodersjukhuset, Stockholm, Sweden, 6South Älvsborgs Hosp, Bords, Sweden

432 PHARMACOKINETICS OF DOLUTEGRAVIR IN PEOPLE LIVING WITH HIV OVER THE AGE OF 60
Emilie Elliot, Xinzhao Wang, Nicole Pagani, Alison Jenkin, Jaime Vera-Rojas, Isaac Day-Weber, Graeme Moyle, Myra McClure, Marta Boffito
470  **LONG-TERM EFFECTS OF IMMEDIATE VERSUS DEFERRED C-ART IN PRIMARY HIV INFECTION (PHI)**  
Kees Brinkman, Sebastian Tawil, Guido van den Berk, Daoud Ait Moha, Willem Blok  
OLVG, Amsterdam, Netherlands

471  **WITHDRAWN**

472  **EARLY TREATMENT IS LIKELY MORE IMPORTANT THAN PREVIOUSLY THOUGHT**  
Katherine E. Schlusser¹, Shweta Sharma², Julia A. Metcalf³, Angie N. Pinto⁴, Rika Draenert⁵, Pola de la Torre⁶, Giuseppe Tambussi⁷, James Neaton⁸, Oliver Laeyendecker⁹  
¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Univ of Minnesota, Minneapolis, MN, USA, ³NIAID, Bethesda, MD, USA, ⁴Kirby Inst, Sydney, Australia, ⁵Klinikum der Univ Munich, Munich, Germany, ⁶Cooper Univ Hosp, Camden, NJ, USA, ⁷Ospedale San Raffaele, Milano, Italy, ⁸NIAID, Bethesda, MD, USA

473  **ART IN HIV PERSONS WITH PRETREATMENT VIREMIA ≤3000 C/ML: THE START STUDY**  
Irini Sereti¹, Roy M. Gulick², Sonya Krishnan³, Stephen A. Migueles¹, Adrian Palfreeman³, Veronique Touzeau-Römer², Waldo Belloso³, Sean Emery⁶, Matthew Law⁶  
¹NIAID, Bethesda, MD, USA, ²Weill Cornell Med, New York, NY, USA, ³Leicester Royal Infirmary, Leicester, UK, ⁴Med Univ of Vienna, Vienna, Austria, ⁵Hosp Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Kirby Inst, Sydney, Australia

474  **BENEFIT OF CONTINUOUS/IMMEDIATE ART ON DISEASE RISK: SMART & START COMBINED ANALYSIS**  
Álvaro H. Borges¹, Jacqueline Neuhäusler¹, Shweta Sharma², James Neaton², Keith Henry³, Olga Anagnostou¹, Therese Staub¹, Sean Emery⁴, Jens D. Lundgren⁴, for the INSIGHT SMART & START Study Groups  
¹RigsHosp, Copenhagen, Denmark, ²Univ of Minnesota, Minneapolis, MN, USA, ³Hennepin County Med Ctr, Minneapolis, MN, USA, ⁴Univ of Athens, Athens, Greece, ⁵Cntr Hosp de Luxembourg, Luxembourg, Luxembourg, ⁶Kirby Inst, Sydney, Australia

475  **NO PER-PATIENT COST INCREASE UNDER IMMEDIATE ART FOR ALL: EVIDENCE FROM SWAZILAND**  
Shaoukat Khan¹, Emma Mafara¹, Pascal Geldsetzer², Salinda Phanitsiri¹, Cebele Wong¹, Charlotte Lejeune¹, Fiona Walsh¹, Velephi Okello⁴, Till Baernighausen¹  
¹Clinton Hlth Access Initiative, Mbabane, Swaziland, ²Harvard Univ, Boston, MA, USA, ³Clinton Hlth Access Initiative, Boston, MA, USA, ⁴Swaziland Ministry of Hlth, Mbabane, Swaziland, ⁵Heidelberg Univ, Heidelberg, Germany
COST-EFFECTIVENESS AND BUDGET IMPACT OF IMMEDIATE ART INITIATION IN CÔTE D’IVOIRE

Eric N. Ouattara1, Rachel L. MacLean2, Christine Daniel1, Ethan D. Borre2, Delphine Gabillard2, Mingshu Huang2, A. David Paltiel1, Xavier Anglaret2, Serge Eholie1, Kenneth Freedberg2

1Prog PAC-CI, ANRS Rsr site, Abidjan, Cote d’Ivoire, 2Massachusetts General Hosp, Boston, MA, USA, 1INSERM, Bordeaux, France, 4Yale Univ, New Haven, CT, USA, 5Service des Maladies Infectieuses et Tropes, Abidjan, Cote d’Ivoire

Poster P-J1 PREVALENCE AND INCIDENCE OF HIV DRUG RESISTANCE
Poster Hall - 4 EF 2:30 PM - 4:00 PM

477 CORRELATES OF DRUG RESISTANCE MUTATIONS IN ART-NAIVE INDIVIDUALS WITH HIV INFECTION

Sarah E. Porter1, Ellsworth Campbell1, Emily Westheimer1, Cynthia L. Gay1, Stephanie E. Cohen1, Anupama Shankar1, Jin-Fen Li1, Jeffrey A. Johnson1, William M. Switzer1, Philip J. Peters1

1CDC, Atlanta, GA, USA, 2New York City DHMH, New York, NY, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4San Francisco Dept of Pub Hlth, San Francisco, CA, USA

478 HIV INTEGRASE GENOTYPIC TESTING AND RESISTANCE IN THE UNITED STATES—9 JURISDICTIONS

Angela L. Hernandez1, M. Cheryl B. Ocfemia1, Neeraja Saduvala2, Alexandra Oster1, Walid Heneine1, Jeffrey A. Johnson1, Irene Hall1

1CDC, Atlanta, GA, USA, 2ICF Intl, Atlanta, GA, USA

479 PREDICTORS OF HIV GENOTYPE TESTING AMONG NEW DIAGNOSES LINKED TO CARE IN PHILADELPHIA

Melissa Miller, Tanner Nassau, Makeda Carroll, Coleman Terrell, Kathleen Brady

Philadelphia Dept of Pub Hlth, Philadelphia, PA, USA

480 PRETREATMENT DRUG-RESISTANCE INCREASE IN 3 FOCAL POINTS OF MEXICO, 2012–2015

Claudia García-Morales1, Santiago Avila-Rios1, Daniela Tapia-Trejo1, Verónica S. Quiroz-Morales1, Samuel Navarro2, Carlos A. Barrera-Arellano2, Jesús Casillas-Rodríguez2, Akio Murakami-Ogasawara2, Gustavo Reyes-Terán1, for the HIV MexNet Group

1Natl Inst of Respiratory Diseases, Mexico City, Mexico, 2Hosp General Tijuana, Tijuana, Baja California, USA, 3Capasits Cancún, Cancún, Quintana Roo, Mexico, 4Clínica Especializada Condesa, Mexico City, Mexico

481 HIV DRUG RESISTANCE: A UNIQUE PERSPECTIVE ACROSS 4 AFRICAN COUNTRIES

Brook Danboise1, Christina Polyak1, Alex Kasembeli2, Samoel Khamadi3, Babajide Keshinro Keshinro4, Hannah Kibuuka4, John Owwooth4, Sheila A. Peel5, Julie Ake1, Trevor Crowell1

1US Military HIV Rsr Prog, Bethesda, MD, USA, 2Walter Reed Proj—Kenya, Kericho, Kenya, 3Walter Reed Prog—Tanzania, Mbeya, Tanzania, 4Walter Reed Prog—Nigeria, Abuja, Nigeria, 5Makerere Univ Walter Reed Proj, Kampala, Uganda, 6Walter Reed Proj, Kisumu, Kenya
482 HIV PRETREATMENT DRUG RESISTANCE IN CAMEROON: FIRST NATIONWIDE STUDY
Gaëlle F. Tchouwa1, Jenny Domyeum1, Sabrina Eymard-Duvernyay2, Amandine Courmiil3, Eric Delaporte1, Martine Peeters1, Elliot Raizes1, Eitel Mpoudi-Ngole1, Avelin F. Aghokeng1
1CREMER, Yaoundé, Cameroon, 2Univ de Montpellier, Montpellier, France, Montpellier, France, 3CDC, Atlanta, GA, USA, 4IRD, Yaoundé, Cameroon

483 LOW PREVALENCE OF HIV DRUG RESISTANCE WITH MODERN AGENTS
Thibaut Davy, Laurence Brunet, Sonia Napravnik, Oksana Zakharova, Ann M. Dennis, Joseph J. Eron
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

484 LOW PREVALENCE OF NRTI, NNRTI, AND PI DRUG RESISTANCE MUTATIONS IN BOTSWANA
Sikhulile Moyo1, Simani Gaseitsiwe1, Melissa Zahralban-Steele2, Dorcas Maruapula1, Phillimon P. Sebogodi1, Madisa Mine1, Elliot Raizes3, Shahin Lockman2, Max Essex3, Vlad Novitsky2
1Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana, 2Harvard Univ, Boston, MA, 3Natl Hlth Lab, Gaborone, Botswana, CDC, Atlanta, GA, USA

485 ARV RESISTANCE MUTATIONS IN PATIENTS RECEIVING A WHO TDF-CONTAINING 1ST-LINE REGIMEN
Soo-Yon Rhee1, John Gregson2, Ravindra K. Gupta1, Robert Shafer3, for the TenoRes Study Group

486 VIRAL SUPPRESSION AND ACQUIRED HIV DRUG RESISTANCE IN CAMEROON: A NATIONWIDE STUDY
Gaëlle F. Tchouwa1, Jenny Domyeum1, Sabrina Eymard-Duvernyay2, Amandine Courmiil3, Eric Delaporte1, Martine Peeters1, Eitel Mpoudi-Ngole1, Elliot Raizes1, Avelin F. Aghokeng1
1CREMER, Yaoundé, Cameroon, 2Univ de Montpellier, Montpellier, France, Montpellier, France, 3CDC, Atlanta, GA, USA, 4IRD, Yaoundé, Cameroon

487 HIGH HIV DRUG RESISTANCE OF FIRST-LINE ART TREATMENT IN BENIN PEDIATRIC POPULATION
Djeneba Bocar Fofana1, Marcelline d’Almeida2, Pierre-Marie Girard2, Bernabé Lafia1, Sidonie Lambert1, Lutecia Zohoun-Guidigbi1, Rene Keke1, Cathia Soulie1, Anne-Geneviève Marcelin1, Laurence Morand-Joubert2
1Saint-Antoine Hosp, Paris, France, 2Univ d’Abomey–Calavi, Benin, 3CNHU—HKM, Cotonou, Benin, 4Reference Lab of the Natl Cntr for the Treatment of HIV, Cotonou, Benin, 5Pitie-Salpetriere Hosp, Paris, France

488 DRUG-RESISTANT HIV-1 DURING LONG-TERM SECOND-LINE ANTIRETROVIRAL TREATMENT IN KENYA
Seth Inzaule1, Raph L. Hamers2, Irene Mukui2, Kennedy Were1, Preston Owiti1, Daniel Kwaro1, Tobias R. de Wit1, Clement Zeh1
1Academic Med Cntr of the Univ of Amsterdam, Amsterdam, Netherlands, 2Natl AIDS and STI Control Prog, Nairobi, Kenya, 3Kenya Med Rsr Inst, Kisumu, Kenya, 4US CDC, Kisumu, Kenya

489 ELIMINATING DRUG RESISTANCE IN SOUTH AFRICA BY USING DOLUTEGRAVIR
Katie Sharp1, Thibault Mesplede2, Mark A. Wainberg1, Sally Blower1
1Univ of California Los Angeles, Los Angeles, CA, USA, 2McGill Univ, Montreal, Quebec, Canada
| Poster P-J2 IMPACT OF RESISTANCE ON RESPONSE TO ART  
Poster Hall - 4 EF | 2:30 PM - 4:00 PM |
|---|---|
| **490** IMPACT OF PRETREATMENT HIV-DRUG RESISTANCE ON VIROLOGIC OUTCOME OF FIRST-LINE ART  
Ingrid A. Beck1, Molly Levine1, Ross Milne1, Isaac So1, Nina Andersen1, Michael Watling2, Michael H. Chung3, James Munyao4, Catherine Kiptinness1, Lisa Frenkel1  
1Seattle Children’s Rsr Inst, Seattle, WA, USA, 2Univ of Washington, Seattle, WA, USA, 3Coptic Hope Cntr, Nairobi, Kenya |
| **491** RESPONSE TO FIRST-LINE ART IN ADULTS WITH DRUG RESISTENT HIV, ANRS 12249 TASP TRIAL  
Collins C. Iwuji1, Anne Derache2, Kathy Baisley3, Siva Danaviah4, Tulio de Oliveira5, Franckis Dabis6, Kholoud Porter1, Deenan Pillay2, for the ANRS 12249 TasP Study Group  
1Univ Coll London, London, UK, 2Africa Hlth Rsr Inst, Mtubatuba, South Africa, 3London Sch of Hygiene and Trop Med, London, UK, 4Africa Cntr for Pop Heath, Mtubatuba, South Africa, 5Univ of KwaZulu-Natal, Durban, South Africa, 6Univ de Bordeaux, Bordeaux, France |
| **492** ASSOCIATION BETWEEN HIV DRUG RESISTANCE AND BASELINE FAILURE IN THE ACTG PEARLS STUDY  
Rami Kantor1, Saran Vardhanabhuti2, Srikanth Tripathy3, Mariza Morgado4, Shanmugam Saravanan5, Carole Wallis6, Sarah E. Hudelson7, Susan H. Eshleman8, Thomas Campbell9  
1Brown Univ, Providence, RI, USA, 2Harvard Univ, Cambridge, MA, USA, 3Natl Inst for Rsr in TB, Chennai, India, 4Osvaldo Cruz Inst, Rio de Janeiro, Brazil, 5YRG CARE, Chennai, Tamilnadu, 6Lancet Labs and BARC-SA, Johannesburg, South Africa, 7The Johns Hopkins Univ, Baltimore, MD, USA, 8Univ of Colorado Denver, Aurora, CO, USA |
| **493** SHOULD WE BE TESTING FOR BASELINE INTEGRASE RESISTANCE?  
Yiannis Koullias1, Paul E. Sax1, Rochelle P. Walensky2, Emily P. Hyle3  
1Brigham and Women’s Hosp, Boston, MA, USA, 2Massachusetts General Hosp, Boston, MA, USA |
| **494** COST-EFFECTIVENESS ANALYSIS OF PRE-ART HIV DRUG RESISTENCE TESTING IN KENYA  
Horacio A. Duarte1, Joseph Babigumira2, David Stauffer3, Robert Shafer4, Ingrid Beck5, Louis Garrison6, Michael H Chung7, Lisa Frenkel8, Eran Bendavid9  
1Univ of Washington/Seattle Children’s Rsr Inst, Seattle, WA, USA, 2Univ of Washington, Seattle, WA, USA, 3Stanford Univ, Stanford, CA, USA, 4Seattle Children’s Rsr Inst, Seattle, WA, USA |

---

| Poster P-L7 HEPATITIS IS NOT ALL C  
Poster Hall - 4 EF | 2:30 PM - 4:00 PM |
|---|---|
| **577** HIGH PREVALENCE OF HEPATITIS DELTA VIRUS AMONG CAMEROONIAN HBSAG-POSITIVE SPECIMENS  
Mary Rodgers1, Kelly Coller1, Ka-Cheung Luk1, Emily Butler1, Jill Fuhrman1, Elizabeth Krillich1, Devin Barnaby2, Nicolas Ndemb1, Lazare Kaptue1, Gavin Cloherty1  
1Abbott Labs, Abbott Park, IL, USA, 2Franciscan Univ of Steubenville, Steubenville, OH, USA, 3Inst for Human Virology, Abuja, Nigeria, 4Univ of Montagnes, Bangangté, Cameroon |
578 WITHDRAWN

579 UNCONVENTIONAL T CELLS IN A PEG-INF-2α ADD-ON STRATEGY FOR SUPPRESSED HBV INFECTION
Camilla Tincati¹, Elvira S. Cannizzo¹, Francesca Binda², Paola Ronzi², Federico A. Cazzaniga¹, Antonella d’Arminio Monforte¹, Giulia Marchetti¹, Laura Milažer²
¹Univ of Milan, Milan, Italy, ²Luigi Sacco Univ Hosp, Milan, Italy

580 INCREASED RATES OF HBV SEROCONVERSION UNDER LONG-TERM HBV ACTIVE THERAPY IN HBV/HIV
Christoph Boesecke¹, Fabian Busch¹, Clara Lehmann¹, Carolynne Schwarze-Zander¹, Jakob Malin¹, Joerg Janne Vehreschild², Jan-Christian Wasmuth¹, Gerd Fätkenheuer², Jürgen K. Rockstroh¹, for the Cologne Bonn Cohort
¹Bonn Univ Hosp, Bonn, Germany, ²Cologne Univ Hosp, Cologne, Germany

581 MORTALITY OF HIV/HBV COINFECTED PATIENTS ON ART IN URBAN AND RURAL SOUTHERN AFRICA
Jonas Hector¹, Michael J. Vinikoor², Kalo Musukuma³, Roma Chilengi², Laura Jefferys³, Michael A. Hobbins¹, Mary-Ann Davies⁴, Matthias Egger⁵, Gilles Wandeler⁴
¹SolidarMed, Luzern, Switzerland, ²Cntr for Infectious Disease Rsr in Zambia, Lusake, Zambia, ³SolidarMed, Pemba, Mozambique, ⁴Univ of Cape Town, Cape Town, South Africa, ⁵Univ of Bern, Bern, Switzerland

582 EFFECTIVENESS OF HAV VACCINATION AMONG HIV-POSITIVE PATIENTS DURING AN HAV OUTBREAK
Kuan-Yin Lin¹, Szu-Min Hsieh¹, Hsin-Yun Sun¹, Yi-Chun Lo², Wang-Huei Sheng¹, Yu-Chung Chuang¹, Sung-Ching Pan¹, Chien-Ching Hung¹, Shan-Chwen Chang¹
¹Natl Taiwan Univ Hosp, Taipei, Taiwan, ²Taiwan Cntrs for Disease Control, Taipei, Taiwan

583 ACTIVE HPGV-2 INFECTION IS RESTRICTED TO COCIRCULATING HCV INFECTION
Kelly Coller, Michael Berg, Matthew Frankel, Kenn Forberg, John Hackett, Gavin Cloherty, George Dawson
Abbott Labs, Abbott Park, IL, USA

584LB TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP)
Gonzague Jourdain¹, Nicole Ngo-Giang-Huong¹, Linda J. Harrison², Luc Decker³, Camlin Tierney³, Tim R. Cressey¹, Jullapong Achalapong⁴, George K. Siberry⁵, Noele Nelson⁶, Nantasak Chotivanich⁷
¹IRD, Chiang Mai, Thailand, ²Harvard Univ, Boston, MA, USA, ³Prog for HIV Prevention and Treatment, Chiang Mai, Thailand, ⁴Chiangrai Prachanukroh Hosp, Chiang Rai, Thailand, ⁵NIH, Bethesda, MD, USA, ⁶CDC, Atlanta, GA, USA, ⁷Chonburi Hospital, Chonburi, Thailand
585 EFFECTS OF TREATMENT WITH MARAVIROC—A CCR5 INHIBITOR ON HUMAN HEPATIC STELLATE CELLS
Salvatore Martini1, Angelica Perna1, Angela Lucariello1, Margherita Macera1, Maria Aurora Carleo1, Germano Guerra1, Vincenzo Esposito1, Antonio De Luca2, Nicola Coppola1
1Second Univ of Naples, Naples, Italy, 2AORN dei Colli, Naples, Italy, 3Univ of Molise, Campobasso, Italy

586 CORRELATION OF BLOOD TRANSCRIPTOME WITH OUTCOME AFTER DAA TREATMENT FOR HCV INFECTION
Cody Orr1, Paul Nietert1, Shyam Kottili2, Gary Hardiman1, Eric G. Meissner1
1Med Univ of South Carolina, Charleston, SC, USA, 2Univ of Maryland, Baltimore, MD, USA

587 DO MAIT CELLS IMPACT FIBROSIS IN HCV AND HIV/HCV COINFECTED PATIENTS?
Boris J. Beudeker1, Gertine van Oord1, Joop Arends2, Julian Schulze zur Wiesch3, Marieke van Heide – Mulder1, Robert de Knecht1, Annelies Verbon1, Andre Boonstra1, Mark Claassen1
1Erasmus Univ Med Cntr, Rotterdam, Netherlands, 2Univ Med Cntr Utrecht, Utrecht, Netherlands, 3Univ Med Cntr Hamburg-Eppendorf, Hamburg, Germany, 4Rijnstate Hosp, Arnhem, Netherlands

588 PATHOGENESIS OF HIV-INDUCED LIVER DISEASE IN DUAL IMMUNE AND LIVER HUMANIZED MICE
Raghubendra S. Dagur, Weimin Wang, Yan Cheng, Weizhe Li, Edward Makarov, Natalia Osna, Santhi Gorantla, Larisa Y. Poluektova
Univ of Nebraska, Omaha, NE, USA

589 PERIPHERAL ENDOTHELIAL FUNCTION IS SUBOPTIMAL IN HCV-UNTREATED, HIV-SUPPRESSED ADULTS
Kara W. Chew1, Eric Daar2, Jordan E. Lake3, Chrisandra L. Shufelt4, Zhaoping Li1, Diana Liao1, Wilbert Jordan3, C. Noel Bairey Merz2, Judith S. Currier1, Debika Bhattacharya1
1Univ of California Los Angeles, Los Angeles, CA, USA, 2Los Angeles Biomed Rsr Inst at Harbor–UCLA Med Cntr, Torrance, CA, USA, 3Univ Texas Houston, Houston, TX, USA, 4Cedars-Sinai Med Cntr, Los Angeles, CA, USA, 5Charles R. Drew Univ of Med and Sci, Los Angeles, CA, USA

590 LEUKOCYTE TELOMERE ATTRITION IS RAPID FOLLOWING HIV BUT NOT HCV SEROCONVERSION
Alejandro Gonzalez-Serna1, Abhinav Ajaykumar2, Izabelle Gadawski2, M. Angeles Muñoz-Fernández2, Kanna Hayashi2, M.J. Milloy1, P. Richard Harrigan1, Helene C. Cote1
1BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 2Univ of British Columbia, Vancouver, British Columbia, Canada, 3General Univ Hosp Gregorio Marañón, Madrid, Spain
**Poster P-M3 AIDS-RELATED CANCER: LYMPHOMA, KAPOSI SARCOMA, LUNG, AND LIVER**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

603  **LYMPHOMA IN HIV-2-INFECTED PATIENTS IN CART ERA: A 15-PATIENT SINGLE-CENTER SERIES**
1Saint Louis Hosp, Paris, France, 2Bichat-Claude Bernard Hosp, Paris, France, 3INSERM, Bordeaux, France

604  **EPSTEIN-BARR VIRUS DNA LOAD: A POSSIBLE PREDICTOR OF AIDS-RELATED LYMPHOMA**
Simone H. Hijlkema, Jeroen J. van Kampen, David van de Vijver, Ineke van der Ende.  
Erasmus Univ Med Cntr, Rotterdam, Netherlands

605  **THE IMMUNE ACTIVATION PROFILE LINKED TO KAPOSI SARCOMA IN HIV-1-POSITIVE ADULTS**
Christina Psomas, Mehwish Younas, Jacques Reynes, Pierre Portales, Jean-François Eliaou, Pierre Corbeau.  
1Univ Hosp of Montpellier, Montpellier, France, 2Inst of Human Genetics, Montpellier, France

606  **TREATMENT AND OUTCOMES OF NON–SMALL-CELL LUNG CANCER IN LATER ART-ERA HIV INFECTION**
1Icahn Sch of Med at Mt Sinai, New York, NY, USA, 2Univ of Washington, Seattle, WA, USA, 3James J. Peters VA Med Cntr, Bronx, NY, USA, 4Washington, DC, VA Med Cntr, Washington, DC, USA, 5VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, 6VA North Texas Hlth Care Cntr, Dallas, TX, USA, 7VA Connecticut Hlthcare System, West Haven, CT, USA, 8Baylor Coll of Med, Houston, TX, USA, 9Yale Univ, New Haven, CT, USA, 10Stanford Med, Stanford, CA, USA

607  **ETIOLOGY OF HEPATOCELLULAR CARCINOMA IN WEST AFRICA: THE HIV CONTRIBUTION**
Antoine Jaquet, Boris Tchounga, Aristophane Tanon, Aklesso Bagny, Didier K. Ekouevi, Hamar A. Traore, Annie J. Sacco, Moussa Maiga, Francois Dabis, for the IeDEA West Africa Collaboration.  
1Univ de Bordeaux, Bordeaux, France, 2CHU de Treichville, Abidjan, Cote d’Ivoire, 3CHU Campus, Lomé, Togo, 4Univ de Lomé, Lomé, Togo, 5CHU du Point G, Bamako, Mali, 6Hôpital Gabriel Touré, Bamako, Mali

---

**Poster P-O10 ORGAN TRANSPLANTATION**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

688  **KIDNEY TRANSPLANT OUTCOMES IN HIV-POSITIVE AND HIV-NEGATIVE RECIPIENT PAIRS**
Esther Gathogo, Frank Post.  
1King’s Coll London, London, UK, 2King’s Coll Hosp NHS Fndn Trust, London, UK

689  **PLANNED PRACTICE OF HIV POSITIVE-TO-POSITIVE TRANSPLANTS IN US TRANSPLANT CENTERS**
Sarah Rasmussen, Mary Grace Bowring, Ashton Shaffer, Allan Massie, Aaron Tobian, Dorry Segev, Christine Durand.  
The Johns Hopkins Univ, Baltimore, MD, USA
**Poster P-011 METABOLIC COMPLICATIONS**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

**690 FOOD INSECURITY IS ASSOCIATED WITH POOR DIABETES CONTROL IN THE WIHS**

Kartika Palar, Edward A. Frongillo, Tracey Wilson, Margde Cohen, Eryka Wentz, Adaora Adimora, Daniel Merenstein, Janet M. Turan, Phyllis Tien, Sheri Weiser

1 Univ of California at San Francisco, San Francisco, CA, USA, 2 Univ of South Carolina, Columbia, SC, USA, 3 SUNY Downstate Med Ctr, Brooklyn, NY, USA, 4 Stroger Hosp, Chicago, IL, USA, 5 The Johns Hopkins Univ, Baltimore, MD, USA, 6 Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 7 Georgetown Univ, Washington, DC, USA, 8 Univ of Alabama at Birmingham, Birmingham, AL, USA

**691 ADIPOSE MITOCHONDRIAL FUNCTION, ADIPONECTIN, AND INSULIN RESISTANCE IN ACTG A5224S**

Todd Hulgan, Benjamin Ramsey, John R. Koethe, David C. Samuels, Mariana Gerschenson, Daniel Libutti, Grace A. McComsey, Paul E. Sax, Todd Brown, for the AIDS Clinical Trials Group Study A5224S Team

1 Vanderbilt Univ, Nashville, TN, USA, 2 Univ of South Carolina, Greenville, SC, USA, 3 Univ of Hawaii--Manoa, Honolulu, HI, USA, 4 Case Western Reserve Univ, Cleveland, OH, USA, 5 Brigham and Women's Hosp, Boston, MA, USA, 6 The Johns Hopkins Univ, Baltimore, MD, USA

**692 PLASMINOGEN ACTIVATOR INHIBITOR-1 PREDICTS REDUCED INSULIN SENSITIVITY IN HIV**

Kamonkiat Wirunsawanya, Dominic Chow, Loni Belyea, Cecilia Shikuma, Richard M Watanabe, Lindsay Kohorn, Bruce Shiramizu, Brooks Mitchell, Scott A. Souza, Lishomwa Ndhlovu

1 Univ of Hawaii, Honolulu, HI, USA, 2 Univ of Southern California, Los Angeles, CA, USA

---

**Poster P-012 OBESITY AND FATTY LIVER DISEASE**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

**693 BODY MASS INDEX AND THE RISK OF SERIOUS NON-AIDS EVENTS: THE D:A:D STUDY**

Amrit C. Achhra, Caroline Sabin, Lene Ryom, Antonella d’Arminio Monforte, Stephane de Wit, Andrew Phillips, Christian Pradier, Jens D. Lundgren, Matthew Law, for the the DAD Study Group

1 Kirby Inst, Sydney, Australia, 2 Univ Coll London, London, UK, 3 CHIP, Copenhagen, Denmark, 4 Univ of Milan, Milan, Italy, 5 Univ Libre de Bruxelles, Brussels, Belgium, 6 Univ Hosp, Nice, France, 7 Univ of Copenhagen, Copenhagen, Denmark

**694 RANDOMIZED TRIAL OF BEHAVIORAL WEIGHT LOSS FOR HIV-INFECTED PATIENTS**

Katie Becofsky, Edward J. Wing, Jeanne McCaffery, Matthew Boudreau, Rena R. Wing

1 Univ of Massachusetts Amherst, Amherst, MA, USA, 2 Brown Univ, Providence, RI, USA, 3 The Miriam Hosp, Providence, RI, USA

**695 PREDICTORS OF SEVERE WEIGHT/BODY MASS INDEX GAIN FOLLOWING ANTIRETROVIRAL INITIATION**

Priya Bhagwat, Igho Ofotokun, Grace A. McComsey, Todd Brown, Carlee Moser, Catherine A. Sugar, Judith S. Currier

1 Univ of California Los Angeles, Los Angeles, CA, USA, 2 Emory Univ, Atlanta, GA, USA, 3 Case Western Reserve Univ, Cleveland, OH, USA, 4 The Johns Hopkins Univ, Baltimore, MD, USA, 5 Harvard Univ, Boston, MA, USA
696 RALTEGRAVIR SWITCH AND BIOMARKERS OF LIVER STEATOSIS AND METABOLIC SYNDROME IN WOMEN
David Reynoso1, Anoma Somasunderam1, Maitreyee Nigalye1, Judith S. Currier1, Netanya S. Uty1, Jordan E. Lake2
1Univ of Texas Med Branch at Galveston, Galveston, TX, USA, 2Univ of California Los Angeles, Los Angeles, CA, USA

697 CHANGES IN LIVER STEATOSIS AFTER SWITCHING EFAVIRENZ TO RALTEGRAVIR: THE STERAL STUDY
Juan Macias1, Dolores Merino2, Francisco Téllez3, Federico Pulido4, Juan González-García5, Manuel Márquez6, Antonio Rivero7, María Mancebo1, Juan A. Pineda1, for the RIS-HEP09
1Hosp Univ de Valme, Sevilla, Spain, 2Complejo Hospitario Univ de Huelva, Huelva, Spain, 3Hosp Univ de Puerto Real, Cádiz, Spain, 4Hosp 12 de Octubre, Madrid, Spain, 5Hosp Univ La Paz, Madrid, Spain, 6Hosp Virgen de la Victoria, Málaga, Spain, 7Hosp Univ Reina Sofia, Cordoba, Spain

698 OBESITY IN ANTIRETROVIRAL-TREATED HIV-INFECTED ADULTS: PREDICTORS AND COMORBIDITIES
Anchalee Avihingsanon1, Sivaporn Gatechompol1, Opass Putcharoen2, Jiratchaya Sophanphon1, Supalak Phonphithak1, Sasiwimol Uboylam1, Stephen J. Kerr1, Kiat Ruxrungtham2, Praphan Phanunphak2, for the HIV-NAT 006 Study Group
1HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 2Chulalongkorn Univ, Bangkok, Thailand

699 WOMEN GAIN MORE WEIGHT THAN MEN FOLLOWING INITIATION OF ANTIRETROVIRAL THERAPY
Sara H. Bares1, Laura M. Smeaton1, Ai Xu1, Catherine Godfrey4, Grace A. McComsey1
1Univ of Nebraska, Omaha, NE, USA, 2Harvard Univ, Cambridge, MA, USA, 3DAIDS, NIAID, Bethesda, MD, USA, 4Case Western Reserve Univ, Cleveland, OH, USA

700 CT FAT DENSITY REFLECTS HISTOLOGIC FAT QUALITY IN ART-TREATED, HIV-1-INFECTED ADULTS
Jordan E. Lake1, Carlee Moser2, Liz Johnston3, Clara Magyar3, Scott D. Nelson3, Kristine Erlandson4, Todd Brown5, Grace A. McComsey1
1Univ of Texas, Houston, TX, USA, 2Harvard Univ, Boston, MA, USA, 3Univ of California Los Angeles, Los Angeles, CA, 4Univ of Colorado, Aurora, CO, USA, 5The Johns Hopkins Univ, Baltimore, MD, USA, 6Case Western Reserve Univ, Cleveland, OH, USA

701 ASSOCIATION OF NAFLD WITH ADIPOKINE AND INFLAMMATORY MARKERS DIFFERS BY HIV STATUS
Jennifer Price1, Ruibin Wang2, Eric Seaberg3, Matthew Budoff4, Lawrence Kingsley4, Frank J. Palella5, Mallory Witt6, Wendy Post2, Chloe Thio7
1Univ California San Francisco, San Francisco, CA, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Harbor–UCLA Med Cntr, Torrance, CA, USA, 4Univ of Pittsburgh, Pittsburgh, PA, USA, 5Northwestern Univ, Chicago, IL, USA, 6Los Angeles Biomed Rsr Inst, Harbor–UCLA Med Cntr, Torrance, CA, USA
702 PREVALENCE AND RISK FACTORS FOR HEPATIC STEATOSIS IN HIV+ PERSONS
Jessie Torgersen1, Kaku So-Armah2, Matthew Freiberg3, Matthew Budoff4, Joseph Lim5, Adeel Butt6, Maria Rodriguez-Barradas7, Amy Justice1, Jay Kostman1, Vincent Lo Re1
1Univ of Pennsylvania, Philadelphia, PA, USA, 2Boston Univ, Boston, MA, USA, 3Vanderbilt Univ, Nashville, TN, USA, 4Harbor–UCLA Med Cntr, Torrance, CA, USA, 5Yale Univ, New Haven, CT, USA, 6Univ of Pittsburgh, Pittsburgh, PA, USA, 7Bayor Coll of Med, Houston, TX, USA, 8VA Connecticut Hlthcare System, West Haven, CT, USA, 9Philadelphia FIGHT Community Hlth Cntrs, Philadelphia, PA, USA

703 LIVER STEATOSIS AND FIBROSIS IN AT-RISK EUROPEAN HIV-MONOINFECTED PATIENTS
Maud Lemoine1, Lambert Assoumou2, Patrick Ingiliz3, Pierre-Marie Girard4, Stephane de Wit5, Marc-Antoine Valantin6, Anja Huefner7, Jacqueline Capeau8, Dominique Costagliola9, Georg Behrens10

704 CHANGES IN LIVER FIBROSIS AND STEATOSIS IN HIV MONOINFECTED PATIENTS OVER 24 MONTHS
Raphael Mohr, Christoph Boesecke, Carolyne Schwarze-Zander, Jan-Christian Wasmuth, Jonel Trebicka, Jürgen K. Rockstroh
Univ Hosp Bonn, Bonn, Germany

Poster P-05 PREDICTORS OF INFLAMMATION ON ART
Poster Hall - 4 EF 2:30 PM - 4:00 PM

672 BIOMARKERS OF AGING IN HIV-POSITIVE INDIVIDUALS AND MATCHED CONTROLS
Davide De Francesco1, Sebastian Oehlke2, Alexander Bürkle2, Ferdinand Wit3, Claudio Franceschini3, Neeltje A. Kootstra3, Claude Libert4, Peter Reiss5, Caroline Sabin6, for the Co-morbidity in Relation to AIDS (COBRA) Collaboration
1Univ Coll London, London, UK, 2Univ of Konstanz, Konstanz, Germany, 3Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands, 4Alma Mater Studiorum Univ di Bologna, Bologna, Italy, 5Academic Med Cntr, Amsterdam, Netherlands, 6VIB, Ghent, Belgium

673 LONGITUDINAL ASSOCIATION BETWEEN ALCOHOL USE AND INFAMMATORY BIOMARKERS
Kaku So-Armah1, Matthew Freiberg2, Debbie Cheng3, Gregory Patts1, Russell Tracy1, Margaret Doyle1, Natalia Gnatienko4, Kendall J. Bryant5, Evgeny Krupitsky6, Jeffrey H. Samet1
1Boston Univ, Boston, MA, USA, 2Vanderbilt Univ, Nashville, TN, USA, 3Univ of Vermont, Colchester, VT, USA, 4Boston Med Cntr, Boston, MA, USA, 5Natl Inst on Alcohol Abuse and Alcoholism, Bethesda, MD, USA, 6St.Petersburg Pavlov State Med Univ, St. Petersburg, Russia

674 ASSOCIATION OF ANISOCYTOSIS WITH MARKERS OF INFAMMATION AND IMMUNE EXHAUSTION IN HIV
Sadeer Al-Kindi, David A. Zidar, Grace A. McComsey, Chris T. Longenecker
Case Western Reserve Univ, Cleveland, OH, USA
**675** GREATER ART ADHERENCE IS ASSOCIATED WITH LESS INFLAMMATION IN HIV-SUPPRESSED UGANDANS

Jose Castillo-Mancilla¹, Mary Morrow², Yap Boum³, Jessica E. Haberer⁴, Jeffrey N. Martin⁵, David Bangsberg⁶, Samantha MaWhinney⁷, Nicholas Musinguzi², Peter W. Hunt⁵, Mark J. Siedner⁴

¹Univ of Colorado Denver, Aurora, CO, USA, ²Colorado SPH, Aurora, CO, USA, ³Epicentre, MSF, Mbarara, Uganda, ⁴Massachusetts General Hosp, MA, USA, ⁵Univ of California San Francisco, San Francisco, CA, USA, ⁶MGH-Ragon Inst, Boston, MA, USA, ⁷Mbarara Univ of Sci and Tech, Mbarara, Uganda

**676** IMMUNOLOGICAL EFFECTS OF SYNBIONT SUPPLEMENTATION IN ADVANCED HIV DISEASE

Sergio Serrano-Villar¹, Maria Lagarde¹, Jose I. Bernardino¹, Mariano Matarranz², Alfonso Cabello³, Judit Villar⁴, Jose Ramón Blanco⁵, Otilia Bisbal¹, Alberto Diaz de Santiago⁴, Vicente Estrada⁴

¹Hosp Univ Ramón y Cajal, Madrid, Spain, ²Hosp 12 de Octubre, Madrid, Spain, ³Hosp Univ La Paz–IdiPAZ, Madrid, Spain, ⁴Hosp Univ Fndn Jiménez Díaz, Madrid, Spain, ⁵Hosp del Mar, Barcelona, Spain, ⁶Hosp San Pedro, La Rioja, Spain, ⁷Hosp Puerta de Hierro, Madrid, Spain, ⁸Hosp Univ Clínico San Carlos, Madrid, Spain

**Poster P-06 BONE DISEASE: RISK PREDICTION**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

**677** BONE MICROARCHITECTURAL CHANGES AND FRACTURE-RISK PREDICTION IN HIV AND HCV

Roger Bedimo¹, Beverley Adams-Huet², John Poindexter³, Irfan Farukhi³, Rosinda Castanon³, Geri Brown³, Diana Turner³, Teresa Moore³, Pablo Tebas⁴, Naim Maalouf²

¹VA North Texas Hlth Care Cntr, Dallas, TX, ²Univ of Texas Southwestern Med Cntr, Dallas, TX, ³VA North Texas Hlthcare System, Dallas, TX, ⁴Univ of Pennsylvania, Philadelphia, PA

**678** FRAX-TOOL FRACTURE-RISK COMPARISON: HAVE A LITTLE BACKBONE!

Linda Battalora¹, Carl Armon², Kate Buchacz³, John Hammer⁴, John Spear⁵, John T. Brooks¹, Benjamin Young⁵, Edgar T. Overton⁵

¹Colorado Sch of Mines, Golden, CO, USA, ²Cerner Corporation, Kansas City, MO, USA, ³CDC, Atlanta, GA, USA, ⁴Denver Infectious Disease Consultants, Denver, CO, USA, ⁵APEX Family Med, Denver, CO, USA, ⁶Univ of Alabama at Birmingham, Birmingham, AL, USA

**679** FRACTURE-RISK ESTIMATES IN HIV-POSITIVE AND -NEGATIVE SUBJECTS: DATA FROM HIV UPBEAT

Aoife G. Cotter¹, Dylan Shannon¹, Tara McGinty¹, Alan Macken¹, Eoin Kavanagh¹, Geraldine McCarthy¹, Jennifer J. Brady¹, Juliet Compston¹, Caroline Sabin¹, Patrick W. Mallon¹

**Poster P-O7 BONE DISEASE: MECHANISMS**

**Poster Hall - 4 EF**
**2:30 PM - 4:00 PM**

680 **SOCS-1/TRAFF-6 UP-REGULATION IN BONE IMPAIRMENT IN HIV+ PATIENTS ON EFFECTIVE CART**
Elvira S. Cannizzo, Federico A. Cazzaniga, Esther Merlini, Camilla Tincati, Lidia Gazzola, Nathalie Iannotti, Angelo Del Sole, Antonella d’Arminio Monforte, Giulia Marchetti
Univ of Milan, Milan, Italy

681 **BONE DENSITY, MICROARCHITECTURE, AND BONE STRENGTH AFTER 1 YEAR OF TDF**
Robert Güerri-Fernández, Hernando Knobel, Judit Villar, Alicia González-Mena, Ana Gueral, Ludovic Humbert, Elisabet Lerma-Chipirraz, Marta Trenches-Rodriguez, Adolfo Diez-Pérez
1Hosp del Mar, Barcelona, Spain, 2Galgo Med, Inc, Barcelona, Spain, 3CAP Passeig de Sant Joan, Barcelona, Spain

**Poster P-O8 BONE DISEASE: INTERVENTIONS**

**Poster Hall - 4 EF**
**2:30 PM - 4:00 PM**

682 **A RANDOMIZED TRIAL OF VITAMIN D3 (3000 VERSUS 1000 IU) IN HIV+ POSTMENOPAUSAL WOMEN**
Michael T. Yin, Chengchen Zhang, Mariana Bucovsky, David Ferris, Susan Olender, Arindam Roy Choudhury, Anjali Sharma, Cosmina Zeana, Barry S. Zingman, Elizabeth Shane
1Columbia Univ, New York, NY, USA, 2Columbia Univ, New York, NY, USA, 3Icahn Sch of Med at Mt Sinai, New York, NY, USA, 4Albert Einstein Coll of Med, Bronx, NY, USA, 5Braxo Lebanon Hosp Cntr, Bronx, NY, USA, 6Montefiore Med Cntr, Bronx, NY, USA

683 **SWITCHING FROM TDF TO TAF IN HIV-INFECTED ADULTS WITH LOW BMD: A POOLED ANALYSIS**
Todd Brown, Michael T. Yin, Samir Gupta, Christine Katlama, Adriano Lazzarin, Kathy Melbourn, Calvin Cohen, YaPei Liu, Thai Nguyen-Cleary, Scott McCallister
1The Johns Hopkin Univ, Baltimore, MD, USA, 2Columbia Univ, New York, NY, USA, 3Indiana Univ, Indianapolis, IN, USA, 4Pierre and Marie Curie Univ, Paris, France, 5Vita-Salute San Raaffaele Univ, Milan, Italy, 6Gilead Scis, Inc, Foster City, CA, USA

684 **ANTIRETROVIRAL BONE LOSS IS DURABLY SUPPRESSED BY A DOSE OF ZOLEDRONIC ACID**
Igho Ofotokun, Kehmia Titanji, Aswani Vunnava, Antonina Foster, Anandi N. Sheth, Cecile D. Lahiri, Jeffrey J. Lennox, Andrea Knezevic, Kirk A. Easley, M. N. Weitzmann
Emory Univ, Atlanta, GA, USA

685LB **HIGH DOSE VITAMIN D3 INCREASES SPINE BONE DENSITY IN HIV+ YOUTH ON TENOFOVIR (TDF)**
Peter L. Havens, Charles Stephensen, Marta Van Loan, Brandy Rutledge, Bob Harris, Patricia M. Flynn, Catherine Gordon, Bill Kapogiannis, Kathleen Mulligan, for the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team
1Med Coll of Wisconsin, Wauwatosa, WI, USA, 2USDA, Davis, CA, USA, 3Westat, Rockville, MD, USA, 4St. Jude Children’s Rsr Hosp, Memphis, TN, USA, 5Univ of Cincinnati, Cincinnati, OH, USA, 6NICHHD, Bethesda, MD, USA, 7Univ of California San Francisco, San Francisco, CA, USA
### Poster P-O9 RENAL DISEASE
**Program Hall - 4 EF**

**2:30 PM - 4:00 PM**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Presenters</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>686</td>
<td>PREVALENCE AND RISK FACTORS OF RENAL INJURY IN OPTION B+ DURING THE FIRST 6 MONTHS</td>
<td>Caroline Melhado, Jacob Phulusa, Mathius John, Allan Jumbe, Bryna Harrington, Bryan Mthiko, Mina C. Hosseinipour, for the 54 Team</td>
<td>Univ of North Carolina Proj–Malawi, Lilongwe, Malawi</td>
</tr>
</tbody>
</table>

### Poster P-O10 NEUROSYPHILIS
**Program Hall - 4 EF**

**2:30 PM - 4:00 PM**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Presenters</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>749</td>
<td>HOW WELL DO NEUROLOGIC SYMPTOMS IDENTIFY HIV-INFECTED INDIVIDUALS WITH NEUROSYPHILIS?</td>
<td>Arielle P. Davis, Joshua Stern, Sheila Dunaway, Lauren Tantalo, Sharon Sahi, Abigail Crooks, Claire Stevens, Sarah Holte, Christina Marra</td>
<td>1Harborview Med Cntr, Seattle, WA, USA, 2Univ of Washington, Seattle, WA, USA, 3FRCHC, Seattle, WA, USA</td>
</tr>
</tbody>
</table>

### Poster P-P10 PROTOZOAL OIs
**Program Hall - 4 EF**

**2:30 PM - 4:00 PM**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Presenters</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>751</td>
<td>STOPPING SECONDARY TE PROPHYLAXIS IN SUPPRESSED PATIENTS WITH CD4 100-200 IS NOT SAFE</td>
<td>Jose M. Miro, for the Opportunistic Infection Team of the COHERE in EuroCoord</td>
<td>IDIBAPS, Barcelona, Spain</td>
</tr>
</tbody>
</table>

### Poster P-P11 NEUROSYPHILIS
**Program Hall - 4 EF**

**2:30 PM - 4:00 PM**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Presenters</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>752</td>
<td>ASYMPTOMATIC INFECTION IN AN HIV COHORT: LEISHMANIASIS OUTBREAK IN FUENLABRADA, SPAIN</td>
<td>Alicia Castro, Eugenia Carrillo, Juan V. San Martin, Laura Botana, Laura Molina, Laura Fernandez, Belen Matia, Carmen Sanchez, Jose Manuel Ruiz-Giardin, Javier Moreno</td>
<td>1Hosp Univ de Fuenlabrada, Fuenlabrada, Madrid, Spain, 2Inst de Salud Carlos III, Majadahonda, Spain</td>
</tr>
</tbody>
</table>
Alejandro Pérez, John Weiser, Heather Bradley
CDC, Atlanta, GA, USA

738  SIGNIFICANT HIGHER CMV-REACTIVATION IN PJP PATIENTS WITH ADJUNCTIVE CORTICOSTEROIDS
Gundolf Schuettfort, Sarah Tomasini, H.R. Brodt, Philipp De Leuw, Siri Goepel, Gerrit Kann, Annette E. Haberl, Eva Herrmann, Timo Wolf, Christoph Stephan
Univ Hosp Frankfurt, Frankfurt, Germany

739  WITHDRAWN

740  PREVALENCE OF ADVANCED HIV DISEASE AND CRYPTOCOCCAL INFECTION IN GABORONE, BOTSWANA
Kwana Lechiile1, Hannah K. Mitchell1, Fredah Mulenga2, Irene Goercke3, Martin S. Azama2, Mooketsi Molefi1, Tshepo B. Leeme1, Mark W. Tenforde4, Madisa Mine, Joseph N. Jarvis5
1Botswana–UPenn Partnership, Gaborone, Botswana, 2Ministry of Hlth, Gaborone, Botswana, 3Univ of Botswana, Gaborone, Botswana, 4Univ of Washington, Seattle, WA, USA, 5US CDC, Gaborone, Botswana

741  CRYPTOCOCCAL ANTIGEN SCREENING AMONG PATIENTS WITH ADVANCED HIV INFECTION IN VIETNAM
Dat Q. Vu1, Kinh V. Nguyen1, Dung T. Nguyen2, Moses Bateganya3, Sheryl Lyss3, Anh T. Ho4, Jonathan Kaplan5, Presented by Hanzhu Qian, for the CRICS Team
1Hanoi Med Univ, Hanoi, Vietnam, 2Natl Hosp for Trop Diseases, Hanoi, Vietnam, 3CDC, Atlanta, GA, USA, 4CDC, Hanoi, Vietnam

742  CHANGES IN CRAG TITERS AMONG ASYMPTOMATIC HIV-POSITIVE PATIENTS
Agnes Kiragga1, Francis Kakooza1, Bozena M. Morawski2, Elizabeth Nalintya1, Radha Rajasingham1, David Boulware2, David Meya3, Yukari C. Manabe4
1Infectious Diseases Inst, Kampala, Uganda, 2Univ of Minnesota, Minneapolis, MN, USA, 3Makerere Univ, Kampala, Uganda, 4The Johns Hopkins Univ, Baltimore, MD, USA

743  HIGH PREVALENCE OF CNS DISSEMINATION WITH ASYMPTOMATIC CRYPTOCOCCAL ANTIGENEMIA
Azure T. Makadzange1, Admir Hlupeni1, Kathryn F. Boyd1, Takudzwa Chagumaira1, Christine Ross1, Snigdha Vallabhaneni1, Shirish Balachandra4, Moses Bateganya4, Chiradzidzo E. Ndhlouv1
1Massachusetts General Hosp, Cambridge, MA, USA, 2Univ of Zimbabwe, Harare, Zimbabwe, 1Infectious Disease Rsr Lab, Harare, Zimbabwe, 4CDC, Atlanta, GA, USA
744 SERTRALINE AND HIGH-DOSE FLUCONAZOLE TREATMENT OF CRYPTOCOCCAL MENINGITIS IN TANZANIA
Katende Andrew1, Gladys Mbwanji1, Diana Faini1, Aneth Kalinjuma1, Katherine Hullsiekk1, Josh Rhein1, Maja Weisserr1, David Meyaz1, David Boulwaree1, Emilio Letang1
1Ifakara Hlth Inst, Morogoro, Tanzania, 2Univ of Minnesota, Minneapolis, MN, USA, 3Infectious Disease Inst, Kampala, Uganda

745 MORTALITY DUE TO HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS IN BOTSWANA IN THE ART ERA
Tshepo B. Leeme1, Raju K. Patel1, Caitlin Azzo2, Nametso Lekwape1, Katlego Tsholo1, Ephraim Tawanana1, Mooketsi Molefi4, Margaret Mokomane1, Mark W. Tenforde5, Joe N. Jarvis1
1Botswana–UPenn Partnership, Gaborone, Botswana, 2Univ of Pennsylvania, Philadelphia, USA, 3Botswana Ministry of Hlth, Gaborone, Botswana, 4Univ of Botswana, Gaborone, Botswana, 5Univ of Washington, Seattle, WA, USA, 6US CDC, Gaborone, Botswana

746 CSF IMMUNE RESPONSES ASSOCIATED WITH DEPRESSION FOLLOWING CRYPTOCOCCAL MENINGITIS
Sarah Lofgren1, Kathy Huppler Hullsiek1, Bozena M. Morawski1, Josh Rhein1, David Meyaz1, Mahsa Abassi1, Noeline Nakasuji1, Abdu Musubire1, David Boulwaree1, for the Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis (ASTRO-CM) Study Group
1Univ of Minnesota, Minneapolis, MN, USA, 2Infectious Disease Inst, Kampala, Uganda, 3Makarere Univ, Kampala, Uganda

747 CLINICAL PERFORMANCE OF THE MP1P IMMUNOASSAY FOR RAPID DIAGNOSIS OF TALAROMYCOSIS
Thu T. Nguyen1, Jasper F. Chan2, Hien T. Ha3, Nguyen Le Nhu Tung1, Jeremy Day1, Chau V. Nguyen1, Guy Thwaites1, Patrick C. Woo2, Kwok-Yung Yuen2, Thuy Le1
1Oxford Univ Clinical Rsr Unit, Ho Chi Minh, Vietnam, 2Univ of Hong Kong, Hong Kong, 3Hosp for Trop Diseases, Ho Chi Minh City, Vietnam

748 PREDICTING THE RISK OF DEATH IN HIV-ASSOCIATED TALAROMYCES MARNEFFEII INFECTION
Thanh T. Nguyen1, Thu T. Nguyen1, Nguyen Le Nhu Tung1, Jeremy Day1, Cecilia Shikuma3, Chau V. Nguyen1, Guy Thwaites1, Thuy Le1
1Oxford Univ Vietnam Collaboration, Ho Chi Minh City, Vietnam, 2Hosp for Trop Diseases, Ho Chi Minh City, Vietnam, 3Univ of Hawaii, Honolulu, HI, USA

Poster P-Q1 PK AND SAFETY OF ARVs AND MONOCLONAL ANTIBODIES FOR PMTCT
Poster Hall - 4 EF 2:30 PM - 4:00 PM

753 DOING FOR TWO: PLACENTAL TRANSFER OF DARUNAVIR AND SIMULATION OF FETAL EXPOSURE
Stein Schalkwijk, Aaron O. Buaben, Angela Colbers, David M. Burger, Rick Greupink, Frans G. Russel
Radboud Univ Med Cntr, Nijmegen, Netherlands
574 SUBSTANTIALLY LOWER RILPIVIRINE PLASMA CONCENTRATIONS DURING PREGNANCY

Angela Colbers1, Stein Schalkwijk1, Deborah Konopnicki2, Andrea Gingelmaier1, John Lambert1, Ineke van der Ende1, José Moltó1, David M. Burger1, for the PANNA Network
1Radboud Univ Med Cntr, Nijmegen, Netherlands, 2Saint-Pierre Univ Hosp, Brussels, Belgium, 3Klinikum der Univ München, München, Germany, 4Mater Misericordiae Univ Hosp Dublin, Dublin, Ireland, 5Erasmus Univ Med Cntr, Rotterdam, Netherlands, 6Fundació Lluita Contra la Sida, Baladona, Spain

575 ELVITEGRAVIR/COBICISTAT PHARMACOKINETICS IN PREGNANCY AND POSTPARTUM

Brookie Best1, Edmund Capparelli1, Alice Stek2, Edward Acosta3, Elizabeth Smith4, Nahida Chakhtoura5, Jiajia Wang6, Adriane Hernandez7, Mark Mirochnick8, for the IMPAACT P1026s Protocol Team
1Univ of California San Diego, La Jolla, CA, USA, 2Univ of Southern California, Los Angeles, CA, USA, 3Univ of Alabama at Birmingham, Birmingham, AL, USA, 4DAIDS, NIAID, Rockville, MD, USA, 5NICH, Bethesda, MD, USA, 6Harvard Univ, Boston, MA, USA, 7Frontier Sci & Tech Rsr, Amherst, NY, USA, 8Boston Med Cntr, Boston, MA, USA

576 PROTEASE-INHIBITOR–BASED CART IS ASSOCIATED WITH HIGH ESTRADIOL LEVELS IN PREGNANCY

Kayode Balogun1, Monica Guzman1, Eszter Papp1, Mona Loutfy1, Mark Yudin2, Jay MacGillivray4, Kellie Murphy2, Sharon Walmsley6, Michael Silverman2, Lena Serghides3
1Univ Hlth Network, Toronto, Ontario, Canada, 2Women’s Coll Rsr Inst, Toronto, Ontario, Canada, 3St. Michael’s Hosp, Toronto, Ontario, Canada, 4Mt Sinai Hosp, Toronto, Ontario, Canada, 5Univ of Toronto, Toronto, Ontario, Canada, 6Univ of Western Ontario, London, Ontario, Canada

577 Raltegravir Pharmacokinetics and Safety in HIV-1 Exposed Neonates: DoSE-Finding Study

Diana F. Clarke1, Edward Acosta1, Anne Chain1, Mae Cababasay4, Jiajia Wang2, Heddy Teppier1, Elizabeth Smith4, Rohan Haza2, Mark Mirochnick8, for the IMPAACT P1110 Protocol Team
1Boston Med Cntr, Boston, MA, USA, 2Univ of Alabama at Birmingham, Birmingham, AL, USA, 3Merck Rsr Labs, Rahway, NJ, USA, 4Harvard Univ, Boston, MA, USA, 5Merck Rsr Labs, North Wales, PA, USA, 6DAIDS, NIAID, Rockville, MD, USA, 7NICH, Bethesda, MD, USA, 8Boston Univ, Boston, MA, USA

578 Pharmacokinetics of Nevirapine Prophylaxis in HIV-Exposed Low Birth Weight Infants

Adrie Bekker1, Avy Violari1, Mae Cababasay1, Jiajia Wang2, Lubbe Wiesner4, Edmund Capparelli1, Mark Cotton5, Firdose Nakwa6, Mark Mirochnick8, for the IMPAACT P1106 Team
1Stellenbosch Univ, Cape Town, South Africa, 2Univ of Witwatersrand, Johannesburg, South Africa, 3Harvard Univ, Boston, MA, USA, 4Univ of Cape Town, Cape Town, South Africa, 5Univ of California San Diego, La Jolla, CA, USA, 6Boston Med Cntr, Boston, MA, USA
759 SAFETY OF 6-WEEK TRIPLE ANTIRETROVIRAL PROPHYLAXIS IN HIGH-RISK HIV-EXPOSED INFANTS
Suvaporn Anugulruengkit1, Piyarat Suntarattiwong2, Pradthana Ounchanum1, Ussanee Srirompotong2, Watsamon Jantarabenchakul1, Jiratchaya Sophonphan2, Tim R. Cressy2, Chitsanu Pancharoen1, Thanyawee Puthanakit1, for the CIPHER_AEPEP Study Team
1Chulalongkorn Univ, Bangkok, Thailand, 2Queen Sirikit Natl Inst of Child Hlth, Bangkok, Thailand, 3Chiang Rai Prachanukroh Hosp, Chiang Rai, Thailand, 4Khon Kaen Hosp, Khon Kaen, Thailand, 5HIV Netherlands Australia Thailand Rsr Collab, Thai Red Cross AIDS Rsr, Bangkok, Thailand, 6Prog for HIV Prevention and Treatment, Chiang Mai, Thailand

760 SAFETY & PHARMACOKINETICS OF THE MONOCLONAL ANTIBODY, VRC01, IN HIV-EXPOSED NEWBORNS
Coleen K. Cunningham1, Elizabeth J. McFarland2, Edmund V. Capparelli2, Petronella Muresan4, Charlotte Perlowski3, Megan Valentine2, Elizabeth Smith1, John R. Mascola7, for the IMPAACT P1112 Team
1Duke Univ, Durham, NC, USA, 2Univ of Colorado, Aurora, CO, USA, 3Univ of California San Diego, La Jolla, CA, USA, 4Harvard Univ, Boston, MA, USA, 5FHI360, Durham, NC, USA, 6DAIDS, NIAID, Rockville, MD, USA, 7Vaccine Rsr Cntr, NIAID, Bethesda, MD, USA

Posters

Poster P-Q3 PREGNANCY AND PREGNANCY OUTCOMES
Poster Hall - 4 EF 2:30 PM - 4:00 PM

772 SUBSEQUENT PREGNANCY OUTCOMES IN WOMEN DURING FOLLOW-UP IN PROMISE 1077HS
Jose H. Pilotto1, Sean Brummel2, Risa M. Hoffman1, Paula Britto2, Gaerolwe Masheto4, Linda Aurpibul3, Nahida Chakhtoura1, Karin Klingman2, Judith S. Currier1, for the 1077HS Team
1Fiocruz, Rio de Janeiro, Brazil, 2Harvard Univ, Boston, MA, USA, 3Univ of California Los Angeles, Los Angeles, CA, USA, 4Harvard Univ-Botswana Collaboration, Gaberone, Botswana, 5Chiang Mai Univ, Chiang Mai, Thailand, 6MH, Bethesda, MD, USA, 7AIDS, NIAID, Bethesda, MD, USA

773 HIV AND RISK OF POSTPARTUM INFECTION, COMPLICATIONS, AND MORTALITY IN RURAL UGANDA
Lisa Bebell1, Joseph Ngonzi2, Mark J. Siedner2, Winnie Muyindike4, Bosco M. Bwana1, Laura E. Riley1, Yap Boum2, David Bangsberg1, Ingrid V. Bassett1
1Massachusetts General Hosp, Boston, MA, USA, 2Mbarara Univ of Sci and Tech, Mbarara, Uganda, 3Epicentre, MSF, Mbarara, Uganda, 4MGH-Ragon Inst, Boston, MA, USA

774 CMV VIREMIA IN HIV-POSITIVE AND -NEGATIVE PREGNANT WOMEN IN BOTSWANA
Natasha O. Moraka1, Maryanne R. Ibrahim2, Sikhulile Moyo3, Prisca Thami4, Gloria Mayondo1, Christiana Smith1, Adriana Weinberg5, Rosemary Musonda1, Simani Gaseitsiwe1, Shahin Lockman5
1Botswana Harvard AIDS Inst Partnership, Gaberone, Botswana, 2Doris Duke Intl Clinical Rsr Fellowship, Los Angeles, CA, USA, 3Univ of Colorado, Denver, CO, USA, 4Univ of Colorado, Aurora, CO, USA, 5Harvard Univ, Boston, MA, USA
775 PREGNANCIES IN WOMEN WHO ACQUIRED HIV PERINATALLY
Mira Hleyhel1, Catherine Dollfus2, Roland Tubiana3, Christine Rouzioux4, Pierre Frange5, Stephane Blanche6, Jérôme Le Chenadec7, Albert Faye8, Laurent Mandelbrot9, Josiane Warszawski1

776 ANTENATAL ANTIRETROVIRAL THERAPY AND ADVERSE BIRTH OUTCOMES: THE PROMISE TRIAL
Benjamin H. Chi1, Mona Farhad2, Maxensia Owor3, Tsungai Chipato4, Min Qin5, Sufia Dadabha6, Devasena Gnanashanmugam7, Nahida Chakhtoura8, Mary Glenn Fowler9, Jeffrey S. Stringer1
1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Harvard Univ, Boston, MA, USA, 3Makerere Univ–Johns Hopkins Univ Rsr Collab, Kampala, Uganda, 4Univ of Zimbabwe, Harare, Zimbabwe, 5The Johns Hopkins Univ, Baltimore, MD, USA, 6DAIDS, NIAID, Rockville, MD, USA, 7NICHD, Bethesda, MD, USA

777 RISK FACTORS FOR LOW BIRTH WEIGHT AND PRETERM DELIVERY IN THE PROMISE TRIAL
Dorothy Sebikari1, Min Qin2, Maxensia Owor3, Jeffrey S. Stringer1, Mona Farhad1, Nahida Chakhtoura3, Benjamin H. Chi1, Karin Klingman4, Gerhard Theron5, Mary Glenn Fowler7
1Makerere Univ–Johns Hopkins Univ Rsr Collab, Kampala, Uganda, 2Harvard Univ, Boston, MA, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4NICHD, Bethesda, MD, USA, 5DAIDS, NIAID, Bethesda, MD, USA, 6Stellenbosch Univ, Cape Town, South Africa, 7The Johns Hopkins Univ, Baltimore, MD, USA

778 DO HIV+ WOMEN ON PROTEASE INHIBITORS DELIVER PRETERM? FINDINGS FROM A UK STUDY
Graziella Favarato, Claire Townsend, Heather Bailey, Claire Thorne, for the UK and Ireland National Study of HIV in Pregnancy and Childhood (NSHPC)
Univ Coll London, London, UK

779 TDF/FTC IN PREGNANCY SHOWS NO INCREASE IN ADVERSE INFANT BIRTH OUTCOMES IN US COHORTS
Kathryn Rough1, George R. Seage1, Paige L. Williams1, Sonia Hernandez-Diaz2, Yanling Huo3, Ellen G. Chadwick4, Risa M. Hoffman5, Emily Barr6, David E. Shapiro7, Kunjal Patel8
1Harvard Univ, Boston, MA, USA, 2Ann & Robert H. Lurie Children’s Hosp of Chicago, Chicago, IL, USA, 3Univ of California Los Angeles, Los Angeles, CA, USA, 4Children’s Hosp Colorado, Aurora, CO, USA

Poster P-R3 PHARMACOKINETICS AND DOSING OF ARVS AND COTREATMENTS IN CHILDREN AND YOUTH
Poster Hall - 4 EF
2:30 PM - 4:00 PM

806 DOLUTEGRAVIR PHARMACOKINETICS, SAFETY AND EFFICACY IN HIV+ CHILDREN 2 TO <6 YEARS OLD
Theodore Ruel1, Edward Acosta2, Rajendra P. Singh3, Carmelita Alvero3, Kathleen George4, Stephanie Popson4, Cindy Vavro5, Rohan Hazra6, Andrew Wiznia6, for the P1093 Team
1Univ of California, San Francisco, San Francisco, CA, USA, 2Univ of Alabama at Birmingham, Birmingham, AL, USA, 3GlaxoSmithKline, King of Prussia, PA, USA, 4Harvard Univ, Boston, MA, USA, 5FHI 360, Durham, NC, USA, 6Frontier Sci & Tech Rsr Fndn, Inc., Amherst, NY, USA, 7ViiV Hlthcare, Rsr Triangle Park, NC, USA, 8NICHD, Bethesda, MD, USA, 9Albert Einstein Coll of Med, Bronx, NY, USA
807 **PHARMACOKINETICS OF RILPIVIRINE AFTER SWITCHING FROM EFAVIRENZ IN ADOLESCENTS**

Watsamon Jantarabenjakul\(^1\), Narukjaporn Thammajaruk\(^2\), Torsak Bunupuradah\(^2\), Jirathaya Sophonphan\(^1\), Tim R. Cresssey\(^1\), Angela Colbers\(^4\), David M. Burger\(^5\), Wanatpreeya Phongsamart\(^1\), Thanyawee Puthanakit\(^1\), Chitsanu Pancharoen\(^1\)

\(^1\)Chulalongkorn Univ, Bangkok, Thailand, \(^2\)HIV Netherlands Australia Thailand Rsr Collab, Thai Red Cross Aids Rsr, Bangkok, Thailand, \(^3\)Prog for HIV Prevention and Treatment, Chiang Mai, Thailand, \(^4\)Radboud Univ, Nijmegen, Netherlands, \(^5\)Mahidol Univ, Bangkok, Thailand

808 **NEVIRAPINE PK, VIROLOGICAL OUTCOME, AND AE:s IN AFRICAN CHILDREN ON PAEDIATRIC FDCs**

Andrzej Bienczak\(^1\), Paolo Denti\(^1\), Adrian Cook\(^2\), Lubbe Wiesner\(^1\), Diana Gibb\(^2\), David M. Burger\(^3\), Sarah Walker\(^2\), Helen Mcilleron\(^1\), for the CHAPAS-3 Study Team

\(^1\)Univ of Cape Town, Cape Town, South Africa, \(^2\)Univ Coll London, London, UK, \(^3\)Radboud Univ Med Cntr, Nijmegen, Netherlands

809 **AN EASY-TO-USE PAEDIATRIC DOSING TOOL: ONE MG/KG DOSE DOES NOT FIT ALL**

Paolo Denti\(^1\), Nandita Sugandhi\(^2\), Tim R. Cresssey\(^1\), Mark Mirochnick\(^2\), Edmund V. Capparelli\(^3\), Martina Penazzato\(^4\), for the Paediatric ARV Working Group

\(^1\)Univ of Cape Town, Cape Town, South Africa, \(^2\)Clinton Hlth Access Initiative, New York, NY, USA, \(^3\)Prog for HIV Prevention and Treatment, Chiang Mai, Thailand, \(^4\)Boston Med Cntr, Boston, MA, USA, \(^5\)Univ of California San Diego, La Jolla, CA, USA, \(^6\)WHO, Geneva, Switzerland

810 **SERTRALINE PHARMACOKINETICS IN HIV-INFECTED ON ARV AND UNINFECTED YOUTH**

Nathan Hanan\(^1\), Mary Paul\(^1\), Yanling Huo\(^3\), Edmund Capparelli\(^1\), Suad Kapetanovic\(^3\), J. L. Ariansen\(^2\), Elizabeth Smith\(^1\), Pim Brouwers\(^4\), Brookie Best\(^5\), for the IMPAACT P1080 Protocol Team

\(^1\)Univ of California San Diego, La Jolla, CA, USA, \(^2\)Baylor Coll of Med, Houston, TX, USA, \(^3\)Harvard Univ, Boston, MA, USA, \(^4\)NIMH, Rockville, MD, USA, \(^5\)FHI 360, Durham, NC, USA, \(^6\)NIAID, Rockville, MD, USA

811 **SUBOPTIMAL COTRIMOXAZOLE PROPHYLACTIC CONCENTRATIONS IN CHILDREN**

Claire Pressiat\(^1\), Véronique Mea-Assande\(^2\), Caroline Yonaba\(^3\), Jean-Marc Treluyer\(^4\), Désiré Lucien Dahourou\(^5\), Madeleine Amorissani-Folquet\(^6\), Stephane Blanche\(^7\), Valeriane Leroy\(^8\), Déborah Hirt\(^9\), for the MONOD Study Group

\(^1\)Paris Descartes Univ, Paris, France, \(^2\)PACCI Prog, Abidjan, Cote d’Ivoire, \(^3\)CHU Yalgado Ouédraogo, Ouagadougou, Burkina Faso, \(^4\)Paris Cntr Hosp Group, Paris, France, \(^5\)Cntr de Rsr Intl Pour la Santé, Ouagadougou, Burkina Faso, \(^6\)CHU de Cocody, Abidjan, Cote d’Ivoire, \(^7\)Necker Hosp, Paris, France, \(^8\)INSERM, Toulouse, France, \(^9\)Paris Cntr Hosp Group, Paris, France
812 DOLUTEGRAVIR-BASED CART IN VERTICALLY HIV-1–INFECTED ADOLESCENTS, REAL-WORLD SETTING
Coralie Briand1, Catherine Dollfus1, Marion Caseris1, Elie Kantor2, Veronique Avettrand-Fenoël1, Diane Descamps3, Veronique Schneider1, Marie-Dominique Tabone1, Stephane Blanche1, Pierre Frange1
1Necker Hosp, Paris, France; 2Trouseau Hosp, Paris, France; 3Robert Debre Hosp, Paris, France; 4Bichat Hosp, Paris, France; 5Tenon Hosp, Paris, France

813 LONG-TERM EFFECTS OF WEEKENDS OFF ART IN HIV-1 INFECTED YOUNG PEOPLE ON EFV+2NRTI
Anna Turkova, for the BREATHER (PENTA 16) Trial Group
Univ Coll London, London, UK

814 COST-EFFECTIVENESS OF PREEMPTIVE SWITCH TO EFAVIRENZ (EFV) IN HIV-INFECTED CHILDREN
Sophie Desmonde1, Simone C. Frank2, Ashraf Coovadia3, Désiré Lucien Dahourou4, Elaine J. Abrams5, Rochelle P. Walensky6, Kenneth Freedberg7, Louise Kuhn8, Valeriane Leroy9, Andrea L. Ciaramello10
1Univ of Bordeaux, Bordeaux, France; 2Massachusetts General Hosp, Boston, MA, USA; 3Empilweni Service and Rsr Unit, Johannesburg, South Africa; 4Cntr de Rsr Intl Pour la Sante, Ouagadougou, Burkina Faso, 5ICAP at Columbia Univ, New York, NY, USA; 6Columbia Univ, New York, NY, USA, 7INSERM, Toulouse, France

815 PREDICTORS OF SWITCH TO SECOND-LINE ART IN HIV-POSITIVE CHILDREN: A GLOBAL ANALYSIS
Kara K. Wools-Kaloustian1, Colette J. Smith2, Ruth Goodall1, Intira J. Collins1, Elaine J. Abrams1, Mary-Ann Davies1, Mary Paul1, Jorge Pinto4, Russell B. Van Dyke4, for the CIPHER Durability of First Line Project Team
1Indiana Univ, Indianapolis, IN, USA; 2Univ Coll London, London, UK; 3ICAP at Columbia Univ, New York, NY, USA, 4Univ of Cape Town, Cape Town, South Africa, 5Baylor Coll of Med, Houston, TX, USA, 6Univ Fed de Minas Gerais, Belo Horizonte, Brazil, 7Tulane Univ, New Orleans, LA, USA

816 FREQUENT FAILURE AFTER SECOND-LINE ART IN HIV-POSITIVE CHILDREN FROM LATIN AMERICA
Bryan E. Shepherd1, Cathy Jenkins1, Regina Succ1, Daisy Machado1, Jorge Pinto1, Vanessa Rouzier4, Marco Luque5, Sten Vermund5, Catherine McGowan1, for the Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet)
1Vanderbilt Univ, Nashville, TN, USA; 2Univ Fed de Sao Paulo, Sao Paulo, Brazil, 3Univ Fed de Minas Gerais, Belo Horizonte, Brazil, 4Les Cntrs GHESKIO, Port-au-Prince, Haiti, 5Hosp Escuela Univ, Tegucigalpa, Honduras

817LB HIV-INFECTED CHILDREN WITH SEVERE ACUTE MALNUTRITION: EARLY VS DELAYED ART INITIATION
Moherndran Archary1, Benn Sartorius1, Philip La Russa2, Thobekile Sibaya1, Micheal Healy1, Raziya Bobat1
1Univ of KwaZulu-Natal, Durban, South Africa, 2Columbia Univ, New York, NY, USA
842 RACIAL DISPARITIES IN HIV PREVALENCE AND COMPOSITION OF RISK NETWORKS, HPTN 037
Florence Momplaisir1, Mustafa Hussein2, Danielle Fiore3, Laramie Smith4, David Bennett5, Carl Latkin6, David Metzger7
1Drexel Coll of Med, Philadelphia, PA, USA, 2Univ of Wisconsin-Milwaukee, Milwaukee, WI, USA, 3Univ of Pennsylvania, Philadelphia, PA, USA, 4Univ of California San Diego, La Jolla, CA, USA, 5Drexel Univ, Philadelphia, PA, USA, 6The Johns Hopkins Univ, Baltimore, MD, USA

843 CONCURRENCY IN THE SEXUAL NETWORKS OF Racially Diverse YMSM
Patrick Janulis, Gregory Phillips, Brian Mustanski, Michelle Birkett
Northwestern Univ, Chicago, IL, USA

844 HIV TRANSMISSION IN TIJUANA, MEXICO: REAL-TIME IDENTIFICATION OF A NEW CLUSTER
Antoine Chaillon1, Patricia Gonzalez-Zuniga1, Tommi O. Gaines1, Horacio Almanza1, Jose R. Chavez1, Jesus Vera2, Thomas L. Patterson2, Davey M. Smith3, Steffanie A. Strathdee2, Sanjay R. Mehta1
1Univ of California San Diego, San Diego, CA, USA, 2Autonomous Univ of Baja California, Tijuana, Mexico, 3Univ of California San Diego, La Jolla, CA, USA

845LB IDENTIFYING AND INVESTIGATING A RAPIDLY GROWING HIV TRANSMISSION CLUSTER IN TEXAS
Analise C. Monterosso1, Sydney Minnerly1, Samuel Goings1, Allyson Morris1, Anne Marie France1, Sharoda Dasgupta1, Alexandra Oster1, Miranda Fanning1
1Texas Dept of State Hlth Services, Austin, TX, USA, 2CDC, Atlanta, GA, USA

846 SEXUAL NETWORKS OF CIS AND TRANSGENDER PEOPLE WITH & AT-RISK FOR HIV, KING COUNTY, WA
Julia Hood1, David A. Katz2, Lindley A. Barbee2, Sara N. Glick2, Amy Bennett1, Susan Buskin1
1Pub Hlth–Seattle & King County, Seattle, WA, USA, 2Univ of Washington, Seattle, WA, USA

847 SPATIAL CLUSTERING OF HIV IN KENYA MAY NOT MATCH WELL-KNOWN EPIDEMIC PATTERN
Anthony Waruru1, Thomas Achia1, James Nganga1, Joyce Wamicwe1, James Tobias4, Mary Mwangi1, Evelyn Muthama1, Emily Zielinski-Gutierrez2, Tom Oluoch2, Thorkild Tylleskär1

848 A FRAMEWORK FOR PREDICTING PHYLOGENETIC CLUSTERS OF HIV AT HIGH RISK FOR GROWTH
David McVea1, Richard Liang2, Jeffrey Joy3, P. Richard Harrigan2, Art Poon3
1Univ of British Columbia, Vancouver, Canada, 2BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 3Western Univ, London, Ontario, Canada
849 NETWORK VIRAL LOAD: A CRITICAL METRIC FOR HIV ELIMINATION
Britt Skaathun, Aditya Khanna, Ethan Morgan, Samuel R. Friedman, John A. Schneider
1Univ of Chicago, Chicago, IL, USA, 2Natl Development & Rsr Insts, New York, NY, USA

850 IDENTIFYING A GEOSPATIAL RELATIONSHIP BETWEEN COMMUNITY-LEVEL RISK AND HIV PREVALENCE
Laurence Palk, Sally Blower
Univ of California Los Angeles, Los Angeles, CA, USA

Poster P-S10 STIGMA, MENTAL HEALTH, AND SEXUAL VIOLENCE
Poster Hall - 4 EF 2:30 PM - 4:00 PM

918 STIGMA ASSOCIATED WITH HIV/STI INCIDENCE AMONG NIGERIAN MEN WHO HAVE SEX WITH MEN
Cristina Rodriguez-Hart, Rebecca G. Nowak, Rashelle Musci, Danielle German, Ifeanyi Orazulike, Uchenna Ononaku, Hongjie Liu, Trevor Crowell, Stefan Baral, Man Charurat
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Univ of Maryland, Baltimore, MD, USA, 3Inst Hlth Advocacy & Rights to Hlth, Abuja, Nigeria, 4Inst of Human Virology Nigeria, Abuja, Nigeria, 5Univ of Maryland, Coll Park, Coll Park, MD, USA, 6US Military HIV Rsr Prtg, Bethesda, MD, USA

919 POPULATION TRENDS IN HIV STIGMA IN LUSAKA, ZAMBIA, 2004–2011
Margaret P. Kasaro, Marie Stoner, Sujit Rathod, Tessa Roberts, Jennifer Winston, Richard Banda, Thankian Kusanthan, Jeffrey S. Stringer, Benjamin H. Chi

920 DEPRESSION AND ART INITIATION AMONG HIGH-RISK HIV SERODISCORDANT COUPLES IN AFRICA
Jennifer Velloza, Connie L. Celum, Haberer Jessica, Kenneth Ngure, Elizabeth Irungu, Nelly Mugo, Jared Baeten, Renee Heffron, for the Partners Demonstration Project Team
1Univ of Washington, Seattle, WA, USA, 2Cntr for Global Hlth, Massachusetts General Hosp, Boston, MA, USA, 3Kenya Med Rsr Inst, Nairobi, Kenya

921 HIV STIGMA, DEPRESSION, ADHERENCE, AND VIRAL LOAD AMONG HIV+ AFRICAN-AMERICAN WOMEN
Lauren Lipira, Emily C. Williams, David Huh, Patrick J. Heagerty, Audrey French, Susan E. Cohn, Janet M. Turan, Michael J. Mugavero, Deepa Rao
1Univ of Washington, Seattle, WA, USA, 2Ruth M. Rothstein CORE Cntr, Chicago, IL, USA, 3Northwestern Univ, Chicago, IL, USA, 4Univ of Alabama at Birmingham, Birmingham, AL, USA

922 THE CAUSAL EFFECT OF DEPRESSION ON VIRAL SUPPRESSION AMONG ADULTS IN HIV CARE
Alison Hughes, Susan Scheer
San Francisco Dept of Pub Hlth, San Francisco, CA, USA
923 SOCIAL ECOLOGICAL FACTORS ASSOCIATED WITH SEX WORK AMONG TRANSGENDER WOMEN IN JAMAICA
Carmen H. Logie1, Ying Wang1, Nicolette Jones2, Uzma Ahmed1, Kendasi Levermore2, Tyrone Ellis1, Ava Neil1, Annecka Marshall1, Ashley A. Lacombe-Duncan1, Peter A. Newman1
1Univ of Toronto, Toronto, Canada, 2Jamaica AIDS Support for Life, Kingston, Jamaica, 3Univ of the West Indies, Mona Campus, Kingston, Jamaica

924 SEXUAL ORIENTATION DIFFERENCES IN HEALTH AND WELLBEING AMONG WOMEN WITH HIV IN CANADA
Carmen H. Logie1, Ashley A. Lacombe-Duncan1, Ying Wang1, Angela Kaida2, Alexandra de Pokomandy1, Kath Webster1, Tracey Conway1, Mona Loutfy2
1Univ of Toronto, Toronto, Canada, 2Simon Fraser Univ, Vancouver, Canada, 3McGill Univ, Montreal, Canada, 4Women's Coll Rsr Inst, Toronto, Canada

925 HEALTH OUTCOMES ASSOCIATED WITH GENDER-BASED VIOLENCE AMONG WOMEN WITH HIV IN CANADA
Carmen H. Logie1, Angela Kaida2, Alexandra de Pokomandy1, Erin Ding1, Nadia O'Brien2, Uzma Ahmed1, Tracey Conway1, Val Nicholson2, Mona Loutfy2
1Univ of Toronto, Toronto, Canada, 2Simon Fraser Univ, Vancouver, Canada, 3McGill Univ, Montreal, Canada, 4BC Cntr for Excellence in HIV Rsr, Vancouver, Canada, 5Women’s Coll Rsr Inst, Toronto, Ontario

926 TRANS WOMEN WITH HIV IN CANADA: RESULTS OF A NATIONAL COMMUNITY-BASED COHORT STUDY
Ashley A. Lacombe-Duncan1, Yasmeen Persad2, Greta R. Bauer3, Carmen H. Logie1, Angela Kaida4, Alexandra de Pokomandy1, Nadia O'Brien2, Mona Loutfy4, for the CHIWOS Research Team
1Univ of Toronto, Toronto, ON, Canada, 2The 519, Toronto, ON, Canada, 3Western Univ, London, Ontario, Canada, 4Simon Fraser Univ, Vancouver, Canada, 5McGill Univ, Montreal, Canada, 6Women’s Coll Rsr Inst, Toronto, Ontario, Canada

927 THE HEALTH IMPACT OF SEXUAL VIOLENCE AMONG WOMEN IN A PLATINUM MINING BELT
Meiwen Zhang1, Sarah Jane Steele1, Amir Shroufi1, Gilles van Cutsem1, Junaid Khan2, Garret Barnwell2, Julia Hill2, Kristal Duncan1
1MSF, Cape Town, South Africa, 2MSF, Rustenburg, South Africa

Poster P-S11 MORBIDITY, MORTALITY, AND VIRAL DYNAMICS
Poster Hall - 4 EF
2:30 PM - 4:00 PM

928 ASSOCIATION OF SEX AND RACE WITH HIV-/NON-HIV–RELATED DEATH IN TREATED HIV INFECTION
David B. Hanna1, Donald R. Hoover2, Qihu Shi3, Uriel Felsen1, Mark H. Kuninholm1, Mindy S. Ginsberg1, Howard D. Strickler1, Kathryn Anastos1
1Albert Einstein Coll of Med, Bronx, NY, USA, 2Rutgers, the State Univ of New Jersey, New Brunswick, NJ, USA, 3New York Med Coll, Valhalla, NY, USA, 4State Univ of New York at Albany, Rensselaer, NY, USA

929 IMPACT OF INJECTION DRUG USE AND SELECTED COMORBIDITIES ON HEALTHY LIFE EXPECTANCY
Robert S. Hogg, Oghenowede Eyawo, Wendy Zhang, Paul Serada, Mark Hull, Jean A. Shoveller, Karyn Gabler, Viviane D. Lima, Julio S. Montaner, for the Comparative Outcomes And Service Utilization Trends (COAST) study
BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
LONGITUDINAL ASSOCIATION BETWEEN HIV STATUS AND MEDICALLY SIGNIFICANT FALLS
Julie A. Womack1, Terrence E. Murphy2, Harini Bathulapalli1, Jonathan Bates3, Cynthia L. Gibert1, Maria Rodriguez-Barradas3, Phyllis Tien2, Michael T. Yin1, Cynthia A. Brandt1, Amy Justice1
1VA Connecticut Healthcare System, West Haven, CT, USA, 2Yale Univ, New Haven, CT, USA, 3Washington, DC, VA Med Ctr, Washington, DC, USA, 4Baylor Coll of Med, Houston, TX, USA, 5Univ of California San Francisco, San Francisco, CA, USA, 6Columbia Univ, New York, NY, USA

VIREMIA COPY-YEARS & MORTALITY IN HIV+ MEN STARTING ART: HOW MUCH HISTORY IS NEEDED?
Ruibin Wang1, Sabina Haberlen1, Frank J. Palella2, Joseph B. Margolick1, Bernard Macatangay1, Otoniel Martinez-Maza3, Lisa Jacobson1, Alison Abraham1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Northwestern Univ, Chicago, IL, USA, 3Univ of Pittsburgh, Pittsburgh, PA, USA, 4Univ of California, Los Angeles, Los Angeles, CA, USA

LOW-LEVEL VIREMIA IS ASSOCIATED WITH VIROLOGIC FAILURE IN A LARGE MILITARY COHORT
Christie Joya1, Seung Hyun Won1, Karl Kronmann1, Jason Okulicz4, Timothy Whitman1, Robert Deiss1, Christina Schofield4, Julie Pavlin1, Brian K. Agan1, Anuradha Ganesan5
1Walter Reed Natl Military Med Ctr, Bethesda, MD, USA, 2Henry M. Jackson Fndn for Advancement of Military Med, Bethesda, MD, USA, 3Naval Med Ctr Portsmouth, Portsmouth, VA, USA, 4Brooke Army Med Ctr, San Antonio, TX, USA, 5Uniformed Services Univ of the Hlth Scis, Rockville, MD, USA, 6Madigan Army Med Ctr, Tacoma, WA, USA

LONGITUDINAL VIRAL TRAJECTORY AMONG WOMEN IN THE WOMEN’S INTERAGENCY HIV STUDY
Seble Kassaye1, Cuiwei Wang1, Jeff Collmann1, Tracey Wilson2, Kathryn Anastos1, Mardge H. Cohen1, Ruth Greenblatt, Joel Milam1, Steven Gange1, Michael Plankey1
1Georgetown Univ, Washington, DC, USA, 2SUNY Downstate Med Ctr, Brooklyn, NY, USA, 3Albert Einstein Coll of Med, Bronx, NY, USA, 4John H.Stroger Jr. Hosp of Cook County, Chicago, IL, USA, 5Univ of California San Francisco, San Francisco, CA, USA, 6Univ of Southern California, Los Angeles, CA, USA, 7The Johns Hopkins Univ, Baltimore, MD, USA

THE EPIDEMIOLOGY OF HIV IN PEOPLE BORN OUTSIDE THE UNITED STATES, 2010–2014
Roxanne P. Kerani1, Anna S. Johnson2, Susan Buskin1, Deepa Rao1, Matthew R. Golden1, Xiaohong Hu2, Irene Hall3
1Univ of Washington, Seattle, WA, USA, 2CDC, Atlanta, GA, USA, 3Pub Hlth—Seattle & King County, Seattle, WA, USA

CHANGES IN HIV RISK FACTORS AMONG MEN WHO HAVE SEX WITH MEN AND WOMEN, 2008–2014
Wade Ivy1, Thema Chapple1, Gabriela Paz-Bailey1, for the NHBS Study Group
1CDC, Atlanta, GA, USA, 2Morehouse Coll, Atlanta, GA, USA
ASSOCIATION BETWEEN HOUSING STABILITY AND NEW HIV DIAGNOSIS IN SEEK AND TEST STUDIES

Bridget Whitney¹, Bridget Kruszka¹, Jennifer Lorvick², Gregory M. Lucas³, Wendee Wechsberg⁴, Irene Kuo⁵, William E. Cunningham⁶, Asa Clemenz-Alien⁶, Julie Franks⁵, Heidi M. Crane⁶
¹Univ of Washington, Seattle, WA, USA, ²RTI Intl, Berkeley, CA, USA, ³The Johns Hopkins Univ, Baltimore, MD, USA, ⁴RTI Intl, Rsr Triangle Park, NC, USA, ⁵George Washington Univ, Washington, DC, USA, ⁶Univ of California Los Angeles, Los Angeles, CA, USA, ⁷Univ of California San Francisco, San Francisco, CA, USA, ⁸Columbia Univ, New York, NY, USA

HIV INCIDENCE AND RISK BEHAVIORS IN THE BANGKOK MSM COHORT STUDY, THAILAND, 2006–2015

Timothy H. Holtz¹, Anchalee Varangrat², Philip Mock³, Waruneen Thienkrua⁴, Wannee Chonwattana⁵, Wipas Wimonsate⁶, Wichuda Sukwicha⁷, Marcel Curlin⁸, Eileen Dunne⁹, Anupong Chitwarakorn¹⁰
¹CDC, Atlanta, GA, USA, ²Thailand Ministry of Pub Hlth–US CDC Collab, Nonthaburi, Thailand, ³Oregon Hlth and Scis Univ, Portland, OR, USA, ⁴US CDC, Nonthaburi, Thailand, ⁵Thailand Ministry of Pub Hlth, Nonthaburi, Thailand

CHANGES IN RISK BEHAVIORS AFTER HIV SEROCONVERSION, BANGKOK MSM COHORT STUDY

Wipas Wimonsate¹, Sarika Pattanasin¹, Pikunchai Luechai¹, Jaray Tongtoyai¹, Wichuda Sukwicha¹, Chaiwat Ungsedhapand¹, Anupong Chitwarakorn¹, Michael Thigpen², Eileen Dunne³, Timothy Holtz¹
¹Thailand Ministry of Pub Hlth–US CDC Collab, Nonthaburi, Thailand, ²Thailand Ministry of Pub Hlth, Nonthaburi, Thailand, ³US CDC, Nonthaburi, Thailand

AN EMPIRIC RISK SCORE TO GUIDE PREP UPTAKE IN MSM IN COASTAL KENYA

Elizabeth Wahome¹, Alexander N. Thiong’o¹, Oscar Chirro¹, Evans Gichuru¹, John Mwambi¹, Matt A. Price², Susan M. Graham³, Eduard Sanders⁴
¹KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya, ²Intl AIDS Vaccine Initiative, New York, NY, USA, ³Univ of Washington, Seattle, WA, USA, ⁴Kenya Med Rsr Inst, Kilifi, Kenya

VALIDATION OF A RISK SCORE FOR HIV ACQUISITION IN YOUNG AFRICAN WOMEN WITH FACTS 001

Emma K. Burgess¹, Sinead Delany-Moretwe², Pedro Pisa³, Khatija Ahmed³, Sydney Sibiya⁴, Cynthia Gama⁵, Busiswe Nkala⁶, Gustavo Doncel⁷, Glenda Gray⁸, Helen Rees⁹
¹Global Hlth Fellows Internship at USAID, Arlington, VA, USA, ²Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, ³Setshaba Rsr Cntr, Pretoria, South Africa, ⁴Qhakaza Mbokodo Rsr Clinic, Ladysmith, South Africa, ⁵MatCH, Durban, South Africa, ⁶Perinatal HIV Rsr Unit, Soweto, South Africa, ⁷CONRAD, Arlington, VA, USA

SELF-ASSESSED HIV RISK 3 YEARS AFTER HIV “TEST AND TREAT” IMPLEMENTED IN SEARCH

James Ayieko¹, Dalsone Kwariisima², Catherine A. Koss³, Craig Cohen³, Elizabeth A. Bukusi⁴, Tamara D. Clark⁴, Edwin D. Charlebois⁴, Moses R. Kamya⁵, Maya L. Petersen⁶, Diane V. Havlir⁷
¹Kenya Med Rsr Inst, Nairobi, Kenya, ²Makerere Univ Joint AIDS Prog, Kampala, Uganda, ³Univ of California San Francisco, San Francisco, CA, USA, ⁴Makerere Univ, Kampala, Uganda, ⁵Univ of California Berkeley, Berkeley, CA, USA
859 HIV RISK FACTORS AND RISK PERCEPTION AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN MALAWI
Joan T. Price1, Nora E. Rosenberg2, Bertha Maseko3, Savvy Brar2, Twambibille Phanga2, Audrey Pettifor1, Linda-Gail Bekker3
1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Univ of North Carolina Proj–Malawi, Lilongwe, Malawi, 3Univ of Cape Town, Cape Town, South Africa

860 GENDERED PATTERNS OF MOBILITY PREDICT HIV PREVALENCE IN UGANDA/KENYA IN SEARCH STUDY
Carol S. Camlin1, Tor Neilands1, Jane Kabami2, Gabriel Chami1, Elizabeth A. Bukusi1, Tamara D. Clark1, Moses R. Kamya4, Maya L. Petersen2, Diane V. Havlir1, Edwin D. Charlebois1
1Univ of California San Francisco, San Francisco, CA, USA, 2Infectious Diseases Rsr Collab, Kampala, Uganda, 3Kenya Med Rsr Inst, Nairobi, Kenya, 4Makerere Univ, Kampala, Uganda, 5Univ of California Berkeley, Berkeley, CA, USA

861 HIGH RISK BEHAVIOR IN MARRIED PEOPLE LIVING WITH HIV: IMPLICATIONS FOR PREVENTION
Zachary A. Kwena1, Catherine K. Makokha1, David O. Ang’awa1, Elizabeth A. Bukusi1

862 HIV AND SYPHILIS COINFECTION IN MEN WHO HAVE SEX WITH MEN, BANGKOK, 2005–2016
Chaiwat Ungsedhapand1, Kanokpan Panchoien1, Anuwat Sriporn1, Wichuda Sukwicha1, Witas Wimonsate1, Nutthawoot Promda1, Santi Winaihant1, Anupong Chitwarakorn2, Eileen F. Dunne2, Michael Thigpen3
1Thailand MOPH–US CDC Collab, Nonthaburi, Thailand, 2Thailand MOPH, Nonthaburi, Thailand, 3US CDC, Nonthaburi, Thailand

863 SUBSEQUENT AND RECURRENT STI AMONG THAI MSM AND TG IN TEST AND TREAT COHORT
Akarin Hiransuthikul1, Supanit Pattanachaiewit1, Nipat Teeratakulpisarn1, Parinya Chamnan3, Panita Pathipvanich3, Suchart Thongpaen3, Supabhorn Pengnonyang3, Deondara Trachunthong3, Nittaya Phanuphak3, for the Thai MSM/TG Test and Treat Study Group
1The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 2Sanpasitthiprasong Hosp, Ubonratchathani, Thailand, 3Lampang Hosp, Lampang, Thailand, 4Mahasarakham Hosp, Mahasarakham, Thailand

Richard Novak1, Abdelhamid Ghanem1, Rachel Hart2, Douglas Ward3, Carl Armon1, Kate Buchacz2
1Univ of Illinois at Chicago, Chicago, IL, USA, 2Cerner Corp, Kansas City, MO, USA, 3Dupont Circle Physicians Group, Washington, DC, USA, 4CDC, Atlanta, GA, USA
**INCIDENT SYPHILIS INFECTIONS DECLINED IN WELL-CHARACTERIZED COHORT OF HIV+ PERSONS**

Anuradha Ganesan¹, Xun Wang², Robert Deiss³, Julie Pavlin⁴, Tomas Ferguson⁵, Thomas O'Bryan⁶, Jason Okulicz⁷, Ryan Maves⁷, Karl Kronmann⁷, Grace Macalino¹

¹Uniformed Services Univ of the Hlth Scis, Rockville, MD, USA, ²Henry M. Jackson Fndn for the Advancement of Military Med, Rockville, MD, USA, ³Tripler Army Med Cntr, Honolulu, HI, USA ⁴Uniformed Services Univ of the Hlth Scis, San Antonio, TX, USA, ⁵San Antonio Military Med Cntr, San Antonio, TX, USA, ⁶Naval Med Cntr San Diego, San Diego, CA, USA, ⁷Naval Med Cntr Portsmouth, Portsmouth, VA, USA

**INCIDENT SYPHILIS INFECTIONS IN HIV-POSITIVE PATIENTS IN CARE**

Raynell Lang¹, Ron Read², Soheil Ramazani³, John Gill²

¹Alberta Hlth Services, Calgary, Canada, ²Univ of Calgary, Calgary, Canada, ³Southern Alberta Clinic, Calgary, Canada

**SCREENING FOR EXTRAGENITAL CT/GC AMONG HIV-INFECTED MSM: A COMPARISON OF 4 NAATs**

Jodie Dionne-Odom, Kristal Aaron, Mary Banasiewicz, Sarah Dougherty, Brice Daniels, James Raper, Edward Hook, Barbara Van Der Pol

Univ of Alabama at Birmingham, Birmingham, AL, USA

**NALTREXONE IMPLANT IMPROVES HIV TX OUTCOMES VS ORAL NTX IN OPIATE ADDICTED PATIENTS**

Evgeny Krupitsky¹, Edwina Zwartau¹, E. Blokhina¹, Elena Verbitskaya¹, D. Liozovο¹, T. Yaroslavtseva¹, Sabrina Poole², Robert Gross², George Woody²

¹First Pavlov State Med Univ of St. Petersburg, St. Petersburg, Russian Federation, ²Univ of Pennsylvania, Philadelphia, PA, USA

**RISK- AND SYMPTOM-BASED SCREENING IMPROVES IDENTIFICATION OF ACUTE HIV INFECTION**

Maartje Dijkstra¹, Godelieve J. de Bree², Ineke Stolte¹, Udi Davidovich¹, Eduard Sanders¹, Maria Prins¹, Maarten F. Schim van der Loeff¹

¹Pub Hlth Service Amsterdam, Netherlands, ²Academic Med Cntr, Amsterdam, Netherlands, ³Kenya Med Rsr Inst, Kilifi, Kenya

**IMPLEMENTATION OF A RAPID TRAJECTORY TO IDENTIFY ACUTE HIV INFECTION IN AMSTERDAM**

Maartje Dijkstra¹, Elske Hoornenborg¹, Udi Davidovich¹, Arjan Hogewoning¹, Henry J.C. de Vries¹, Sylvia Bruisten¹, Maria Prins¹, Maarten F Schim van der Loeff¹, Godelieve J. de Bree¹

¹Pub Hlth Service Amsterdam, Netherlands, ²Academic Med Cntr, Amsterdam, Netherlands

**COMPARISON OF SELF-REPORT TO BIOMARKERS OF RECENT INFECTION**

Katherine E. Schlusser¹, Shweta Sharma², Pola de la Torre³, Giuseppe Tambussi³, Rika Draenert³, Angie N. Pinto³, Julia A. Metcalf³, Danielle German¹, James Neaton², Oliver Laeyendecker²

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Univ of Minnesota, Minneapolis, MN, USA, ³Cooper Univ Hosp, Camden, NJ, USA, ⁴Ospedale San Raffaele, Milano, Italy, ⁵Klinikum der Univ Munich, Munich, Germany, ⁶Kirby Inst, Sydney, Australia, ⁷NIAID, Bethesda, MD, USA
USE OF TESTING HISTORY TO IDENTIFY HIV-INFECTED PEOPLE AT HIGH RISK OF TRANSMISSION
Laurie Linley1, Richard M. Selik1, Xiaona Qian2, Alexandra Oster1
1CDC, Atlanta, GA, USA, 2ICF Intl, Atlanta, GA, USA

VIRAL LOADS NEAR HIV DIAGNOSIS: VARIATION WITH STAGE (0, 1, 2, OR 3) AT DIAGNOSIS
Richard M. Selik, Laurie Linley, Mi Chen
CDC, Atlanta, GA, USA

Poster P-T4 LESSONS FROM SEROCONVERSION ON PREP AND MICROBICIDES
Poster Hall - 4 EF 2:30 PM - 4:00 PM

DOES THE E138A MUTATION IN ASPIRE SEROCONVERTERS AFFECT SUSCEPTIBILITY TO DAPIVIRINE?
Kerri Penrose1, Breanna J. Goetz1, Kelley C. Gordon1, Daniel W. Szydlo2, Marla J. Husnik1, Thesla Palanee-Phillips1, Jared Baeten1, John Mellors1, Urvi Parikh1, for the MTN020/ASPIRE Study Team
1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Statistical Cntr for HIV/AIDS Rsr and Prevention (SCHARP), Seattle, WA, USA, 3Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, 4Univ of Washington, Seattle, WA, USA

NNRTI-CONTAINING ART IS EFFECTIVE FOR DAPIVIRINE RING BREAKTHROUGH HIV-1 INFECTION
Sharon Riddler1, Jennifer Balkus1, John Mellors1, Urvi Parikh1, Carolyne Akello1, Sofia Dadabhai1, Felix Mhlanga1, Colin O’Rourke1, Jared Baeten1, John Mellors1, Urvi Parikh1, for the MTN020/ASPIRE Study Team
1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 3Makerere Univ-Johns Hopkins Univ Rsr Collab, Kampala, Uganda, 4The Johns Hopkins Univ, Baltimore, MD, USA, 5Univ of Zimbabwe, Harare, Zimbabwe, 6Univ of Washington, Seattle, WA, USA

ACUTE INFECTION WITH A WILD-TYPE HIV-1 VIRUS IN PREP USER WITH HIGH TDF LEVELS
Elske Hoornenborg1, Godelieve J. de Bree2, for the Amsterdam PrEP Project in the HIV Transmission Elimination Amsterdam Consortium (H-TEAM)
1Pub Hlth Service Amsterdam, Amsterdam, Netherlands, 2Academic Med Cntr, Amsterdam, Netherlands

HIV GENETIC DIVERSITY TO INFERENCE PREP ADHERENCE AT THE ESTIMATED TIME OF INFECTION
Olivia Council1, Susan Ruone1, Philip Mock2, George Khalil1, Marcel Curnl1, Walid Heneine1, Kachit Choopanya1, Michael Martin2, Gerardo Garcia-Lerma1
1CDC, Atlanta, GA, USA, 2Thailand MOPH-US CDC Collab, Nonthaburi, Thailand, 3Oregon Hlth and Scis Univ, Portland, OR, USA, 4Bangkok Tenofovir Study Group, Bangkok, Thailand

CHARACTERIZATION OF HIV SEROCONVERTERS IN A TDF/FTC PREP STUDY: HPTN 067
Mariya V. Sivay1, Yinfeng Zhang1, Sarah E. Hudelson1, Maoji Li2, Estelle Piwowar-Manning1, Mark A. Marzinke1, Kevin Boko2, Robert Grant1, Susan H. Eshleman1, for the HPTN 067 Study Team
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 3HHI 360, Durham, NC, USA, 4Univ of California San Francisco Gladstone Insts, San Francisco, CA, USA
982  PREDICTORS OF MEDICAL MALE CIRCUMCISION UPTAKE BY MEN AGED 25-39 YEARS IN NYANZA
Donath Emusu, Kawango Agot, Jonathan Grund, Paul K Musingila, Frankline Onchiri, Edward Mboya, Jacob Onyang, Eunice Omanga, Elijah Odoyo-June, Boaz Otieno-Nyunya
1US CDC, Nairobi, Kenya, 2Impact Rsr and Development Org, Kisumu, Kenya, 3CDC, Atlanta, GA, USA
4US CDC, Kisumu, Kenya, 5Seattle Children’s Rsr Inst, Seattle, WA, USA

983  MALE CIRCUMCISION AND RISK COMPENSATION IN KWAZULU-NATAL, SOUTH AFRICA
Katrina F. Ortblad, Guy Harling, Joshua A. Salomon, Frank Tanser, Deenan Pillay, Tinaofa Mutevedzi, Till Baernighausen
1Harvard Univ, Boston, MA, USA, 2Africa Cntr for Pop Hlth, Mtubatuba, South Africa, 3Africa Hlth Rsr Inst, Mtubatuba, South Africa, 4Heidelberg Univ, Heidelberg, Germany

984  RISK COMPENSATION OVER 2 YEARS AMONG MEN IN A NATIONAL VMMC ROLL-OUT IN ZIMBABWE
Daniel E. Montano, Danuta Kasprzyk, Deven T. Hamilton, Mufuta Tshimanga
1Univ of Washington, Seattle, WA, USA, 2Univ of Zimbabwe, Harare, Zimbabwe

985  WITHDRAWN

986  AGREEMENT OF SELF-REPORTED AND PHYSICALLY VERIFIED MALE CIRCUMCISION STATUS IN KENYA
Elijah Odoyo-June, Kawango Agot, Edward Mboya, Jonathan Grund, Paul K Musingila, Donath Emusu, Leonard Soo, Boaz Otieno-Nyunya
1US CDC, Nairobi, Kenya, 2Impact Rsr and Development Org, Kisumu, Kenya, 3CDC, Atlanta, GA, USA

987  VOLUNTARY MEDICAL MALE CIRCUMCISION FOR NONCOMMUNICABLE DISEASE CASE FINDING, NAMIBIA
Nikki Soboil, Shawn J. Rooiinasie, Catherine Laube, Abubakari Mwinyi, Amir Shaker
1Jhpiego, Swakopmund, Republic of Namibia, 2Ministry of Hlth and Social Services, Erongo Regional Directorate, Swakopmund, Republic of Namibia, 3Jhpiego, Baltimore, MD, USA
Poster P-X1 MODELLING HIV TRANSMISSION
Poster Hall - 4 EF  2:30 PM - 4:00 PM

1024  DISTRIBUTION OF HIV TRANSMISSION BY NETWORK AND CLINICAL FACTORS AMONG US MSM
Johanna Chapin-Bardales¹, Samuel Jenness², Eli Rosenberg², Patrick Sullivan¹, Steven M. Goodreau¹
¹Emory Univ, Atlanta, GA, USA, ²Univ of Washington, Seattle, WA, USA

1025  HIV TRANSMISSION IN GENERALIZED, CONCENTRATED, AND MIXED EPIDEMICS IN WESTERN KENYA
Anna Bershteyn¹, Vibhuti Hate², Daniel J. Klein¹, Zindoga Mukandavire³, Graham F. Medley¹, Wanjurui Mukoma¹, Michael K. Kiragu¹, Kristine Torjesen², Nduku Kilonzo³, Katharine Kripke³, for the OPTIONS Consortium

1026  ANALYZING “MISSING MEN” IN THE UK HETEROSEXUAL HIV EPIDEMIC BY DSPS-HIV SIMULATIONS
Emma B. Hodcroft¹, Manon Ragonnet-Cronin², Joel O. Wertheim³, Samantha Lycett⁴, Sergei L. Kosakovsky Pond⁵, Andrew Leigh Brown⁶
¹Univ of Edinburgh, Edinburgh, Scotland, ²Univ of Edinburgh, Midlothian, Scotland, ³Univ of California San Diego, San Diego, CA, ⁴Temple Univ, Philadelphia, PA, USA

1027  TEMPORAL EVOLUTION OF HIV SERODISCORDANCY AMONG STABLE COUPLES IN SUB-SAHARAN AFRICA
Susanne Awad, Hiam Chemaitelly, Laith J. Abu-Raddad
Weill Cornell Med Coll in Qatar, Doha, Qatar

Poster P-X4 MODELLING TO GUIDE IMPROVEMENTS IN THE CARE CASCADE
Poster Hall - 4 EF  2:30 PM - 4:00 PM

1040  PAST AND FUTURE IMPACT OF ART SCALE-UP IN BRAZIL: PROGRAMME DATA ANALYSIS 1996–2014
Juan F. Vesga¹, Ana R. Pati Pascom², Tara Mangal¹, Marcelo Freitas¹, Juliana M. Givisiez², Ronaldo de Almeida Coelho², Mariana Veloso Meirelles², Clarissa Habkost Dutra de Barros⁵, Adele Benzaken⁵, Timothy B. Hallett¹
¹Imperial Coll London, London, UK, ²Ministry of Hilt, Brasilia (DF), Brazil

1041  EARLIER DIAGNOSIS AND TREATMENT REDUCES HIV TRANSMISSION IN MSM IN THE NETHERLANDS
Ard van Sighem¹, Daniela Bezemer¹, Eline Op de Coul², Judith Branger³, Mark de Boer⁴, Peter Reiss², for the ATHENA National Observational HIV Cohort
¹Stichting HIV Monitoring, Amsterdam, Netherlands, ²Natl Inst for Pub Hilt and the Environment, Bilthoven, Netherlands, ³Flevziekenhuis, Almere, Netherlands, ⁴Leiden Univ Med Cntr, Leiden, Netherlands, ⁵Stichting HIV Monitoring and Academic Med Cntr Amsterdam, Amsterdam, Netherlands

1042  ACHIEVING THE 90-90-90 TARGET BY 2020: THE EXPERIENCE IN BRITISH COLUMBIA, CANADA
Viviane D. Lima, Martin St-Jean, Jean A. Shoveller, P. Richard Harrigan, Bohdan Nosyk, Robert S Hogg, Paul Sereda, Rolando Barrios, Julio S. Montaner
BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
1043  THE CLINICAL AND ECONOMIC IMPACT OF ATTAINING NHAS TREATMENT TARGETS IN THE US
Ethan D. Borre 1, Emily P. Hyle 1, Paul E. Sax 2, A. David Paltiel 3, Anne M. Neillan 1, Kenneth Freedberg 1, Rochelle P. Walensky 4
1Massachusetts General Hosp, Boston, MA, USA, 2Brigham and Women’s Hosp, Boston, MA, USA, 3Yale Univ, New Haven, CT, USA

1044  IMPROVING THE PRISON CARE CONTINUUM REDUCES RACIAL HIV DISPARITIES: A MODELING STUDY
Brandon D. Marshall 1, Maximilian King 1, Alexandria Macmadu 2, Lauren Brinkley-Rubinstein 3, M.-J. Milloy 4, Curt G. Beckwith 1, Frederick Altice 5, Josiah D. Rich 6
1Brown Univ, Providence, RI, USA, 2The Miriam Hosp, Providence, RI, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Univ of British Columbia, Vancouver, British Columbia, Canada, 5Yale Univ, New Haven, CT, USA

1045  THE COST-EFFECTIVENESS OF FINANCIAL INCENTIVES FOR VIRAL SUPPRESSION IN HPTN 065
Blythe J. Adamson 1, Deborah J. Donnell 2, Dobromir Dimitrov 2, Louis Garrison 1, Geetha Beauchamp 2, Theresa Gamble 3, Wafaee M. El-Sadr 4
1Univ of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 3FHI 360, Durham, NC, USA, 4ICAP at Columbia Univ, New York, NY, USA

1046  WITHDRAWN

1047  POPULATION-LEVEL IMPACT OF REACHING UNAIDS HIV PREVENTION TARGETS IN CÔTE D’IVOIRE
Mathieu Maheu-Giroux 1, Juan F. Vesga 2, Souleymane Dabate 1, Michel Alary 1, Stefan Baral 1, Douada Diouf 1, Kouame Abo 1, Marie-Claude Boily 2
1Imperial Coll London, London, UK, 2Laval Univ, Quebec, Canada, 3The Johns Hopkins Univ, Baltimore, MD, USA, 4Enda Santé, Dakar, Senegal, 5Ministère de la Santé et de l’Hygiène Pub, Abidjan, Cote d’Ivoire

1048  ART RETENTION AND VIRAL SUPPRESSION KEY TO MAXIMISING TREATMENT AS PREVENTION IMPACT
Nicky McCreesh 1, Ioannis Andrianakis 1, Mark Strong 2, Rebecca N. Nsubuga 1, Ian Vernon 1, Trevelyan J. McKinley 1, Jeremy E. Oakley 1, Michael Goldstein 2, Richard Hayes 2, Richard G. White 1
1London Sch of Hygiene and Trop Med, London, UK, 2Sheffield Univ, Sheffield, UK, 3MRC/UVRRI Rsr Unit on AIDS, Entebbe, Uganda, 4Durham Univ, Durham, UK, 5Exeter Univ, Exeter, UK
1049LB  COST-EFFECTIVENESS OF A COMBINATION STRATEGY FOR THE HIV CARE CASCADE IN SWAZILAND

Elizabeth Stevens1, Kimberly Nucifora1, Qinlian Zhou1, Lingfeng Li1, Scott Braithwaite1, Margaret McNairy2, Averie B. Gachuhi2, Matthew R. Lamb2, Velephi Okello2, Wafaa M. El-Sadr2

1New York Univ, New York City, NY, USA, 2ICAP Columbia Univ, New York, NY, USA, 4Columbia Univ, New York, NY, USA, 5Swaziland Ministry of Hlth, Mbabane, Swaziland

1050  COST-EFFECTIVENESS OF SAME-DAY TREATMENT INITIATION IN SOUTH AFRICA

Lawrence Long1, Mhairi Maskew1, Alana Brennan1, Constance Mongwenyana1, Cynthia Nyoni1, Given Malete1, Ian Sanne1, Matthew Fox2, Sydney Rosen2

1Univ of the Witwatersrand, Johannesburg, South Africa, 2Boston Univ, Boston, MA, USA

1051  COST OF STREAMLINED HIV CARE IN RURAL KENYAN AND UGANDAN CLINICS IN THE SEARCH STUDY

Starley B. Shade1, Thomas Osmand1, Florence Mwangwa2, Asiphas Oswaraganise2, Tamara D. Clark1, Edwin D. Charlebois1, Moses R. Kamya1, Maya L. Petersen4, Diane V. Havlir1, Vivek Jain1

1Univ of California San Francisco, San Francisco, CA, USA, 2Infectious Diseases Rsr Collab, Kampala, Uganda, 3Makerere Univ Coll of Hlth Scis, Kampala, Uganda, 4Univ of California Berkeley, Berkeley, CA, USA

1052  DIFFERENTIATED HIV RNA VIRAL-LOAD MONITORING IN UGANDA: A COST-EFFECTIVENESS ANALYSIS

Diana M. Negoescu1, Zhenhuan Zhang1, Heiner C. Bucher2, Eran Bendavid3, for the Swiss HIV Cohort Study

1Univ of Minnesota, Minneapolis, MN, USA, 2Basel Inst for Clinical Epi and Biostatistics, Basel, Switzerland, 3Stanford Univ, Stanford, CA, USA

1053  PROJECTING FUTURE DONOR ASSISTANCE FOR HIV/AIDS GLOBAL FUNCTION SUPPORT

Eran Bendavid1, Marco Marco Schäferhoff2, Jessica Kraus2, Dean Jamison3, Sebastian Martinez2

1Stanford Univ, Stanford, CA, USA, 2SEEK Development, Berlin, Germany, 3Univ of California San Francisco, San Francisco, CA, USA
POSTER SESSIONS, BY CATEGORY

All poster sessions will be held in Poster Hall in Room 4 EF from 2:30 PM to 4:00 PM on the scheduled day (listed in parenthesis below).

A. VIROLOGY
P-A1 VIROLOGY TRAFFICKING (Tuesday)
P-A2 VIRUS AND CELL RNA IN HIV REPLICATION (Wednesday)
P-A3 HIV CELL INTERACTION (Thursday)
P-A4 HIV AND HOST DEFENSE (Wednesday)
P-A5 VIRUS ADAPTATION TO IMMUNITY (Thursday)

B. MOLECULAR EPIDEMIOLOGY AND HIV/SIV EVOLUTION
P-B1 UNDERSTANDING NETWORKS AND LINKED INFECTIONS: FROM LOCAL TO GLOBAL (Tuesday)
P-B2 VIRAL DIVERSITY (Wednesday)
P-B3 TIMING INFECTION AND DEFINING FOUNDER SEQUENCES AND DUAL INFECTIONS (Thursday)

C. PATHOGENESIS: HUMAN STUDIES AND ANIMAL MODELS
P-C1 PRIMARY HIV INFECTION AND SPREAD (Wednesday)
P-C2 HOW DOES THE MICROBIOME AFFECT HIV INFECTION? (Wednesday)
P-C3 HIV INFECTION AND THE MICROBIOME (Wednesday)
P-C4 ANIMAL MODELS OF HIV INFECTION (Tuesday)
P-C5 EFFECT OF ANTIRETROVIRAL THERAPY ON HIV DISEASE AND RECOVERY (Tuesday)
P-C6 CORRELATES OF HIV DISEASE (Thursday)
P-C7 INTERACTIONS OF HIV WITH OTHER INFECTIONS (Thursday)

D. HOST IMMUNE RESPONSES TO INFECTION, VACCINES, AND IMMUNOTHERAPY
P-D1 HIV-SPECIFIC ANTIBOdIES AND HOW TO INDUCE THEM (Tuesday)
P-D2 INFLAMMATION AND IMMUNITY (Thursday)
P-D3 CD4 T CELLS: MORE THAN JUST HELP (Thursday)
P-D4 CD8 T CELLS: WHERE AND HOW THEY KILL (Wednesday)
P-D5 NK AND MAIT CELLS (Wednesday)

E. HIV RESERVOIRS, LATENCY, AND ALL CURATIVE STRATEGIES INCLUDING THERAPEUTIC VACCINES AND GENE THERAPY
P-E1 PERSISTENT VIREMIA AND IMMUNITY ON ART (Tuesday)
P-E2 CHARACTERIZING THE HIV RESERVOIR (Thursday)
P-E3 WHERE IS HIV HIDING? (Wednesday)
P-E4 HIV PERSISTENCE: SEND IN THE CLONES (Thursday)
P-E5 PARSGING PERSISTENT PROVIRUSES (Tuesday)
P-E6 LATENCY REVERSAL (Wednesday)
P-E7 EFFECT OF TRANSPLANTATION ON THE HIV RESERVOIR (Tuesday)
P-E8 MODIFYING THE RESERVOIR: CLINICAL STUDIES (Thursday)
P-E9 NEW TREATMENTS TO MODIFY THE HIV RESERVOIR (Wednesday)
F. NEUROPATHOGENESIS AND CNS HIV COMPLICATIONS
P-F1 THE CNS AND SYSTEMATIC IMMUNE ACTIVATION (Thursday)
P-F2 CEREBROVASCULAR EVENTS AND HIV (Wednesday)
P-F3 NEUROCOGNITIVE FUNCTIONING, VIRAL SUPPRESSION, AND ASSOCIATED RISKS (Thursday)
P-F4 CNS RESERVOIRS/ESCAPE (Wednesday)
P-F5 VIROLOGY/BASIC NEUROSCIENCE (Tuesday)
P-F6 INTERVENTION-FOCUSED (Tuesday)
P-F7 HOST AND VIRAL BIOMARKERS (Tuesday)
P-F8 NEUROIMAGING AND ASSOCIATED BIOMARKERS (Wednesday)

G. CLINICAL PHARMACOLOGY
P-G1 INTRACELLULAR AND TISSUE PHARMACOLOGY (Tuesday)
P-G2 DRUG - DRUG INTERACTIONS (Wednesday)
P-G3 PHARMACOKINETICS AND PHARMACOGENETICS: NEW AND EXISTING DRUGS AND FORMULATIONS (Tuesday)
P-G4 EXPOSURE-RESPONSE RELATIONSHIPS OF ANTIRETROVIRAL DRUGS (Wednesday)
P-G5 ANTIRETROVIRAL PHARMACOKINETICS: SPECIAL PROBLEMS AND POPULATIONS (Thursday)

H. ANTIRETROVIRAL THERAPY: PRE-CLINICAL AND RANDOMIZED TRIALS
P-H1 I WANT A NEW DRUG (Wednesday)
P-H2 ANTIRETROVIRAL CLINICAL TRIALS (Tuesday)

I. ANTIRETROVIRAL THERAPY: EFFICACY AND EFFECTIVENESS STUDIES
P-I1 ART: SAFETY AND PRESCRIBING OVER THE LONG TERM (Tuesday)
P-I2 MAINTENANCE: SECOND- AND THIRD-LINE THERAPY (Tuesday)
P-I3 ART: VIRAL RESPONSE OVER THE LONG TERM (Wednesday)
P-I4 ART: PREDICTORS OF OUTCOMES (Wednesday)
P-I5 IMMEDIATE VS DELAYED ART (Thursday)

J. HIV DRUG RESISTANCE
P-J1 PREVALENCE AND INCIDENCE OF HIV DRUG RESISTANCE (Thursday)
P-J2 IMPACT OF RESISTANCE ON RESPONSE TO ART (Thursday)
P-J3 INTEGRASE STRAND TRANSFER INHIBITOR RESISTANCE (Tuesday)
P-J4 REVERSE TRANSCRIPTASE INHIBITOR RESISTANCE (Tuesday)
P-J5 RESISTANCE TO PROTEASE AND MATURATION INHIBITORS (Tuesday)

K. HIV DIAGNOSTICS
P-K1 HIV DETECTION AND RECENCY METHODS (Tuesday)

L. HEPATITIS VIRUSES AND LIVER COMPLICATIONS
P-L1 HCV TRANSMISSION: THE CASCADE IS NOT RUNNING DRY (Tuesday)
P-L2 PROGRESSION OF LIVER DISEASE IN THE HCV-INFECTED POPULATION (Tuesday)
P-L3 HCV: PROGRESSION TO CIRRHOSIS AND HEPATOCELLULAR CARCINOMA (Tuesday)
P-L4 HCV: THE RAINBOW AT THE END OF THE CASCADE (Wednesday)
P-L5 HCV: RESISTANCE AND RETREATMENT (Wednesday)
P-L6 DAAs: TREATMENT AND ITS COMPLEXITIES (Wednesday)
P-L7 HEPATITIS IS NOT ALL C (Thursday)
P-L8 PATHOGENESIS OF HCV INFECTION (Thursday)
M. MALIGNANCIES
P-M1 ANAL CANCER: SCREENING AND HPV (Tuesday)
P-M2 AIDS-RELATED CANCER: ART, RISK, INCIDENCE, AND BURDEN (Wednesday)
P-M3 AIDS-RELATED CANCER: LYMPHOMA, KAPOSI SARCOMA, LUNG, AND LIVER (Thursday)

N. CARDIOVASCULAR COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY
P-N1 CARDIOVASCULAR RISK AND ART EFFECTS (Wednesday)
P-N2 DYSLIPIDEMIA AND HDL FUNCTION (Wednesday)
P-N3 INTERVENTIONS TO PREVENT AND TREAT CARDIOVASCULAR DISEASE (Wednesday)
P-N4 VASCULAR, CARDIAC, AND PULMONARY EVENTS (Wednesday)
P-N5 INFLAMMATION, BIOMARKERS, AND RISK FACTORS FOR VASCULAR DISEASE (Tuesday)
P-N6 INTEGRATION OF SCREENING AND TREATMENT OF NCD INTO HIV CARE IN RESOURCE-LIMITED SETTINGS (Tuesday)

O. OTHER COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY
P-O1 IMMUNOLOGIC PREDICTORS OF MORBIDITY AND MORTALITY (Tuesday)
P-O2 ART TOXICITY (Tuesday)
P-O3 PULMONARY COMPLICATIONS (Wednesday)
P-O4 FRAILTY AND MULTIMORBIDITY (Wednesday)
P-O5 PREDICTORS OF INFLAMMATION ON ART (Thursday)
P-O6 BONE DISEASE: RISK PREDICTION (Thursday)
P-O7 BONE DISEASE: MECHANISMS (Thursday)
P-O8 BONE DISEASE: INTERVENTIONS (Thursday)
P-O9 RENAL DISEASE (Thursday)
P-O10 ORGAN TRANSPLANTATION (Thursday)
P-O11 METABOLIC COMPLICATIONS (Thursday)
P-O12 OBESITY AND FATTY LIVER DISEASE (Thursday)

P. TUBERCULOSIS AND OTHER OPPORTUNISTIC INFECTIONS
P-P1 TB PREVENTION (Tuesday)
P-P2 TB PATHOGENESIS AND DIAGNOSIS (Tuesday)
P-P3 TB TREATMENT, OUTCOMES, AND MORTALITY (Tuesday)
P-P4 TB EPIDEMIOLOGY AND BURDEN OF DISEASE (Wednesday)
P-P5 TB AND CONTINUUM OF CARE (Wednesday)
P-P6 TB AND OI IRIS (Wednesday)
P-P7 TB COMORBIDITIES (Wednesday)
P-P8 OI EPIDEMIOLOGY AND PATHOGENESIS (Thursday)
P-P9 CRYPTOCOCCAL MENINGITIS AND OTHER FUNGAL OIs (Thursday)
P-P10 NEUROSYPHILIS (Thursday)
P-P11 PROTOZOAL OIs (Thursday)

Q. MATERNAL/FETAL HIV
P-Q1 PK AND SAFETY OF ARVs AND MONOCLONAL ANTIBODIES FOR PMTCT (Thursday)
P-Q2 THE PMTCT CASCADE: TRANSMISSION, TESTING, AND VIRAL SUPPRESSION (Tuesday)
P-Q3 PREGNANCY AND PREGNANCY OUTCOMES (Thursday)
P-Q4 OUTCOMES OF HIV AND ARV-EXPOSED INFANTS (Tuesday)
P-Q5 HIV DIAGNOSIS IN NEWBorns AND INFANTS (Wednesday)
R. PEDIATRICS AND ADOLESCENTS
P-R1 HIV DETECTION AND LATENT RESERVOIR IN CHILDREN (Wednesday)
P-R2 IMMUNE RESPONSE AND ACTIVATION IN CHILDREN (Wednesday)
P-R3 PHARMACOKINETICS AND DOSING OF ARVs AND COTREATMENTS IN CHILDREN AND YOUTH (Thursday)
P-R4 ART STRATEGIES AND OUTCOMES IN CHILDREN AND YOUTH (Thursday)
P-R5 COMORBIDITIES AND COMPLICATIONS IN CHILDREN AND YOUTH (Tuesday)
P-R6 APPROACHING 90:90:90 IN ADOLESCENTS AND YOUNG ADULTS (Wednesday)

S. EPIDEMIOLOGY
P-S1 NETWORKS OF HIV RISK (Thursday)
P-S2 RISK FACTORS FOR HIV INFECTION (Thursday)
P-S3 HIV AND STIs: BACK TO THE FUTURE (Thursday)
P-S4 HIV AND SUBSTANCE USE: DOUBLE TROUBLE (Wednesday)
P-S5 MEASURING HIV INCIDENCE AND PREVALENCE (Tuesday)
P-S6 ACUTE AND EARLY HIV INFECTION (Thursday)
P-S7 HIV SELF TESTING: KNOW YOURSELF (Tuesday)
P-S8 MEASURING THE US HIV EPIDEMIC (Tuesday)
P-S9 FACTORS INFLUENCING HIV OUTCOMES (Tuesday)
P-S10 STIGMA, MENTAL HEALTH, AND SEXUAL VIOLENCE (Thursday)
P-S11 MORBIDITY, MORTALITY, AND VIRAL DYNAMICS (Thursday)

T. PREVENTION INTERVENTIONS
P-T1 FERTILITY, CONTRACEPTION, PREGNANCY, AND REPRODUCTIVE HEALTH (Wednesday)
P-T2 HOT FLASHES: HORMONAL CONTRACEPTION AND HIV RISK (Wednesday)
P-T3 GENITAL INFECTIONS: MISHAPS AT THE MUCOSA (Wednesday)
P-T4 LESSONS FROM SEROCONVERSION ON PREP AND MICROBICIDES (Thursday)

U. PREVENTION SCALE-UP
P-U1 STRATEGIES TO INCREASE HIV TESTING (Tuesday)
P-U2 PREP WITHOUT BORDERS: NEW DELIVERY OPTIONS (Wednesday)
P-U3 PREP AWARENESS, TARGETING, AND UPTAKE (Wednesday)
P-U4 PREP PERSISTENCE, ADHERENCE, AND OUTCOMES (Wednesday)
P-U5 VOLUNTARY MEDICAL CIRCUMCISION (Thursday)

W. IMPLEMENTATION AND SCALE-UP OF TREATMENT AND CARE
P-W1 MEASURING THE GLOBAL HIV CARE CASCADE (Wednesday)
P-W2 INTERVENTIONS TO IMPROVE THE CARE CASCADE (Tuesday)
P-W3 HIV, MIGRATION, AND ACCESS TO CARE (Wednesday)
P-W4 ADVANCED HIV, AND LONG-TERM CARE (Tuesday)

X. POPULATION AND COST MODELING
P-X1 MODELLING HIV TRANSMISSION (Thursday)
P-X2 COST-EFFECTIVENESS OF HIV TESTING AND SCREENING STRATEGIES (Tuesday)
P-X3 IMPROVING THE EFFECTIVENESS AND COST EFFECTIVENESS OF PREP AND OTHER PREVENTION APPROACHES (Wednesday)
P-X4 MODELLING TO GUIDE IMPROVEMENTS IN THE CARE CASCADE (Thursday)

Y. EMERGING VIRUSES: ZIKA VIRUS
P-Y1 EMERGING VIRUSES: ZIKA VIRUS (Tuesday)

Please refer to the Index of Studies Related to Women for presentations that include, among others, studies on contraceptive and reproductive health in women (Category V).
DISCLOSURE OF FINANCIAL RELATIONSHIPS WITH COMMERCIAL CONCERNS

Disclosure information is presented generally as submitted by the corresponding presenting abstract author or invited speaker. The authors and speakers below provided their relevant disclosures of financial relationships with commercial entities for themselves and their spouses or partners, as well as funding provided to their

Abu-Raddad, Laith, J.
For self, paid to my institution:
Research grant recipient from the Qatar National Research Fund

Achhra, Amit, C.
Self: Employee of NCBH Hosp and JJP VA Med Ctr, Bronx, NY

Achilles, Sharon, L.
Self: Consultant of Merck & Co, Inc

Adkison, Kimberly, K.
Self: Employee of ViiV Healthcare

Althoff, Keri, N.
Self: Consultant Gilead Sciences, Inc

Anaworanich, Jintanat
Self: Honoraria from ViiV Healthcare and Merck & Co, Inc
For self, paid to my institution:
Research grant recipient from Cooperative agreements between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of the Army

Anderson, Jenny, L.
For self, paid to my institution:
Contracted researcher Merck & Co, Inc

Anderson, Peter, L.
For self, paid to my institution:
Research grant recipient from contract work and study drug donation from Gilead Sciences, Inc

Anderson, Sarah-Jane
Self: Consultant for Bill and Melinda Gates Foundation and consultant for Avenir Health

Andrade, Adriana
Self: Board member of Ginseng Board of Wisconsin and research grant recipient Gilead Sciences, Inc

Andrew, Katende
Self: Employee of IFAKARA Health Institute

Ankrom, Wendy
Self: Employee of Merck & Co., Inc
Spouse or Partner: Contracted researcher for Certara

Anugulruengkitt, Suvaporn
Self: Research grant recipient from The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme

Arribas, Jose, R.
Self: Research grant recipient from and speaker’s bureau for ViiV Healthcare, Janssen Therapeutics, AbbVie, Bristol-Myers Squibb, and Gilead Sciences, Inc

Barber, Tristan
Self: Consultant and speaker’s bureau for Gilead Sciences, Inc, Janssen Therapeutics, and ViiV Healthcare

Bares, Sara, H.
Self: Research grant recipient from Gilead Sciences, Inc.

Barnard, Richard
Self: Employee of Merck and Co., Inc

Bauer, Wolfgang
Self: Consultant of GlaxoSmithKline and Pharma GmbH

Bedimo, Roger
Self: Research grant recipient from and consultant for Merck & Co, Inc and Bristol-Myers Squibb

Bekker, Linda-Gail
For self, paid to my institution:
Research grant recipient from The Desmond Tutu HIV Centre

Berenguer, Juan
For self, paid to my institution:
Research grant recipient from ABBVIE, Gilead Sciences, Inc, Merck & Co, Inc, ViIV Healthcare
Self: Speaker’s bureau for ABBVIE, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Janssen Therapeutics, and ViIV Healthcare

Bhattacharya, Debika
For self, paid to my institution:
Research grant recipient from AbbVie, Bristol Myers Squibb, and Merck & Co, Inc

Boesecke, Christoph
Self: Consultant and speaker’s bureau AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, and ViIV Healthcare
For self, paid to my institution:
Research grant recipient from Deutsches Zentrum für Infekionsforschung (DZIF), Deutsche Leberstiftung, and NEAT ID
<table>
<thead>
<tr>
<th>Name</th>
<th>Role and Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boffito, Marta</td>
<td>Self: Consultant and speaker’s bureau for Gilead Sciences, Inc, ViIV Healthcare, Bristol-Myers Squibb, Janssen Therapeutics, Mylan, Inc, and Teva</td>
</tr>
<tr>
<td></td>
<td><strong>Self, For self, paid to my institution:</strong> Research grant recipient from Gilead Sciences, Inc, ViIV Healthcare, Bristol-Myers Squibb, Janssen Therapeutics, Mylan, Inc, and Teva</td>
</tr>
<tr>
<td>Bollen, Pauline</td>
<td><strong>For self, paid to my institution:</strong> Grant from ViIV Healthcare</td>
</tr>
<tr>
<td>Brehm, Jessica</td>
<td>Self: Employee of GlaxoSmithKline</td>
</tr>
<tr>
<td>Brinkman, Kees</td>
<td>Self: Consultant for Merck &amp; Co, Inc, Gilead Sciences, Inc, ViIV Healthcare, Roche Diagnostics, Bristol-Myers Squibb, and Janssen Therapeutics</td>
</tr>
<tr>
<td>Brockmeyer, Norbert, H.</td>
<td><strong>Self:</strong> Consultant Merck &amp; Co, Inc For self, paid to my institution:** Research grant recipient from ViIV Healthcare, Bristol-Myers Squibb, and Janssen Therapeutics</td>
</tr>
<tr>
<td>Brown, Kimberley</td>
<td>Self: Janssen Therapeutics</td>
</tr>
<tr>
<td>Brown, Todd</td>
<td>Self: Consultant for Gilead Sciences, Bristol-Myers Squibb, Merck &amp; Co, Inc, EMD-Serono, and Theratechnologies</td>
</tr>
<tr>
<td>Bucher, Heiner, C.</td>
<td><strong>For self, paid to my institution:</strong> Research grant recipient from Gilead Sciences, Bristol-Myers Squibb, and ViIV Health Care</td>
</tr>
<tr>
<td>Butt, Adeel, A.</td>
<td>Self: Research grant recipient from Gilead Sciences, Inc, Merck &amp; Co, Inc, and AbbVie</td>
</tr>
<tr>
<td>Cai, Suqin</td>
<td>Self: Employee of Monogram Biosciences</td>
</tr>
<tr>
<td>Calcagno, Andrea</td>
<td>Self: Consultant of Abbvie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen-Cilag, Merck &amp; Co, Inc, ViIV Healthcare For self, paid to my institution:** Research grant recipient from Gilead Sciences, Inc, Bristol-Myers Squibb, ViIV Healthcare</td>
</tr>
<tr>
<td>Cambiano, Valentina</td>
<td>Self: Other for Merck &amp; Co, Inc</td>
</tr>
<tr>
<td>Ceccherini Silberstein, Francesca</td>
<td>Self: Research grant recipient from consultant, and speaker’s bureau for AbbVie, Abbott Molecular, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck &amp; Co, Inc, Roche Diagnostics, ViIV Healthcare</td>
</tr>
<tr>
<td>Cento, Valeria</td>
<td>Self: Speaker’s bureau for Abbvie, Bristol-Myers Squibb, Merck Sharp &amp; Dohme, and Janssen Therapeutics</td>
</tr>
<tr>
<td>Chew, Kara, W.</td>
<td><strong>Self, For self, paid to my institution:</strong> Research grant recipient from Merck &amp; Co, Inc</td>
</tr>
<tr>
<td>Christopoulos, Katerina</td>
<td>Self: Other for Roche Diagnostics and Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Clarke, Diana, F.</td>
<td><strong>Self:</strong> Consultant for Merck &amp; Co, Inc</td>
</tr>
<tr>
<td>Clement, Meredith</td>
<td>Spouse or Partner: Royalty holder (company not stated)</td>
</tr>
<tr>
<td>Cloherty, Gavin</td>
<td>Self: Employee of Abbott Laboratories</td>
</tr>
<tr>
<td>Coller, Kelly</td>
<td>Self: Employee of Abbott Laboratories</td>
</tr>
<tr>
<td>Corbin, John, A.</td>
<td>Self: Employee of Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Costagliola, Dominique</td>
<td>Self: Consultant for Gilead Sciences, Inc and Innnavirvax</td>
</tr>
<tr>
<td>Cotte, Laurent</td>
<td><strong>For self, paid to my institution:</strong> Research grant recipient from ViIV Healthcare, Janssen-Cilagm, Merck &amp; Co, Inc.</td>
</tr>
<tr>
<td>Custodio, Joseph, M.</td>
<td>Self: Employee of Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Dean, Bonnie</td>
<td>Self: Research grant recipient from Cerner, Inc</td>
</tr>
<tr>
<td>DeJesus, Edwin</td>
<td>Self: Consultant of Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck &amp; Co, Inc, and Vertex, Inc For self, paid to my institution:** Research grant recipient from Abbott Laboratories, Achillion Pharmaceuticals, Aveixa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Roche Diagnostics, Idenix, Janssen Therapeutics, Merck &amp; Co, Inc, Pfizer, Sangamo, Taimed, Tobira, and Vertex, Inc</td>
</tr>
<tr>
<td>Devillé, Walter</td>
<td><strong>For self, paid to my institution:</strong> Research grant recipient from Orasure Company</td>
</tr>
<tr>
<td>Dolci, Giovanni</td>
<td><strong>Self:</strong> Consultant of Gilead Sciences, Inc For self, paid to my institution:** Research grant recipient from Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Dunham, Richard, M.</td>
<td>Self: Employee of GlaxoSmithKline</td>
</tr>
<tr>
<td>Durand, Christine</td>
<td>Self: Consultant Gilead Sciences Research grant recipient from Merck Pharmaceuticals Consultant Bristol-Myers Squibb</td>
</tr>
</tbody>
</table>
Durham, Phillip, G.  
**Self:** Employee of RTI International  
**For self, paid to my institution:** Research grant recipient from Other  
Bristol-Myers Squibb Virology Fellowship  
Recipient, Analyst on Merck-funded project  
**Eckard, Allison, R.**  
**Self:** Consultant Gilead Sciences  
**For self, paid to my institution:** Research grant recipient from Bristol-Myers Squibb, Cubist Pharmaceuticals, and GlaxoSmithKline  
**Eckhardt, Benjamin,**  
**Self:** Research grant recipient from and consultant Gilead Sciences, Inc  
**Ellis, Ronald, J.**  
**Spouse or Partner:** Stockholder of Merck & Co, Inc, Abbott, and Johnson and Johnson  
**Emu, Brinda**  
**Self:** Consultant for Taimed and 3V Biosciences  
**Erlanson, Kristine**  
**Self:** Research grant recipient from and consultant for Gilead Sciences, Inc and Theratechnologies  
**Esser, Stefan**  
**Self:** Consultant for Gilead Sciences, Inc, Avaya, Gilead, Merck & Co, Inc, Janssen, ViIV  
**Evans, Ceri**  
**Self:** Other for GlaxoSmithKline  
**Fleisher, Ilan**  
**Self:** Employee of MedStar Health Research  
**Flexner, Charles, W.**  
**Self:** Consultant for Merck & Co, Inc, Mylan, Inc, and ViIV Healthcare  
**For self, paid to my institution:** Research grant recipient from Consultant  
Abbvie, BMS, Gilead, Merck & Co, Inc, Janssen, ViIV  
**Gandhi, Rajesh, T.**  
**For self, paid to my institution:** Grants from EBSCO Information Services, Gilead Sciences, Inc, Merck & Co, Inc, and ViIV Healthcare  
**Gatell, Jose, M.**  
**Self:** Consultant of Gilead Sciences, Inc, Merck & Co, Inc, ViIV Healthcare, and Janssen Therapeutics  
**For self, paid to my institution:** Research grant recipient from ViIV Healthcare, Merck & Co, Inc, Gilead Sciences, Inc, and Janssen Therapeutics  
**Gaur, Aditya**  
**Self:** Employee of Medecins Sans Frontieres  
**Gerstenhaber, Rodd**  
**Self:** Employee of Medecins Sans Frontieres  
**Girardi, Enrico**  
**Self:** Speaker’s bureau for Janssen  
Therapeutics, Gilead Sciences, Inc, Otsuka, and Angelini. Research grant recipient from Gilead Sciences, Inc  
**Gob, Sarit, A.**  
**Self:** Gilead provides free study drug to project participants and covers the cost of some testing  
**González-García, Juan**  
**Self:** Consultant and speaker’s bureau for ViIV Healthcare, Gilead Sciences, Inc, Abbvie, and Merck Sharp Dohme  
**For self, paid to my institution:** Research grant from ViIV Healthcare, Gilead Sciences, Inc, Merck Sharp Dhome, Abbvie, Bristol-Myers Squibb, and Janssen-Cilag  
**Gonzalez-Perez, Maria Paz**  
**Self:** Employee of (company not indicated)  
**Grattoni, Alessandro**  
**Self:** Stockholder of NanoMedical Systems  
**Grimwood, Ashraf**  
**Self:** Employee of Keth’Impilo  
**Grinsztejn, Beatriz**  
**Self:** Employee of Fundação Oswaldo Cruz  
**Guaraldi, Giovanni**  
**Self:** Consultant and speaker’s bureau for Gilead Sciences, Inc, Janssen Therapeutics, Bristol-Myers Squibb, GlaxoSmithKline. Grant recipient from ViIV Healthcare and Merck & Co, Inc  
**Gupta, Ravindra, K.**  
**Self:** Speaker’s bureau for Janssen Therapeutics  
**Hagins, Debbie**  
**For self, paid to my institution:** Research grant recipient from Gilead Sciences, Inc  
**Hamzah, Lisa**  
**Self:** Other from Gilead Sciences, Inc  
**Hayes, Richard**  
**Self:** Royalty holder from Chapman and Hall  
**Hileman, Corrilynn, O.**  
**Self:** Consultant for Gilead Sciences, Inc  
**Hill, Andrew**  
**Self:** Consultant for Merck & Co, Inc and Janssen Therapeutics  
**Hillier, Sharon, L.**  
**Self:** Consultant for Merck & Co, Inc, Cepheid, and Symboimix, LLC  
** Hodder, Sally**  
**Self:** Consultant for Bristol-Myers Squibb, ViIV Healthcare, Gilead Sciences, Inc, and Janssen Therapeutics  
**Spouse or Partner:** Consultant for Sanofi, Novartis, and Johnson & Johnson  
**Hogan, Michael, J.**  
**Self:** Recipient of Intellectual Property Rights from University of Pennsylvania.
Holzmayer, Vera  
Self: Employee of and stockholder of Abbott Laboratories

Hsu, Ricky,  
Self: Research grant recipient from consultant, speaker's bureau, and contracted researcher for Gilead Sciences, Inc. Consultant and speaker's bureau for Janssen Therapeutics, and Bristol-Myers Squibb. Consultant for ViIV Healthcare. Speaker's bureau for Merck & Co, Inc

Huang, Wei  
Self: Employee of Monogram Biosciences

Hultquist, Judd, F.  
Self: Contracted researcher for Roche Diagnostics and consultant for BlueCatBio Ltd.

Imaz, Arkaitz  
Self: Research grant recipient from consultant, and speaker's bureau for Gilead Sciences, Inc, ViIV Healthcare, Bristol-Myers Squibb, Janssen Therapeutics, Merck & Co, Inc, and Abbvie

Iwuji, Collins, C.  
Self: Speaker's bureau for Gilead Sciences, Inc

Jarvis, Joseph, N.  
For self, paid to my institution: Research grant recipient from for an investigator initiated award from Gilead Sciences, Inc

Keating, Sheila  
Self: Other for Ortho Clinical Diagnostics

Khalilieh, Sauzanne  
Self: Employee of Merck & Co., Inc.

Kosloski, Matthew, P.  
Self: Employee of and stockholder of AbbVie

Koss, Catherine, A.  
For self, paid to my institution: I am involved with a study for which Gilead Sciences, Inc awarded study drug to my institution.

Lansdon, Eric  
Self: Employee of and stockholder of Gilead Sciences, Inc

Lathouwers, Erkki  
Self: Employee of Janssen Therapeutics

Leal, Lorna  
Self: Other for Gilead Sciences, Inc

Letendre, Scott  
Self: Consultant for ViIV Healthcare, Gilead Sciences, Inc., Merck & Co, Inc, and Janssen Therapeutics

Levy, Itzhak  
Self: Speaker's bureau for Gilead Sciences, Inc and Merck & Co, Inc

For self, paid to my institution: Research grant recipient from Gilead Sciences, Inc

Lewis, Stanley  
Self: Employee of TaiMed Biologics

Li, Jonathan  
Self: Research grant recipient and consultant for Gilead Sciences, Inc and Merck & Co, Inc

Link, John, O.  
Self: Employee and stockholder of Gilead Sciences, Inc

Longenecker, Chris, T.  
Self: Consultant for Gilead Sciences, Inc

Macias, Juan  
Self: Investigator in clinical trials supported by Roche Diagnostics, Bristol-Myers Squibb and Abbott Pharmaceuticals. Lectures fees from Roche Diagnostics, Gilead Sciences, Inc, Boehringer Ingelheim, and Bristol-Myers Squibb. Consulting fees from Boehringer Ingelheim

Maddon, Paul, J.  
Self: Consultant and stockholder of CytoDyn Inc. Stockholder of Progenics Pharmaceuticals, Inc.

Majeed, Sophia, R.  
Self: Employee and stockholder for Gilead Sciences

Makadzange, Azure, T.  
Self: Employee of and stockholder of Gilead Sciences

Maleche Obimbo, Elizabeth  
Self: Stockholder Nairobi Securities Exchange

Mangia, Alessandra  
Self: Research grant recipient from Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, and Merck & Co, Inc

Marconi, Vincent, C.  
Self: Research grant recipient from ViIV Healthcare

Margolis, David, A.  
Self: Employee and stockholder for ViIV Healthcare

Martinez, Esteban  
Self: Research grant recipient from Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and ViIV Healthcare

Matheron, Sophie  
For self, paid to my institution: Research grant recipient from Merck & Co, Inc

Mauss, Stefan  
Self: Consultant, speaker's bureau and advisory board for: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, and ViIV Healthcare

McClelland, R. Scott  
For self, paid to my institution: Research grant recipient from Hologic Corporation

McFarland, Elizabeth, J.  
For self, paid to my institution: Research grant recipient from Gilead Sciences, Inc
Meintjes, Graeme
Self: Other relationship with Gilead Sciences, Inc

Meissner, Eric, G.
For self, paid to my institution:
Research grant recipient from Gilead Sciences, Inc

Mills, Lisa, A.
Spouse or Partner: Employee of Leidos Biomedical

Mitchell, Michael, L.
Self: Employee of Gilead Sciences, Inc

Molina, Jean-Michel
Self: Consultant and speaker’s bureau
Gilead Sciences, Inc. Consultant for Merc & Co, Inc and ViIV Healthcare
For self, paid to my institution:
Research grant recipient from Gilead Sciences

Morris, Sheldon
Self: Research grant recipient from Gilead Sciences

Mosicki, Anna-Barbara
Self: Other Merck & Co, Inc

Mothe, Beatriz
Self: Consultant Aelix Therapeutics, AlbaJuna Therapeutics

Murry, Jeffrey
Self: Employee of Gilead Sciences, Inc

Nijhawan, Ank, E.
Self: Research grant recipient from Gilead Sciences, Inc

Novak, Richard
Self: Consultant for Gilead Sciences, Inc. Contracted researcher for Merck & Co, Inc and GlaxoSmithKline

Ofoetokun, Igho
Self: Consultant for Accordant

Owen, Andrew
Self: Consultant Merck & Co, Inc and Norgine
For self, paid to my institution:
Research grant recipient from Merck & Co, Inc, ViIV Healthcare, and AstraZeneca, Inc

Palella, Frank, J.
Self: Consultant and speaker’s bureau
Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, Bristol-Myers Squibb

Palma, Paolo
For self, paid to my institution:
Research grant recipient from ViIV Healthcare

Pérez-Valero, Ignacio
Self: Other relationship with ViIV Healthcare, Gilead Sciences, Inc, and Bristol-Myers Squibb

Petoumenos, Kathy
Self: Research grant from Merck Sharp & Dohme; Gilead Sciences, Inc, Bristol-Myers Squibb, Boehringer Ingelheim, Janssen-Cilag and ViIV Healthcare

Pérez-Valero, Ignacio
Self: Consultant and speaker’s bureau
Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, Bristol-Myers Squibb

Petoumenos, Kathy
Self: Research grant recipient from Gilead Sciences, Inc and GlaxoSmithKline

Rijnders, Bart

Rodgers, Mary
Self: Employee and stockholder for Abbott Laboratories

Rose, Rebecca
Self: Consultant for BioInfoExperts

Rough, Kathryn
Self: Consultant for Bayer Pharmaceuticals

Ruelas, Debbie, S.
Self: Employee of Merck & Co, Inc

Sabin, Caroline
Self: Speaker’s bureau for Gilead Sciences, Inc. Other relationship with ViIV Healthcare and Janssen-Cilag

Sax, Paul, E.
Self: Research grant recipient from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Janssen Therapeutics

Schalkwijk, Stein
For self, paid to my institution:
Research grant from Bristol-Myers Squibb, Merck & Co, Inc, ViIV Healthcare and Janssen Therapeutics

Silverberg, Michael, J.
For self, paid to my institution:
Research grant recipient from Gilead Sciences, Inc

Soriano, Vincent
Self: Consultant and speaker’s bureau
for Gilead Sciences, Inc, Merck & Co, Inc, Janssen Therapeutics, Bristol-Myers Squibb

Squillace, Nicola
Self: Consultant for ViIV Healthcare.
speaker’s bureau for Merck & Co, Inc and Bristol-Myers Squibb. Other relationship with Janssen Therapeutics and Gilead Sciences, Inc
Squires, Kathleen  
**Self:** Consultant for Bristol Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and ViIV Healthcare  
**For self, paid to my institution:** Research grant recipient from Clinical trials research grants to Thomas Jefferson University from Gilead Sciences, Inc

Tam, Edward  
**Self:** Consultant and speaker's bureau for AbbVie, Bristol-Mys Squibb, Gilead Sciences, Inc, Janssen Pharmaceutica, Merck & Co, Inc, and Pendopharm  
**For self, paid to my institution:** Research grant recipient from AbbVie

Tan, Darrell, H.S.  
**For self, paid to my institution:** Research grant recipient from ViIV Healthcare and Gilead Sciences, Inc

Telisinghe, L  
**For self, paid to my institution:** Other QIAGEN provided non-financial support by providing the QuantiFERON®-TB Gold Plus kits free of charge to use in the study.

Thomsen, Nathan, D.  
**Self:** Employee of Gilead Sciences, Inc

Thorne, Claire  
**For self, paid to my institution:** Research grant recipient from AbbVie and ViIV Healthcare

Tieu, Hong Van  
**Self:** Research grant recipient from Merck & Co, Inc

Todesco, Eve  
**Self:** Speaker’s bureau for Bristol-Myers Squibb

Tort, Olivia  
**For self, paid to my institution:** Research grant recipient from Gilead Sciences, Inc

Tse, Winston, C.  
**Self:** Employee of Gilead Sciences

Tung, Elyse  
**Self:** Other relationship with Gilead Sciences, Inc

Ukaegbu, Chinyere  
**Self:** Research grant recipient from Gilead Sciences, Inc

Utay, Netanya, S.  
**Self:** Consultant for Gilead Sciences, Inc. Consultant and contracted researcher for Tobira Therapeutics, Inc and Entera Health, Inc

van der Heijden, Wouter, A.  
**For self, paid to my institution:** Research grant recipient from Merck Sharp & Dohme, Merck & Co, Inc

van Sighem, Ard  
**For self, paid to my institution:** Research grant from Janssen-Cilag and ViIV Healthcare

van Zoest, Rosan  
**For self, paid to my institution:** Research grant from Gilead Sciences, Inc

Vannappagari, Vani  
**Self:** Employee of ViIV Healthcare and stockholder of GlaxoSmithKline

Volpe, Joseph, M.  
**Self:** Employee of LabCorp

Vos, Alinda,  
**Self:** Employee of University Medical Center Utrecht, The Netherlands, Departmentn Julius Center.

Vourvahis, Manoli  
**Self:** Employee and stockholder Pfizer, Inc

Wagner, Thor  
**Self:** Research grant from Gilead Sciences, Inc

Wandeler, Gilles  
**Self:** Research grant from Gilead Sciences, Inc

Warszawski, Josiane  
**For self, paid to my institution:** Research grant from ViIV Healthcare and Parexel

Weinberg, Adriana  
**Self:** Research grant recipient from GlaxoSmithKline and Medimmune  
**Spouse or Partner:** Research grant recipient from and royalty holder from Merck & Co, Inc

Weinheimer, Steven  
**Self:** Employee of TaiMed Biologics USA

White, Douglas, A. E.  
**Self:** Research grant recipient from Gilead Sciences, Inc

White, Kirsten, L.  
**Self:** Employee and stockholder of Gilead

Wiley, Dorothy, J.  
**Self:** Research grant recipient from Merck Sharp & Dohme Corp, Merck & Co., Inc

Wong, Wingwai  
**For self, paid to my institution:** Research grant recipient from United BioPharma  
**Self,For self, paid to my institution:** Research grant from Gilead Sciences, Inc, Viiv Healthcare, Merck 7 Co, Inc, and Bristol-Myers Squibb  
**Spouse or Partner:** Research grant from United BioPharma

Yin, Michael, T.  
**Self:** Consultant for Gilead Sciences, Inc

Zhang, Heather  
**Self:** Employee and stockholder of Gilead Sciences, Inc
The following have no relevant financial relationships to disclose. Any updates will be reflected in the Mobile App.

Aamer, Hadega
Abaasa, Andrew, M.
Abdel Mohsen, Mohamed
Abdo, Mona
Abewe, Hosiana
Aboulnasr, Fatma
Abutaima, Rana
Adamson, Blythe, J.
Adewumi, Olubusuyi, M.
Adland, Emily
Aghan, Brian, K.
Aghokeng, Avelin, F.
Agot, Kawan
Agrell, Chiara
Agelidis, Chrysa
Ahn, Daniel, E.
Ahlgren, Erika
Ajayi, S.B.
Akay-Espinoza, Cagla
Alcalde, Maria, L.
Aldamiz-Echevarria, Teresa
Alessandra, Sacchi
Almirol, Ellen
Alvez, Angeles
Alwan, Mary Grace
Amado, Faizana
An, Jan
Ancona, Giuseppe
Andany, Nisha
Anderson, Albert
Anderson, Elizabeth, M.
Angelovich, Thomas, A.
Araujo, Marilia, L.
Archary, Moherndran
Armstrong, Heather, L.
Arnedo, Mireia
Arpadi, Stephen, M.
Attia, Engi, F.
Avi, Radko
Avihingsanon, Ananchee
Avila-Rios, Santiago
Ayieko, James
Bachanas, Pamela, J.
Bachmann, Nadine
Badje, Anani, D.
Bai, Francesca
Bailin, Samuel
Baker, Jason
Balkus, Jennifer
Balogun, Kayode
Bang, Riddhima
Bangham, Charles, R.M.
Bardhi, Ariola
Barnabas, Ruanne, V.
Barcos, Joshua, A.
Batavia, Ashita, S.
Battalora, Linda
Baxter, Amy, E.
Bearden, David
Bebell, Lisa
Beck, Ingrid, A
Becker, James, T.
Becofsky, Katie
Bekker, Adrie
Belaunzaran-Zamudio, Pablo, F.
Beloukas, Apostolos
Bendavid, Eran
Bengtson, Angela
Bershteyn, Anna
Berteri, Ada
Bhagwat, Priya
Bienzak, Andrzej
Biliotti, Elisa
Billioux, Veena, G.
Birnbaum, Jeanette
Bisson, Gregory
Blanco, Jose, L.
Blockeisen, Charlotte
Boehme, Catharina, C.
Boerekamps, Anne
Boivin, Michael, J.
Bonar, Michal
Bordoni, Veronica
Borges, Alvaro, H.
Borre, Ethan, D.
Bosman, Kobus
Boulougoura, Afrodit
Bowen-Test, Kevin, W.
Bozzi, Giorgio
Bracchi, Margherita
Bradley, Heather
Brenner, Bluma
Brittain, Kirsty
Broekhuis, Jordan
Brooks, Kristina, M.
Brown, Lillian
Broz, Dita
Bruce, Veronica
Bruhl, Maria, C.
Brunet, Laurence
Buchacz, Kate
Buggert, Marcus
Bull, Marta, E.
BuranaPAD2T1Kun, Supranee
Burchell, Ann, N.
Burdick, Ryan, C.
Burger, Adam
Burgess, Emma, K.
Burke, Mark, W.
Buseyne, Florence
Bush, William, S.
Buskin, Susan
Butt, Zahid, A.
Cachay, Edward, R.
CamaCMACHo-Gonzalez, Andres
Camlin, Carol, S.
Campbell, Ellsworth
Cannizzaro, Elvira, S.
Capoferri, Adam
Carrillo, Mayra, A.
Carroll, Makeda
Carryl, Heather
Casazza, Joseph, P.
Castagna, Antonella
Castel, Amanda, D.
Castelli, Francesco
Castillo-Mancilla, Jose, R.
Dickey, Amy, K.
Dickinson, Laura
Dijkstra, Maartje
Dillon, Stephanie
Drake, Alison, L.
Duerras, Henning, J.
Dryden-Peterson, Scott
Duarte, Horacio, A.
Duenas Decamp, Maria Jose
Duerr, Ralf
Dumchev, Kostyantyn
Dumond, Julie, B.
Eaton, Jeffrey
Edelstein, Zoe, R.
Edelstein, Ann
Edelstein, Zoe, R.
Edger, Matthias
El Kamari, Vanessa
Elliot, Emilie
Emery, Ann
Esmail, Hanif
Evans, Henry, W.
Fabbrì, Gabriele
Falade-Nwulia, Oluwaseun
Fanjul, Francisco
Farhadian, Shelli
Faria de Oliveira, Michelli
Favaro, Graziella
Feinstein, Matthew, J.
Fenner, Lukas
Fernandez McPhee, Carolina
Fielding, Katherine
Firmhaber, Cindy
Fitch, Katherine, V.
Flenady, Cindy
Fox, Julie
Franco, Sandra
Freeman, Michael, L.
Freiman, J. Morgan
Frias, Mario
Fulcher, Jennifer, A.
Galvez Celada, Cristina
Gandhi, Monica
Ganesan, Anuradha
Ganser-Pornillos, Barrie, K.
Ganter, Pierre
Garcia, Erin, I.
Garcia, Federico
Garcia-Lerma, Gerardo
Garcia-Morales, Claudia
Garland, Wendy, H.
Gates, Thomas
Gatho, Esther
Gavegnano, Christina
Geboy, Alexander
Gelman, Benjamin, B.
Genberg, Becky, L.
George, Varghese
Gerard, Laurence
Gervasoni, Cristina
Giacobbi, Nicholas, S.
Giacomet, Vania
Gianella, Sara
Gilada, Trupti, J.
Gill, Alexander, J.
Gill, John
Gingrich, David
Giron, Leila, B.
Gissel, Magnus
Glick, Sara, N.
Golden, Matthew, R.
Gonzalo-Gil, Elena
Goodreau, Steven, M.
Gorin, Aleksandr
Graham, Susan, M.
Greatheast, Louise
Greene, Sharon, A.
Grund, Jonathan
Gu, Diane
Güerri-Fernández, Robert
Gupta, Amita
Gupta, Kushol
Gupte, Akshay
Gutierrez, Jose
Haaland, Richard
Haas, Andreas
Haberlen, Sabina
Hachiya, Atsuko
Haddad, Lisa, B.
Hader, Shannon, L.
Hakim, Avi
Hale, Malika
Hammarlund, Gustaf, O.
Hanan, Nathan
Hanna, David, B.
Harada, Shigeyoshi
Hassan, Amin, S.
Hassan, Jaythooshan
Hassouneh, Said
Havens, Peter, L.
Haworth, Kevin, G.
Hecht, Frederick, M.
Hector, Jonas
Heffron, Renee
Hellmuth, Joanna
Hendrickson, Cheryl, J.
Hensley-McBain, Tiffany
Hermans, Lucas, E.
Hermansson, Linn
Hernandez-Ramirez, Raul
Hessol, Nancy, A.
Hiender, Bonnie
Hijkema, Simone, H.
Hikichi, Yuta
Hiransuthikul, Akarin
Hlupeni, Admir
Ho, Ya-Chi
Hodcroft, Emma, B.
Hoenigl, Martin
Hope, Peter, L.
Hoof, Malon, Van den
Hofstra, Laura Marije
Hogg, Robert, S.
Holtz, Timothy, H.
Hood, Julia
Hoornenborg, Elke
Hoots, Brooke
Horner, Marie-Josephe
Howard, Andrea
Hoyte, Ashley, C.
Hsu, Denise, C.
Hsu, Hilary, K.
Hsu, Ling
Huang, Sezuan
Huang, Yunda
Hubbard, Mark
Hughes, Alison
Hughes, Stephen, H.
Hul, Kristi
Hulgan, Todd
Hussens, Sophia, A.
Hutchinson, Angela, B.
Ibrahim, Maryanne, R.
Iamichi, Hiromi
Imp, Brandon, M.
Indravudh, Pitchaya
Inglis, Patrick
Innes, Steve
Inzaule, Seth
Ita, Sergio
Iyer, Shilpa, S.
Izopet, Jacques
Jagodzinski, Linda
Jani, Ilesh
Janjua, Naveed, Z.
Jantarabenjakul, Watsamon
Janulis, Patrick
Jao, Jennifer
Jaquet, Antoine
Jarrin, Imma
Jenness, Samuel
Jiamasakul, Awachana
Johnson, Anna, S.
Johnson, Eric, O.
Johnson, Erik, J.
Johnson, Jeremy, A.
Joly, Veronique
Jones, Bradley, R.
Jones, Matthew, L.
Joseph, Sarah Beth
Jourdain, Gonzague
Joya, Christine
Justman, Jessica, E.
Kadelka, Claus
Kahn, James
Kaida, Angela
Kakkar, Fatima
Kallianpur, Asha, R.
Kallianpur, Kalpana, J.
Kalmin, Mariah, M.
Kamal, Susan
Kan, Melissa
Kantor, Rami
Kapito-Tembo, Atupele, P.
Kaplan, Justin, A.
Kaplan, Samantha
Karajeanes, Esmeralda
Kasaro, Margaret, P.
Kassaye, Seble
Katuramu, Richard
Katz, David, A
Kaufmann, Daniel, E
Kaur, Harpreet
Kearney, Mary, F
Keiser, Olivia
Keiser, Christine
Khan, Shaikat
Khan, Isha
## INDEX OF STUDIES RELATED TO WOMEN

The following index lists abstracts that noted women or women’s issues as the focus of the study. This index was developed for attendees with an interest in these issues. We encourage you to refer to the full program for other presentations that may address this subject.

**TUESDAY, FEBRUARY 14, 2017**

<table>
<thead>
<tr>
<th>#</th>
<th>Title</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>RANDOMIZED TRIAL OF LEEP VS CRYOTHERAPY TO TREAT CIN2/3 IN HIV-INFECTED WOMEN</td>
<td>Oral Abstract Session O-2</td>
</tr>
<tr>
<td>23</td>
<td>NATURAL HISTORY OF CERVICAL INTRAEPITHELIAL NEOPLASIA-2 AMONG HIV-INFECTED WOMEN</td>
<td>Oral Abstract Session O-2</td>
</tr>
<tr>
<td>24</td>
<td>INTEGRATION OF POSTNATAL SERVICES IMPROVES MCH AND ART OUTCOMES: A RANDOMISED TRIAL</td>
<td>Oral Abstract Session O-2</td>
</tr>
<tr>
<td>242</td>
<td>A BROAD POLyclonal RESPONSE IS MEDIATED BY SUPERINFECTION WITH 2 DISTINCT VIRUSES</td>
<td>Poster Session P-D1</td>
</tr>
<tr>
<td>25</td>
<td>ADVERSE BIRTH OUTCOMES DIFFER BY ART REGIMEN FROM CONCEPTION IN BOTSWANA</td>
<td>Oral Abstract Session O-2</td>
</tr>
<tr>
<td>266</td>
<td>LYMPH NODE HIV-SPECIFIC CXCR5+ CTLs ARE ASSOCIATED WITH ENHANCED VIRAL CONTROL</td>
<td>Themed Discussion TD-1</td>
</tr>
<tr>
<td>281</td>
<td>SEX-BASED DIFFERENCES IN HIV RESERVOIR ACTIVITY AND RESIDUAL IMMUNE ACTIVATION</td>
<td>Poster Session P-E1</td>
</tr>
<tr>
<td>376</td>
<td>IFN-β REDUCES MACROPHAGE HEME OXYGENASE-1 EXPRESSION: ROLE IN HIV NEUROPATHOGENESIS</td>
<td>Poster Session P-F5</td>
</tr>
<tr>
<td>421LB</td>
<td>HPTN 076: TMC278 LA SAFE, TOLERABLE AND ACCEPTABLE FOR HIV PREEXPOSURE PROPHYLAXIS</td>
<td>Poster Session P-G3</td>
</tr>
<tr>
<td>443</td>
<td>Efficacy &amp; Safety of Switching to EVG/COBI/FTC/TAF in Virologically Suppressed Women</td>
<td>Poster Session P-H2</td>
</tr>
<tr>
<td>502</td>
<td>Drug Resistance After Cessation of Efavirenz-Based Antiretroviral Treatment</td>
<td>Poster Session P-J4</td>
</tr>
<tr>
<td>526</td>
<td>Gut Epithelial Damage, Immune Activation &amp; Liver Fibrosis in HIV and HCV Infection</td>
<td>Poster Session P-L2</td>
</tr>
<tr>
<td>591</td>
<td>Multiple-Test Screening Strategies Improve Biopsy-Proven HSIL-Detection in HIV+ Women</td>
<td>Poster Session P-M1</td>
</tr>
<tr>
<td>627</td>
<td>Epicardial Fat, Immune Activation, and Coronary Plaque Among HIV+ and HIV- Women</td>
<td>Poster Session P-N5</td>
</tr>
<tr>
<td>629</td>
<td>CRP Predicts Subclinical CVD Progression in HIV- but NOT HIV+ Women</td>
<td>Poster Session P-N5</td>
</tr>
<tr>
<td>634</td>
<td>Impaired Antivasular Contraction of Perivasculare Adipose Tissue in HIV Individuals</td>
<td>Poster Session P-N5</td>
</tr>
<tr>
<td>646</td>
<td>Longitudinal HIV Viral Trajectories and Comorbidities in the WIHS</td>
<td>Poster Session P-O1</td>
</tr>
<tr>
<td>696</td>
<td>Raltegravir Switch and Biomarkers of Liver Steatosis and Metabolic Syndrome in Women</td>
<td>Themed Discussion TD-4</td>
</tr>
<tr>
<td>762</td>
<td>Missed Opportunities for Repeat HIV Testing and Early Art Initiation in Pregnancy</td>
<td>Poster Session P-Q2</td>
</tr>
</tbody>
</table>
Index of Studies Related to Women Program and Agenda CROI 2017

763 LOW HIV INCIDENCE IN SOUTH AFRICAN PREGNANT WOMEN RECEIVING A PREVENTION INTERVENTION (Poster Session P-Q2)

764 HIV INCIDENCE, CASCADE, AND TESTING AMONG MOTHERS IN WESTERN KENYA (Poster Session P-Q2)

765 DETECTION OF HIV IN BREAST MILK AMONG PREGNANT/POSTPARTUM WOMEN WITH RECENT HIV (Poster Session P-Q2)

766 UPTAKE AND RETENTION IN CARE OF PREGNANT WOMEN STARTING OPTION B+ IN MAPUTO PROVINCE (Poster Session P-Q2)

767 STRATEGIES FOR VIRAL-LOAD MONITORING DURING PREGNANCY IN RESOURCE-LIMITED SETTINGS (Poster Session P-Q2)

768 VIRAL SUPPRESSION AMONG HIV+ PREGNANT WOMEN ENTERING ANTENATAL CARE ON ART IN UGANDA (Poster Session P-Q2)

769 MEASURES OF ENGAGEMENT IN ROUTINE HIV CARE TO PREDICT ELEVATED VIRAL LOAD ON ART (Poster Session P-Q2)

770 SELF-REPORT AND DRY BLOOD SPOTS AS MARKERS OF ANTIRETROVIAL ADHERENCE IN PREGNANCY (Poster Session P-Q2)

771 UNINTENDED PREGNANCY PREDICTS SUBSEQUENT RAISED VIRAL LOAD IN THE POSTNATAL PERIOD (Poster Session P-Q2)

879 IDENTIFICATION AND VALIDATION OF AN INCIDENCE-TESTING ALGORITHM FOR HIV-1 SUBTYPE C (Poster Session P-S5)

913 FOOD INSECURITY AND HIV TREATMENT OUTCOMES IN THE WOMEN’S INTERAGENCY HIV STUDY (Poster Session P-S9)

914 HIV STATUS AWARENESS AND ART COVERAGE AMONG FEMALE SEX WORKERS IN JUBA, SOUTH SUDAN (Poster Session P-S9)

915 “TEST AND TREAT” ANTIRETROVIRAL THERAPY AMONG FEMALE SEX WORKERS IN KAMPALA, UGANDA (Poster Session P-S9)

958 STRENGTHENING MALE-PARTNER TESTING IN ANTENATAL CARE: FINDINGS FROM SOUTH AFRICA (Poster Session P-U1)

959 HPTN 071 HOME-BASED TESTING IMPROVES UPTAKE OF HCT AMONG PREGNANT WOMEN IN ZAMBIA (Poster Session P-U1)

1006 LOWER RETENTION IN CARE WHEN ART IS INITIATED WITH CD4≥500CELLS/ΜL (Poster Session P-W2)

WEDNESDAY, FEBRUARY 15, 2017

85 DAILY ORAL PREP IS EFFECTIVE AMONG WOMEN WITH ABNORMAL VAGINAL MICROBIOTA (Oral Abstract Session O-8)

86LB IMPACT OF VAGINAL MICROBIOTA ON GENITAL TISSUE AND PLASMA CONCENTRATIONS OF TENOFOVIR (Oral Abstract Session O-8)

88 DAPIVIRINE RING USE DOES NOT DIMINISH THE EFFECTIVENESS OF HORMONAL CONTRACEPTION (Oral Abstract Session O-8)

209 MARAVIROC INHIBITS HIV TARGET T-CELL TRAFFICKING INTO THE FEMALE GENITAL LUMEN (Poster Session P-C2)

210 INVESTIGATING THE EFFECT OF PH ON CERVICOVAGINAL MUCUS BARRIER PROPERTIES TO HIV (Poster Session P-C2)

266 LYMPH NODE HIV-SPECIFIC CXCR5+ CTLs ARE ASSOCIATED WITH ENHANCED VIRAL CONTROL (Poster Session P-D4)
COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION (Themed Discussion TD-7)

AN IN VITRO–IN SILICO STUDY OF REDUCED-DOSE Efavirenz Interaction with Levonorgestrel (Poster Session P-G4)

TIMING OF CART INITIATION INFLUENCES CANCER RISK AMONG WOMEN LIVING WITH HIV (Poster Session P-M2)

FACTORS ASSOCIATED WITH PULMONARY IMPAIRMENT IN HIV-INFECTED SOUTH AFRICAN ADULTS (Poster Session P-D3)

TARGETED HIV SCREENING AT BIRTH CAN IDENTIFY THE MAJORITY OF IN UTERO TRANSMISSIONS (Poster Session P-Q5)

DELAYED HIV DNA PCR DETECTION AMONG INFANTS WHO RECEIVED COMBINATION ART PROPHYLAXIS (Poster Session P-Q5)

LOCAL SOCIAL NETWORKS PREDICT RETENTION & SUPPRESSION IN YOUNG WOMEN IN SEARCH TRIAL (Poster Session P-R6)

REDUCING ALCOHOL CONSUMPTION IMPROVED HIV VIRAL SUPPRESSION IN WOMEN (Poster Session P-S4)

PREP USED IN PREGNANCY DOES NOT INCREASE POOR BIRTH OUTCOMES (Poster Session P-T1)

PREGNANCY INCIDENCE AND OUTCOMES AMONG WOMEN USING THE DAPIVIRINE VAGINAL RING (Poster Session P-T1)

PREFERENCE AND CHOICE OF MULTIPURPOSE PREVENTION TECHNOLOGIES IN YOUNG AFRICAN WOMEN (Poster Session P-T1)

MODERN CONTRACEPTIVE USE AND UNPROTECTED SEX IN HIGH-RISK HIV-POSITIVE WOMEN IN KENYA (Poster Session P-T1)

INTERACTION BETWEEN ETONOGESTREL-RELEASING IMPLANT AND 3 ANTIRETROVIRAL REGIMENS (Poster Session P-T1)

FERTILITY AND REPRODUCTIVE OUTCOMES OF HIV+ AND HIV- WOMEN IN THE CARMA COHORT STUDY (Poster Session P-T1)

EARLY ONSET MENOPAUSE AMONG WOMEN LIVING WITH HIV IN CANADA (Poster Session P-T1)

COST-EFFECTIVENESS OF 2 METHODS TO TREAT CERVICAL DYSPLASIA IN HIV-POSITIVE WOMEN (Poster Session P-T1)

DEPOT MEDROXYPROGESTERONE ACETATE INCREASES HIV-1 REPLICATION IN MUCOSAL TISSUE (Poster Session P-T2)

ZIM-CHIC: IMPACT OF CONTRACEPTIVE INITIATION ON IMMUNE CELLS IN THE CERVIX AND PBMCS (Poster Session P-T2)

HIV GENITAL-TRACT SHEDDING WHILE ON PROGESTIN CONTRACEPTION (Poster Session P-T2)

HORMONAL CONTRACEPTION DOES NOT AFFECT ART EFFECTIVENESS OR GENITAL HIV SHEDDING (Poster Session P-T2)

MUCOSAL INFLAMMATION ABROGATES TENOFOVIR-GEL–MEDIATED PROTECTION FROM HIV INFECTION (Poster Session P-T3)

IS SYNDROMIC DIAGNOSIS OF REPRODUCTIVE TRACT INFECTIONS ANTIQUATED IN THE HIV ERA? (Poster Session P-T3)

IDENTIFYING PREGNANT WOMEN FOR PREP USING ROUTINE ANTENATAL CARE INDICATORS IN KENYA (Poster Session P-U3)

MISDIAGNOSED HIV INFECTION IN PREGNANT WOMEN INITIATING UNIVERSAL ART IN SOUTH AFRICA (Poster Session P-W1)
Index of Studies Related to Women
Program and Agenda
CROI 2017

230

MARKED MORTALITY AND RETENTION UNDER-REPORTING IN A LARGE HIV PROGRAM IN ZAMBIA (Poster Session P-W1)

COST-EFFECTIVENESS OF PREEXPOSURE PROPHYLAXIS ACROSS COUNTIES IN WESTERN KENYA (Poster Session P-X3)

THE POTENTIAL IMPACT AND COST-EFFECTIVENESS OF MULTIPURPOSE PREVENTION TECHNOLOGIES (Poster Session P-X3)

THURSDAY, FEBRUARY 16, 2017

BONE DENSITY AND TRABECULAR BONE SCORE IMPROVE FRACTURE PREDICTION IN HIV+ WOMEN (Oral Abstract Session O-12)

HIV-1 SEQUENCES FROM EARLY INFECTION PREDICT THE AGE OF THE INFECTION (Poster Session P-B3)

MARAVIROC INHIBITS HIV TARGET T-CELL TRAFFICKING INTO THE FEMALE GENITAL LUMEN (Themed Discussion TD-16)

INVESTIGATING THE EFFECT OF PH ON CERVICOVAGINAL MUCUS BARRIER PROPERTIES TO HIV (Themed Discussion TD-16)

MONOCYTE ACTIVATION IS ASSOCIATED WITH COGNITION IN SUPPRESSED HIV-INFECTED WOMEN (Poster Session P-F1)

COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION (Poster Session P-F3)

COGNITIVE COMPLAINTS AND DEVELOPMENT OF FALLS AMONG HIV+ AND HIV- WOMEN (Poster Session P-F3)

TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP) (Poster Session P-L7)

A RANDOMIZED TRIAL OF VITAMIN D3 (3000 VERSUS 1000 IU) IN HIV+ POSTMENOPAUSAL WOMEN (Poster Session P-O8)

PREVALENCE AND RISK FACTORS OF RENAL INJURY IN OPTION B+ DURING THE FIRST 6 MONTHS (Poster Session P-O9)

FOOD INSECURITY IS ASSOCIATED WITH POOR DIABETES CONTROL IN THE WIHS (Poster Session P-O11)

RALTEGRAVIR SWITCH AND BIOMARKERS OF LIVER STEATOSIS AND METABOLIC SYNDROME IN WOMEN (Poster Session P-O12)

WOMEN GAIN MORE WEIGHT THAN MEN FOLLOWING INITIATION OF ANTIRETROVIRAL THERAPY (Poster Session P-O12)

DOsing FOR TWO: PLACENTAL TRANSFER OF DARUNAVIR AND SIMULATION OF FETAL EXPOSURE (Poster Session P-Q1)

SUBSTANTIALLY LOWER RILPIVIRINE PLASMA CONCENTRATIONS DURING PREGNANCY (Poster Session P-Q1)

ELVITEGRAVIR/Cobicistat Pharmacokinetics in Pregnancy and Postpartum (Poster Session P-Q1)

PROTEASE-INHIBITOR–BASED CART IS ASSOCIATED WITH HIGH ESTRADIOL LEVELS IN PREGNANCY (Poster Session P-Q1)

SUBSEQUENT PREGNANCY OUTCOMES IN WOMEN DURING FOLLOW-UP IN PROMISE 1077HS (Poster Session P-Q3)

HIV AND RISK OF POSTPARTUM INFECTION, COMPLICATIONS, AND MORTALITY IN RURAL UGANDA (Poster Session P-Q3)
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>774</td>
<td>CMV VIREMIA IN HIV-POSITIVE AND -NEGATIVE PREGNANT WOMEN IN BOTSWANA</td>
<td>P-Q3</td>
</tr>
<tr>
<td>775</td>
<td>PREGNANCIES IN WOMEN WHO ACQUIRED HIV PERINATALLY</td>
<td>P-Q3</td>
</tr>
<tr>
<td>776</td>
<td>ANTENATAL ANTIRETROVIRAL THERAPY AND ADVERSE BIRTH OUTCOMES: THE PROMISE TRIAL</td>
<td>P-Q3</td>
</tr>
<tr>
<td>778</td>
<td>DO HIV+ WOMEN ON PROTEASE INHIBITORS DELIVER PRETERM? FINDINGS FROM A UK STUDY</td>
<td>P-Q3</td>
</tr>
<tr>
<td>779</td>
<td>TDF/FTC IN PREGNANCY SHOWS NO INCREASE IN ADVERSE INFANT BIRTH OUTCOMES IN US COHORTS</td>
<td>P-Q3</td>
</tr>
<tr>
<td>836</td>
<td>LOCAL SOCIAL NETWORKS PREDICT RETENTION &amp; SUPPRESSION IN YOUNG WOMEN IN SEARCH TRIAL</td>
<td>TD-12</td>
</tr>
<tr>
<td>857</td>
<td>VALIDATION OF A RISK SCORE FOR HIV ACQUISITION IN YOUNG AFRICAN WOMEN WITH FACTS 001</td>
<td>P-S2</td>
</tr>
<tr>
<td>921</td>
<td>HIV STIGMA, DEPRESSION, ADHERENCE, AND VIRAL LOAD AMONG HIV+ AFRICAN-AMERICAN WOMEN</td>
<td>P-S10</td>
</tr>
<tr>
<td>924</td>
<td>SEXUAL ORIENTATION DIFFERENCES IN HEALTH AND WELLBEING AMONG WOMEN WITH HIV IN CANADA</td>
<td>P-S10</td>
</tr>
<tr>
<td>925</td>
<td>HEALTH OUTCOMES ASSOCIATED WITH GENDER-BASED VIOLENCE AMONG WOMEN WITH HIV IN CANADA</td>
<td>P-S10</td>
</tr>
<tr>
<td>927</td>
<td>THE HEALTH IMPACT OF SEXUAL VIOLENCE AMONG WOMEN IN A PLATINUM MINING BELT</td>
<td>P-S10</td>
</tr>
<tr>
<td>928</td>
<td>ASSOCIATION OF SEX AND RACE WITH HIV-/NON-HIV–RELATED DEATH IN TREATED HIV INFECTION</td>
<td>P-S11</td>
</tr>
<tr>
<td>933</td>
<td>LONGITUDINAL VIRAL TRAJECTORY AMONG WOMEN IN THE WOMEN'S INTERAGENCY HIV STUDY</td>
<td>P-S11</td>
</tr>
<tr>
<td>944</td>
<td>DEPOT MEDROXYPROGESTERONE ACETATE INCREASES HIV-1 REPLICATION IN MUCOSAL TISSUE</td>
<td>TD-13</td>
</tr>
<tr>
<td>945</td>
<td>ZIM-CHIC: IMPACT OF CONTRACEPTIVE INITIATION ON IMMUNE CELLS IN THE CERVIX AND PBMCS</td>
<td>TD-13</td>
</tr>
<tr>
<td>946</td>
<td>HIV GENITAL-TRACT SHEDDING WHILE ON PROGESTIN CONTRACEPTION</td>
<td>TD-13</td>
</tr>
<tr>
<td>947</td>
<td>HORMONAL CONTRACEPTION DOES NOT AFFECT ART EFFECTIVENESS OR GENITAL HIV SHEDDING</td>
<td>TD-13</td>
</tr>
<tr>
<td>951</td>
<td>DOES THE E138A MUTATION IN ASPIRE SEROCONVERTERS AFFECT SUSCEPTIBILITY TO DAPIVIRINE?</td>
<td>P-T4</td>
</tr>
<tr>
<td>952</td>
<td>NNRTI-CONTAINING ART IS EFFECTIVE FOR DAPIVIRINE RING BREAKTHROUGH HIV-1 INFECTION</td>
<td>P-T4</td>
</tr>
<tr>
<td>1025</td>
<td>HIV TRANSMISSION IN GENERALIZED, CONCENTRATED, AND MIXED EPIDEMICS IN WESTERN KENYA</td>
<td>P-X1</td>
</tr>
<tr>
<td>Author</td>
<td>Page Numbers</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------</td>
<td></td>
</tr>
<tr>
<td>Aamer, Hadega</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>Aaron, Justin</td>
<td>546</td>
<td></td>
</tr>
<tr>
<td>Aaron, Kristal</td>
<td>867</td>
<td></td>
</tr>
<tr>
<td>Abaasa, Andrew Max.</td>
<td>976</td>
<td></td>
</tr>
<tr>
<td>Abacassamo, Fatima</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td>Abana, Chike O.</td>
<td>230</td>
<td></td>
</tr>
<tr>
<td>Abassi, Mahsa</td>
<td>746</td>
<td></td>
</tr>
<tr>
<td>Abbas, Zaheer</td>
<td>418</td>
<td></td>
</tr>
<tr>
<td>Abbate, Isabella</td>
<td>466</td>
<td></td>
</tr>
<tr>
<td>Abdel Mohsen, Mohamed</td>
<td>284, 314</td>
<td></td>
</tr>
<tr>
<td>Abdo, Mona</td>
<td>665, 666</td>
<td></td>
</tr>
<tr>
<td>Abdool Karim, Quarraish</td>
<td>879, 949</td>
<td></td>
</tr>
<tr>
<td>Abdool Karim, Salim</td>
<td>949</td>
<td></td>
</tr>
<tr>
<td>Abewe, Hosiana</td>
<td>307</td>
<td></td>
</tr>
<tr>
<td>Ablan, Sherimay</td>
<td>507</td>
<td></td>
</tr>
<tr>
<td>Abo, Kouame</td>
<td>1047</td>
<td></td>
</tr>
<tr>
<td>Abou-Samra, Abdul-Badi</td>
<td>574</td>
<td></td>
</tr>
<tr>
<td>Aboud, Michael</td>
<td>44LB, 664</td>
<td></td>
</tr>
<tr>
<td>Aboulnasr, Fatma</td>
<td>273</td>
<td></td>
</tr>
<tr>
<td>Abouzid, Omar</td>
<td>1035</td>
<td></td>
</tr>
<tr>
<td>Abraham, Alison</td>
<td>87, 624, 645, 662, 931</td>
<td></td>
</tr>
<tr>
<td>Abrams, Elaine J.</td>
<td>24, 27, 767, 769, 771, 780, 814, 815, 837, 950, 992, 1023</td>
<td></td>
</tr>
<tr>
<td>Abu-Raddad, Laith J.</td>
<td>1027</td>
<td></td>
</tr>
<tr>
<td>Abubakar, Ibrahim</td>
<td>736</td>
<td></td>
</tr>
<tr>
<td>Abuna, Felix</td>
<td>1032</td>
<td></td>
</tr>
<tr>
<td>Abutaima, Rana</td>
<td>416</td>
<td></td>
</tr>
<tr>
<td>Achalapong, Jullapong</td>
<td>584LB</td>
<td></td>
</tr>
<tr>
<td>Achan, Jane</td>
<td>797</td>
<td></td>
</tr>
<tr>
<td>Acharya, Priyamvada</td>
<td>14LB</td>
<td></td>
</tr>
<tr>
<td>Achenbach, Chad J.</td>
<td>598, 622</td>
<td></td>
</tr>
<tr>
<td>Achhra, Amit C.</td>
<td>693</td>
<td></td>
</tr>
<tr>
<td>Achia, Thomas</td>
<td>847</td>
<td></td>
</tr>
<tr>
<td>Achilles, Sharon L.</td>
<td>945</td>
<td></td>
</tr>
<tr>
<td>Achterbergh, Roel CA</td>
<td>519</td>
<td></td>
</tr>
<tr>
<td>Achut, Victoria</td>
<td>914</td>
<td></td>
</tr>
<tr>
<td>Ackerman, Daniel</td>
<td>334</td>
<td></td>
</tr>
<tr>
<td>Ackerman, Margaret</td>
<td>253</td>
<td></td>
</tr>
<tr>
<td>Ackers, Marta</td>
<td>882</td>
<td></td>
</tr>
<tr>
<td>Acosta, Edward</td>
<td>755, 757, 806</td>
<td></td>
</tr>
<tr>
<td>Acquistapace, Alessandra</td>
<td>396</td>
<td></td>
</tr>
<tr>
<td>Adams-Huet, Beverley</td>
<td>677</td>
<td></td>
</tr>
<tr>
<td>Adamson, Blythe J.</td>
<td>1045</td>
<td></td>
</tr>
<tr>
<td>Adedoyin, Adebayo</td>
<td>430</td>
<td></td>
</tr>
<tr>
<td>Adelsberger, Joseph</td>
<td>159, 287</td>
<td></td>
</tr>
<tr>
<td>Adewumi, Olubusuyi M.</td>
<td>369</td>
<td></td>
</tr>
<tr>
<td>Adeyeye, Adeola</td>
<td>421LB</td>
<td></td>
</tr>
<tr>
<td>Adimora, Adaora</td>
<td>690, 913</td>
<td></td>
</tr>
<tr>
<td>Adkison, Kimberly Kalp.</td>
<td>428</td>
<td></td>
</tr>
<tr>
<td>Adland, Emily</td>
<td>272, 799</td>
<td></td>
</tr>
<tr>
<td>Aebersold, Ruedi</td>
<td>263</td>
<td></td>
</tr>
<tr>
<td>Afzal, Saira</td>
<td>302</td>
<td></td>
</tr>
<tr>
<td>Agaba, Tifu</td>
<td>712</td>
<td></td>
</tr>
<tr>
<td>Agan, Brian K.</td>
<td>358, 668, 932</td>
<td></td>
</tr>
<tr>
<td>Aghokeng, Avelin F.</td>
<td>482, 486</td>
<td></td>
</tr>
<tr>
<td>Agnew, Emily</td>
<td>111</td>
<td></td>
</tr>
<tr>
<td>Agot, Kwangura</td>
<td>894, 936, 982, 986</td>
<td></td>
</tr>
<tr>
<td>Agrati, Chiara</td>
<td>203, 366</td>
<td></td>
</tr>
<tr>
<td>Afsheen, Garcia, Melissa</td>
<td>395</td>
<td></td>
</tr>
<tr>
<td>Aguilera, Antonio</td>
<td>578</td>
<td></td>
</tr>
<tr>
<td>Aguilera, Victoria</td>
<td>540</td>
<td></td>
</tr>
<tr>
<td>Agwu, Allison</td>
<td>827, 828, 968</td>
<td></td>
</tr>
<tr>
<td>Aighren, Erika</td>
<td>431</td>
<td></td>
</tr>
<tr>
<td>Ahmed, Aabid</td>
<td>800</td>
<td></td>
</tr>
<tr>
<td>Ahmed, Khatija</td>
<td>857, 936</td>
<td></td>
</tr>
<tr>
<td>Ahmed, Uzma</td>
<td>923, 925</td>
<td></td>
</tr>
<tr>
<td>Ahoua, Laurence</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td>Aid, Malika</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>Ait Moha, Daoud</td>
<td>470</td>
<td></td>
</tr>
<tr>
<td>Aitken, Celia</td>
<td>185</td>
<td></td>
</tr>
<tr>
<td>Ajaykumar, Abhinav</td>
<td>590</td>
<td></td>
</tr>
<tr>
<td>Ajibola, Gbolahon</td>
<td>502, 789, 790</td>
<td></td>
</tr>
<tr>
<td>Akama, Ebu</td>
<td>762</td>
<td></td>
</tr>
<tr>
<td>Akanbi, Maxwell</td>
<td>369</td>
<td></td>
</tr>
<tr>
<td>Akapirat, Simwat</td>
<td>291</td>
<td></td>
</tr>
<tr>
<td>Akay-Espinosa, Cagla</td>
<td>74, 378</td>
<td></td>
</tr>
<tr>
<td>Ake, Julie</td>
<td>355, 481</td>
<td></td>
</tr>
<tr>
<td>Akello, Carolynne</td>
<td>952</td>
<td></td>
</tr>
<tr>
<td>Akgün, Kathleen</td>
<td>658</td>
<td></td>
</tr>
<tr>
<td>Akullian, Adam N.</td>
<td>1037</td>
<td></td>
</tr>
<tr>
<td>Al-Kindi, Sadeer</td>
<td>674</td>
<td></td>
</tr>
<tr>
<td>Alary, Michel</td>
<td>1047</td>
<td></td>
</tr>
<tr>
<td>Albert, Brianne Y.</td>
<td>939</td>
<td></td>
</tr>
<tr>
<td>Alcaide, Maria L.</td>
<td>770</td>
<td></td>
</tr>
<tr>
<td>Aldámiz-Echavarria, Teresa</td>
<td>530, 534</td>
<td></td>
</tr>
<tr>
<td>Aldrovandi, Grace M.</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>Alejos, Belén</td>
<td>400</td>
<td></td>
</tr>
<tr>
<td>Alessandra, Sacchi</td>
<td>203</td>
<td></td>
</tr>
<tr>
<td>Alessandrini-Gradi, Elodie</td>
<td>192</td>
<td></td>
</tr>
<tr>
<td>Alfaro, Raul</td>
<td>409a</td>
<td></td>
</tr>
<tr>
<td>Alfaro, Ricardo</td>
<td>446</td>
<td></td>
</tr>
<tr>
<td>Allana, Salim</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>Alland, David</td>
<td>76LB</td>
<td></td>
</tr>
<tr>
<td>Allen, Isabel Elaine.</td>
<td>355</td>
<td></td>
</tr>
<tr>
<td>Allen, Susan</td>
<td>200, 202</td>
<td></td>
</tr>
<tr>
<td>Allender, Christopher</td>
<td>715LB</td>
<td></td>
</tr>
<tr>
<td>Alliae, Tiziano</td>
<td>379</td>
<td></td>
</tr>
<tr>
<td>Almanza, Horacio</td>
<td>844</td>
<td></td>
</tr>
<tr>
<td>Amirol, Ellen</td>
<td>969</td>
<td></td>
</tr>
<tr>
<td>Almonte, Alexi</td>
<td>968</td>
<td></td>
</tr>
<tr>
<td>Alon, Leigh</td>
<td>969</td>
<td></td>
</tr>
<tr>
<td>Altet, Maria Nieves Altet</td>
<td>734</td>
<td></td>
</tr>
<tr>
<td>Althoff, Keri N.</td>
<td>130, 596, 619, 662, 840</td>
<td></td>
</tr>
<tr>
<td>Altice, Frederick</td>
<td>1044</td>
<td></td>
</tr>
<tr>
<td>Alvarado, Luisa</td>
<td>1055LB</td>
<td></td>
</tr>
<tr>
<td>Alvarado, Maria</td>
<td>1056LB</td>
<td></td>
</tr>
<tr>
<td>Álvarez, Angeles</td>
<td>609</td>
<td></td>
</tr>
<tr>
<td>Álvarez, Beatriz</td>
<td>572</td>
<td></td>
</tr>
<tr>
<td>Alviero, Carmelita</td>
<td>806</td>
<td></td>
</tr>
<tr>
<td>Alwano, Mary Grace</td>
<td>993, 1009, 1017</td>
<td></td>
</tr>
<tr>
<td>Amanyire, Gideon</td>
<td>1005</td>
<td></td>
</tr>
<tr>
<td>Amasio, Maria Enrica</td>
<td>379</td>
<td></td>
</tr>
<tr>
<td>Ambegaonkar, Suren A.</td>
<td>375</td>
<td></td>
</tr>
<tr>
<td>Ambinder, Richard</td>
<td>318</td>
<td></td>
</tr>
<tr>
<td>Ambrozak, David R.</td>
<td>61, 165</td>
<td></td>
</tr>
<tr>
<td>Amedee, Angela M.</td>
<td>217</td>
<td></td>
</tr>
<tr>
<td>Amendola, Alessandra</td>
<td>466</td>
<td></td>
</tr>
<tr>
<td>Amiel, Corinne</td>
<td>349, 520</td>
<td></td>
</tr>
<tr>
<td>Ammassari, Adriana</td>
<td>203, 354, 366, 466</td>
<td></td>
</tr>
<tr>
<td>Amodo, Faïziana</td>
<td>818</td>
<td></td>
</tr>
<tr>
<td>Amofa-Sekyi, M</td>
<td>711</td>
<td></td>
</tr>
<tr>
<td>Amorossi-Folquet, Madeleine</td>
<td>811</td>
<td></td>
</tr>
<tr>
<td>An, Qian</td>
<td>902</td>
<td></td>
</tr>
<tr>
<td>Anagnostou, Olga</td>
<td>474</td>
<td></td>
</tr>
<tr>
<td>Anand, Santhanam</td>
<td>559, 883</td>
<td></td>
</tr>
<tr>
<td>Anamwaranich, Jintanat</td>
<td>12, 124, 125, 205,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>214, 249, 270, 282, 285, 291, 299LB, 339,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>344, 363, 387, 394, 71</td>
<td></td>
</tr>
<tr>
<td>Anastos, Kathryn</td>
<td>132, 237LB, 350, 514,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>636LB, 646, 928, 933</td>
<td></td>
</tr>
<tr>
<td>Ances, Beau M.</td>
<td>397, 401</td>
<td></td>
</tr>
<tr>
<td>Ancona, Giuseppe</td>
<td>215</td>
<td></td>
</tr>
<tr>
<td>Ancuta, Petronela</td>
<td>204</td>
<td></td>
</tr>
<tr>
<td>Andaluz, Adriana</td>
<td>898</td>
<td></td>
</tr>
<tr>
<td>Andany, Nisha</td>
<td>940</td>
<td></td>
</tr>
<tr>
<td>Author</td>
<td>Page Numbers</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Andersen, Nina</td>
<td>490</td>
<td></td>
</tr>
<tr>
<td>Andersen, Ove</td>
<td>235</td>
<td></td>
</tr>
<tr>
<td>Andersen, Albert</td>
<td>353</td>
<td></td>
</tr>
<tr>
<td>Andersen, Christy M.</td>
<td>134</td>
<td></td>
</tr>
<tr>
<td>Andersen, Elizabeth Marion</td>
<td>297, 303</td>
<td></td>
</tr>
<tr>
<td>Anderson, Albert</td>
<td>353</td>
<td></td>
</tr>
<tr>
<td>Anderson, Christy M.</td>
<td>134</td>
<td></td>
</tr>
<tr>
<td>Anderson, Elizabeth Marion</td>
<td>297, 303</td>
<td></td>
</tr>
<tr>
<td>Anderson, Hanne</td>
<td>1057LB</td>
<td></td>
</tr>
<tr>
<td>Anderson, Jason R.</td>
<td>725</td>
<td></td>
</tr>
<tr>
<td>Anderson, Jenny L.</td>
<td>288, 311</td>
<td></td>
</tr>
<tr>
<td>Anderson, Matt</td>
<td>412</td>
<td></td>
</tr>
<tr>
<td>Anderson, Meegan R.</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Anderson, Peter L.</td>
<td>404, 405, 419, 422LB, 976, 977</td>
<td></td>
</tr>
<tr>
<td>Andersen, Ove</td>
<td>235</td>
<td></td>
</tr>
<tr>
<td>Andersson, Lars-Magnus</td>
<td>431</td>
<td></td>
</tr>
<tr>
<td>Andrade, Adriana</td>
<td>469</td>
<td></td>
</tr>
<tr>
<td>Anders, Michele</td>
<td>897</td>
<td></td>
</tr>
<tr>
<td>Andreoni, Massimo</td>
<td>564</td>
<td></td>
</tr>
<tr>
<td>Andrews, Jason R.</td>
<td>725</td>
<td></td>
</tr>
<tr>
<td>Anderman, John</td>
<td>1048</td>
<td></td>
</tr>
<tr>
<td>Andrieux-Meyer, Isabelle</td>
<td>523</td>
<td></td>
</tr>
<tr>
<td>Arcin, Nancie</td>
<td>123</td>
<td></td>
</tr>
<tr>
<td>Aouizerat, Bradley E.</td>
<td>237LB</td>
<td></td>
</tr>
<tr>
<td>Araujo, Carlos</td>
<td>306</td>
<td></td>
</tr>
<tr>
<td>Arezes, Elisa</td>
<td>821</td>
<td></td>
</tr>
<tr>
<td>Ariansen, JL</td>
<td>810</td>
<td></td>
</tr>
<tr>
<td>Arias, Ana</td>
<td>562</td>
<td></td>
</tr>
<tr>
<td>Arkangelo, Gilda</td>
<td>394</td>
<td></td>
</tr>
<tr>
<td>Armon, Carl</td>
<td>32, 663, 678, 864</td>
<td></td>
</tr>
<tr>
<td>Armstrong, Abigail</td>
<td>207, 208</td>
<td></td>
</tr>
<tr>
<td>Armstrong, Heather L.</td>
<td>966</td>
<td></td>
</tr>
<tr>
<td>Armel, Miriam</td>
<td>614</td>
<td></td>
</tr>
<tr>
<td>Arpadi, Stephen M.</td>
<td>819</td>
<td></td>
</tr>
<tr>
<td>Arribas, Jose R.</td>
<td>1048</td>
<td></td>
</tr>
<tr>
<td>Arrington-Sanders, Renata</td>
<td>968</td>
<td></td>
</tr>
<tr>
<td>Arrive, Elisabeth</td>
<td>821</td>
<td></td>
</tr>
<tr>
<td>Arthur, James</td>
<td>464LB</td>
<td></td>
</tr>
<tr>
<td>Aschheim, Joshua</td>
<td>132</td>
<td></td>
</tr>
<tr>
<td>Ashley, Prince</td>
<td>406</td>
<td></td>
</tr>
<tr>
<td>Aseem, Stephen</td>
<td>934</td>
<td></td>
</tr>
<tr>
<td>Assoumou, Lambert</td>
<td>441, 703</td>
<td></td>
</tr>
<tr>
<td>Ataca, Sila</td>
<td>177</td>
<td></td>
</tr>
<tr>
<td>Atkins, Elizabeth</td>
<td>248</td>
<td></td>
</tr>
<tr>
<td>Atfield, Marcus</td>
<td>176</td>
<td></td>
</tr>
<tr>
<td>Atin, Engi Farouk</td>
<td>660</td>
<td></td>
</tr>
<tr>
<td>Atwine, Martha</td>
<td>1001</td>
<td></td>
</tr>
<tr>
<td>Aubert, Vincent</td>
<td>191</td>
<td></td>
</tr>
<tr>
<td>Auer, Jim</td>
<td>236</td>
<td></td>
</tr>
<tr>
<td>Augusto, Orvalho</td>
<td>730, 766, 818</td>
<td></td>
</tr>
<tr>
<td>Auld, Sara C.</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>Austin, Michele</td>
<td>86LB</td>
<td></td>
</tr>
<tr>
<td>Avi, Radko</td>
<td>461</td>
<td></td>
</tr>
<tr>
<td>Avyieko, James</td>
<td>638, 836, 858</td>
<td></td>
</tr>
<tr>
<td>Avey, Helen</td>
<td>711, 834, 959, 1010, 1011</td>
<td></td>
</tr>
<tr>
<td>Avinash, Sanhorn</td>
<td>443, 698</td>
<td></td>
</tr>
<tr>
<td>Avila, Rios, Santiago</td>
<td>182, 480</td>
<td></td>
</tr>
<tr>
<td>Awad, Soussema</td>
<td>1027</td>
<td></td>
</tr>
<tr>
<td>Aweka, Francesca</td>
<td>414</td>
<td></td>
</tr>
<tr>
<td>Axelsson, Markus</td>
<td>383</td>
<td></td>
</tr>
<tr>
<td>Ayat, Feriel</td>
<td>821</td>
<td></td>
</tr>
<tr>
<td>Ayt, Colby</td>
<td>467</td>
<td></td>
</tr>
<tr>
<td>Azeem, M.</td>
<td>919</td>
<td></td>
</tr>
<tr>
<td>Aznar, Esther</td>
<td>441</td>
<td></td>
</tr>
<tr>
<td>Azzo, Caitlin</td>
<td>745</td>
<td></td>
</tr>
<tr>
<td>Azzoni, Livio</td>
<td>326</td>
<td></td>
</tr>
<tr>
<td>——</td>
<td>——</td>
<td></td>
</tr>
<tr>
<td>Ba, Selly</td>
<td>440, 508</td>
<td></td>
</tr>
<tr>
<td>Babigumira, Joseph</td>
<td>494</td>
<td></td>
</tr>
<tr>
<td>Babudieri, Sergio</td>
<td>565</td>
<td></td>
</tr>
<tr>
<td>Bacchetti, Peter</td>
<td>170, 281, 288, 362, 978</td>
<td></td>
</tr>
<tr>
<td>Bachmann, Nadine</td>
<td>191</td>
<td></td>
</tr>
<tr>
<td>Badje, Anandi D.</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Badley, Andrew</td>
<td>273, 319</td>
<td></td>
</tr>
<tr>
<td>Baeminnashainsen, Till</td>
<td>475, 639, 916, 960, 983, 991, 994</td>
<td></td>
</tr>
<tr>
<td>Baeten, Jared</td>
<td>85, 88, 920, 934, 935, 947, 951, 952, 967, 1003</td>
<td></td>
</tr>
<tr>
<td>Baggage, Rachel</td>
<td>1030</td>
<td></td>
</tr>
<tr>
<td>Bagiire, Daniel</td>
<td>915</td>
<td></td>
</tr>
<tr>
<td>Bagney, Aklesso</td>
<td>607</td>
<td></td>
</tr>
<tr>
<td>Bahemana, Emmanuel</td>
<td>355</td>
<td></td>
</tr>
<tr>
<td>Bai, Francesca</td>
<td>357</td>
<td></td>
</tr>
<tr>
<td>Bailey, Heather</td>
<td>778</td>
<td></td>
</tr>
<tr>
<td>Bailey, Justin R.</td>
<td>141</td>
<td></td>
</tr>
<tr>
<td>Bailey, S.L.</td>
<td>711</td>
<td></td>
</tr>
<tr>
<td>Bailin, Samuel</td>
<td>229</td>
<td></td>
</tr>
<tr>
<td>Bailon, Lucia</td>
<td>400</td>
<td></td>
</tr>
<tr>
<td>Bailor, Robert</td>
<td>415</td>
<td></td>
</tr>
<tr>
<td>Bairey Merz, C. Noel</td>
<td>589</td>
<td></td>
</tr>
<tr>
<td>Balsey, Kathy</td>
<td>491</td>
<td></td>
</tr>
<tr>
<td>Bariyegunhi, Omoala</td>
<td>266</td>
<td></td>
</tr>
<tr>
<td>Baker, David</td>
<td>670</td>
<td></td>
</tr>
<tr>
<td>Baker, Jason</td>
<td>319, 608, 623</td>
<td></td>
</tr>
<tr>
<td>Balachandra, Shishir</td>
<td>743</td>
<td></td>
</tr>
<tr>
<td>Balagopall, Ashwin</td>
<td>648</td>
<td></td>
</tr>
<tr>
<td>Balalakrishnan, Mini</td>
<td>329, 434</td>
<td></td>
</tr>
<tr>
<td>Baldelli, Sara</td>
<td>411</td>
<td></td>
</tr>
<tr>
<td>Bale, Michael J.</td>
<td>294</td>
<td></td>
</tr>
<tr>
<td>Balestra, Pietro</td>
<td>354</td>
<td></td>
</tr>
<tr>
<td>Balkan, Suna</td>
<td>523</td>
<td></td>
</tr>
<tr>
<td>Balkus, Jennifer</td>
<td>85, 88, 935, 952</td>
<td></td>
</tr>
<tr>
<td>Ballana, Estor</td>
<td>259</td>
<td></td>
</tr>
<tr>
<td>Baller, Marie</td>
<td>714</td>
<td></td>
</tr>
<tr>
<td>Balogun, Kayode</td>
<td>756</td>
<td></td>
</tr>
<tr>
<td>Balotta, Claudia</td>
<td>227, 303</td>
<td></td>
</tr>
<tr>
<td>Baloyi, Kabelo</td>
<td>958</td>
<td></td>
</tr>
<tr>
<td>Balzer, Laura B.</td>
<td>36, 726, 832</td>
<td></td>
</tr>
<tr>
<td>Banasiwicz, Mary</td>
<td>867</td>
<td></td>
</tr>
<tr>
<td>Banda, Karen M.</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Banda, Richard</td>
<td>919</td>
<td></td>
</tr>
<tr>
<td>Auletta, John, Chloe</td>
<td>789, 790, 885</td>
<td></td>
</tr>
<tr>
<td>Aurlipol, Linda</td>
<td>771, 820</td>
<td></td>
</tr>
<tr>
<td>Austin, Gregory</td>
<td>211</td>
<td></td>
</tr>
<tr>
<td>Austin, Michele</td>
<td>86LB</td>
<td></td>
</tr>
<tr>
<td>Avi, Radko</td>
<td>461</td>
<td></td>
</tr>
<tr>
<td>Avinash, Sanhorn</td>
<td>443, 698</td>
<td></td>
</tr>
<tr>
<td>Avila, Rios, Santiago</td>
<td>182, 480</td>
<td></td>
</tr>
<tr>
<td>Awad, Soussema</td>
<td>1027</td>
<td></td>
</tr>
<tr>
<td>Aveeka, Francesca</td>
<td>414</td>
<td></td>
</tr>
<tr>
<td>Axelsson, Markus</td>
<td>383</td>
<td></td>
</tr>
<tr>
<td>Ayat, Feriel</td>
<td>821</td>
<td></td>
</tr>
<tr>
<td>Ayers, Colby</td>
<td>467</td>
<td></td>
</tr>
<tr>
<td>Ayeiko, James</td>
<td>638, 836, 858</td>
<td></td>
</tr>
<tr>
<td>Ayles, Helen</td>
<td>711, 834, 959, 1010, 1011</td>
<td></td>
</tr>
<tr>
<td>Aynalem, Getahun</td>
<td>1007, 1019</td>
<td></td>
</tr>
<tr>
<td>Ayobu, Ahiibjo</td>
<td>218</td>
<td></td>
</tr>
<tr>
<td>Azama, Martin S.</td>
<td>740</td>
<td></td>
</tr>
<tr>
<td>Aznar, Esther</td>
<td>441</td>
<td></td>
</tr>
<tr>
<td>Azzo, Caitlin</td>
<td>745</td>
<td></td>
</tr>
<tr>
<td>Azzoni, Livio</td>
<td>326</td>
<td></td>
</tr>
</tbody>
</table>
Bandason, Tsitsi 841LB
Bandeen-Roche, Karen 133
Bandera, Alessandra 222, 306
Bandermann, Silke 716LB
Bang, Riddhima 289
Bangham, Charles R.M. 109
Bangirana, Paul 797
Bangsberg, David 675, 773
Banta-Green, Caleb 873, 967
Bao, Jing 717
Bapati, William 993, 1017
Baral, Stefan 918, 997, 1047
Barbaliscia, Silvia 565
Barbee, Lindley A. 846, 979
Barber, Tristan 382
Barber, Xavier 647
Barblu, Lucie 264
Bardhi, Ariola 328
Barnabas, Ruanne V. 107, 1032
Barnaby, Devin 293, 305
Barnard, Richard 311, 337
Barnes, Grace 657, 707
Barnhart, Scott 111
Barnwell, Garret 927
Baro, Elande 372
Barrios, Lisa C. 1033
Barrios, Rolando 875, 1042
Barth, Roos 656
Bartlett, Jeffrey S. 322
Barton, Kirston 293, 305
Barton, Simon 447
Basch, Peter 517, 543, 545
Bassett, Ingrid Valerie. 773
Bearden, David 827, 828
Beauchamp, Geetha 1045
Beck, Ingrid A. 490, 494
Becker, James T. 356
Becker, David 408, 699, 963
Becofsky, Katie 694
Bedimo, Roger 468, 606, 677
Begg, Subul 318
Behel, Stephanie 1017
Behrens, Georg 703
Beiser, Marguerite 557
Bekele, Alemayehu 713
Bekker, Adrie 758
Bekker, Linda-Gail 1036, 421LB, 859
Behrens, Georg 703
Beiser, Marguerite 557
Bekele, Alemayehu 713
Bekker, Adrie 758
Bekker, Linda-Gail 1036, 421LB, 859
Belaunzaran-Zamudio, Pablo Francisco. 225
Belikova-Bethell, Nadejda 307
Belkaid, Yasmine 214
Bell, Jennifer 297
Bell, Kelsi 89
Bellamy, Scarlett 384
Bellecave, Pantxika 349
Bellini, Giulia 531
Bellón, José M. 533
Bellosa, Waldol 473
Bentley, Alonzo 445
Béniguel, Lydie 441
Benitez, Laura 562, 572
Benjamin, Christopher 125, 387
Benki-Nugent, Sarah 796
Ben, Kiya 117
Benne, Clarisse 321
Bennett, Amy 846
Bennett, David 842
Bennett, Kara 502, 640
Bennoit, Anita 940
Benson, Paul 41
Benzaque, Adele 1040
Benzekri, Noelle A. 642
Berdasco, Maria 228
Berenguer, Juan 530, 533, 534, 572
Berg, Michael 583
Berger, Florian 551, 567, 576
Berghout, Ben 286
Berkeley, Jay 117
Berlicher, Kathryn 624
Bermudez, Elkin Hernandez. 464
Bernard, Nicole 274
Bernardino, Jose L. 652, 676
Bertagnolio, Silvia 112
Bertero, Luca 379
Bertine, Mélanie 194, 290
Bertsch, Barbara 596
Bertoli, Ada 564
Bertrand, Rachel 722, 835
Besirh, Anna 1025, 1035, 1036, 1037
Bertagno, Silvia 112
Bertero, Luca 379
Betts, Michael R. 65, 267
Beudeker, Boris J.B. 587
Beural, Lac 267
Beyers, Niudia 1010, 1011
Besseghir, Amel 448, 603
Besseghir, Amel 448, 603
Best, Brookline 755, 810, 938
Best, John 344
Besu, Giuilia 655
Betz, Edward 190
Betts, Michael R. 65, 267
Beudeker, Boris J.B. 587
Beural, Lac 267
Beyers, Niudia 1010, 1011
Bezemere, Daniela 1041
Bhagani, Sanjay 9
Bhagwat, Priya 695
Bhardwaj, Nina 256
Bharti, Ajay 74, 390
Bhaskar, Kavitha 427
<table>
<thead>
<tr>
<th>Author Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bhattacharya, Debika</td>
<td>9, 589</td>
</tr>
<tr>
<td>Bhattacharya, Jayantha</td>
<td>245</td>
</tr>
<tr>
<td>Bhaumik, Siddhartha</td>
<td>1056LB</td>
</tr>
<tr>
<td>Biasin, Mara</td>
<td>222</td>
</tr>
<tr>
<td>Bibbolino, Giulia</td>
<td>466</td>
</tr>
<tr>
<td>Bibollet-Ruche, Frederic</td>
<td>181LB</td>
</tr>
<tr>
<td>Bidwell, Gabriella</td>
<td>82</td>
</tr>
<tr>
<td>Biello, Katie</td>
<td>971</td>
</tr>
<tr>
<td>Bienczak, Andrej</td>
<td>808</td>
</tr>
<tr>
<td>Bieniasz, Paul</td>
<td>1, 160LB, 220</td>
</tr>
<tr>
<td>Bierman, Wouter</td>
<td>451LB, 620</td>
</tr>
<tr>
<td>Bila, Dulce</td>
<td>730, 766, 818</td>
</tr>
<tr>
<td>Bile, Ebi</td>
<td>93</td>
</tr>
<tr>
<td>Biliotti, Elisa</td>
<td>575</td>
</tr>
<tr>
<td>Bibollet-Ruche, Frederic</td>
<td>181LB</td>
</tr>
<tr>
<td>Bichko, Vadim</td>
<td>222</td>
</tr>
<tr>
<td>Bibollet-Ruche, Frederic</td>
<td>181LB</td>
</tr>
<tr>
<td>Bלתz, Valerie</td>
<td>120</td>
</tr>
<tr>
<td>Bonar, Michæl</td>
<td>154</td>
</tr>
<tr>
<td>Bonfanti, Paolo</td>
<td>542LB</td>
</tr>
<tr>
<td>Boltal, Emili</td>
<td>350</td>
</tr>
<tr>
<td>Bontem, Fabrice</td>
<td>131, 630</td>
</tr>
<tr>
<td>Bonnet, Marion</td>
<td>263</td>
</tr>
<tr>
<td>Bonora, Stefano</td>
<td>360, 379, 565</td>
</tr>
<tr>
<td>Boojamma, Constantine</td>
<td>436</td>
</tr>
<tr>
<td>Bone, Denali</td>
<td>516</td>
</tr>
<tr>
<td>Bononstra, Andre</td>
<td>587</td>
</tr>
<tr>
<td>Boonsuk, Sarawut</td>
<td>793</td>
</tr>
<tr>
<td>Bot, Jacob</td>
<td>960</td>
</tr>
<tr>
<td>Bordoni, Veronica</td>
<td>203</td>
</tr>
<tr>
<td>Borges, Álvaro H.</td>
<td>474</td>
</tr>
<tr>
<td>Borghi, Lidia</td>
<td>357</td>
</tr>
<tr>
<td>Boritz, Eli</td>
<td>61</td>
</tr>
<tr>
<td>Borjas Howard, Jaime</td>
<td>620</td>
</tr>
<tr>
<td>Borkowsky, William</td>
<td>800</td>
</tr>
<tr>
<td>Borre, Ethan Daniel</td>
<td>476, 1043</td>
</tr>
<tr>
<td>Borrow, Persephone</td>
<td>181LB</td>
</tr>
<tr>
<td>Bosch, Marjolein</td>
<td>610</td>
</tr>
<tr>
<td>Bosch, Ronald</td>
<td>277, 279, 280, 325, 343, 803, 840</td>
</tr>
<tr>
<td>Bos, Meera</td>
<td>299LB</td>
</tr>
<tr>
<td>Bosch, Ronald</td>
<td>252, 62LB</td>
</tr>
<tr>
<td>Bosman, Robus</td>
<td>320</td>
</tr>
<tr>
<td>Botana, Laura</td>
<td>752</td>
</tr>
<tr>
<td>Boucher, Charles</td>
<td>137LB, 451LB</td>
</tr>
<tr>
<td>Boucher, Marc</td>
<td>785</td>
</tr>
<tr>
<td>Boudreau, Matthew</td>
<td>694</td>
</tr>
<tr>
<td>Boulle, Andrew</td>
<td>727, 769, 990</td>
</tr>
<tr>
<td>Boulougoura, Afroditi</td>
<td>221, 238</td>
</tr>
<tr>
<td>Boulware, David</td>
<td>368, 742, 744, 746</td>
</tr>
<tr>
<td>Boum, Yaf</td>
<td>675, 773</td>
</tr>
<tr>
<td>Bowman, Natalie M.</td>
<td>73</td>
</tr>
<tr>
<td>Bowring, Mary Grace</td>
<td>689</td>
</tr>
<tr>
<td>Boyd, Kathryn Fortunate</td>
<td>345, 743</td>
</tr>
<tr>
<td>Bozzi, Giorgio</td>
<td>227</td>
</tr>
<tr>
<td>Bracchi, Margherita</td>
<td>418</td>
</tr>
<tr>
<td>Bradley, Heather</td>
<td>737, 907, 1012</td>
</tr>
<tr>
<td>Bradley-Stewart, Amanda</td>
<td>185</td>
</tr>
<tr>
<td>Brady, Jennifer J.</td>
<td>679</td>
</tr>
<tr>
<td>Brady, Kathleen</td>
<td>479, 911</td>
</tr>
<tr>
<td>Brathwaite, Scott</td>
<td>1049LB</td>
</tr>
<tr>
<td>Brander, Christian</td>
<td>119LB, 228, 271, 541</td>
</tr>
<tr>
<td>Brande, Peter</td>
<td>380</td>
</tr>
<tr>
<td>Brandt, Cynthia A.</td>
<td>930</td>
</tr>
<tr>
<td>Brandt, Mary-Grace</td>
<td>187</td>
</tr>
<tr>
<td>Branger, Judith</td>
<td>1041</td>
</tr>
<tr>
<td>Brar, Savvy</td>
<td>859</td>
</tr>
<tr>
<td>Brassard, Nathalie</td>
<td>264</td>
</tr>
<tr>
<td>Braun, Dominique Laurent</td>
<td>327, 521</td>
</tr>
<tr>
<td>Braunstein, Sarah</td>
<td>1013</td>
</tr>
<tr>
<td>Breen, Elizabeth</td>
<td>593</td>
</tr>
<tr>
<td>Brehm, Jessica</td>
<td>123</td>
</tr>
<tr>
<td>Breidinger, Sheila</td>
<td>435</td>
</tr>
<tr>
<td>Brenchley, Jason</td>
<td>214</td>
</tr>
<tr>
<td>Brennan, Alana</td>
<td>1050</td>
</tr>
<tr>
<td>Brenner, Bluma</td>
<td>42</td>
</tr>
<tr>
<td>Brew, Bruce</td>
<td>351, 398</td>
</tr>
<tr>
<td>Briand, Coralie</td>
<td>812</td>
</tr>
<tr>
<td>Bridgford, Bob F.</td>
<td>903</td>
</tr>
<tr>
<td>Brieva, Teresa</td>
<td>573</td>
</tr>
<tr>
<td>Brinkley-Rubinstein, Lauren</td>
<td>912, 1044</td>
</tr>
<tr>
<td>Brinkman, Kees</td>
<td>136, 470</td>
</tr>
<tr>
<td>Brinsson, Cynthia</td>
<td>442, 44LB</td>
</tr>
<tr>
<td>Brittain, Eran L.</td>
<td>621</td>
</tr>
<tr>
<td>Brittain, Kirsty</td>
<td>24, 771, 992</td>
</tr>
<tr>
<td>Author</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>--------</td>
<td>--------------</td>
</tr>
<tr>
<td>Britto, Paula</td>
<td>772</td>
</tr>
<tr>
<td>Brizgys, Gediminas</td>
<td>434</td>
</tr>
<tr>
<td>Brockmeyer, Norbert H.</td>
<td>633</td>
</tr>
<tr>
<td>Brodt, H.-R.</td>
<td>738</td>
</tr>
<tr>
<td>Broekhuis, Jordan</td>
<td>963</td>
</tr>
<tr>
<td>Bronson, Heather W.</td>
<td>633</td>
</tr>
<tr>
<td>Brown, Alison E.</td>
<td>186, 736</td>
</tr>
<tr>
<td>Brown, Diane M.</td>
<td>317</td>
</tr>
<tr>
<td>Brown, Geri</td>
<td>677</td>
</tr>
<tr>
<td>Brown, Kevin W.</td>
<td>252</td>
</tr>
<tr>
<td>Brown, Kimberley</td>
<td>505</td>
</tr>
<tr>
<td>Brown, Lillian</td>
<td>836</td>
</tr>
<tr>
<td>Brown, Nakita</td>
<td>943</td>
</tr>
<tr>
<td>Brown, Rachel</td>
<td>260LB</td>
</tr>
<tr>
<td>Brown, Sheldon T.</td>
<td>606, 658</td>
</tr>
<tr>
<td>Brown, Todd</td>
<td>237</td>
</tr>
<tr>
<td>Brown, Alison E.</td>
<td>846, 851, 973</td>
</tr>
<tr>
<td>Bruckner, Zabrina</td>
<td>190</td>
</tr>
<tr>
<td>Brumfield, Sean</td>
<td>772</td>
</tr>
<tr>
<td>Brun-Vezinet, Francoise</td>
<td>290, 448</td>
</tr>
<tr>
<td>Brunet, Laurence</td>
<td>483</td>
</tr>
<tr>
<td>Bruns, Anke</td>
<td>320</td>
</tr>
<tr>
<td>Brust, James CM.</td>
<td>77</td>
</tr>
<tr>
<td>Bryant, Kendall J.</td>
<td>673, 874</td>
</tr>
<tr>
<td>Buaben, Aaron Ohene</td>
<td>753</td>
</tr>
<tr>
<td>Buchacz, Kate</td>
<td>32, 663, 678, 864, 907</td>
</tr>
<tr>
<td>Buchbinder, Susan P.</td>
<td>419, 974, 978</td>
</tr>
<tr>
<td>Brunner, Katherine</td>
<td>279, 284, 511, 512, 876</td>
</tr>
<tr>
<td>Brusch, Michael P.</td>
<td>279, 284, 511, 512, 876</td>
</tr>
<tr>
<td>Buseyne, Florence</td>
<td>190</td>
</tr>
<tr>
<td>Bush, Tim</td>
<td>597</td>
</tr>
<tr>
<td>Bush, William S.</td>
<td>377, 392, 393</td>
</tr>
<tr>
<td>Bushman, Frederic</td>
<td>171LB</td>
</tr>
<tr>
<td>Bushman, Lane R.</td>
<td>404, 405, 419</td>
</tr>
<tr>
<td>Bukusi, Elizabeth A.</td>
<td>85, 762, 832, 858, 861, 934, 947</td>
</tr>
<tr>
<td>Bull, Marta Eileen</td>
<td>224</td>
</tr>
<tr>
<td>Bulken, Cynthia</td>
<td>134</td>
</tr>
<tr>
<td>Capobianchi, Maria Rosaria</td>
<td>466</td>
</tr>
<tr>
<td>Capoferri, Adam</td>
<td>296, 318</td>
</tr>
<tr>
<td>Capparelli, Edmund V.</td>
<td>755, 758, 760, 809, 810, 938</td>
</tr>
<tr>
<td>Cardinaud, Sylvain</td>
<td>262</td>
</tr>
<tr>
<td>Cardoso, Lena</td>
<td>557</td>
</tr>
<tr>
<td>Cardoso, Sandra Wagner</td>
<td>457, 648</td>
</tr>
<tr>
<td>Author Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Chipato, Tsungai</td>
<td>776</td>
</tr>
<tr>
<td>Chirenje, Zvavahera M.</td>
<td>945</td>
</tr>
<tr>
<td>Chino, Oscar</td>
<td>856, 893, 1022</td>
</tr>
<tr>
<td>Chirwa, Zengani</td>
<td>464</td>
</tr>
<tr>
<td>Chisunkha, Blessings</td>
<td>896</td>
</tr>
<tr>
<td>Chitwarakorn, Anupong</td>
<td>854, 855, 862</td>
</tr>
<tr>
<td>Chiwete, K</td>
<td>711</td>
</tr>
<tr>
<td>Chmiel, Joan Sander</td>
<td>942</td>
</tr>
<tr>
<td>Cho, Josalyn</td>
<td>232</td>
</tr>
<tr>
<td>Choffe, Awilly Aden.</td>
<td>82</td>
</tr>
<tr>
<td>Chohan, Vasha</td>
<td>765</td>
</tr>
<tr>
<td>Chokephaibulkit, Kul Krankya</td>
<td>425</td>
</tr>
<tr>
<td>Choko, Augustine</td>
<td>895</td>
</tr>
<tr>
<td>Chomchey, Nitaya</td>
<td>214, 291</td>
</tr>
<tr>
<td>Chomont, Nicolas</td>
<td>1, 124, 281, 282, 285, 288, 291, 293, 319, 326</td>
</tr>
<tr>
<td>Chomont, Nicolas</td>
<td>1, 124, 281, 282, 285, 288, 291, 293, 319, 326</td>
</tr>
<tr>
<td>Chow, Dominic</td>
<td>255, 385, 612, 692</td>
</tr>
<tr>
<td>Chow, Felicia C.</td>
<td>347, 399</td>
</tr>
<tr>
<td>Chow, Shein-Chung</td>
<td>552</td>
</tr>
<tr>
<td>Chowdhury, Navin Fatema</td>
<td>292</td>
</tr>
<tr>
<td>Christ, Frauke</td>
<td>155</td>
</tr>
<tr>
<td>Christensen, Stefan</td>
<td>551, 567, 576</td>
</tr>
<tr>
<td>Christensen-Quick, Aaron</td>
<td>166</td>
</tr>
<tr>
<td>Christopoulos, Katerina</td>
<td>838</td>
</tr>
<tr>
<td>Chrystostomou, Anastasia</td>
<td>687</td>
</tr>
<tr>
<td>Chu, Fang-Yeh</td>
<td>594</td>
</tr>
<tr>
<td>Chuang, Yu-Chung</td>
<td>582</td>
</tr>
<tr>
<td>Chueca, Natalia</td>
<td>566</td>
</tr>
<tr>
<td>Chun, Tae-Wook</td>
<td>319</td>
</tr>
<tr>
<td>Chung, Hannah</td>
<td>950</td>
</tr>
<tr>
<td>Chung, Michael H.</td>
<td>22, 490, 494</td>
</tr>
<tr>
<td>Chung, Raymond F.</td>
<td>404, 574</td>
</tr>
<tr>
<td>Ciacci, Gianguido C.</td>
<td>15</td>
</tr>
<tr>
<td>Ciancio, Alessia</td>
<td>565</td>
</tr>
<tr>
<td>Ciambella, Andrea L.</td>
<td>814, 833</td>
</tr>
<tr>
<td>Cicale, Claudia</td>
<td>644LB</td>
</tr>
<tr>
<td>Cifuentes, Carmen</td>
<td>533</td>
</tr>
<tr>
<td>Cihu, Tomas</td>
<td>118, 309, 313, 338LB, 436</td>
</tr>
<tr>
<td>Cillo, Anthony R.</td>
<td>121, 309, 313</td>
</tr>
<tr>
<td>Cimini, Eleonora</td>
<td>203</td>
</tr>
<tr>
<td>Ciuffi, Angela</td>
<td>162</td>
</tr>
<tr>
<td>Claassen, Mark</td>
<td>137LB, 587</td>
</tr>
<tr>
<td>Clapham, Paul</td>
<td>246, 365</td>
</tr>
<tr>
<td>Clark, Andrew</td>
<td>417</td>
</tr>
<tr>
<td>Clark, Devon</td>
<td>975</td>
</tr>
<tr>
<td>Clark, Tamara D.</td>
<td>36, 638, 726, 766, 836, 858, 860, 1051</td>
</tr>
<tr>
<td>Clarke, Amanda</td>
<td>447, 453</td>
</tr>
<tr>
<td>Clarke, Diana F.</td>
<td>757</td>
</tr>
<tr>
<td>Clarke, William</td>
<td>904</td>
</tr>
<tr>
<td>Clayton, Kiera L.</td>
<td>233</td>
</tr>
<tr>
<td>Clement, Meredith</td>
<td>615</td>
</tr>
<tr>
<td>Clementi, Emilio</td>
<td>410, 411</td>
</tr>
<tr>
<td>Clemenzi-AIlen, Angelo Asa</td>
<td>413</td>
</tr>
<tr>
<td>Clerici, Mario</td>
<td>222, 804</td>
</tr>
<tr>
<td>Clement, Nuria</td>
<td>336</td>
</tr>
<tr>
<td>Clise, Clary</td>
<td>636LB</td>
</tr>
<tr>
<td>Cloherty, Gavin</td>
<td>510, 522, 577, 583</td>
</tr>
<tr>
<td>Cloitet, Bonaventura</td>
<td>119LB, 259</td>
</tr>
<tr>
<td>Coban, Hamza</td>
<td>343</td>
</tr>
<tr>
<td>Cobelens, Frank</td>
<td>727</td>
</tr>
<tr>
<td>Cocker, Alexander</td>
<td>275</td>
</tr>
<tr>
<td>Cofan, Montserrat</td>
<td>614</td>
</tr>
<tr>
<td>Coffin, John</td>
<td>294, 297, 298</td>
</tr>
<tr>
<td>Cogswell, Andrew</td>
<td>211</td>
</tr>
<tr>
<td>Cohan, Deborah</td>
<td>768</td>
</tr>
<tr>
<td>Cohen, Calvin</td>
<td>683</td>
</tr>
<tr>
<td>Cohen, Craig</td>
<td>36, 85, 762, 832, 858</td>
</tr>
<tr>
<td>Cohen, Margie H.</td>
<td>132, 237LB, 514, 646, 690, 933</td>
</tr>
<tr>
<td>Cohen, Myron S.</td>
<td>198, 406, 1002</td>
</tr>
<tr>
<td>Cohen, Sophie</td>
<td>825, 830</td>
</tr>
<tr>
<td>Cohen, Stephanie E.</td>
<td>189, 477, 978</td>
</tr>
<tr>
<td>Cohn, Silvia</td>
<td>707</td>
</tr>
<tr>
<td>Cohn, Susan E.</td>
<td>921, 942</td>
</tr>
<tr>
<td>Colbers, Angela</td>
<td>429, 753, 754, 807</td>
</tr>
<tr>
<td>Colby, Donn</td>
<td>124, 249, 270, 339, 363</td>
</tr>
<tr>
<td>Cole, James H.</td>
<td>352LB</td>
</tr>
<tr>
<td>Cole, Stephen R.</td>
<td>908</td>
</tr>
<tr>
<td>Collella, Elisa</td>
<td>222</td>
</tr>
<tr>
<td>Colle, Christine</td>
<td>25</td>
</tr>
<tr>
<td>Collado, Antonio</td>
<td>570</td>
</tr>
<tr>
<td>Collado-Diaz, Victor</td>
<td>609</td>
</tr>
<tr>
<td>Coller, Kelly</td>
<td>510, 577, 583</td>
</tr>
<tr>
<td>Coller, Ann</td>
<td>280, 457</td>
</tr>
<tr>
<td>Collin, Fideline</td>
<td>194, 195, 448</td>
</tr>
<tr>
<td>Collin, Gilles</td>
<td>499</td>
</tr>
<tr>
<td>Collins, Ben</td>
<td>263</td>
</tr>
<tr>
<td>Collins, Bryan C.</td>
<td>962</td>
</tr>
<tr>
<td>Collins, Deborah</td>
<td>977</td>
</tr>
<tr>
<td>Collins, Intira Jeannie</td>
<td>815, 831</td>
</tr>
<tr>
<td>Collins, Lauren Frances.</td>
<td>138, 552</td>
</tr>
<tr>
<td>Collins, Louis</td>
<td>397</td>
</tr>
<tr>
<td>Collins, Pamela</td>
<td>153</td>
</tr>
<tr>
<td>Collmann, Jeff</td>
<td>646, 933</td>
</tr>
<tr>
<td>Colman, Rebecca</td>
<td>715LB</td>
</tr>
<tr>
<td>Colomer-Lluch, Marta</td>
<td>168</td>
</tr>
<tr>
<td>Colucci, Amy</td>
<td>424</td>
</tr>
<tr>
<td>Comi, Laura</td>
<td>460</td>
</tr>
<tr>
<td>Comins, Kyla</td>
<td>80LB</td>
</tr>
<tr>
<td>Compston, Juliet</td>
<td>679</td>
</tr>
<tr>
<td>Cone, Richard</td>
<td>210</td>
</tr>
<tr>
<td>Cong, Mian-er</td>
<td>84, 209</td>
</tr>
<tr>
<td>Conley, Lois</td>
<td>597</td>
</tr>
<tr>
<td>Connick, Elizabeth</td>
<td>63, 616</td>
</tr>
<tr>
<td>Connor, James R.</td>
<td>377</td>
</tr>
<tr>
<td>Conradi, Almari</td>
<td>724LB</td>
</tr>
<tr>
<td>Conradi, Francesca</td>
<td>51, 1020, 80LB</td>
</tr>
<tr>
<td>Constantino, Stephanie</td>
<td>548</td>
</tr>
<tr>
<td>Conway, Brian</td>
<td>553</td>
</tr>
<tr>
<td>Conway, Tracey</td>
<td>924, 925</td>
</tr>
<tr>
<td>Conyngham, Caitlin</td>
<td>975</td>
</tr>
<tr>
<td>Cook, Adrian</td>
<td>808</td>
</tr>
<tr>
<td>Cook, Jennifer</td>
<td>563</td>
</tr>
<tr>
<td>Cook, Robert L.</td>
<td>874</td>
</tr>
<tr>
<td>Cook, Ryan</td>
<td>770</td>
</tr>
<tr>
<td>Cook, Victoria</td>
<td>735</td>
</tr>
<tr>
<td>Cookson, Debralee</td>
<td>390</td>
</tr>
<tr>
<td>Coombs, Robert</td>
<td>224, 446, 508, 947</td>
</tr>
<tr>
<td>Cooper, Curtis</td>
<td>138, 553</td>
</tr>
<tr>
<td>Cooper, David A.</td>
<td>670</td>
</tr>
<tr>
<td>Coovadia, Ashraf</td>
<td>27, 29LB, 814, 819</td>
</tr>
<tr>
<td>Copans, Amanda</td>
<td>568LB</td>
</tr>
<tr>
<td>Cope, Fred 635LB</td>
<td>351, 537, 585</td>
</tr>
<tr>
<td>Corebelloe, Pierre</td>
<td>605</td>
</tr>
<tr>
<td>Corbett, Amanda</td>
<td>783</td>
</tr>
<tr>
<td>Corbett, Elizabeth L.</td>
<td>1030</td>
</tr>
<tr>
<td>Corbett, Liz</td>
<td>895, 896</td>
</tr>
<tr>
<td>Corbin, John A.</td>
<td>329</td>
</tr>
<tr>
<td>Cordero, Elsa</td>
<td>541</td>
</tr>
<tr>
<td>Corey, Kathleen</td>
<td>574</td>
</tr>
<tr>
<td>Corey, Larry</td>
<td>415</td>
</tr>
<tr>
<td>Corleis, Bjorn</td>
<td>232</td>
</tr>
<tr>
<td>Cornell, Morna</td>
<td>998</td>
</tr>
</tbody>
</table>
de Pokomandy, Alexandra 924, 925, 926, 940
de Souza, Mark 125, 285, 299LB
de Spiegelaere, Ward 162, 302
de Stefano, Giorgio 537
de Vries - Slujs, Theodora 451LB
De Vuyst, Hugo 22
de Wilt, Stephane 693, 703
DeAlwis, Paba M. 402
Dean, Bonnie 663
Debyser, Zeger 155
Decker, Luc 584LB
Deeks, Steven G. 65, 126, 267, 281, 284, 288, 293, 391, 407, 512
DeHovitz, Jack 514
Deiss, Robert 358, 865, 932
DeJesus, Edwin 41, 453, 45LB
DeKadt, Julia 111
Del Amo, Julia 1028
Del Campo, Santos 541
del Rio, Carlos 90
Del Río-Estrada, Perla 65
Del Sole, Angelo 680
Delagreverie, Heloise M. 278, 323, 325
Delaney, Kevin 509
Delany-Moretlwe, Sinead 857
Delaporte, Eric 482, 486
Delaugerre, Constance 278, 323, 441, 91LB
Deleage, Claire 70, 226
Delelis, Olivier 499
Delgado-Fernández, Marcial 139, 571
Delong, Kevin 210
Delpech, Valerie 736
Delucchi, Kevin L. 547
Delvink-Frankenberry, Krista 334
Demers, Andrew J. 182, 198, 483
Dempsey, Antigone 1012
Deng, Wenjie 304
Deng, Xutao 284
Deng, Yanhong 257
Denkinger, Claudia M. 76LB
Dennis, Ann M. 198, 483
Denti, Paolo 39LB, 808, 809
Denton, Robin W. 314
Deroche, Anne 43, 491
Dermody, Nadene 351
DeRosa, Stephen 321
Desi, Tejal 420
Descamps, Diane 194, 195, 349, 448, 458, 499, 812
Desmangles, Ashish A. 591
Desmang, Savitha 307
Desimifi, Belete A. 164, 173, 227
Desier, Fidel A. 840
Desmond, Sophie 814
Desouza, Christopher 616
Deulina, Marina 452LB
Defilipe, Walter 656
Dean, Robin L. 227
Dezzutti, Charlene S. 86LB, 944
Dhillon, Dilsher 661
Dhody, Kush 437
Di Perri, Giovanni 360, 379
Diabaté, Souleymane 1047
Diaco, Andreas Henri. 79, 80LB
Diallo, Mamadou Hassimiou. 1018
Diallo, Mariama 290
Diamond, Jan 556
Díaz, Asunción 1028
Díaz, Carmen 527
Diaz, Laura 802
Diaz de Santiago, Alberto 676
Dickey, Amy Kathleen. 232
Dickinson, Gordon 234, 258
Dickinson, Laura 39
Diehl, Kyle 616
Dietrich, Douglas 138
Diz, Cristina 530
Diz, Jose Luis 306
Díez-Pérez, Adolfo 681
Dige, Anders Kirch. 314
Dijkstra, Maartje 886, 887
Dillon, Stephanie 211
Dimba-Obou, Jodie 867
Dion, Douda 1047
Diraalj-Fargo, Sahera 618
Dickson, Suzanne 528
Dirix, Lieve 155
Diso, Modiegi 25
Dlami, Nduimoso 994
Dlami, Phibwiyinkhosi 994
Do Duy, Guong 463
Dubs, Adrian 669
Dodd, Lori E. 238
Doherty, Meg 112
Dolan, Michael 14LB
Dolci, Giovanni 532
Dollfus, Catherine 775, 812
Donanico, Paul 39
Dombrowski, Julia C. 89, 964, 979
Dominguez-Dominguez, Louards 534, 572
Domyeum, Jenny 482, 486
Doncel, Gustavo 857
Dong, Krista 266
Donnell, Deborah J. 3, 85, 1045
Doria-Rose, Nicole 244
Dorman, Robin 469
Dorman, Susan E. 76LB
Dorrell, Lucy 271
Dow, Daniel 60, 61, 165, 175
Dougherty, Sarah 867
Douglas, Pamela 615
Douglas, Steven D. 827, 828
Dow, Caitlin 616
Downhour, Diane 20
Doyle, Katherine 1055LB
Doyle, Margaret 673
Doyle, Ronan 801
Draenert, Rika 472, 888
Dragavon, Joan 224
Dragunova, Julia 569
Drahe, Alison L. 765
Drechsel, Henning J. 468
Dreyer, Dan 435
Droit, Lindsay 213
Droz, Daniel 347, 625
Drummond, M. Brad 661
Draz, Aliaksandr 14LB
Dryden-Peterson, Scott 787
Du, Yushen 268, 500LB
Du Pasquier, Renaud 362
Dunaia, Horacio A. 494
<table>
<thead>
<tr>
<th>Author</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duarte, Wellington</td>
<td>388</td>
</tr>
<tr>
<td>Dube, Michael</td>
<td>977</td>
</tr>
<tr>
<td>Dube, Queen</td>
<td>783</td>
</tr>
<tr>
<td>Dubrow, Robert</td>
<td>257, 600</td>
</tr>
<tr>
<td>Duenas Decamp, Maria Jose</td>
<td>246</td>
</tr>
<tr>
<td>Duerr, Ann</td>
<td>380, 446</td>
</tr>
<tr>
<td>Duerr, Ralf</td>
<td>881</td>
</tr>
<tr>
<td>Duissenberg-van Essenborg,</td>
<td>429</td>
</tr>
<tr>
<td>Marjolijn</td>
<td></td>
</tr>
<tr>
<td>Dukhovnikova, Elena</td>
<td>369</td>
</tr>
<tr>
<td>Duchmech, Kostyantyn</td>
<td>884</td>
</tr>
<tr>
<td>Dumond, Julie B</td>
<td>406</td>
</tr>
<tr>
<td>Dunaway, Shelia</td>
<td>749, 750</td>
</tr>
<tr>
<td>Duncan, Kristal</td>
<td>927</td>
</tr>
<tr>
<td>Dunham, Richard M</td>
<td>252</td>
</tr>
<tr>
<td>Dunn, David</td>
<td>186</td>
</tr>
<tr>
<td>Dunne, Eileen F</td>
<td>854, 855, 882</td>
</tr>
<tr>
<td>Dunville, Richard</td>
<td>833, 1033</td>
</tr>
<tr>
<td>Dupnik, Kathryn</td>
<td>471</td>
</tr>
<tr>
<td>Dupon, Michel</td>
<td>630</td>
</tr>
<tr>
<td>Durand, Christine</td>
<td>317, 318, 330, 689</td>
</tr>
<tr>
<td>Durfee, Joshua</td>
<td>528</td>
</tr>
<tr>
<td>Durham, Natasha</td>
<td>256</td>
</tr>
<tr>
<td>Durham, Phillip G</td>
<td>420</td>
</tr>
<tr>
<td>Dutertre, Marine</td>
<td>732</td>
</tr>
<tr>
<td>Dutta, Sandeep</td>
<td>413</td>
</tr>
<tr>
<td>Duwve, Joan</td>
<td>878</td>
</tr>
<tr>
<td>Dyavar Shetty, Ravi</td>
<td>408</td>
</tr>
<tr>
<td>Dzamalala, Charles Patrick</td>
<td>602</td>
</tr>
<tr>
<td>d’Almeida, Marcelline</td>
<td>487</td>
</tr>
<tr>
<td>—E—</td>
<td></td>
</tr>
<tr>
<td>Easley, Kirk A</td>
<td>684</td>
</tr>
<tr>
<td>Eaton, Ellen F</td>
<td>454, 455</td>
</tr>
<tr>
<td>Eaton, Jeffrey</td>
<td>115, 1031</td>
</tr>
<tr>
<td>Ebner, Hanna</td>
<td>66, 67</td>
</tr>
<tr>
<td>Eckard, Allison Ross</td>
<td>822</td>
</tr>
<tr>
<td>Eckhardt, Benjamin</td>
<td>554</td>
</tr>
<tr>
<td>Edagwa, Benson</td>
<td>439</td>
</tr>
<tr>
<td>Edelstein, Zoe R</td>
<td>891, 898</td>
</tr>
<tr>
<td>Edén, Arvid</td>
<td>340, 431</td>
</tr>
<tr>
<td>Eden, John-Sebastian</td>
<td>293</td>
</tr>
<tr>
<td>Edlefsen, Paul</td>
<td>304</td>
</tr>
<tr>
<td>Edlin, Brian</td>
<td>554</td>
</tr>
<tr>
<td>Edwards, Jessie K</td>
<td>454</td>
</tr>
<tr>
<td>Efronson, Emilie</td>
<td>1004</td>
</tr>
<tr>
<td>Egubuje, Bon</td>
<td>763</td>
</tr>
<tr>
<td>Egger, Matthias</td>
<td>581, 596, 714</td>
</tr>
<tr>
<td>Eholie, Serge</td>
<td>78, 476</td>
</tr>
<tr>
<td>Eichner, Allyson</td>
<td>961</td>
</tr>
<tr>
<td>Eilers, Grant</td>
<td>171LB</td>
</tr>
<tr>
<td>Eisenberg, Anna</td>
<td>515</td>
</tr>
<tr>
<td>Eisenberg, Marcia</td>
<td>1054</td>
</tr>
<tr>
<td>Ekouevi, Didier Koumavi</td>
<td>607</td>
</tr>
<tr>
<td>El Kamari, Vanessa</td>
<td>618</td>
</tr>
<tr>
<td>El-Fakhri, Georges</td>
<td>635LB</td>
</tr>
<tr>
<td>El-Halabi, Shenaz</td>
<td>1008</td>
</tr>
<tr>
<td>El-Sadr, Waafa M</td>
<td>1023, 1045, 1049,LB, 1280,LB, 637, 706</td>
</tr>
<tr>
<td>Elashoff, David</td>
<td>592, 593</td>
</tr>
<tr>
<td>Elbezanti, Wearn</td>
<td>308</td>
</tr>
<tr>
<td>Eld, Amy</td>
<td>428</td>
</tr>
<tr>
<td>Elde, Nels</td>
<td>20</td>
</tr>
<tr>
<td>Eley, Brian</td>
<td>763</td>
</tr>
<tr>
<td>Eliaou, Jean-François</td>
<td>605</td>
</tr>
<tr>
<td>Elion, Richard</td>
<td>978</td>
</tr>
<tr>
<td>Elliot, Emilie</td>
<td>432</td>
</tr>
<tr>
<td>Elliott, Jennifer</td>
<td>16</td>
</tr>
<tr>
<td>Ellis, Ronald J</td>
<td>343, 353, 367, 377, 386, 392, 393</td>
</tr>
<tr>
<td>Ellis, Shanon</td>
<td>84</td>
</tr>
<tr>
<td>Ellis, Tyrone</td>
<td>923</td>
</tr>
<tr>
<td>Ellison, Lucas</td>
<td>405</td>
</tr>
<tr>
<td>Ellner, Jerrold</td>
<td>709, 76LB</td>
</tr>
<tr>
<td>Else, Laura</td>
<td>416, 418</td>
</tr>
<tr>
<td>Elul, Bayta</td>
<td>110, 837</td>
</tr>
<tr>
<td>Emerman, Michael</td>
<td>19, 172</td>
</tr>
<tr>
<td>Emery, Ann</td>
<td>163</td>
</tr>
<tr>
<td>Emery, Sandy</td>
<td>765</td>
</tr>
<tr>
<td>Emery, Sean</td>
<td>473, 474</td>
</tr>
<tr>
<td>Emiliozzi, Arianna</td>
<td>445</td>
</tr>
<tr>
<td>Emperor, Devy</td>
<td>33</td>
</tr>
<tr>
<td>Emu, Brinda</td>
<td>257, 449LB, 72</td>
</tr>
<tr>
<td>Emusu, Donath</td>
<td>982, 985, 986</td>
</tr>
<tr>
<td>Engelbrecht, Susan</td>
<td>120</td>
</tr>
<tr>
<td>Engelman, Alan N</td>
<td>157, 292</td>
</tr>
<tr>
<td>Engels, Eric A</td>
<td>598, 600, 661</td>
</tr>
<tr>
<td>Engelthaler, David M</td>
<td>715LB</td>
</tr>
<tr>
<td>Engen, Philip A</td>
<td>240, 241</td>
</tr>
<tr>
<td>Ensign, Laura</td>
<td>210</td>
</tr>
<tr>
<td>Enstone, Joanne</td>
<td>1039</td>
</tr>
<tr>
<td>Eple, Fanny</td>
<td>780</td>
</tr>
<tr>
<td>Eriksen, Jaran</td>
<td>431</td>
</tr>
<tr>
<td>Erlandson, Kristine</td>
<td>356, 665, 666, 700</td>
</tr>
<tr>
<td>Ernest, Oscar</td>
<td>950</td>
</tr>
<tr>
<td>Eron, Joseph J.</td>
<td>73, 198, 277, 279, 280, 298, 342, 442, 454, 465, 483, 619</td>
</tr>
<tr>
<td>Esbjörnsson, Joakim</td>
<td>37, 202</td>
</tr>
<tr>
<td>Escota, Gerome</td>
<td>597</td>
</tr>
<tr>
<td>Escribà, Tuixent</td>
<td>614</td>
</tr>
<tr>
<td>Eshleman, Susan H</td>
<td>492, 879, 955, 1002</td>
</tr>
<tr>
<td>Eshun-Wilson, Ingrid</td>
<td>995</td>
</tr>
<tr>
<td>Esmail, Hanif</td>
<td>739</td>
</tr>
<tr>
<td>Espinoza, Luis</td>
<td>874</td>
</tr>
<tr>
<td>Esplugues, Juan V</td>
<td>609</td>
</tr>
<tr>
<td>Esposito, Vincenzo</td>
<td>585</td>
</tr>
<tr>
<td>Esser, Stefan</td>
<td>633</td>
</tr>
<tr>
<td>Essex, Max</td>
<td>25, 184, 484</td>
</tr>
<tr>
<td>Este, Jose A.</td>
<td>259</td>
</tr>
<tr>
<td>Esteller, Manel</td>
<td>228</td>
</tr>
<tr>
<td>Estes, Jacob D</td>
<td>70, 226, 251</td>
</tr>
<tr>
<td>Esteve, Anna</td>
<td>651</td>
</tr>
<tr>
<td>Estill, Janne</td>
<td>596, 782</td>
</tr>
<tr>
<td>Estrada, Vicente</td>
<td>676</td>
</tr>
<tr>
<td>Esvan, Rozenn</td>
<td>575</td>
</tr>
<tr>
<td>Ethridge, Steven</td>
<td>509</td>
</tr>
<tr>
<td>Eugen-Olsen, Jesper</td>
<td>235</td>
</tr>
<tr>
<td>Eusuff, Jasur</td>
<td>364</td>
</tr>
<tr>
<td>Euvard, Jonathan</td>
<td>990</td>
</tr>
<tr>
<td>Evans, Ceri</td>
<td>786</td>
</tr>
<tr>
<td>Evans, David</td>
<td>2</td>
</tr>
<tr>
<td>Evans, Denise</td>
<td>917</td>
</tr>
<tr>
<td>Evans, Henry W</td>
<td>346, 546</td>
</tr>
<tr>
<td>Even, Sophie</td>
<td>290</td>
</tr>
<tr>
<td>Everitt, Daniel</td>
<td>80LB</td>
</tr>
<tr>
<td>Eyawo, Oghenowede</td>
<td>601, 619, 929</td>
</tr>
<tr>
<td>Eymard-Duverney, Sabrina</td>
<td>482, 486, 654</td>
</tr>
<tr>
<td>—F—</td>
<td></td>
</tr>
<tr>
<td>Fabbiani, Massimiliano</td>
<td>222, 445</td>
</tr>
<tr>
<td>Fabbri, Gabriele</td>
<td>354</td>
</tr>
<tr>
<td>Fabre, Roxane</td>
<td>72</td>
</tr>
<tr>
<td>Farente, Shelley</td>
<td>511, 876</td>
</tr>
<tr>
<td>Fafi-Kremer, Samira</td>
<td>495</td>
</tr>
<tr>
<td>Faini, Diana</td>
<td>744</td>
</tr>
<tr>
<td>Falade-Nwulia, Olusaweun</td>
<td>560</td>
</tr>
<tr>
<td>Faller, Jean-Pierre</td>
<td>495</td>
</tr>
<tr>
<td>Fan, Li</td>
<td>412, 430</td>
</tr>
<tr>
<td>Fane, Othusiste</td>
<td>729</td>
</tr>
<tr>
<td>Fang, Annie</td>
<td>417</td>
</tr>
<tr>
<td>Fanjul, Francisco</td>
<td>659</td>
</tr>
<tr>
<td>Fanning, Miranda</td>
<td>845LB</td>
</tr>
<tr>
<td>Farber-Eger, Eric</td>
<td>621</td>
</tr>
</tbody>
</table>
Farella, Nunzia 527
Farhad, Mona 776, 777
Farhadian, Shelli 257
Farquhar, Carey 1032
Farrior, Jennifer Hannia. 421LB
Faruhi, Irfan 677
Fade, Gwendolyn 417
Fäktenheuer, Gerd 176, 183, 580
Fatti, Geoffrey 763
Fauci, Anthony S. 64LB
Favarato, Graziella 778
Favre, David 123, 252
Fawcett, Tracy 186
Fayadat-Dilman, Laurence 337
Fay, Albert 775
Fedele, Valentina 366
Fehr, Jan Sven. 521
Fennema-Notestine, Chris 403
Fenner, Lukas 714, 721
Fenwick, Craig 265LB
Ferguson, Tomas 865
Ferlazzo, Gabriella 718
Fernández, Marta 641
Fernandez, Jose Ramon. 540
Fernandez, Laura 752
Fernández, Marta 647
Fernandez, Stephen 517, 543, 545
Fernández Mckhe, Carolina 527
Fernández-Rodríguez, Amanda 530
Ferris, Bridget 798
Ferrand, Rashida 841LB
Ferrari, Marta 396
Ferris, David 682
Ferris, Robert 123
Fessel, Jeffrey 449LB, 506
Fey, Jordan M. 405
Fichtenbaum, Carl 251, 342
Fidler, Sarah 261, 324, 834, 959, 1010, 1011
Fielding, Katherine 723LB
Fierer, Daniel S. 404
Figueroux, Carmen 1030
Figueruela López, Blanca 571
Fillgrove, Jerry 435
Finlayson, Teresa 902
Fiore, Danielle 842
Fiore, Vito 542LB
Finhamb, Cindy 941
Fischer, Laurent 381
Fischl, Margaret 234, 258
Fishman, Dawn 517, 543, 545
Fisher, Arren 1054
Fisher, Bridget 260LB
Fisher, Cole 260LB
Fitch, Kathleen V. 627
Fitzgerald, Daniel 471, 722, 835
Fitzgerald, Felicity 801
Fleisher, Alan 517
Fleissner, Zach 169
Fleming, Ira 897
Fleenor, Nina Campbell. 269
Fletcher, Courtvney V. 79, 408
Fletcher, James LK. 71, 394
Fleming, Andrew I. 141
Flynn, Colin 904
Flynn, Patricia M. 685LB
Focà, Emmanuele 460
Fofana, Djeneba Bocar 487
Fogel, Jessica M. 1002
Folli, Julia 800
Folivawd, Joy 63
Fomundam, Henry 1007, 1019
Forleo, Peter 993
Fonseca, Luiz Augusto. 388
Forber, Kenv 583
Force, Lisa M. 535, 651
Ford, Christopher 176
Forgione, Lisa A. 903
Folranini, Federica 804
Fortuny, Rosa 382
Foster, Antonina 684
Foucat, Emilie 630
Fourati, Slim 60
Fowler, Mary Glenn 776, 777
Fox, Julie 324
Fox, Matthew 459, 917, 1020, 1021, 1050
Frampton, Dan 193
France, Anne Marie 187, 188, 845LB
France, John 788
Franceschi, Claudio 672
Francis, Kate 831
Franco, Sandra 541
Frangi, Pierre 775, 812
Frank, Daniel N. 211
Frank, Simone C. 814
Frankel, Matthew 583
Franklin, Donald 74, 201, 392, 393
Franks, Julie 853
Frantzelm, Arne 563
Frasier, Nicole 1046
Frates, John 261, 301, 324
Freddo, Carol 435
Freed, Eric O. 156, 158, 180, 507
Freedberg, Kenneth 116, 456, 476, 814, 1028, 1043
Freeman, Michael L. 276
Freeman, Zachary 253
Freiberg, Matthew 127, 574, 626, 667, 673, 702
Freiman, J. Morgan 709
Freitas, Marcelo 1040
French, Audrey 341, 526, 921
Frenkel, Lisa 224, 304, 490, 494
Frias, Mario 532, 573
Fried, Michael 522
Friedman, Samuel R. 849
Frieson, Krystal 839
Froinmets, Rémi 288, 293
Fronzillo, Edward A. 690, 913
Fronza, Raffaele 302
Frost, Eric H. 522
Fuchs, Dietmar 340, 383, 389
Fuchs, James R. 16, 157
Fuhrman, Jill 510, 577
Fujii, Ken 180
Fulcher, Jennifer A. 500LB
Funderburg, Nicholas 618
Furcardo, Carolina 218
Fusco, Gregory 664
Fusco, Jennifer 664
Fwamba, Franck 522
Gabaitiri, Lesego 988
Gabillard, Delphine 78, 476
Gabler, Karyn 840, 929
Gachuis, Averie B. 1049LB, 637
Gadd, Isabelle 590
Gaddis, Nathan C. 237LB
Gadisa, Tsigereda 706
Gaines, Tommi O. 844
Gale, Michael 260LB
Galicier, Lionel 323, 603
Galindo, Maria J. 139
Gall, Astrid 272
Galli, Laura 460
Galli, Massimo 303, 410, 411
Galloway, Sebastien 448
Galvez Celada, Cristina 306
Gama, Cynthia 857
Gambacort, Therese 1045
Gandhi, Neel R. 77
Gandhi, Rajesh T. 277, 279, 280
Ganesan, Anuradha 590
Ganesh, Barbie K. 95
Gantner, Pierre 495
Ganz, Peter 126, 625
Gao, Zachary 885, 988
Garcia, Erin I. 172
Garcia-Deltoro, Miguel 538, 566, 570
Garcia-Lerma, Gerardo 84, 209, 954
Garcia-Morales, Claudia 182, 480
Gardner, William 427
Garfield, David 808
Garforth, Andrew 439
Garfinkle, Mark 995, 1000, 1004, 1005
Garske, Lindsay 967
Garza, Rolando 376
Gasim, Maria Rita 388
Gasquet, Simon 184, 484, 774
Gaspar, Gabriel 534
Gastonguay, Marc 384
Gatechompol, Sivaporn 698
Gatell, Jose Maria. 336, 614
Gates, Thomas 351, 398
Gatho, Esther 688
Gatto, Greg 420
Gaudinier, Silvana 229
Gaul, Janeta 839
Gaur, Aditya 424
Gaur, Ritu 507
Gavegnano, Christina 829
Gay, Cynthia L. 189, 406, 477
Gazzola, Lidia 680
Geary, Rebecca 1038
Gebo, Kelly 130, 662
Geboy, Alexander 517, 543, 545
Geffner, Mitchell 780
Gelatin, Otto 788
Gelt, Maria 631
Gelderblom, Huub C. 1022
Geldsetzer, Pascal 475, 916, 991, 994
Geleizescas, Romas 309, 338LB
Gelman, Benjamin B. 68, 375
Gelman, Rebecca 789
Genberg, Becky L. 908, 999
Gendelman, Howard E. 219, 439
Geng, Elvin 995, 1000, 1004, 1005
George, John M. 409, 409a
George, Kathleen 806
George, Varghese 234, 258
Gerard, Laurence 323, 603
Gheretti, Anna Maria 370, 549
German, Danielle 888, 904, 918
Gershenson, Mariana 691
Gerstenhaber, Rodd 998
Gervasoni, Cristina 396, 410, 411
Gessain, Antoine 190
Getz, Rachel 325
Ghanem, Abdelhamid 864
Ghanoum, Mahmood 213
Gherset, Valeria 379
Ghova, Margaret 786
Giacobbi, Nicholas Scott. 501
Giacomelli, Andrea 411
Giacomet, Vania 804
Gianella, Sara 166, 206, 211, 240, 241, 367, 390
Giardullo, Marco 39
Gibb, Diana 117, 808
Gilbert, Cynthia L. 606, 930
Gichuhi, Evans 856
Giddly, Janet 791
Gill, Thomas 1034
Gill-Martin, Angela 534
Gillald, Trupti Ishwar. 446
Gilbert, Mark 735
Gilbert, Peter 415
Giles, Michelle 670
Gilles, Robert 628
Gill, Alexander J. 68, 375, 376, 827, 828
Gill, John 662, 866
Gill, Surinder P. 62LB
Gillespie, Scott 839
Gilmore, Hailey 111
Gilmour, Jill 202
Gingelmaier, Andrea 754
Gingich, David 414
Ginsberg, Mindy S. 928
Girard, Pierre-Marie 44LB, 487, 703
Girardi, Enrico 466, 734
Giraud, Pierre-Marie 44LB, 487, 703
Gislev, Magnus 72, 73, 340, 364, 383, 389, 391, 431
Givisiez, Juliana Machado. 1040
Glancy, Margaret 668
Glashoff, Richard 795, 824
Glück, Sara Nelson 846, 873, 973
Gliddon, David 1005
Glover, Tynisha 269
Gnanashanmugam, Devasana 776
Gnatienko, Natalia 673
Gocke, Christopher 318
Godfrey, Catherine 699
Godin, Ophélie 75
Godsell, Richard 261
Golpe, Sira 738
Gorcke, Irene 740
G联络e, Breanna J. 951
Goetz, Matthew Bidwell. 127, 257, 606, 626, 658
Goggins, Kathryn 912
Goh, Shih Lin 18
Gogins, Samuel 845LB
Goldberg, David 185
Golden, Matthew R. 56, 89, 851, 973, 979, 1032
Goldhaber-Fiebert, Jeremy D. 725
Goldstein, Harris 269, 328
Goldstein, Michael 1048
Golovin, Sergey 569
Golub, Elizabeth T. 132, 237LB, 341, 514, 629, 632
Golub, Jonathan 657
Golub, Sarit A. 965
Gomez-Olive, Xavier 639, 916, 991
Gonzalez-Baeza, Alicia 400
González-García, Juan 533, 534, 572, 697
González-Mena, Alexa 681
González-Tomé, María Isabel 527
Gonzalez-Zuniga, Patricia 844
Gonzalo-Gil, Elena 236
Goodall, Ruth 815
Goodreau, Steven M. 1024, 1033, 1034
Gopal, Satish 602
Gorantla, Santhi 219, 588
Gordon, Catherine 685LB
Gordon, Kelley C. 951
Gordon, Lori A. 409
Gordon, Peter 546
Gordon, Shanlea 939
Gorelick, Rob 281, 287, 297
Gorgens, Marelize 1046
Gori, Andrea 222
Gorin, Aleksandr 268
Gorman, Daniel 337
Gosalbes, María José 802
Gosselin, Annie 204
Gott, Chloe 351
Gotuzzo, Eduardo 719
Gouaux, Ben 367
Gouard, Cécile 278
Gould, Philip J.R. 272, 799
Goulet, Julie 190
Goyal, Rajat 245
Greene, Sharon A. 22
Greene, Stephen A. 406
Greene, Warner C. 312
Grezes, Anna 18
Greupink, Rick 753
Greuel, Germano 585
Gruenberg, Carl 526
Guaraldi, Giovanni 532, 655
Guelati, Calixte 78
Guerrero-Fernández, Robert 681
Guha, Anika 401
Guilick, Roy M. 473, 981
Guimarães, Roberto 542LB
Gutbrod, Klemens 362
Guiard, Felix 647
Guatemala, John 346
Guaraldi, Joseph Maria 535
Guerrero, Ana 681
Gum, Diann 648
Gusso, Maria 542LB
Gustafson, Deborah 132, 350
Gutbrod, Ken 362
Guy, Rebecca J. 57
Guyer, William D. 627
Guzman, Monica 756
Guzzo, Christina 64LB

H–
Ha, Hien Thuc Ai. 747
Haaland, Richard 943
Haas, Andreas 782
Haas, Bernhard 453, 631
Haberkost Dutra de Barros, Clarissa 1040
Haberer, Jessica E. 675, 838, 920, 976
Haberl, Annette Elisabeth. 738
Habib, Jakob 1056LB
Hachiya, Atsuko 496
Hackett, John 583
Hadigan, Colleen 409, 409a, 525, 649
Haeri Mazanderani, Ahmad 794
Hafeez, Maria 517
Hafner, Richard 79
Hagberg, Lars 340, 383, 389, 391
Hager, Cindy 230
Hagins, Debbie 443

Greiner, Jared 616
Gres, Anna 18
Grimwood, Ashraf 763
Grinspoon, Steven K. 627, 635LB
Grinszteijn, Beatriz 149, 447, 714, 948, 1002
Grubbe, Diederick 113, 656
Grubler, Jay 345, 440
Gross, Robert 384, 868LB
Grube, Christina 521
Grudé, Maxime 278, 349
Gu, Diane 729
Guaraldi, Giovanni 532, 655
Guattari, Josep Maria. 535
Guile, Diann 648
Guimaraes, Roberto 542LB

Gregson, Simon 1031
Greeley, David 185
Gres, Anna 18
Gregg, Anne 22
Gregg, Michael 1048
Golovin, Sergey 569
Golub, Jonathan 657
Golub, Sarit A. 965
Gomez-Olive, Xavier 639, 916, 991
Gonzalez-Baeza, Alicia 400
González-García, Juan 533, 534, 572, 697
González-Mena, Alexa 681
González-Tomé, María Isabel 527
Gonzalez-Zuniga, Patricia 844
Gonzalo-Gil, Elena 236
Goodall, Ruth 815
Goodreau, Steven M. 1024, 1033, 1034
Gopal, Satish 602
Gorantla, Santhi 219, 588
Gordon, Catherine 685LB
Gordon, Kelley C. 951
Gordon, Lori A. 409
Gordon, Peter 546
Gordon, Shanlea 939
Gorelick, Rob 281, 287, 297
Gorgens, Marelize 1046
Gori, Andrea 222
Gorin, Aleksandr 268
Gorman, Daniel 337
Gosalbes, María José 802
Gosselin, Annie 204
Gott, Chloe 351
Gottardo, Raphael 265LB
Gottlieb, Geoffrey 440, 508, 642
Gottlieb, Eduardo 719
Gouaux, Ben 367
Gouard, Cécile 278
Gould, Philip J.R. 272, 799
Goulet, Julie 190
Goyal, Rajat 245
Grabowski, Kate 880, 996, 1015
Grabowski, Mary K. 34LB
Graham, Barney S. 59, 760
Graham, Christine 739
Graham, Susan M. 856, 893, 1022
Granados, Rafael 570
Grant, Igor 74, 390
Grant, Robert M. 955
Grattoni, Alessandro 422LB
Gravel, Catherine 782
Graves, Chanda 839
Gray, Glenda 857, 1036
Gray, Richard 1046
Gray, Ronald H. 1015, 34LB, 359, 87, 880, 996
Greathead, Louise 275
Grebe, Eduard 511, 876
Ghele, Christine 61
Green, Richard 260LB
Greenberg, Alan 872, 909
Greenblatt, Ruth 237LB, 632, 646, 933
Greene, Sharon A. 22
Greene, Stephen A. 406
Greene, Warner C. 312
Gregson, John 485
Gregson, Simon 1031

Hafeez, Maria 517
Hafner, Richard 79
Hagberg, Lars 340, 383, 389, 391
Hager, Cindy 230
Hagins, Debbie 443
Hahn, Beatrice H. 181LB
Hah, Judith 709
Hakim, Avi 11, 1002
Hale, Malik 335
Hall, Irene 30, 31, 478, 851, 899
Hall, Jake 511
Hallett, Timothy B. 115, 1036, 1038, 1039, 1040
Hallett, Travis R. 627
Halvas, Elias K. 120
Hamers, Raph L. 467, 488
Hamilton, Deven T. 984, 1033
Hammarlund, Gustaf Olof. 340
Hampel, Benjamin Hans. 521
Hamunime, Ndapewa 35
Hamzah, Lisa 650
Han, Xiaoyan 384
Han, Nathan 810
Hanash, Samir 661
Hancox, Dana B. 478
Hancox, Gemma 271
Handley, Scott 213
Hanes, Justin 210
Haneuze, Sebastien 463
Han, Doan Thi Hong. 83
Hanke, Tomas 119LB
Hanna, David B. 1016, 632, 636LB, 928
Hanna, Debra 878
Hanna, George 45LB
Hannah, Stacey 2
Hanson, Debra 876
Hane, Jonathan 202
Hargreaves, James R. 4
Harkoo, Ishana 88
Harling, Guy 639, 916, 983
Harrington, Bryna 686
Harris, Bob 685LB
Harris, Kathryn 801
Harrison, Linda C. 972
Harrison, Thomas S. 82
Hart, Clyde 943
Hart, Rachel 663, 864
Hartman, Christine 539
Hartogensis, Wendy 170, 288
Hasan, Amin S. 202
Hasan, Jaythoon 513
Hasson, Hamid 531
Hassounah, Said 498
Hasty, Alyssa 230
Hatao, Hiroyu 407
Hayashi, Hironori 503
Hatzianastou, Theodora 220
Hatziioannou, Theodora 220
Hayashi, Kanna 590
Hayes, Richard 1010, 1011, 1048, 834, 841LB, 959
Hayford, Christina Sage. 942
Haynes, Barton F. 1057LB
Hayot, Maurice 654
Hayward, Katry 428
Hazen, Stanley 625
Hazra, Rohan 649, 757, 806
Hazar, Maria 334
Hassounah, Said 498
Hastings, Timothy 1057
Hatao, Hiroyu 407
Hattori, Shinichiro 503
Hawkins, David 418
Haworth, Kevin G. 322
Hayashi, Hironori 503
Hayashi, Kanna 590
Hayes, Richard 1010, 1011, 1048, 834, 841LB, 959
Hayford, Christina Sage. 942
Haynes, Barton F. 1057LB
Hayot, Maurice 654
Hayward, Katry 428
Hazen, Stanley 625
Hazra, Rohan 649, 757, 806
Hazar, Maria 334
Hajegh, Patrick J. 921
Healy, Michael 817LB
Heaps, An 611
Heaton, Robert K. 74, 201, 353, 377, 390, 392, 393
Hecht, Frederick M. 170
Heckman, Barbara 803
Hector, Jonas 581
Heera, Jayvant 471
Heffron, Renee 85, 920, 934, 947, 1003
Heide - Mulder, Marieke van der. 587
Hella, Jerry 721
Hecker, Theo 525
Helmuth, Joanna 339, 344, 394
Hempill, Linda C. 640
Hendrickson, Cheryl Jane. 1021
Hendrix, Craig 86LB, 976
Hendrix, Jelle 155
Henegar, Cassidy 664
Heneine, Walid 84, 478, 954
Hennequin, William 116
Henry, Amy R. 61
Henry, Keith 474, 597
Hensley-McBain, Tiffany 216, 231
Hersiszmutsch, Anna 275
Herdmann, Bruce 911
Heresi, Gloria P. 425
Herryhy, Therese 613
Hermans, Lucas 723LB
Hermans, Lucas Etienne. 113
Hermans, Sabine 727
Hermansson, Linn 383
Hernandez, Adriane 755
Hernandez, Angela L. 187, 478
Hernandez-Diaz, Sonia 779
Hernandez-Nova, Beatriz 595
Hernandez-Ramirez, Raul Ulises 600
Herrmann, Eva 738
Hessling, Joseph 309, 313, 338LB
Hesseling, Anneke 728
Hessol, Nancy A. 910
Heydeman, Rob 641
Hicks, Katherine A. 1029
Hienes, Bonnie 293, 305
Hicco, Loreto 527
Higgs, Chris 416
Hijhberger, Helene 368
Hijikena, Simone Helene. 604
Haubrich, Richard 568LB
Haukoos, Jason 956
Hau, Samuel 708
Haussinger, Dieter 161
Havenar-Daughton, Colin 264
Havens, Joshua 408, 963
Havens, Peter Lucas. 685LB
Havir, Diane V. 33, 36, 312, 638, 726, 768, 797, 832, 836, 856, 860, 1005, 1051
Havlir, Diane 161
Havranek, Edward 528
Hayes, Stephen E. 642
Hawk, Mark 1023
Hawkins, David 418
Haworth, Kevin G. 322
Hayashi, Hironori 503
Hayashi, Kanna 590
Hayes, Richard 1010, 1011, 1048, 834, 841LB, 959
Hayford, Christina Sage. 942
Haynes, Barton F. 1057LB
Hayot, Maurice 654
Hayward, Katry 428
Hazen, Stanley 625
Hazra, Rohan 649, 757, 806
Hazarda, Daria 311, 435
Heagerty, Patrick J. 921
Healy, Michael 817LB
Hears, An 611
Heaton, Robert K. 74, 201, 353, 377, 390, 392, 393
Hecht, Frederick M. 170
Heckman, Barbara 803
Hector, Jonas 581
Heera, Jayvant 471
Heffron, Renee 85, 920, 934, 947, 1003
Heide - Mulder, Marieke van der. 587
Hella, Jerry 721
Heller, Theo 525
Helmuth, Joanna 339, 344, 394
Hemphill, Linda C. 640
Hendrickson, Cheryl Jane. 1021
Hendrix, Craig 86LB, 976
Hendrix, Jelle 155
Henegar, Cassidy 664
Heneine, Walid 84, 478, 954
Hennequin, William 116
Henry, Amy R. 61
Henry, Keith 474, 597
Hensley-McBain, Tiffany 216, 231
Hersiszmutsch, Anna 275
Herdmann, Bruce 911
Heresi, Gloria P. 425
Herryhy, Therese 613
Hermans, Lucas 723LB
Hermans, Lucas Etienne. 113
Hermans, Sabine 727
Hermansson, Linn 383
Hernandez, Adriane 755
Hernandez, Angela L. 187, 478
Hernandez-Diaz, Sonia 779
Hernandez-Nova, Beatriz 595
Hernandez-Ramirez, Raul Ulises 600
Herrmann, Eva 738
Hessling, Joseph 309, 313, 338LB
Hesseling, Anneke 728
Hessol, Nancy A. 910
Heydeman, Rob 641
Hicks, Katherine A. 1029
Hienes, Bonnie 293, 305
Hicco, Loreto 527
Higgs, Chris 416
Hijhberger, Helene 368
Hijikena, Simone Helene. 604
Author Index

Program and Agenda

CROI 2017

Hikichi, Yuta 247
Hilderbrand, Katherine 990
Hileman, Corrilynn O. 617, 628
Hill, Alison 178, 338LB
Hill, Andrew 569
Hill, Julia 927
Hill, Shawn 297
Hilley, Amy 965
Hillier, Sharon L. 86LB, 945
Hiransuthikul, Akarin 863
Hirasen, Kamban 459
Hirozawa, Anne 974
Hirsch-Moverman, Yael 706
Hirt, Déborah 811
Hleyhel, Mira 775
Hlupeni, Admire 345, 743
Ho, Anh Thi Van. 741
Ho, Emily 347
Ho, Ya-Chi 122, 295, 296
Hogewoning, Arjan 519, 887
Hogg, Robert S. 599, 601, 929, 966, 1042
Hollabaugh, Kimberly M. 404
Hollins, Charles B. 326
Holtz, Timothy H. 854
Holtzemer, Angelique 176
Holzendorf, Volker 633
Holzmayer, Vera 510, 522
Homan, Francesc 651
Hong, Ting 934, 947
Hontanon, Victor 400
Hoo, Julia 846, 973
Hoofnagle, Andrew 645
Hook, Edward 867
Hoornenborg, Elske 519, 887, 953
Hoos, David 114LB
Hoos, David 1023
Hoots, Brooke 871
Hoover, Donald R. 361, 928
Hoover, Karen W. 980, 1034
Hope, Michael J. 1057LB
Hope, Thomas 15, 231
Hopkins, Emily 956
Hopkins, Emily 324
Hopkins, Mark 549
Horacek, Joshua 196
Horberg, Micheal A. 130, 619, 840
Horner, Marie-Josephe 602
Horng, Howard 277, 978
Horsburgh, Bethany A. 293
Horsburgh, C. Robert 709
Hosseinipour, Mina C. 686, 710, 717, 720, 783, 946
Houghton-Price, Vicky 569
Howard, Andrea 706
Howell, Bonnie J. 326
Howell, Pauline 80LB
Hower, Martin 633
Hoy, Jennifer 670, 687
Hoyle, Ashley Christopher. 157
Hsia, Yang 21
Hsiao, Nei-Yuan M. 767, 769, 771, 989, 992
Hsieh, Szu-Min 582
Hsu, Denise C. 70, 733
Hsyu, Hsiao-O 927
Hsu, Jeffrey 669
Hsu, Joanne 1013
Hsu, Katherine K. 833
Hsu, Ling 906, 910
Hsu, Ricky 664
Hsue, Priscilla 126, 414, 625
Hsueh, Yu-Mei 594
Hu, Jianfei 60, 61
Hu, Ming 422LB
Hu, Shiu-Lok 321, 322
Hu, Wei-Shih 17, 164, 173, 334
Hu, Xiaohong 851
Hu, Y Eric 329
Hu, Yinghuan 399
Hua, Simin 636LB
Huang, Eugene 353
Huang, Minghu 456, 476
Huang, Mingxiong 403
Huang, Robin 670
Huang, Szuhan 122
Huang, Wei 84, 140, 563
Huang, Ya-Lin A. 980
Huang, Yunda 415
Hubbard, Johnathan 905
Hubbard, Mark 2
Hudelson, Sarah E. 492, 955
Hue, Sophie 630
Hue, Stephane 186, 195, 520
Hufnner, Anja 703
Huppler, Dietrich 567
Hughes, Alison 922
Hughes, Jennifer 718
Hughes, Michael D. 404, 457, 710, 728, 790
Hughes, Stephen H. 298
Huh, David 921
Hui, Krist 461
Huleux, Thomas 135, 550, 732
Hulgan, Todd 229, 377, 392, 393, 691
Hull, Mark 599, 601, 929, 966
Hullsiek, Katherine 744
Hultquist, Judd F. 6
Humbert, Ludovic 681
Humphrey, Jean 786
Hundley, Lee 914
Hung, Chien-Ching 44LB, 582
Hung, Magdelena 329
Hunter, Peter W. 407, 625, 675
Hunter, Eric 200
Huo, Yanling 779, 810
Huppert, Hugh 348, 746
Hur, Sophia 126
Hurst, Jacob 301
Hurst, Stacey 946
Husnik, Marla J. 951
Hussein, Mustafa 842
Hussen, Sophia A. 839
Hutchinson, Angela B. 1029
Hüttner, Gero 320
Hwang, Carey 45LB
Hwang, Young 171LB
Hyle, Emily P. 493, 1043

Hussein, Sophia A. 839
Hutchinson, Angela B. 1029
Hüttner, Gero 320
Hwang, Carey 45LB
Hwang, Young 171LB
Hyle, Emily P. 493, 1043

Iannotti, Nathalie 680
Iannuzzi, Francesca 357
Ibarra, Sofia 538
Ibrahim, Fauz 893
Ibrahim, Manyanne Rose. 774, 789, 790
Ichikawa, David 64LB
Ido, Yoko 496
Ignacio, Caroline 300
Igoe, Derval 513
Ikediobi, Uchenna 236
Imami, Nesrina 275
Imamichi, Hiromi 159, 371
Imamura, Junji 496
Imaz, Arkaitz 557
Ingiliz, Patrick 551, 567, 576, 703
Innes, Steve 823, 824
Intasan, Jintana 270
Invernizzi, Alessandro 396
Inwolny, André 78
Inzaule, Seth 488
Iodice, Valentina 537
Iribarren, Jose A. 647
Iriri, Alivelu 118
Irungu, Elizabeth 920
Iqbal, Abbis 415
Iqbal, Shahide 28
Iscache, Anne Laure 223
Ishai, Amorina Eliana. 126
Ismail, Nazir 77
Ita, Sergio 178
Itindi, Janet 970
Iudicello, Jennifer 353
Ivaniukas, Emma 157
Ivy, Wade 852
Iwamoto, Marian 412, 430
Iwatani, Yasumasa 496
Jabbari, Shahab 599
Jackson, Akil 39
Jackson, Celia 185
Jackson, Debra 763
Jackson, Elise 274
Jagodzinski, Linda 363
Jain, Priya 422LB
Jain, Sonia 870, 977
Jain, Vivek 1051
Jaiswal, Tara 308
Jalbert, Emilie 227
Jamaloodien, Khadija 1020
James, Catherine 974
Jamin, Auguste V. 157
Jamison, Dean 1053
Janetopoulos, Christopher J. 308
Jang, Karen S. 506
Jani, Conred 834
Jani, Ilesh 26, 110
Janjua, Naveed Zafar. 524, 735
Janse van Rensburg, Anika 28
Jansson, Marianne 37
Jantarabenchakul, Watsamon 759, 807
Janulis, Patrick 843
Jao, Jennifer 780
Jaoko, Walter 937
Japar, Antoine 607
Jara, Paloma 527
Jarrin, Imma 534
Jarvis, Joseph N. 82, 740, 745, 988, 993, 1008, 1017
Jaworowski, Anthony 611
Jayathilake, Karu 719
Jean Juste, Marc Antoine 471
Jefferys, Greg 569
Jefferys, Laura 581
Jeffrey, Jerry 171LB
Jen, I-An 348
Jenkins, Cathy 719, 816
Jennex, Samuel 1024, 1033, 1034
Jerome, Keith 321
Jia, Hongwei 509
Jia, Peilin 74
Jiamsakul, Awachana 705
Jiang, Li 246
Jiang, Shuping 443
Jibrib, Haruna 787
Jiménez, Miguel 566
Jiménez-Hernández, Nuria 802
Jiménez-Sousa, María Ángeles. 530
Jin, Chengshi 978
Jin, Haolun 497
Jinarat, Varunee 793
Jogeda, Ene-Ly 461
John, Mathius 686
John-Stewart, Grace 22, 761, 765, 796, 970
Johns, Brian A. 252
Johnson, Anna Satcher. 30, 851, 899
Johnson, Cheryl 895, 896, 1030, 1031
Johnson, Eric Otto. 237LB
Johnson, Erica L. 829
Johnson, Jeffrey A. 189, 370, 477, 478
Johnson, Leah 420
Johnson, R. Paul 62LB
Johnson, Rachel 1013
Johnson, Welkin E. 178
Joloba, Moses L. 712
Joly, Veronique 458, 732
Jonas, Anna 35
Jonas, Bradley Robert. 196, 561
Jones, Deborah 770
Jones, Jennifer 328
Jones, Mathew Lee. 301
Jones, Nicolette 923
Jones, R. Brad 122, 296
Jones, Rachel 650
Jones, Rona R. 905
Jones, Sara 227, 297, 649

Jalbert, Emilie 227
Jalbert, Emilie 227
Jones, Simon 398
Jooste, Pieter 799
Jordan, Michael 112
Jordan, Parris S. 200
Jordan, Wilbert 589
Jordan-Sciutto, Kelly L. 74, 378
Jose, Sophie 650
Joseph, Sarah Beth 73, 364
Josh, Keder 705
Jospeh, Bernadette 835
Jost, Nancy 593
Jourdain, Gonzague 584LB
Joy, Jeffrey 196, 561, 848
Joya, Christie 932
Judd, Ali 831
Juge, Lauriane 398
Jumbe, Allan 686
June, Carl H. 13
Justice, Amy 127, 257, 630, 658, 662, 667, 702, 930
Justman, Jessica E. 1023, 114LB, 421LB, 950
Kabami, Jane 860
Kabongo, Cila 958
Kabran, Mathieu 78
Kabudula, Chodziwadziwa 991
Kabwigu, Samuel 88
Kadelka, Claus 66, 67, 191
Kadima, Etienne 885
Kah, Lesley 44LB
Kahn, James 33
Kahn, Kathleen 916, 991
Kaid, Angela 599, 924, 925, 926, 940
Kaimal, Arvind 191
Kapit, Emanuel 1001
Kapitany, Patience 783
Kaplan, Jonathan 741
Kaplan, Justin 507
Kaplan, Robert C. 629, 632, 636LB
Kapogiannis, Bill 685LB
Kapogiannis, Bill 685LB
Kappes, John C. 328
Kapte, Daze 577
Karanjade, Esmeralda 730, 766
Karlilius, Brad 805
Karrat, Sarah 122
Karn, Jonathan 281
Karis, Maile 824
Kasai, Abraham 761, 970
Kates, Jennifer 1012
Katz, Mary Grace K. 28, 120, 795
Kat, David A. 89, 846, 896, 901
Katz, David A. 89, 846, 896, 901
Kaufmann, Stefan 716LB
Kaul, Rupert 87
Kaur, Jasmine 118
Kavanagh, Eoin 679
Kay, Steve 324
Kayombo, Asungu 950
Kaunda, Kukuhumuya 950
Kazempour, Kazem 437
Keango, Robert 1006
Kearney, Brian P. 40, 427
Kearney, Mary F. 47, 120, 294, 298
Keats, Ann 1033
Keating, Sheila 170, 279, 284, 511, 876
Keele, Brandon 294, 322, 368
Keifer, John 64LB
Keiser, Olivia 596, 782
Kellam, Paul 272
Kelleher, Peter 248, 275
Kelley, Colleen F. 90
Kelly, Christine 641
Kelly, Karina 504LB
Kennedy, Arion 230
Kennedy, V. Logan 940
Kennedy, Patrick 96
Kenny, Julia 801
Keran, Roxanne 851
Kerr, Stephen J. 444, 698
Kervan, Jerome 262
Kappogiannis, Bill 685LB
Kappes, John C. 328
Kapte, Daze 577
Karanjade, Esmeralda 730, 766
Karlilius, Brad 805
Karrat, Sarah 122
Karn, Jonathan 281
Karis, Maile 824
Kasai, Abraham 761, 970
Kates, Jennifer 1012
Katz, Mary Grace K. 28, 120, 795
Kat, David A. 89, 846, 896, 901
Katz, David A. 89, 846, 896, 901
Kaufmann, Stefan 716LB
Kaul, Rupert 87
Kaur, Jasmine 118
Kavanagh, Eoin 679
Kay, Steve 324
Kayombo, Asungu 950
Kaunda, Kukuhumuya 950
Kazempour, Kazem 437
Keango, Robert 1006
Kearney, Brian P. 40, 427
Kearney, Mary F. 47, 120, 294, 298
Keats, Ann 1033
Keating, Sheila 170, 279, 284, 511, 876
Keele, Brandon 294, 322, 368
Keifer, John 64LB
Keiser, Olivia 596, 782
Kellam, Paul 272
Kelleher, Peter 248, 275
Kelley, Colleen F. 90
Kelly, Christine 641
Kelly, Karina 504LB
Kennedy, Arion 230
Kennedy, V. Logan 940
Kennedy, Patrick 96
Kenny, Julia 801
Keran, Roxanne 851
Kerr, Stephen J. 444, 698
Kervan, Jerome 262
Kappogiannis, Bill 685LB
Kappes, John C. 328
Kapte, Daze 577
Karanjade, Esmeralda 730, 766
Karlilius, Brad 805
Karrat, Sarah 122
Karn, Jonathan 281
Karis, Maile 824
Kasai, Abraham 761, 970
Kates, Jennifer 1012
Katz, Mary Grace K. 28, 120, 795
Kat, David A. 89, 846, 896, 901
Katz, David A. 89, 846, 896, 901
Kaufmann, Stefan 716LB
Kaul, Rupert 87
Kaur, Jasmine 118
Kavanagh, Eoin 679
Kay, Steve 324
Kayombo, Asungu 950
Kaunda, Kukuhumuya 950
Kazempour, Kazem 437
Keango, Robert 1006
Kearney, Brian P. 40, 427
Kearney, Mary F. 47, 120, 294, 298
Keats, Ann 1033
Keating, Sheila 170, 279, 284, 511, 876
Keele, Brandon 294, 322, 368
Keifer, John 64LB
Keiser, Olivia 596, 782
Kellam, Paul 272
Kelleher, Peter 248, 275
Kelley, Colleen F. 90
Kelly, Christine 641
Kelly, Karina 504LB
Kennedy, Arion 230
Kennedy, V. Logan 940
Kennedy, Patrick 96
Kenny, Julia 801
Keran, Roxanne 851
Kerr, Stephen J. 444, 698
Kerven, Jerome 262
Kappogiannis, Bill 685LB
Kappes, John C. 328
Kapte, Daze 577
Karanjade, Esmeralda 730, 766
Karlilius, Brad 805
Karrat, Sarah 122
Karn, Jonathan 281
Karis, Maile 824
Kasai, Abraham 761, 970
Kates, Jennifer 1012
Katz, Mary Grace K. 28, 120, 795
Kat, David A. 89, 846, 896, 901
Katz, David A. 89, 846, 896, 901
Kaufmann, Stefan 716LB
Kaul, Rupert 87
Kaur, Jasmine 118
Kavanagh, Eoin 679
Kay, Steve 324
Kayombo, Asungu 950
Kaunda, Kukuhumuya 950
Kazempour, Kazem 437
Keango, Robert 1006
Kearney, Brian P. 40, 427
Kearney, Mary F. 47, 120, 294, 298
Keats, Ann 1033
Keating, Sheila 170, 279, 284, 511, 876
Keele, Brandon 294, 322, 368
Keifer, John 64LB
Keiser, Olivia 596, 782
Kellam, Paul 272
Kelleher, Peter 248, 275
Kelley, Colleen F. 90
Kelly, Christine 641
Kelly, Karina 504LB
Kennedy, Arion 230
Kennedy, V. Logan 940
Kennedy, Patrick 96
Kenny, Julia 801
Keran, Roxanne 851
Kerr, Stephen J. 444, 698
Kervan, Jerome 262
Kroon, Eugene 124, 125, 270, 282, 291, 339, 387
Krupitsky, Evgeny 673, 868LB
Kruksza, Bridget 853
Ku, Wen-Wei 705
Kuball, Jürgen 320
Kufa-Chakeza, Tendesayi 794
Kuh, Louise 27, 814, 819
Kujawski, Stephanie 110
Kukolj, George 118
Kulkarni, Rima 443
Kulkarni, Sonali P. 1014
Kumar, Muniratnam S. 559, 883
Kumar, Parag 409, 409a
Kumar, Princy 449LB, 905
Kumar, Sudeep 512
Kumarasamy, Nagalingeswaran 456, 1002
Kummer, Kim 873
Kumwenda, Johnstone 710, 717, 720
Kumwenda, Moses 895, 896
Kuniholm, Mark H. 928
Kunze, Ursula 362
Kuo, Irene 853, 872
Kuo, Kuei-Ling 438
Kuo, Lillian 180
Kuritzkes, Daniel R. 325, 790
Kurland, Irwin J. 780
Kuruc, Joann D. 298
Kuruppu, Nishani 507
Kusanthan, Thankian 919
Kutluay, Sebla B. 16
Kvaratskhelia, Nina 525
Kvist, Anders 37
Kwariisima, Dalsone 638, 726, 858
Kvaratskhelia, Nina 94, 157, 16, 160LB
Labbato, Danielle 838
Laboune, Farida 60, 61
Lacabaratz, Christine 812
Lachowsky, Nathan J. 966
Lacombe-Duncan, Ashley A. 923, 924, 926
Lada, Steven 240, 241, 300
Laethem, Tine 412
Laevendecker, Oliver 244, 472, 515, 516, 518, 558, 879, 880, 881, 888, 904
Laferriere, Valerie-Martel 553
Laia, Bernabei 487
Lagarde, Marie 676
Lage, Silvia 733
Laguno, Montse 535
Lahiri, Cecile Delille. 684
Lahuerta, Maria 110
Lai, Alexia 303
Lai, Ming-Tain 435
Lai, Rachel 739
Lai, YingAn 438
Lain, Maria 766
Laird, Gregory 317

Lake, Jordan E. 251, 356, 589, 696, 700
Laker, Leana 799
Lalama, Christana 279, 280, 325
Lalezari, Jay 116, 126, 437
Lallemand, Marc 299LB
Lalley-Chareczko, Linden 975
Lalor, Maeve K. 736
Lam, Evan 178
Lama, Javier R. 380, 446
Lamarre, Valerie 785
Lamb, Matthew R. 1049LB, 110
Lambert, Caroline 190
Lambert, John 613, 754
Lam, Evan 178
Lambert, Sidonie 278, 487
Lamers, Susanna 518
Lamirel, Cédric 75
Lammert, Sara 838
Lamorde, Mohammed 423, 1001
Lampiris, Harry 312
Lang, Karl Sebastian. 161
Lang, Philipp A. 161
Lang, Raynell 866
Langat, Agnes 761, 796, 970
Langat, Deborah 720
Langat, Rither 355
Lange, Camille 287, 368
Langer, Robert 1035
Langham, Freya 687
Langkilde, Anne 235
Lansdon, Eric 434
Lapointe, Normand 785
Larmandarange, Joseph 1018
Larsen, Anna 1007, 1019
Lathouwers, Erkki 505
Latini, Alessandra 445
Lattin, Carl A. 5, 842, 904
Lau, Bryan 908
Laube, Catherine 987
Laufs, Stephanie 302
Laughton, Barbara 28, 120, 823, 824, 826
Lauw, Fanny 137LB
Law, Matthew 473, 653, 670, 693
Lawler, Leo 613
Lawlor, Sidney 944
Lawson, Dana Quinn. 16
Lazar, Jason 636LB
Lazerwith, Scott E. 497
Lazzarin, Adriano 460, 531, 683
Le, Leah T. 72
Le, Phong Thanh. 882
Le, Thuy 83, 747, 748
Le Campion, Armelle 785
Le Chenadec, Jérôme 775
Le Hingrat, Quentin 194
Le Moing, Vincent 654
Le Roux, Stanzi M. 24
Leaf, David 667
Leal, Lorna 336
Learn, Gerald H. 181LB
Lebelonyane, Refletswe 1008, 1017
LeBlanc, Roger P. 442
Lechille, Kwiana 740
<table>
<thead>
<tr>
<th>Author</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ledergerber, Bruno</td>
<td>631</td>
</tr>
<tr>
<td>Lederman, Michael M.</td>
<td>225, 251, 276</td>
</tr>
<tr>
<td>Ledgerwood, Julie</td>
<td>330LB, 415</td>
</tr>
<tr>
<td>Lee, Eric</td>
<td>231</td>
</tr>
<tr>
<td>Lee, Eunok</td>
<td>293</td>
</tr>
<tr>
<td>Lee, Guinevere Q.</td>
<td>292, 495</td>
</tr>
<tr>
<td>Lee, Ha Yoon</td>
<td>514</td>
</tr>
<tr>
<td>Lee, Hana</td>
<td>908</td>
</tr>
<tr>
<td>Lee, Janice</td>
<td>29LB</td>
</tr>
<tr>
<td>Lee, Jeanette</td>
<td>591</td>
</tr>
<tr>
<td>Lee, Kelly K.</td>
<td>242</td>
</tr>
<tr>
<td>Lee, KyeongEun</td>
<td>18</td>
</tr>
<tr>
<td>Lee, Myung Hee</td>
<td>251, 276</td>
</tr>
<tr>
<td>Lee, Sarah</td>
<td>408</td>
</tr>
<tr>
<td>Lee, Sulggi</td>
<td>407</td>
</tr>
<tr>
<td>Lee, Susan Shin-Jung</td>
<td>438</td>
</tr>
<tr>
<td>Lee, William</td>
<td>338LB</td>
</tr>
<tr>
<td>Leeme, Tshoep Botho.</td>
<td>82, 740, 745</td>
</tr>
<tr>
<td>Lefebvre, Eric</td>
<td>381</td>
</tr>
<tr>
<td>Lefever, Steve</td>
<td>162</td>
</tr>
<tr>
<td>Leff, Jared A.</td>
<td>547</td>
</tr>
<tr>
<td>Leider, Dara</td>
<td>796</td>
</tr>
<tr>
<td>Lelievre, Jean Daniel</td>
<td>441, 630</td>
</tr>
<tr>
<td>Leib, Jack</td>
<td>192</td>
</tr>
<tr>
<td>Leifer, Gisela</td>
<td>631</td>
</tr>
<tr>
<td>Leigh Brown, Andrew</td>
<td>185, 186, 193, 1026</td>
</tr>
<tr>
<td>Leipsic, Jonathon</td>
<td>655</td>
</tr>
<tr>
<td>Lettman, Ellen M.</td>
<td>272</td>
</tr>
<tr>
<td>Leg, Eric</td>
<td>360</td>
</tr>
<tr>
<td>Lemmens, Veerle</td>
<td>155</td>
</tr>
<tr>
<td>Lemmer, Darrin</td>
<td>715LB</td>
</tr>
<tr>
<td>Lemoine, Maud</td>
<td>703</td>
</tr>
<tr>
<td>Lemmos, Maria</td>
<td>897</td>
</tr>
<tr>
<td>Lemsalu, Lits</td>
<td>1028</td>
</tr>
<tr>
<td>Leng, Sean K.</td>
<td>133</td>
</tr>
<tr>
<td>Lennox, Jeffrey J.</td>
<td>684</td>
</tr>
<tr>
<td>Leon, Casey</td>
<td>557</td>
</tr>
<tr>
<td>Lez, Marie</td>
<td>192</td>
</tr>
<tr>
<td>Leport, Catherine</td>
<td>278</td>
</tr>
<tr>
<td>Lerma-Chipirraz, Elisabet</td>
<td>681</td>
</tr>
<tr>
<td>LeRoith, Derek</td>
<td>780</td>
</tr>
<tr>
<td>Leroy, Valeriane</td>
<td>811, 814</td>
</tr>
<tr>
<td>Lesigue, François-Xavier</td>
<td>75</td>
</tr>
<tr>
<td>Lesosky, Maia</td>
<td>767, 989</td>
</tr>
<tr>
<td>Lester, Richard T.</td>
<td>106, 964</td>
</tr>
<tr>
<td>Leta, Valentina</td>
<td>396</td>
</tr>
<tr>
<td>Letang, Emilio</td>
<td>744</td>
</tr>
<tr>
<td>Letendre, Scott</td>
<td>74, 353, 358, 378, 386, 390, 392, 393</td>
</tr>
<tr>
<td>Leung, Janice</td>
<td>655</td>
</tr>
<tr>
<td>Lerner, Kandasi</td>
<td>923</td>
</tr>
<tr>
<td>Levin, Myron</td>
<td>803</td>
</tr>
<tr>
<td>Levine, Andrew</td>
<td>356</td>
</tr>
<tr>
<td>Levine, Molly</td>
<td>490</td>
</tr>
<tr>
<td>Levy, David N.</td>
<td>63</td>
</tr>
<tr>
<td>Levy, Itzchak</td>
<td>226</td>
</tr>
<tr>
<td>Levy, Yves</td>
<td>262, 441, 630</td>
</tr>
<tr>
<td>Lewin, Sharon R.</td>
<td>125, 281, 288, 311</td>
</tr>
<tr>
<td>Lewis, John</td>
<td>874</td>
</tr>
<tr>
<td>Lewis, Mark G.</td>
<td>1057LB, 199</td>
</tr>
<tr>
<td>Lewis, Stanley</td>
<td>438, 449LB</td>
</tr>
<tr>
<td>Leyden, Wendy</td>
<td>598</td>
</tr>
<tr>
<td>Leyes, Maria</td>
<td>659</td>
</tr>
<tr>
<td>Leyre, Louise</td>
<td>124, 285, 291</td>
</tr>
<tr>
<td>Leyten, Eliane</td>
<td>137LB</td>
</tr>
<tr>
<td>Lhomme, Edouard</td>
<td>801</td>
</tr>
<tr>
<td>Li, Danny</td>
<td>126</td>
</tr>
<tr>
<td>Li, Guhan</td>
<td>371</td>
</tr>
<tr>
<td>Li, Jean</td>
<td>378</td>
</tr>
<tr>
<td>Li, Jin-fen</td>
<td>189, 370, 477</td>
</tr>
<tr>
<td>Li, Jonathan</td>
<td>325</td>
</tr>
<tr>
<td>Li, Lingfeng</td>
<td>1049LB</td>
</tr>
<tr>
<td>Li, Maoji</td>
<td>955</td>
</tr>
<tr>
<td>Li, Peilin</td>
<td>312</td>
</tr>
<tr>
<td>Li, Qingshen</td>
<td>199, 326</td>
</tr>
<tr>
<td>Li, Sam</td>
<td>207, 208</td>
</tr>
<tr>
<td>Li, Shuying Sue.</td>
<td>421LB</td>
</tr>
<tr>
<td>Li, Taisheng</td>
<td>399</td>
</tr>
<tr>
<td>Li, Wei-ze.</td>
<td>588</td>
</tr>
<tr>
<td>Li, Yanling</td>
<td>399</td>
</tr>
<tr>
<td>Li, Yuan</td>
<td>337</td>
</tr>
<tr>
<td>Li, Zhaoping</td>
<td>589</td>
</tr>
<tr>
<td>Liang, Ben</td>
<td>179</td>
</tr>
<tr>
<td>Liang, Richard</td>
<td>848</td>
</tr>
<tr>
<td>Liao, Diana</td>
<td>589</td>
</tr>
<tr>
<td>Liao, Mei-June.</td>
<td>450LB</td>
</tr>
<tr>
<td>Liberatore, Rachel A.</td>
<td>220</td>
</tr>
<tr>
<td>Libert, Claude</td>
<td>672</td>
</tr>
<tr>
<td>Liberty, Aaalf</td>
<td>29LB</td>
</tr>
<tr>
<td>Libutti, Daniel</td>
<td>691</td>
</tr>
<tr>
<td>Lichterfeld, Mathias</td>
<td>292, 319, 790</td>
</tr>
<tr>
<td>Liebenberg, Lenine</td>
<td>949</td>
</tr>
<tr>
<td>Liechti, Thomas</td>
<td>66, 67</td>
</tr>
<tr>
<td>Liegler, Teri</td>
<td>170, 407, 832</td>
</tr>
<tr>
<td>Lenhardt, Christian</td>
<td>723LB</td>
</tr>
<tr>
<td>Lifson, Jeffrey D.</td>
<td>10, 281</td>
</tr>
<tr>
<td>Ligabue, Guido</td>
<td>655</td>
</tr>
<tr>
<td>Lija, Gissenge Jackson</td>
<td>950</td>
</tr>
<tr>
<td>Lim, Joseph</td>
<td>127, 702</td>
</tr>
<tr>
<td>Lim, So-Yon</td>
<td>179, 338LB</td>
</tr>
<tr>
<td>Lima, Viviane Dias.</td>
<td>875, 929, 1042</td>
</tr>
<tr>
<td>Lin, Amy</td>
<td>364</td>
</tr>
<tr>
<td>Lin, Angel</td>
<td>308</td>
</tr>
<tr>
<td>Lin, Haqiu</td>
<td>598</td>
</tr>
<tr>
<td>Lin, Hsi-Hsun</td>
<td>438</td>
</tr>
<tr>
<td>Lin, Kuan-Yin</td>
<td>582</td>
</tr>
<tr>
<td>Lin, Li</td>
<td>615</td>
</tr>
<tr>
<td>Linas, Benjamin</td>
<td>547, 557, 709</td>
</tr>
<tr>
<td>Lince-Derococo, Naomi</td>
<td>941</td>
</tr>
<tr>
<td>Lindman, Jacob</td>
<td>37</td>
</tr>
<tr>
<td>Lindsay, Joanne</td>
<td>601</td>
</tr>
<tr>
<td>Lindsey, Jane</td>
<td>803</td>
</tr>
<tr>
<td>Ling, John</td>
<td>40</td>
</tr>
<tr>
<td>Link, John O.</td>
<td>38, 433</td>
</tr>
<tr>
<td>Linley, Laurie</td>
<td>889, 890</td>
</tr>
<tr>
<td>Lioznow, D.</td>
<td>868LB</td>
</tr>
<tr>
<td>Lipira, Lauren</td>
<td>921</td>
</tr>
<tr>
<td>Lippman, Sheri A.</td>
<td>111</td>
</tr>
<tr>
<td>Lisante, Antonella</td>
<td>232</td>
</tr>
<tr>
<td>Lisco, Andrea</td>
<td>221, 226</td>
</tr>
<tr>
<td>Lisinichia, Joshua G.</td>
<td>68</td>
</tr>
<tr>
<td>Lisovsky, Irene</td>
<td>274</td>
</tr>
<tr>
<td>Little, Francesca</td>
<td>990</td>
</tr>
<tr>
<td>Little, Susan J.</td>
<td>134, 206</td>
</tr>
<tr>
<td>Litwin, Alain H.</td>
<td>544</td>
</tr>
<tr>
<td>Liu, Albert Y.</td>
<td>419, 978</td>
</tr>
<tr>
<td>Liu, Chenglong</td>
<td>514, 634</td>
</tr>
<tr>
<td>Liu, Cindy M.</td>
<td>87</td>
</tr>
<tr>
<td>Liu, Hongjie</td>
<td>918, 997</td>
</tr>
<tr>
<td>Liu, Jingxia</td>
<td>972</td>
</tr>
<tr>
<td>Liu, Jun</td>
<td>233</td>
</tr>
<tr>
<td>Liu, Qingbo</td>
<td>14LB</td>
</tr>
<tr>
<td>Liu, Wei</td>
<td>413</td>
</tr>
<tr>
<td>Liu, Xiaohei</td>
<td>283</td>
</tr>
<tr>
<td>Liu, Yang</td>
<td>164</td>
</tr>
<tr>
<td>Liu, YaPei</td>
<td>683</td>
</tr>
<tr>
<td>Livelli, Alessandro</td>
<td>360</td>
</tr>
<tr>
<td>Llibre, Josep M.</td>
<td>44LB, 651</td>
</tr>
<tr>
<td>Lloyd-Jones, Donald M.</td>
<td>622</td>
</tr>
</tbody>
</table>
Lo, Janet 627
Lo, Yi-Chun 582
Lo Re, Vincent 127, 702
Loarec, Anne 523
Locatelli, Isabella 362
Lockman, Shahin 25, 484, 502, 640, 774, 787, 789, 1008, 1009
Loefgren, Sarah 746
Logie, Carmen H. 923, 924, 925, 926
Loiseau, Claire 223
Lombaard, Johan 45LB
Lombrando, Joao 26
Lombardi, Francesca 445
Londoño, Maria Carlota 540
Longenecker, Chris T. 628, 674, 822
Long, Lawrence 459, 1050
Looby, Sara E. 627
Loomba, Rohit 99
López, Alondra 225
Lopez, Miguel 228
López-Bernaldo, Juan Carlos 336
Lopez-Lopez, Pedro 573
Love, Tanzy 514
Lowrance, David W. 35
Lozier, Jay 409
Luban, Jeremy 18
Lucarello, Angela 585
Lucera, Mark 169
Lucero, Constantza 336
Lucy, Debbie 897
Luechai, Pikunchai 855
Luetkemeyer, Annie 568LB
Luisi, Nico 90
Lu, Ka-Cheung 577
Lumpa, Mwansa 1004
Lundgren, Jens D. 128LB, 131, 474, 653, 693
Luo, Dajie 1054
Luo, Donghan 505
Luo, Ma 179
Luong Nguyen, Liem Binh 116
Lupo, David 943
Luque, Marco 816
Lusso, Paolo 14LB, 64LB
Lutsar, Irja 461
Lutz, Thomas 551, 567, 576
Lyagoba, Frederick 193
Lycett, Samantha 1026
Lycke, Jan 383
Lynch, Briana 881
Lynen, Lutgarde 81LB
Lynn, Shugene 450LB
Lyons, Michael S. 956
Lyss, Sheryl 741
–M–
Ma, Fangrui 199
Ma, Yifei 526, 625
Ma, Zhong-Min 252
Maelow, Naim 648, 677
Maan, Evelyn J. 939
Maartens, Gary 1020, 81LB
Maas, Brian 406
Mabileau, Guillaume 1028
Mabunda, Nedio 26
Macalino, Grace 865
Macatangay, Bernard 280, 330LB, 931
MacBrayne, Christine E. 404
Macer, Margherita 585
MacGillivray, Jay 756
Machado, Daisy 816
Macias, Juan 532, 536, 555, 570, 697
Macio, Ingrid 944
Mack, Wendy 514
Macken, Alan 679
Mackman, Richard 436
Maclean, Rachel L. 476
MacLeod, David 834, 1010
Macmadu, Alexandria 1044
Macuacua, Nello 730, 766
Maddon, Paul J. 437
Madjid, Shabir 787
Madison, Michaela 16
Maeda, Kenji 503
Mafara, Emma 475, 994
Magambo, Brian 193
Maganga, Lucas 197
Magi, Carlo 542LB
Magnus, Manya 872
Magwaza, Sphindile 958
Magyar, Clara 251, 700
Maer, Andrew D. 35
Maheu-Giroux, Mathieu 1047
Mahiga, Hellin 788
Mahjoubia, Nadia 603
Malatinkova, Eva 302
Malete, Given 1050
Mali, Sarah 370
Malinga, Jakob 580
Mallolas, Josep 42
Mallol, Patrick W.G. 613, 679
Maluzi, K 711
Maman, David 116, 464, 523, 764, 792, 1006
Mamede, João L. 15
Manabe, Yukari C. 712, 742
Manara, Justen 506
Mancebo, Maria 532, 697
Mandell, Sundhiya 275, 382
Mandelbrot, Laurent 775
Manenzhe, Kgahliso 936
McClure, Myra 432
McCoy, Laura 798
McCoy, Helen 408
McCoy, Linda 408
McCoy, Laura 798
McCoy, Laura 798
McCrae, Edward 408
McCrae, Edward 408
McCrae, Edward 408
McCullough, John 20
McDavid, Andrew 265LB
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
McDowell, Cheryl 453
Milne, Ross 490
Milojevic, Catriona 185
Milush, Jeffery 293
Milani, Rumi 649
Mine, Madisa 750, 843, 988
Minichiello, Carmen 537
Minisci, Davide 411
Minkoff, Howard 23
Minnerly, Sydney 845LB
Minnis, Alexandra 936
Miro, Jose M 540, 541, 651, 751
Mirochnick, Mark 755, 757, 717, 720
Mitchell, Brooks I. 385, 612, 692
Mitchell, Caroline 224
Mitchell, Hannah K. 740
Mitchell, James 84
Mitchell, Julie 125
Mitchell, Michael Lloyd. 434
Mitsuya, Hiroaki 503
Mitsuyasu, Ronald T. 592
Mittal, Maria Luisa 870
Miyahara, Sachiko 79, 342, 710, 717, 720
Mlambo, Makungureyi 958
Mlay, Mokotoni 25
Mock, Philip 854, 954
Mocroft, Amanda 128LB, 131, 653
Modesitt, Jacob 216
Modise, Sylvia 993
Modongo, Margaret 745
Moffatt, Koetsi 82, 740, 745
Molino, Laura 119LB, 754
Mondal, Sydney 523
Molina, Jean-Michel 55, 45LB, 91LB
Montaner, Julio SG. 599, 875, 929, 966, 1042
Montaner, Luis 326
Montano, Daniel E. 984
Montano, Laurita 752
Mollan, Katie 454
Molloy, Sile 82
Moltó, José 119LB, 754
Monplaisir, Florence 842
Moncla, Bernard John. 86LB
Mondi, Annalisa 203, 466
Money, Deborah M. 939
Mongwenyana, Constance 1050
Montana, Livio 639, 916
Montaño, Juan Carlos 526
Monteiro, Daniel 715
Monteiro, Marcos 311
Montejo, Aneesa 1021
Moon, Juhi 560
Moore, David 462, 966
Moore, David J. 353, 358, 367, 977
Moore, Janet 1009
Moore, Michael 433
Moore, Penny 142
Moore, Raeanne 358
Moore, Richard D. 330, 347, 454, 560, 619, 662, 840
Moore, Teresa 677
Moorman, Michelle Anne. 113, 1020
Moorthy, Ganesh S. 975
Mosha, Mahomed-Yunus 1020
Moraga, Catalina A. 629
Morgan, Matthew 592
Morgan-Dawes, Laurence 349, 487
Morton-Amado, Luis E. 536, 555, 570, 571
Morawski, Bozena M. 742
Moreau, Yvonne 177
Moremi, Sello 958
Moreno, Ana 540, 572
Moreno, Javier 752
Moreno, Santiago 647
Moreno, Victoria 572
Morgan, Ethan 849
Morgan, Jake R. 547
Mori, Luisa 799
Mori, Masahiko 799
Morlat, Philippe 653
Moron-Lopez, Sara 228
Morris, Allyson 845LB
Morris, David 592
Morris, Martina 900
Morris, Sheldon 977
Morrison, Charles S. 879
Morrison, Douglass 679
Morrison, Justin T. 628
Morrow, Mary 675
Morose, Caryn 226, 525
Moscicki, Anna-Barbara 805
Mosoe, Ellen 960
Mosepele, Mosepele 384, 640
Moser, Carlee 695, 700
Mosina, Myriam 1019
Moss, Allison 687
Moss, Darren Michael. 423
Mothe, Beatriz 119LB, 228, 271, 336
Mothibi, Eula 763
Motswe, Catherine 1009
Moulignier, Antoine 75
Mounzur, Karam 326, 664, 975
Muir, Graeme 418, 432
Moyo, Crispin 114LB
Moyo, Faith 794
Moyo, Sikhulile 184, 484, 502, 774, 789, 790
Mou, Ngole, Eitel 482, 486
Msandiwa, Reginald 657
Msika, Albans 946
Msukwa, Malango T. 782
Mthiko, Bryan 686
Muhibi, Frank 712
Mucunguzi, Atukunda 726
Mudenzangwa, Chishamiso 26
Mudrikova, Tania 504LB
Mugavero, Michael J. 454, 455, 838, 908, 921
Mugeni, Peter 117
Mugenyi, Mark 712
Mugisha, Deodatha 950
Mugo, Nelly 22, 85, 920, 934, 947
Mugurungi, Owen 114LB
Mugyenyi, Peter 117

CROI 2017
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nelson, Margaret</td>
<td>803</td>
</tr>
<tr>
<td>Nelson, Noele</td>
<td>584LB</td>
</tr>
<tr>
<td>Nelson, Scott D.</td>
<td>700</td>
</tr>
<tr>
<td>Nemeth, Johannes</td>
<td>263</td>
</tr>
<tr>
<td>Nepal, Suniti</td>
<td>417</td>
</tr>
<tr>
<td>Nérè, Marie-Laure</td>
<td>323</td>
</tr>
<tr>
<td>Nerlander, Lena</td>
<td>871</td>
</tr>
<tr>
<td>Nieblitt, Ariel</td>
<td>939</td>
</tr>
<tr>
<td>Neugebauer, Romain</td>
<td>598</td>
</tr>
<tr>
<td>Neuhäus, Jacqueline</td>
<td>474</td>
</tr>
<tr>
<td>Neukam, Karin</td>
<td>536, 555, 570, 571</td>
</tr>
<tr>
<td>Neuman, Melissa</td>
<td>896</td>
</tr>
<tr>
<td>Neumann, Till</td>
<td>633</td>
</tr>
<tr>
<td>Newell, Evan William</td>
<td>7</td>
</tr>
<tr>
<td>Newman, Peter A.</td>
<td>923</td>
</tr>
<tr>
<td>Newsum, Astrid</td>
<td>136</td>
</tr>
<tr>
<td>Newton, Alicia</td>
<td>140, 563</td>
</tr>
<tr>
<td>Ng’an’ga, Lucy</td>
<td>761, 970</td>
</tr>
<tr>
<td>Nganga, James</td>
<td>847</td>
</tr>
<tr>
<td>Nganou Makamdop, Kristy</td>
<td>60</td>
</tr>
<tr>
<td>Nghiem, Khanh</td>
<td>409</td>
</tr>
<tr>
<td>Ngidi, Julia</td>
<td>988</td>
</tr>
<tr>
<td>Nguo-Giang-Huang, Nicole</td>
<td>584LB</td>
</tr>
<tr>
<td>Ngongondo, McNeil</td>
<td>457, 710</td>
</tr>
<tr>
<td>Ngonzi, Joseph</td>
<td>773</td>
</tr>
<tr>
<td>Ngure, Kenneth</td>
<td>920</td>
</tr>
<tr>
<td>Nguyen, Bach-Yen T.</td>
<td>45LB</td>
</tr>
<tr>
<td>Nguyen, Chau Van Vinh</td>
<td>747, 748</td>
</tr>
<tr>
<td>Nguyen, Dung Thai Hoai</td>
<td>463, 741</td>
</tr>
<tr>
<td>Nguyen, Kinh Van.</td>
<td>463, 741</td>
</tr>
<tr>
<td>Nguyen, Mindie H.</td>
<td>97</td>
</tr>
<tr>
<td>Nguyen, Nam Hoang.</td>
<td>882</td>
</tr>
<tr>
<td>Nguyen, Son</td>
<td>65, 267</td>
</tr>
<tr>
<td>Nguyen, Tam Van.</td>
<td>882</td>
</tr>
<tr>
<td>Nguyen, Thanh Tat.</td>
<td>748</td>
</tr>
<tr>
<td>Nguyen, Thu Thi Mai.</td>
<td>747, 748</td>
</tr>
<tr>
<td>Nicholas, Brooke</td>
<td>129</td>
</tr>
<tr>
<td>Nichols, Sharon</td>
<td>403</td>
</tr>
<tr>
<td>Nichols, Whitney</td>
<td>517, 543, 545</td>
</tr>
<tr>
<td>Nicholson, Val</td>
<td>925</td>
</tr>
<tr>
<td>Nicolini, Laura Ambra</td>
<td>542LB</td>
</tr>
<tr>
<td>Nie, Zil</td>
<td>273</td>
</tr>
<tr>
<td>Niedziela-Majka, Anita</td>
<td>38, 497</td>
</tr>
<tr>
<td>Niertert, Paul</td>
<td>586</td>
</tr>
<tr>
<td>Nieves-Lugo, Karen</td>
<td>667</td>
</tr>
<tr>
<td>Nigalye, Maitreeye</td>
<td>396</td>
</tr>
<tr>
<td>Nightingale, Sam</td>
<td>370</td>
</tr>
<tr>
<td>Nijhawan, Anke E.</td>
<td>957</td>
</tr>
<tr>
<td>Nijhuis, Monique</td>
<td>306, 320, 504LB</td>
</tr>
<tr>
<td>Nikolaitchik, Olga A.</td>
<td>164, 334</td>
</tr>
<tr>
<td>Nikuze, Alliance</td>
<td>764, 792</td>
</tr>
<tr>
<td>Nilsson, Staffan</td>
<td>340, 431</td>
</tr>
<tr>
<td>Ning, Yuming</td>
<td>544</td>
</tr>
<tr>
<td>Nishida, Yasuharu</td>
<td>426</td>
</tr>
<tr>
<td>Nityapahan, Sorachai</td>
<td>197</td>
</tr>
<tr>
<td>Nitz, T.J.</td>
<td>507</td>
</tr>
<tr>
<td>Niubo, Jordi</td>
<td>382</td>
</tr>
<tr>
<td>Nkala, Busiwse</td>
<td>857</td>
</tr>
<tr>
<td>Nkele, Isaac</td>
<td>640</td>
</tr>
<tr>
<td>Nkoma, Chiwawa</td>
<td>896</td>
</tr>
<tr>
<td>Nkoma, Prince</td>
<td>1006</td>
</tr>
<tr>
<td>Nkomani, Sanele</td>
<td>117</td>
</tr>
<tr>
<td>Nkomo, Bornaparte</td>
<td>988</td>
</tr>
<tr>
<td>Nogglet, Arianna</td>
<td>69</td>
</tr>
<tr>
<td>Noguchi, Lisa</td>
<td>935</td>
</tr>
<tr>
<td>Nogueira-Julian, Antoni</td>
<td>527</td>
</tr>
<tr>
<td>Nogueira-Julian, Marc</td>
<td>212</td>
</tr>
<tr>
<td>Nolan, David J.</td>
<td>69</td>
</tr>
<tr>
<td>Nolle, Robert T.</td>
<td>171LB</td>
</tr>
<tr>
<td>Nordell, Miranda</td>
<td>974</td>
</tr>
<tr>
<td>Nortgren, Hans</td>
<td>37</td>
</tr>
<tr>
<td>Norton, Thomas D.</td>
<td>333</td>
</tr>
<tr>
<td>Nosyk, Bohdan</td>
<td>875, 1042</td>
</tr>
<tr>
<td>Noto, Alessandra</td>
<td>265LB</td>
</tr>
<tr>
<td>Novak, David S.</td>
<td>971</td>
</tr>
<tr>
<td>Novak, Richard</td>
<td>32, 663, 864</td>
</tr>
<tr>
<td>Novikov, Nikolai</td>
<td>497</td>
</tr>
<tr>
<td>Novikova, Marita</td>
<td>158</td>
</tr>
<tr>
<td>Novitsky, Vlad</td>
<td>184, 484</td>
</tr>
<tr>
<td>Novotny, Paul</td>
<td>669</td>
</tr>
<tr>
<td>Nowak, Piotr</td>
<td>212</td>
</tr>
<tr>
<td>Nowak, Rebecca G.</td>
<td>918, 997</td>
</tr>
<tr>
<td>Noyan, Kajsa</td>
<td>212</td>
</tr>
<tr>
<td>Nsubuga, Rebecca N.</td>
<td>193, 1048</td>
</tr>
<tr>
<td>Ntema, Charity</td>
<td>35</td>
</tr>
<tr>
<td>Notzini, Robert</td>
<td>786</td>
</tr>
<tr>
<td>Nucifora, Kimberly</td>
<td>1049LB</td>
</tr>
<tr>
<td>Nugeyre, Marie-Thérèse</td>
<td>262</td>
</tr>
<tr>
<td>Nunn, Amy</td>
<td>968, 972</td>
</tr>
<tr>
<td>Nunnari, Giuseppe</td>
<td>283</td>
</tr>
<tr>
<td>Nussenzeig, Michel</td>
<td>145</td>
</tr>
<tr>
<td>Nuwagaba-Birbonmohar, Harriet</td>
<td>637, 837, 950</td>
</tr>
<tr>
<td>Nyaibi, Hansette Bebe</td>
<td>1019</td>
</tr>
<tr>
<td>Nyaobi, Phillippe N.</td>
<td>881</td>
</tr>
<tr>
<td>Nye, Mindy</td>
<td>1054</td>
</tr>
<tr>
<td>Nyiranda, Rose</td>
<td>114LB</td>
</tr>
<tr>
<td>Nyongesa-Malava, Evans</td>
<td>22</td>
</tr>
<tr>
<td>Nyoni, Cynthia</td>
<td>1050</td>
</tr>
<tr>
<td>Nzomukundu, Yvonne</td>
<td>523</td>
</tr>
<tr>
<td>O'Brien, Luke</td>
<td>613</td>
</tr>
<tr>
<td>O'Brien, Meagan</td>
<td>256</td>
</tr>
<tr>
<td>O'Brien, Nadia</td>
<td>925, 926</td>
</tr>
<tr>
<td>O'Bryan, Thomas</td>
<td>865</td>
</tr>
<tr>
<td>O'Connell, James</td>
<td>557</td>
</tr>
<tr>
<td>O'Connell, Robert J.</td>
<td>70</td>
</tr>
<tr>
<td>O'Doherty, Una</td>
<td>283, 300</td>
</tr>
<tr>
<td>O'Donnell, James</td>
<td>628</td>
</tr>
<tr>
<td>O'Donnell, Kate</td>
<td>513</td>
</tr>
<tr>
<td>O'Garra, Anne</td>
<td>739</td>
</tr>
<tr>
<td>O'Halloran, Jane A.</td>
<td>613</td>
</tr>
<tr>
<td>O'Neal, Justin</td>
<td>1056LB</td>
</tr>
<tr>
<td>O'Neill, Jennifer</td>
<td>408</td>
</tr>
<tr>
<td>O'Riordan, Mary Ann</td>
<td>822</td>
</tr>
<tr>
<td>O'Rourke, Colin</td>
<td>952</td>
</tr>
<tr>
<td>Oakley, Jeremy E.</td>
<td>1048</td>
</tr>
<tr>
<td>Ocampo, Antonio</td>
<td>595</td>
</tr>
<tr>
<td>Odelfia, Cheryl Banez</td>
<td>187, 478, 833</td>
</tr>
<tr>
<td>Ochieng, Teddy</td>
<td>768</td>
</tr>
<tr>
<td>Ochsenbauer, Christina</td>
<td>328</td>
</tr>
<tr>
<td>Odek, James</td>
<td>985</td>
</tr>
<tr>
<td>Odhiambo, Jacob</td>
<td>985</td>
</tr>
<tr>
<td>Odoyo-June, Elijah</td>
<td>382, 985, 986</td>
</tr>
<tr>
<td>Oduor, Clifford</td>
<td>893, 1022</td>
</tr>
<tr>
<td>Oelheke, Sebastien</td>
<td>672</td>
</tr>
<tr>
<td>Ofotokun, Igbo</td>
<td>629, 684, 695, 913, 943</td>
</tr>
<tr>
<td>Ogata-Arakaki, Debra</td>
<td>381</td>
</tr>
<tr>
<td>Oghara, Kasmari</td>
<td>247</td>
</tr>
<tr>
<td>Ogochale, Cassie</td>
<td>21</td>
</tr>
<tr>
<td>Ogoposete, Matarsi</td>
<td>729</td>
</tr>
<tr>
<td>Ogunniyi, Adesola</td>
<td>369</td>
</tr>
<tr>
<td>Ogunshola, Funsho</td>
<td>266</td>
</tr>
<tr>
<td>Ohainle, Molly</td>
<td>19</td>
</tr>
<tr>
<td>Oka, Shinichi</td>
<td>463</td>
</tr>
<tr>
<td>Okazaki, Reiko</td>
<td>496</td>
</tr>
<tr>
<td>Okere, Nwora Lance</td>
<td>615</td>
</tr>
<tr>
<td>Okello, Velephi</td>
<td>1049LB, 475, 637, 994</td>
</tr>
<tr>
<td>Okiria, Alfred Geoffrey</td>
<td>914</td>
</tr>
<tr>
<td>Okoboi, Stephen</td>
<td>462</td>
</tr>
<tr>
<td>Author</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Oksenhendler, Eric</td>
<td>323, 603</td>
</tr>
<tr>
<td>Okulicz, Jason</td>
<td>358, 668, 865, 932</td>
</tr>
<tr>
<td>Olaiya, Oluwatosin</td>
<td>907</td>
</tr>
<tr>
<td>Olavore, Oluwasolape M.</td>
<td>1015</td>
</tr>
<tr>
<td>Oldenburg, Catherine E.</td>
<td>968, 972</td>
</tr>
<tr>
<td>Oldener, Rodrigo Alejandro</td>
<td>225</td>
</tr>
<tr>
<td>Olney, Jack</td>
<td>115</td>
</tr>
<tr>
<td>Oluch, Tom</td>
<td>847</td>
</tr>
<tr>
<td>Omganga, Eunice</td>
<td>982</td>
</tr>
<tr>
<td>Omari, Habib R.</td>
<td>997</td>
</tr>
<tr>
<td>Omwoyo, Willis</td>
<td>764, 792</td>
</tr>
<tr>
<td>Onchiri, Frankline</td>
<td>982</td>
</tr>
<tr>
<td>Onoda, Pascale</td>
<td>467</td>
</tr>
<tr>
<td>Onogbo, Dennis</td>
<td>783</td>
</tr>
<tr>
<td>Onyango, Jacob</td>
<td>982</td>
</tr>
<tr>
<td>Onyango, Mathews</td>
<td>985</td>
</tr>
<tr>
<td>Oord, Gertine van</td>
<td>587</td>
</tr>
<tr>
<td>Oosthuizen, Christa</td>
<td>990</td>
</tr>
<tr>
<td>Op de Coul, Eline</td>
<td>1014</td>
</tr>
<tr>
<td>Oropamiento, Don</td>
<td>892</td>
</tr>
<tr>
<td>Opoku, Bernievieve</td>
<td>872, 905</td>
</tr>
<tr>
<td>Orlova, Nina</td>
<td>396</td>
</tr>
<tr>
<td>Orland, Gabriella</td>
<td>655</td>
</tr>
<tr>
<td>Orlova, Nina</td>
<td>292</td>
</tr>
<tr>
<td>Osier, Mark</td>
<td>434</td>
</tr>
<tr>
<td>Osier, Meg</td>
<td>990</td>
</tr>
<tr>
<td>Osman, Nathan</td>
<td>498</td>
</tr>
<tr>
<td>Osmand, Thomas</td>
<td>1051</td>
</tr>
<tr>
<td>Osna, Natalee</td>
<td>588</td>
</tr>
<tr>
<td>Oster, Alexander</td>
<td>187, 188, 478, 845LB, 889</td>
</tr>
<tr>
<td>Ostrander, Darin</td>
<td>317</td>
</tr>
<tr>
<td>Ostrowski, Mario</td>
<td>233</td>
</tr>
<tr>
<td>Osuna, Christa</td>
<td>338LB</td>
</tr>
<tr>
<td>Otun, Luis</td>
<td>562</td>
</tr>
<tr>
<td>Otsi-Kuffour, Edmund</td>
<td>161</td>
</tr>
<tr>
<td>Osler, Mark</td>
<td>434</td>
</tr>
<tr>
<td>Osman, Nathan</td>
<td>498</td>
</tr>
<tr>
<td>Osman, Thomas</td>
<td>1051</td>
</tr>
<tr>
<td>Osna, Natalee</td>
<td>588</td>
</tr>
<tr>
<td>Oster, Alexander</td>
<td>187, 478, 845LB, 889</td>
</tr>
<tr>
<td>Ostrander, Darin</td>
<td>317</td>
</tr>
<tr>
<td>Ostrowski, Mario</td>
<td>233</td>
</tr>
<tr>
<td>Osuna, Christa</td>
<td>338LB</td>
</tr>
<tr>
<td>Otero, Luis</td>
<td>562</td>
</tr>
<tr>
<td>Otieno-Nunya, Boaz</td>
<td>982, 986</td>
</tr>
<tr>
<td>Otowombo, Kennedy</td>
<td>823, 824</td>
</tr>
<tr>
<td>Otuaatara, Eric</td>
<td>476</td>
</tr>
<tr>
<td>Ounchanum, Pradthana</td>
<td>759, 820</td>
</tr>
<tr>
<td>Oursler, Krisann</td>
<td>667</td>
</tr>
<tr>
<td>Ouyang, Zhengyu</td>
<td>250</td>
</tr>
<tr>
<td>Oyung, Zhengyu</td>
<td>250</td>
</tr>
<tr>
<td>Overbaugh, Julie</td>
<td>242, 243, 765, 796</td>
</tr>
<tr>
<td>Overton, Edgar Turner</td>
<td>213, 678</td>
</tr>
<tr>
<td>Owaragione, Asphas</td>
<td>638, 836, 1051</td>
</tr>
<tr>
<td>Owen, Andrew</td>
<td>39, 416, 418, 423</td>
</tr>
<tr>
<td>Owen, Christopher Leigh</td>
<td>197</td>
</tr>
<tr>
<td>Owen, Douglas K.</td>
<td>725</td>
</tr>
<tr>
<td>Owino, Fredrick</td>
<td>936</td>
</tr>
<tr>
<td>Owino, George</td>
<td>762</td>
</tr>
<tr>
<td>Owitti, Preston</td>
<td>488</td>
</tr>
<tr>
<td>Ower, Maxensia</td>
<td>776, 777</td>
</tr>
<tr>
<td>Owuoth, John</td>
<td>481</td>
</tr>
<tr>
<td>Oyaro, Patrick</td>
<td>762</td>
</tr>
<tr>
<td>Oyengua, Laura</td>
<td>764, 792</td>
</tr>
<tr>
<td>Ozerturk, Ayse Naz.</td>
<td>16</td>
</tr>
<tr>
<td>O’Ceirigh, Connall</td>
<td>454</td>
</tr>
</tbody>
</table>

---

Pace, Craig S. 329
Pachankis, John 965
Padgett, Denis 719
Padian, Nancy 995, 1000, 1004
Padilla, Sergio 647
Pagani, Nicole 418, 432
Page, Kimberly 516
Pahwa, Rajendra 234, 258
Pahwa, Savita 234, 258, 798
Paiardini, Mirko 48
Paiva, Raquel 388
Pajkrt, Daya 825, 830
Palai, Tommy 640
Palanee-Phillips, Thesla 88, 935, 951
Palar, Kartika 690, 913
Palazza, Donatella 575
Paley, Joel 23, 591, 597
Pall, Frank Joseph. 32, 130, 624, 632, 645, 663, 665, 666, 701, 931
Palfreeman, Adrian 473
Palich, Romain 323
Palk, Laurence 850
Pallier, Coralie 349
Pallikkuth, Suresh 234, 258
Palm, Angelica 37
Palma, Antonio M. 637
Palma, Paolo 798
Palmateer, Norah 185
Palmer, Brent E. 207, 208
Palmer, Sar 293, 305
Palou, Elsa Y. 182
Paltiel, A. David 456, 476, 1028, 1043
Palumbo, Paul 826
Pan, Li 258
Pan, Sung-Ching 582
Pancharoen, Chitsawan 759, 807
Panchooren, Kanokpan 862
Paneervelam, Nandagopal 245, 559
Pankau, Mark David 796
Panneer, Nivedha 187, 188
Pantaleo, Giuseppe 265LB, 289
Panwelker, Nina 378
Papadakis, Georgios Z. 238
Papadimitropoulos, Athanasios 549
Papasavvas, Emmanuel 326
Papazian, Emily 69
Pape, Jean W. 471, 722, 835
Papp, Eszter 756
Pardi, Norbert 1057LB
Paredes, Roger 212
Parikh, Urvi 951, 952
Park, Chung 64LB
Park, Eun-Young 255
Park, Lawrence 138
Park, Lesley 257, 606
Park, Seo Young 944
Park, Sung Yong 518
Parker, Robert A. 116, 833
Parr, Jonathan 522
Parruti, Giustino 564
Partisani, Marialuisa 495
Pascasio, Juan Manuel 566
Pascoe, Sophie 1021
Paspamare, Munyadarzi 708
Pasquazi, Caterina 564
Passmore, Jo-Ann 949
Pastermak, Alexander 286
<table>
<thead>
<tr>
<th>Author Index</th>
<th>Program and Agenda</th>
<th>CROI 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramogola-Masire, Doreen 152</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramos, Jose Tomas 802</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramsey, Benjamin 691</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rannard, Steve 39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ransier, Amy 60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rao, Deepa 811, 921</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raoofi, Fahimeh 337</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raper, James 867</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rappold, Michaela 631</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rapuano, Patrick Burns. 236</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rasmussen, Sarah 689</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rasmussen, Thomas Aagaard. 305</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ratanshi, Rosalind Parkes. 1001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rathod, Sujit 919</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rathig, Dana 440, 508</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rawlings, David J. 335</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rawls, Anthony 872</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Real, Luis M. 532</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rebeiro, Peter F. 840, 912</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rebensburg, Stephanie 157, 160LB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Redd, Andrew D. 244, 317, 318, 881</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rees, Helen 857, 935, 1036</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Registre, Ludy 177</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rego, Dalila 818</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rehema, Winnie 355</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reil, Lindsey 722, 835</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reinsch, Nico 633</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reiss, Peter 1041, 128LB, 129, 131, 136, 352LB, 467, 653, 672, 731, 825</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reliquet, Véronique 821</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remien, Robert 24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rentsch, Christopher 626</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Requena, Silvia 562</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resino, Salvador 530</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resnati, Chiara 396</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reust, Julie 471</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revill, Paul 112, 1030</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revollo, Boris 139, 538</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rewari, Bharat Bhushan 456</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rey, David 495</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reyes-Terán, Gustavo 65, 182, 267, 480</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reynolds, James 649</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reynolds, Steven J. 104, 34LB, 880, 996</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renshaw, Douglas D. 113, 200, 201, 300, 307, 319, 326</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richman, Douglas D. 113, 200, 201, 300, 307, 319, 326</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richman, Gary J. 442, 449LB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richter, Clemens 136</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richter, Hendrik 464</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ricciotti, Martina 354</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rich, Joseph 1044</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richarz, Léa 190</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richardson, Barbara A. 22, 765</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richardson, Kelly 803</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richmond, David 626</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rinaldi, Stefano 234, 258</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rinaldo, Charles 280</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rinke de Wit, Tobias F. 467, 488</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rios, Jessica 380</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rios Prego, Monica 734</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rivas-Villegas, Maria J. 139, 536, 570</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risch, Lorentz 721</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Riva, Agostino 265LB, 396, 410</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Riviere, Cynthia 648, 720</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rizzita, Stacey 319</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roan, Nadia R. 170</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robbins, Gregory K. 838</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roberts, Owain 423</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roberts, Tessa 919</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robertson, Kevin 72, 73, 342, 343, 359, 369, 380, 665</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robichaux, Spencer 217</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robinson, Cameron 1056LB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robinson, Nicola 301, 324</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roby, Greg 287</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rocha, Salvatore 798</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rocha, Susana 155</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rodriguez, Allan 234, 258</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rodríguez-Arrondo, Francisco 139, 538</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rodríguez-Barradas, María 127, 606, 626, 658, 702, 930</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rodriguez-Cano, Diego 573</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rodriguez-Hart, Cristina 918</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rogers, Anna Joy 762</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rohan, Lisa C. 865LB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rohr, Julia K. 639, 916, 991</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rojanawiwat, Archawin 793</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rojas, John 1013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rojas, Sarah 548</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rojas-Castro, Daniela 91LB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rolland, Morgane 197, 299LB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rolle, Charlotte-Paige Melanie. 90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Romano Ibarra, Guillermo 335</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Romano, Jorge 595</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Romano-Palacios, Alberto 538</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ronan, Agnes 769, 771</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roncadori, Andrea 460</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author Name</td>
<td>Page Numbers</td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Ronchetti, Anne-Marie</td>
<td>603</td>
<td></td>
</tr>
<tr>
<td>Ronzi, Paola</td>
<td>579</td>
<td></td>
</tr>
<tr>
<td>Rooienasie, Shawn Jarroth</td>
<td>987</td>
<td></td>
</tr>
<tr>
<td>Roon, Laura</td>
<td>405</td>
<td></td>
</tr>
<tr>
<td>Rossa Umbert, Miriam</td>
<td>271</td>
<td></td>
</tr>
<tr>
<td>Ross, Charles</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>Rose, Herbert</td>
<td>903</td>
<td></td>
</tr>
<tr>
<td>Rose, Rebecca</td>
<td>518</td>
<td></td>
</tr>
<tr>
<td>Rosebush, Julia C.</td>
<td>822</td>
<td></td>
</tr>
<tr>
<td>Rosen, Sydney</td>
<td>1050</td>
<td></td>
</tr>
<tr>
<td>Rosenberg, Eli</td>
<td>1024, 1033, 1034, 1055LB, 90</td>
<td></td>
</tr>
<tr>
<td>Rosenberg, Eric</td>
<td>292</td>
<td></td>
</tr>
<tr>
<td>Rosenberg, Molly</td>
<td>991</td>
<td></td>
</tr>
<tr>
<td>Rosenberg, Nora E.</td>
<td>859</td>
<td></td>
</tr>
<tr>
<td>Rosenblom, Daniel I.S.</td>
<td>318</td>
<td></td>
</tr>
<tr>
<td>Roskam-Kwint, Marieke</td>
<td>429</td>
<td></td>
</tr>
<tr>
<td>Ross, Christine</td>
<td>743</td>
<td></td>
</tr>
<tr>
<td>Ross, Jonathan</td>
<td>1016</td>
<td></td>
</tr>
<tr>
<td>Ross, Michael</td>
<td>653</td>
<td></td>
</tr>
<tr>
<td>Rossaro, Lorenzo</td>
<td>568LB</td>
<td></td>
</tr>
<tr>
<td>Rossi, Fiorella Patricia</td>
<td>376</td>
<td></td>
</tr>
<tr>
<td>Rossi, Francesca</td>
<td>531</td>
<td></td>
</tr>
<tr>
<td>Rossi, Paolo</td>
<td>798</td>
<td></td>
</tr>
<tr>
<td>Roth, David</td>
<td>735</td>
<td></td>
</tr>
<tr>
<td>Roth, Eric</td>
<td>966</td>
<td></td>
</tr>
<tr>
<td>Rothman, Richard</td>
<td>956</td>
<td></td>
</tr>
<tr>
<td>Rothrock, Ginger</td>
<td>420</td>
<td></td>
</tr>
<tr>
<td>Rotta, Indiana</td>
<td>386</td>
<td></td>
</tr>
<tr>
<td>Roudiere, Laurent</td>
<td>520</td>
<td></td>
</tr>
<tr>
<td>Rough, Kathryn</td>
<td>779</td>
<td></td>
</tr>
<tr>
<td>Rouskin, Silvi</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Routy, Jean-Pierre</td>
<td>123, 204, 264, 274</td>
<td></td>
</tr>
<tr>
<td>Rouzier, Vanessa</td>
<td>816</td>
<td></td>
</tr>
<tr>
<td>Rouzioux, Christine</td>
<td>775</td>
<td></td>
</tr>
<tr>
<td>Rowan, Sarah E.</td>
<td>528</td>
<td></td>
</tr>
<tr>
<td>Rowe, William</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>Rowland-Jones, Sarah</td>
<td>202</td>
<td></td>
</tr>
<tr>
<td>Rowley, Christopher</td>
<td>502</td>
<td></td>
</tr>
<tr>
<td>Roy, Daisy</td>
<td>512</td>
<td></td>
</tr>
<tr>
<td>Roy, Monika</td>
<td>1000</td>
<td></td>
</tr>
<tr>
<td>RoyChoudhury, Arindam</td>
<td>682</td>
<td></td>
</tr>
<tr>
<td>Royse, Kathryn E.</td>
<td>539</td>
<td></td>
</tr>
<tr>
<td>Rozera, Gabriella</td>
<td>466</td>
<td></td>
</tr>
<tr>
<td>Rua, Réjane</td>
<td>190</td>
<td></td>
</tr>
<tr>
<td>Rubin, Leah H.</td>
<td>341, 350</td>
<td></td>
</tr>
<tr>
<td>Rude, Eric</td>
<td>903</td>
<td></td>
</tr>
<tr>
<td>Ruel, Theodore</td>
<td>726, 768, 797, 806, 832</td>
<td></td>
</tr>
<tr>
<td>Ruelas, Debbie Sophia</td>
<td>337</td>
<td></td>
</tr>
<tr>
<td>Ruff, Joshua H.</td>
<td>822</td>
<td></td>
</tr>
<tr>
<td>Ruffner, Andrew</td>
<td>956</td>
<td></td>
</tr>
<tr>
<td>Ruiz, Carlos Perez</td>
<td>427</td>
<td></td>
</tr>
<tr>
<td>Ruiz, Eduardo</td>
<td>380</td>
<td></td>
</tr>
<tr>
<td>Ruiz-Giardin, Jose</td>
<td>752</td>
<td></td>
</tr>
<tr>
<td>Rukobo, Sandra</td>
<td>786</td>
<td></td>
</tr>
<tr>
<td>Ruone, Susan</td>
<td>954</td>
<td></td>
</tr>
<tr>
<td>Rupert, Adam</td>
<td>126, 225, 226</td>
<td></td>
</tr>
<tr>
<td>Rusconi, Stefano</td>
<td>303, 396</td>
<td></td>
</tr>
<tr>
<td>Ruset, Peter</td>
<td>66, 67</td>
<td></td>
</tr>
<tr>
<td>Russel, Frans G.M.</td>
<td>753</td>
<td></td>
</tr>
<tr>
<td>Russell, Ronnie M.</td>
<td>181LB</td>
<td></td>
</tr>
<tr>
<td>Russo, Amiello</td>
<td>537</td>
<td></td>
</tr>
<tr>
<td>Rutledge, Brandy</td>
<td>685LB</td>
<td></td>
</tr>
<tr>
<td>Rüütel, Kristi</td>
<td>1028</td>
<td></td>
</tr>
<tr>
<td>Ruxrungham, Kiat</td>
<td>698, 705</td>
<td></td>
</tr>
<tr>
<td>Ryan, Pablo</td>
<td>534</td>
<td></td>
</tr>
<tr>
<td>Ryom, Lene</td>
<td>128LB, 131, 653, 693</td>
<td></td>
</tr>
<tr>
<td>Saag, Michael</td>
<td>138</td>
<td></td>
</tr>
<tr>
<td>Sabi, Issa</td>
<td>788</td>
<td></td>
</tr>
<tr>
<td>Sabin, Caroline</td>
<td>128LB, 352LB, 650, 672, 679, 693</td>
<td></td>
</tr>
<tr>
<td>Sacdalan, Carlo</td>
<td>344</td>
<td></td>
</tr>
<tr>
<td>Sacktor, Ned</td>
<td>356, 359</td>
<td></td>
</tr>
<tr>
<td>Saduvala, Neeraja</td>
<td>478</td>
<td></td>
</tr>
<tr>
<td>Saeed, Salar</td>
<td>533</td>
<td></td>
</tr>
<tr>
<td>Sagar, Manish</td>
<td>177</td>
<td></td>
</tr>
<tr>
<td>Sagnelli, Caterina</td>
<td>531</td>
<td></td>
</tr>
<tr>
<td>Sagnelli, Evangelista</td>
<td>531, 537</td>
<td></td>
</tr>
<tr>
<td>Sah Bandar, Ivo</td>
<td>255</td>
<td></td>
</tr>
<tr>
<td>Sah, Sharon</td>
<td>749, 750</td>
<td></td>
</tr>
<tr>
<td>Sahni, Jaya</td>
<td>335</td>
<td></td>
</tr>
<tr>
<td>Sahoo, Debashis</td>
<td>374</td>
<td></td>
</tr>
<tr>
<td>Sailsutasa, Napapon</td>
<td>339, 363, 394</td>
<td></td>
</tr>
<tr>
<td>Sainz, Talia</td>
<td>527, 802</td>
<td></td>
</tr>
<tr>
<td>Saito, Suzue</td>
<td>706</td>
<td></td>
</tr>
<tr>
<td>Sakala, Doreen</td>
<td>895</td>
<td></td>
</tr>
<tr>
<td>Sakowicz, Roman</td>
<td>434</td>
<td></td>
</tr>
<tr>
<td>Sakr, Sameh</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Salanave, Benoit</td>
<td>821</td>
<td></td>
</tr>
<tr>
<td>Salazar-Austin, Nicole</td>
<td>707</td>
<td></td>
</tr>
<tr>
<td>Salcuni, Paul M.</td>
<td>891, 898</td>
<td></td>
</tr>
<tr>
<td>Saleri, Marco</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>Salgado, Maria</td>
<td>306, 320</td>
<td></td>
</tr>
<tr>
<td>Salomon, Joshua A.</td>
<td>833, 983, 991</td>
<td></td>
</tr>
<tr>
<td>Salters, Kate</td>
<td>599, 601</td>
<td></td>
</tr>
<tr>
<td>Salumu, Leon</td>
<td>464, 764, 792, 1006</td>
<td></td>
</tr>
<tr>
<td>Samandari, Taraz</td>
<td>980</td>
<td></td>
</tr>
<tr>
<td>Sambucetti, Lidia</td>
<td>283</td>
<td></td>
</tr>
<tr>
<td>Samet, Jeffrey H.</td>
<td>673</td>
<td></td>
</tr>
<tr>
<td>Samleerat, Tanawanz</td>
<td>793</td>
<td></td>
</tr>
<tr>
<td>Samoff, Erika</td>
<td>198</td>
<td></td>
</tr>
<tr>
<td>Sampériz, Gloria</td>
<td>659</td>
<td></td>
</tr>
<tr>
<td>Samir, Assa</td>
<td>290</td>
<td></td>
</tr>
<tr>
<td>Samuel, David C.</td>
<td>229, 377, 392, 393, 691, 752</td>
<td></td>
</tr>
<tr>
<td>San Martin, Juan Victor</td>
<td>752</td>
<td></td>
</tr>
<tr>
<td>Sanchez, Carmen</td>
<td>752</td>
<td></td>
</tr>
<tr>
<td>Sanchez, Rosa</td>
<td>412, 430</td>
<td></td>
</tr>
<tr>
<td>Sanchez, Travis</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>Sanchez Mellado, Diana Sanchez Mellado</td>
<td>734</td>
<td></td>
</tr>
<tr>
<td>Sánchez Rivas, Elena</td>
<td>504LB</td>
<td></td>
</tr>
<tr>
<td>Sanchez-Lopez, Anhoo</td>
<td>609</td>
<td></td>
</tr>
<tr>
<td>Sanders, Eduard</td>
<td>202, 856, 886, 893, 976, 1022</td>
<td></td>
</tr>
<tr>
<td>Sanders-Buell, Eric</td>
<td>197, 299LB, 71</td>
<td></td>
</tr>
<tr>
<td>Sanderson, Jeremy</td>
<td>324</td>
<td></td>
</tr>
<tr>
<td>Sands, Bryan</td>
<td>335</td>
<td></td>
</tr>
<tr>
<td>Sane Schepisi, Monica</td>
<td>734</td>
<td></td>
</tr>
<tr>
<td>Sanford, Ryan</td>
<td>397</td>
<td></td>
</tr>
<tr>
<td>Sang, Norton</td>
<td>36, 832</td>
<td></td>
</tr>
<tr>
<td>Sangal, Neel</td>
<td>167</td>
<td></td>
</tr>
<tr>
<td>Sanne, Ian</td>
<td>225, 1050</td>
<td></td>
</tr>
<tr>
<td>Sansom, Stephanie L.</td>
<td>1029</td>
<td></td>
</tr>
<tr>
<td>Santana, Bárbara</td>
<td>388</td>
<td></td>
</tr>
<tr>
<td>Santelli, John</td>
<td>1015</td>
<td></td>
</tr>
<tr>
<td>Santiago, Gilberto</td>
<td>1055LB</td>
<td></td>
</tr>
<tr>
<td>Santiago, Mario</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>Santoro, Antonella</td>
<td>655</td>
<td></td>
</tr>
<tr>
<td>Santos, Ignacio</td>
<td>534</td>
<td></td>
</tr>
<tr>
<td>Sanz, Gonzalez</td>
<td>595</td>
<td></td>
</tr>
<tr>
<td>Sanz, Jose</td>
<td>572</td>
<td></td>
</tr>
<tr>
<td>Sarafianos, Stefan G.</td>
<td>18, 503</td>
<td></td>
</tr>
<tr>
<td>Sarah Hau, Sarah</td>
<td>549</td>
<td></td>
</tr>
<tr>
<td>Saravanan, Shanmugam</td>
<td>492, 559</td>
<td></td>
</tr>
<tr>
<td>Sarletti, Mario</td>
<td>631</td>
<td></td>
</tr>
<tr>
<td>Sardo, Luca</td>
<td>308</td>
<td></td>
</tr>
<tr>
<td>Sartorius, Benn</td>
<td>817LB</td>
<td></td>
</tr>
<tr>
<td>Sasco, Annie Jeanne</td>
<td>607</td>
<td></td>
</tr>
<tr>
<td>Sastri, Jaya</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Sastry, Jagannadha</td>
<td>422LB</td>
<td></td>
</tr>
<tr>
<td>Satapathy, Sanjaya</td>
<td>568LB</td>
<td></td>
</tr>
<tr>
<td>Author Name</td>
<td>Pages</td>
<td></td>
</tr>
<tr>
<td>----------------------------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>Shehu, Nathan</td>
<td>369</td>
<td></td>
</tr>
<tr>
<td>Sheikh, Virginia</td>
<td>221, 238, 287, 733</td>
<td></td>
</tr>
<tr>
<td>Sheira, Lila Aziz.</td>
<td>913</td>
<td></td>
</tr>
<tr>
<td>Sheng, Wang-Huei</td>
<td>582</td>
<td></td>
</tr>
<tr>
<td>Shepherd, Bryan E.</td>
<td>644, 719, 816</td>
<td></td>
</tr>
<tr>
<td>Shepherd, Leah</td>
<td>131</td>
<td></td>
</tr>
<tr>
<td>Sherrill-Mix, Scott</td>
<td>181LB</td>
<td></td>
</tr>
<tr>
<td>Sherman, Brad</td>
<td>371</td>
<td></td>
</tr>
<tr>
<td>Sherman, Gayle Gillian.</td>
<td>27, 794</td>
<td></td>
</tr>
<tr>
<td>Sherrill-Mix, Scott</td>
<td>171LB</td>
<td></td>
</tr>
<tr>
<td>Sherwat, Adam</td>
<td>372</td>
<td></td>
</tr>
<tr>
<td>Sheth, Anandi N.</td>
<td>629, 684, 942, 943</td>
<td></td>
</tr>
<tr>
<td>Shi, Margaret D.</td>
<td>611</td>
<td></td>
</tr>
<tr>
<td>Shi, Qiu Hu</td>
<td>361, 928</td>
<td></td>
</tr>
<tr>
<td>Shiau, Stephanie</td>
<td>27, 819</td>
<td></td>
</tr>
<tr>
<td>Shiboski, Caroline H.</td>
<td>213</td>
<td></td>
</tr>
<tr>
<td>Shiers, Meredith S.</td>
<td>600, 661</td>
<td></td>
</tr>
<tr>
<td>Shigemi, Urara</td>
<td>496</td>
<td></td>
</tr>
<tr>
<td>Shih, Margaret D.</td>
<td>611</td>
<td></td>
</tr>
<tr>
<td>Shih, Qiuhu</td>
<td>361, 928</td>
<td></td>
</tr>
<tr>
<td>Shiau, Stephanie</td>
<td>27, 819</td>
<td></td>
</tr>
<tr>
<td>Shiboski, Caroline H.</td>
<td>213</td>
<td></td>
</tr>
<tr>
<td>Shiers, Meredith S.</td>
<td>600, 661</td>
<td></td>
</tr>
<tr>
<td>Shigemi, Urara</td>
<td>496</td>
<td></td>
</tr>
<tr>
<td>Shih, Margaret D.</td>
<td>611</td>
<td></td>
</tr>
<tr>
<td>Shih, Qiuhu</td>
<td>361, 928</td>
<td></td>
</tr>
<tr>
<td>Shiau, Stephanie</td>
<td>27, 819</td>
<td></td>
</tr>
<tr>
<td>Shiboski, Caroline H.</td>
<td>213</td>
<td></td>
</tr>
<tr>
<td>Shiers, Meredith S.</td>
<td>600, 661</td>
<td></td>
</tr>
<tr>
<td>Shigemi, Urara</td>
<td>496</td>
<td></td>
</tr>
<tr>
<td>Shih, Margaret D.</td>
<td>611</td>
<td></td>
</tr>
<tr>
<td>Shih, Qiuhu</td>
<td>361, 928</td>
<td></td>
</tr>
<tr>
<td>Shiau, Stephanie</td>
<td>27, 819</td>
<td></td>
</tr>
<tr>
<td>Shiboski, Caroline H.</td>
<td>213</td>
<td></td>
</tr>
<tr>
<td>Shiers, Meredith S.</td>
<td>600, 661</td>
<td></td>
</tr>
<tr>
<td>Shigemi, Urara</td>
<td>496</td>
<td></td>
</tr>
<tr>
<td>Shih, Margaret D.</td>
<td>611</td>
<td></td>
</tr>
<tr>
<td>Shih, Qiuhu</td>
<td>361, 928</td>
<td></td>
</tr>
<tr>
<td>Shiau, Stephanie</td>
<td>27, 819</td>
<td></td>
</tr>
<tr>
<td>Shiboski, Caroline H.</td>
<td>213</td>
<td></td>
</tr>
<tr>
<td>Shiers, Meredith S.</td>
<td>600, 661</td>
<td></td>
</tr>
<tr>
<td>Shigemi, Urara</td>
<td>496</td>
<td></td>
</tr>
<tr>
<td>Author</td>
<td>Page Numbers</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Spira, Bonnie</td>
<td>498</td>
<td></td>
</tr>
<tr>
<td>Spoor, Adrian</td>
<td>602, 782</td>
<td></td>
</tr>
<tr>
<td>Spreen, William</td>
<td>84, 442</td>
<td></td>
</tr>
<tr>
<td>Springer, Gayle</td>
<td>350</td>
<td></td>
</tr>
<tr>
<td>Spudich, Serena</td>
<td>1, 70, 71, 73, 339, 344, 363, 364, 380, 387, 391, 394</td>
<td></td>
</tr>
<tr>
<td>Squillace, Nicola</td>
<td>222</td>
<td></td>
</tr>
<tr>
<td>Squires, Kathleen</td>
<td>443, 45LB</td>
<td></td>
</tr>
<tr>
<td>Sridharan, Aylur K.</td>
<td>245, 558, 559, 883</td>
<td></td>
</tr>
<tr>
<td>Srinivas, Suman</td>
<td>627</td>
<td></td>
</tr>
<tr>
<td>Sriporn, Adrian</td>
<td>602, 782</td>
<td></td>
</tr>
<tr>
<td>Spreen, William</td>
<td>84, 442</td>
<td></td>
</tr>
<tr>
<td>Springer, Gayle</td>
<td>350</td>
<td></td>
</tr>
<tr>
<td>Spudich, Serena</td>
<td>1, 70, 71, 72, 339, 344, 363, 364, 380, 387, 391, 394</td>
<td></td>
</tr>
<tr>
<td>Squillace, Nicola</td>
<td>222</td>
<td></td>
</tr>
<tr>
<td>Squires, Kathleen</td>
<td>443, 45LB</td>
<td></td>
</tr>
<tr>
<td>Sridharan, Aylur K.</td>
<td>245, 558, 559, 883</td>
<td></td>
</tr>
<tr>
<td>Srinivas, Suman</td>
<td>627</td>
<td></td>
</tr>
<tr>
<td>Sriporn, Anuwat</td>
<td>862</td>
<td></td>
</tr>
<tr>
<td>Srimompotong, Anuwat</td>
<td>759</td>
<td></td>
</tr>
<tr>
<td>Ssekasamu, Joseph</td>
<td>880, 996</td>
<td></td>
</tr>
<tr>
<td>Ssekubugu, Robert</td>
<td>996, 1015</td>
<td></td>
</tr>
<tr>
<td>Ssemwanga, Deogratius</td>
<td>193</td>
<td></td>
</tr>
<tr>
<td>St-Jean, Martin</td>
<td>1042</td>
<td></td>
</tr>
<tr>
<td>Stagg, Helen R.</td>
<td>736</td>
<td></td>
</tr>
<tr>
<td>Stancil, Britt S.</td>
<td>442</td>
<td></td>
</tr>
<tr>
<td>Stauffer, Brian</td>
<td>616</td>
<td></td>
</tr>
<tr>
<td>Stauffer, David</td>
<td>494</td>
<td></td>
</tr>
<tr>
<td>Stecher, Melanie</td>
<td>183</td>
<td></td>
</tr>
<tr>
<td>Steele, Sarah Jane</td>
<td>718, 791, 927, 998</td>
<td></td>
</tr>
<tr>
<td>Stefanescu, Andrei</td>
<td>277</td>
<td></td>
</tr>
<tr>
<td>Stein, James H.</td>
<td>414</td>
<td></td>
</tr>
<tr>
<td>Steinbach, Sally</td>
<td>402</td>
<td></td>
</tr>
<tr>
<td>Stek, Alice</td>
<td>755, 938</td>
<td></td>
</tr>
<tr>
<td>Stek, Carl</td>
<td>81LB</td>
<td></td>
</tr>
<tr>
<td>Stekler, Joanne</td>
<td>901, 967</td>
<td></td>
</tr>
<tr>
<td>Stella-Ascariz, Natalia</td>
<td>652</td>
<td></td>
</tr>
<tr>
<td>Stengelin, Martin</td>
<td>512</td>
<td></td>
</tr>
<tr>
<td>Stepman, George</td>
<td>433, 436</td>
<td></td>
</tr>
<tr>
<td>Stephan, Christoph</td>
<td>738</td>
<td></td>
</tr>
<tr>
<td>Stephens, Charles</td>
<td>685LB</td>
<td></td>
</tr>
<tr>
<td>Stephenson, Sarah E.</td>
<td>660</td>
<td></td>
</tr>
<tr>
<td>Stephenson, Sophie</td>
<td>407</td>
<td></td>
</tr>
<tr>
<td>Sterling, Timothy R.</td>
<td>644, 719, 912</td>
<td></td>
</tr>
<tr>
<td>Sterman, Felicia</td>
<td>124</td>
<td></td>
</tr>
<tr>
<td>Stern, Anna L.</td>
<td>378</td>
<td></td>
</tr>
<tr>
<td>Stern, Joshua</td>
<td>749</td>
<td></td>
</tr>
<tr>
<td>Serrantino, Gaetana</td>
<td>460</td>
<td></td>
</tr>
<tr>
<td>Stevens, Claire</td>
<td>749, 750</td>
<td></td>
</tr>
<tr>
<td>Stevens, Elizabeth</td>
<td>1049LB</td>
<td></td>
</tr>
<tr>
<td>Stevenson, Mario</td>
<td>174</td>
<td></td>
</tr>
<tr>
<td>Stevenson, Alexandra B.</td>
<td>622</td>
<td></td>
</tr>
<tr>
<td>Steward, Wayne T.</td>
<td>111</td>
<td></td>
</tr>
<tr>
<td>Stier, Elizabeth A.</td>
<td>591</td>
<td></td>
</tr>
<tr>
<td>Stingl, Georg</td>
<td>716LB</td>
<td></td>
</tr>
<tr>
<td>Stinson, Kathryn</td>
<td>990</td>
<td></td>
</tr>
<tr>
<td>Stoeckle, Marcel</td>
<td>596</td>
<td></td>
</tr>
<tr>
<td>Stoffel, Nicole</td>
<td>721</td>
<td></td>
</tr>
<tr>
<td>Stolte, Ineke</td>
<td>886</td>
<td></td>
</tr>
<tr>
<td>Stoner, Kevin A.</td>
<td>945</td>
<td></td>
</tr>
<tr>
<td>Stoner, Marie</td>
<td>919</td>
<td></td>
</tr>
<tr>
<td>Storto, Alexandre</td>
<td>195</td>
<td></td>
</tr>
<tr>
<td>Strain, Matthew</td>
<td>300</td>
<td></td>
</tr>
<tr>
<td>Strathdee, Steffanie A.</td>
<td>844, 887</td>
<td></td>
</tr>
<tr>
<td>Stray, Kirsten</td>
<td>436</td>
<td></td>
</tr>
<tr>
<td>Streeck, Hendrik</td>
<td>282</td>
<td></td>
</tr>
<tr>
<td>Strehlau, Renate</td>
<td>27, 819</td>
<td></td>
</tr>
<tr>
<td>Streicher, Elizabeth</td>
<td>715LB</td>
<td></td>
</tr>
<tr>
<td>Strickler, Howard D.</td>
<td>23, 928</td>
<td></td>
</tr>
<tr>
<td>Stringer, Jeffrey S.</td>
<td>776, 777, 919</td>
<td></td>
</tr>
<tr>
<td>Strizki, Julie</td>
<td>337</td>
<td></td>
</tr>
<tr>
<td>Strong, Mark</td>
<td>1048</td>
<td></td>
</tr>
<tr>
<td>Strouvelle, Victoria Pamela</td>
<td>263, 327</td>
<td></td>
</tr>
<tr>
<td>Struble, Kimberly</td>
<td>372</td>
<td></td>
</tr>
<tr>
<td>Strumpf, Erin C.</td>
<td>553</td>
<td></td>
</tr>
<tr>
<td>Sturdevant, Daniel</td>
<td>733</td>
<td></td>
</tr>
<tr>
<td>Su, Hang</td>
<td>219</td>
<td></td>
</tr>
<tr>
<td>Subra, Frédéric</td>
<td>499</td>
<td></td>
</tr>
<tr>
<td>Suc, Bertrand</td>
<td>223</td>
<td></td>
</tr>
<tr>
<td>Succi, Regina</td>
<td>816</td>
<td></td>
</tr>
<tr>
<td>Sudjaritruk, Taviyita</td>
<td>820</td>
<td></td>
</tr>
<tr>
<td>Sugandhi, Nandita</td>
<td>809</td>
<td></td>
</tr>
<tr>
<td>Sugai, Catherine Ann</td>
<td>695</td>
<td></td>
</tr>
<tr>
<td>Sukwica, Wichuda</td>
<td>854, 855, 862</td>
<td></td>
</tr>
<tr>
<td>Sulkowski, Mark</td>
<td>138, 558, 559, 560</td>
<td></td>
</tr>
<tr>
<td>Sullivan, Claire E.</td>
<td>628</td>
<td></td>
</tr>
<tr>
<td>Sullivan, Patrick</td>
<td>90, 901, 1024, 1033, 1034</td>
<td></td>
</tr>
<tr>
<td>Summers, Angola</td>
<td>402</td>
<td></td>
</tr>
<tr>
<td>Sun, Hsin-Yun</td>
<td>582</td>
<td></td>
</tr>
<tr>
<td>Sun, Li</td>
<td>435</td>
<td></td>
</tr>
<tr>
<td>Sun, Ly Penh</td>
<td>705</td>
<td></td>
</tr>
<tr>
<td>Sun, Philena</td>
<td>634</td>
<td></td>
</tr>
<tr>
<td>Sun, Ren</td>
<td>268, 500LB</td>
<td></td>
</tr>
<tr>
<td>Sun, Xiaoming</td>
<td>292</td>
<td></td>
</tr>
<tr>
<td>Sun, Xiaoying</td>
<td>870, 977</td>
<td></td>
</tr>
<tr>
<td>Sun, Xin</td>
<td>79, 710, 717, 720</td>
<td></td>
</tr>
<tr>
<td>Sundquist, Wes</td>
<td>20, 21</td>
<td></td>
</tr>
<tr>
<td>Suntarattiwong, Piyarat</td>
<td>285, 759, 820</td>
<td></td>
</tr>
<tr>
<td>Suyankumthorn, Piyanate</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>Sura, Monali</td>
<td>412</td>
<td></td>
</tr>
<tr>
<td>Surie, Diya</td>
<td>937</td>
<td></td>
</tr>
<tr>
<td>Sutcliffe, Catherine</td>
<td>560</td>
<td></td>
</tr>
<tr>
<td>Suthar, Mehul</td>
<td>1056LB</td>
<td></td>
</tr>
<tr>
<td>Suttichom, Duangthai</td>
<td>205, 344</td>
<td></td>
</tr>
<tr>
<td>Sutton, Kathryn</td>
<td>442</td>
<td></td>
</tr>
<tr>
<td>Sutton, Madelaine</td>
<td>839</td>
<td></td>
</tr>
<tr>
<td>Sutton, Richard</td>
<td>236</td>
<td></td>
</tr>
<tr>
<td>Sutton, Sarah H.</td>
<td>469</td>
<td></td>
</tr>
<tr>
<td>Swadling, Leo</td>
<td>239</td>
<td></td>
</tr>
<tr>
<td>Swaminathan, Shobha</td>
<td>421LB</td>
<td></td>
</tr>
<tr>
<td>Swan, Ashley Robb.</td>
<td>403</td>
<td></td>
</tr>
<tr>
<td>Swanstrom, Ronald</td>
<td>73, 163, 198, 364, 369</td>
<td></td>
</tr>
<tr>
<td>Swerner, Stephanie</td>
<td>420</td>
<td></td>
</tr>
<tr>
<td>Swartz, Tia</td>
<td>256</td>
<td></td>
</tr>
<tr>
<td>Swaithirajan, Chinnambedu</td>
<td>245</td>
<td></td>
</tr>
<tr>
<td>Sweiboda, Dominika</td>
<td>829</td>
<td></td>
</tr>
<tr>
<td>Swindells, Susan</td>
<td>79, 408, 728, 963</td>
<td></td>
</tr>
<tr>
<td>Switzer, William M.</td>
<td>189, 477, 877, 878</td>
<td></td>
</tr>
<tr>
<td>Swordy, Alice</td>
<td>799</td>
<td></td>
</tr>
<tr>
<td>Sykes, Craig</td>
<td>406</td>
<td></td>
</tr>
<tr>
<td>Symonds, Geoff F.</td>
<td>322</td>
<td></td>
</tr>
<tr>
<td>Szadkowski, Leah</td>
<td>447</td>
<td></td>
</tr>
<tr>
<td>Szubert, Alexander J.</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>Szymilin, Elisabeth</td>
<td>116, 464, 764, 792, 1006</td>
<td></td>
</tr>
<tr>
<td>Szydl, Daniel W.</td>
<td>951</td>
<td></td>
</tr>
<tr>
<td>Segaard, Ole Schmelz.</td>
<td>305, 314</td>
<td></td>
</tr>
<tr>
<td>Tabor, Agnieszka</td>
<td>499</td>
<td></td>
</tr>
<tr>
<td>Tabano, David C.</td>
<td>528</td>
<td></td>
</tr>
<tr>
<td>Tabler, Caroline</td>
<td>169</td>
<td></td>
</tr>
<tr>
<td>Tabone, Marie-Dominique</td>
<td>812</td>
<td></td>
</tr>
<tr>
<td>Tabrizifard, Mohammad</td>
<td>337</td>
<td></td>
</tr>
<tr>
<td>Tachedjian, Gilda</td>
<td>316</td>
<td></td>
</tr>
<tr>
<td>Tada, Takuya</td>
<td>333</td>
<td></td>
</tr>
<tr>
<td>Tadesse, Mualemah</td>
<td>713</td>
<td></td>
</tr>
<tr>
<td>Tagomori, Takeshi</td>
<td>896</td>
<td></td>
</tr>
<tr>
<td>Taguj, Ayumu</td>
<td>661</td>
<td></td>
</tr>
<tr>
<td>Tai, Vincent</td>
<td>123</td>
<td></td>
</tr>
<tr>
<td>Taiwo, Babafemi</td>
<td>342, 369, 665, 666</td>
<td></td>
</tr>
<tr>
<td>Takahama, Seiichiro</td>
<td>643</td>
<td></td>
</tr>
<tr>
<td>Takamatsu, Yuki</td>
<td>503</td>
<td></td>
</tr>
<tr>
<td>Takata, Hiroshi</td>
<td>270</td>
<td></td>
</tr>
<tr>
<td>Takata, Matthew</td>
<td>160LB</td>
<td></td>
</tr>
<tr>
<td>Talliani, Gloria</td>
<td>564, 575</td>
<td></td>
</tr>
<tr>
<td>Tallon, Benjamin</td>
<td>274</td>
<td></td>
</tr>
</tbody>
</table>
Valdez, Rogelio Miguel 446
Valdez Madurga, Jose 447, 498
Valentine, Megan 760
Valin, Nadia 75
Vallabhaneni, Snigdha 743
Van, Phu 265LB
Van Bortel, Luc 412
Van Crevel, Reinout 429, 610
Van Culem, Gilles 791, 927
Van de Perre, Philippe 781
Van de Vijver, David 604
Van den Berk, Guido 137LB, 470
Van der Elst, Elisabeth Maria. 893, 1022
Van der Ende, Ineke 604, 731, 754
Van der Heijden, Wouter Anton. 610
Van Der Pol, Barbara 867
Van der Straten, Ariane 420, 936
Van der Valk, Marc 129, 136
Van der Ven, André 610
Van Duyne, Gregory 171LB
Van Duyne, Rachel 156, 180
Van Dyke, Russell B. 815, 827, 828
Van Gorp, Eric 451LB
Van Hecke, Clarissa 162
Van Kampen, Jeroen Jacob Alexander. 604
Van Lancker, Gret 412
Van Loan, Marta 685LB
Van Niekerk, Christo 80LB
Van Ommen, Clara E. 939
Van Oosterhout, Joep J. 782
Van Oosterhout, Joep J. 782
Van der Ende, Ineke 604, 731, 754
Van der Ven, André 610
Van Duyne, Gregory 171LB
Van Duyne, Rachel 156, 180
Van Dyke, Russell B. 815, 827, 828
Van Gorp, Eric 451LB
Van Hecke, Clarissa 162
Van Kampen, Jeroen Jacob Alexander. 604
Van Lancker, Gret 412
Van Loan, Marta 685LB
Van Niekerk, Christo 80LB
Van Ommen, Clara E. 939
Van Oosterhout, Joep J. 782
Van Rensburg, Craig 941
Van Schaik, Nienke 958
Van Sighem, Ard 1041
Van Vuuren, Coetze 261
Van Wilgenburg, Bonnie 239
Van Zyl, Gert U. 28, 120, 795
VanBelen, Jake 300
Vance, David 350
Vandekerckhove, Linos 162, 302
Vandenbulcke, Alexandra 116, 764, 792
Vandergeeten, Claire 291
Vandermeulen, Kati 44LB
Vandesompele, Jo 162
Vangala, Sitram 593
Vannappagari, Vani 664
VanWidenfelt, Erik 885
Varangrat, Anchalee 854
Vardhanabhuti, Saran 492
Varetska, Olga 884
Vargala, Milenka 206
Varghese, Vici 506
Varkila, Meri 656
Vasan, Sandhya 70
Wasneys, Ricardo de Paula. 948
Vashishtha, Devesh 870
Vassallo, Matteo 72
Vasconcelos, Ricardo de Paula. 948
Vasconcelos, Ricardo de Paula. 948
Vasconcelos, Ricardo de Paula. 948
Vassallo, Matteo 72
Vasudev, Ganjeevaram K. 883
Vavrek, Marissa 435
Vavro, Cindy 806
Vaz, Paula 730, 766, 818
Veenvliet, Rebecca 253
Vehreschild, Joerg Janne 183, 580
Veldsman, Kirsten Abigail 28
Velloza, Jennifer 92, 920
Veloso, Valdelia 719, 948
Veloso Meirelles, Mariana 1040
Velthuisen, Emile 171LB
Venter, Willem Daniel. 113, 1020
Vera, Jesus 844
Vera-Rojas, Jaime 432
Verbey, Jennifer 634
Verbistkaya, Elena 868LB
Verbon, Annelies 587
Verdu, Javier 659
Vergas, Jorge 572
Vergori, Alessandra 354
Vermeire, Jolien 19
Vermund, Sten 816
Vernon, Ian 1048
Vesga, Juan Fernando. 1040, 1047
Vesterbacka, Jan 212
Vezain, Myriam 192
Viani, Rolando M. 413
Vidal, Francesca 542LB
Vidal, Francesc 647
Vieira, Vinícius Adriano. 948
Vigón, Lorena 530
Vigouroux, Corinne 821
Vilaplana, Cristina 306
Vilchez, Helem Haydee 535, 659
Villares, Maria 350
Villar, Judit 676, 681
Villaseñor, Armando G. 38
Vinikoor, Michael J. 581
Virlogeu, Victor 135
Vishwasrao, Harshad D. 308
Voets, Andrew 114LB
Voigt, Robin M. 240, 241
Vojnov, Lara 26
Vollbrecht, Thomas 310
Volpe, Joseph M. 1054
Volpicelli, Lorenzo 575
Wade, Alisha 639
Wadja, Roxanne 606
Wafula, Rose 761
Walensky, Rochelle P. 456, 493, 814, 833, 1028, 1043
Walder, Bruce D. 250, 266
Walder, Rowan G. 687
Walder, Sarah 117, 641, 801, 808
Wallenta, Jeanne 638, 1005
Wall, Carole 492
Walsum, Sharon 447, 553, 756
Walshe, Fiona 475
Walston, Jeremy D. 133
Walter, Kizito 523
Wamalwa, Dalton 796
Wamicwe, Joyce 847
Wamutti, Beatrice 1032
Wandel, Gilles 581
Wang, Bingjie 242
Wang, Cheng 634
Wang, Chi-Chao 594
Wang, Chunhui 1023
Wang, Guimei 23, 634, 646, 933
Wang, Dan 634
Wang, Dong 199
Wang, Huanling 399
Ward, Andrew B. 144
Ward, Douglas 41, 663, 864
Ward, John W. 98
Waring, Robert 433
Warrenchik, Albert 295
Warrenchik, Albert 295
Warrenchik, Albert 295
Warrenchik, Albert 295
Warrendale, Michael 490
Waterman, Stephen 1055LB
Watkins, Melynda 39
Watling, Michael 490
Watling, Michael 490
Watling, Michael 490
Watling, Michael 490
Wawer, Maria 1015, 34LB, 359, 880, 996
Weber, Kathleen M. 361
Weber, Rainer 128LB, 263
Weber, Rainer 128LB, 263
Weber, Rainer 128LB, 263
Weber, Rainer 128LB, 263
Weber, Rainer 128LB, 263
Weber, Rainer 128LB, 263
Weber, Rainer 128LB, 263
Weber, Rainer 128LB, 263
Weber, Rainer 128LB, 263
Weber, Rainer 128LB, 263
Weber, Rainer 128LB, 263
Author Index

Program and Agenda

Wegner, Matthew  70
Wehmeyer, Malte  576
Wei, Xuelian  40, 41
Weinberg, Adriana  774, 803
Weinheimer, Steven  438, 449LB
Weinrib, Rachel  936
Weiser, John  737
Weisgerber, Sheri  690, 913
Weiss, Helen  841LB
Weiss, Jeffrey  544
Weiss, Kevin  1034
Weiss, Stephen  770
Weisser, Maja  744
Weissman, Drew  1057LB
Weitzmann, M Neale.  684
Wejnert, Cyprian  902
Weke, Elly  762
Wells, David  298
Wells, Quinn S.  621
Wentz, Eryka  690, 913
Werb, Dan  870
Were, Kennedy  488
Wertheim, Austin  783
Wesolowski, Laura  509
Wesson, Jennifer  914
Westheimer, Emily  189, 477
Whitcomb, Jeannette  140
White, Douglas A. E.  956
White, Elizabeth  506
Wightman, Robert  739, 81LB
Wild, Carl  507
Wilder, Julius M.  552
Wiley, Dorothy Joann.  591, 592, 593
Wilkin, Timothy  981
Wilkinson, Eduan  504LB
Wilkinson, Robert  739, 811LB
Wilks, Moses Q.  635LB
Willic, Christopher  634
Widhani, Alvina  705
Wiegand, Ann  120, 294
Wiener, Jeff  946
Wiesner, Lubbe  758, 808
Wiewel, Ellen  1013
Witten, Joanne R.  736
Winter, Matthew  167
Wirth, Kathleen  184, 885
Wiseman, Sam  599
Wit, Ferdinand  129, 467, 620, 672, 731, 825, 830
Witkowski, H. Ewa  170
Witt, Mallory  624, 645, 701
Wiznia, Andrew  806
Wohl, David  453
Wohlfheiler, Michael  664
Wolbers, Marcel  83
Wolf, Eva  42
Wolff, Timo  738
Wolstenholme, Allen  428
Womack, Julie A.  667, 930
Won, Seung Hyun  668, 932
Wong, Alexander  553
Wong, Audrey J.  508
Wong, Betele  475
Wong, Cherise  662
Wong, Chun-Shu  221, 226
Wong, Eric Y.  505
Wong, Jason  735
Wong, Joseph K.  312, 797
Wong, Michelle  657
Wong, Pamela  425
Wong, Sophie S.  556
Wong, Wingwai  450LB, 705
Wongtrakool, Cherry  658, 660
Woo, Patrick C.Y.  747
Wood, Evan  875
Wood, Linda S.  417
Wood, Matthew  260LB
Wood, Robin  727
Woody, George  868LB
Woolley, Ian  687
Woolnough, Emily  687
Wools-Kaloustian, Kara Kay.  815, 837
 Worlock, Andrew  284
Wrammert, Jens  1056LB
Wray, Tyler B.  892
Wright, Mary E.  227
Wu, Kunling  343
Wu, Ning  302
Wu, Vincent  440
Wu, Xiaolin  298
Wu, Xiaotian  908
Wu, Xingye  728
Wuthoh, Anthony  1007
Wyatt, Monique A.  1003
Wyles, David L.  134
Wynn, Brian  44LB

Xia, Qiang  903
Xu, Ai  699
Xu, Jianqiang  199
Xu, Meng  621
Xu, Weihai  399
Xu, Xia  45LB
Xu, Xiao-Ning  248
Xuan Chua, Corrine  422LB

Wimonsate, Wipas  854, 855, 862
Winnatham, Santi  862
Winckelmann, Anni  305
Wing, Edward J.  694
Wing, Rena R.  694
Winston, Alan  352LB
Winston, Jennifer  919
Winter, Joanne R.  736
Winter, Matthew  167
Wirth, Kathleen  184, 885
Wirunsavany, Kamonkiet  692
Wit, Ferdinand  129, 467, 620, 672, 731, 825, 830
Wittkowska, H. Ewa  170
Witt, Mallory  624, 645, 701
Wiznia, Andrew  806
Wohl, David  453
Wohlfheiler, Michael  664
Wolbers, Marcel  83
Wolf, Eva  42
Wolf, Timo  738
Wolstenholme, Allen  428
Womack, Julie A.  667, 930
Won, Seung Hyun  668, 932
Wong, Alexander  553
Wong, Audrey J.  508
Wong, Betele  475
Wong, Cherise  662
Wong, Chun-Shu  221, 226
Wong, Eric Y.  505
Wong, Jason  735
Wong, Joseph K.  312, 797
Wong, Michelle  657
Wong, Pamela  425
Wong, Sophie S.  556
Wong, Wingwai  450LB, 705
Wongtrakool, Cherry  658, 660
Woo, Patrick C.Y.  747
Wood, Evan  875
Wood, Linda S.  417
Wood, Matthew  260LB
Wood, Robin  727
Woody, George  868LB
Woolley, Ian  687
Woolnough, Emily  687
Wools-Kaloustian, Kara Kay.  815, 837
 Worlock, Andrew  284
Wrammert, Jens  1056LB
Wray, Tyler B.  892
Wright, Mary E.  227
Wu, Kunling  343
Wu, Ning  302
Wu, Vincent  440
Wu, Xiaolin  298
Wu, Xiaotian  908
Wu, Xingye  728
Wuthoh, Anthony  1007
Wyatt, Monique A.  1003
Wyles, David L.  134
Wynn, Brian  44LB

—X—
Xia, Qiang  903
Xu, Ai  699
Xu, Jianqiang  199
Xu, Meng  621
Xu, Weihai  399
Xu, Xia  45LB
Xu, Xiao-Ning  248
Xuan Chua, Corrine  422LB
<table>
<thead>
<tr>
<th>Xue, Guangai</th>
<th>18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yagura, Hiroki</td>
<td>426</td>
</tr>
<tr>
<td>Yamamoto, Masahiro</td>
<td>643</td>
</tr>
<tr>
<td>Yamamoto, Takuya</td>
<td>165</td>
</tr>
<tr>
<td>Yamashita, Masahiro</td>
<td>160LB</td>
</tr>
<tr>
<td>Yamazaki, Kunio</td>
<td>426</td>
</tr>
<tr>
<td>Yan, Peng</td>
<td>574</td>
</tr>
<tr>
<td>Yang, Hongbing</td>
<td>271</td>
</tr>
<tr>
<td>Yang, Huanle</td>
<td>133</td>
</tr>
<tr>
<td>Yang, Jingyan</td>
<td>132</td>
</tr>
<tr>
<td>Yang, Xiaohe</td>
<td>353</td>
</tr>
<tr>
<td>Yang, Z</td>
<td>116, 458, 1028</td>
</tr>
<tr>
<td>Ye, Monica</td>
<td>599, 601</td>
</tr>
<tr>
<td>Ye, Kelly</td>
<td>412, 430</td>
</tr>
<tr>
<td>Ye, Lynn M.</td>
<td>469</td>
</tr>
<tr>
<td>Yin, Michael T.</td>
<td>346, 389</td>
</tr>
<tr>
<td>Yin, Z</td>
<td>683, 819, 930</td>
</tr>
<tr>
<td>Yip, Roger</td>
<td>1032</td>
</tr>
<tr>
<td>Yokomaku, Yoshiyuki</td>
<td>496</td>
</tr>
<tr>
<td>Yona, Caroline</td>
<td>811</td>
</tr>
<tr>
<td>Yong, Gerald</td>
<td>151</td>
</tr>
<tr>
<td>Yoshimura, Kazuhsia</td>
<td>247</td>
</tr>
<tr>
<td>Yoshino, Munehiro</td>
<td>426</td>
</tr>
<tr>
<td>You, Chunli</td>
<td>780</td>
</tr>
<tr>
<td>You, Huilen</td>
<td>329, 434, 436</td>
</tr>
<tr>
<td>Yu, Jungen</td>
<td>558</td>
</tr>
<tr>
<td>Yu, Sue</td>
<td>21</td>
</tr>
<tr>
<td>Yannioussos, Constantin</td>
<td>837</td>
</tr>
<tr>
<td>Yilmaz, Aylin</td>
<td>340, 389</td>
</tr>
<tr>
<td>Yin, Michael T.</td>
<td>132, 213, 346, 361, 546, 682, 683, 819, 930</td>
</tr>
<tr>
<td>Ying, Roger</td>
<td>1032</td>
</tr>
<tr>
<td>Yoko, S</td>
<td>517</td>
</tr>
<tr>
<td>Yoko, Yohsuke</td>
<td>946</td>
</tr>
<tr>
<td>Yong, Stephon</td>
<td>592, 593</td>
</tr>
<tr>
<td>Yu, Helen</td>
<td>329, 434, 436</td>
</tr>
<tr>
<td>Yu, Hyun Jae</td>
<td>18</td>
</tr>
<tr>
<td>Yu, Kimberly</td>
<td>544</td>
</tr>
<tr>
<td>Yu, Xi G.</td>
<td>250, 292</td>
</tr>
<tr>
<td>Yuan, Chun-Su</td>
<td>669</td>
</tr>
<tr>
<td>Yuan, Zhe</td>
<td>199</td>
</tr>
<tr>
<td>Yudin, Mark</td>
<td>756, 940</td>
</tr>
<tr>
<td>Yue, Feng Yun</td>
<td>233</td>
</tr>
<tr>
<td>Yuen, Kwok-Yung</td>
<td>747</td>
</tr>
<tr>
<td>Yueuling, Katharine</td>
<td>706</td>
</tr>
<tr>
<td>Yua, Krista</td>
<td>937</td>
</tr>
<tr>
<td>Yuli, Steven A.</td>
<td>312</td>
</tr>
<tr>
<td>--Z--</td>
<td>--Z--</td>
</tr>
<tr>
<td>Zaccarelli, Mauro</td>
<td>354, 460</td>
</tr>
<tr>
<td>Zack, Jerome</td>
<td>332</td>
</tr>
<tr>
<td>zadzika, Amanda A.</td>
<td>803</td>
</tr>
<tr>
<td>Zahralban-Steele, Melissa</td>
<td>184, 484</td>
</tr>
<tr>
<td>Zakhrova, Oksana</td>
<td>465, 483</td>
</tr>
<tr>
<td>Zang, Trinity</td>
<td>160LB, 220</td>
</tr>
<tr>
<td>Zang, Xiao</td>
<td>875</td>
</tr>
<tr>
<td>Zangari, Paola</td>
<td>798</td>
</tr>
<tr>
<td>Zangerle, Robert</td>
<td>631</td>
</tr>
<tr>
<td>Zanni, Markella V.</td>
<td>627, 635LB</td>
</tr>
<tr>
<td>Zanoni, Brian C.</td>
<td>838</td>
</tr>
<tr>
<td>Zash, Rebecca</td>
<td>25</td>
</tr>
<tr>
<td>Zean, Cosmina</td>
<td>682</td>
</tr>
<tr>
<td>Zedler, Ulike</td>
<td>716LB</td>
</tr>
<tr>
<td>Zeh, Clement</td>
<td>488</td>
</tr>
<tr>
<td>Zellman, Hannah</td>
<td>911</td>
</tr>
<tr>
<td>Zerbato, Jennifer M.</td>
<td>298, 316</td>
</tr>
<tr>
<td>Zerbe, Allison</td>
<td>24, 769, 771, 992</td>
</tr>
<tr>
<td>Zetola, Nicola M.</td>
<td>729</td>
</tr>
<tr>
<td>Zetterberg, Henrik</td>
<td>72, 73, 340, 383, 389</td>
</tr>
<tr>
<td>Zevin, Alexander Simon</td>
<td>216, 231</td>
</tr>
<tr>
<td>Zevo, Leonel</td>
<td>730</td>
</tr>
<tr>
<td>Zeymo, Alexander</td>
<td>517</td>
</tr>
<tr>
<td>Zhang, Chengchen</td>
<td>682</td>
</tr>
<tr>
<td>Zhang, Heather</td>
<td>40, 424, 425</td>
</tr>
<tr>
<td>Zhang, Hongliang</td>
<td>233</td>
</tr>
<tr>
<td>Zhang, Jennifer R.</td>
<td>38</td>
</tr>
<tr>
<td>Zhang, Lily</td>
<td>415</td>
</tr>
<tr>
<td>Zhang, Long</td>
<td>356, 645</td>
</tr>
<tr>
<td>Zhang, Meiwen</td>
<td>927</td>
</tr>
<tr>
<td>Zhang, Peng</td>
<td>14LB</td>
</tr>
<tr>
<td>Zhang, Tianchi</td>
<td>187</td>
</tr>
<tr>
<td>Zhang, Wendy</td>
<td>929</td>
</tr>
<tr>
<td>Zhang, Xiaodong</td>
<td>1056LB</td>
</tr>
<tr>
<td>Zhang, Xin Yu</td>
<td>274</td>
</tr>
<tr>
<td>Zhang, Xinyi C.</td>
<td>1002</td>
</tr>
<tr>
<td>Zhang, Xue</td>
<td>329</td>
</tr>
<tr>
<td>Zhang, Yinfeng</td>
<td>955</td>
</tr>
<tr>
<td>Zhang, Yuwei</td>
<td>204</td>
</tr>
<tr>
<td>Zhan, Zhenhuan</td>
<td>1052</td>
</tr>
<tr>
<td>Zhang, Zhiping</td>
<td>428</td>
</tr>
<tr>
<td>Zhao, Mitchell</td>
<td>367</td>
</tr>
<tr>
<td>Zhou, Anjie</td>
<td>254, 331, 332, 333</td>
</tr>
<tr>
<td>Zheng, Amy</td>
<td>456</td>
</tr>
<tr>
<td>Zheng, Jia-Hua</td>
<td>405</td>
</tr>
<tr>
<td>Zheng, Jianhua</td>
<td>269</td>
</tr>
<tr>
<td>Zheng, Jiayin</td>
<td>552</td>
</tr>
<tr>
<td>Zheng, Jim</td>
<td>38</td>
</tr>
<tr>
<td>Zhen, Lu</td>
<td>330LB, 457</td>
</tr>
<tr>
<td>Zeng, Wenjing</td>
<td>36, 836</td>
</tr>
<tr>
<td>Zheng, Yanyan</td>
<td>337</td>
</tr>
<tr>
<td>Zhong, Yaoyu</td>
<td>1013</td>
</tr>
<tr>
<td>Zhou, Qinlan</td>
<td>1049LB</td>
</tr>
<tr>
<td>Zhou, Shuntai</td>
<td>198, 369</td>
</tr>
<tr>
<td>Zhou, Tian</td>
<td>439</td>
</tr>
<tr>
<td>Zhou, Zhi</td>
<td>874</td>
</tr>
<tr>
<td>Zhu, Julia</td>
<td>462</td>
</tr>
<tr>
<td>Zhu, Yuan-Shan</td>
<td>471</td>
</tr>
<tr>
<td>Zidar, David A.</td>
<td>628, 674</td>
</tr>
<tr>
<td>Zielinski-Gutierrez, Emily</td>
<td>847</td>
</tr>
<tr>
<td>Zimmerman, Scott J.</td>
<td>198</td>
</tr>
<tr>
<td>Zingman, Barry S.</td>
<td>682, 903</td>
</tr>
<tr>
<td>Zins, Marie</td>
<td>654</td>
</tr>
<tr>
<td>Zinckatira, Nesbth</td>
<td>727</td>
</tr>
<tr>
<td>Zlotorzynska, Maria</td>
<td>869, 901</td>
</tr>
<tr>
<td>Zohoun-Guidiqi, Luteica</td>
<td>487</td>
</tr>
<tr>
<td>Zola, Courtney</td>
<td>321</td>
</tr>
<tr>
<td>Zona, Stefano</td>
<td>655</td>
</tr>
<tr>
<td>Zozulya, Olga</td>
<td>452LB</td>
</tr>
<tr>
<td>Zubik, Wendy</td>
<td>447</td>
</tr>
<tr>
<td>Zuccotti, GianVincenzo</td>
<td>804</td>
</tr>
<tr>
<td>Zucker, Jason</td>
<td>546</td>
</tr>
<tr>
<td>Zunt, Joseph</td>
<td>347</td>
</tr>
<tr>
<td>Zuppa, Athena</td>
<td>384, 975</td>
</tr>
<tr>
<td>Zurawski, Gerard</td>
<td>262</td>
</tr>
<tr>
<td>Zurawski, Sandy</td>
<td>262</td>
</tr>
<tr>
<td>Zurick, Kathrin</td>
<td>714</td>
</tr>
<tr>
<td>Zurnic, Irena</td>
<td>155</td>
</tr>
<tr>
<td>Z warto, Edwina</td>
<td>868LB</td>
</tr>
<tr>
<td>Zwahlen, Marcel</td>
<td>721</td>
</tr>
<tr>
<td>Òstergaard, Lars</td>
<td>305, 314</td>
</tr>
</tbody>
</table>
## Conference Schedule Overview

<table>
<thead>
<tr>
<th>Time</th>
<th>Monday, February 13, 2017</th>
<th>Tuesday, February 14, 2017</th>
<th>Wednesday, February 15, 2017</th>
<th>Thursday, February 16, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM</td>
<td>Plenary Session Auditorium 4 AB 8:30 AM THE EMERGING POTENTIAL FOR HIV CURE FOR INFANTS CHILDREN, AND ADULTS 9:00 AM ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV</td>
<td>Plenary Session Auditorium 4 AB 8:30 AM (PREVENTING) THE COMING EPIDEMIC: HIV IN YOUTH 9:00 AM ANTIVIRAL VACCINE DEVELOPMENT FROM A (AIDS) TO Z (ZIKA)</td>
<td>Plenary Session Auditorium 4 AB 8:30 AM IF YOU CAN MAKE IT THERE: ENDING THE HIV EPIDEMIC IN NEW YORK 9:00 AM HTLV-1: THE OTHER HUMAN RETROVIRUS</td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td>PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES Room 6 AB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>CONCURRENT ORAL ABSTRACT SESSIONS: 0-1 GETTING HIV THROUGH THE CELL Room 611-614 0-2 CRITICAL ISSUES IN WOMEN’S HEALTH, MTCT, AND HIV TREATMENT IN CHILDREN Room 606-609 0-3 HIDING IN PLAIN SIGHT: DISCOVERING THE UNDIAGNOSED AND UNDERTREATED HIV EPIDEMIC Room 6 E 0-4 NEW HIV DRUGS, FORMULATIONS, COMBINATIONS, AND RESISTANCE Room 6 AB</td>
<td>CONCURRENT ORAL ABSTRACT SESSIONS: 0-5 ROLE OF HOST AND IMMUNE FACTORS IN HIV INFECTION Room 611-614 0-6 CNS RESERVOIRS, NEUROPATHOGENESIS, AND HOST FACTORS Room 606-609 0-7 TB AND OTHER OPPORTUNISTIC INFECTIONS Room 6 C 0-8 COMMON BEDFELLOWS: PREP, STIs, AND THE MICROBIOME Room 6 AB</td>
<td>CONCURRENT ORAL ABSTRACT SESSIONS: 0-9 HEPATITIS C: PROBLEMS AND PROGRESS Room 606-609 0-10 IMPROVING THE HIV CARE CASCADE Room 6 C 0-11 HIV PERSISTENCE AND REACTIVATION Room 6 E 0-12 INFLAMMATION AND AGE-RELATED COMPLICATIONS Room 6 AB</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>LUNCH AND MARTIN DELANEY PRESENTATION FROM LAB TO LICENSURE: THE IMPORTANCE OF GOOD PARTICIPATORY PRACTICE IN RESEARCH Room 6 AB</td>
<td>LUNCH 12:00 PM - 1:30 PM</td>
<td>LUNCH 12:00 PM - 1:30 PM</td>
<td>LUNCH 12:00 PM - 1:30 PM</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>CONCURRENT THEMED DISCUSSIONS TD-1 CD8 T CELLS: WHERE AND HOW THEY KILL Room 611-617 TD-2 VIRUS AND CELL RNA IN HIV REPLICATION Room 611-614 TD-3 HIV, MIGRATION, AND ACCESS TO CARE Room 606-609 TD-4 OBESITY AND FATTY LIVER DISEASE Room 6 C TD-5 PREP WITHOUT BORDERS: NEW DELIVERY OPTIONS Room 6 E</td>
<td>CONCURRENT THEMED DISCUSSIONS TD-6 INTRACELLULAR AND TISSUE PHARMACOLOGY Room 611-617 TD-7 CNS TREATMENT STRATEGIES: RISK AND BENEFITS Room 611-614 TD-8 SCREENING FOR HSL: ALTERNATIVES TO CYTOLOGY Room 606-609 TD-9 HIV SELF-TESTING: KNOW YOURSELF Room 6 C TD-10 HIV PERSISTENCE: CLONES, CLONES, AND MORE CLONES Room 6 AB TD-11 INTEGRATION OF SCREENING AND TREATMENT OF NCD INTO HIV CARE IN RESOURCE LIMITED SETTINGS Room 6 E</td>
<td>CONCURRENT THEMED DISCUSSIONS TD-12 THE IMPOSSIBLE DREAM: POPULATION PERSPECTIVES ON 90:90:90 IN ADOLESCENTS AND YOUNG ADULTS Room 611-617 TD-13 HIV AND SUBSTANCE ABUSE: DOUBLE TROUBLE Room 606-609 TD-15 I WANT A NEW DRUG Room 6 C TD-16 HOW DOES THE MICROBIOME AFFECT HIV INFECTION? Room 6 E TD-17 EMERGING VIRUSES: THE ZIKA VIRUS Room 6 AB</td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>CONCURRENT WORKSHOPS 2:15 PM TO 4:00 PM CLINICAL TRIAL DESIGN AND ANALYSIS Room 6 C FRONTIERS IN LABORATORY SCIENCE Room 611-614 INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C Room 6 E</td>
<td>POSTER SESSIONS 2:30 PM TO 4:00 PM POSTER HALL 6 E</td>
<td>POSTER SESSIONS 2:30 PM TO 4:00 PM POSTER HALL 4 EF</td>
<td>POSTER SESSIONS 2:30 PM TO 4:00 PM POSTER HALL 4 EF</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>OPENING SESSION Auditorium - 4 AB Bernard Fields Lecture N’Galy-Mann Lecture CRIO Foundation Special Event</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Welcome Reception 7:00 - 9:00 PM</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>